Pretty Keen for a Protein: Development of Small Molecule Inhibitors for a Protein-Protein Interaction Domain by Jayne, Stephanie
Pretty Keen for a Protein:




A thesis submitted for the degree of
Doctor of Philosophy
Department of Chemistry, School of Physical Sciences
The University of Adelaide

List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
List of Schemes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
Declaration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xv
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvi
List of Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvii
1 Introduction 1
1.1 Protein-protein interactions as drug targets . . . . . . . . . . . . . . . . . . 1
1.1.1 Challenges of PPI therapeutic design . . . . . . . . . . . . . . . . . 1
1.1.2 Progress in development of ligands for PPIs . . . . . . . . . . . . . . 2
1.2 SH3 domain structure and function . . . . . . . . . . . . . . . . . . . . . . 4
1.2.1 Tec family kinases . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.2 SH3 domain structure . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.3 Native SH3 domain ligands . . . . . . . . . . . . . . . . . . . . . . 7
1.3 Development of ligands for SH3 domains . . . . . . . . . . . . . . . . . . . 9
1.3.1 Peptide-based SH3 domain ligands . . . . . . . . . . . . . . . . . . 9
1.3.2 Development of Small-Molecule SH3 Ligands . . . . . . . . . . . . . 10
1.4 Structure-based design of ligands for an SH3 domain . . . . . . . . . . . . . 11
1.4.1 Measurement of relative binding affinity of ligands . . . . . . . . . . 12
1.4.2 Investigation of 2-aminoquinoline binding model . . . . . . . . . . . 15
1.4.3 Development of 2-aminoquinoline derivatives with increased binding
affinity for SH3 domain . . . . . . . . . . . . . . . . . . . . . . . . 16
1.4.4 Progress towards selective and competitive SH3 domain inhibitors . . 20
1.4.5 Limitations in development of SH3 domain inhibitors . . . . . . . . . 22
1.5 Project aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.5.1 Synthetic targets . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2 Synthesis of 6-position substituted 2-aminoquinolines 27
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.2 General synthetic pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3 Synthesis of 2-aminoquinoline derivatives with a 6-position benzylpiperidine
substituent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.3.1 Investigation of Horner-Emmons pathway for synthesis of benzylpiperidine
derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.3.2 Synthesis of diethyl benzylphosphonate and triphenylphosphonium salt
derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
i
2.3.3 Synthesis of benzylpiperidine derivatives . . . . . . . . . . . . . . . . 48
2.3.4 Synthesis of 6-position substituted 2-chloroquinolines: Selective
Buchwald-Hartwig coupling . . . . . . . . . . . . . . . . . . . . . . 77
2.3.5 Synthesis of 6-position substituted 2-aminoquinolines by Buchwald-
Hartwig amination . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
2.4 Binding studies of 6-position extended 2-aminoquinoline derivatives . . . . . 113
2.4.1 Assay aims and proposed method . . . . . . . . . . . . . . . . . . . 113
2.4.2 Screening method: Surface plasmon resonance (SPR) assays . . . . . 114
2.4.3 Results of screening. . . . . . . . . . . . . . . . . . . . . . . . . . . 121
2.4.4 Results of SPR assays and insight into binding model . . . . . . . . 126
3 Synthesis of 6-position biarylpiperidine substituted 2-aminoquinolines 129
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
3.2 Synthesis of 2-aminoquinolines with 6-position biaryl substituents . . . . . . 131
3.2.1 General synthetic pathway . . . . . . . . . . . . . . . . . . . . . . . 131
3.2.2 Synthesis of biphenyl/biaryl substituted 4-methylpiperidines . . . . . 133
3.2.3 Synthesis of 2-aminoquinolines via Buchwald-Hartwig aminations . . 141
3.3 Binding studies of 6-position biaryl extended 2-aminoquinoline derivatives . . 147
4 Synthesis of extended 3-position 2-aminoquinolines 153
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
4.1.1 General synthetic pathways . . . . . . . . . . . . . . . . . . . . . . 154
4.2 Synthesis of biaryl extended 2-aminoquinoline derivatives . . . . . . . . . . . 157
4.2.1 Investigation of synthetic pathways for 3-position extended quinoline
derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
4.2.2 Synthesis of biaryl-extended 2-chloroquinoline derivatives . . . . . . . 171
4.2.3 Synthesis of 3-position extended 2-aminoquinoline derivatives via
Buchwald-Hartwig amination . . . . . . . . . . . . . . . . . . . . . 175
4.2.4 Alternate synthesis of 3-position extended 2-aminoquinoline derivatives 177
4.3 Binding studies of 3-position extended 2-aminoquinoline derivatives . . . . . 183
4.4 Synthesis of pyridinylethyl-extended quinoline derivatives . . . . . . . . . . . 185
4.5 Synthesis of simple 3-phenethyl-extended quinoline derivatives . . . . . . . . 190
4.6 Binding studies of simple 3-position extended 2-aminoquinoline derivatives . 192
5 Conclusions and Future Directions 194
5.1 6-Position extended 2-aminoquinoline ligands . . . . . . . . . . . . . . . . . 194
5.2 3-Position extended 2-aminoquinoline ligands . . . . . . . . . . . . . . . . . 195
5.3 Development of extended 2-aminoquinoline ligands for the Tec SH3 Domain 196
5.4 Proposed future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
5.4.1 Investigation of tetrahydropyridine formation and stability . . . . . . 196
ii
5.4.2 Binding assays of most effective ligands . . . . . . . . . . . . . . . . 197
5.4.3 Further development of strong binding Tec SH3 domain ligands . . . 198
6 Experimental 202
6.1 General Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.2 2-Aminoquinolines with a 6-position benzylpiperidine substituent . . . . . . . 203
6.2.1 Synthesis of 4-benzylpiperidine derivatives . . . . . . . . . . . . . . 203
6.2.2 Investigation of 4-benzylpiperidine synthesis . . . . . . . . . . . . . . 240
6.2.3 Synthesis of benzylpiperidine variants . . . . . . . . . . . . . . . . . 249
6.2.4 Synthesis of pyridinylmethylpiperidine derivatives . . . . . . . . . . . 261
6.2.5 Synthesis of 2-chloroquinoline derivatives . . . . . . . . . . . . . . . 269
6.2.6 Synthesis of 2-aminoquinoline derivatives by Buchwald-Hartwig
amination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292
6.2.7 Synthesis of 2-aminoquinolines via benzylidenepiperidines . . . . . . 305
6.3 2-Aminoquinolines with 6-position biaryl substituents . . . . . . . . . . . . . 317
6.3.1 Synthesis of biaryl-extended 4-piperidine derivatives . . . . . . . . . 317
6.3.2 Synthesis of 2-aminoquinoline derivatives with 6-position biaryl-extended
substituents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
6.4 2-Aminoquinolines with a 3-position phenethyl-type substituent . . . . . . . 353
6.4.1 Investigation of synthetic pathway for 3-position extended quinolines 353
6.4.2 Synthesis of biaryl-extended diethylphosphonate derivatives . . . . . 364
6.4.3 Synthesis of 3-position extended 2-chloroquinoline derivatives via
Horner-Emmons reaction . . . . . . . . . . . . . . . . . . . . . . . 369
6.4.4 Synthesis of 3-position biaryl-extended 2-aminoquinoline derivatives . 377
6.4.5 Exploration of synthetic pathway for 3-position extended
2-aminoquinolines . . . . . . . . . . . . . . . . . . . . . . . . . . . 382
6.4.6 Synthesis of 3-position pyridinylethyl-extended 2-aminoquinoline
derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
6.4.7 Synthesis of simple 3-position phenethyl-extended 2-aminoquinoline
derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
Appendix A: Assays of small-molecule ligands with Tec SH3 domain
via SPR method 398
Appendix B: Summary of SPR assay results for extended 2-aminoquinoline




1 Small-molecule inhibitors of protein-protein interactions. . . . . . . . . . . . 2
2 Sequence alignment of murine Tec SH3 domain with selected human SH3
domains showing key conserved motifs. . . . . . . . . . . . . . . . . . . . . 4
3 A representation of the domain sequence of mouse Tec protein . . . . . . . 5
4 Solution structure of murine Tec SH3 Domain . . . . . . . . . . . . . . . . 6
5 Binding orientations of Class I and Class II polyproline type 2 helices accommodated
by shallow binding grooves of SH3 domain. . . . . . . . . . . . . . . . . . . 8
6 Reported peptide-peptoid ligands for SH3 domains. . . . . . . . . . . . . . . 10
7 Structure of UCS15A, a small molecule found to regulate protein-protein
interactions of the Src kinase SH3 domain with the Sam68 protein. . . . . . 11
8 Fragment-based screening method using LUDI software, for identification of
lead compounds predicted to bind to murine Tec SH3 domain. . . . . . . . . 12
9 Small molecule compounds initially investigated as potential lead compounds
for Tec SH3 domain inhibition. . . . . . . . . . . . . . . . . . . . . . . . . 12
10 Example overlay of HSQC spectrum overlay showing shifts of binding residues
in NMR chemical shift perturbation assays. . . . . . . . . . . . . . . . . . . 13
11 Example analysis of NMR chemical shift perturbation experiments. . . . . . 14
12 Proposed binding model of 2-aminoquinoline with Tec SH3 domain . . . . . 15
13 Proposed extended binding model of 2-aminoquinoline in Tec SH3 domain
binding site . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
14 Proposed binding model of N-substituted 2-aminoquinoline derivatives with
the D196 residue in Tec SH3 domain binding site. . . . . . . . . . . . . . . 17
15 N-Substituted-2-aminoquinoline derivatives tested for binding with the Tec
SH3 domain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
16 Structures of 4-substituted 2-aminoquinolines tested for binding with the Tec
SH3 domain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
17 Structures of 3-substituted 2-aminoquinolines used to investigate additional
binding interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
18 Structures of 6-position heterocyclic substituted 2-aminoquinoline derivatives
found to access additional binding interaction. . . . . . . . . . . . . . . . . 19
19 Structures of 6-position aryloxy substituted 2-aminoquinolines found to strongly
interact with the Tec SH3 domain but with atypical binding interactions. . . 20
20 Sequence alignment of murine Tec SH3 domain with selected human SH3
domains. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
21 Sequence alignment of murine Tec SH3 domain with selected human SH3
domains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
22 General structure of proposed 6-position extended 2-aminoquinoline ligands. . 25
iv
23 Structures of proposed 6-position extended 2-aminoquinoline ligands with biphenyl
structures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
24 General structure of proposed 6-position extended 2-aminoquinoline ligands
with biaryl structures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
25 General structure of proposed 3-position extended 2-aminoquinoline ligands
with biaryl structures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
26 General structure of proposed simple 3-position extended 2-aminoquinoline
ligands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
27 Key series of 6-position substituted 2-aminoquinoline ligands proposed to
investigate hydrophobic binding interaction. . . . . . . . . . . . . . . . . . . 28
28 Potential products obtained from Buchwald-Hartwig coupling reactions of quinoline
and piperidine reagents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
29 Proposed retrosynthesis of 2-aminoquinoline derivatives with a 6-position
benzylpiperidine substituent. . . . . . . . . . . . . . . . . . . . . . . . . . . 30
30 Range of piperidine derivatives required for synthesis of target 2-aminoquinoline
ligands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
31 Potential retrosynthetic pathways for target piperidine compounds, shown for
required 4-benzylpiperidine derivatives. . . . . . . . . . . . . . . . . . . . . 34
32 Proposed retrosynthesis of 3-benzylpiperidine and 3-benzylpyrrolidine derivatives. 35
33 Proposed retrosynthesis of pyridinylmethylpiperidine derivatives. . . . . . . . 35
34 Structures of Boc-protected piperidines showing partial double-bond character
of C-N bond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
35 Example HSQC correlations used to identify broad 13C NMR piperidine ring
signals of Boc-protected benzylidenepiperidine derivatives. . . . . . . . . . . 38
36 ROESY correlations showing assignment of piperidine ring signals. . . . . . . 39
37 Comparison of 13C NMR spectra of Boc-protected and benzyl-protected Horner-
Emmons reaction products. . . . . . . . . . . . . . . . . . . . . . . . . . . 40
38 Structure of Boc-protected benzylpiperidine structure showing planarised bond
and different chemical environment of axial and equatorial hydrogen atoms. . 42
39 Example 1H NMR spectra demonstrating loss of aryl bromide under hydrogenation
conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
40 1H NMR spectrum comparison for benzyl and Boc-protected benzonitrile Horner-
Emmons products. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
41 2D NMR experiments used to determine structure of Horner-Emmons side-
product. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
42 Comparison of 1H NMR spectra demonstrating isomerisation of benzonitrile-
extended Horner-Emmons reaction products upon treatment with sodium hydride. 61
43 ROESY correlations showing 1H NMR signals corresponding to E -/Z - isomers
of N-Boc-3-benzylidenepiperidine. . . . . . . . . . . . . . . . . . . . . . . . 70
v
44 Proposed retrosynthesis of pyridinyl-extended piperidines. . . . . . . . . . . 74
45 Comparison of 1H NMR spectra for products obtained from Friedel-Crafts
acylation with aluminium trichloride. . . . . . . . . . . . . . . . . . . . . . 80
46 2D NMR experiments used to determine reaction position from Buchwald-
Hartwig amination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
47 Piperidine compounds for which attempted Buchwald-Hartwig amination reactions
did not yield the target extended quinoline compound. . . . . . . . . . . . . 85
48 Key 2D NMR experiments used to identify product of Buchwald-Hartwig
amination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
49 HMBC correlations with C2 showing connectivity of piperidine with quinoline
ring, and ROESY correlations showing correlations between piperidine hydrogen
atoms and the quinoline ring demonstrating 2-position substitution. . . . . . 89
50 HMBC correlations with C6 observed for product of Buchwald-Hartwig coupling
showing successful coupling of piperidine at 6-position of quinoline ring. . . . 92
51 Synthesis of benzylidenepiperidine-extended 2-aminoquinoline derivative. . . 98
52 2D NMR experiments used to assign signals of benzylidene-substituted ligand. 100
53 Comparison of 1H NMR spectra of 2-aminoquinoline ligands. . . . . . . . . . 101
54 ROESY correlations between piperidine ring and quinoline ring, demonstrating
successful synthesis of 6-position substituted 2-chloroquinoline. . . . . . . . 103
55 Further proposed 2-aminoquinoline target compounds with more planarised
alkene substituents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
56 Comparison of alkene compounds demonstrating the structure of the product
from Boc-deprotection of tetrahydropyridine compound. . . . . . . . . . . . 108
57 Comparison of 1H NMR spectra for structurally different 6-position extended
2-chloroquinoline compounds. . . . . . . . . . . . . . . . . . . . . . . . . . 110
58 1H NMR spectrum of crude mixture after attempted amination of
tetrahydropyridine-extended 2-chloroquinoline and proposed products. . . . . 111
59 Surface plasmon resonance as applied to sensing of biological interactions. . 114
60 Preparation of the SPR sensor with covalently attached Tec SH3 domain for
the binding assays. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
61 Structure of the Tec SH3 domain target and nucleophilic residues available for
coupling to sensor surface. . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
62 Typical SPR assay sensorgrams used for determination of equilibrium
dissociation binding constant Kd for a small-molecule ligand. . . . . . . . . 117
63 Typical binding response curves for SPR assay used for determination of
dissociation binding constant Kd. . . . . . . . . . . . . . . . . . . . . . . . 118
vi
64 Structurally different extended 2-aminoquinoline compounds, which could be
investigated to probe the effects of piperidine ring conformations and free
rotation of the benzyl substituent upon the strength of SH3 domain binding
interactions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
65 Structures of strongest binding 2-aminoquinoline ligands for the Tec SH3
domain, as determined using SPR assays. . . . . . . . . . . . . . . . . . . . 127
66 Comparison of biphenyl ligands made previously, and target biphenyl ligands. 130
67 Target biaryl extended 2-aminoquinoline ligands. . . . . . . . . . . . . . . . 130
68 Common palladium-catalysed methods used to synthesise biaryl compounds
from aryl bromide reagents. . . . . . . . . . . . . . . . . . . . . . . . . . . 131
69 Proposed retrosynthesis of 2-aminoquinoline derivatives with 6-position biaryl-
extended substituents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
70 Comparison of signals in the 1H NMR spectra of Boc-protected 4-piperidines
before and after Suzuki coupling. . . . . . . . . . . . . . . . . . . . . . . . 136
71 HMBC correlations between aromatic rings demonstrating successful Suzuki
coupling to make biaryl structure. . . . . . . . . . . . . . . . . . . . . . . . 139
72 Comparison of piperidine ring signals in the 1H NMR spectra of Boc-protected
4-piperidines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
73 Comparison of 1H NMR spectra of Buchwald-Hartwig amination products,
showing distinctive signal and chemical shift differences. . . . . . . . . . . . 143
74 HMBC correlations between piperidine signals and quinoline ring signals showing
substitution position of major Buchwald-Hartwig amination products. . . . . 145
75 HMBC correlations for C8a signal, which was not always distinctly observed in
the 13C NMR spectra of 2-aminoquinoline derivatives. . . . . . . . . . . . . 147
76 Comparison of Kd values for the previously studied phenoxy compounds tested
using NMR assays, and the novel biaryl extended 2-aminoquinoline ligands
assayed using the SPR method as part of this project. . . . . . . . . . . . . 152
77 Strongest binding 3-position extended 2-aminoquinoline ligand identified by
previous studies, and novel target compounds. . . . . . . . . . . . . . . . . 153
78 Previous synthesis of 3-position extended 2-aminoquinoline derivatives with
simple phenethyl substituents via a Horner-Emmons reaction. . . . . . . . . 154
79 Proposed amination of the 3-position extended 2-chloroquinoline derivatives,
via the previously reported method with para-methoxybenzyl amine or via the
proposed Buchwald-Hartwig amination procedure. . . . . . . . . . . . . . . 155
80 Proposed synthetic pathways for 3-position extended 2-aminoquinoline derivatives
with biaryl groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
81 Proposed synthetic pathways for simple 3-position extended 2-aminoquinoline
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
vii
82 HMBC correlations observed for 3-position substituted quinoline products of
a Horner-Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . 160
83 Comparison of 1H NMR spectra for quinoline reagent and the reaction mixture
after treatment with LiHMDS in THF. . . . . . . . . . . . . . . . . . . . . 164
84 Key HMBC correlations used to determine structure of the major product from
attempted quinoline Suzuki reaction. . . . . . . . . . . . . . . . . . . . . . 167
85 Initial target derivatives used for investigation of alternate Horner-Emmons
synthesis pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
86 Sample HMBC correlations observed for Horner-Emmons reaction products,
demonstrating success of the sequence of carbon-carbon bond forming reactions
to make the target scaffold. . . . . . . . . . . . . . . . . . . . . . . . . . . 172
87 Comparison of 1H NMR spectra for products obtained from 3-step amination
procedure, to yield 3-position extended 2-aminoquinoline products. . . . . . 179
88 Proposed synthetic pathways to yield pyridinylethyl extended 2-aminoquinoline
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
89 Comparison of 1H NMR spectra for synthesis of 2-aminoquinolines via Buchwald-
Hartwig reaction pathway. . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
90 6-Position extended 2-aminoquinoline derivatives with strongest binding affinity
for the Tec SH3 domain, as determined by the SPR assay method. . . . . . 194
91 Isomerisation of benzylidenepiperidine and tetrahydropyridine compounds. . 197
92 Target tetrahydropyridine-extended 2-aminoquinoline compounds. . . . . . 197
93 Proposed pyridine analogues of strongest binding ligands to date. . . . . . . 199
94 6-Position extended 2-aminoquinoline derivatives with alternate
electron-withdrawing functional groups. . . . . . . . . . . . . . . . . . . . . 200
95 Alternate structures of 6-position extended 2-aminoquinoline derivatives with
bridging of heteroaromatic rings. . . . . . . . . . . . . . . . . . . . . . . . 200
96 Structure of complex potential ligand, combining favourable structures identified
from SPR assays of 2-aminoquinoline derivatives with the Tec SH3 domain. 201
A-1 Example of solvent correction applied in assay runs to compensate for shift in
bulk refractive index due to addition of DMSO. . . . . . . . . . . . . . . . . 400
A-2 Example of assay sensorgrams and selected report point. . . . . . . . . . . . 400
A-3 Example of steady-state affinity analysis used to determine the Kd value. . . 401
A-4 Example of anomalous behaviour affecting accuracy of results for some
concentrations in the SPR screening assays. . . . . . . . . . . . . . . . . . . 402
A-5 Example of low response binding, giving results which are not representative
of strength of binding interaction. . . . . . . . . . . . . . . . . . . . . . . . 403
viii
List of Tables
1 Results of initial NMR chemical shift perturbation assays. . . . . . . . . . . 14
2 Fluorescence polarisation competition assay results of 2-aminoquinoline and
6-position substituted 2-aminoquinoline with the Tec SH3 domain. . . . . . 21
3 Fluorescence polarisation competition assay results of 2-aminoquinoline and
6-position substituted 2-aminoquinoline with several SH3 domains. . . . . . 22
4 Yields of diethyl 4-benzylphosphonate derivatives obtained by Michaelis-Arbuzov
rearrangement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
5 Results from synthesis of triphenylphosphonium salts. . . . . . . . . . . . . 47
6 Yields of Boc-protected 4-benzylidene piperidine derivatives obtained by Horner-
Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
7 Results of attempted hydrogenations of bromobenzylidene-extended piperidines
under standard conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
8 Results of sequential reactions of Boc-protected 4-benzylidenepiperidine derivatives
to give 4-benzylpiperidines. . . . . . . . . . . . . . . . . . . . . . . . . . . 52
9 Yields of 4-benzylpiperidine hydrochloride derivatives from three-step synthesis
via a Horner-Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . 53
10 Results of Horner-Emmons reaction with selected derivatives which give undesired
side-product. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
11 Results of attempted Horner-Emmons hydrolysis reactions of
benzylphosphonates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
12 Combined yield and (E /Z )-selectivity of Horner-Emmons reaction for synthesis
of 3-benzylidenepiperidine and 3-benzylidenepyrrolidine derivatives. . . . . . 69
13 Yields of Boc-protected 3-benzylidenepyrrolidine derivatives by Horner-Emmons
reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
14 Yields of 3-benzylpiperidine derivatives from hydrogenation and Boc-deprotection
of benzylidenepiperidines. . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
15 Yields of 3-benzylpyrrolidine derivatives from hydrogenation and Boc-deprotection
of benzylidenepyrrolidines. . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
16 Results of Wittig reactions to give pyridinyl derivatives. . . . . . . . . . . . 76
17 Yields of 4-pyridinylmethylpiperidine derivatives. . . . . . . . . . . . . . . . 77
18 Buchwald-Hartwig coupling reaction: yields of 6-position substituted
2-chloroquinoline derivatives with 4-benzylpiperidine substituent. . . . . . . . 82
19 Results of Buchwald-Hartwig coupling reactions for synthesis of target
6-position substituted 2-chloroquinoline derivatives with a
benzylpiperidine-type substituent. . . . . . . . . . . . . . . . . . . . . . . . 84
20 Results of Buchwald-Hartwig amination reactions to give 6-position substituted
2-aminoquinoline derivatives with a 4-benzylpiperidine substituent. . . . . . . 95
ix
21 Results of Buchwald-Hartwig aminations for synthesis of target 6-position
substituted 2-aminoquinoline derivatives with a benzylpiperidine-type substituent. 96
22 Results of SPR assays for 6-position substituted 2-aminoquinoline ligands. . . 119
23 Exploration of Suzuki coupling conditions for synthesis of a biphenyl-extended
piperidine derivative based upon literature Suzuki conditions. . . . . . . . . . 135
24 Yields of biphenyl-extended piperidine derivatives from Suzuki reactions. . . . 136
25 Yields of biaryl-extended piperidine derivatives from Suzuki reactions. . . . . 138
26 Yields of biaryl-extended 4-piperidine derivatives. . . . . . . . . . . . . . . . 140
27 Results of Buchwald-Hartwig amination reactions for biaryl-extended piperidine
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
28 Results of Buchwald-Hartwig amination reactions for synthesis of biaryl-extended
2-aminoquinoline derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . 146
29 Results of SPR assays for 2-aminoquinoline ligands with a 6-position biaryl-
extended piperidine substituent. . . . . . . . . . . . . . . . . . . . . . . . . 148
30 Comparison of product distribution from Horner-Emmons reaction based upon
solvent and base. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
31 Structures of potential products from Suzuki reaction, and mass identified by
HRMS analysis of crude reaction mixture. . . . . . . . . . . . . . . . . . . 168
32 Results of Suzuki reactions to yield biaryl-extended diethyl phosphonate
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
33 Results of Horner-Emmons reactions with biaryl-extended diethyl phosphonate
derivatives to give 2-chloroquinoline products. . . . . . . . . . . . . . . . . 174
34 Yields of 3-position extended 2-aminoquinoline derivatives from Buchwald-
Hartwig amination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
35 Results of amination and hydrogenation procedure and characteristic NMR
signals demonstrating successful reaction at each step. . . . . . . . . . . . . 180
36 Results of three-step amination procedure, and characteristic NMR signals
demonstrating successful removal of the para-methoxybenzyl group. . . . . . 182
37 Results of SPR assays for 2-aminoquinoline ligands with a 3-position biaryl
substituent. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
38 Results of Wittig reactions to give pyridinylvinyl-extended 2-chloroquinoline
products. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
39 Results of Horner-Emmons reactions with diethyl benzylphosphonate derivatives,
to give 3-position extended 2-chloroquinoline products. . . . . . . . . . . . . 191
40 Results of amination and hydrogenation procedure for simple 3-position phenethyl-
extended 2-aminoquinolines. . . . . . . . . . . . . . . . . . . . . . . . . . . 192
41 Results of 3-step amination procedure, and characteristic NMR signals
demonstrating successful removal of the para-methoxybenzyl group. . . . . . 192
x
42 Results of SPR assays for simple 2-aminoquinoline ligands with a 3-position
phenethyl-type substituent. . . . . . . . . . . . . . . . . . . . . . . . . . . 193
A-1 Concentrations of small-molecule ligands used for screening assays. . . . . . 399
A-2 Fitted values determined by nonlinear regression analysis. . . . . . . . . . . 401
B-1 Results of SPR assays for 6-position substituted 2-aminoquinoline ligands. . . 404
B-2 Results of SPR assays for 2-aminoquinoline ligands with a 3-position biaryl
substituent. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408
xi
List of Schemes
1 Reported synthesis of 6-position heterocyclic 2-aminoquinoline derivatives by
successive Buchwald-Hartwig aminations. . . . . . . . . . . . . . . . . . . . 29
2 General synthesis of 4-benzylidenepiperidine derivatives via a Horner-Emmons
or Wittig reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3 Example of literature synthesis of 4-benzylpiperidine derivatives by Grignard
reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
4 Literature reported synthesis of 3-benzylpiperidine hydrochloride derivatives
via Wittig reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
5 Literature reported synthesis of 3-benzylpyrrolidine hydrochloride derivative via
Wittig reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
6 Literature reported synthesis of (4-piperidinylmethyl)-pyridine hydrochloride
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
7 Literature reported synthesis of (4-piperidinylmethyl)-pyridine hydrochloride
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
8 Literature reported synthesis of (3-piperidinylmethyl)-pyridine hydrochloride
derivatives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
9 Proposed general synthesis of 4-benzylpiperidine derivatives from commercially
available benzyl halides via Horner-Emmons reaction pathway. . . . . . . . . 35
10 Synthesis of diethyl 3-methylbenzylphosphonate via the Michaelis-Arbuzov
rearrangement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
11 Proposed hydrolysis reaction of diethyl benzylphosphonate derivatives. . . . . 37
12 Synthesis of Boc-protected benzylidenepiperidine derivative via Horner-Emmons
reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
13 Result of Horner-Emmons reaction with N-Bn-4-piperidone and diethyl
3-methylbenzylphosphonate. . . . . . . . . . . . . . . . . . . . . . . . . . . 40
14 Synthesis of Boc-protected benzylpiperidine derivative via hydrogenation. . . 41
15 Synthesis of 3-methylbenzyl extended piperidine derivative via removal of the
Boc-protecting group under acidic conditions. . . . . . . . . . . . . . . . . . 43
16 Synthesis of benzylpiperidine hydrochloride derivative via Horner-Emmons reaction
and HCl-catalysed Boc-deprotection. . . . . . . . . . . . . . . . . . . . . . 44
17 General synthesis of benzylphosphonate derivatives via Michaelis-Arbuzov
rearrangment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
18 Proposed synthesis of pyridinylmethylphosphonate derivatives via Michaelis-
Arbuzov rearrangment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
19 Attempted synthesis of a pyridyl phosphonate derivative. . . . . . . . . . . . 46
20 Synthesis of pyridinylmethyltriphenylphosphonium salt derivatives in toluene. 47
xii
21 General synthesis of Boc-protected 4-benzylidenepiperidine derivatives via a
Horner-Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
22 General synthesis of 4-benzylpiperidine derivatives. . . . . . . . . . . . . . . 50
23 Attempted syntheses of 4-benzylpiperidine derivatives with bromine substituent. 50
24 Synthesis of 4-benzylpiperidine derivatives via hydrochloride salt intermediate. 53
25 Attempted Horner-Emmons reaction for synthesis of 4-benzylidenepiperidine
derivatives where production of a piperidine-type side-product was observed. 54
26 Products of Horner-Emmons reaction with N-Bn-4-piperidone and
4-cyanobenzylphosphonate. . . . . . . . . . . . . . . . . . . . . . . . . . . 58
27 Hydrogenation of isomeric products isolated from Horner-Emmons reaction. . 59
28 Deduced products of Horner-Emmons reaction with N-Boc-4-piperidone and
diethyl 4-cyanobenzylphosphonate. . . . . . . . . . . . . . . . . . . . . . . 60
29 Horner-Emmons reaction of diethyl 4-cyanobenzylphosphonate with LiHMDS
used as base. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
30 Published Horner-Emmons reaction of diethyl 4-cyanobenzylphosphonate with
potassium hydroxide used as base. . . . . . . . . . . . . . . . . . . . . . . . 63
31 Products of Horner-Emmons hydrolysis reaction with N-Boc-4-piperidone and
diethyl 4-cyanobenzylphosphonate. . . . . . . . . . . . . . . . . . . . . . . 63
32 Products of Horner-Emmons hydrolysis reaction with N-Bn-4-piperidone and
diethyl 4-cyanobenzylphosphonate. . . . . . . . . . . . . . . . . . . . . . . 64
33 Attempted Horner-Emmons hydrolysis reactions of benzylphosphonates . . . 65
34 Synthesis of benzamide-extended piperidine compound via hydrogenation of a
mixture of alkenes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
35 Synthesis of Boc-protected 4-benzylidenepiperidine via Heck reaction pathway. 67
36 Proposed synthesis of 3-benzylidenepiperidine and 3-benzylidenepyrrolidine
derivatives via Horner-Emmons reaction. . . . . . . . . . . . . . . . . . . . 68
37 Attempted 3-step synthesis of 3-benzylpiperidine hydrochloride salts via Horner-
Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
38 Attempted synthesis of Boc-protected 3-benzylidenepiperidine via Heck reaction
pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
39 Synthesis of 3-benzylpiperidine and 3-benzylpyrrolidine derivatives. . . . . . . 73
40 Attempted synthesis of a pyridinyl extended piperidine derivative via a Horner-
Emmons reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
41 Synthesis of pyridyl-extended 4-piperidine derivatives via Wittig reaction. . . 75
42 Synthesis of a 3-pyridinylmethylpiperidine derivative via Wittig reaction. . . . 76
43 Synthesis of pyridinylmethylpiperidine derivatives. . . . . . . . . . . . . . . . 77
44 Synthesis of a 3-(2-pyridinylmethyl)piperidine derivative. . . . . . . . . . . . 77
45 Attempted synthesis of 4-pyridinylmethylpiperidine derivatives via a Heck
reaction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
xiii
46 Synthesis of cinnamanilide intermediate. . . . . . . . . . . . . . . . . . . . 78
47 Synthesis of 6-bromo-2-chloroquinoline from prepared cinnamanilide via literature
method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
48 Synthesis of side product in attempted reaction of AlCl3 with cinnamanilide. 79
49 Previously reported coupling reaction of piperidine derivatives with 6-bromo-
2-chloroquinoline via Buchwald-Hartwig amination. . . . . . . . . . . . . . . 80
50 Synthesis of 6-position substituted 2-chloroquinoline derivatives via Buchwald-
Hartwig amination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
51 Synthesis of 2-chloroquinoline derivatives with a 6-position 3-benzylpiperidine
or 3-benzylpyrrolidine substituent via Buchwald-Hartwig amination. . . . . . 83
52 Synthesis of 2-chloroquinoline derivatives with a 6-position pyridinylmethylpiperidine
substituent via Buchwald-Hartwig amination. . . . . . . . . . . . . . . . . . 84
53 Attempted synthesis of a 3-benzylpiperidine extended 2-chloroquinoline derivative,
giving only 2-position coupled product. . . . . . . . . . . . . . . . . . . . . 86
54 Attempted synthesis of a 6-substituted 2-aminoquinoline derivative which gave
the 2-substituted product only. . . . . . . . . . . . . . . . . . . . . . . . . 87
55 Attempted coupling reaction of 4-benzylpiperidine and 6-bromo-2-chloroquinoline
under Buchwald-Hartwig conditions in the absence of palladium catalyst. . . 88
56 Attempted coupling reaction of 4-benzylpiperidine and 6-bromo-2-chloroquinoline
under Buchwald-Hartwig conditions in the absence of palladium catalyst. . . 88
57 Attempted modified procedure for Buchwald-Hartwig amination of
amido-substituted derivative. . . . . . . . . . . . . . . . . . . . . . . . . . 90
58 Attempted modified procedure for synthesis of 3-methoxy-substituted derivative
via Buchwald-Hartwig amination. . . . . . . . . . . . . . . . . . . . . . . . 91
59 Attempted synthesis of 3-pyridinylmethylpiperidine extended quinoline via
Buchwald-Hartwig amination. . . . . . . . . . . . . . . . . . . . . . . . . . 92
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Summary
Protein-protein interactions facilitate the formation of large multi-protein complexes which are
integral to all biological processes. Dysregulation of these processes has been implicated in
the progression of many diseases, and therefore many protein-protein interactions have been
identified as potential drug targets. Development of drugs for these non-traditional targets
has been slow, due to intrinsic difficulties in designing small-molecule compounds able to
competitively and selectively inhibit formation of the target multi-protein complexes.
Over 200 proteins containing SH3 domains are encoded by the human genome, and many have
known roles in progression of diseases including cancer, HIV, and osteoporosis. SH3 domains
bind to proline-rich regions of a protein binding partner, thereby facilitating formation of multi-
protein complexes involved in cell signalling. Targeting SH3 domains with small-molecule
drugs is considered a considerable challenge due to the large number of structurally similar
SH3 domains and the specificity of their binding interactions with protein binding partners.
Using a structure-based design approach, 2-aminoquinoline was previously identified as a
small-molecule ligand for the murine Tec SH3 domain. Further investigations demonstrated
stronger binding ligands could be achieved with extended 2-aminoquinoline structures with
largely hydrophobic scaffolds.
In order to develop more effective SH3 domain inhibitors, further investigation required
identification of stronger binding yet more hydrophilic and drug-like ligands. In this project, a
range of novel extended 2-aminoquinoline compounds were designed based upon the strongest
binding ligands identified previously. The primary investigation focused on 2-aminoquinolines
with 6-position benzylpiperidine-type substituents, and incorporation of hydrophilic structures
was prioritised in the design process. Investigation of the structure-activity relationship
and attempted optimisation of binding interactions with the protein target was explored
through modifications in the overall ligand shape. A general synthesis of the designed novel
6-substituted 2-aminoquinolines was developed using Horner-Emmons or Wittig reactions as
key carbon-carbon bond-forming steps, followed by successive Buchwald-Hartwig aminations.
6-Position extended 2-aminoquinolines with biaryl substituents were also investigated, as
biphenyl structures were previously shown to favourably interact with the target SH3 domain.
A secondary investigation into the development of 3-substituted 2-aminoquinolines with
phenethyl-type substituents was pursued to supplement previous investigations, which had
identified that these types of compounds interact favourably with the target SH3 domain. A
generalisable synthetic pathway for this range of ligands using Horner-Emmons reactions was
investigated.
The relative binding affinities of the novel ligands with the Tec SH3 domain was investigated
using surface plasmon resonance experiments. While the binding affinities of the 3-substituted
xviii
quinoline ligands was not sufficiently strong for investigation using this assay method, several
of the 6-substituted 2-aminoquinoline derivatives were found to be the strongest binding
2-aminoquinoline ligands for the Tec SH3 domain identified to date. The strongest binding
ligands contained more hydrophilic structures, demonstrating that development of effective
drug-like inhibitors for the SH3 domain is feasible.
The results indicated several areas for further investigation which could yield stronger binding
SH3 domain ligands. Furthermore, the effectiveness of the design strategies employed in this
project provides insight into the methodology and principles which may aid development of
inhibitors for a vast range of challenging protein targets.
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1.1 Protein-protein interactions as drug targets
Interactions between proteins to form large multi-protein complexes are integral to cellular
processes. These protein-protein interactions (PPIs) govern all important cell functions
including apoptosis, proliferation, growth and development, however deregulated pathways
involving PPIs are implicated in the progression of many diseases.1,2 This has led to the
identification of many key PPI targets for drug development, and consequently PPI inhibitors
are being developed for many therapeutic purposes.3,4,5
1.1.1 Challenges of PPI therapeutic design
Although the need for PPI inhibitors is well recognized, the development of small molecules
to bind to the proteins encounters significant challenges due to the nature of the binding
interactions. The interactions of the proteins to form multi-protein complexes do not typically
occur through deep or distinct complementary binding pockets, and instead the strength and
selectivity of the interactions is the result of many smaller favourable interactions over a large
surface area on the exterior of the protein structures.
Traditional drug targets, such as enzyme active sites, typically contain deep binding pockets
in the protein structure which can conveniently bind small molecules with a high density
of functional groups facilitating a strong binding interaction. In contrast, the surfaces of
proteins involved in PPIs do not generally contain distinctive features to enable strong binding
interactions. The surfaces are largely hydrophobic and comparatively flat, and opportunities
for hydrogen bonding or other strong polar interactions are limited and dispersed over a larger
area. Instead, a small-molecule inhibitor must compete with a large protein for binding on
the hydrophobic surface where there are not sufficiently strong features that can be targeted
by a much smaller molecular structure.
Methods for detection of binding regions are often incapable of identifying strong features
or potential binding interactions, and the development of a small-molecule drug which can
interact with several binding regions while still maintaining favourable bioavailability is a
further challenge. Small molecules are typically preferable from a drug design perspective, as
they are more likely to have sufficient membrane permeability and resistance to hydrolysis.
Compared to peptide-based drugs, small molecules are more likely to be effective and reach
the intended cellular target when administered orally, which is the preferred drug delivery
method.
The typical methods used to identify lead compounds for drug targets, such as high-throughput
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screening of small-molecule compound libraries, have proven ineffective when applied to PPI
targets.6 Alternate methods are instead required to identify and optimise small-molecule
ligands for PPI targets. Design and development of PPI inhibitors has therefore required
a much more considerable investment of time and resources compared to the high-throughput
methods for conventional drug targets.
1.1.2 Progress in development of ligands for PPIs
Despite the challenges and time investment required, the increasing number of PPI inhibitors
in development demonstrates that it is possible for small molecules to favourably bind to these
protein surfaces in at least some select instances.
In some cases a structural feature of one of the protein-protein interaction partners can be
imitated by a non-peptide small molecule, thereby giving a competitive lead compound which
can be further optimised and lead to a stronger binding inhibitor. The p53-MDM2 protein-
protein interaction has been a well-studied target for potential anti-cancer drugs due to the
known role of MDM2 in suppressing the anti-tumour activity of p53. This interaction was
considered an attractive target because the binding of p53 was found to be largely mediated
by three key hydrophobic residues, and therefore a non-peptide structural mimic (RG7112,
Figure 1) was developed as a potential competitive inhibitor of the p53-MDM2 interaction.7,8
RG7112 was the first MDM2 inhibitor to progress to human clinical trials, and demonstrated



























Figure 1: Small-molecule inhibitors of protein-protein interactions. RG7112: inhibitor of p53-MDM2
interaction, currently progressing though clinical trials.7 Venetoclax: approved by the FDA in 2016 for
treatment of chronic lymphocytic leukaemia, by targeting protein-protein interactions of BCL2.10
For many other PPI targets, however, a suitable well-defined short peptide sequence could
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not be readily identified or adapted by a small non-peptide structure. In cases where the 3D
structure of the protein target and the binding region are known, an alternate structure-based
approach from fragment screening has been effectively utilised to design competitive small-
molecule inhibitors. Venetoclax (Figure 1) was the first small-molecule PPI inhibitor designed
by fragment screening to successfully progress through clinical trials and drug approval
processes, and is now an orally administered medication used in the treatment of chronic
lymphocytic leukaemia.10
Despite the success of Venetoclax and several other small-molecule PPI inhibitors currently
progressing through clinical trials, the wider research and development of therapeutics
targeting PPIs is still slow and challenging. The PPI inhibitors which are reaching clinical
trials, however, tend to have very different structural characteristics when compared to typical
small-molecule drugs. Higher molecular mass (>500 Da), largely hydrophobic scaffolds, cyclic
structures, and low density of charged or polar functional groups are some of the key differences
found to be characteristic of small-molecule PPI inhibitors. These characteristics reflect the
structure of the target PPI binding surfaces, which are also relatively flat, hydrophobic, and
lacking in well-defined structural features (such as hydrogen-bonding opportunities) which
could be targeted in traditional drug design.
Based on assessment of protein-protein interaction interfaces and current development of PPI
inhibitors, it has been predicted that successful compounds are required to access at least
three sub-pockets on the binding surface in order to achieve a sufficient favourable binding
interaction.11 As a result, PPI inhibitors will tend to be larger structures than those targeting
more traditional targets like enzyme active sites, which have more defined pockets and a
higher density of potential binding interactions in one site which can be conveniently targeted
by a small molecule.
The different characteristics of PPI binding surfaces means established methodologies for
drug identification and development are ineffective. In cases where a competitive small-
molecule mimic of the native binding partner cannot be readily developed, other methods
are required to identify a lead compound. High-throughput compound screening libraries are
typically used to rapidly find a lead compound for protein drug targets, but these libraries
contain simple small molecules with a high density of functional groups, which are typical
structures for targeting deep binding pockets in a protein structure but are not sufficient to
register a binding interaction for PPI binding surfaces. Some work is progressing on developing
compound libraries with larger and more structurally complex molecules specifically designed
to increase the number of hit compounds identified in high-throughput screening for PPI
targets, particularly taking advantage of complex and interesting natural products structures.
Given the increasing number of 3D structures of protein complexes, however, a computational
approach to fragment or compound screening is also becoming increasingly viable. As more
PPI inhibitors are developed, the successes improve understanding of the requirements to
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competitively inhibit protein-protein interactions and enable more effective inhibitor design.
1.2 SH3 domain structure and function
The SH3 domain is a non-catalytic protein domain which binds specifically to proline-rich
peptide sequences of proteins to form large multi-protein complexes which are involved in many
signalling pathways.12 Signalling pathways involving SH3 domain interactions have functions
including regulation of cell growth, cell proliferation and immune responses.13 The deregulation
of these signalling pathways has been implicated in the progression of diseases including
cancer and osteoporosis, making many SH3 domains highly attractive targets for design of
therapeutics.14
Proteins containing SH3 domains are very common in living organisms and SH3-like domains
have also been found in bacteria, indicating the wide range of their utility in biological
processes.15,16 The 3D structures of SH3 domains are very similar due to key conserved
peptide sequences or ’motifs’ which dictate the overall structure and binding site (Figure
2). The human genome encodes over 200 proteins containing SH3 domains, with several
containing multiple SH3 domains.17 Many of these proteins also contain catalytic protein
domains to assist in the protein’s role but others, such as Grb2 and Nck, are adapter proteins
which contain only non-catalytic sequences and function only to build multi-protein complexes
though connections between PPI domains.18 The Src family of kinases all contain SH3 domains
which are among the most studied due to the known roles of Src kinases in disease.
Figure 2: Sequence alignment of murine Tec SH3 domain with selected human SH3 domains. Key
conserved motifs known to be important for binding have been indicated. Alignment of sequences was
assisted by SMART domain analysis tool.19
Although SH3 binding is known to be involved in signalling pathways for many biological
processes, the roles and mechanics of the SH3 domain binding specifically are generally not
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well studied or understood.20 Identification and development of ligands for SH3 domains has
been identified as a possible method for studying their roles, however due to the challenges
of targeting PPIs the development of suitable inhibitors has been slow.
1.2.1 Tec family kinases
The Tec family of tyrosine kinases comprises five members — Tec, Btk, Itk, Bmx and Txk/Rlk
— which are predominantly expressed in hematopoietic tissue.21 The family of kinases have a
common domain sequence, and from the N-terminus Tec kinases contain pleckstrin homology
(PH) and Tec homology (TH) domains followed by the non-catalytic SH3 and SH2 domains
and a catalytic kinase domain (Figure 3).22 The presence of a PH domain is unique amongst
all families of tyrosine kinases and through binding this domain facilitates localisation of the
protein to the cell membrane, although Txk/Rlk does not contain a PH domain and instead
binds to the cell membrane through a cysteine peptide sequence.23 The kinases typically
contain a proline-rich region adjacent to the SH3 domain, resulting in an intramolecular binding
interaction which suspends the kinase in an inactive state and controls binding of the SH3
domain to other ligands.24 The kinases generally become activated through binding to the cell
membrane and phosphorylation by an Src family kinase, which potentially changes the activity
of the SH3 domain and reduces the potency of the intramolecular binding interaction.25
CN PH TH SH3 SH2 kinase domain
Btk PRR
Figure 3: Representation of the domain sequence of mouse Tec protein, which is illustrative of the typical
domain structure of the Tec family kinases. The TH domain contains Btk and proline-rich regions.
The Tec family of kinases are known to have involvement in signalling pathways regulating
immune responses, including mediation of T-cell and B-cell activity.25 Btk kinase is specifically
involved in mediation of B-cell processes, and anticancer drugs that reduce the proliferation of
B-cells by inhibiting the activity of Btk kinase have been developed.26 Tec kinase is necessary
for B-cell proliferation and can compensate for inhibition of Btk kinase, indicating that their
roles have some overlap.27 In T-cells, the Tec protein is able to bind through its SH3 domain
to the proline-rich region of CD28 and thus stimulates CD28 signalling pathways which assist
in full T-cell activation.28
Tec kinase also has an important role in inflammatory response to infection. Tec protein
regulates the production of cytokines in response to fungal infection but activity of Tec kinase
has no effect on response to bacterial infection.29 Inhibition of Tec kinase in animal models
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decreased the inflammatory response to fungal infections and thus dramatically reduced the
mortality rate due to hyper-inflammation and fungal sepsis, indicating a potential therapeutic
use of Tec inhibitors.
1.2.2 SH3 domain structure
The structure and binding of various SH3 domains has been studied using various methods
including NMR spectroscopy and X-ray crystallography. While the vast majority of SH3
domain structures are yet to be fully investigated, derived structures identified to date
demonstrate a high degree of structural similarity. Amongst SH3 domains there is a moderate
amount of primary sequence conservation, however the core hydrophobic sequences and
residues are the most conserved and lead to stability of the common SH3 domain structure.15
The solution structure of the murine Tec SH3 domain was determined using NMR spectroscopy
and the overall structure is consistent with other known SH3 domains (Figure 4).30 The murine
Tec SH3 domain contains 60 peptide residues which form a β-barrel structure comprised of
two anti-parallel, three-stranded β-sheets at right angles to each other in a formation referred










Figure 4: A: Solution structure of murine Tec SH3 Domain, indicating the β-strands forming the two
β-sheets (indicated in purple and blue) and the 310 helix (indicated in green), and B: surface representation
highlighting residues found to shift upon binding to proline-rich peptide binding partner, indicating binding
region (blue). PDB ID: 1GL5.30
The β-sandwich structure forms a hydrophobic core surrounded by conserved aromatic residues
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between the RT and n-SRC loops. Studying changes in NMR shifts upon binding to a peptide
ligand demonstrated that this hydrophobic surface region forms the ligand binding site. The
binding site is a shallow indentation on the protein surface containing three binding pockets:
the first two pockets contain highly conserved hydrophobic residues which selectively bind
to proline-rich peptides, and the third pocket is surrounded by residues of the RT and nSrc
loops which are less conserved and bind to charged residues of the ligand, thus establishing
specificity amongst ligands.
Particular conserved sequence motifs in SH3 domains have been found to be important for
interactions with ligands: the ALYDY motif in the RT loop, PXXY motif in the 3 10 helix
and the core WW motif surround the binding site and enable the selectivity for proline-rich
ligands.15 Hydrogen bonds with ligands can be formed with some residues, including the
tryptophan residues and the tyrosine of the PXXY motif, which increase the strength of the
binding interaction and improve selectivity. The low sequence conservation in the RT and
n-Src loops surrounding these motifs in the binding site can be potentially exploited to improve
the selectivity of ligands.
1.2.3 Native SH3 domain ligands
SH3 domains selectively bind to proline-rich sequences in their protein binding partners, which
enables formation of the large multi-protein complexes involved in cell signalling pathways.
Proteins containing a proline-rich region with two proline residues separated by two amino
acid residues (referred to as the PxxP motif) are readily accommodated by the SH3 domains.
These peptides form a polyproline type II (PPII) helix containing three residues per turn, which
aligns the proline residues on one edge of the helix. The specificity of the interaction between
SH3 domains and PxxP motifs is due to the two xP sequences aligned on one side which
favourably interact with the two hydrophobic binding pockets of the SH3 domain binding
site (Figure 5).31 The proline-rich peptides are separated into two classes, each of which
form a PPII helix but the two classes of ligands bind in opposite orientations depending on
the position of a charged residue, usually arginine, which is identified by the third binding
pocket. Class one sequences have the form [R/K]xxPxxP and class two sequences have the
form PxxPx[R/K].32
In addition to these consensus PxxP ligands, atypical proline-containing motifs are also
recognised by some SH3 domains. The protein Eps8 binds to peptides containing a PxxDY
motif, and the cortacin SH3 domain binds to RxxPxxxP peptides.33,34 In both of these cases
the proline residue was found to be essential to the binding of the ligand. Some SH3 domains
have also been found to bind to non-proline containing peptides or bind through hydrophobic
interactions that require no particular peptide motif, for example the binding of ubiquitin to
















Figure 5: Binding orientations of Class I and Class II polyproline type 2 helices accommodated by shallow
binding grooves of SH3 domain (shown in green). Image adapted from Mayer.31
Approximately 25% of human proteins contain proline-rich sequences, which provides a large
array of possible ligands for SH3 domains.36 Despite this, it has been found that SH3
domains can be very selective for a particular peptide sequence in their native environment.36
The proline-rich region of Pbs2 protein in yeast is selective for the Sho1 SH3 domain and
will not bind to any of the other 27 yeast SH3 domains.37 SH3 domain selectivity is also
found in humans despite the large number of proteins containing SH3 domains. A selective
interaction and the tightest natural ligand-SH3 interaction found is between the Nef protein,
which contains a proline-rich region, and the Hck SH3 domain (Kd = 130 nM), with the
strong binding attributed to additional hydrophobic interactions with RT loop residues.38
Other SH3 domains, such as in PAK2, bind to many different proteins. The binding affinity
does not necessarily indicate selectivity, and most SH3 domain-peptide ligand interactions
exhibit binding with moderate to weak affinity (typical dissociation constants are Kd = 1
– 200 µM) but even comparatively weak interactions can show high selectivity in vivo, and
additional interactions outside the consensus PxxP motif improve the strength of the binding
interaction.39,40,41 Aside from sequences and favourable peptide interactions over a large
surface area, other factors can also assist the selectivity of the interactions. For example,
localisation of the protein may limit the number of potential partners, as Src kinases are
anchored to plasma membrane and therefore only interact with other proteins in the same
environment.14
SH3 domains are considered particularly challenging as therapeutic targets, even compared
to other protein-protein interaction targets. The particular issues of developing of a selective
and competitive drug-like inhibitor for a target SH3 domain is considered an intimidating
prospect due to the characteristics of SH3 domains, and they have even been referred to as
’undruggable’ targets.42,43
Competition challenge
The strength of the interactions of SH3 domains with their binding partners is due to the
binding of the proline-rich peptide region with the hydrophobic binding grooves, and then
further contacts with the larger binding surfaces over a large area. Effective drug compounds
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need to be smaller while still making sufficient favourable binding interactions for a strong
binding affinity. The SH3 domain surfaces are relatively flat and hydrophobic and don’t
contain close structural features which could readily be targeted by a smaller drug, due to a
low density and high dispersion of any identifiable hydrogen-bonding opportunities or deeper
pockets. It is therefore not considered feasible that a compound smaller than a protein or large
peptide would be able to bind to an SH3 domain with a sufficiently strong binding affinity to
disrupt interactions with the native binding partner proteins.
Selectivity challenge
Due to the overall conserved 3D structure and amount of sequence homology shared between
SH3 domains and specifically the hydrophobic sequences forming the binding surface, the
idea that a small ligand could be designed to interact selectively with only one SH3 domain
is an ambitious and challenging proposition. While selectivity for SH3 domain interactions is
observed in nature, this is again achieved by many small interactions over a larger surface area
of the protein structures, which, so far, has not been possible to mimic with a small drug-like
compound.
1.3 Development of ligands for SH3 domains
1.3.1 Peptide-based SH3 domain ligands
Substantial investigation and modification of peptides containing the core PxxP binding motif
has been explored in order to develop more potent ligands for the SH3 domain of Src kinase.
Using a combinatorial library approach, the peptide motif necessary for Src kinase binding was
found to be RPLPPLP (Kd = 17.7 µM).44 Addition of further amino acid residues VSLAR
to the N-terminus of the peptide was able to target the specificity pocket and resulted in
increased binding affinity compared to the core motif (Kd = 0.45 µM).45
Development of ligands using non-natural amino acids has given significant improvements in
both binding affinity and selectivity for SH3 domains. Replacement of the proline residues
of the consensus ligand motif with non-natural N-alkyl substituted amino acids was found
to retain or improve the binding affinity of the ligands with SH3 domains, indicating that
the selectivity of SH3 domains for proline-rich peptides is due to proline’s unique structural
characteristics as the only naturally occurring N-substituted amino acid.46 Sequences
containing N-substituted glycines mimic the backbone structure of the proline-rich peptide
and the side-chains can be modified to improve the interactions with the SH3 binding site
which has lead to the development of peptide-peptoid ligands with significantly stronger
binding affinity. Specificity for SH3 domains could also be achieved using this approach, and
a peptide-peptoid ligand (1) was identified which bound to the Grb2 SH3 domain with strong
9




























Figure 6: Reported peptide-peptoid ligands for SH3 domains.39,47
Metallopeptide inhibitors derived from known peptide ligands for SH3 domains have recently
been developed as more potent inhibitors with improved selectivity and biological stability
compared to peptide ligands. By addition of a dirhodium core, interactions with non-
conserved histidine residues near the binding site of SH3 domains can be targeted which
lead to significantly stronger binding than the peptide ligands.47 A metallopeptide ligand (2)
was developed that bound to the Lyn SH3 domain with strong binding affinity (Kd = 6 nM)
and showed weaker interactions with other Src family SH3 domains (Figure 6). Strong binding
to other Src family kinases and a non-Src family kinase (Abl) SH3 domain was achieved by
selective positioning of the rhodium to facilitate metal coordination to non-conserved histidine
residues, showing the potential of this approach in developing targeted and possibly selective
inhibitors of SH3 domains.
The development of peptide and peptide-peptoid ligands has been useful in investigation of
the binding model of SH3 domains, and these ligands may achieve strong binding affinity and
some specificity in their interactions, however their use as therapeutics is limited. Peptide
drugs have difficulty reaching their target due to degradation by proteases and acids in the
stomach if ingested, and may still be unable to cross the cell membrane if injected. Non-
peptide drugs are considered more likely to be readily delivered to the target. An entirely
peptoid or non-peptide SH3 domain ligand would be resistant to proteases and would be
more likely to be membrane permeable, however none have yet been developed.
1.3.2 Development of Small-Molecule SH3 Ligands
While most successful inhibitors of SH3 domain interactions have been peptide or peptide-
based ligands, some studies have investigated the potential of small-molecule compounds to
disrupt the activity of SH3 domain containing proteins. These typically target the kinase
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domain of the protein or form covalent bonds to prevent phosphorylation, rather than directly
targeting the SH3 domain to prevent a binding interaction with a partner protein. The small-
molecule drug UCS15A (Figure 7) was the first reported non-peptide ligand to successfully
inhibit SH3 domain mediated PPIs and disrupted signalling of the Src kinase in yeast-based
assays.48 Although UCS15A was shown to disrupt the binding of the Src kinase SH3 domain
to the proline-rich region of Sam68 protein, this inhibition of the protein-protein binding was
subsequently determined to be due to interaction with the proline-rich binding region of the








Figure 7: Structure of UCS15A, a small molecule found to regulate protein-protein interactions of the Src
kinase SH3 domain with the Sam68 protein.48
Development of small-molecule ligands to directly target the SH3 domains of proteins would
enable important investigations into the roles of proteins and PPIs in signalling pathways, and
could lead to the discovery of effective therapeutics for PPIs which are currently considered
’undruggable’. Small molecule ligands for SH3 domains may also have the potential to be
more selective inhibitors and have more favourable biological availability compared to the
peptide-based ligands, making them more effective therapeutic compounds and more useful
in biologically relevant studies.
1.4 Structure-based design of ligands for an SH3 domain
Given the current availability of structural information for many SH3 domains, structure-
based ligand design is an increasingly viable option to develop higher affinity ligands that
compete for the binding site. To design effective small-molecule ligands using this approach
the structure solution of the target SH3 domain must be known, and the target SH3 domain
and a known proline-rich peptide binding partner must be available for experimental binding
and competition studies to quantitatively compare strength and efficacy of the small-molecule
ligands. The murine Tec SH3 domain was identified as a feasible target for targeted design of
small-molecule inhibitors as the solution structure of the SH3 domain was known (see Figure
4A, Section 2.2) and a suitable proline-rich peptide was known to bind to the SH3 domain
and could therefore be used for competition assays.50
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Given the structural information of the Tec SH3 domain, LUDI software was used to design
small molecules which would be expected to competitively bind to the SH3 domain binding
surface, at the same position as the native binding partners (Figure 8).50 The software
identifies potential favourable binding interactions on the protein target site and fits small
molecular fragments to maximise the interactions, such as fragments optimising hydrogen
binding opportunities and filling hydrophobic pockets with hydrophobic fragments. Proximity
of these fitted fragments is then assessed, and several close fragments are chosen and then









Figure 8: Fragment-based screening method using LUDI software, for identification of lead compounds
predicted to bind to murine Tec SH3 domain.50,51
Of the simple compounds proposed by the software, 2-aminoquinazoline 3 was identified
as a chemically suitable compound for experimental testing. This compound and a range
of structurally similar compounds, including 2-aminoquinoline, were initially investigated as
potential Tec SH3 domain inhibitors (Figure 9). In order to determine the lead compound an





Figure 9: Small molecule compounds initially investigated as potential ligands for the Tec SH3 domain.50
1.4.1 Measurement of relative binding affinity of ligands
Protein-Ligand Binding Assays: NMR chemical shift perturbation experiments
NMR chemical shift perturbation assays were used to determine the relative binding affinities
of the potential Tec SH3 domain ligands. This assay method uses [1H,15N]-HSQC experiments
to measure the difference in chemical shifts observed for the uniformly 15N-labelled Tec SH3







Figure 10: Example [1H,15N]-HSQC spectrum overlay showing shifts of binding residues in NMR chemical
shift perturbation assays. Example is binding experiment of 2-aminoquinoline with Tec SH3 domain.
Reprinted with permission from Inglis et al., 2004.50 Copyright 2004 American Chemical Society.
For a protein in equilibrium with its protein-ligand complex, the equilibrium dissociation binding












When the concentration of free protein and protein-ligand complex are equal ([P] = [PL]),
then Kd is equal to the ligand concentration ([L]). From this, the Kd value referred to in
this work is the ligand concentration when half the saturation binding sites of the protein are
occupied, and this Kd is used as a measure of the relative binding affinity of a protein target
and the ligand. The value can be compared to different complexes to determine the relative
strengths of the binding interactions as a lower Kd value implies a stronger binding affinity of
the protein and small-molecule ligand.
Determination of the Kd value via analysis of the [1H,15N]-HSQC experiments is only feasible
if the ligand is in fast exchange with the protein-ligand complex on the NMR experimental
timescale. If the ligand is in slow or intermediate exchange with the protein-ligand complex
on the NMR timescale then the signals are broadened and the precise positions cannot be
determined, and therefore the binding isotherm cannot be generated. However, if a ligand is
in slow exchange with the complex, NOE build-up and transfer can occur between the ligand
and protein which can be used to determine the 3D structure of the protein-ligand complex.
The 3D structure would give valuable insight into the binding model of the ligand and give
information which could lead to much more effective ligand design, and therefore a strongly
binding small-molecule ligand which binds in slow exchange on the NMR timescale is the
ultimate goal.
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From the [1H,15N]-HSQC experiments of the ligand and labelled protein, the chemical shift
difference for signals which shifted significantly upon binding (typically ∆δH > 0.1 ppm) was
normalised and plotted against the ligand concentration to generate a binding isotherm, and








A Upfield δH shift
Downfield δH shiftB
Figure 11: Example analysis of NMR chemical shift perturbation experiments. A: Binding isotherm for
signficantly sifted residues upon binding to the ligand, used to determine the equilibrium dissociation
binding constant, Kd. B: Mapping of shifted residues onto the Tec SH3 domain structure. Example is
binding experiment of 2-aminoquinoline with Tec SH3 domain.50
Using the NMR chemical shift perturbation experiments, 4 was found to bind to the Tec SH3
domain with a moderate binding affinity (Kd = 125 µM), and had a stronger binding affinity
than 3 (Table 1).








Further information about the position of the binding interaction can also be obtained via
this assay method. Residues which have an observed change in chemical shift as the ligand
is added are therefore affected by the the binding interaction and likely near the binding site,
thus the key binding residues can be identified directly from the NMR spectra and mapped
14
onto a 3D model of the SH3 domain to give structural information of the protein-ligand
complex (Figure 11B).
For both molecules similar shifted peaks were observed which corresponded to residues in the
binding site specified in the LUDI ligand design, indicating both ligands bind to the same key
residues as the native binding ligands and may be competitive inhibitors.
1.4.2 Investigation of 2-aminoquinoline binding model
The binding model of 4 with the Tec SH3 domain was investigated using site-directed
mutagenesis experiments and analysis of the NMR chemical shift perturbation assays to assist
further development of ligands.
The NMR shift perturbation experiments showed a significant upfield shift in the signal
corresponding to the indole N-H of the W215 residue of the protein. This indicated there
was likely a π − π stacking interaction between the W215 residue and the aromatic system
of 4, and therefore the quinoline ring was important for binding of the ligand to the Tec SH3
domain.
This interaction was not sufficient to explain the moderate binding affinity of ligand 4 as other
aromatic ligands had weaker binding affinity, and therefore site-directed mutagenesis studies
were used to identify residues necessary in the binding site for a moderate binding affinity to
be observed. These studies identified a nearby aspartic acid residue, D196, was also essential
for ligand binding. It was proposed that the formation of a salt-bridge between the D196
residue and the 2-aminoquinoline core structure occurs simultaneously with the W215 π − π














Figure 12: Proposed binding model of 2-aminoquinoline with Tec SH3 domain.50
These two key binding interactions result in a moderate binding affinity for ligand 4. To
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develop a ligand with a strong binding affinity additional favourable interactions with the
binding surface were required and, as previously mentioned, optimisation of 3 - 5 interactions
with the protein binding surface has been identified as necessary for effective PPI inhibitors
discovered to date. In further development of 4 ligands for the Tec SH3 domain, further
information on the binding surface can be obtained by strategically extending the ligand
core with functional structures and using assay methods to determine the impact upon the
binding affinity. While the exact structure of the protein-ligand binding surface cannot be
determined without strong binding or slow exchange of the ligand, NMR chemical shift
perturbation assays can provide information on the nature of further interactions by mapping
the change in shift onto the SH3 domain structure, giving valuable information on the
proximate residues which can be targeted and how the ligands can be further optimised
to exploit favourable interactions.
Using the proposed binding model of 4 and the structure solution of the Tec SH3 domain,
several residues near the ligand binding site were identified as possible target contacts to
further improve binding of the ligand (Figure 13). It was predicted that 6-position extended
2-aminoquinolines could potentially interact with the hydrophobic L213 residue and the
hydrophilic residues N211, D212 and H214. On the other side of the binding site, it was
predicted that N-substituted 2-aminoquinolines could also make further contacts with



























Figure 13: Proposed extended binding model of 2-aminoquinoline in Tec SH3 domain binding site, showing
neighbouring residues for possible further interaction.52
1.4.3 Development of 2-aminoquinoline derivatives with increased binding affinity
for SH3 domain
Based upon this understanding of the binding surface, a range of 2-aminoquinoline derivatives
were designed, synthesised and assayed to probe the potential interactions on the binding
surface. An investigation into N-alkylated 2-aminoquinolines indicated that these compounds
bind to the SH3 domain as one of two possible rotamers, one of which is in the incorrect
orientation to form a salt bridge with the aspartic acid D196 residue, and so a significant
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reduction in binding affinity was observed (Figure 14).53 N-Benzylated derivatives (for example
5) recovered some of the loss in binding affinity and gave a twofold increase in binding affinity
relative to the N-methylated derivative 6, possibly due to an additional lipophilic interaction
with the binding surface (Figure 15). None of the N-substituted derivatives bound with
comparable binding affinity to the lead compound 4. From these results it was determined
that the essential interaction with the D196 residue was best facilitated by retaining the non-
substituted 2-amino group. The identification of a potential favourable lipophilic interaction
with benzyl substituents at this position was promising, but could potentially be explored
further by alternate 2-aminoquinoline substituents rather than compromising optimisation of











Figure 14: Proposed binding model of N-substituted 2-aminoquinoline derivatives with the D196 residue in






Kd = 193 µM Kd = 380 µM
Figure 15: N-Substituted-2-aminoquinoline derivatives tested for binding with the Tec SH3 domain.53
Substitution at each position of the quinoline ring has been investigated with varied impacts
upon binding affinity. The binding affinity of 5-substituted 2-aminoquinolines was similar
to that of 4 and the range of substituents tested gave no observable difference in binding
interactions, which supported the model’s prediction that substituents at this position are
directed away from the protein binding surface and therefore make no additional contacts to
improve the binding interaction.54 One ligand was found to exhibit improved binding affinity,
possibly through formation of a hydrogen bond with a nearby residue.
Introduction of a substituent at the 7-position of the 2-aminoquinoline ring was generally
not tolerated in the binding site and resulted in reduced binding affinity, indicating that
substituents were directed into the protein surface resulting in steric clashes which hindered the
optimal interaction with key binding residues on the protein surface.54 Similarly, addition of a
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tolyl subsitutent at the 4-position was not tolerated, again potentially due to steric hindrance,
although a methyl substituent enabled some improvement in binding affinity. These results
indicated a small or more flexible substituent may be better tolerated and make additional
favourable contacts from the 4-position of 2-aminoquinoline, although this has not been
investigated further (Figure 16).55
N NH2 N NH2
7 8
Kd = 65 µM Kd = 350 µM
Figure 16: Structures of 4-substituted 2-aminoquinolines tested for binding with the Tec SH3 domain.55
The most significant improvements in binding affinity have been achieved by addition of
substituents at the 3- and 6-positions of 2-aminoquinoline. It was postulated that substituents
at the 3-position may potentially access the same interactions that gave improved binding
affinity for N-benzylated derivatives. While addition of a phenylethyl substituent was not
found to impact binding (ligand 9), adding substituents at the para-position of the ring was
found to improve binding. Addition of a large t-butyl group (ligand 10) gave the greatest
improvement in binding, likely due to favourable hydrophobic interactions with the protein
surface (K d = 40 µM, Figure 17).56
N NH2 N NH2
9 10
Kd = 128 µM Kd = 40 µM
Figure 17: Structures of 3-substituted 2-aminoquinolines used to investigate additional binding
interactions.56
Substitution at the 6-position of the 2-aminoquinoline was also found to increase contacts with
the protein binding surface and improved the binding affinity relative to the lead compound 4,
giving the most successful small-molecule SH3 domains ligands to data. The 2-aminoquinoline
derivative 11 with an acetal group at the 6-position of the 2-aminoquinoline showed
significantly improved binding affinity (Figure 18, K d = 22 µM), however acetals, including
18























Kd = 28 µM Kd = 9 µM
Figure 18: Structures of 6-position heterocyclic substituted 2-aminoquinoline derivatives found to access
additional binding interaction, and structure of 6-position extended 2-aminoquinoline 15, with the strongest
binding to date.52
To develop a ligand with better stability to optimise these favourable binding interactions, a
series of 6-position heterocyclic 2-aminoquinolines were synthesised and tested for binding with
the Tec SH3 domain (some results shown in Figure 18). This work identified that addition of a
piperidine or piperazine substituent increased the strength of the ligand’s binding interaction
with the Tec SH3 domain compared to 4, potentially by the same binding interaction as
the acetal 11. In particular, several 4-piperidine substituents were tested and observed to
give lower Kd values. The best results were seen with a benzyl substituent, as with both
piperidine and piperazine rings it was observed that the large substituent (ligands 13 and
15) further improved the strength of the binding interaction over heterocycles with just a
methyl group (ligands 12 and 14, Figure 18).52 The 2-aminoquinoline derivative 15 with a
4-benzylpiperidine substituent was the strongest binding Tec SH3 domain ligand identified.
Chemical shift mapping of 15 demonstrated that additional residues were shifted in the
NMR binding assay, indicating that a hydrophobic binding interaction of the benzylpiperidine
substituent and the protein surface was contributing to the stronger binding interaction.
The addition of aryloxymethyl substituents at the 6-position of 2-aminoquinoline was also
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investigated.57 While these substituents showed promising results in the improvement of
binding affinity for the Tec SH3 domain (comparable to the strongest binding 6-heterocyclic
substituted derivatives, Figure 18), the binding interactions of the ligands with the Tec
SH3 domain was demonstrably different in the NMR assays (Figure 19). Compounds 16a
and 16b both demonstrated strong binding interactions with the SH3 domain, but the
results from NMR binding assays indicated that this was due to multiple favourable binding
interactions between the ligand’s functional groups with the protein binding surface but that
these interactions could not be simultaneously accessed. Instead, the observations indicated
that the biphenyl group or the core 2-aminoquinoline structure could favourably interact
with the protein surface, and the ligand alternated binding between the competing sites.
It was hypothesised that the rigid structures and constrained overall shape of the molecule







Kd = 8 ± 3 µM* Kd = 7 ± 2 µM
Figure 19: Structures of 6-position aryloxy substituted 2-aminoquinolines found to strongly interact with
the Tec SH3 domain but with atypical binding interactions.57 *16a was assayed as a 7:1 mixture with 16b.
1.4.4 Progress towards selective and competitive SH3 domain inhibitors
Addition of substituents to the 2-aminoquinoline ring has resulted in significant improvements
to the binding affinity for the Tec SH3 domain, and made additional favourable contacts with
the protein binding surface. Some experiments were also undertaken to investigate whether
these small-molecule ligands also had potential to overcome the key competition and selectivity
challenges of drugging SH3 domains which have led some to call them ’undruggable’ targets.
Fluorescence polarisation assays were used to investigate whether the 2-aminoquinolines could
displace a proline-rich peptide from the Tec SH3 domain binding surface (Table 2)50,53.
The concentration of lead compound 4 required to displace half of the bound proline-rich
peptide from saturated Tec SH3 domain was determined to be EC50 = 160 ± 35 µM.50
The assay results indicated that even this small compound with a moderate binding affinity
would compete with a proline-rich peptide for the SH3 binding site, and also demonstrates
that the small-molecule compound interacts directly with the same residues on the binding
surface that would bind to a proline-rich peptide binding partner, as targeted and predicted
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in the computational design of ligands. The competition assay for a 6-position extended
2-aminoquinoline derivative (17) demonstrated further improved results, showing that further
extended 2-aminoquinolines may overcome the competition challenge and be effective
competitive inhibitors of SH3 domain.
Table 2: Fluorescence polarisation competition assay results of 2-aminoquinoline and 6-position substituted
2-aminoquinoline (17) with the Tec SH3 domain.50
Compound EC50
N NH2





17 26 ± 6 µM
The other significant challenge for small-molecule inhibitors of SH3 domains is achieving
selective binding to one of over 200 human proteins containing SH3 domains, which is
considered particularly challenging given the highly conserved structure and sequence homology.
For the 2-aminoquinoline ligands, it was known that the binding affinity is primarily due to
the formation of a salt-bridge with an aspartic acid residue, and stacking with a tryptophan
residue. These two residues are highly conserved amongst human SH3 domains (Figure 20).
Figure 20: Sequence alignment of murine Tec SH3 domain with selected human SH3 domains. The
conservation of the tryptophan and aspartic acid residues known to be important for binding of
2-aminoquinoline ligands to the Tec SH3 domain has been indicated. Alignment of sequences was assisted
by SMART domain analysis tool.19
Aside from these two residues and other highly conserved sequences (see Figure 2), there are
regions with a lower degree of sequence conservation. For the 2-aminoquinoline ligands, it
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would be expected that extending the structure may form additional favourable contacts with
less conserved residues on the SH3 domain surface, and therefore may achieve some selectivity
for the Tec SH3 domain over others. Using the fluorescence polarisation displacement assay,
the binding activity of 2-aminoquinoline and the 6-position extended 2-aminoquinoline 17
with selected other human SH3 domains was investigated, and some selectivity was observed
in both cases (Table 3, with sequences of the selected SH3 domains highlighted in Figure 20).
Table 3: Fluorescence polarisation competition assay results of 2-aminoquinoline and 6-position substituted
2-aminoquinoline (17) with several SH3 domains.50
Tec EC50 Nck EC50 Hck EC50 Fyn EC50
Compound (µM) (µM) (µM) (µM)
N NH2





17 26 ± 6 > 500 - -
The EC50 value was similar for Tec and the Nck adapter protein but was diminished for Fyn
and Hck, showing that even a simple ligand which binds to highly conserved residues displays
some selectivity between different SH3 domains.50 Furthermore, the 6-position extended
2-aminoquinoline ligand showed stronger binding affinity for Tec SH3 and only weak affinity
for the Nck protein, which is a substantial improvement in selectivity. This effectively
demonstrated that using a structure-based ligand design approach can achieve competitive
and selective ligands for a protein-protein interaction surface, even for a target considered as
challenging as the SH3 domain.
1.4.5 Limitations in development of SH3 domain inhibitors
Promising binding affinity improvements had been demonstrated with the extended 2-amino-
quinoline derivatives, however some limitations of the ligands developed by the structure-
based design approach were evident. Firstly, determining the effect of structural change
upon binding affinity for the Tec SH3 domain was determined primarily by comparison of
Kd values. A ligand which bound sufficiently strongly with the Tec SH3 domain surface to
achieve slow exchange of protein and protein-ligand complex on the NMR timescale or to
obtain a crystal structure of the protein-ligand complex had not been identified. Without
determining the 3D structure of the complex the exact binding site could not be determined,
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and therefore potential further interactions could not be accurately identified to assist with
designing better ligands. Instead, until the structure of the complex can be determined, the
progress of determining the structure-activity relationship and improving binding affinity is
slower.
The other major limitation is the increasing lipophilicity of the scaffold for the stronger binding
extended 2-aminoquinoline ligands. This is a common issue experienced when attempting to
target a protein interaction surface, as PPI interfaces are typically flat and largely hydrophobic,
and therefore favourable interactions can be made using large and hydrophobic ligand
structures. One of the challenges is designing a more drug-like ligand, ideally a small
molecule which has suitable water solubility to be used in biological applications. For the
2-aminoquinoline ligands for the Tec SH3 domain, significant improvements in binding affinity
have been achieved be adding large and lipophilic aromatic substituents, particularly a bulky
tert-butyl substituted phenethyl group at the 3-position (compound 10) or a benzylpiperidine
at the 6-position (compound 15). As mentioned previously, successful PPI inhibitors typically
access 3-5 favourable sub-interactions with the protein surface. Therefore, it would be
expected that a compound combining these bulky substituents (such as compound 18) could
access all the favourable interactions identified to date and be a strongly binding inhibitor for




Figure 21: Proposed structure which, based upon previous work, could potentially access more favourable
binding interactions with the Tec SH3 domain.
Although this largely hydrophobic scaffold is highly unlikely to have sufficient water solubility
to be an effective ligand for the Tec SH3 domain, it was anticipated that the incorporation of
structures which access the favourable binding interactions with a less hydrophobic scaffold
may be possible with some further investigation. In order to develop ligands which may
access all of the identified binding interactions, improving the hydrophilicity of the substituent
structures must first be achieved.
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1.5 Project aims
2-Aminoquinolines have clearly demonstrated potential as SH3 domain inhibitors, but further
development is required to obtain small-molecule ligands which can be used to investigate
inhibition of SH3 domain-mediated PPIs and inform the structure-based development of PPIs
inhibitors more generally. The primary aim of this project is to design and synthesise more
effective Tec SH3 domain ligands, with a focus on compounds with stronger binding affinity
for the Tec SH3 domain and improved drug-like characteristics.
The most promising ligands identified previously incorporated aromatic substituents at the
3-position or 6-position of the 2-aminoquinoline core structure. Investigating the nature of
these interactions was therefore a promising avenue to develop stronger binding ligands. By
strategically modifying and extending the ligand it was expected that the most favoured
functional groups could be identified, and the relative orientations to simultaneously access
all favourable binding interactions could be determined, thereby optimising the overall binding
affinity.
It was also considered critical to explore whether less lipophilic or bulky substituents would also
access these favourable interactions, as more hydrophobic scaffolds would reduce the water
solubility of the compound and therefore be ineffective under biologically relevant conditions.
In this work strategies will be investigated to improve water solubility while retaining overall
structures which facilitate binding interactions, primarily by addition of polar functional groups
and replacement of hydrophobic rings and chains with more hydrophilic structures.
Ideally, a strongly binding ligand would be achieved which would enable determination of the
3D structure of the protein-ligand complex by NMR spectroscopy or X-ray crystallography.
This information would give the most accurate determination of the binding site and
orientation, and would enable more efficient design of small-molecule ligands for the Tec
SH3 domain. Obtaining a strongly binding ligand would give valuable information about
design of SH3 ligands more generally, and open up a new array of protein interaction which
could be targeted by small-molecule inhibitors.
1.5.1 Synthetic targets
2-Aminoquinoline derivatives with a 6-position benzylpiperidine substituent
6-Position substituted derivatives of 4 were the strongest binding ligands developed in previous
work, with significant increases in binding affinity obtained by addition of heterocyclic
substituents. A 4-benzylpiperidine substituent was the most effective as it accessed an
additional hydrophobic binding interaction while maintaining the key interactions of the
2-aminoquinoline core structure. The first series of targets in this project are based upon
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Figure 22: General structure of proposed 6-position extended 2-aminoquinoline ligands.
The nature of the interactions between the benzyl group and the protein surface will be
investigated by addition of simple substituents to the benzene ring: the range of substituents
will explore the effects of changing size, electronic properties and lipophilicity upon the
strength of the interaction. In previous work only 4-substituted heterocycles were used, so
further work in this project will investigate whether access to the binding interactions can be
improved by positionally modified structures. The issue of solubility will also be investigated
by addition of more hydrophilic substituents or replacement of the benzyl group with a more
hydrophilic group.
The second series of target ligands were designed to further investigate the promising results
from biphenyl-containing substituents at the 6-position. These compounds (16a and 16b,
see Figure 19) showed stronger binding interactions with the Tec SH3 domains in assays
but the irregular binding results indicated the potential interactions could not be accessed
simultaneously. In this work biphenyl-extended piperidine compounds were instead proposed,
based upon the favourable binding interactions accessed by a 4-benzylpiperidine substituent
which suggest the heterocyclic ring may better orientate the aromatic group to access the





Figure 23: Structures of proposed 6-position extended 2-aminoquinoline ligands with biphenyl structures.
While the biphenyl structures are significantly hydrophobic in nature, a series of biaryls
containing more hydrophilic rings were also proposed to determine if the overall hydrophobicity
of the ligand can be reduced while accessing the favourable binding interactions with the largely








Ar = pyridinyl, pyrimidinyl
Figure 24: General structure of proposed 6-position extended 2-aminoquinoline ligands with biaryl
structures.
2-Aminoquinoline derivatives with a 3-position substituent
The hydrophobic interaction identified with 3-position extended 2-aminoquinolines had
previously been favourably accessed with a large substituted phenethyl group. The best ligand
had a bulky lipophilic para-t-butyl group on the benzene ring (Ligand 10), however this is
a very unfavourable structure in a small-molecule inhibitor due to the overall hydrophobicity
which reduces the aqueous solubility of the compound. The replacement of the tert-butyl
substituted benzene ring with less lipophilic heteroaromatic groups was instead proposed in
an attempt to reduce the increasingly hydrophobic ligand structure while still accessing the






Figure 25: General structure of proposed 3-position extended 2-aminoquinoline ligands with biaryl
structures.
Simpler 3-position extended 2-aminoquinolines may also be expected to improve the strength
of the binding interaction, or to assist identifying structures which reduce the hydrophobicity
of the scaffold and improve water solubility without compromising binding affinity. Only a
small range of phenethyl groups with alkyl or fluoro substituents were investigated in previous
work, and therefore alternate hydrophilic substituents were also proposed as targets to expand
upon the SAR data for this library of compounds (Figure 26). Target 2-aminoquinolines to
investigate the replacement of the phenethyl substituent with a pyridinylethyl substituent were
also proposed to determine the effect of a change in electron density and lipophilicity of the





Figure 26: General structure of proposed simple 3-position extended 2-aminoquinoline ligands.
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2 Synthesis of 6-position substituted 2-aminoquinolines
2.1 Introduction
Previous work into development of 6-position heterocyclic substituted 2-aminoquinolines as
Tec SH3 domain ligands identified that addition of a piperidine substituent improved the
binding affinity relative to the 2-aminoquinoline lead compound.52 Further extension of the
ligand with a benzyl group again resulted in an improved binding affinity to give the strongest
binding ligand to date (Ligand 15, see Figure 18), and it was proposed the improvement is
a result of the benzyl group interacting favourably with an additional hydrophobic binding
site on the protein surface. Further work is required to investigate the nature of this binding
interaction on the protein surface and to determine whether alternative compounds similar
to 15 would improve upon the binding affinity. As the 3D structure of a protein-ligand
complex could not be definitively determined from any previously made 2-aminoquinoline
ligand, exploration of the binding surface is best achieved by measuring changes in the
binding affinity to the Tec SH3 domain with a series of structurally similar 2-aminoquinoline
compounds.
It was proposed that a range of 2-aminoquinolines with benzylpiperidine-type substituents
appended at the 6-position could be used to gain further information about the nature
and relative position of the additional binding interaction on the Tec SH3 domain binding
surface, and potentially give a strong binding ligand which could then ultimately be used
to unambiguously determine the 3D structure of the protein-ligand complex. The range of
derivatives investigated in this work (Figure 27) were designed to investigate the effects of
adding substituents to the benzyl group (19) and changing the position of the benzene ring
relative to the 2-aminoquinoline ligand core (20 and 21). In addition, a limitation identified
in previous work was the relatively poor solubility of the 6-position extended 2-aminoquinoline
derivatives in the aqueous conditions required for binding assays, and therefore investigation
into the replacement of the benzyl group with pyridine variants was also undertaken to
investigate the effect on binding and the potential for improved solubility (22 and 23).
For the benzylpiperidine targets, a range of simple benzyl substituents were chosen to explore
the impact of various small structural changes. The functional groups range from bulky
lipophilic groups (a) to smaller methyl substituents (b-d) and fluoro-substituents (h-j) to
determine the sizes and positions of extended ligands which can be tolerated at this site
on the binding surface. Adding bulky lipophilic substituents, like tert-butyl groups, is not
preferable from a drug development perspective because it is likely to cause further issues
with ligand solubility, however as PPI binding surfaces are generally largely hydrophobic these
have potential from an exploratory perspective as lipophilic substituents will likely interact


























R = a: 4-t-butyl b: 2-CH3 e: 2-OCH3 h: 2-F k: 2-Br n: 2-CF3 q: 2-CN
c: 3-CH3 f: 3-OCH3 i: 3-F l: 3-Br o: 3-CF3 r: 3-CN
d: 4-CH3 g: 4-OCH3 j: 4-F m: 4-Br p: 4-CF3 s: 4-CN
Figure 27: Lead compound (15) identified by previous studies to bind to the Tec SH3 domain,52 and key
series of 6-position substituted 2-aminoquinoline ligands proposed to investigate hydrophobic binding
interaction accessed by 15.
effects, to determine how the electron density in the ring impacts the binding interaction: both
electron-donating substituents (including methoxy-substituted derivatives e-g), and electron
withdrawing substituents (including trifluoromethyl groups n-p and nitrile derivatives q-s)
were proposed as useful targets.
The bromo-substituted derivatives k-m would also be useful targets to compare with the small
fluoro-substituents. In addition, aryl bromides are useful intermediates which could be further
functionalised to introduce more complex substituted aromatic structures (see Chapter 3).
2.2 General synthetic pathway
The synthesis of 6-position heterocyclic-substituted 2-aminoquinolines has been thoroughly
investigated in previous work, where the development of a pathway involving successive
palladium-catalysed Buchwald-Hartwig aminations proved to be the most effective method.52
In this procedure, piperidine derivatives were coupled with 6-bromo-2-chloroquinoline (24)
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selectively at the 6-position in the presence of the 2-position activated aryl chloride bond,
enabling another amine source to react at the 2-position to give the 2-aminoquinoline





















Scheme 1: Reported synthesis of 6-position heterocyclic 2-aminoquinoline derivatives by successive
Buchwald-Hartwig aminations.52
For the first Buchwald-Hartwig amination, it was initially found that the results of the
amination reaction varied significantly for different piperidine reagents and with different
reaction conditions, and in some cases a range of minor products were also isolated in small


























Figure 28: Potential products obtained from Buchwald-Hartwig coupling reactions of quinoline 24 and
piperidine reagents.52
The predominant side-product observed was the 6-bromoquinoline product 27 due to the
competing amination reaction with the aryl chloride at the 2-position of the quinoline, which
is activated due to the neighbouring quinoline nitrogen. Other minor side-products were
the result of substitution of the tert-butoxide base at the 2-position (28 and 29), and loss
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of the 6-position aryl bromide under the relatively harsh reaction conditions which require
high temperatures and increased pressure (30). The Buchwald-Hartwig catalyst system
and reaction conditions for the selective amination were subsequently optimised, and yielded
predominately or exclusively the target 6-position substituted 2-chloroquinoline products for
a range of piperidine reagents (compound 25).52
Following isolation of the target 2-chloroquinoline derivatives, several methods were
investigated to convert the 2-chloroquinolines to 2-aminoquinolines (26), and the most
effective method was determined to be a second palladium catalysed Buchwald-Hartwig
amination.52 For the synthesis of the 6-heterocyclic target compounds, the same successive
Buchwald-Hartwig amination method was expected to effectively yield the desired 6-position






















Figure 29: Proposed retrosynthesis of 2-aminoquinoline derivatives with a 6-position benzylpiperidine
substituent based on previous work.52
By this method, the benzylpiperidine-type substituents needed to first be prepared before
coupling to the quinoline (Figure 30). 4-Benzylpiperidines with substitution of simple groups
on the benzene ring (31) were required to make the proposed target derivatives of 19. To
investigate the binding affinity of ligands 20 and 21 with a similar shape, 3-benzylpiperidines
(32) and 3-benzylpyrrolidines (33) were required. The pyridinylmethylpiperidine structures
(34 and 35) were also required to synthesise the target compounds 22 and 23.
The 4-benzylpiperidine reagent used to synthesise 15 in the previous work was commercially
available. The extended range of benzylpiperidine derivatives required for this work were not
available commercially and therefore an effective synthesis of a range of these derivatives was
required. It was also desirable that a method would be readily generalisable to make all the
derivatives required. Several methods had been reported in the literature to make various
4-benzylpiperidine derivatives from commercially available starting materials, although none









Figure 30: Range of piperidine derivatives required for synthesis of target 2-aminoquinoline ligands. For
range of target R-groups see Figure 27.
The use of a Horner-Emmons or a Wittig reaction as the key carbon-carbon bond forming
step has been widely utilised in reported syntheses to make a range of 4-benzylpiperidines
via a benzylidenepiperidine intermediate from a N-protected 4-piperidone and either a diethyl
benzylphosphonate (36) or benzyltriphenylphosphonium salt (37) derivative with reasonable
















37, X = Cl, Br
Scheme 2: General synthesis of 4-benzylidenepiperidine derivatives via a Horner-Emmons or Wittig
reaction. PG = protecting group.
Several of the required benzylpiperidine derivatives had reportedly been synthesised via a
Grignard reaction from a bromobenzene derivative and pyridine-4-carbaldehyde followed by
selective hydrogenation of the pyridine ring (Scheme 3).58 The reported yields for this process
varied significantly for the range of derivatives attempted, with yields of 23-81% obtained
for derivatives of 31 with methyl-, methoxy-, fluoro- or trifluoromethyl-substituents. Several
different methods were required for the various derivatives and a general synthetic procedure
was not found to maximise yields of all the target compounds desired in this work. Despite
achieving some required derivatives in a high yield, the Grignard method was not attempted
due to the lack of reliability across the reported range of compounds synthesised, which would
require extensive investigation of reaction conditions for preparation of each target derivative.
Instead, the reported literature processes indicated the most effective and generalisable method
would be a Horner-Emmons or Wittig reaction as the key bond-forming step to synthesise 31
derivatives from a N-protected 4-piperidone derivative.



















Scheme 3: Example of literature synthesis of 4-benzylpiperidine derivatives by Grignard reaction.58
31 derivatives from a 4-piperidone would also be expected to yield 32 and 33 derivatives
from N-protected 3-piperidone and 3-pyrrolidinone respectively. Despite the similar structure,
however, a much smaller range of 3-benzylpiperidine (32) and 3-benzylpyrrolidine (33)
derivatives were reported in the literature and, unlike the 4-benzylpiperidines, Horner-Emmons
reactions were not a typical method used for the synthesis of the compounds. The synthesis
of several 3-benzylpiperidine hydrochlorides (38) via a Wittig reaction had been mentioned
in the literature, but as the method and results were not reported in the publications it is













R = 2-F, 3-F, 4-F, 4-CF3, H
Scheme 4: Literature reported synthesis of 3-benzylpiperidine hydrochloride derivatives via Wittig
reaction.59
For the 3-benzylpyrrolidine derivatives only one literature synthesis via a Wittig reaction was
reported, and it was noted that the yield for the 2-fluorobenzyl compound 40h was less than
the corresponding 4-benzylpiperidine derivative in the same work, although the reasons for
this were not discussed (Scheme 5).61
Similarly, there were few reported syntheses of the desired pyridine derivatives (34 and 35).
For the 4-piperidine derivatives, a synthesis of 2-(4-piperidinylmethyl)pyridine hydrochloride
and 3-(4-piperidinylmethyl)pyridine hydrochloride (42a and 42b) was reported in a 2015
patent by hydroboration with 9-borabicyclo[3.3.1]nonane (9-BBN) and palladium-catalysed











Scheme 5: Literature reported synthesis of 3-benzylpyrrolidine hydrochloride derivative 40h via Wittig
reaction.61
the yield of a similar compound was reported to be 46% (Scheme 6).62 More recently,
the synthesis of 42b was achieved by a photochemical reaction through a pyridyl radical
intermediate (Scheme 7).63 The synthesis of a similar extended 3-piperidine compound 43b
has been reported previously as a four step synthesis from benzyl bromide and 2-piperidone,
although again the overall yield for this process was very low compared to various syntheses of
4-benzylpiperidine derivatives (Scheme 8).64,65
1. 9-BBN
    PdCl2(PPh3)2











Scheme 6: Literature reported synthesis of (4-piperidinylmethyl)-pyridine hydrochloride derivatives, shown

















Scheme 7: Literature reported synthesis of (4-piperidinylmethyl)-pyridine hydrochloride compound 42b.63
Given the availability of the required starting materials and the potential generalisability of
the approach to synthesise all derivatives, it was expected that the Horner-Emmons or Wittig
reactions were the most effective synthetic pathways to make the required benzylpiperidines.
These methods had been applied to synthesise many derivatives of 31 previously, and it was
expected the full range of required derivatives could be synthesised by either of these pathways
from commercially available benzylhalides (Pathways 1 and 2, Figure 31). The Heck reaction
(Pathway 3, Figure 31) was another potential method considered, although again this was
less preferable because an additional carbon-carbon bond-forming reaction, usually a Wittig




























Scheme 8: Literature reported synthesis of (3-piperidinylmethyl)-pyridine hydrochloride compound 43b.64
also not be utilised to make the desired bromo-substituted derivatives due to the multiple aryl





















Pathway 1 Pathway 2
Pathway 3
Figure 31: Potential retrosynthetic pathways for target piperidine compounds, shown for required
4-benzylpiperidine derivatives (31). PG = Protecting group.
A Wittig reaction (Pathway 2) was less preferable to the Horner-Emmons reaction as the
triphenylphosphine oxide by-product of the reaction is not water-soluble and therefore typically
complicates purification of the alkene products, therefore the Horner-Emmons reaction
pathway (Pathway 1) was the preferred method. In the proposed Horner-Emmons reaction
pathway, the diethyl benzylphosphonates (36) would be prepared from commercially available
benzylhalide derivatives and then reacted with an N-protected 4-piperidone via a Horner-
Emmons reaction (Scheme 9). The alkene products would then be converted to the desired
benzylpiperidines (31) via hydrogenation followed by deprotection of the amine protecting
34






















Scheme 9: Proposed general synthesis of 4-benzylpiperidine derivatives (31) from commercially available
benzyl halides via Horner-Emmons reaction pathway.
Despite their wide utilisation in the synthesis of 4-benzylpiperidines, the Horner-Emmons
and Wittig reactions had not been commonly applied in the syntheses of the other target
benzylpiperidine ananlogues (32, 33, 34, and 35). It was however anticipated that the same
synthetic methods used to synthesise the 4-benzylpiperidine derivatives could then be used
to synthesise the various benzylpiperidines from analogous starting materials which were also










n = 2: 32
n = 1: 33














Figure 33: Proposed retrosynthesis of pyridinylmethylpiperidine derivatives 34 and 35.
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2.3 Synthesis of 2-aminoquinoline derivatives with a 6-position
benzylpiperidine substituent
2.3.1 Investigation of Horner-Emmons pathway for synthesis of benzylpiperidine
derivatives
Several of the required benzylpiperidine derivatives had previously been reported in the literature
but were synthesised via alternate methods which could not be used to synthesise the full range
of target derivatives. As an example, the methyl-substituted 4-benzylpiperidine derivative 31c
had only been synthesised via a Grignard reaction with the highest reported yield of 59%
(Scheme 3).58 However, as the Horner-Emmons reaction would be the preferable method, the
attempted synthesis of 31c via a Horner-Emmons reaction was first explored to test whether
this was a suitable alternative to the literature method.
The first step in the synthetic procedure was reaction of the commercially available reagent
3-methylbenzyl chloride with triethylphosphite, which was achieved using typical Michaelis-
Arbuzov reaction conditions (Scheme 10). The product was isolated by distillation with
no further purification required, with quantitative yield. The spectroscopic data for the
product was consistent with previously reported data, with the 1H NMR spectrum showing
the characteristic HP doublet at 3.11 ppm with integration corresponding to two hydrogen







Scheme 10: Synthesis of diethyl 3-methylbenzylphosphonate (36c) via a Michaelis-Arbuzov rearrangement.
Previous work on the synthesis of similar compounds had shown typical Horner-Emmons
reaction conditions with sodium hydride as the base and tetrahydrofuran as the solvent under
anhydrous conditions had been most successful in yielding benzylidene products, whereas
experiments with other bases and solvents had shown lower yields (unpublished work). The
success of this reaction is highly dependent on the purity of the sodium hydride dispersion
used as the base, the elimination of water from the reaction vessel, and rate of reaction
as degradation of the sodium hydride to sodium hydroxide in the presence of water was
proposed to result in hydrolysis of the benzylphosphonate reagent (Scheme 11) and therefore
adversely impact the reaction yield. Both benzyl-protected and Boc-protected 4-piperidones
are commercially available, however the simple and fast removal of Boc-protecting groups
under acidic conditions was considered preferable to the removal of the benzyl-protecting
36













Scheme 11: Proposed hydrolysis reaction of diethyl benzylphosphonate derivatives (36) due to presence of
NaOH in reaction mixture.
Using these reaction conditions, diethyl 3-methylbenzylphosphonate (36c) was reacted with
N-Boc-4-piperidone (44) and one product was formed (Scheme 12). Spectroscopic analysis
of the crude mixture showed a characteristic singlet alkene signal in the 1H NMR spectrum at
















Scheme 12: Synthesis of Boc-protected benzylidenepiperidine 45c via Horner-Emmons reaction.
Isolation of the product and analysis by spectroscopic methods indicated successful synthesis
of the desired product 45c with a good yield (87%). HRMS analysis of the product showed
a mass peak of 232.1332 corresponding to the product with loss of the labile t-butyl group
(expected m/z 232.1338), although the mass peak corresponding to the parent structure
was not observed. Analysis of the 1H NMR data for the product showed the alkene singlet
signal at 6.33 ppm, and the group of four broad signals upfield of the alkene signal in
the 1H NMR spectrum corresponding to the hydrogens in the piperidine ring. Each of the
piperidine hydrogen signals integrated for two hydrogen atoms, and the [1H,13C]-HSQC data
demonstrated that each of these signals corresponded to a CH2 group. This pattern would not
be expected of a piperidine ring in a chair conformation, as the axial and equatorial hydrogen
atoms would be in distinct environments and therefore have different 1H NMR signals. In
this case, however, the 4-position substituent is an alkene and therefore planar, and the
Boc-protecting group also has partial double bond character (Figure 34), and therefore it is
expected that the piperidine ring of 45c is substantially planarised, leading to the lack of
distinct axial and equatorial hydrogen environments for the piperidine ring.
The broadness of the signals is also indicative of the restricted conformation of the ring
which results in slow ring-flipping on the NMR timescale. This broadening effect had a












Figure 34: Structures of Boc-protected piperidines showing partial double-bond character of C-N bond.
significantly broadened and the signals for the carbons adjacent to the nitrogen atom were
almost indistinguishable from the baseline of the spectrum, although the [1H,13C]-HSQC NMR
experiment could be effectively used to definitively determine the position of the signals which
appeared to coincide or overlap due to the broadness (Figure 35).
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Figure 35: Example HSQC correlations used to identify broad 13C NMR piperidine ring signals of
Boc-protected benzylidenepiperidine derivatives. A: 13C NMR spectrum of 45c showing broadened signals,
and B: DEPT-edited [1H,13C]-HSQC spectrum used to identify broad 13C NMR piperidine ring signals
of 45c.
The piperidine ring had reduced symmetry compared to the piperidone starting material due
to the asymmetrical alkene, therefore one side of the piperidine ring is in closer proximity
38
to the large substituted benzene ring. ROESY correlations could be used to show which
signals corresponded to piperidine hydrogen atoms on the side further from the benzene ring
as these hydrogens showed a ROESY correlation to the alkene hydrogen (Figure 36). The
ROESY experiment indicated that the signals for piperidine hydrogen atoms adjacent to the
alkene bond were shifted slightly downfield if on the same side of the alkene as the benzene
substituent, showing these are slightly deshielded by the aromatic ring relative to the hydrogen














Figure 36: ROESY correlations showing assignment of asymmetric piperidine ring signals for 45c.
Given the broadness of the signals which hinders identification and assignment of all signals,
use of an alternate protecting group was investigated to ascertain whether the Boc-protecting
group is affecting the piperidine ring conformation and if better clarity in the NMR spectra
could be achieved for a similar compound with an amine protecting group which does not
effectively planarise the piperidine the ring. The benzyl-protected piperidone reagent 46
was used and with the same Horner-Emmons reaction conditions one product was obtained
(Scheme 13). The alkene signal at 6.24 ppm in the 1H NMR spectrum was clearly present,
indicating that the reaction had proceeded successfully to give the alkene 47c. Piperidine ring
signals very similar to that observed for 45c were observed in the hydrogen NMR spectrum,
with broad signals appearing for each CH2 in the ring instead of the more complex pattern
expected if the ring was in a chair-like conformation. Again, this indicates that the planar
alkene bond is resulting in a substantially planarised ring with no distinct axial and equatorial
hydrogen atoms observed in the 1H NMR experiments, and therefore the planarised ring
conformation proposed for the Boc-protected compound 45c previously is not solely due to
the partial double bond character of the Boc-protecting group. Because of these changes
in conformation (c.f. the results from synthesis of 45c above) the 13C NMR signals for the
benzyl-protected product were not also broadened and did not overlap, making the spectra
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Figure 37: Comparison of 13C NMR spectra of A: Boc-protected Horner-Emmons product 45c, and B:
benzyl-protected Horner-Emmons reaction product 47c.
The difference in broadness for the 13C NMR spectra of the two Horner-Emmons products
was confirmation that the protecting group changes the characteristics of the piperidine ring,
but aside from this key difference the spectra were directly comparable and similar. With
comparison to these results from the benzyl-protected product 47c, the evidence from the
NMR data for the Boc-protected product 45c clearly demonstrates the synthesis of 45c
was achieved, and provides evidence of the conformation of the structure and the factors
influencing the conformations: the planarised piperidine ring is primarily due to the external
planar alkene bond as designed, and the Boc-protecting group on the piperidine nitrogen slows
the interconversion of the ring conformations. The data collected sufficiently demonstrates
successful formation of the desired Boc-protected piperidine product 45c in a high yield from
40
the Horner-Emmons reaction.
The Boc-protected Horner-Emmons product 45c was reacted under standard Pd-catalysed
hydrogenation conditions to give the product 48c in almost quantitative yield (Scheme 14).
The reaction was shown by NMR spectroscopy and mass spectrometry to be successful, most
distinctively by the loss of the alkene signal in the 1H NMR spectrum and a new signal
appearing as a doublet and with integration for two hydrogen atoms, corresponding to the
methylene bridge. The HRMS data showed the expected peak of 234.1491 for the product
with loss of the labile tert-butyl group (calculated m/z 234.1494), showing successful mass
increase corresponding to two hydrogen atoms as expected for a hydrogenation of one carbon-
carbon double bond. In addition to the expected fragmented product peak, a comparatively
small mass peak corresponding to the full molecule was observed for 48c (HRMS found m/z










Scheme 14: Synthesis of Boc-protected benzylpiperidine 48c via hydrogenation under standard conditions.
The change in shape of the piperidine ring was evidenced by an increased number of signals
and complexity observed for the piperidine ring hydrogen atoms in the 1H NMR spectrum,
as the ring was less planarised due to the loss of the planar external alkene and therefore
adopted a more chair-like conformation resulting in the observed distinct signals for axial and
equatorial hydrogens on each carbon atom in the ring. Unlike the alkene 45c there is free
rotation of the substituted benzyl group and therefore the piperidine ring has more symmetry.
This is demonstrated clearly in the HSQC spectrum of the product which shows two 2H
signals correlating to each carbon signal, indicating distinct axial and equatorial hydrogen
environments for chemically equivalent CH2 groups, and is therefore consistent with expected
observations for this structure.
In both the 1H NMR and 13C NMR spectra the piperidine ring signals are still broad due to
the presence of the Boc-protecting group, so the magnitude of the J values could not be
determined and interpreted. The signals for the CH2 groups adjacent to the nitrogen atom
(H2 and H6) are the broadest and show no discernable splitting patterns, but in contrast the
H3 and H5 signals are further from the Boc-protecting group and some resolution of a splitting
pattern can be observed. The equatorial signals are overlapped with the H4 signal and cannot
be directly analysed, but the upfield axial signal shows a clear doublet-of-quartets splitting
pattern, which would be expected for the axial hydrogen signals with large coupling constants
for geminal coupling and vicinal axial-axial coupling to the H4 and H2 signals (2Jax,eq ≈ 3Jax,ax
≈ 12 Hz), and the smaller coupling to the equatorial H2 signal (3Jax,eq ≈ 3 Hz), which
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indicates the ring has a more chair-like shape than its precursor 45c. Further evidence for the
change in conformation is demonstrated by comparison of the chemical shifts for the H2/6ax
and the H2/6eq signals. The equatorial hydrogen signals appear as a broad signal at 4.06 ppm
compared to the axial signals at 2.63 ppm, which is a substantial difference, especially given
in the precursor 45c the different conformation meant there was no difference in chemical
shift between two hydrogen atoms attached to the same carbon atom. Some difference is
expected for axial and equatorial chemical shifts and equatorial hydrogen signals generally are
shifted downfield relative to the axial signals, as observed in the difference between the H3/5ax
and the H3/5eq signals which have a shift difference of 0.47 ppm, but a difference of 1.44
ppm is beyond the difference which would be typically expected due to C-C bond anisotropy
or sigma-bond donating effects alone. As the Boc-group has partial double bond character
and is therefore planarised, the adjacent equatorial hydrogen atoms are in the plane of the
π-bonded system and therefore deshielded by anisotropy, resulting in a significant downshield
shift of the signal relative to the axial hydrogen signals (Figure 38). If this is the case, the
difference between the H2/6ax and the H2/6eq signals would be expected to be significantly less
















Figure 38: Structure of Boc-protected benzylpiperidine structure showing planarised bond and different
chemical environment of axial and equatorial hydrogen atoms.
The final step to yield the desired benzylpiperidine 31c was removal of the protecting group
to give the free amine. The Boc-protecting group is commonly removed under TFA-catalysed
conditions in a typically fast reaction. Using this typical method, the compound 48c was
treated with trifluoroacetic acid in dichloromethane, then the acid was neutralised with
saturated sodium bicarbonate solution and the amine product 31c was isolated via extraction
(Scheme 15). Due to the water solubility of the amine product, the recovery of the amine
was not quantitative despite the fast and complete reaction. A high recovery by liquid-liquid
extraction was obtained (88%), showing this was still an effective method for isolation of this
derivative.
A fluorine-19 NMR experiment was used to confirm that any residual TFA had been removed
from the product sample by evaporation under reduced pressure, and the 1H and 13C NMR
spectra showed distinctive changes which confirmed the identity of the product as 31c. The
loss of the large 9H singlet signal in the 1H NMR spectrum for the Boc tert-butyl group









Scheme 15: Synthesis of 3-methylbenzyl extended piperidine derivative 31c via removal of the
Boc-protecting group under acidic conditions.
NH was observed. In contrast to the precursors 45c and 48c, the 13C NMR signals of
the piperidine ring were not broadened and in the 1H NMR spectrum of the product the
characteristic coupling constants corresponding to axial-axial and geminal coupling for a chair-
like conformation of the piperidine could be determined. The differences indicate the increased
rate of interconversion between conformations of the piperidine on the NMR timescale due to
loss of the Boc-protecting group, and clarify the signals to enable analysis of the spectroscopic
results. The change in chemical shift of the H2/6eq signal was significant, and the observed
upfield shift of this signal to 3.08 ppm (compared to 4.07 for the H2/6eq signal of 48c)
was consistent with the previously postulated hypothesis that the Boc-protecting group was
resulting in significantly deshielded equatorial spins for 48c relative to the H2/6ax signal.
Overall, the yield of 31c from commercially available starting materials was 77% over 4 steps,
with simple purification and isolation of the compounds for each step of the reaction. The
high yield and generalisability of the synthetic process to achieve the required range of target
benzylpiperidine derivatives was preferable to the alternate literature processes including the
reported Grignard synthesis of 31c, and therefore expected to be the most effective method
for synthesis of the remaining required benzylpiperidine derivatives.
An alternate Boc-deprotection method employing a solution of hydrogen chloride in an organic
solvent (diethyl ether or 1,4-dioxane) instead of TFA can potentially be used to simplify the
isolation of the product. As the reaction with HCl produces the hydrochloride salt of the
benzylpiperidine product (49c), it would then be anticipated that the product would be
a solid and precipitate from the reaction mixture if a relatively non-polar solvent is used,
thereby enabling a simpler isolation of the product. The benzylpiperidine hydrochloride is
expected to be the only precipitate, and as the synthesis of 45c and 48c by Horner-Emmons
and hydrogenation reactions respectively were so effective, it was expected that purification
of the products at each step would be unneccessary and that collection of precipitated 49c
would be sufficient isolation and would therefore save repeated purification steps (Scheme
16).
This method was attempted using solutions of hydrogen chloride in either diethyl ether or 1,4-
dioxane, and in each case the product 49c precipitated from the solution and was collected by




















Scheme 16: Synthesis of substituted benzylpiperidine hydrochloride (49c) via Horner-Emmons reaction
and acid-catalysed Boc-deprotection, with yields from different HCl solution solvents.
deprotection reaction in 1,4-dioxane, indicating that the hydrochloride salt may potentially be
partially soluble in 1,4-dioxane which reduced the amount of product isolated by this method.
The free amine 31c was isolated by neutralisation of the hydrochloride salt with aqueous
sodium bicarbonate solution and extraction. Good recovery of the product was achieved
although, as this required extraction from an aqueous solution, there was some product which
was not recovered, similar to the recovery from the TFA-catalysed method. Overall the
yield of the desired product 31c was 41% via isolation of the hydrochloride salt, which was
significantly lower than the yield obtained by the stepwise method although it was less labour
intensive due to the reduced number of purification steps. Given the recovery of product was
still reasonable from this shortened method, it is proposed that either pathway could be used
to effectively synthesise a range of benzylpiperidine derivatives.
2.3.2 Synthesis of diethyl benzylphosphonate and triphenylphosphonium salt
derivatives
The Horner-Emmons approach which was effectively used to synthesise 31c was then
generalised for the attempted syntheses of all remaining derivatives of 31, as well as the
variants 32, 33, 34, and 35.
The Horner-Emmons reaction pathway requires the diethyl benzylphosphonate derivatives
as reagents, and more specifically substituted benzylphosphonates (36) were required to
synthesise 31, 32 and 33, and the diethyl pyridinylmethylphosphonates (50) were required
for the synthesis of derivatives of 34 and 35.
The synthesis of a range of mono-substituted diethyl benzylphosphonates had been reported
previously and could be achieved readily by reaction of the corresponding benzyl halide with
triethylphosphite (Scheme 17).67,68 In each case the successful reaction was clearly indicated
by appearance of a doublet with a large coupling constant (typically 2JH,P = 21-22 Hz)
in the 1H NMR spectrum corresponding to hydrogen-phosphorous coupling in the product
benzylphosphonate. The excess triethylphosphite was distilled from the products which were
then used without further purification. The yields of the Michaelis-Arbuzov reactions were
44
typically high, although reduced yield was observed from some benzyl chlorides which were








X = Cl, Br 36
Scheme 17: General synthesis of benzylphosphonate derivatives (36) via Michaelis-Arbuzov
rearrangment.56
Table 4: Yields of diethyl 4-benzylphosphonate derivatives (36) obtained by Michaelis-Arbuzov
rearrangement.
R X δH PCH2 (ppm) 2JH,P (Hz) Yield 36 (%)
a: 4-tBu Br 3.12 21.4 100
b: 2-CH3 Br 3.17 22.0 100
c: 3-CH3 Cl 3.11 21.5 100
d: 4-CH3 a
e: 2-OCH3 Cl 3.25 21.7 88
f: 3-OCH3 Cl 3.13 21.6 93
g: 4-OCH3 Cl 3.09 21.2 95
h: 2-F Cl 3.20 21.6 97
i: 3-F Br 3.14 21.8 89
j: 4-F Cl 3.11 21.4 96
k: 2-Br Br 3.41 22.0 100
l: 3-Br Br 3.11 21.7 100
m: 4-Br Br 3.09 21.7 100
n: 2-CF3 Cl 3.37 22.7 89
o: 3-CF3 Cl 3.20 21.8 94
p: 4-CF3 Cl 3.20 22.0 99
r: 3-CN Br 3.17 21.9 100
s: 4-CN Cl 3.20 22.3 91
x: H Br 3.15 21.6 100
a 36d was synthesised as part of a previous project.
The pyridinyl phosphonate derivatives (50) did not have a reported synthesis in the literature,
and in this work they proved more difficult to synthesise under the same Michaelis-Arbuzov
reaction conditions used for the benzylphosphonates. Initially it was anticipated that the
commercially available pyridinylmethylhalide hydrochloride or hydrobromide salts could be
treated with aqueous sodium bicarbonate solution to give the pyridine compound 51 which
45
could be extracted into a volatile solvent, such as dichloromethane or toluene, and then
isolated by evaporation of the solvent before the Michaelis-Arbuzov rearrangment under the











X = Cl, Br 51 50
Scheme 18: Proposed synthesis of pyridinylmethylphosphonate derivatives (50) via Michaelis-Arbuzov
rearrangment.
The process was complicated by the volatility of the pyridinylmethylhalides (51) which meant
the starting materials could not be isolated after treatment with the sodium bicarbonate
solution required to remove the hydrohalide prior to reaction at reflux in triethylphosphite. This
method was attempted in the synthesis of 50c from 4-(bromomethyl)pyridine hydrobromide
but resulted in a pink residue that was found to contain none of the desired product 50c
or the starting material 51c. Instead, a modified procedure was attempted which involved
treatment with the bicarbonate solution and extraction of 51c into a solvent (toluene or














Scheme 19: Attempted synthesis of a pyridinyl-extended phosphonate derivative (50c) via a
Michaelis-Arbuzov rearrangement.
The reaction in toluene resulted in a crude black mixture which was again found by 1H
NMR analysis to contain neither 51c nor 50c, and it was suspected that 51c may have
evaporated at the reaction temperature faster than the reaction could occur. The reaction
in dichloromethane was at a lower temperature, and gave a small amount of 50c in a crude
mixture. The product was somewhat purified by filtration to remove insoluble impurities
and distillation to remove the triethylphosphite, and the resulting brown crude residue was
used without complete purification. While not isolated, the signals corresponding to the
desired product were evident in the 1H NMR spectrum of the partially purified mixture, and in
particular the HP doublet signal (δH ≈ 3.1 ppm and 2JH,P = 22.3 Hz) which was a distinctive
observation from the benzylpiperidines above, was clearly evident in the 1H NMR spectrum.
Due to the issues encountered when attempting to make the pyridinyl-analogues of the diethyl
phosphonates, alternative methods which avoid the problematic Michaelis-Arbuzov reaction
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step were explored. Triphenylphosphonium salts, required for Wittig reactions, are often solids
and it was therefore expected that the corresponding pyridinylphosphonium salts (52) would be
easier to isolate than the phosphonates (50) required for Horner-Emmons reactions (Scheme
20). In addition, the reaction to produce Wittig reagents typically proceeds faster than the
reaction to make phosphonate derivatives, and it was therefore expected that the formation
of 52 derivatives would be higher yielding than the synthesis of 50 as the desired reaction in
toluene could potentially progress faster than the evaporation of the volatile pyridine reagent
which was considered a factor in the low yield of 50c.
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Scheme 20: General synthesis of pyridinylmethyltriphenylphosphonium salt derivatives (52) in toluene.
The proposed synthesis of the Wittig reagent was used in the attempted synthesis of 52c
from 4-(bromomethyl)pyridine hydrobromide and resulted in a significantly improved yield of
52c. The product was a solid which could be isolated by filtration, in contrast to the difficult
and unsuccessful attempts to isolate the phosphonate 50c. The expected HP doublet was
evident in the 1H NMR spectrum of the product (δH ≈ 5.9 ppm, 2JH,P = 15.9 Hz), with the
distinctive 2-signal splitting pattern for a p-substituted ring observed in the aromatic region
of the spectrum, as well as large signals corresponding to the phenyl groups.
The other required derivatives (52a and 52b) were also successfully synthesised by this
method, with the 1H NMR spectra also consistent with the expected products and an evident
HP doublet signal (Table 5). The yield obtained for 52a was very high, however the yield of
52b was significantly lower as the chloride reagent was used and therefore the reaction was
expected to be slower, giving more opportunity for evaporation of the pyridinyl reagent, 51b.





Substituent Yield δH PCH2
position X (%) (ppm) 2JH,P (Hz)
52a: 2 Br 85 5.63 14.4
52b: 3 Cl 34 5.83 14.9
52c: 4 Br 75 5.86 15.9
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From this, the simpler and higher yielding synthesis of the Wittig reagent likely means
the Wittig pathway is more feasible for the synthesis of the pyridinylmethylpiperidine (53)
derivatives, although this is dependent upon the relative reactivity of the reagents in the
subsequent Horner-Emmons and Wittig reactions.
2.3.3 Synthesis of benzylpiperidine derivatives
From the results of the synthesis of 31c, the proposed method to synthesise the remaining
benzylpiperidine derivatives was via a Horner-Emmons reaction with a Boc-protected piperidone
or pyrrolidinone, followed by palladium-catalysed hydrogenation of the double bond and TFA-
catalysed removal of the Boc protecting group. Although this had not previously been
utilised in literature syntheses of the similar 3-benzylpiperidine (32) or 3-benzylpyrrolidine
(33) derivatives it was expected that the same method could be utilised as the same diethyl
benzylphosphonate derivatives were required and the Boc-protected reagents 39 and 54 were
commercially available.
Given the poor results from attempted synthesis of the analogous pyridine-substituted
phosphonate 50c, the use of a Horner-Emmons reaction in the synthesis of 34 and 35 did
not appear to be as viable, and therefore the use of the Wittig reaction would also be explored
given the synthesis of the required Wittig reagents 52 had been achieved.
Synthesis of 4-benzylidenepiperidine derivatives via a Horner-Emmons reaction
The Horner-Emmons reactions of the synthesised phosphonates (36) with N-Boc-4-piperidone
(44) were conducted using the same conditions as for 45c above, generally resulting in
moderate to good yields of the desired alkene products (Scheme 21, Table 6). In all cases the
















Scheme 21: General synthesis of Boc-protected 4-benzylidenepiperidine derivatives (45) via a
Horner-Emmons reaction.
Success of the reaction was clearly identified by similar observations in the NMR spectra and
HRMS data to that observed for 45c previously. From the 1H NMR spectra of the products,
the presence of an alkene hydrogen signal near 6.3 ppm was distinctive for the desired products
(Table 6). Due to the reduced symmetry, four 2H piperidine hydrogen signals were observed
for the alkene products instead of the two 4H signals for the piperidone reagent. The piperidine
hydrogen signals resembled broad triplets instead of indicating distinct axial and equatorial
48










R δH HA (ppm) Yield 45 (%)
45a: 4-tBu 6.32 39
45c: 3-CH3 6.33 87
45d: 4-CH3 6.32 51
45e: 2-OCH3 6.35 56
45g: 4-OCH3 6.30 27
45i: 3-F 6.32 84
45j: 4-F 6.31 69
45k: 2-Br 6.31 100
45l: 3-Br 6.29 67
45m: 4-Br 6.28 70
45n: 2-CF3 6.50 82
45o: 3-CF3 6.37 59
45p: 4-CF3 6.37 57
hydrogen signals. The lack of separate axial and equatorial hydrogen signals and the broadness
of the resultant piperidine signals in both the 1H and 13C NMR spectra again implies that the
piperidine ring is substantially planarised and ring-flipping is slow on the NMR timescale for
all derivatives synthesised, as the ring structure is constrained by the planar external alkene
and the Boc protecting group which has partial double-bond character. Typically, the 13C
NMR signals for N-adjacent carbon atoms in the piperidine ring were very broad and almost
indistinguishable from the baseline of the spectrum, and use of [1H,13C]-HSQC experiments
was required to identify the shift of the 13C NMR signals, as was used for 45c (see Figure
35).
The isolated derivatives of 45 were converted to the Boc-protected 4-benzylpiperidines (48)
by hydrogenation with palladium on carbon (Pd-C) catalyst under an atmosphere of hydrogen
gas in methanol (Scheme 22). The reaction proceeded in quantitative yield to give 48, and
filtration to remove the solid catalyst followed by evaporation of the solvent gave the product
typically without the need for further purification.
















Scheme 22: General two-step synthesis of 4-benzylpiperidine derivatives (31) from benzylidene derivatives
(45).
signal observed for 45 derivatives and the increase in mass observed by mass spectrometry
(HRMS) corresponding to two hydrogen atoms. A more complicated pattern of piperidine
ring hydrogen signals was observed, as the loss of the planar alkene enables faster conversion
between the ring conformations on the NMR timescale, and so the axial and equatorial signals
have distinct shifts. The presence of the Boc-protecting group broadens the signals, as was
observed for the precursor 45 derivatives.
Different results were observed for the derivatives with a bromine substituent. The products
48(k-m) were not isolated from the hydrogenation reaction (Scheme 23, Table 7), and instead
the NMR spectra and HRMS showed the same product was produced in each of the three
reactions. In all cases the alkene signal was not present and the NMR signals observed were
consistent with the Boc-protected piperidine rings similar to the other derivatives: instead
of the asymmetric piperidine signals observed for the starting material, separate signals
corresponding to axial- and equatorial-like hydrogen atoms were observed, with DEPT-edited
HSQC experiments showing two inequivalent hydrogen atoms attached to carbon atoms in















Scheme 23: Attempted syntheses of 4-benzylpiperidine derivatives with bromine substituent 48(k-m),
giving instead the un-substituted product Boc-protected 4-benzylpiperidine (48x).
Table 7: Results of attempted hydrogenations of bromobenzylidene-extended piperidines (48) under
standard conditions.
Reagent Br position Yield 48 (%) Yield 48x (%)
45k: 2 0 98
45l: 3 0 98
45m: 4 0 100
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In contrast to the expected product, however, the aromatic region of the 1H NMR spectrum
had higher integration consistent with one additional hydrogen atom, and the splitting pattern
of the signals was consistent with a mono-substituted benzene ring instead of the target
products (Figure 39). HRMS analysis of the obtained product gave a mass peak consistent
with the formula C17H25NO2 instead of the two isotope masses required for the bromo-
substituted product, which with the 1H NMR data demonstrates that 48x was the product
obtained from the reaction. The synthesis of 48x has previously been reported in the
literature,69 and the spectroscopic data for the isolated hydrogenation product from the
alkenes 45(k-m) was consistent with the reported data for 48x. In this project, each
attempted synthesis of 48(k-m) gave a high or quantitative yield of 48x, indicating complete


























Figure 39: Example 1H NMR spectra demonstrating loss of aryl bromide under hydrogenation conditions.
A: Horner-Emmons product with 3’-position bromide substituent 45l, and B: product from hydrogenation of
45l, Boc-protected 4-benzylpiperidine 48x.
Given the hydrogenation resulted in the loss of the aryl bromide bond, the synthesis of the
target piperidines 31(k-m) and therefore the target quinoline compound 19(k-m) could not
be obtained. The aryl bromides 19(k-m) were not primarily intended to be key target ligand
compounds, and instead were intended as intermediates to make more complex extended
ligands (see Chapter 3), and these results demonstrate that the proposed synthesis of more
complex derivatives must occur via a different intermediate which does not require
hydrogenation of an aryl bromide compound.
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In the cases where the desired derivative of 48 could be obtained, the Boc-protecting group
was removed by treatment with TFA in dichloromethane to give the free amine products
31 (Scheme 22, Table 8). The yield from the deprotection reactions varied: some product
amines were likely to be more water-soluble and therefore yield was likely lost in the reaction
work-up procedure. The removal of the Boc-protecting group simplified the NMR spectra of
the products significantly: the line broadening as a result of restricted rotation of the Boc
protecting group was no longer evident and therefore was not preventing identification of
signals and coupling constants for hydrogen atoms in the piperidine ring: geminal axial-axial
coupling and vicinal axial-axial coupling constants (typically 12 Hz) were observed, as well as
the smaller vicinal axial-equatorial coupling constants (generally 2-4 Hz). The loss of the large
t-butyl signals (distinctive 9H singlet at approximately 1.45 ppm in the 1H NMR spectrum,
and 28 ppm and 80 ppm in the 13C NMR spectrum) was also observed.
Table 8: Results of sequential reactions of Boc-protected 4-benzylidenepiperidine derivatives (45), to give
derivatives of 48 and the desired 4-benzylpiperidines 31.
Hydrogenation Boc-deprotection
δH H(2/6)eq Yield δH H(2/6)eq Yield
R (ppm) (%) (ppm) (%)
4-tBu 48a: 4.07 99 31a: 3.04 100
3-CH3 48c: 4.06 99 31c: 3.27 88
4-CH3 48d: 4.06 100 31d: 3.16 100
2-OCH3 48e: 4.04 100 31e: 3.04 100
4-OCH3 48g: 4.09 100 31g: 3.34 100
3-F 48i: 4.08 100 31i: 3.35 94
4-F 48j: 4.07 100 31j: 3.06 94
2-CF3 48n: 4.08 100 31n: 3.35 100
3-CF3 48o: 4.08 100 31o: 3.30 100
4-CF3 48p: 4.09 92 31p: 3.36 96
The alternate method for the synthesis and isolation of 31 derivatives via Horner-Emmons
reaction and deprotection with a hydrogen chloride solution (Scheme 24) was attempted for
many derivatives in an attempt to obtain the products with less purification steps. The
product hydrochloride salts of the 4-benzylpiperidines (49) were all solids and precipitated
from the hydrogen chloride solution in diethyl ether, which enabled easier isolation of the
products but was highly dependent on the quality of the hydrogen chloride solution and also
appeared to work poorly for derivatives with more hydrophilic functional groups, and therefore
yields varied significantly (Table 9). The hydrogen chloride deprotection conditions resulted
in higher yields for some derivatives of 49 compared to TFA deprotection, but the high
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variation in the results indicates that the TFA deprotection conditions were more reliable as a
























Scheme 24: Synthesis of 4-benzylpiperidine derivatives (31) via hydrochloride salt intermediate (49).
Table 9: Yields of 4-benzylpiperidine hydrochloride derivatives (49) from three-step synthesis via a
Horner-Emmons reaction (Scheme 24), and recovery of free amine products (31).
R Deprotection Solvent Yield 49 (%) Yield 31 (%)
a: 4-tBu diethyl ether 45 79
b: 2-CH3 diethyl ether 52 70
c: 3-CH3 diethyl ether 60 69
1,4-dioxane 37 -
d: 4-CH3 a 41
e: 2-OCH3 diethyl ether 53 85
f: 3-OCH3 diethyl ether 59 92
g: 4-OCH3 diethyl ether 65 77
h: 2-F a a
i: 3-F diethyl ether 52 68
j: 4-F diethyl ether 74 74
n: 2-CF3 diethyl ether 27 -
o: 3-CF3 diethyl ether 59 -
a 49d, 49h, and 31h were synthesised as part of a previous project.
53
Investigation of Horner-Emmons reaction products
While the Horner-Emmons reaction was generally effective and gave the desired products as
reported above, the attempted reactions of N-Boc-4-piperidone (44) with 36p, 36r, or 36s
gave a significant quantity of undesired side-product 55 (Scheme 25). The isolated yield of
the desired product was low compared to the other Horner-Emmons reactions despite the
complete consumption of the piperidone reagent (Table 10), which with other observations
indicated that the undesired product was formed by a competing side-reaction with the limiting
reagent. The competing reaction significantly reduced the yield of 45 obtained, and also
caused complications in the purification of the desired product. The side-products had a















44 36(p,r,s) 45(p,r,s) 55(p,r,s)
7-61%
Scheme 25: Attempted Horner-Emmons reaction for synthesis of 4-benzylidenepiperidine derivatives (45)
where production of a piperidine-type side-product was observed.
Table 10: Results of Horner-Emmons reaction with selected derivatives which give undesired side-product.
Rf values given are for TLC with 9:1 hexane/ethyl acetate solvent system.
Isolated
R yield (%) Rf value Rf value
4-CF3 45p: 57 0.32 55p: 0.30
3-CN 45r: 39 0.19 55r: 0.18
4-CN 45s: 7 0.13 55s: 0.10
The difference was most apparent for the attempted synthesis of 45s where the isolated yield of
pure product was only 7%, although a significant amount of impure product
co-eluted with the side-product and was also recovered. The amount of the unknown product
was considerable: by NMR analysis of the crude reaction mixture or the co-eluted mixture,
it was observed that the recovered amount of the side-product 55s was comparable to the
desired product 45s obtained. The side-product showed similarities to the desired product
in the NMR spectra, with signals consistent with a para-substituted benzonitrile and a Boc-
protecting group, however the side-product also shows distinct differences from the product in
the 1H NMR spectrum, with a broad signal at 5.41 ppm instead of the sharper alkene signal
at 6.36 ppm observed for 45s. The presence of signals corresponding to the Boc-protecting
group in the spectra of 55s confirms that the product forms from a competing reaction of
the limiting reagent 44, resulting in the extremely low yield of 45s recovered compared to
other derivatives of 45.
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Although the number of other signals and relative integration of signals were the same as
those observed for 45s, the chemical shifts varied significantly and the signals were broader
and had unresolved coupling constants (demonstrated by correlations in the [1H,1H]-COSY
NMR experiment). As mentioned previously, broadness in NMR signals is expected if the
molecule contains a Boc-protected piperidine group which slows interconversion of the ring
conformations on the NMR timescale, however the broadness in the 1H NMR and 13C NMR
signals for the side-product was even more enhanced than observed for any derivatives of
45, and identification by 2D NMR was complicated by the broadness of the signals which
both reduced the intensity of any cross-peaks and meant some carbon signals were partially
overlapping, therefore making any interpretation unreliable for structure determination. The
samples containing the unknown product appeared to be oils, which meant crystallographic
methods could not be used for characterisation. Attempted determination of the exact mass
found only the mass corresponding to the expected product 45s.
As identification of the unknown product could not be reliably determined from the data
obtained for 55s, alternative methods of investigating the outcomes of the reaction were
explored. As the Boc-protecting group results in broadened NMR signals and hinders analysis
of the spectra, and the spectra for indicated 55s contains a Boc-proecting group, the synthesis
of the benzyl-protected analogue 47s was expected to have more clarified NMR signals and
enable use of 2D NMR experiments for characterisation. These expectations were based
upon the results observed previously in the synthesis of 3-methylbenzylpiperidine precursor
47c (see Scheme 13): the desired product 47c had been obtained in a reasonable yield with
no piperidine side-products observed, and NMR experiments showed all 13C NMR signals of
47c were easily distinguishable and not broadened, and therefore simpler to analyse than the
Boc-protected analogue. It was expected that the same change of the protecting group to
benzyl would enable better characterisation of the products of the attempted Horner-Emmons
reaction with the benzonitrile phosphonate derivative 36s.
The same Horner-Emmons reaction conditions were used to best replicate the experiment
which gave the unknown side-product, although the reaction time for the benzyl-protected
piperidone 46 with 36s was significantly faster than the reaction of N-Boc-4-piperidone 44
with 36s. By 1H NMR analysis of the crude mixture, the reaction appeared to give benzyl-
protected product 47s and a side-product 56s analogous to the Boc-protected 45s and
55s made previously (Figure 40). Aside from the signals corresponding to the protecting
groups, the number and shape of the signals in the 1H NMR spectra were the same, although
the chemical shifts were different for signals upfield of the aromatic signals which would be
expected with a different protecting group. The desired alkene product 47s had a 1H NMR
singlet signal at 6.25 ppm corresponding to the alkene hydrogen (c.f. 6.36 ppm for Boc-
protected product 45s) and four other signals integrating for two hydrogen atoms each for
the piperidine ring, similar to the observed spectrum of 45s (Figure 40A and 40B). Similarly
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the side-product had a distinctive broad signal at 5.41 ppm (c.f. broad signal at 5.38 ppm
for Boc-protected side-product 55s) and a series of four upfield broad 2H signals similar to
those observed for 55s (Figure 40C and 40D). From these observations, it was reasonable to
suppose that the products were largely analogous, and therefore that characterisation of the






Figure 40: 1H NMR spectrum comparison for benzyl and Boc-protected benzonitrile products (signals
upfield of aromatic hydrogen signals shown, δ 5.6-1.4 ppm). A: Boc-protected product 45s, B:
benzyl-protected 47s, C: Boc-protected side-product 55s, D: benzyl-protected side-product 56s. Signals
corresponding to atoms in protecting groups are not labelled.
In contrast to the attempted synthesis of the Boc-protected Horner-Emmons reaction product
45s, the desired benzyl-protected benzylidenepiperidine product 47s was produced in a
significantly higher proportion compared to the unknown side-product 56s. The reason for this
is unclear, but may indicate the rate of formation of unknown product is slower than formation
of the Horner-Emmons product, or that the unknown compound is the product of a further
reaction from the Horner-Emmons product that occurs given sufficient time, and given the
much faster reaction with the benzyl-protected piperidone the side-reaction had less time to
progress. The products were still difficult to completely separate by column chromatography
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but the unknown benzyl-protected product streaked less which meant pure fractions of each
product could be obtained.
The 1H NMR spectrum of the unknown product 56s still contained many broad signals with
unresolved coupling constants, indicating that some structural feature was affecting the bond-
rotation or interconversion of conformations of the structure even without the presence of a
Boc-protecting group. Despite this, and in contrast to the Boc-protected analogue, it was
observed that the 13C NMR signals of the side-product were sharp and did not overlap. The
increased clarity of the 13C NMR spectrum enabled more reliable interpretation of 2D NMR
experiments to characterise the structure of the unknown side-product.
The [1H,13C]-HMBC data for 56s was used to confirm that the para-benzonitrile structure
was indeed present, however signals from the benzonitrile ring showed correlations to a broad
signal with a 2H integration in the 1H NMR spectrum. This signal was confirmed to be
a methylene CH2 group by the DEPT-edited HSQC experiment, which indicates that the
reaction product is not a cyano-substituted benzylidene: in contrast, a benzylidene product
like 47s would show a correlation to a 1H integration alkene signal. The HSQC experiment
also showed that the characteristic side-product 1H signal at 5.38 ppm is attached to a carbon
atom with a shift at 122.3 ppm in the 13C NMR spectrum, and therefore the side-product is
also likely an alkene (Figure 41A).
Further analysis of the spectroscopic data and the 2D NMR experiments led to postulation of a
new structure for the benzyl-protected side product. HRMS analysis of the isolated compounds
identified that these are likely structural isomers, as the same mass peak was observed for
each product. The DEPT-edited HSQC experiment was used to determine which NMR signals
corresponded to methylene groups (Figure 41A), and the HMBC correlations of these signals
to other methylene groups and the sp2 hybridised carbon atoms demonstrated that the data
was consistent with a tetrahydropyridine structure instead of a piperidine (Figure 41B).
Following identification and characterisation of the side-product, it could be determined from
1H NMR analysis of the Horner-Emmons reaction mixture that the two isomeric benzyl-
protected products were produced in a 9:1 ratio, favouring the desired piperidine product 47s
(Scheme 26).
As the benzyl-protected postulated structure 56s is a structural isomer of the Horner-Emmons
reaction product 47s with the alkene in an adjacent position, it was therefore expected that
the hydrogenation reactions of 47s and 56s would yield the same product, 57s (Scheme
27). Firstly, the hydrogenation of 47s was conducted under standard conditions to give
one major product which was determined to be 57s. The structure of the product was
confirmed by HRMS which showed mass increase corresponding to two hydrogen atoms and
the NMR spectroscopic data which was consistent with the expected structure, with loss of

































Figure 41: 2D NMR experiments used to determine structure of Horner-Emmons side-product.
A: DEPT-edited HSQC for upfield hydrogen signals, and B: HMBC spectrum showing correlations between




















Scheme 26: Products of Horner-Emmons reaction with N-Bn-4-piperidone (46) and diethyl
4-cyanobenzylphosphonate (36s). Ratio of products determined from 1H NMR spectrum was 9:1,
favouring 47s.
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piperidine ring and para-substituted benzyl group, all consistent with 57s, and the benzyl-
protecting group was still evidently present. While the desired product 57s was the major
product of the reaction, there were traces of other products observed by NMR analysis of
the crude reaction mixture. It is expected that these signals are due to further reduction of
the CN functional group, but these were only present in small quantities which could not
be isolated and characterised. Using the same reaction conditions, the hydrogenation of the
Horner-Emmons side-product 56s, postulated to be the tetrahydropyridine isomer of 47s, was
performed and resulted in one major product with the same spectroscopic results consistent



















Scheme 27: Hydrogenation of isomeric products (56s and 47s) isolated from Horner-Emmons reaction.
Notably, the hydrogenation reaction of 56s took a significantly longer time to achieve complete
reduction of the alkene bond. The conversion of 47s to 57s took 2 hours, which was typical
for hydrogenation of the benzylidenepiperidine derivatives, whereas 56s required a longer
reaction time of up to 16 hr for complete reaction. The difference in reaction time therefore
indicates significant differences in the 3D conformations of the structure. The slower reaction
suggests that the alkene of the tetrahydropyridine ring in 56s is less sterically accessible than
the alkene of the benzylidenepiperidine isomer 47s, which therefore resulted in a reduction in
the rate of palladium catalysed reduction under the same reaction conditions.
Given that the products of the benzyl-protected reaction could be characterised, the
observations and spectroscopic results were then compared to the Boc-protected version
to determine if the analogous deductions could be made. There were obvious differences
between the syntheses of 55s and 56s, particularly that with a benzyl-protecting group
the side-product 56s was produced in significantly lower quantities compared to the target
benzylidenepiperidine product 47s. There were also very obvious similarities in the
spectroscopic data (see Figure 40). As mentioned previously, the HRMS data for a sample
of 55s showed a mass peak the same as what was observed for 45s, showing this product
could also be a structural isomer of the expected Horner-Emmons product 45s. While the
2D NMR experiments could not be reliably analysed due to overlap and broadness of signals,
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the 1H NMR spectrum and 13C NMR spectrum of 55s showed broad similarity to the spectra
of the benzyl analogue 56s. In particular, with the exception of signals for the protecting
groups, the number of signals and relative integrations of signals for each product were the
same and appeared very similar. The 1H NMR signals for the methylene groups adjacent
to the protected nitrogen atoms were shifted significantly further downfield relative to the
signals for 56s, however this is expected due to the change in protecting group. Overall,
the consistencies in spectroscopic data observed strongly support that the side-product of
the reaction with Boc-protected 44 and 36s is the tetrahydropyridine compound 55s - the




















Scheme 28: Deduced products of Horner-Emmons reaction with N-Boc-4-piperidone (44) and diethyl
4-cyanobenzylphosphonate (36s). Ratio of products determined from 1H NMR spectrum was 2:7,
favouring 55s.
The tetrahydropiperidine compound 55s had not been reported in the literature previously.
Interestingly, the reaction of 36s and the piperidone 44 had been reported in patents previously,
although there was no reference to the structure 55s or any indication of any side-reaction
reported in either instance.62,70 Similar syntheses of tetrahydropyridine compounds had also
not been previously reported. Tetrahydropyridines are interesting structures in organic synthesis
and various derivatives have been promising targets in drug development research, but they are
not widely reported due to the difficulties in selectively preparing and isolating this particular
structure.71,72 Commonly, tetrahydropyridines are synthesised via selective hydrogenation of
a pyridine ring, and while complex reagents and methodologies have been studied in order to
improve the selectivity and avoid complete reduction to the saturated piperidine ring, only a
limited scope of extended tetrahydropyridines structures have been effectively prepared.73,74
In comparison, the Horner-Emmons reaction conditions which yielded the tetrahydropyridine
product 55s are very mild and the reaction was comparatively fast, and the tetra-
hydropyridine was the major product of the reaction. High pressures and expensive catalysts
were not used, and therefore if conditions could be obtained which optimise formation of
the tetrahydropyridine (such as 55s), over the benzylidenepiperidine product (45s) then this
approach would be a substantially improved method upon reported synthetic processes.
The mechanism of synthesis for the side-product 55s was still unclear. The side-product was
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never the only product, and some of the desired product 45s was always present, therefore it
was considered that the side-product 55s may be a product of a further reaction after 45s had
formed by the Horner-Emmons reaction mechanism under the reaction conditions. To test
this, a pure sample of 45s (1H NMR spectrum shown in Figure 42A) was treated with sodium
hydride in THF for 16 hours, and resulted in a mixture of both 45s and 55s (Figure 42B),
showing that 55s can be produced from 45s under the Horner-Emmons reaction conditions
in the absence of any further piperidone or phosphonate reagents. The same experiment was
attempted using a pure sample of 55s (Figure 42C) treated with the same conditions, which




























Figure 42: Comparison of 1H NMR spectra (δH 1.8 - 6.6 ppm) demonstrating isomerisation of
benzonitrile-extended Horner-Emmons reaction products (45s and 55s) upon treatment with sodium
hydride in THF. A: Pure sample of expected Horner-Emmons product 45s, B: mixture after treating 45s
with sodium hydride in THF for 16 hr, C: pure sample of Horner-Emmons side-product 55s, and D: mixture
after treating 55s with sodium hydride in THF for 16 hr. In each case, the ratio of products was
approximately 7:2, favouring the side-product 55s.
The experiments showed the two structural isomers are able to interconvert under Horner-
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Emmons reaction conditions, and interestingly the ratio of the two isomers was the same
in each resultant reaction mixture, both times favouring formation of the tetrahydropyridine
isomer 55s over the expected Horner-Emmons reaction product (Figure 42). No reaction
intermediates or other products were observed and there was complete mass recovery from
the reactions. Similar tests without addition of the base, NaH, showed no isomerisation,
indicating the reaction is base-catalysed.
The interconversion of the isomers appears to be dependent upon the benzyl substituent:
as reported above, most derivatives were successfully synthesised with reasonable yields and
there were no observations of the side-product 55. For only a few derivatives was the presence
of the tetrahydropyridine side-product observed, and all of these derivatives contained an
electron-withdrawing benzyl substituent. For these derivatives, the relative quantities of the
side-product varied significantly, and some derivatives favour the production of the side-
product over the desired product. While no experiment so far has indicated the presence
of any reaction intermediates, the need for an electron-withdrawing functional group could
indicate that the isomerisation proceeds through a charged intermediate which is stabilised
by the ability to delocalise electrons into the electron-poor benzene ring. In this process, it
was speculated that the sodium hydride base could be facilitating the isomerisation reaction,
or that the degradation of the base over time may result in some sodium hydroxide being
present in the reaction mixture, which could potentially result in an unanticipated reversible
side-reaction.
To test the effect of the base on the resultant product mixture, LiHMDS was used in the
Horner-Emmons reaction to make 45s from Boc-protected piperidone 44 and phosphonate
36s, keeping all other conditions the same (Scheme 29). In this experiment the product 55s
was not detected at all, and a high yield (91%) of pure 45s was isolated. This experiment
supports the theory that the synthesis of 55s is base dependent and may involve reaction with

















Scheme 29: Horner-Emmons reaction of diethyl 4-cyanobenzylphosphonate (36s) with Boc-protected
piperidone 44, using LiHMDS used as the base.
Although these results indicate that the synthesis of both structural isomers 45 and 55 may
be expected with hydride or hydroxide bases under Horner-Emmons reaction conditions when
the benzyl substituent is an electron-withdrawing group, a similar synthesis reported in a
patent suggested that the Horner-Emmons reaction with 36s and a N-protected piperidone
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Scheme 30: Published Horner-Emmons reaction of diethyl 4-cyanobenzylphosphonate (36s) with
benzyl-protected piperidone 46, using potassium hydroxide as the base.75
In the reported literature synthesis, the hydrolysis of the benzonitrile to a benzamide also
occurs to give the product 58. Both nitrile and amide benzyl substituents are electron-
withdrawing by resonance, and the previous results of this project have indicated that
electron-withdrawing functional groups facilitate the unexpected isomerisation to give the
tetrahydropyridine products. The reported method had no mention of side-product formation,
which would indicate that sodium hydride, instead of any hydroxide present, is the base
enabling the isomerisation under the Horner-Emmons reaction conditions in the attempted
syntheses of this project. The use of hydroxide as the base for a Horner-Emmons reaction
is not common as it is not typically a strong enough base to deprotonate the phosphonate
and might instead be expected to hydrolyse the phosphonate (see Scheme 11). To test the
efficacy of the literature method, the reaction of 36s with N-Boc-4-piperidone (44) was
attempted under the published condtions to determine if only the benzamide product 59
would be obtained (Scheme 31), and the reaction with N-Bn-4-piperidone (46) as reported
























Scheme 31: Products of Horner-Emmons hydrolysis reaction with N-Boc-4-piperidone (44) and diethyl
4-cyanobenzylphosphonate (36s). The ratio of products 59 and 60 was approximately 3:4, as determined by
1H NMR analysis of the mixture.
In both cases the presence of significant amounts of the tetrahydropyridine isomer product
























Scheme 32: Products of Horner-Emmons hydrolysis reaction with N-Bn-4-piperidone (46) and diethyl
4-cyanobenzylphosphonate (36s), following the literature method reported previously (see Scheme 30).75
The ratio of products 58 and 61 was approximately 9:1, as determined by 1H NMR analysis of the mixture.
than the desired product for the Boc-protected piperidine (3:4 ratio by 1H NMR analysis,
not separable), although in the Bn-protected analogue the side-product 61 was produced
in significantly lower quantities (<10% by 1H NMR analysis, not separable from mixture).
The results obtained for these experiments, and the consistency with the previous Horner-
Emmons reaction attempts (Table 10), indicated that the published method was likely to
have also produced the tetrahydropyridine isomer (61) even though this was not reported,
and therefore the use of potassium hydroxide as the base was not useful to resolve the issue
of isomerisation.
While this supported the initial hypothesis that the isomerisation is dependent on the presence
of hydroxide base, it also demonstrated that potassium hydroxide was an effective base for
Horner-Emmons synthesis of the isomeric mixture only when the phosphonate had electron-
withdrawing benzyl substituents (Scheme 33, Table 11). No reaction was observed with other
derivatives when potassium hydroxide was the only base used. It is possible that the ability
to delocalise charge into the electron-poor benzyl group stabilises a reaction intermediate to
enable the Horner-Emmons reaction to proceed, therefore a weaker base such as hydroxide can
be used. While stability of the reaction intermediate appears to be a key factor in enabling the
reaction, there is not sufficient evidence to conclude that the formation of the two isomeric
products proceeds via a Horner-Emmons reaction mechanism, and it is possible that both
isomers are formed by an alternate pathway.
The hydrogenation of the benzonitrile isomers 45s and 55s gave predominantly the desired
product 48s but there were still some undesired minor side-products, likely due to further
reduction of the nitrile bond. The benzonitrile target compounds were the only compounds
containing a benzyl susbtituent which was electron withdrawing by resonance and increased
the lipophilicity of the final target ligand compounds, however given the synthesis of 59 and


















36: R = alkyl, Br, CF3
36r, 36s: R = CN
44 45: R’ = alkyl, Br, CF3
62, 59 : R’ = 3-CONH2, 4-CONH2
55: R’ = alkyl, Br, CF3
63, 60 : R’ = 3-CONH2, 4-CONH2
Scheme 33: Attempted Horner-Emmons hydrolysis reactions of benzylphosphonates (36) and
N-Boc-4-piperidone (36) with potassium hydroxide.
Table 11: Results of attempted Horner-Emmons hydrolysis reactions of benzylphosphonates (36) and










Observed Product 45: Side-product 55: Approx. ratio
R’ = products δH HA (ppm) δH *H3 (ppm) 45:55
a: 4-tBu none - - -
c: 3-CH3 none - - -
l: 3-Br 45l, 55l 6.29 5.39 5:1
n: 2-CF3 45n, 55n 6.50 5.28 49:1
p: 4-CF3 45p, 55p 6.38 5.41 1:3
Observed Product Side-product Approx.
R’ = products δH HA (ppm) δH *H3 (ppm) product ratio
3-CONH2 62, 63 6.38 5.39 7:1
4-CONH2 59, 60 6.38 5.40 3:4
benzamide derivatives were likely to be preferable synthetic targets to the benzonitriles. The
amide group is also electron-withdrawing by resonance and hydrophilic, and the synthesis is
simplified despite the isomerisation to two alkenes in the hydrolysis reaction as both alkene
isomers can be reduced to give the benzylpiperidine 64 by hydrogenation without any further
reduction of the functional group. The nitrile group is also reactive and less likely to be an
useful functional group in a final ligand compound due to reactivity in biologically-relevant
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conditions, even though it is an interesting structure to investigate the binding affinity with
the target protein. The amide is more stable, although it is likely to hydrolyse to the carboxylic
acid under harsher conditions.
Using the standard hydrogenation conditions, a mixture of the two products of the Horner-
Emmons reaction (59 and 60, 2:7 ratio) was reduced to the Boc-protected piperidine (Scheme
34). A longer hydrogenation reaction time of 16 hr was required to ensure complete reduction
of the structurally different alkenes 59 and 60, as had been observed for the hydrogenation
of benzonitrile-substituted tetrahydropyridine compound 56s previously. Treatment with TFA
then removed the Boc-protecting group to give 65, with spectroscopic analysis used to
confirm the expected chair-like confirmation of the piperidine ring as described previously, and
demonstrate successful removal of the Boc-protecting group. Despite the mixture of alkenes
used in the synthetic procedure and the longer reaction time required for the hydrogenation,
the synthesis of the benzamide compound 65 gave results consistent with the other



























Scheme 34: Synthesis of benzamide-extended piperidine compound 65, via hydrogenation of a mixture of
alkenes 59 and 60.
Alternate methods for synthesis of 4-benzylpiperidine derivatives
As an alternate method, the Heck reaction pathway was attempted to avoid complications
with the phosphonate reactivity and competing reactions observed for the Horner-Emmons
reactions. This involved synthesis of N-Boc-4-methylidenepiperidine (66) using a Wittig
reaction, followed by palladium-catalysed coupling with bromobenzene. Wittig reaction
conditions were investigated to give 66 from N-Boc-4-piperidone and methyltriphenyl-
phosphonium bromide in good yield (Scheme 35). A range of reaction conditions were
66
investigated, and using sodium hydride as the base gave the highest conversion to the desired
product. The synthesis of the terminal alkene was evident by NMR analysis of the purified
product, with the 2H alkene signal at 4.75 ppm. Other signals were very similar to the

















Scheme 35: Attempted synthesis of Boc-protected 4-benzylidenepiperidine (45x) via Wittig and Heck
reaction pathway.
A range of Heck reaction conditions were attempted on a small scale to test the efficacy of
the palladium-catalysed reaction. For most conditions no reaction was observed. A catalyst
system of Pd(OAc)2 and tri(o-tolyl)phosphine (P(o−tol)3) appeared to show some successful
synthesis of 45x as a minor component of a complex mixture of products which could not
be purified. The poor results of the Heck reactions attempted and the need for an additional
carbon-carbon bond forming reaction to make 66 (compared to the very successful synthesis
of phosphonate derivatives 36 required for Horner-Emmons reactions) meant the Horner-
Emmons reaction pathway was most effective in this work and used to make all derivatives of
31.
Horner-Emmons synthesis of 3-benzylpiperidine and 3-benzylpyrrolidine derivatives
Due to the success of the Horner-Emmons reactions in the synthesis of the range of
4-benzylidenepiperidine derivatives 45, this method was also expected to yield the required
Boc-protected 3-benzylidinepiperidine and 3-benzylidenepyrrolidine derivatives, 67 and 68
respectively. While this method was not utilised in the literature preparations of the small range
of reported derivatives of 32 and 33, the reported syntheses were typically lower yielding and
expected to be more complicated than the Horner-Emmons reactions method which proved
to be effective for the syntheses of 45 derivatives in this work. It was therefore expected
that the optimised Horner-Emmons reaction conditions used to synthesise the 45 derivatives
would yield the corresponding 3-substituted products (Scheme 36) .














n = 1: 54
n = 2: 39 36
n = 1: 68
n = 2: 67
Scheme 36: General synthesis of 3-benzylidenepiperidine (67) and 3-benzylidenepyrrolidine (68) derivatives
via Horner-Emmons reaction, analogous to synthesis of 4-benzylpiperidine (45) derivatives
vary significantly using the same reaction conditions. Using the same method and conditions
used to make 45 derivatives from 44, the reactions of 36 with N-Boc-3-piperidone (39)
were observed to take much longer at room temperature (48 hours instead of 16 hours for
synthesis of 45 derivatives, and longer for reactions with N-Boc-3-pyrrolidinone 54 which
typically did not go to completion). In contrast to the reactions with 44, the results indicated
that in some cases the hydrolysis of the phosphonate was significantly faster than the Horner-
Emmons reaction with N-Boc-3-piperidone or N-Boc-3-pyrrolidinone, resulting in loss of the
phosphonate reagent before complete consumption of the limiting piperidone or pyrrolidinone
reagent even when a significant excess is used (see Scheme 11).
For reactions with N-Boc-3-piperidone (39), using a large excess of 36 and base resulted in
the piperidone reagent being completely consumed in most cases. Despite this, the yields of
product 67 after column chromatography were consistently low, potentially indicating that
these derivatives are not effectively isolated and purified by the same work-up procedure (Table
12). The reasons for this have not been identified, but the amount of crude product before
column chromatography combined with NMR analysis of this crude mixture anticipated a
higher expected yield which was not collected, potentially indicating that interactions with
the column during chromatographic separation resulted in loss of product. It was observed
that while these derivatives had similar Rf values to the corresponding 4-substituted piperidine
derivatives (45), attempts to purify the products by column chromatography on silica gel were
hindered by the seemingly stronger interactions of the compounds with the silica, and yielded
significantly more dilute fractions. From the observations and low yield obtained, it was
considered possible that the products did not completely elute from the column, even when
more polar elution solvents were used.
The Horner-Emmons reaction gave predominantly the E -isomer of 67. The favourable
formation of the E -isomer is expected from the Horner-Emmons reaction, as the reaction
progresses through a less sterically-hindered intermediate in a conformation with the bulky
benzene ring and Boc-protecting group on opposite sides, resulting in the E -isomer product.
The NMR signals corresponding to each isomer were identified using 2D NMR experiments
(Figure 43), and the 1H NMR spectrum signals were integrated to obtain the relative proportion
of each isomer in the mixture. The signals corresponding to atoms in the piperidine ring were
typically broadened due to slow rotation of the Boc-protecting group and some 13C NMR
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Table 12: Combined yield and (E/Z )-selectivity of Horner-Emmons reaction for synthesis of
3-benzylidenepiperidine derivatives (67). (E/Z )-Isomer ratio was determined by comparing integration of
1H NMR signals. * Denotes signals corresponding to the minor Z -isomer.
Combined (E/Z)-Isomer δH HA,*HA
R Yield (%) Ratio (ppm)
67c: 3-CH3 39 4:1 6.38,6.30
67f: 3-OCH3 21 7:3 6.39,6.30
67h: 2-F 27 4:1 6.34,6.27
67j: 4-F 23 7:3 6.36,6.27
67x: H 47 7:3 6.40,6.33
signals adjacent to the nitrogen atom were so broad they were not observed. The slow
rotation also affected the appearance of the alkene hydrogen signal, as in the E -isomer the
Boc-protecting group is closer in space which results in the observed broadness of the signal.
In all cases the broader alkene hydrogen signal of the major E -isomer appeared downfield of
the Z -isomer alkene signal in the 1H NMR spectrum, and HSQC experiments were used to
determine the shifts of the broad 13C NMR signals which were difficult to assign unambigously
otherwise.
In an attempt to reduce any significant loss of intermediate compounds by column
chromatography, the alternate method for Boc-deprotection using hydrogen chloride solutions
was investigated (Scheme 37). This deprotection method had been mentioned in the literature
preparation of 3-benzylpiperidines, and was expected to give a solid hydrochloride product
38 which could be collected by filtration from the crude reaction mixture and therefore
avoid any need for column chromatography to purify 67 or the hydrogenation product 69
before the deprotection step.59 This was attempted for the unsubstituted derivative 38x and
the methyl-substituted derivative 38c, however using the same method used to make the
4-benzylpiperidine derivatives yielded no precipitated product in the final step of the method.
As an alternate strategy, the hydrogenation products 48x and 48c were purified prior to the
deprotection step, and the solvent was evaporated from the deprotection reaction mixture.
It was found that the hydrochloride salts of the 3-benzylpiperidine derivatives, unlike the
4-benzylpiperpdine hydrochlorides, were not solids: although the reaction was successful, the
product could not be collected by filtration from the hydrogen chloride solution, and therefore
did not offer any advantage over the TFA deprotection method.
As a further attempt to isolate workable quantities of these 3-benzylpiperidine compounds,
the alternate Heck reaction to make 67x was investigated. This pathway first required the
Wittig reaction of N-Boc-3-piperidone to synthesise the alkene 70, followed by palladium-
catalysed coupling with bromobenzene to give the desired piperidine 67 (Scheme 38). It was


















Figure 43: ROESY correlations showing 1H NMR signals corresponding to the E - and Z -isomers of
N-Boc-3-benzylidenepiperidine products (67). ROESY spectrum shown corresponds to












c: R = 3-CH3
x: R = H
Scheme 37: Attempted 3-step synthesis of 3-benzylpiperidine hydrochloride salts (38) via a
Horner-Emmons reaction, analogous to synthesis of 4-benzylpiperidine derivatives (49).
yield, see Scheme 35) were not as successful in the synthesis of 70. A range of conditions
were attempted in the synthesis of this product, but only very low yields were obtained and
the product could not be completely purified from the triphenylphosphine oxide by-product.
The 1H NMR spectrum of the asymmetric product 70 had alkene signals at 4.75 ppm and
4.81 ppm and the signals consistent with the Boc-protected piperidine ring. The yield, even
impure, was very low compared to the yields achieved using the alternate Horner-Emmons
reaction pathway.














Scheme 38: Attempted synthesis of Boc-protected 3-benzylidenepiperidine (67x) via a Wittig and Heck
reaction pathway.
bromobenzene and 66 (see Scheme 35) were then unsuccessfully applied to the attempted
synthesis of 45x from bromobenzene and the crude 70. A comparison of the crude 1H NMR
spectrum from the Heck reaction mixture with the data from the isolated product 67x from
the Horner-Emmons reaction clearly demonstrated that the product alkene was not present
in the mixture. The clearest indication that no product was present in the mixture was the
absence of the alkene hydrogen signals at 6.33 and 6.41 ppm, which each correspond to the
E - and Z -isomers of the desired product. Instead, the 1H NMR spectrum of the reaction
mixture contained signals corresponding to the reagents only. Due to the low yielding synthesis
of the methylidenepiperidine 70 and the ineffective Heck reaction conditions, this method was
not pursued further.
From this investigation it was determined that the Horner-Emmons method was the most
effective method to synthesise these derivatives of 67, but due to the very low yields the
full range of 3-piperidine derivatives (analogous to the range of 4-piperidine derivatives,
45) were not synthesised in this work. The compounds that were made and successfully
purified from the Horner-Emmons reaction were deemed sufficient to compare the difference
between the benzylpiperidine-type compounds, and ultimately to assess whether the change
in benzylpiperidine shape will impact the binding of the target benzylpiperidine-extended
aminoquinoline ligands with the Tec SH3 domain.
Following the attempted Horner-Emmons reactions with N-Boc-3-piperidine, the analogous
synthesis of 68 derivatives by the Horner-Emmons reaction of N-Boc-3-pyrrolidine 54 and 36
derivatives was also found to be low yielding (Scheme 36) but some required derivatives were
successfully isolated in workable quantities (Table 13).
In contrast to synthesis of the 3-benzylpiperidine derivatives the selectivity for the E -isomer
was not observed, and the mixture of products was shown by integration of the 1H NMR
signals to contain the two alkene isomers in approximately equal concentrations. The ROESY
NMR experiment did not identify correlations between the alkene signals and any pyrrolidine
ring hydrogen signals and therefore the signals corresponding to each isomer could not be
definitively assigned: the shape of the flattened five-membered ring could mean weaker
correlations are observed, and the broadness of the 1H NMR signals may also contribute to the
lack of observed ROESY correlations. By use of other 2D NMR experiments — specifically
71
Table 13: Yields of Boc-protected 3-benzylidenepyrrolidine derivatives (68) by Horner-Emmons reaction.




Combined Isomer δH HA
R Yield (%) ratio (ppm)
68c: 3-CH3 2 11:9 6.26,6.33
68h: 2-F 8 11:9 6.23,6.29
68i: 3-F 4 1:1 6.27,6.35
68x: H 10 1:1 6.25,6.33
COSY, HSQC and HMBC experiments — the correlations could be used to determine which
of the signals corresponded to each isomer, and therefore determine that the signals were
consistent with the expected structures even though stereochemistry could not be assigned.
Hydrogenation of the 3-substituted piperidines (E /Z -67) and 3-substituted pyrrolidines
(E /Z -68) yielded the corresponding 69 or 71 derivative (Scheme 39). Characterisation of
the 3-piperidine products was hindered by the broadness of the signals in the NMR spectra,
although this feature is indicative of a Boc-protected piperidine ring and shows the changes in
ring conformation are slow on the NMR timescale. HRMS analysis of the purified products and
integration of the 1H NMR signals were consistent with the target structures, but broadness
and overlap of the 13C NMR signals meant unambiguous assignment of all NMR signals was
not possible - it was anticipated that the subsequent Boc-deprotection step would resolve
the factor of slow conformation change of the piperidine ring, and therefore enable better
characterisation of the 3-piperidine products. In contrast, the NMR signals of the 3-pyrrolidine
products were not as significantly broadened, and splitting of the piperidine ring signals in
the 1H NMR spectrum (and the 13C NMR spectrum when the molecule contained a fluoro-
substituent) was evident. Each pyrrolidine hydrogen atom had is own distinct signal in the
1H NMR spectrum, indicating a substantial change in shape of the pyrrolidine ring occurred
as a result of hydrogenation of the alkene. Each of the products was obtained from the
hydrogenation reaction with a high yield (Tables 14 and 15).
TFA-catalysed deprotection of the derivatives of 69 and 71 yielded the corresponding
3-piperidine and 3-pyrrolidine derivatives (32 and 33 respectively) with good yields (Tables
14 and 15), with success of reaction clearly demonstrated by loss of the protecting group
signals in the NMR spectra and corresponding mass loss in the HRMS analysis of the product
samples. The complete removal of residual TFA catalyst was confirmed using 19F NMR
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n = 1: 68 n = 1: 71 n = 1: 33
n = 2: 67 n = 2: 69 n = 2: 32
Scheme 39: General synthesis of 3-benzylpiperidine (32) and 3-benzylpyrrolidine (33) derivatives by
hydrogenation and Boc-deprotection.
Table 14: Yields of 3-benzylpiperidine derivatives from hydrogenation and Boc-deprotection of
benzylidenepiperidines 67.
R Yield 69 (%) Yield 32 (%)
c: 3-CH3 100 98
f: 3-OCH3 100 95
h: 2-F 70 92
j: 4-F 97 92
x: H 100 96
Table 15: Yields of 3-benzylpyrrolidine derivatives from hydrogenation and Boc-deprotection of
benzylidenepyrrolidines 68.
R Yield 71 (%) Yield 33 (%)
h: 2-F 99 33
x: H 100 100
spectroscopy. For the 3-piperidine derivatives, the broadness in the 1H NMR signals of the
precursor was not observed in the deprotected product, and signals with splitting and coupling
constants consistent with a more chair-like piperidine structure were present. Distinct axial and
equatorial hydrogen signals were observed, and a substantial upfield shift of the equatorial
hydrogen atoms adjacent to the piperidine nitrogen was also observed due to loss of the
carbonyl of the protecting group. For the 3-pyrrolidine products, only small differences in the
NMR data were observed compared to the Boc-protected precursor. The signals corresponding
to the protecting group were no longer present, but the chemical shifts and appearance of other
signals in the 1H and 13C NMR spectra were largely unchanged, indicating the 5-membered
heterocyclic ring was substantially less affected by the planarised Boc-protecting group.
Synthesis of pyridinylmethylpiperidines
While Horner-Emmons reactions were also the preferable pathway for the synthesis of pyridinyl-
extended piperidines (Pathway 1, Figure 44), the poor yielding synthesis of the phosphonate
50c indicated that other pathways may be more viable. Given that a relatively simple synthesis
of phosphonium salts 52 was achieved, the Wittig reaction pathway (Pathway 2) would be
more viable for the synthesis of 53 derivatives if higher-yielding reaction conditions with
73
N-Boc-4-piperidone and an effective work-up procedure to separate the triphenylphosphine
oxide by-product (72) could be found. The Heck reaction pathway (Pathway 3) was also
considered because the synthesis of the intermediate 73 had already been achieved, and
therefore reaction of a bromopyridine instead of bromobenzene in the Heck reaction would
yield the required products. All three of these methods were attempted to determine whether





























Figure 44: Proposed retrosynthesis of pyridinyl-extended piperidines (34).
The Horner-Emmons reaction of impure 50c (see Scheme 19) with Boc-protected piperidone
44 and sodium hydride was attempted (Scheme 40). As observed in the 1H NMR spectrum
of the crude reaction mixture, some desired product 53c was formed alongside undesired
side-products. Distinct 1H NMR signals showing successful synthesis of the desired alkene
product were observed, including the singlet at approximately 6.3 ppm for the alkene hydrogen
and the series of broad signals consistent with the Boc-protected 4-piperidine ring. A large
amount of unreacted piperidone reagent was also recovered. None of the products could be
isolated and characterised due to the small scale of the reaction and the number of impurities
present. Given the poor yield of the Horner-Emmons reaction and the unreliable synthesis of
















Scheme 40: Attempted synthesis of a pyridinyl-extended piperidine derivative (53c) via a Horner-Emmons
reaction of piperidone 44 and pyridinyl-extended phosphonate 50c.
The Wittig reaction was potentially a more viable method as the phosphonium salts (52)
had been easier to synthesise and isolate. Wittig reactions using n-BuLi or LiHMDS as the
74
base were successful in achieving the desired products (Scheme 41). In most cases addition
of base to the phosphonium salt caused a colour change of the mixture to bright orange
or red, but for the reaction of 52c the mixture turned a dark red/black colour when either
n-BuLi or LiHMDS were added. The different colour of that particular reaction potentially
indicated that some degradation or unknown side-reaction had occurred, however no further
compounds were present in sufficient quantities to be isolated even though 1H NMR analysis
of the crude mixture demonstrated that a more complex mixture of compounds was present.
For all target products 53(a-c), spectroscopic analysis was used to clearly demonstrate the
alkenes were successfully synthesised and isolated. The characteristic broad singlet signal for
the alkene in the 1H NMR spectrum was observed in each case, and the broad signals for
the Boc-protected piperidine were observed in both the 1H and 13C NMR spectra, directly


















X = Cl, Br
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Scheme 41: General synthesis of pyridinyl-extended 4-piperidine derivatives (53) via Wittig reaction.
Initially, it was found that very low yields were recovered from the reaction work-up despite
complete consumption of the reagent piperidone. As the work-up required a liquid-liquid
extraction and these compounds were expected to be more water-soluble than the
benzylpiperidine analogues, the work-up was amended to avoid liquid-liquid extraction. The
mixture was instead quenched with water and concentrated to dryness under reduced pressure,
then suspended in a solvent mixture (3:1 hexane/ethyl acetate) and filtered before column
chromatography. This filtration removed the water-soluble impurities and also removed some
of the by-product of the reaction, triphenylphosphine oxide (74). The residual impurities were
successfully removed by column chromatography to give the desired products in low-moderate
yields (Table 16).
The same method was used to synthesise 3-(2-pyridinylmethyl)piperidine in moderate yield
(Scheme 42). As with the 3-benzylidenepiperidine derivatives synthesised by a Horner-
Emmons reaction mechanism, the Wittig reaction showed some selectivity for the E -isomer,
but the NMR data demonstrated that this was less significant as the ratio of products was
determined to be 5:4, by integration of the alkene signals in the 1H NMR analysis. Similar
to the previous 3-benzylidenepiperidine derivatives, the NMR signals of the two isomers were
substantially broadened and many were overlapping in both the 1H and 13C NMR spectra which
made determination of chemical shift and unambiguous assignment of all signals difficult,
although correlations in 2D NMR experiments were used to assign signals to their respective
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Pyridinyl Yield δH HA
substitution (%) (ppm)
53a: 2 81 6.37
53b: 3 36 6.30
53c: 4 53 6.28
isomer. As with all other benzylidenepiperidines, there were not distinct axial and equatorial
hydrogen signals in the 1H NMR spectum, indicating the piperidine ring is substantially
















Scheme 42: Synthesis of a Boc-protected 3-pyridinylmethylidenepiperidine derivative (75a) via Wittig
reaction of 52d and piperidone 39.
Each of the alkene products, 53(a-c) and 75a, were converted to the required piperidines
by hydrogenation and deprotection with TFA under standard conditions as previously described
for the 4-benzylpiperidine derivatives (Schemes 43, 44). Characteristic chemical shift
differences were observed in the NMR spectra in each case to demonstrate the reaction
was successful, as described for benzylpiperidines previously: loss of the alkene signals and
presence of distinct but broad axial and equatorial piperidine ring signals were observed
for hydrogenation product, and after the subsequent Boc-deprotection reaction the signals
corresponding to the protecting group were no longer present and the 1H NMR signals for
the equatorial hydrogens adjacent to the piperidine ring were significantly upfield compared
to the Boc-protected compound (Table 17). The yields of each piperidine varied due to the
water solubility which reduced the recovery of the piperidine product during work-up of the
deprotection reaction, and one derivative, 34b, could not be recovered from the reaction
mixture.
Due to the lack of reliability in the Horner-Emmons and Wittig reactions used to synthesise
derivatives of 53, the Heck reaction was also investigated as a potential pathway to pyridinyl













Scheme 43: General synthesis of pyridinylmethylpiperidine derivatives (34) by hydrogenation and

















Scheme 44: Synthesis of 3-(2-pyridinylmethyl)piperidine (35a) via hydrogenation and Boc-deprotection.














Pyridinyl δH HA δH H(2/6)eq δH H(2/6)eq Yield
substitution (ppm) (ppm) (ppm) (%)
76a: 2’ 2.71 4.07 34a: 3.26 41
76b: 3’ 2.55 4.08 34b: - 0
76c: 4’ 2.53 4.08 34c: 3.05 59
77a: 2’ 2.66/2.72 3.89 35a: 3.25 84
some 4-benzylidenepiperidine 45x (see Scheme 35) were attempted using 2-bromopyridine or
3-bromopyridine, however no product 53a or 53b was observed in the reaction mixture and
only reagents were recovered (Scheme 45). A range of palladium-catalysed conditions were
tested but no formation of product was observed in any case, and this method was not deemed
viable compared to the Wittig reaction pathway which yielded the desired products.
2.3.4 Synthesis of 6-position substituted 2-chloroquinolines: Selective Buchwald-
Hartwig coupling
Synthesis of 6-bromo-2-chloroquinoline










Scheme 45: Attempted synthesis of 4-pyridinylmethylpiperidine derivatives (53) via Heck reaction of 66
with bromopyridines.
6-position substituted 2-aminoquinolines is 6-bromo-2-chloroquinoline 24. The two halide
substituents are necessary in order for the successive amination reactions to occur under
Buchwald-Hartwig conditions to yield the extended 2-aminoquinolines. A literature method
for synthesis of 24 had been reported previously and was utilised in this work; the three-
step synthesis from commercially available starting materials was reported to give 24 with
reasonable yield.76
By this literature method, cinnamanilide 78 was prepared from 4-bromoaniline and cinnamoyl
chloride with moderate yield (Scheme 46). The NMR spectra of the product were consistent
with literature reporting of the compound, showing the distinctive 1H NMR trans-alkene
signals with a large coupling constant (3JH,H = 15.5 Hz) and para-substituted benzene ring















Scheme 46: Synthesis of cinnamanilide intermediate 78 via a literature method.76
By the literature method, ring closure to give the quinolone 79 was achieved with a Friedel-
Crafts acylation as a melt reaction, and subsequent reaction of the product with phosphorous


















Scheme 47: Synthesis of 6-bromo-2-chloroquinoline (24) from prepared cinnamanilide (78) via literature
method.76
The melt reaction of 78 with AlCl3 had variable results, and the reaction success was highly
dependent on the quality of the AlCl3 used. Successful synthesis of 79 (Scheme 48) was
78
observed by the loss of the trans-alkene 1H NMR signals with a large coupling constant and
instead signals with a smaller alkene coupling constant (3JH,H = 9.5 Hz) were observed to
indicate the ring-closing reaction was successful, but another similar product was often formed
and reduced the yield of 79 obtained. The 1H NMR spectrum of the side-product showed
distinctive triplet signals which would not be observed for a 2,6-substituted quinolone product
such as 79, however the side-product appeared to also be the product of the ring-closure
reaction as signified by the two doublets with a coupling constant of 3JH,H = 9.5 Hz at similar
shifts to those observed for 79 (Figure 45). Instead of the splitting pattern of doublets with
both larger 3JH,H and smaller 4JH,H coupling constants observed for 79 (8.7 Hz and 2.1 Hz
respectively), there was an additional hydrogen signal observed in the 1H NMR spectrum for
the side-product, and the presence of two triplet and doublet signals coupling to each other
















Scheme 48: Synthesis of side product 80 in attempted synthesis of 79 by reaction of AlCl3 with
cinnamanilide. Approximate ratio of products determined from crude 1H NMR spectrum varied from 1:4 to
1:1, favouring 79.
The formation of the undesired side-product appeared to be dependant on the purity of the
AlCl3 used and exposure of the reagent mixture to atmospheric moisture when handled, which
would cause degradation of AlCl3 to Al(OH)3. Although air exposure was not eliminated,
the relative quantity of 80 produced could be minimised by using AlCl3 which had not been
exposed to air prior to mixing with the reagent 78. While small amounts of 80 were sometimes
still present in the reaction mixture, this product was removed in the work-up after reaction
with phosphorous oxychloride.
Reaction of 79 with POCl3 proceeded to give the required quinoline intermediate 24, which
precipitated from the reaction and was purified by recrystallisation. The successful conversion
to this product was demonstrated by analysis of the 1H NMR spectrum which showed loss
of the broad NH signal from the quinolone, and a significant downfield shift for the H3
signal consistent with that reported in literature.77 Slow crystallisation of the filtrate from
the reaction work-up yielded 2-chloroquinoline, which was formed due to reaction of 80 (an
impurity from the previous reaction) with POCl3.
Synthesis of 6-substituted 2-chloroquinolines via Buchwald-Hartwig Amination
The Buchwald-Hartwig amination conditions used to synthesise a range of 6-heterocyclic































Figure 45: Comparison of 1H NMR spectra for products obtained from Friedel-Crafts acylation with
aluminium trichloride. A: Expected 6-bromoquinolin-2(1H)-one product (79), and B: side-product
quinolin-2(1H)-one (80). Broad NH signals not shown: appears at 12.21 ppm for product 79, and 12.36
ppm for side-product 80.
a range of substituted 2-chloroquinolines with good yield and generalisability to a range of












24 X = C, N
Scheme 49: Previously reported coupling reaction of piperidine derivatives with 6-bromo-2-chloroquinoline
(24) via Buchwald-Hartwig amination.52
The success of the coupling reaction is dependent on the reaction conditions including base,
catalyst system, solvent, pressure and temperature. A catalyst system of palladium acetate
and CataCXium® A ligand 81 had previously been determined to give the highest yield of the
desired products while minimising undesired side-reactions. The base also contributed to the
mixture of products obtained: potassium tert-butoxide and sodium tert-butoxide gave higher
yield but use of cesium carbonate as the base resulted in no formation of undesired coupling
80
side-products.52
Best results were achieved in previous work using microwave radiation as a fast and effective
method to synthesise the 2-chloroquinolines, and the best alternative method involved heating
the reaction mixture in a sealed tube. The solvents used for each of these methods was
different, however, because while toluene was used as the solvent in sealed-tube reactions it is
not a suitable solvent for microwave reactions, and therefore the similar solvent
α,α,α-trifluoromethylbenzene (BTF) was used for microwave-assisted reactions.78
In this work, microwave-assisted synthesis was initially attempted for coupling of 24 with 31c,
but a complex mixture of products was observed in the crude reaction mixture and none of the
2-chloroquinoline product could be isolated for characterisation (Scheme 50). In comparison,
a sealed-tube reaction using BTF as the solvent instead of toluene gave a much cleaner
reaction with no identified side-products. The sealed-tube reactions required a significantly
longer reaction time (16 hr, compared to 20-30 minutes for the microwave-assisted method
in previous work), but there was more conversion to the desired product rather than side-
products so the product could be isolated, therefore sealed-tube reactions were deemed the
most effective method for synthesis of the target benzylpiperidine-extended 2-chloroquinoline
derivatives. The change of solvent to BTF may have assisted the desired reaction by improving
solubility of the reagents, resulting in the apparent success of the sealed-tube reaction method

















Scheme 50: General synthesis of 6-position substituted 2-chloroquinoline derivatives (82) via
Buchwald-Hartwig amination. Amination reaction was first unsuccessfully attempted using
microwave-assisted conditions, then conducted successfully as sealed-tube reactions.
Using these conditions, the 4-benzylpiperidine derivatives (31) were reacted with 24 to give
predominately or exclusively the 2-chloroquinoline product with 6-position benzylpiperidine
substitution (Table 18). To confirm that the coupling had occurred at the 6-position of
the quinoline ring as desired, all significant quinoline and piperidine shifts in both 1H and
13C NMR were analysed compared to the reagents, HRMS data was collected to confirm
81
the distinctive isotope peaks for a chloro-compound instead of a bromo-compound, and 2D
NMR data was collected to determine whether the observed correlations were consistent with
the target structure. The 1H NMR spectra showed significant upfield shifts for the H5 and
H7 signals (typically 1.0 ppm and 0.3 ppm difference respectively) compared to the bromo-
substituted reagent 24, as would be expected if the electron-donating amine had reacted
at the 6-position. Comparatively, the H3 signal had a smaller upfield shift. Similarly, the
2D NMR experiments showed correlations of piperidine ring signals with C6 and adjacent
atoms, instead of to C2 (Figure 46). Specifically, the [1H,13C]-HMBC spectrum correlations
between the C6 quinoline signal and the signals of the axial hydrogen signals adjacent to the
piperidinyl nitrogen atom indicated successful coupling (Figure 46A), and the ROESY data
clearly demonstrated coupling had occurred at the 6-position of the quinoline structure as
correlation of the equatorial H2’/6’ piperidine signals with those of H5 and H7 was observed
(Figure 46B). Together with the HRMS data showing the mass consistent with the expected
82 derivative, including distinctive chlorine isotope peaks, the spectroscopic results confirmed
in each case that the desired product was formed.
Table 18: Results of Buchwald-Hartwig coupling reaction to give 6-position substituted 2-chloroquinoline
derivatives with 4-benzylpiperidine substituent (82). For purposes of comparison, the 1H NMR chemical







R Yield (%) δH H3 (ppm) δH H5 (ppm)
82a: 4-tBu 69 7.25 6.97
82b: 2-CH3 23 7.26 6.98
82c: 3-CH3 46 7.25 6.98
82d: 4-CH3 58 7.26 6.98
82e: 2-OCH3 53 7.25 6.98
82f: 3-OCH3 68 7.26 6.97
82g: 4-OCH3 56 7.26 6.98
82h: 2-F 70 7.25 6.98
82i: 3-F 56 7.26 6.99
82j: 4-F 45 7.24 6.97
82n: 2-CF3 32 7.26 6.99
82o: 3-CF3 51 7.26 6.99
82p: 4-CF3 62 7.25 6.98

























Figure 46: 2D NMR experiments used to determine reaction position from Buchwald-Hartwig amination.
A; HMBC correlations with C6 showing connectivity of piperidine with quinoline ring, and B: ROESY
correlations showing correlations between piperidine hydrogen atoms and the quinoline ring demonstrating
successful 6-position substitution. Example spectra shown are for 4-methylbenzyl derivative 82d.
The Buchwald-Hartwig coupling reaction of the 3-benzylpiperidine and 3-benzylpyrrolidine
derivatives (33 and 32 respectively) proceeded with similar results to those observed in the
preparation of 82 (Scheme 51, Table 19). Although the yields for the coupling of 33 and
32 with 24 were very varied, in most cases the reaction proceeded and gave the 6-position
substituted 2-chloroquinolines as the only product. Similarly to 82 derivatives, the most
significant upfield shifts in the 1H NMR spectra for 83 and 84 derivatives corresponded to
the H5 and H7 signals, which together with consistent shifts in the 13C NMR spectra, 2D NMR

















n = 1: 33 24 n = 1: 84
n = 2: 32 n = 2: 83
Scheme 51: Synthesis of 2-chloroquinoline derivatives with a 6-position 3-benzylpiperidine or
3-benzylpyrrolidine substituent (84 and 83) via Buchwald-Hartwig amination.
The same Buchwald-Hartwig coupling conditions were used to synthesise a methylpyridinyl-
extended 4-piperidine derivative 85a from 34a and 24 (Scheme 52). The structure of
83
Table 19: Results of Buchwald-Hartwig coupling reactions for synthesis of target 6-position substituted
2-chloroquinoline derivatives with a benzylpiperidine-type substituent.
R Yield (%) δH H3 (ppm) δH H5 (ppm)
3-benzylpiperidines
83c: 3-CH3 42 7.26 6.92
83h: 2-F 54 7.25 6.93
83j: 4-F 36 7.25 6.91
83x: H 32 7.25 6.90
3-benzylpyrrolidines
84h: 2-F 44 7.21 6.58
84x: H 54 7.20 6.56
4-pyridinylmethylpiperidines
85a: 48 7.25 6.98
85a: 0 - -
85a: 0 - -
the desired product was confirmed using spectroscopy in the same way as for the previous
2-chloroquinoline derivatives. The synthesis of the other isomers 85b and 85c was not
achieved using the same method, because the reagents 34b and 34c were not isolated
in sufficient quantities or with sufficient purity respectively. While the Buchwald-Hartwig
aminations were attempted using the reagents despite the low purity or scale, the desired














Scheme 52: Synthesis of 2-chloroquinoline derivatives with a 6-position pyridinylmethylpiperidine
substituent (85) via Buchwald-Hartwig amination.
Investigation of Buchwald-Hartwig reaction products
For the benzylpiperidine derivatives utilised in this work, it was determined by NMR analysis
that the vast majority of Buchwald-Hartwig coupling reactions did not give other quinoline
side-products and the purification of the product was achieved by column chromatography.
There were very few exceptions to the highly selective coupling of the piperidine to the
6-position of the quinoline ring. The competing 2-position substitution reaction was favoured
when coupling of the piperidines 65c and 32f to 24 was attempted, and a further undesired








Figure 47: Piperidine compounds for which attempted Buchwald-Hartwig amination reactions with 24 did
not yield the target 6-position extended quinoline product.
The only isolated product of the reaction of methoxy-substituted 3-piperidine derivative 32f
and 24 under Buchwald-Hartwig reaction conditions had NMR spectra inconsistent with the
expected product 83f. As demonstrated above, the upfield shift of the H5 and H7 signals
compared to the starting material 24 is one of the key indicators that the 6-position coupling
reaction occurred to give the desired 2-chloroquinoline, and further spectroscopic evidence
could be used to conclusively determine that the piperidine has coupled at the 6-position of
the quinoline structure. The product from reaction of 32f did not show such a significant
upfield shift for the H5 and H7 signals in the 1H NMR spectrum, and instead a large upfield
shift was observed for the H3 signal (6.87 ppm, compared to 7.42 ppm for reagent 24 or
7.26 ppm for the 6-position coupled product 83c). In addition, the piperidine signals for
H2’eq and H6’eq adjacent to the piperidine nitrogen were significantly deshielded compared
to derivatives of 83 (4.34/4.36 ppm, compared to 3.67/3.72 ppm for 83c). These results
are consistent with coupling at the 2-position of the quinoline ring, as the electron donating
amine substituent would result in the observed increased election density and shielding of the
neighbouring H3 atom, and the proximity of the electronegative quinoline nitrogen to the
piperidinyl hydrogen atoms and the quinoline nitrogen would cause the piperidinyl hydrogen
atoms to be comparatively deshielded compared to the 6-position coupled piperidine signals.
The 2D NMR experiments also did not show the correlations that would be observed for
6-position substituted quinoline products. Instead, the HMBC experiment showed correlations
between the equatorial H2’ and H6’ piperidine signals and C2, and the ROESY experiment also
showed correlations between these piperidine signals and the H3 quinoline signal (Figure 48).
HRMS of the isolated product gave the masses corresponding to the two isotopes of the
2-position substituted bromoquinoline product, in equal abundance. Combined, these results
show that the 2-position substitution reaction had occurred to give product 87f instead of


























Figure 48: Key 2D NMR experiments used to identify product of Buchwald-Hartwig amination from 32f
and 24. A: HMBC correlations with C2 showing connectivity of piperidine with quinoline ring, and B:























Scheme 53: Attempted synthesis of the 3-benzylpiperidine extended 2-chloroquinoline derivative 83f,
giving only 2-position coupled product 87f.
Similarly, the attempted Buchwald-Hartwig amination of 65 with 24 resulted in none of
the expected 6-position coupled product 88 (Scheme 54). Attempts to purify the reaction
mixture were unsuccessful, however 1H NMR analysis of the crude material identified that
the mixture contained mostly recovered reagents. While signals corresponding to the target
6-position coupled product 88 were not observed in the spectrum, some signals with shifts and
coupling consistent with a 2-position substituted quinoline were observed. These signals for
the potential product appeared to be similar to those observed for the 2-position substituted
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quinoline 87f (see Scheme 53). The upfield shift of the H3 signal indicated that the product
likely had an electron-donating substituent at the 2-position of the quinoline ring, and it
was therefore postulated that the only coupled product was the result of substitution of
the benzylpiperidine reagent to give 89. Due to the low conversion under these reaction























Scheme 54: Attempted synthesis of a 6-substituted 2-aminoquinoline derivative (88) which gave the
2-substituted product 89 only.
The absence of any desired 6-position substituted quinoline product in these reactions indicated
that some aspect of the conditions was no longer effective with these particular piperidine
derivatives. It was hypothesised that the palladium catalyst promoted the highly selective
6-position coupling reaction observed for all other tested benzylpiperidine derivatives, and
therefore that solely 2-position substitution in these few cases was the result of these specific
piperidine derivatives deactivating or inhibiting the activity of the palladium catalyst. It
would be expected that the nucleophilic aromatic substitution reaction of a piperidine at the
2-position aryl chloride of 24 would occur without the need for any catalyst, but whether
this substitution reaction would readily occur without an excess of the piperidine reagent and
under the sealed-tube reaction conditions in BTF was previously untested. If this nucleophilic
substitution reaction of 24 would otherwise occur under the Buchwald-Hartwig conditions
used, then the palladium catalyst also serves to prevent this substitution reaction and enable
only the desired 6-position coupling reaction.
The reaction of 24 and a benzylpiperidine both with and without addition of a palladium
catalyst under these sealed-tube reaction conditions had not been attempted previously,
but it was proposed that these experiments could be used to test the plausibility of the
hypothesis. The selective coupling of unsubstituted 4-benzylpiperidine 31x with 24 using a
Buchwald-Hartwig amination had been reported previously, and was found to selectively give
the 6-position coupled quinoline product 82x (Scheme 55).52
As this was reported to give only one product, it was proposed that the reaction of 31x with















Scheme 55: Reported Buchwald-Hartwig amination reaction of 4-benzylpiperidine (31x) and
6-bromo-2-chloroquinoline (24).52 *Product not isolated, conversion determined by NMR analysis of crude
mixture.
6-position coupled quinoline 82x or 2-position substitution product 27x. If the anomalous
2-position substitution products obtained from attempted Buchwald-Hartwig coupling
reactions (89 and 87f, see Schemes 54 and 53) were a result of inhibited catalyst activity,
then it would be expected that the nucleophilic aromatic substitution reaction would occur in
the absence of palladium catalyst to give a significant amount of the 2-position substituted
quinoline 27x. Concurrently, it would also be expected that if the palladium catalyst prevents
the nucleophilic substutition reaction at the 2-position of the quinoline and enables only the
6-position coupling reaction, then only the 6-position coupled quinoline product 82x would
be observed if the palladium catalyst is present, as previously reported.52 Both of these






















Scheme 56: Reactions of 4-benzylpiperidine (31x) and 6-bromo-2-chloroquinoline (24) under
Buchwald-Hartwig conditions, with or without addition of the palladium catalyst.
In the absence of palladium catalyst, none of the Buchwald-Hartwig coupling product 82x
was observed or isolated, and instead the only reaction product was 27x. The identity of the
product 27x was clearly demonstrated by the HMBC and ROESY correlations between the
piperidine hydrogen atoms and the quinoline ring which demonstrate the different substitution.
In contrast to the NMR spectra of the 6-position substituted products (for example, Figure
46) which show ROESY correlations of equatorial piperidine hydrogen atoms with the H5 and
H7 doublet signals, the equatorial piperidine hydrogen signals for the product 27x show a
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ROESY correlation with the H3 signal which is distinguished from the other doublet signals
by the larger 3JH,H coupling constant (Figure 49). In addition, the HMBC correlations show
the piperidine ring is directly connected to the more deshielded C2 atom adjacent to the
quinoline nitrogen atom. HRMS analysis demonstrated the 6-position bromide substituent





















Figure 49: 2D NMR experiments used to determine substitution position for product of uncatalysed
coupling reaction, 89x. A: HMBC correlations with C2 showing connectivity of piperidine with quinoline
ring, and B: ROESY correlations showing correlations between piperidine hydrogen atoms and the quinoline
ring demonstrating 2-position substitution.
Given that the only difference between the successful and unsuccessful Buchwald-Hartwig
coupling reactions using the optimised conditions is the piperidine reagent, these experiments
indicate that some amines may be inhibiting the activity of the palladium catalyst, and
therefore preventing the selective 6-position amination reaction. It is possible that some
benzyl substituents are able to coordinate to the palladium catalyst and the shape and
flexibility of those piperidine derivatives enable the compounds to bind and deactivate the
palladium catalyst. If this is the case, an alternate method for the synthetic process could be
considered: the hydrogenation of the benzylidenepiperidine derivative (for example, reduction
of 45 to give 48) can be postponed until after the Buchwald-Hartwig aminations, thereby
maintaining some rigidity in the piperidine derivative which may prevent adverse interactions
with the palladium catalyst and enable the Buchwald-Hartwig amination to proceed.
This method was attempted with the Buchwald-Hartwig amination of 4-benzamide derivative
90 with 24, but very poor conversion meant that any products could not be isolated (Scheme
89
57). By inspection of the 1H NMR spectra of the crude reaction mixture, it appeared the
formation of 2-substituted product (91) had occurred although signals consistent with the
desired 6-substituted product (92) were also observed. The characterisation of components
in the reaction mixture was further complicated as the alkenes isomerise in the presence of
hydroxide, and as sodium tert-butoxide can react with moisture to give sodium hydroxide it
appears the isomerisation reaction occurred. The result of this reaction is likely each of the
two isomers of the desired product (92 and 93) and the 2-substituted product (91 and 94),
which could not be separated. The coupling reactions did not progress substantially with
this particular amine reagent, and it was proposed that the relative hydrophilicity reduced
the solubility of the amine in the non-polar BTF solvent. The same reaction was attempted
using 1,4-dioxane as the solvent, and while it appeared there was better conversion to some




































Scheme 57: Attempted modified procedure for Buchwald-Hartwig amination of benzamide-substituted
piperidine derivative 90 with 24, with proposed major products of the reaction.
The same alternate pathway was attempted for the 3-methoxy extended 3-piperidine derivative
95f, which was not known to isomerise in the same manner as the benzamides. In a small
scale Buchwald-Hartwig reaction of 95f with 24 a complex mixture of products was obtained
and could not be purified (Scheme 58). From analysis of the crude 1H NMR spectrum, signals
were observed indicating that the mixture could contain both the 6-position and 2-position
90
coupled products (96f and 97f respectively), although as E - and Z -isomers would be expected
for each piperidine reagent and product the overlap of signals prevented any more accurate
analysis. As signals were present consistent with the desired 6-position coupled product, the
results indicate that constricting the shape of the benzylpiperidine reagent may restrict its
ability to deactivate the palladium catalyst so there is more opportunity for the Buchwald-
Hartwig amination to progress, at least to some extent. The low yield of this reaction meant
the products could not be purified, but repeating the reaction on a larger scale, and potentially























Scheme 58: Attempted modified procedure for coupling of 3-methoxybenzyl-extended piperidine derivative
95f with 24 via Buchwald-Hartwig amination, which gave a mixture of products including 2-position
coupled product 97f.
The other Buchwald-Hartwig amination with atypical products was the attempted coupling
of the 3-pyridinylmethylpiperidine derivative 35a with 24, expected to give the 6-position
extended quinoline compound 98a. Instead, the coupling reaction gave 99a, with a
2-position tert-butoxy substituent, as the only product (Scheme 59). The synthesis of this
compound indicates that the 6-position substitution has successfully occurred, as shown by
the HMBC correlations for C6 to piperidine hydrogen signals (Figure 50), but observation of
the very distinctive tert-butyl signal also shows the tert-butoxide base has reacted further in a
substitution reaction for the chlorine group at the 2-position. Under the optimised Buchwald-
Hartwig reaction conditions the base is in excess (1.3 mol equiv), but typically substitution
of the base at the 2-position is not observed. In the previously reported investigation of
Buchwald-Hartwig conditions the 2-tert-butoxy product was observed under some reaction






















Scheme 59: Attempted synthesis of 3-pyridinylmethylpiperidine extended quinoline 98a via














HA + H6ax H2ax
Figure 50: HMBC correlations with C6 observed for product of Buchwald-Hartwig coupling with 35a and
24, showing successful coupling of piperidine at 6-position of quinoline ring.
In an attempt to reduce the formation of this undesired product, the reaction was repeated
without using excess base. In this attempt only the reagents were recovered and no reaction
proceeded. The reactivity of this piperidine appears to significantly differ from the other
pyridine derivatives and from the other 3-benzylpiperidine derivatives, and in this work the
synthesis of the target 2-chloroquinoline compound could not be achieved.
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2.3.5 Synthesis of 6-position substituted 2-aminoquinolines by Buchwald-Hartwig
amination
A variety of methods have been used in previous work to convert 2-chloroquinolines to
2-aminoquinolines. The Kóródi method was the most used amination procedure, however this
required a very high reaction temperature and it was found to typically give low to moderate
yields (4-64%, Scheme 60).79,50,54 Another method involving 2-position substitution of a para-
methoxybenzyl-protected amine has also been used, but while the reaction conditions are not
as harsh as those required for the Kóródi method a further deprotection step is needed to










Scheme 60: Previously utilised Kóródi amination method for conversion of 2-chloroquinoline derivatives to
corresponding 2-aminoquinolines.52
Most significantly, a second Buchwald-Hartwig amination was found to be an effective method
used to convert several 6-position substituted 2-chloroquinolines to the corresponding
2-aminoquinolines, and higher yields of the 2-aminoquinolines could be achieved (typically
90% or greater), compared to low-moderate yields for the Kóródi method (Scheme 61).52
The Buchwald-Hartwig amination had not been previously attempted in the synthesis of
the benzylpiperidine extended ligand 15, but given it was used very successfully to achieve
amination of other 6-heterocyclic 2-chloroquinolines it was expected to work similarly with















Scheme 61: Previously used Buchwald-Hartwig amination for synthesis of 6-position extended
2-aminoquinoline derivatives.52
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These reported Buchwald-Hartwig amination conditions were applied to the conversion of
2-chloroquinoline derivatives (82) to the corresponding 2-aminoquinolines (19) using LiHMDS
as both the base and ammonia source (Scheme 62). The reported catalyst system of Pd(dba)2
and DavePhos (100) was found to be effective for all these derivatives when conducted as
sealed-tube reactions in 1,4-dioxane. The reaction proceeded in all cases with typically high
to complete consumption of the 2-chloroquinoline compound to give moderate to good yields















Scheme 62: General method for synthesis of target 4-benzylpiperidine extended 2-aminoquinoline
derivatives (19) via a Buchwald-Hartwig amination reaction.
The varied results may be due to the more difficult purification of the amines by column
chromatography, and also due to degradation of the product. It was observed that the
isolated 2-aminoquinoline products were susceptible to some degradation over time, and this
degradation was accelerated upon exposure to light. The only amendment to the previous
reported method was the work-up of the reaction mixture after the sealed-tube reaction, as
the previous method employed a liquid-liquid extraction which had the potential to decrease
recovery of the more polar 2-aminoquinoline products if there was improved water solubility.
In this work it was expected that more product could be isolated by simply quenching the
mixture with methanol and filtering through Celite® before column chromatography, and
therefore recovery of the more hydrophilic target compounds could be improved. The success
of the 2-position amination was evident in the 1H NMR and 13C NMR spectra as the H3 and
C3 signals are shielded due to the electron-donating amine substituent, and therefore shifted
upfield relative to the corresponding signals for the 2-chloroquinoline precursor. Other signals
in the quinoline ring which are also shielded by resonance due to the amino group were shifted
upfield compared to the starting material. The presence of a broad amine hydrogen signal
integrating for two hydrogen atoms was also observed for each of these products.
Likewise, for each 2-chloroquinoline derivative with a 3-benzylpiperidine or 3-benzylpyrrolidine
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Table 20: Results of Buchwald-Hartwig amination reactions to give 6-position substituted 2-aminoquinoline








R Yield (%) δH H3 (ppm)
19a: 4-tBu 88 6.66
19b: 2-CH3 61 6.66
19c: 3-CH3 46 6.67
19d: 4-CH3 41 6.66
19e: 2-OCH3 62 6.66
19f: 3-OCH3 93 6.68
19g: 4-OCH3 56 6.66
19h: 2-F 87 6.66
19i: 3-F 45 6.70
19j: 4-F 29 6.66
19n: 2-CF3 63 6.66
19o: 3-CF3 64 6.67
19p: 4-CF3 33 6.67
substituent (83 and 84 respectively) that could be synthesised in a workable quantity, the
Buchwald-Hartwig amination was able to successfully yield the target 2-aminoquinoline
compounds 20 (Scheme 63, Table 21). The same observations used to demonstrate success
for the 4-benzylpiperidine derivatives were observed for these derivatives, particularly the
upfield signals in the 1H and 13C NMR spectra for atoms which are comparatively shielded
due to the introduction of the amino group. HRMS analysis of the products also showed loss
















n = 1: 84 n = 1: 21x, 70%
n = 2: 83 n = 2: 20, 40-70%
Scheme 63: Buchwald-Hartwig amination for synthesis of 2-aminoquinoline derivatives 21 and 20 from the
corresponding 2-chloroquinolines 84 and 83. These compounds are the only 2-aminoquinoline ligands
synthesised in this work that contain a stereocentre (denoted by *).
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Table 21: Results of Buchwald-Hartwig aminations for synthesis of target 6-position substituted
2-aminoquinoline derivatives with a benzylpiperidine-type substituent.
R Yield (%) δH H3 (ppm)
3-benzylpiperidines
20c: 3-CH3 79 6.65
20h: 2-F 78 6.67
20j: 4-F 52 6.67
20x: H 40 6.65
3-benzylpyrrolidines
21x: H 70 6.67
4-pyridinylmethylpiperidines
22a: 53 6.67
From the 2-chloroquinoline derivatives 85a and 85b the corresponding 2-aminoquinolines 22a
and 22b could be synthesised using the same Buchwald-Hartwig amination reaction conditions
(Scheme 64), again with spectroscopic analysis including HRMS, 1H and 13C NMR, as well













Scheme 64: Buchwald-Hartwig amination for synthesis of pyridinyl-extended 2-aminoquinoline
derivative 22a.
Alternate synthetic methods used for derivatives with atypical reactivity
The synthesis of the benzamide-subtituted 2-aminquinoline compound 101 had not yet been
achieved by the previous methods, and so alternate approaches were investigated to overcome
the non-selective Buchwald-Hartwig coupling of 24 and the benzamide reagents (see Schemes
54 and 57). It was difficult to identify the products formed under Buchwald-Hartwig amination
conditions as the reaction progressed very slowly and therefore yielded very little product, and
the spectra of the crude reaction mixtures of the alkenes were significantly complicated due
to the isomerisation of benzylidenepiperidines to tetrahydropyridines (see Figure 42).
As solubility was expected to be causing the issues with low reactivity under Buchwald-
Hartwig amination conditions, an alternate strategy via synthesis and then hydrolysis of the
benzonitrile-extended target compound 102s would potentially resolve the poor solubility and
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conversion issues (Scheme 65). This pathway would require the hydrogenation to occur as the
final step after the hydrolysis, otherwise partial reduction of the nitrile bond would be expected
to reduce the yield and complicate purification. It would be anticipated that the hydrolysis
would cause the isomerisation to occur and give both the piperidine and the tetrahydropyridine
products, however subsequent hydrogenation of the mixture of products would be expected






























Scheme 65: Proposed alternate synthetic pathway for benzamide-substituted 2-aminoquinoline ligand 101.
Leaving the hydrogenation until after the Buchwald-Hartwig aminations to make the
2-aminoquinoline structure had not been attempted previously, and therefore the synthesis
of the simpler derivative, 15, via the aminoquinoline 102x was first attempted as a test to
investigate whether this reaction would occur. The proposed synthesis of 102x was again
via a Horner-Emmons reaction to make the Boc-protected benzylidenepiperidine 45x, which
would be followed by deprotection of the Boc-protecting group to give the piperidine 103x
(Figure 51). The successive Buchwald-Hartwig aminations would then give the
2-aminoquinoline compound 102x, following which hydrogenation could be attempted to
give the target 2-aminoquinoline 15.
The synthesis of 45x was achieved via Horner-Emmons reaction of 36x and 44 (Scheme
66). The reaction proceeded with moderate yield and results comparable to those obtained
for other derivatives of 45 previously (see Table 6). Spectroscopic data, including HRMS





















Figure 51: Proposed retrosynthesis of 15 via 4-benzylidenepiperidine extended 2-aminoquinoline 102x.
1H NMR spectrum showed the key singlet signal corresponding to the alkene hydrogen at
6.36 ppm, and broad signals consistent with the substantially planarised piperidine ring




















Scheme 66: Synthesis of 4-benzylidenepiperidine (103x) via Horner-Emmons reaction pathway.
The Boc-protecting group was then removed using the TFA-catalysed deprotection method,
with high yield of the free amine product 103x obtained. The spectroscopic results for the
product were consistent with loss of the Boc-protecting group while the alkene was retained.
The NMR spectra of the product indicate the piperidine ring retained a similar conformation
to the precursor, instead of a more chair-like conformation, as each methylene group of the
piperidine ring corresponds to one signal in the 1H NMR spectrum instead of giving a more
complex pattern of distinct axial and equatorial signals.
4-Benzylidenepiperidine (103x) was then reacted with 24 under the Buchwald-Hartwig
amination conditions used to make the 2-chloroquinoline derivatives previously, with moderate
yield of 106x achieved (Scheme 67). 2D NMR experiments were used to confirm that the
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piperidine coupled successfully at the 6-position of the quinoline ring, and no other products
were isolated or observed in the crude 1H NMR spectrum. HRMS was also used to confirm




























Scheme 67: Synthesis of benzylidenepiperidine- and benzylpiperidine-extended 2-aminoquinoline derivatives
from 103x via Buchwald-Hartwig aminations.
The 2-aminoquinoline product 102x was then synthesised from 106x by Buchwald-Hartwig
amination using LiHMDS, with the successful reaction demonstrated using spectroscopic
techniques including HRMS and distinctive shifts in the NMR spectra as described for synthesis
of other 2-aminoquinoline derivatives previously, most distinctively by the upfield shift of the
H3 signal of the quinoline ring compared to the reagent 106x, due to the electron-withdrawing
amino substituent. The shape of the piperidine ring could be deduced from the spectroscopic
results, as the HSQC experiment showed correlations between each piperidine ring carbon
signal and one broad 2H 1H NMR signal which indicates a substantially planarised ring,
instead of correlations with distinct axial and equatorial signals which would be observed for
a more chair-like ring conformation (Figure 52A). ROESY correlations were used to assign
the hydrogen signals for each methylene group of the asymmetric piperidine ring, and the
ROESY correlations observed between the piperidine signals and the quinoline ring signals
demonstrated the 6-position substituted quinoline structure (Figure 52B).
The final and key step was hydrogenation of 102x, and using standard hydrogenation
conditions it was found that the target 15 could be effectively achieved from 102x in high
yield, with the corresponding increase in mass found by HRMS analysis. The spectroscopic
results were consistent with the change in structure as previously reported,52 with loss of the
alkene hydrogen signal in the 1H NMR spectrum and an additional 2H signal corresponding to























Figure 52: 2D NMR experiments used to assign signals of benzylidene-substituted ligand 102x, and
demonstrating shape of piperidine ring. A: HSQC correlations of methylene signals for substantially
planarised piperidine ring, and B: ROESY correlations demonstrating quinoline substitution position and
assignment of inequivalent methylene hydrogen signals .
in piperidine ring conformation compared to the alkene precursor is also evident due to the
distinct axial and equatorial hydrogen signals observed, and characteristic coupling constants
measured for those signals which were consistent with geminal and axial-axial coupling for a
chair-like piperidine ring conformation (Figure 53).
Following the successful synthesis of 15 via 102x, the similar but more ambitious synthesis of
101 was attempted. A high yield of pure 45s had been achieved via Horner-Emmons reaction
using LiHMDS as the base as described previously, and this product was treated with TFA
under standard Boc-deprotection conditions to give the desired product 103s with a high
yield (Scheme 68). The removal of the Boc-protecting group was clearly demonstrated by
the lack of large t-butyl signals in the NMR spectra, and an upfield shift for the piperidine
hydrogen signals adjacent to the piperidine nitrogen in the 1H NMR spectrum due to loss
of the anisotropically deshielding carbonyl group. The similarities in the spectroscopic data
compared to 103x supported the analysis that the desired benzylidenepiperidine product was
obtained and none of the tetrahydropyridine product was observed.
The product 103s was then coupled with 24 in a Buchwald-Hartwig amination under the
established standard reaction conditions as a sealed tube reaction in BTF. The reaction yielded
a crude mixture which was found by 1H NMR analysis to contain the desired product 106s and



























H6’ H2’ H3’ H5’
Figure 53: Comparison of 1H NMR spectra of 2-aminoquinoline ligands. A: Benzylpiperidine-substituted


























Scheme 68: Attempted synthesis of benzonitrile-extended 2-chloroquinoline 106s via Buchwald-Hartwig
coupling reaction of 24 and 103s in BTF. Side-product 107s could not be isolated.
A low yield (35%) of the desired product was isolated, however a large amount of recovered
reagents was also obtained. The low conversion indicated that the reagents, specifically
101
the benzonitrile compound 103s, may not be sufficiently soluble in the relatively non-polar
















Scheme 69: Synthesis of benzonitrile-extended 2-chloroquinoline derivative 106s via Buchwald-Hartwig
coupling reaction of 24 and 103s in 1,4-dioxane.
A slightly higher yield of the desired 6-position coupled product 106s was isolated from the
attempted Buchwald-Hartwig amination in 1,4-dioxane, and none of the 2-position coupled
product was observed in the crude mixture. The success of the reaction was confirmed
by HRMS of the isolated product which was consistent with the 2-chloroquinoline product
instead of a bromo-substituted product, and by analysis of the NMR spectra. The 1H NMR
signals for the quinoline ring were consistent with 6-position extended 2-chloroquinolines
isolated previously. The distinct dd signal for H7 and the doublet signal for H5 were shifted
upfield for the 6-position substituted product 106s, in contrast the 2-position coupled product
(107s) where the H3 signal is shifted further upfield due to the effect of the electron-donating
piperidine substituent. In addition, the 2D ROESY NMR experiment showed correlations
between the H5 and H7 signals and the piperidine hydrogen atoms adjacent to the nitrogen
atom for the 6-position coupled product only. The signals for the piperidine ring appeared
as broad 2H signals correponding to each methylene in the ring, and the 2D ROESY NMR
experiment was used to determine which signals were closest to the benzonitrile (Figure 54).
These results indicate that the change to a more polar solvent may be preferable for piperidine
reagents which demonstrate poor conversion or poor selectivity under Buchwald-Hartwig
conditions in BTF. In contrast, the synthesis of the simpler 4-benzylpiperidine-extended
compound 82x had been attempted using 1,4-dioxane as the solvent, and was found to yield a
much more complicated mixture of products. Identified products from that reaction included
a substantial amount of the 2-position coupled quinoline product 27x and the products could
not be separated by chromatography showing the change of solvent is not always favourable

































Figure 54: ROESY correlations between piperidine ring and quinoline ring, demonstrating successful
















Scheme 70: Attempted coupling reaction of 4-benzylpiperidine (31x) and 6-bromo-2-chloroquinoline (24)
under Buchwald-Hartwig conditions with 1,4-dioxane. Reaction gave a mixture of products which could not
be separated. By crude 1H NMR analysis and comparison to pure compounds isolated previously,
approximate ratio of products 82x and 89x was 6:1 (c.f. Table 18, Scheme 56).
The 2-chloroquinoline compound 106s was converted to the 2-aminoquinoline compound
102s under the standard amination conditions with LiHMDS as the base and amine source
(Scheme 71). This reaction proceeded effectively, with success indicated by the upfield H3
shift in the 1H NMR spectrum, and the change in mass corresponding to loss of the chloride
103
and introduction of the amino group determined by HRMS analysis, as observed for all











Scheme 71: Buchwald-Hartwig amination of benzonitrile extended 2-chloroquinoline derivative 106s to
give 2-aminoquinoline product 102s.
Hydrogenation at this point would be expected to partially reduce the nitrile bond, as was
indicated by the results of hydrogenation of 45s previously, and so the conversion of the
nitrile group to the amide by hydrolysis was the preferable next step in the synthetic pathway.
This was achieved by hydrolysis using potassium hydroxide in ethanol, similar to those used to
synthesise the benzamide 59 previously (Scheme 72). The hydrolysis reaction did not proceed
under gentle reaction conditions at room temperature, and therefore the reaction progress was
heated at reflux and carefully monitored by TLC in order to minimise further hydrolysis of the
desired amide product. When the reaction was complete the amide product was extracted
from the reaction mixture and purified by column chromatography. Interpretation of the
NMR data for the product was difficult as both alkene isomers of the product were present,
however HRMS was used to show the desired mass peak for the product 104 (and therefore

















Scheme 72: Hydrolysis of benzonitrile-extended 2-aminoquinoline 102s to give inseparable mixture of
benzamide isomer products 104 and 105.
As the final step in the synthesis, the mixture of alkene structural isomers was reacted under
hydrogenation conditions for 24 hours - the extended reaction time is due to the less accessible
alkene in the tetrahydropyridine product 105, which takes longer to reduce to the desired



















Scheme 73: Hydrogenation of inseparable mixture of benzamide-extended 2-aminoquinolines 104 and 105
to give final ligand compound 101.
HRMS analysis was used to confirm an increase in the mass corresponding to two hydrogen
atoms, consistent with the desired product. NMR spectroscopy was used to determine that
only one product was present as the result of the hydrogenation of both alkenes to give 101
as desired. The appearance of the signals in the 1H NMR spectrum of the product was highly
similar to the other substituted benzylpiperidine derivatives. Axial and equatorial signals
with characteristic coupling constants were observed for each piperidine ring signal, and the
comparatively upfield signals observed for the H3 and H5 quinoline ring hydrogen atoms are
indicative of the electron-donating amine substituents attached at the 2- and 6-positions of
the quinoline ring, consistent with the target structure. Broad NH signals were observed
for the 2-position amino substituent on the quinoline ring and for the amide substituent on
the benzylpiperidine group. Combined, the spectroscopic data strongly supports successful
synthesis of the benzamide target 101 by this alternate synthetic pathway.
From the successful synthesis of these 2-aminoquinoline derivatives with benzylidenepiperidine-
type substituents, other similar desired products were also proposed. Given only one
pyridinylmethylpiperidine derivative (22a) had been synthesised via the general method
previously, it was proposed that instead of the low yielding synthetic pathway of the 3-pyridine
derivative 22b the analogous compound 108b could instead be a useful target (Figure 55).
The benzylidene substituent results in a substantially planarised piperidine ring, and therefore
may have an effect upon the strength of the binding interaction with the Tec SH3 domain
and therefore give some information on the shape of the ligand required to optimally bind to
this protein target.
Also, to further investigate the impact of different 3-dimensional shapes of the piperidine
substituent upon binding to the Tec SH3 domain, the tetrahydropyridine-extended compound
109s was also a proposed target compound. From the related compounds made previously,









Figure 55: Further proposed 2-aminoquinoline target compounds with more planarised alkene substituents.
compounds have a substantially planarised ring conformation, likely similar to the
benzylidenepiperidine compounds, however the benzyl group is freely rotating and therefore
may make more similar contacts with the protein target that were achieved with the
benzylpiperidine lead compound.
Firstly, for the synthesis of 108b, the alkene precursor 53b had been prepared via a Wittig
reaction previously. This compound was treated with TFA to remove the Boc-protecting
group (Scheme 74). A low yield of product 110b was achieved, which was again proposed to
be due to the higher water solubility of the pyridine product compared to benzyl-substituted










Scheme 74: Synthesis of pyridinylmethylidenepiperidine derivative 110b via Boc-deprotection of 53b
with TFA.
The compound 110b was then coupled with the quinoline 24 using the established Buchwald-
Hartwig amination procedure, and a moderate yield of the desired 6-position substituted
















Scheme 75: Synthesis of pyridinyl-extended 2-chloroquinoline derivative 111b via Buchwald-Hartwig
coupling reaction of 24 and 110b in BTF.
Importantly, none of the undesired 2-position coupled product was observed after work-up
of the reaction, and the only isolated product was clearly demonstrated by spectroscopic
analysis to be 6-position couple product. HRMS analysis showed peaks consistent with the
106
chloroquinoline product, and the characteristic upfield chemical shifts of the H5 and H7 signals
were observed in the 1H NMR spectrum as expected.
The final step of the synthesis of the target compound was the second Buchwald-Hartwig
amination with LiHMDS, and this yielded the target compound 108b (Scheme 76). The
upfield shift of the H3 signal in the 1H NMR spectrum and the decrease in the HRMS mass
peak found were used to confirm the success of the amination reaction. In contrast to the
pyridinylmethylpiperidine ligand 22a made previously, the 1H NMR spectrum did not give
a series of signals consistent with a chair-like piperidine ring conformation. Instead, the
signals indicated a substantially planarised ring as expected for this type of structure, with
the broader 1H NMR signals corresponding to each of the methylene groups. 2D NMR
experiments, including ROESY, were used to definitively assign each of the signals to each













Scheme 76: Buchwald-Hartwig amination of pyridinyl-extended 2-chloroquinoline derivative 111b to give
the corresponding 2-aminoquinoline product 108b.
The other target ligand, the tetrahydropyridine compound 109s, could not be effectively
synthesised in the same way. Tetrahydropyridines are notoriously difficult to synthesise
selectively, and therefore the method serendipitously discovered in this work was deemed the
most simple method to obtain a tetrahydropyridine compound even though it is not selective.
Using that method, a Horner-Emmons reaction of the Boc-protected piperidone 44 with 36s
gave a mixture of 45s and 55s as described previously, and repeated column chromatography
gave a reasonable yield of pure 55s which could be used in the subsequent synthesis.
The sample of 55s was then treated with TFA to remove the Boc-protecting group (Scheme
77). This gave a crude oil which was purified by column chromatography to give one major
product. The NMR data clearly showed the loss of the signals corresponding to the Boc-
protecting group, and the HRMS data was consistent with the desired product. There were
clear similarities between the signals of the obtained product and the tetrahydropyridine
reagent, and these observations were used with 2D NMR methods to determine that the
major product was definitively the desired tetrahydropyridine 112s (Figure 56). The most
apparent similarity was the broad alkene signal at 5.44 ppm in the 1H NMR spectrum, which
appears upfield compared to the alkene signal for the benzylidenepiperidine isomer 103s (6.32
















































Figure 56: Comparison of 1H NMR spectra for alkene compounds, indicating the distinct 3D structures of
the benzylidene and tetrahydropyridine compounds. A: Boc-protected tetrahydropyridine reagent 55s, B:
product of deprotection reaction 112s, C: benzylidenepiperidine isomer 103s.
The Buchwald-Hartwig coupling of 112s with 24 in BTF was achieved using the general
method previously utilised in this work, and the desired 6-position coupled product 107s
was obtained (Scheme 78). HRMS analysis of the isolated product confirmed that the mass
peaks were consistent with the chloro-substituted product, and none of the 2-position coupled
6-bromoquinoline side-product was observed in this case. The structure of the Buchwald-
Hartwig product was studied by analysis of the NMR spectra. Under the Buchwald-Hartwig
reaction conditions, isomerisation of the product 107s to 106s was not observed in the NMR
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spectra, and instead key spectroscopic characteristics of only the tetrahydropyridine compound
were observed. Clear signals confirming successful coupling of the tetrahydropyridine to the
6-position of the quinoline reagent were distinct in the 1H NMR spectrum of the product,
specifically the upfield chemical shifts of the distinctive H5 doublet signal (4J5,7 = 2.7 Hz) and
the H7 doublet of doublets signal (3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz) compared to the quinoline














Scheme 78: Synthesis of benzonitrile-extended 2-chloroquinoline derivative 107s via Buchwald-Hartwig
coupling reaction of 24 and 112s in BTF.
Similarly to the precursors, the appearance of the tetrahydropyridine signals in the 1H NMR
spectrum could be interpreted to give some indication of the likely conformation of the
ring. The signals appeared very similar to the tetrahydropyridine precursor 112s, although
the signals for the methylene groups adjacent to the tetrahydropyridine nitrogen atom were
shifted downfield due to the deshielding effect of the aromatic quinoline ring system. The
signals corresponding to the hydrogen atoms in the tetrahydropyridine ring were substantially
broadened, indicating slow interconversion between ring conformations on the NMR timescale
and therefore a substantially planarised ring conformation as anticipated (Figure 57A). The
appearance of the signals for the heterocyclic ring were compared to the 6-substitituted
2-chloroquinoline derivative 82x with a 4-benzylpiperidine substituent (Figure 57B) and a
106s with a 4-benzylidenepiperidine substituent (Figure 57C). Whereas the distinct axial
and equatorial hydrogen signals for the benzylpiperidine compound 82x indicate a chair-like
conformation of the heterocyclic ring, the NMR signals for the alkene derivatives 106s and
107s show less signals and no distinct axial and equatorial hydrogen atoms. The broadness
of the signals indicates there is slow interconversion between the ring conformations on the
NMR timescale, and these observations demonstrate the heterocyclic rings for the alkene
compounds 106s and 107s are substantially planarised compared to 82x. Between the two
compounds with substantially planarised heterocyclic rings, there is a still significant structural
variation due to the freely rotating benzyl group of the tetrahydropyridine compound 107s.
In contrast, the planar and asymmetric alkene bridge of 106s has one fewer rotatable bonds
and the spatial position of the substituted benzene ring relative to the quinoline ring is limited






































H6’ H2’ H3’ H5’
Figure 57: Comparison of 1H NMR spectra for structurally different 6-position extended 2-chloroquinoline
compounds. A: Tetrahydropyridine substituted 2-chloroquinoline product 107s, B: 4-benzylpiperidine
substituted 2-chloroquinoline product 82x, and C: 4-benzylidenepiperidine substituted 2-chloroquinoline
106s.
The 2-chloroquinoline 107s was treated with LiHMDS and reacted under Buchwald Hartwig
amination conditions to give an impure mixture of products containing the corresponding
2-aminoquinoline compound 109s (Scheme 79). The products could not be separated using
column chromatography, and therefore the 1H NMR spectrum of the crude mixture was instead











Scheme 79: Buchwald-Hartwig amination of benzonitrile extended 2-chloroquinoline derivative with a



































Figure 58: Upfield region (δ 1.3 ppm - 5.8 ppm) of 1H NMR spectrum of crude mixture after attempted
amination of tetrahydropyridine extended 2-chloroquinoline, and structures of the proposed products. The
NMR signals corresponding to each product are labelled in purple for 109s and blue for 19s, and the
non-overlapped signals for 102s are labelled in green. The NH2 signals for the three compounds are
overlapped and not labelled (broad signal at 4.73 ppm).
It was determined that the major product was the desired 2-aminoquinoline 109s, with a
6-position tetrahydropyridine substituent. The 1H NMR signals consistent with each of the
methylene groups of the tetrahydropyridine substituent were present, and the broad alkene
signal at 5.58 ppm was also evident and characteristic of a tetrahydropyridine product. The
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success of the 2-position amination reaction was evident due to the clear upfield shift of the
H3 doublet signal compared to the 2-chloroquinoline reagent, due to the electron-donating
amino group.
The second major product was in some respects similar to the desired product, and also had
an upfield H3 doublet signal consistent with another 2-aminoquinoline product. Instead of the
broad 2H signals for the methylene groups of the tetrahydropyridine product, however, the
pattern of signals in the upfield region of the 1H NMR spectrum was diagnostic for a chair-like
conformation of a piperidine ring. From this, it was deduced that a significant amount of the
tetrahydropyridine structure had been reduced under the relatively harsh amination reaction
conditions in a sealed tube, therefore yielding the 4-piperidine compound 19s which had been
synthesised previously.
A small amount of a further minor product was also observed in the crude 1H NMR spectrum.
A small singlet signal at 6.38 ppm indicated that some isomerisation may have occurred to
give the benzylidenepiperidine compound 102s. While most of the signals corresponding to
this minor product are overlapping with signals for the major products, the triplet-type signals
present at 2.59 and 3.27 ppm are consistent with the signals expected for the substantially
planarised 4-piperidine ring with a benzylidene substituent, therefore these observations
strongly support that this minor product is indeed the compound 102s.
Each of these compounds are very structurally similar and therefore, although it was clear the
desired product had been synthesised, the compound 109s could not be isolated or assayed
with the Tec SH3 domain. The crude NMR spectrum did indicate that the conformational
structure of the 6-position substituent was as expected, with a substantially planarised
heterocyclic ring. If a more effective and selective synthesis of this type of tetrahydropyridine
compound were developed, the hypothesis that a 6-substituted 2-aminoquinoline with a
substantially planarised heterocyclic ring and a freely rotating benzyl substituent would interact
differently with the Tec SH3 domain could then be tested.
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2.4 Binding studies of 6-position extended 2-aminoquinoline
derivatives
2.4.1 Assay aims and proposed method
The binding activity of the 2-aminoquinoline derivatives with the murine Tec SH3 domain in
previous studies had been investigated using either NMR chemical shift perturbation assays
or Fluorescence Polarisation (FP) assays.52,50,54,53 Both of these methods can give valuable
information regarding the binding position or competitive binding activity of the ligand for the
Tec SH3 domain, however given the large number of compounds prepared in this work it was
determined that an alternate method for higher-throughput screening of the small-molecule
ligands would be preferable. Surface Plasmon Resonance (SPR) assay methods have emerged
as a useful tool for screening of protein interactions, and while this gives less information on
the nature of the binding interaction (compared to NMR assays, for example) the method can
be used to more rapidly and simply identify ’hit’ compounds which interact with the protein
target. A ’hit’ compound is, for the purpose of this investigation, any ligand determined to
bind with similar or improved binding affinity (measured as the equilibrium binding dissociation
constant Kd) compared to the previous lead compound, 15, and therefore determined to be
of interest for further investigation or interpretation of the binding activity.
In this project, an initial SPR assay ’screen’ was first used to investigate whether any of
the synthesised 2-aminoquinoline compounds bound with improved affinity compared to the
previously determined lead compound 15. The screen tests a general concentration range
which would determine a rough binding dissociation constant for compounds which bind with
Kd less than approximately 20 µM. The accuracy of the binding isotherm and Kd determination
is unreliable for Kd outside this range due to the extrapolation required. For Kd values less than
5 µM the screening method was also less accurate due to the limited number of data points
at lower concentrations, which means that the screening Kd for some compounds does not
reflect the true Kd value, and therefore should not be interpreted as an accurate measurement
of the binding affinity.
For any compounds which did appear to have improved binding activity compared to the
previous lead compound, the SPR method was then used to determine the binding dissociation
constants with an optimised method for the indicated Kd value and measurements repeated
in triplicate. Ultimately, it was desired that this would identify a sufficiently strongly binding
ligand which could then be used to determine the 3D structure of the protein-ligand complex
via alternate methods, either NMR assays or crystallographic methods. However, even without
identification of such a strongly binding ligand, the information gained from this SPR method
would enable comparison of the binding affinity for the different ligand structures and therefore
some interpretation of the structure-activity relationship (SAR). This information could then
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be used in further studies to design 2-aminoquinoline ligands which would be predicted to
bind even better than those prepared in this work, and therefore lead to the goal of a strongly
binding 2-aminoquinoline ligand.
2.4.2 Screening method: Surface plasmon resonance (SPR) assays
The testing of biological interactions using this method exploits the principle of surface
plasmon resonance at an interface between a gold surface, known for having a high number of
surface plasmons, and a glass prism (Figure 59A). At a certain critical angle of light on a glass
prism, photons are internally reflected and come into resonance with the surface plasmons of
the gold layer. Due to the excitations of the surface plasmons of the gold layer at resonance,



































Figure 59: Surface plasmon resonance as applied to sensing of biological interactions. A: Experimental
set-up for measurement of SPR angle, solutions passed over sensor surface with bound target protein.
B: Change in SPR angle measured upon binding of small-molecule ligand to bound target protein. (Adapted
from GE Life Sciences, 2015.80)
The angle of incident light required for surface plasmon resonance is affected by the mass
concentration near the gold surface.81 Using this feature, if the target SH3 protein is attached
to the gold surface then binding of a small-molecule ligand to form the SH3-ligand complex
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will result in an increase in mass concentration near the gold surface, and therefore a change
in SPR angle will be observed (Figure 59B). This change in SPR angle upon addition of
ligand is referred to as the ’response’ and is quantified in response units (RU).82 The change
in response is directly proportional to the mass concentration at the gold surface and can
therefore be used to investigate the kinetics or affinity of the protein-ligand interactions.83,84
Unlike NMR assays or FP assays which require modified protein or peptides in order to measure
binding (nitrogen-15 labelled SH3 domain, or fluorescence tagged proline-rich peptide,
respectively), the SPR assay method does not require any modifications to the protein target
or the small-molecule ligand in order to measure the relative binding affinity, which is a
significant experimental advantage. Instead, the sensor surface with attached SH3 domain
target was prepared using what is referred to as the ’amine-coupling method’ (Figure 60).
By this method, the sensor chip (comprised of the glass prism coated with a gold layer) was
obtained with a dense carboxymethylated dextran matrix coating the surface, and the exposed
carboxyl groups were first reacted with NHS to give reactive succinimide esters. The Tec SH3
protein contains amino acid residues with nucleophilic groups, and the NHS esters react with
these nucleophilic groups or the N-terminal amine so that the target SH3 protein is covalently
attached to the sensor surface. After successful immobilisation of the SH3 protein, treatment




























Figure 60: Preparation of the SPR sensor surface with covalently attached Tec SH3 domain, using a
gold-coated glass prism (depicted in blue, yellow) with carboxymethyl-functionalised dextran matrix (grey).
Adapted from Johnsson et al. (1991).85
Using this method, it was considered preferable to utilise the GST-SH3 fusion protein as the
immobilised protein target instead of isolated SH3 domain. The GST-SH3 fusion protein is
simpler to purify, and in this case the GST protein was used as a reference protein for the
SPR binding assays. Previous studies investigating the binding of 2-aminoquinoline ligands
to the Tec SH3 domain had also used the GST-SH3 fusion protein for assays.50
While the label-free method for attaching the SH3 domain protein to the sensor surface is
advantageous and simpler compared to methods which require labelled protein, it also imposes
some limitations on the binding interactions which may be detected. The ’amine-coupling’
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method does not necessarily attach exclusively through amine groups of the lysine side-chains
and the N-terminus amino group, as NHS esters are known to react with several nucleophilic
groups of amino acid side-chains, including the thiol group of cysteine, the imidazole of
histidine, and the phenoxy group of tyrosine.86 Given that several residues containing these
nucleophilic groups are present in the GST-SH3 fusion protein (Figure 61), the covalent
attachment of the target SH3 domain to the sensor surface could occur through several
different residues and therefore the orientation of the bound SH3 domain would not be
consistent. Some of the nucleophilic side-chains are near to the binding region targeted by
the 2-aminoquinoline ligands, and therefore binding through these residues would potentially
hinder the ability of the small-molecule ligands to bind effectively during the SPR assay.
EIVVAMYDFQA TEAHDLRLER GQEYIILEKN DLHWWRARDK YGSEGYIPSN YVTGKK
Figure 61: Structure of the Tec SH3 domain target and nucleophilic residues available for coupling to
sensor surface. Primary sequence of murine Tec SH3 domain with residues known to be important for
binding of 2-aminoquinolines (W216 and D196) highlighted in green, and residues with nucleophilic side
chains known to react with NHS esters shown in blue. Ribbon structure of murine Tec SH3 domain shown
with the side chains visible for highlighted residues only.
The dense carboxymethyldextran matrix on the sensor chip enables a high concentration of
the protein target to be immobilised on the sensor surface. Even though the coupling of
the SH3 domain target to the activated NHS esters may have been non-selective, the high
concentration of immobilised protein should ensure that a large amount of the protein target
is still accessible and available for binding to the small-molecule ligands. A small-molecule
ligand known to bind to the SH3 domain target was used as a positive control to ensure
consistency between the assays and immobilisations, and in each case the measured SPR
response demonstrated that the ligand could successfully bind to the immobilised GST-SH3
fusion protein.
116
The 2-aminoquinoline ligand compounds were all prepared as solutions in 5% DMSO/
1 x PBS buffer of increasing concentration up to 100 µM. The use of DMSO was intended to
aid solubility of the small-molecule ligands for the SPR assays, however the NMR assays used
previously were run in a solution of 10% DMSO, and therefore there was an added limitation
upon the lipophilicity of ligands which could be tested using this SPR method. For the ligand
solutions, the SPR response was measured as the solutions were passed over the protein chip.
Higher concentrations of ligand bound to the protein gave a larger SP response at the protein
surface. The assays resulted in a sensorgram for SP response over time for each concentration
(for example, Figure 62). In each case the sensorgram showed that after injection of the ligand
solution (point A) steady-state binding was rapidly achieved (point B). After sufficient time
to ensure the response was stable, the sensor surface was washed with buffer to remove all
bound ligand (point C). The studied 2-aminoquinoline ligands were rapidly removed from the




Figure 62: Typical SPR assay sensorgrams used for determination of equilibrium dissociation binding
constant Kd for a small-molecule ligand. Example shown is for compound 22a.
Steady-state or equilibrium binding was observed at each concentration of 2-aminoquinoline
ligand, giving a region where the response is consistent and therefore the rate constants for
binding and dissociation of the protein-ligand complex are equal. The steady-state response
(Req) for each sensorgram was therefore plotted against the ligand concentration (C) to
generate the binding isotherm (Figure 63), and nonlinear regression fitting could then be






The nonlinear regression analysis determined fitted values for the response upon saturation of
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protein binding sites (Rmax), equilibrium binding dissociation constant (Kd) and the response
offset due to the bulk refractive index in the sample (RI).87,88 As demonstrated by Equation
2, the Kd value is the concentration of 2-aminoquinoline ligand required to achieve half the
maximum response (Rmax), or occupy half of the saturation SH3 binding sites.
Figure 63: Typical binding response curves for SPR assay used for determination of dissociation binding
constant Kd. Example shown is assay of ligand 22a with Tec GST-SH3 fusion protein.
All prepared 2-aminoquinoline ligands were initially screened using standard concentrations (up
to 100 µM) to determine the screening Kd value, and then repeated in triplicate for the ’hit’
compounds to determine the assay Kd values (Table 22). The range of concentrations tested to
determine the assay Kd values were optimised to avoid extrapolation, especially for the tighter
binding ligands where saturation binding was typically achieved at lower concentrations.
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R = Compound Kd (µM) Kd ± SD (µM)
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19s 1.7a 2.0 ± 0.5
NO
NH2












21x 9.6 9.7 ± 0.3a
NN






R = Compound Kd (µM) Kd ± SD (µM)
N
NC
102s 2.9 2.2 ± 0.7
N
102x 9.0 20 ± 3
N
N
108b 1.5a 1.9 ± 0.1
a Highest concentration data point removed due to precipitation or aggregation of compound under assay
conditions. b Response-concentration curve not at plateau, saturation binding not achieved. c Response too
low for saturation binding.
2.4.3 Results of screening.
As this was a new assay method used for the investigation of small molecules binding the
the Tec SH3 domain, it was not assumed that the Kd values determined by the SPR method
could be directly comparable to the Kd values reported for previous compounds which were
determined by the NMR chemical shift perturbation assay method. The compound 15 had
previously been assayed using the NMR assay method and this determined a Kd value of
9 µM.52 The same compound was therefore assayed with the Tec SH3 domain using the
SPR method, and although initially the screening method gave a consistent Kd value this
was difficult to replicate and a large range of values were obtained (Kd = 27 ± 11 µM).
The high degree of variability with results for this compound meant the lead compound was
not an effective positive control which could be used for comparison of binding affinity with
the novel compounds. The reasons for the lack of reproducibility were not clear, however it
was noted during the synthesis of the majority of the benzylpiperidine-extended derivatives,
including 15, that the 2-aminoquinoline products appeared to degrade over time, and in
particular degradation occurred more rapidly when exposed to light. This degradation was
not noted in the previous studies,52 and changes in the measured Kd value over time had not
been examined previously, so the impact of this upon the results of the NMR assays was not
clear. For the SPR method, however, it was evident that the Kd value could not be effectively
replicated.
In contrast, the novel 2-aminoquinoline ligand 22a with a pyridinylmethylpiperidine substituent
did not appear to have the same rapid decay in light. Binding assays of this compound using
the SPR method were much more consistent with each other and consistent over time. The
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observations indicate that the pyridinyl compound may be less susceptible to degradation
over time compared to the previous lead compound, which is a very favourable incidental
discovery for this project as compounds which degrade rapidly are obviously difficult to study
for bioactivity and, for further applications, would not be useful as potential drug compounds.
It was found over a series of assay runs that when the lead compound 15 and the novel
ligand 22a were both assayed in succession, the novel compound always had a lower Kd
value, and overall the results were much more consistent (Kd = 5 ± 1 µM). From this, it was
determined that 22a was likely a stronger binding ligand than the lead compound, and due
to the consistency of results 22a was subsequently used as the positive control for the SPR
assays.
While the screening identified seven novel 2-aminoquinoline compounds which appeared to
bind with improved binding affinity compared to the previous lead compound, the hit rate
was quite low despite the similarities in structure. The differences indicate that the 6-position
quinoline substituent has a very significant impact upon the strength of the binding interaction
with the Tec SH3 domain, with the potential for the strongest binding small-molecule ligands
identified to date (including 101 and 108b) or dramatically reduced binding affinity (19c and
19p).
Substituted 4-benzylpiperidines
The largest subset of novel compounds tested were 2-aminoquinoline compounds with a
substituted 4-benzylpiperidine substituent, based upon the 4-benzylpiperidine extended lead
compound 15. Unsurprisingly, the largest compound tested, with a bulky t-butyl substituent,
was insoluble under the SPR assay conditions. This compound (19a) had a calculated∗ logP
value of 6.27, whereas the calculated logP values for the other compounds were below 5.6
and appeared to have sufficient solubility under the SPR assay conditions. The majority of
the substituted 4-benzylpiperidine ligands were found to bind with similar or weaker binding
affinity compared to the lead compound.
The size of the benzyl substituent did not appear to be a significant factor affecting the
strength of the binding interaction with the Tec SH3 domain. Correlations between the
substituent position and the binding affinity were not clearly apparent, although ligands with
substituents at the 2-position of the benzene ring mostly tended to have weaker binding affinity
compared to the 3-position and 4-position substituted compounds with the same substituent.
These results indicated that the substituent was not affecting the interaction due to bulk or
size making an additional contact with the Tec SH3 domain upon binding, although the weaker
binding affinity for the ortho-substituted benzene rings may indicate some unfavourable steric
effects upon the binding interaction due to the shape of the ligand. Instead, the results indicate
∗Calculated logP values were obtained using the Marvin chemical editor and calculator, available from
ChemAxon https://www.chemaxon.com.
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that other characteristics of the various benzyl substituents affected the binding interaction
and gave the observed differences in activity.
The two strongest binding compounds identified were the benzonitrile ligand 19s and the
benzamide ligand 101 (Kd = 2.0 ± 0.5 µM and 2.0 ± 0.1 µM respectively). These were
the only ligands with benzyl substituents which were electron-withdrawing by resonance,
indicating that the electron density in the aromatic ring was most likely the major contributing
factor to the significantly improved binding interaction. Interestingly, the trifluoromethyl-
substituted ligands 19n-19p exhibited significantly weaker binding affinity compared to the
other 4-benzylpiperidine ligands, even though this is also an electron-withdrawing substituent.
The para-substituted derivative 19p in particular had a dramatically weaker binding affinity,
outside the range which could be measured using the SPR assay method. This does indicate
that electronic effects of the substituents may not be sufficient to explain the difference in
affinity, but the large difference in lipophilicity of these substituents likely also contributes
to the observed difference. It is expected that the trifluoromethyl-substituted compounds
would be less soluble under the assay conditions compared to more hydrophilic benzamide
and benzonitrile compounds, and the low response values observed in the assay results for
19p may indicate that solubility was a factor in the weaker binding affinity measured. Other
ligands with fluoro or methyl substituents also resulted in low response readings or observed
precipitation of the small molecule ligand at higher concentrations.
Solubility of the ligands under biologically relevant conditions was previously noted as a
significant challenge to developing these small-molecule ligands targeting the Tec SH3 domain.
Incorporating hydrophilic substituents was one strategy proposed to improve the water
solubility of the extended 2-aminoquinoline ligands, and the results of these assays demonstrate
that benzylpiperidines with hydrophilic substituents are not only sufficiently soluble under the
assay conditions, but also appear to have improved binding affinity compared to the other
tested ligands. This is a very favourable result for the overall goal of finding more effective
and more drug-like ligands for the Tec SH3 domain, unnecessitating any requirement to
compromise the strength of the binding interaction in order to improve the aqueous solubility
of the compounds.
Structural analogues of 4-benzylpiperidines: 3-benzylpiperidines and
3-benzylpyrrolidines
The 3-benzylpiperidine and 3-benzylpyrrolidine derivatives were initially proposed to investigate
whether the favourable binding interactions identified by the lead compound 15 could be
further optimised by changing the relative positions of the benzyl substituent and the quinoline
core structure. These compounds were synthesised as a racemic mixture, and the stereoisomers
were not separated for the purposed of the assays. As a result, these assays contain two
structurally different isomers which would be expected to have different interactions with the
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3D protein target. If any improvement in the binding affinity was observed then this would
indicate that at least one of the stereoisomers had improved binding affinity compared to
the lead compound, and therefore further investigation would be warranted. The synthetic
pathway developed for the analogous 4-benzylpiperidines was less effectively applied to the
synthesis of the 3-benzylpiperidine and 3-benzylpyrrolidine targets and could not be sufficiently
optimised, therefore a smaller range of these compounds was available for investigation of the
binding affinity.
The SPR assay results for these ligands did not indicate any improvement in the strength of
the binding interaction compared to the lead compound, with a range of measured Kd values
between 9 and 21 µM, compared to Kd = 9 µM for the lead compound 15, as determine by the
SPR assay. The derivatives with unsubstituted benzyl groups displayed very little difference
to the 4-benzylpiperidine analogue, with Kd = 13 µM for the 3-benzylpiperidine (20x) and
Kd = 10 µM for the 3-benzylpyrrolidine ligand (21x), and similar results were observed with
the substituted benzylpierpidine assayed.
None of the 3-benzylpiperidine or 3-benzylpyrrolidine compounds bound with significantly
improved binding affinity compared to the lead compound, and due to the difficult and low
yielding synthesis of these types of compounds it was concluded that further investigation of
these types of piperidine compounds was not likely to yield any substantial progress towards
achieving the project goals. Nevertheless, once the 3D structure of the SH3 domain complex
with a 6-position extended 2-aminoquinoline is obtained, the binding model might indicate
that further improvements may be made with these asymmetric piperidine type structures
and further investigation may then be warranted as informed by the additional structural
information gained for the binding region.
Structural analogues of 4-benzylpiperidines: 4-benzylidenepiperidines
The 4-benzylidenepiperidine ligands were other structural analogues of the 4-benzylpiperidine
lead compound, and were primarily considered to be interesting targets due to the substantially
planarised piperidine ring conformation and therefore different 3D structure of these
compounds. The bridging alkene instead of the methylene group also restricts the free rotation
of the benzyl group, and therefore investigating the impact of this upon the binding interaction
of the ligands with the Tec SH3 domain would give useful information on the nature of the
binding interaction.
The binding affinities of the benzylidene ligands 102x and 102s were directly compared to the
benzyl analogues 15 and 19s respectively. The assay results for the benzylidenepiperidine and
benzylpiperidine analogues were comparable (within error) in each case, and it was evident
that there was no significant improvement in the strength of the binding interaction achieved
by inclusion of the more planarised benzylidene group. The results therefore demonstrate
that the alkene bridging group is not a favourable structural change from the freely rotating
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methylene bridge.
Comparison of structurally different benzylpiperidine-type ligands
The relatively poor binding of the benzylidenepiperidine ligands is likely due to either restricted
rotation of the benzyl group, or due to the comparatively planarised piperidine ring
conformation which would affect the position of the benzylidene substituent.
As similar results were obtained for the 3-benzylpiperidine and 3-benzylpyrrolidine ligands (20x
and 21x respectively) compared to the lead compound, this may indicate that the position
of the benzyl substituent has little impact upon the strength of the binding interaction.
Therefore, it would be expected that the restricted rotation of the benzyl group is
predominantly causing the reduced strength of the binding interaction, rather than the
piperidine ring conformation.
In order to investigate the effect of planarised piperidine ring conformations upon binding, the
tetrahydropyridine-extended 2-aminoquinoline compound 109x would be a highly valuable
target (Figure 64). NMR studies of the tetrahydropyridine compounds isolated as part
of this project demonstrated that the piperidine ring is substantially planarised, similar to
the benzylidenepiperidine derivatives, but in contrast the benzyl group is freely rotating and











Figure 64: Structurally different extended 2-aminoquinoline compounds, which could be investigated to
probe the effects of piperidine ring conformations and free rotation of the benzyl substituent upon the
strength of SH3 domain binding interactions. Compounds 15, 20x and 102x were tested for binding affinity,
and the proposed structure 109x would be required for further investigation.
The synthesis of the benzonitrile analogue of this compound 109s was attempted but the
product could not be purified and tested for binding activity (see Scheme 79, page 111), and
the synthetic method would not be generalised to yield the unsubstituted derivative 109x.
Tetrahydropyridine compounds such as these would be highly valuable compounds used to
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explore the nature of the binding interactions with the Tec SH3 domain, and therefore would be
worth investigating if an effective and selective synthetic method was at some point developed
to achieve these types of structures.
Further to the benzylidenepiperidine compounds which were directly compared to the
analogous benzylpiperidines, the pyridinylmethylpiperidine derivative 22a had been noted as a
comparatively stable ligand with an improved binding affinity compared to the lead compound,
and therefore the binding affinity of the similar pyridinyl-extended methylidenepiperidine
compound 108b was also investigated as a comparison. It was found that this compound had
a significantly stronger binding affinity compared to the lead compound, and was among the
strongest binding ligands investigated to date with a measured Kd value of 1.9 ± 0.1 µM. The
assay results for the 4-benzylpiperidine and 4-benzylidenepiperidine ligands indicated that a
methylene bridge may be preferable and therefore it was proposed that the 3-pyridine variant
of 22a might have even stronger binding affinity for the Tec SH3 domain, but this target was
not isolated in sufficient yield and purity to be assayed.
2.4.4 Results of SPR assays and insight into binding model
The investigation of 4-benzylpiperidine extended 2-aminoquinoline ligands and a range of
structural variants of these compounds identified several novel compounds which bound
with significantly improved binding affinity for the Tec SH3 domain using SPR assays. Of
particular interest were the 4-benzylpiperidine compounds with a substituent which was
electron withdrawing by resonance (benzonitrile 19s, and benzamide 101) and the pyridinyl-
extended piperidine compounds 22a and 108b (Figure 65).
The stronger binding affinity observed for these particular compounds indicates that an
electron poor aromatic ring improves the strength of the interaction accessed by the
benzylpiperidine substituent, as pyridines are electron poor compared to benzene rings and the
nitrile or cyano benzyl substituents are electron-withdrawing by resonance. While the precise
interaction with the SH3 domain responsible for this change in binding affinity is unknown
until a 3D structure of the protein-ligand complex is determined, this relationship between
electron density of the aromatic system and the strength of the binding interaction may be
useful in guiding the design of further target compounds, and electron donating substituents
in particular should be avoided.
Additional size of the 6-position substituent is not needed to improve the strength of the
binding interaction, as evidenced by the pyridinyl compounds 22a and 108b. It is therefore
expected that adding substituents does not make a further favourable contact with the Tec
SH3 domain surface, and instead the improvement observed in binding affinity is simply the
result of improving the strength of the binding contacts that were being accessed by the
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Kd = 2.0 ± 0.5 µM Kd = 2.0 ± 0.1 µM
Figure 65: Structures of strongest binding 2-aminoquinoline ligands for the Tec SH3 domain, as determined
using SPR assays. Changes in structure compared to previous lead compound 15 are highlighted.
benzylpiperidine lead compound. Additionally, while additional size is not required it also
does not seem to be a hindrance to the binding interaction. The para-substituted benzonitrile
and benzamide ligands 19s and 101 are larger than the pyridines, but the improvement in the
strength of the binding interaction indicates that there is space available to extend the ligand
in this direction without steric clashes of the bound ligand with the protein surface which
would negatively impact the strength of the binding interaction. This suggests that addition
of even larger 6-position substituents to the 2-aminoquinoline ligands may be accommodated
by the binding surface although it is not yet clear whether any further favourable binding
opportunities are available.
Perhaps the most important result, from the perspective of developing more effective ligands
with potential use in biological systems, was the synthesis and discovery of several stronger
binding small-molecule ligands which each contain more hydrophilic structures than the lead
compound 15. The replacement of a benzene ring with a less lipophilic pyridine ring and
the incorporation of hydrophilic substituents were strategies proposed to improve the aqueous
solubility of the Tec SH3 domain ligands, which was an important issue which needed to
be resolved due to the largely hydrophobic core structure of the lead compound developed
in previous work. These compounds not only have reduced lipophilicity and therefore more
drug-like characteristics, but this was achieved while still improving the binding affinity of the
small-molecule ligands for the Tec SH3 domain.
The success of these strategies demonstrates that improving the binding affinity of small-
molecule ligands for an SH3 domain, or even a protein-protein interaction target more generally,
can occur simultaneously with developing ligand with more drug-like characteristics. Although
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design of stronger binding PPI inhibitors with sufficient water solubility has been a significant
challenge to drug design due to the largely hydrophobic nature of the PPI targets, these novel
and more hydrophilic 2-aminoquinoline compounds are the strongest binding small-molecule
ligands for an SH3 domain discovered to date. These promising results demonstrate the
potential of extended 2-aminoquinoline compounds as more effective and drug-like ligands for
the Tec SH3 domain, and also give important information about the nature of the binding
interaction which assists the design of even more effective ligands.
128
3 Synthesis of 6-position biarylpiperidine substituted
2-aminoquinolines
3.1 Introduction
While the range of simple benzylpiperidine-type ligands were designed to investigate and
improve the binding interactions with the Tec SH3 domain, they were not anticipated to
make any substantial additional contacts with the protein surface due to their similar size and
scaffold. It was however envisaged that extending the structure further may increase contacts
with the protein surface and result in a much stronger binding ligand.
The proposal that further interactions with the Tec SH3 domain binding surface can be
accessed by larger 6-position substituents was supported by previous work into phenoxy-
extended quinoline ligands.57 The binding affinity of biphenyl-extended compounds (16a
and 16b, Figure 66) with the Tec SH3 domain had previously been investigated using
[1H,15N]-HSQC chemical shift perturbation experiments.57 The assay results were inconsistent
with those obtained for other 6-position extended 2-aminoquinoline derivatives, and indicated
that the biphenyl ligands could favourably interact with the protein binding surface through
either the key 2-aminoquinoline structure or through the bulky 6-position substituent, but
not both simultaneously. The K d values measured also indicated that the binding affinity
of these ligands with the Tec SH3 domain may be comparable to the strongest identified
2-aminoquinoline ligands, despite the irregular binding interactions. Given the success of
various piperidine-extended ligands binding to the SH3 domain, it was proposed that
2-aminoquinolines with 6-position biphenylmethylpiperidine substituents (113a and 113b,
Figure 66) may be able to access both binding interactions simultaneously and therefore
result in stronger binding to the Tec SH3 domain.
The two isomers of 113, with different substitution position of the second phenyl group, were
each targeted so the optimal contact of the substituent could be found, and potentially find
a ligand shape which will best access all of the identified favourable binding interactions and
avoid the previously observed irregular binding behaviour of the phenoxy ligands.
A study of molecular substructures which enhance the binding interactions of small molecules
with protein targets, including PPI interactions, identified that biphenyl structures were
abundantly represented amongst the active ligands investigated.89 It was hypothesised that
biphenyl structures may have improved binding interactions with a protein target in many
instances, compared to a phenyl or other aromatic structure, due to the size and flexibility
which could enable it to favourably interact with a larger region of protein surface. The
addition of phenyl and other bulky lipophilic groups has proved to be an effective strategy













Figure 66: Comparison of biphenyl ligands 16a and 16b made previously,57 and target biphenyl ligands
113a and 113b. The previously investigated ligands 16a and 16b exhibited irregular binding affinity in the
chemical shift perturbation assays, and revised K d values are shown. *16a was assayed as a 7:1 mixture
with 16b.
previously, but while this has identified additional hydrophobic binding interactions it has also
resulted in a largely aromatic and hydrophobic scaffold. One of the significant challenges
of inhibiting PPIs with small molecules is the typically flat and hydrophobic surfaces being
targeted, which leads to development of similarly hydrophobic small-molecule ligands which
have issues with water solubility and less drug-like properties. The proposed biphenyl-extended
ligands (113a and 113b) were not expected to be very soluble in water and therefore a
wider range of biaryl-extended target compounds were proposed, with the second phenyl ring










113 114 115 116
Figure 67: Target biaryl extended 2-aminoquinoline ligands.
In addition to reducing the hydrophobicity of the structure, the heteroaromatic rings have
lower electron density compared to the biphenyl compounds which may impact the binding
interaction with the Tec SH3 domain. Despite the differences, if biphenyl-extended ligands
can be targeted with heteroaromatic rings without compromising the favourable binding
interactions of benzene rings, then this strategy could be more widely applied in PPI inhibitor
development in cases where largely aromatic scaffolds result in unfavourable water solubility.
130
3.2 Synthesis of 2-aminoquinolines with 6-position biaryl
substituents
3.2.1 General synthetic pathway
The method of successive Buchwald-Hartwig coupling reactions was used effectively to
synthesise a large range of 6-position extended 2-aminoquinoline derivatives reported in the
previous chapter, and therefore it was expected the same method could be used to synthesise
the larger biaryl-extended piperidine structures 113-116 from the quinoline intermediate 24
and an appropriate benzylpiperidine.
The synthesis of biaryl structures has been widely reported in the literature previously, utilising
palladium-catalysed coupling of an aryl halide with another aryl reagent to form the new
carbon-carbon bond. Common methods for synthesis of biaryl compounds include Suzuki,
Stille, or Hiyama reactions which each use different types of aryl reagents (Figure 68), and
each method has demonstrated versatility and been utilised to make a wide range of biaryl
compounds. The Suzuki method, however, has several advantages which made it the preferred
method to synthesise the biaryl-extended piperidine targets. The commercial availability of a
wider range of arylboronic acid derivatives and the low toxicity of these reagents, particularly
compared to the organostannanes, meant the Suzuki reaction was the preferable method for




















Figure 68: Common palladium-catalysed methods used to synthesise biaryl compounds from aryl bromide
reagents.
Given that the bromo-substituted benzylpiperidines 45k-m had been effectively synthesised
already (see Scheme 21, Table 6), it was proposed these could be a suitable aryl halide
intermediate. Ideally, it is desired that an efficient pathway with the lowest number of
intermediates required to obtain the full range of derivatised compounds would be feasible, for
example a process involving coupling of the bromo-substituted benzylpiperidine reagents to
the quinoline with the aryl-couplings as the final step (Pathway 1, Figure 69). The competing
reactivity of the aryl halides in the intermediate compounds makes this infeasible, however,
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as a range of coupling reactions would be expected to occur. Therefore, the formation of the
biaryl group via carbon-carbon bond formation must necessarily occur before the Buchwald-




























Pathway 1 Pathway 2
Figure 69: Proposed retrosynthesis of 2-aminoquinoline derivatives with 6-position biaryl-extended
substituents.
To synthesise the required piperidines (117-120), a similar synthetic procedure was envisaged
to the extended range of substituted benzylpiperidines made previously. As previously
demonstrated, hydrogenation of the aryl halide intermediates results in the hydrogenolysis
of the aryl halide bond, therefore the hydrogenation of the alkene must occur after formation
of the biaryl structure. The proposed synthetic pathway to minimise loss of yield by side-
reactions therefore involves coupling of the second aromatic ring via a carbon-carbon bond
formation reaction, followed by hydrogenation and deprotection of the Boc-protecting group















Scheme 80: Proposed synthesis of novel biaryl-substituted piperidines 117-120.
3.2.2 Synthesis of biphenyl/biaryl substituted 4-methylpiperidines
There were very few previous syntheses reported for the proposed range of biaryl-extended
piperidine compounds targets. One alternate synthesis of a biphenyl compound 117b had
been reported previously in a patent, from biphenylbromide reagents using a Horner-Emmons
reaction as the key carbon bond forming step (Scheme 81),62 very similar to the
benzylpiperidines previously synthesised (see Schemes 10, 12). This method would not be
considered ideal for this project because a large number of aryl-substituted benzyl bromides
and corresponding phosphonates would need to be synthesised, whereas the proposed method
using the previously synthesised bromo-substituted piperidines 45(k-m) reduces the number

















Scheme 81: Reported synthesis for a biphenyl-extended piperidine derivative. Yield and spectroscopic data
for novel compounds were not reported, and products were not purified.62
Of the heteroaromatic-extended piperidine targets, only 4-pyridinyl-substituted derivatives
had a previously reported synthesis.90 These compounds were also only reported in a patent,
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and the synthesis utilised a Suzuki reaction with 4-pyridinylboronic acid to make the biaryl
structure, similar to the method proposed above (Scheme 82). More broadly, Suzuki reactions
have been used to make a range of biaryl compounds from arylboronic acids and aryl bromides
with a wide range of reported reaction conditions. For the proposed targets, coupling of phenyl,
pyridinyl, and pyrimidinyl boronic acid derivatives is required, and of these the heteroaromatic




















Scheme 82: Reported synthesis for a biaryl-extended piperidine derivative. Overall yield and spectroscopic
data for novel compounds was not reported.90
From the literature methods, several reaction conditions that achieved successful results for
coupling of phenylboronic acid with aryl bromides were tested in the attempted coupling of
45m and phenylboronic acid (Scheme 83, Table 23).3,91,92 Under most of the tested reaction
conditions large quantities of reagents were recovered and minimal to zero conversion to the
desired product 121b was observed. In only one case, using a sealed tube reaction, was












Scheme 83: Attempted syntheses of biphenyl-extended piperidine 121b via Suzuki reaction. For conditions
and results see Table 23.
Comparison of the NMR spectra of the bromo-substituted reagent and the phenyl-coupled
product demonstrated that the desired biphenyl product had been obtained. The appearance
and integration of the aromatic signals in the 1H NMR spectrum was consistent with an
additional phenyl group (Figure 70), and 2D NMR experiments were used to conclusively
demonstrate that the coupling reaction had occurred at the desired position. HRMS analysis
of the purified material was consistent with the biphenyl product 121b in contrast to the
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Table 23: Exploration of Suzuki coupling conditions for synthesis of a biphenyl-extended piperidine
derivative (121b) based upon literature Suzuki conditions. *Determined from 1H NMR spectrum of crude
reaction mixture.
Pd Ratio Yield
catalyst/ligand Solvent Base Method 45m:121b* (%)
Pd(PPh3)4 DMF K2CO3 80°C3 9:1
Pd(OAc)2/PPh3 toluene K2CO3 reflux 1:0
Pd(OAc)2/PPh3 toluene K2CO3 100°C, sealed 0:1 73
Pd(PPh3)4 toluene K2CO3 80°C91 1:0
Pd(PPh3)4 toluene K2CO3 80°C, sealed91 3:1
Pd(OAc)2 H2O/DMF Na2CO3 35°C92 1:0
distinctive isotope peaks observed for the bromo-substituted reagent 45m. The signals
corresponding to the atoms of the piperidine ring appeared very similar to those of the reagent,
showing that the piperidine ring of the coupled product is also substantially planarised and
that interconversion between ring conformations is slow on the NMR timescale.
For each of the other reaction conditions tested a mixture of product and recovered reagent
was obtained. These mixtures were not purified, and the approximate ratio of product and
recovered reagent 45m could be determined using 1H NMR spectroscopy of the crude reaction
mixture. While some aromatic and piperidinyl signals were coincident or overlapped in the
1H NMR spectrum, the alkene signals were distinct and therefore the integration of these
signals (at 6.277 ppm for the reagent, and 6.384 ppm for the product) gave the relative molar
ratio of components in the reaction mixture.
The same reaction conditions were used to achieve the synthesis of 121a with a good yield
(Table 24). The formation of the 3-position phenyl-substituted derivative resulted in an
downfield shift of the alkene signal in the 1H NMR spectrum similar to 121b. The shifts of
the aromatic NMR signals, as well as HRMS and 2D NMR data confirmed the structures of
the isolated product.
The synthesis of 122b from 4-pyridinylboronic acid and 45l was attempted using the same
reaction conditions used for the synthesis of 121b, however this did not result in synthesis
of the desired product and only reagents were recovered from the reaction mixture (Scheme
84).
Given the relative hydrophilicity of the heteroaromatic boronic acids it was expected that
poor solubility of the reagents in toluene was potentially an issue. The Suzuki reaction is
tolerant of a wide range of solvents, and so the same reaction was attempted using a 1:1
mixture of toluene and ethanol which was expected to increase solubility of the reagent
































Figure 70: Comparison of signals in the 1H NMR spectra of Boc-protected 4-piperidines before and after
Suzuki coupling, demonstrating successful synthesis of the biphenyl group. A: Downfield region of 1H NMR
spectrum for bromo-substituted reagent 45m, and B: same region of 1H NMR spectrum for
biphenyl-substituted product 121b.













Br δH HA δH HA’ Yield
Reagent position (ppm) Product (ppm) (%)
45l: 3 6.289 121a: 6.422 81
















Solvent (Ratio) Yield 122b (%)
toluene 0
toluene/ethanol (1:1) 100
Scheme 84: Attempted syntheses of biaryl-extended piperidine 122b via Suzuki reaction.
in successful synthesis of the desired product 122b, as clearly demonstrated by the HRMS
data of the product and the 2D NMR spectra. A longer reaction time was required for
complete conversion, and with purification a quantitative yield of 122b was achieved.
Using the same conditions, the other heterocyclic compounds 122-124 were successfully

















Scheme 85: Synthesis of biaryl-extended piperidine derivatives via Suzuki reaction. For Ar groups used, see
Table 25.
Successful coupling of the 2-substituted biaryl derivatives (122a, 123a and 124a) resulted
in an upfield shift of the alkene 1H NMR signal, whereas for the 3- and 4-position substituted
biaryls the alkene signal was shifted downfield compared to the alkene hydrogen signal of the
aryl bromide reagents. The successful coupling of the heteroaromatic ring was demonstrated
by the increased number of signals in the 1H and 13C NMR spectra compared to the bromo-
substituted reagents, and HMBC correlations of the aromatic ring signals were used to
conclusively determine that the coupling had occurred in the desired position (see example in
Figure 71).
Similar to all other Boc-protected piperidine derivatives, the broadness in the piperidine signals
in the 1H and 13C NMR spectra was consistent with the proposed substantially planarised ring
structure and slow rotation of the Boc-protecting group on the NMR timescale. HSQC
experiments were required to determine the chemical shifts of the broadest 13C NMR signals,
which corresponded to carbon atoms adjacent to the Boc-protected nitrogen atom. HRMS
data was also collected and in every case the observed mass confirmed the loss of the bromine
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Ar = Compound Ar position δH HA (ppm) Yield (%)
N
122a: 2 6.164 62
122b: 3 6.432 100
122c: 4 6.396 100
N
123a: 2 6.164 57
123b: 3 6.426 91
123c: 4 6.396 51
N N
124a: 2 6.167 86
124b: 3 6.428 87
124c: 4 6.406 92
atom and was consistent with the expected products.
The following steps were simple hydrogenation and removal of the Boc-protecting group
to give the target piperidine compounds, and the same conditions used for the simpler
benzylpiperidine synthesis were utilised (Scheme 86). Reduction of the alkene products by
hydrogenation took a significantly longer time compared to the simpler benzylidenepiperidines
prepared previously (typically 16 hr, compared to 2 hr for most derivatives of 45), but full




















Figure 71: HMBC correlations between aromatic rings demonstrating successful Suzuki coupling to make




















117 118 119 120
Scheme 86: Synthesis of biaryl-extended piperidine derivatives (117-120) via hydrogenation and
Boc-deprotection reactions.
Aside from the required length of the reaction, the results of the reaction were very similar to
the synthesis of the simpler benzylpiperidine derivatives 48 from 45 previously. The changes in
the 1H NMR spectrum demonstrated a change in conformation of the piperidine ring, showing
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Table 26: Yields of biaryl-extended 4-piperidine derivatives from alkenes over two steps.
Ar group/ δH HA δH H2/6 δH H2/6 2-Step Overall
position (ppm) (ppm) (ppm) Yield (%)
3 125a: 2.60 2.64/4.08 117a: 2.70/3.26
4 125b: 2.57 2.65/4.08 117b: 2.65/3.18 99
N
2 126a: 2.55 2.51/3.97 118a: 2.56/3.13 100
3 126b: 2.62 2.65/4.09 118b: 2.79/3.35 63
4 126c: 2.60 2.65/4.09 118c: 2.74/3.29 74
N
2 127a: 2.54 2.51/3.96 119a: 2.59/3.16 92
3 127b: 2.62 2.65/4.09 119b: 2.79/3.34 100
4 127c: 2.59 2.66/4.09 119c: 2.71/3.26 98
N N
2 128a: 2.54 2.52/3.99 120a: 2.53/3.09 73
3 128b: 2.64 2.66/4.10 120b: 2.67/3.21 65
4 128c: 2.62 2.66/4.10 120c: 2.74/3.28 82
distinct axial and equatorial hydrogen signals indicative of a more chair-like conformation of
the ring, and the overall appearance of the 1H NMR spectrum was analogous to the simpler
benzylpiperidine derivatives observed previously (Figure 72). The signals corresponding to
atoms adjacent to the Boc-protected nitrogen atom were still broadened in the 1H and
13C NMR spectra as due to the protecting group which exhibits slow rotation on the NMR
timescale. An increase in the product mass determined by HRMS also corresponded to addition
of two hydrogen atoms in each case.
The removal of the Boc-protecting group catalysed by TFA proceeded as expected to give the
products 117-120, again with results comparable to the simpler substituted benzylpiperidines
(Table 26). The spectroscopic results were consistent with isolation of the desired piperidine
compounds, most notably the distinct absence of the tert-butoxy signals in the NMR spectra
and the corresponding mass loss as determined by HRMS analysis of the products. The
characteristic sharper piperidine signals in the 1H and 13C NMR spectra were also observed
without the impact of slow rotation of the Boc-protecting group. Aside from the difference
in appearance observed for the 1H NMR signals, an upfield shift for the equatorial hydrogen
atoms adjacent to the piperidine nitrogen was observed compared to the starting material,
































Figure 72: Comparison of piperidine ring signals in the 1H NMR spectra of Boc-protected 4-piperidines,
showing similar characteristics and indicating analogous shape of structures. A: Upfield region of 1H NMR
spectrum for simple benzylpiperidine 48c, and B: same region of 1H NMR spectrum for biaryl-extended
piperidine 126b.
hydrogen atoms to be deshielded by anisotropy. The yields isolated from this method ranged
considerably from moderate to high yields, and it is expected that the variance is due to
the work-up procedure which involves a liquid-liquid extraction and therefore results in lower
yields of some derivatives. Broadly, this method was effective for the range of derivatives
which were the target of this work.
3.2.3 Synthesis of 2-aminoquinolines via Buchwald-Hartwig aminations
The coupling of the piperidines 117-120 to the 6-position of the quinoline compound 24
was attempted using the same Buchwald-Hartwig amination conditions used for the simpler
benzylpiperidine derivatives in the previous chapter, as a sealed-tube reaction (Scheme 87).
From the previous work, it was expected that under the palladium-catalysed reaction conditions
the 6-position substituted quinoline derivatives 129-132 would be the major or exclusive
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products in each case, although some side-reactions could potentially occur. In particular, it
was previously found that coupling at the 2-position of the quinoline could potentially occur

















Scheme 87: Buchwald-Hartwig amination for synthesis of biaryl extended 2-chloroquinoline derivatives.
The presence and relative quantities of these major products could be observed by 1H NMR
analysis of the crude mixture without purification due to the distinctive chemical shift
differences: the quinoline hydrogen signals adjacent to the piperidine substituent had a
significant upfield shift compared to the reagent, appearing near 7 ppm, and therefore by
measuring the coupling constant of the upfield doublet signal (coupling constants were typically
3J3,4 = 9 Hz for H3, or 4J5,7 ≈ 2.5 Hz for H5 signal) the regioselectivity of the reaction could
be determined (Figure 73). Significant differences were also observed for the piperidine ring
signals, with the 2-position substituted side-products showing a more downfield shift for the
equatorial H(2’/6’) signals due to the quinoline nitrogen adjacent to the piperidine substituent.
From the experiments, it was found that the Buchwald-Hartwig aminations generally yielded
moderate yields of the desired products 129-132, with small amounts of the 2-position coupled
products 133-136 observed for a minority of derivatives (Table 27). For only one attempted
reaction, the coupling of 119c with 24, was a sufficient amount of the side-product 135c
produced to enable isolation. Unlike the simpler benzylpiperidine coupling reactions attempted
previously, there were no derivatives for which only 2-position substitution was observed. The
results demonstrate that further exploration of the reaction conditions was not required in
this case to adapt for the coupling of significantly larger piperidine derivatives.
The major products were isolated and in each case the spectroscopic results were used to
confirm the desired product has been successfully synthesised. Coupling of the substituent
at the 6-position of the quinoline was indicated by distinctive shifts differences in the 1H and
13C NMR spectra as noted previously, in particular the large upfield shift of the H5 doublet
signal due to the adjacent piperidine substituent. The C6 signal appears far downfield in





























Figure 73: Comparison of 1H NMR spectra of Buchwald-Hartwig amination products, showing distinctive
signal and chemical shift differences. A: 1H NMR spectrum of target 6-position substituted product 131c,
and B: 1H NMR spectrum of 2-position substituted side-product 135c.
HMBC experiments showed correlations between this C6 signal of the quinoline ring and the
piperidine ring hydrogen signals further demonstrating the successful coupling at only the
6-position (Figure 74A). HRMS data showed distinctive peaks for the isolated compounds,
consistent with the expected isotopic abundances due to the 2-position chloro-substituent of
the quinoline product.
The isolated 2-position substituted product 135c showed contrasting chemical shift differences
in the NMR spectra due to the alternate position of the electron-donating piperidine substituent
on the quinoline ring (see Figure 73B). In the 1H NMR spectrum, an upfield shift of the H3
doublet signal with a larger coupling constant, instead of an upfield shift of the H5 signal,
was observed. The comparatively downfield shift of the equatorial H(2’/6’) signals is also
consistent with substitution adjacent to the quinoline nitrogen atom. The C2 signal in the
13C NMR spectrum was the most downfield signal in the spectra of either 131c or 135c due
to the adjacent quinoline nitrogen and the piperidine substituent, and for 135c the HMBC
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Table 27: Results of Buchwald-Hartwig amination reactions for biaryl-extended piperidine derivatives.



















Ar group/ δH H5 δH H3 Yield δH H3
position (4J) (3J) (%) (3J)
3’ 129a: 6.98 (1.8) 7.25 (8.6) 42
4’ 129b: 6.97 (1.8) 7.24b 55
N
2’ 130a: 6.93 (2.5) 7.25b 67
3’ 130b: 6.98 (2.0) 7.25b 60 134b: 7.01a (9.5)
4’ 130c: 6.99 (2.6) 7.26 (8.6) 56
N
2’ 131a: 6.92 (2.7) 7.25 (8.6) 33
3’ 131b: 6.98 (2.6) 7.24b 56
4’ 131c: 6.99 (2.6) 7.26 (8.6) 26 135c: 6.98 (9.2)
N N
2’ 132a: 6.92 (2.6) 7.24b 46
3’ 132b: 6.98 (2.6) 7.25 (8.7) 60 136b: 6.98a (9.1)
4’ 132c: 6.99 (2.6) 7.26 (8.6) 36
a Identified from NMR data of crude mixture, not isolated. b Peak overlapped, shift identified using 2D NMR
experiments.
experiment showed correlations between the C2 signal and the axial H(2’/6’) piperidine signals
demonstrating the change in substitution position (Figure 74B). HRMS of the isolated product
was consistent with the mass of 135c, including the characteristic 1:1 isotope peaks due to
the bromo-substituent, confirming that the aryl bromide bond (instead of the aryl chloride)
was retained under the reaction conditions.
The 2-chloroquinoline derivatives (129-132) were converted to the corresponding
2-aminoquinoline target compounds 113-116 by a second palladium-catalysed Buchwald-



























Figure 74: HMBC correlations between piperidine signals and quinoline ring signals showing substitution
position of major Buchwald-Hartwig amination products. A; HMBC correlations for C(6) signal of 131c,
and B: HMBC correlations for C6 signal of 135c.
obtained previously for synthesis of simpler 2-aminoquinoline derivatives. The yields varied
substantially although in most cases moderate conversion to the desired product was achieved,













Scheme 88: Buchwald-Hartwig amination for synthesis of biaryl extended 2-aminoquinoline derivatives.
Success of the reaction was confirmed by spectroscopic analysis, with HRMS analysis showing
loss of the chloro-substituent and mass reduction consistent with the target products. From
the NMR spectra, upfield shift of the H3 doublet and C3 signals compared to the reagent
was observed due to the electron-donating amino group, with other signals which are shielded
by resonance, including H8, also showing a smaller upfield shift difference. It was noted in
several instances that the quaternary C8a signal for the 2-aminoquinoline compounds was
very broad and could not be distinguished from the baseline of the 13C NMR spectrum. The
presence of a signal for the C8a atom in these cases was clearly demonstrated using HMBC
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Ar group/ δH H3 δH H8
position (ppm) (ppm) Yield (%)
3 113a: 6.70 7.58 44
4 113b: 6.67 7.57a 54
N
2 114a: 6.69 7.55 55
3 114b: 6.68 7.58 32
4 114c: 6.69 7.58 54
N
2 115a: 6.66 7.55 67
3 115b: 6.66 7.56 59
4 115c: 6.67 7.58 63
N N
2 116a: 6.66 7.54 52
3 116b: 6.70 7.58 37
4 116c: 6.70 7.59 47
experiments, as correlations of the H5, H7 and H4 signals to an indistinguishable 13C NMR
signal at approximately 141 ppm were observed (for example, see Figure 75A). This chemical
shift is consistent with other 2-aminoquinoline derivatives where the broadened C8a signals
were more readily observable as a signal in the 13C NMR spectrum (for example, see Figure
75B), and as there was no overlap with other signals the assignment of the C8a signal was





























Figure 75: HMBC correlations for C8a signal, which was not always distinctly observed in the
13C NMR
spectra of 2-aminoquinoline derivatives. A: HMBC correlations unambiguously denoting position of
indistinguishable C8a signal for 116b, and B: for comparison, HMBC correlations for readily observable C8a
signal of 115b.
3.3 Binding studies of 6-position biaryl extended 2-aminoquinoline
derivatives
The biaryl-extended derivatives 113-116 were assayed using the SPR method, as described for
the simpler benzylpiperidine derivatives assayed previously. As predicted in the design of these
compounds, the biphenyl derivatives (113) were too lipophilic and therefore insoluble under
the assay conditions. Some of the pyridinyl-extended compounds were also insoluble under the
assay conditions, but the strategy of using more hydrophilic heteroaromatic rings was effective,
and the majority of the biaryl-extended compounds had improved solubility and therefore the
impact of the larger biaryl structure upon the binding affinity could be explored. For the
compounds which were soluble under the assay conditions the initial screening method was
first used to determine an approximate Kd value. The concentration range for the assay was
then adjusted for the replicates in order to generate a binding isotherm and more accurately
determine the Kd value (Table 29).
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115a 13.9 10 ± 4
N
N 115b > 20
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Screening Assay
R = Compound Kd (µM) Kd ± SD (µM)
N
N 115c 5.2 7 ± 4a
N
NN
116a 9.3 7 ± 1a
N
N




116c 3.2 2.4 ± 0.2
a Highest concentration data point removed due to precipitation or aggregation of compound under assay
conditions.
Compared to the previous lead compound 15, a comparable or lower Kd value was calculated
for each biaryl-extended ligand where the Kd value could be determined using the SPR method.
Broadly, this demonstrates that adding the additional aromatic ring does improve the strength
of the binding interaction as predicted from the previous experimental results. The reason
for the improvement is not evident, however, because a sufficiently strongly binding ligand
was not obtained and therefore the 3D structure of a protein-ligand complex could not be
determined.
Some limitations of this method were evident in the experimental results, as several of the
pyridine compounds did not give consistent binding isotherms and had a large variance in
the calculated Kd values. Due to this, the calculated error for 114a, 115a and 115b are
significant. Despite the relatively large range in the obtained Kd values, the results still
demonstrated that there was a change in the SPR response and therefore indicate that all
of these compounds bind to the Tec SH3 protein. The obtained results show that these
compounds potentially bind with stronger affinity than the previously identified lead compound
15, but due to the large error this is not conclusive.
More consistent results were obtained for the other derivatives, and in particular the pyrimidinyl-
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extended compounds (116). The three derivatives of 116 all demonstrated an improvement
in binding affinity compared to the lead compound, and are among the strongest binding
small-molecule ligands obtained for the Tec SH3 domain to date. These results indicate that
even substantially increasing the size of the 6-position substituent with an additional aromatic
ring gives ligands which are readily accommodated in the binding site of the Tec SH3 domain
target. The observations that the pyrimidinyl-extended compounds appear to have improved
binding affinity while also improving the aqueous solubility is a very promising result for the
design of more drug-like and effective small-molecule drugs fo the Tec SH3 domain, which
was a key goal of this project. It is apparent from the experimental results for these biaryl-
extended 2-aminoquinoline ligands that addition of a further heteroaromatic ring to a benzyl
group of a SH3 domain ligand may be a very effective strategy for improving the strength
of the binding interaction while not simply extending with further lipophilic structures. The
promising results of utilising heteroaromatic rings instead of benzene rings when targeting the
largely hydrophobic SH3 domain targets, as explored with these biaryl compounds and also
with the compounds 22a and 108b in the previous chapter, demonstrates the efficacy of this
strategy which could also be applied to PPI targets generally and therefore help overcome the
significant challenge of designing drug-like small molecules targeting PPIs.
The more concordant Kd values obtained for assays of some derivatives compared to other
similar compounds is likely due to improved solubility under the assay conditions. While the
ligands were prepared for assays using 5% DMSO in the buffer solution to aid solubility,
this was not sufficient to avoid precipitation of all the ligand compound especially at higher
concentrations. It is therefore plausible that further studies using a higher concentration of
DMSO might improve the solubility of the compounds under assay conditions and reduce the
error margins. While this might give more precise determinations of the Kd values for those
compounds, it does not aid the aim of the project to develop more effective and drug-like
ligands for the Tec SH3 domain. The pyrimidinyl-extended compounds were soluble under
assay conditions and gave the most promising results to address the aims of the project, and
therefore designing alternate methods to improve solubility of the more lipophilic compounds
under assay conditions was not investigated further.
Aside from the improvements to aqueous solubility and the apparent increase in the strength
of the binding interaction for these large 6-position substituted 2-aminoquinolines, some
further structural information was obtained from the assay results. Despite the limited
number of structures, there are indications that the attachment position of the heterocyclic
ring may have some effect upon the strength of the binding interaction, as the 2-position
substituted compounds 115a and 116a had a slightly higher measured Kd value compared to
the corresponding 3-position and 4-position analogues. This difference was consistent with
the observations from the simpler benzylpiperidine ligands in the previous chapter, where the
ortho-substituted ligand compounds also tended to have a weaker binding affinity for the Tec
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SH3 domain. This could be due to steric clashes of the ortho-substituents on the benzene ring,
and if steric hindrance were the key reason then this would be expected to have have a greater
impact for the biaryl compounds, which appears to be consistent with the observations.
The bulky biaryl-extended piperidine ligands 114-116 assayed using the SPR method all
appear to be readily accomodated upon binding to the Tec SH3 domain, even with ortho-
substituted benzene rings. The consistency of these results would indicate that there is
substantial free space in the binding region of the Tec SH3 domain, and therefore even larger
6-position substituents may be accommodated without unfavourable interactions of the ligand
with the protein surface due to steric clashes. It is possible that further aromatic rings may
be added to improve the strength of the binding interaction, although this is unlikely to be
favourable for achieving more drug-like characteristics of the small-molecule ligand.
Initially, the investigation of these biaryl-extended piperidine compounds was proposed due
to the interesting results of some biphenyl compounds which had been studied as part of
a previous project. The biphenyl compounds 16a and 16b (see Figure 66) had unusual
binding activity, hypothesised to be due to alternating binding of the compound to two
binding regions which could not be simultaneously accessed. Despite the proposed sub-optimal
binding to the Tec SH3 domain, the reported binding dissociation constants determined by the
NMR chemical shift perturbation assays was very good, with the Kd values calculated to be
7 ± 2 µM for 16b and 8 ± 3 µM for a mixture of both 16a and 16b.57 Determination of
the Kd values for 16a and 16b using the SPR assay method was attempted, however the
compounds were not soluble under the assay conditions so a direct comparison could not be
obtained.
If the Kd values for for the sub-optimal binding interaction of 16a and 16b with the Tec
SH3 domain determined by the NMR assay method are reliable, it would be expected that
simultaneously accessing both of the proposed binding interactions with an optimal ligand
would result in a very significant decrease in the calculated Kd value for the more effective
ligand due to the additional favourable binding interactions. Arguably, a Kd value even lower
than 2.4 ± 0.2 µM would be expected, and this was the calculated Kd value for the strongest
binding biaryl-extended ligand, 116c. This comparison of results (Figure 76) may indicate
that the biaryl-extended piperidine ligands still do not optimally access the binding interactions
which were identified by the compounds 16a and 16b, and therefore further investigation of
different biaryl-extended ligands may result in a much stronger binding ligand if the optimal
configuration of the 6-position 2-aminoquinoline substituent can be determined.
Even though the results appear to suggest that the optimal 2-aminoquinoline ligand has still
not been identified, significant improvements have been made. Firstly, several of the novel
biaryl-extended piperidine ligands tested by the SPR assay method gave a lower Kd value than

















Kd = 4.1 ± 0.7 µM Kd = 2.4 ± 0.2 µM
Figure 76: Comparison of Kd values for the previously studied phenoxy compounds (16a and 16b) tested
using NMR assays,57 and the novel biaryl extended 2-aminoquinoline ligands (116b and 116c) assayed
using the SPR method as part of this project. *Assayed as mixture with 16b.
a significant improvement although the Kd values obtained from the different assay methods
may not be directly comparable. Secondly, the improvement in the strength of the binding
interaction was achieved while also improving the aqueous solubility of the ligand, whereas the
compounds 16a and 16b were insoluble under the SPR assay conditions. Finally, the results
suggest that further improvements can be made. The range of different benzylpiperidine-
type extended 2-aminoquinoline ligands which were found to effectively bind to the Tec SH3
domain have provided much needed information about favourable structures which improve
the strength of the binding interaction. This new SAR information can be directly applied
to the design of more potent and effective 6-position substituted 2-aminoquinolines targering
the Tec SH3 domain, with very promising indications that a strongly binding ligand will be
obtained and enable the structure of the protein-ligand complex to be determined.
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4 Synthesis of extended 3-position 2-aminoquinolines
4.1 Introduction
Previous research into 3-position extended 2-aminoquinoline derivatives as Tec SH3 domain
ligands identified that a simple substituted phenethyl group could result in improved binding
affinity compared to the 2-aminoquinoline lead compound, and likely makes an additional
favourable hydrophobic contact with the protein binding surface.56 The strongest binding
ligand, with a tert-butyl substituent on the phenethyl group, was the largest 3-position
extended derivative that had been previously investigated (137, Figure 77). The use of
large and hydrophobic groups, such as the tert-butylbenzyl group, is not preferable from a
drug design perspective as water solubility is required, and therefore a range of alternate
3-position substituents investigating the use of similarly large substituents were proposed with








138 139: Ar = 4-pyridinyl
140: Ar = 3-pyridinyl






R = a: CF3, b: CN
Figure 77: Strongest binding 3-position extended 2-aminoquinoline ligand identified by previous studies
(137), and novel target compounds 138-143.
Primarily, the introduction of biphenyl-substituents (138) was expected to access the same
binding interactions with the SH3 domain binding surface as the ligand 137, and these were
153
then compared to a range of biaryl-substituents (139-141) to assess whether the introduction
of less lipophilic heteroaromatic rings will impact the ligand binding interactions. Secondly,
the smaller ligands with a pyridinylethyl-substituent (142) had not been reported previously,
but were proposed as ligands to investigate whether using a pyridine instead of a benzene ring
may be an effective strategy of designing less lipophilic SH3 domain ligands without negatively
impacting the binding affinity.
Finally, the additional proposed ligands 143a and 143b are supplementary to the simple
extended phenethyl-substituted ligands reported previously, as those results indicated that
adding a para-substituent to the benzene ring could improve the binding affinity of the
ligand. Only simple alkyl- or fluoro-substituents had been previously investigated, therefore
substituents which are electron withdrawing by induction (CF3) or by resonance (CN) were
required to provide more information about the binding interaction.
4.1.1 General synthetic pathways
Previously utilised synthetic methods for 3-position extended 2-aminoquinolines
To make simple 3-position phenethyl extended ligands previously, a Horner-Emmons method
was utilised, followed by introduction of a 4-methoxybenzyl protected amino group (Figure
78).56 Investigations into the products of various reaction pathways identified that the
2-position aryl chloride bond is not stable to hydrogenation conditions, and therefore the

























R = H, Me, F, 4-t-butyl
Figure 78: Previous synthesis of 3-position extended 2-aminoquinoline derivatives with simple phenethyl
substituents via a Horner-Emmons reaction.56
It was anticipated that this synthetic pathway could be modified to incorporate methods
effectively used in the earlier sections of this work in order to prepare the more structurally
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complex target 2-aminoquinoline derivatives. Using the previously reported method, it was
proposed that the quinoline intermediate 144 could be used to make all of the target
3-position extended 2-aminoquinoline derivatives. The synthetic process would therefore
use a carbon-carbon bond forming reaction, such as a Horner-Emmons reaction, to attach
each 3-position substituent to give the vinyl compounds. There were two key components
of the synthetic pathway that required investigation in this project to make all of the novel
compounds. Firstly, an alternate method for introduction of the 2-position amino functionality
was proposed using the Buchwald-Hartwig amination procedure developed for 6-position
substituted aminoquinolines previously, which would reduce the number of steps required
to make the required target compounds. Secondly, investigation and development of the
synthesis of additional phosphine reagents was required due to the wider range of novel
3-position substituents proposed.
Methods for 2-position amination of 3-position extended 2-chloroquinoline
derivatives
In the previous synthetic procedure, the 2-position amino group was introduced as a
p-methoxybenzyl-protected amine (Pathway 1, Figure 79), however this method necessitates
an additional deprotection step in the overall synthetic pathway, and therefore it is desirable


















Figure 79: Proposed amination of the 3-position extended 2-chloroquinoline derivatives, via the previously
reported method with para-methoxybenzyl amine56 or via the proposed Buchwald-Hartwig amination
procedure.
Alternate methods had also been attempted to introduce the 2-position amino group to
3-position extended quinolines with little success. The Kóródi method was attempted, however
a complex mixture of products was reported, and it was suspected that decomposition occurred
under the harsh reaction conditions (Scheme 89).79,56









Scheme 89: Previously attempted Kóródi amination method for conversion of 2-chloroquinoline derivatives
to corresponding 2-aminoquinolines.56
6-substituted quinoline derivatives in previous sections of this project, had not been previously
utilised. It was therefore anticipated that the Buchwald-Hartwig amination using LiHMDS as
the ammonia equivalent and base could also be used to synthesise the 3-position substituted
2-aminoquinolines from 2-chloroquinolines. This would remove the necessity for the additional
deprotection step, shortening the overall synthetic pathway (Pathway 2, Figure 79).
Methods for incorporation of various 3-position substituents to quinoline reagent
For the first group of ligands 138-141, it was proposed that a Suzuki reaction could be used to
synthesise the biphenyl or biaryl group from an arylboronic acid derivative and an aryl bromide,
in a very similar method to the synthesis of biaryl-extended piperidine derivatives in a previous
chapter (see Scheme 85). There are several possible synthetic pathways incorporating this
key step, varying in the order of reactions (Figure 80).
For efficiency, it was ideal that Suzuki reactions with the full range of boronic acid derivatives
would occur at a late stage in the synthetic pathway (Pathway 2 or 3, Figure 80) as this
late stage derivatization reduces the number of intermediates required. In this case, however,
the quinoline intermediate (145) also contains a 2-position aryl chloride bond and therefore
it was anticipated that competing reactivity of aryl halides in 145 may result in lower yields
of desired products and complications in purification of compounds. The alternate pathway
uses the Suzuki reaction to synthesise the biaryl structure prior to reaction with the quinoline
reagent 144 (Pathway 1), and would only ever result in a maximum of one aryl halide bond
in each intermediate compound, therefore those competing side-reactions for the Suzuki or
amination reactions would not be expected to occur.
For the second type of proposed ligands with a 3-position pyridinylethyl substituent, 142, it
was known from a previous section of this work that the corresponding phosphonate reagents
required for the Horner-Emmons reaction could not be effectively synthesised and isolated.
Instead, using a Wittig reaction for this group of target compounds was a more feasible
strategy as the Wittig reagents were obtainable (Figure 81). The reaction conditions vary
from the Horner-Emmons reaction and therefore require added investigation, and removal of
the triphenylphosphine oxide by-product is required in the work-up procedure, but in all other
respects the proposed synthetic pathway is the same as for the biaryl derivatives.



































Figure 80: Proposed synthetic pathways for 3-position extended 2-aminoquinoline derivatives with biaryl
groups based upon previously reported Horner-Emmons method and the Suzuki methods established in this
project.
made in the previous work which identified the strongest binding ligand. These only vary
from the previously made SH3 domain ligand 137 by the functional group on the 3-position
phenethyl substituent, and therefore it was anticipated that the same reaction sequence as
reported for that compound could be utilised to make the simpler targets with CF3 and CN
substituents (Figure 81).
4.2 Synthesis of biaryl extended 2-aminoquinoline derivatives
4.2.1 Investigation of synthetic pathways for 3-position extended quinoline
derivatives
To investigate the viability of the proposed synthetic pathway, the synthesis of two derivatives
138c and 139c was first attempted via the first pathway, from the intermediate compounds
144 and 36m. It was expected that a pathway which is effective in the synthesis of these
two compounds could then be applied to the synthesis of the remaining similar derivatives.
























R = CF3, CN
Figure 81: Proposed synthetic pathways for simple 3-position extended 2-aminoquinoline derivatives 142
and 150.
intermediate compounds 145c had been made in moderate yield (50%) previously, and
therefore the reported reaction conditions were initially used for investigations into viability



















Scheme 90: Previously reported synthesis of bromo-substituted 3-phenylvinyl-2-chloroquinolines (145) via
a Horner-Emmons reaction.56
The synthesis of the key aldehyde intermediate, 2-chloro-3-formylquinoline (144), had been
reported in the literature previously.77 The one-step literature method from acetanilide and
phosphoryl chloride with DMF was used to yield the 144 via a Vilsmeier-Haack formylation
reaction with moderate yield (42%, Scheme 91). The presence of the key reactive functional
groups was determined by spectroscopic analysis. Distinctive isoptope masses were found in
HRMS analysis to confirm the presence of the 2-position chloro-substituent, and the 1H NMR
spectrum showed a signal corresponding to the hydrogen of the aldehyde functional group












Scheme 91: Synthesis of 2-chloroquinoline-3-carboxaldehyde intermediate (144) used in the synthesis of all
3-position extended 2-aminoquinoline derivatives, by Vilsmeier-Haack formylation reaction.77
Investigation of Horner-Emmons reaction pathway for synthesis of 3-position
extended 2-aminoquinoline derivatives
Following the proposed pathway (as in Pathway 1, Scheme 80), the next step is the attachment
of the 3-position substituent by a Horner-Emmons reaction with a bromo-substituted
benzylphosphonate reagent. In this case, reactions with the phosphonate reagents 36l and
36m were first investigated. These Horner-Emmons reactions had been reported previously,56
with moderate yields, using typical Horner-Emmons reaction conditions of sodium hydride as
base and DMF as the solvent. In previous sections of this work, however, investigations into
syntheses of benzylpiperidines via a Horner-Emmons reaction identified that high yields of the
desired products was achieved using THF as the solvent (for example, 45c obtained in 87%
yield, see page 37). From those results, it was anticipated that similar reaction conditions
may result in higher yields of the Horner-Emmons reaction products in this case also.
These Horner-Emmons reaction conditions were used in the attempted synthesis of 145b and
145c from quinoline 144 and the corresponding phosphonate derivatives, however only a low



















Scheme 92: Attempted synthesis of 3-position extended 2-chloroquinolines via Horner-Emmons reaction
with sodium hydride.56
In each case both isomers of the desired product were isolated, with more E -isomer product
obtained from the reaction. The two isomers could be readily distinguished by the vicinal
coupling constant for the alkene hydrogen signals in the 1H NMR spectrum. The E -isomer
has a larger vicinal coupling constant for the two alkene doublet signals (3JH,H = 16.2
Hz) and distinct chemical shifts for each signal. In contrast, the alkene signals for the
minor Z -isomer appeared further upfield and had a small chemical shift difference between
the alkenyl signals, therefore appearing as a distinctive strongly coupled AB system in the
1H NMR spectra. Non-first order analysis could be used to determine the chemical shifts
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of the alkene signals for characterisation, and the vicinal coupling constant was measured to
be smaller than the coupling constant for the corresponding E -isomer (3JH,H = 12.5 Hz),
thereby enabling definitive assignment of signals for each product isomer and determination
of the major isomer of the product obtained from the reaction. Compared to the quinoline
reagent 144, the products had an upfield shift of the H4 signal due to the loss of the aldehyde
functional group, and 2D NMR experiments were used to confirm successful formation of the
new carbon-carbon double bond at the C3 position (Figure 82A). The HRMS analysis of the
product was used to determine that both the bromine and chlorine were present in the isolated

























Figure 82: HMBC correlations observed for 3-position substituted quinoline products of a Horner-Emmons
reaction.
A longer reaction time was required for the reaction of 144 and 36l to go to completion,
determined as complete consumption of 144 by TLC analysis, and under these conditions
a sample of an undesired quinoline side-product was also isolated (Scheme 93). Signals
consistent with the quinoline ring and a bromo-substituted 3-phenylvinyl substituent were
observed in the crude NMR spectrum from the reaction, similar to those observed for the
expected product 145b, but additional signals upfield were also observed. The similarity in
aromatic signals observed for the two products demonstrated that the side-product was also
likely formed by the successful Horner-Emmons reaction of 144 and 36l, but a further reaction
had also occurred.




















Scheme 93: Synthesis of 3-position extended 2-chloroquinoline 145b via Horner-Emmons reaction with
sodium hydride, for extended reaction time (16 hr).
were distinctive for an ethyl group, and the comparatively downfield shift of the CH2 quartet
signal compared to the CH3 triplet signal showed it was significantly deshielded, consistent
with an ethoxy group. 2D NMR experiments were used to demonstrate that the ethoxy group
showed HMBC correlations between the CH2 quartet and the C2 signal, indicating that this
side-product could be due to a nucleophilic aromatic substitution reaction at the 2-position
of the quinoline ring to give the 2-ethoxy substituted side-product 151b (Figure 82B). A
nucleophilic substitution reaction at the 2-position of the quinoline ring is not unexpected as
the reactive aryl chloride bond is further activated by the neighbouring quinoline nitrogen, and
in previous sections of this project undesired side-reactions had also occurred at this position
(for example, see Scheme 59, page 92).
Further investigation showed that prolonged Horner-Emmons reaction times (up to 16 hours)
using NaH as the base resulted in a much larger quantity of this side-product being isolated
from the reaction mixture, whereas 151b was not observed for short reaction times (1 hr).
It was expected that the formation of this product was potentially due to hydrolysis of the
excess phosphonate reagent by the sodium hydroxide which is present as an impurity in the
base, followed by nucleophilic aromatic substitution at the 2-position aryl chloride bond of the
desired product 145b. The desired product is produced much faster in the reaction mixture,
and therefore shorter reaction times meant this undesired further reaction could not occur.
The low yields of the desired 2-chloroquinoline 145b and 145c products under these Horner-
Emmons reaction conditions was unexpected, as complete consumption of the limiting reagent
144 was observed both by TLC monitoring of the reaction progress and by analysis of the
crude 1H NMR spectrum after work-up. The distinctive downfield aldehyde signal and other
characteristic signals of the starting material 144 were absent from the spectra, but signals
consistent with a large amount of another simple quinoline compound were evident in the
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1H NMR spectra of the reaction mixtures. It was observed that signals with a splitting pattern
corresponding to the second ring of the quinoline were present at slightly different chemical
shifts, and a singlet peak at a similar shift to the H4 signals of the desired products was also
present. It was anticipated from this that the low yield was due to an undesired side-reaction
involving the limiting reagent 144 which would give this other quinoline type product. The
identity of the product could not be determined from the crude reaction mixtures due to the
overlap in signals from this side-product and the desired products, and also due to a large
amount of unreacted phosphonate reagent present. The side-product could not be separated
from the phosphonate reagent by attempted chromatographic separation.
The large amount of unreacted phosphonate reagents 36l and 36m in the reaction mixtures
was unexpected, as these phosphonates had been used successfully in Horner-Emmons reactions
with ketones under the same conditions and therefore it was known that NaH was a sufficient
base to deprotonate the phosphonate. Due to the reactivity of the quinoline 144, however, the
use of different bases was investigated to determine whether an alternate base would promote
the desired reaction to make 145c. The results show that the base has a significant impact
upon the product distribution, although in each case the side product was observed (Table
30). LiHMDS (added as a solution in THF) gave complete consumption of the quinoline
reagent but only a small amount of the desired product 145c was observed, whereas sodium
tert-butoxide gave a similar result to that observed with sodium hydride.
Table 30: Comparison of product distribution from Horner-Emmons reaction based upon solvent and base.
Ratio Isolated yield Ratio
Solvent Base 145c:152b of 145c (%) (E-/Z)-145c
THF LiHMDSa 1:4 -c 7:3
NaH 7:3 25 4:1
NaOtBu 4:7 36 4:1
DMF LiHMDSa 7:3 -c 2:1
NaH 1:0 77 7:3
NaOtBu 1:0 78 7:4
a LiHMDS was added as a 1M solution in THF; b Determined by comparing integration of distinct peaks in
the 1H NMR spectrum of the crude product mixture after work-up, as complete recovery and purification of
152 by column chromatography was not achievable; c Purification of sample not attempted due to low
conversion to desired product.
The results using LiHMDS as the base required further investigation to determine which
reaction factors contributed to the poor yield obtained in synthesis of 145c. Firstly, the
reaction of base with phosphonate 36m was checked, and a visible colour change of the
solution to red was observed upon addition of the base to 36m, a typical observation upon
formation of the phosphonate anion. Quenching the mixture with D2O and analysing the
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crude mixture with 1H NMR spectroscopy showed the presence of a broader HP doublet
slightly upfield of the HP doublet observed for 36m, showing that the deuterated phosphonate
was present and therefore that the base LiHMDS had been sufficient to deprotonate the
phosphonate reagent in the reaction mixture (Scheme 94). Another test of whether 144 was
reacting in the solvent without base added was undertaken, and it was found that stirring the
reagent in THF for 5 hr (longer than the reaction time to make the side-product previously)
























Scheme 94: Tests used to confirm reactivity of quinoline reagent 144 and phosphonate 36m under
Horner-Emmons reaction conditions.
The final test of reaction conditions investigated whether the quinoline reagent would react
under the Horner-Emmons reaction conditions in the absence of the phosphonate reagent,
and this was investigated using NaH or LiHMDS as the base in the reaction mixture. In each
case, the reagent 144 was almost completely consumed and the 1H NMR spectrum of the
crude product mixtures contained only one major product with a small amount of unreacted
reagent 144 (Scheme 95, Figure 83B). As there were no further major products or recovered
reagents complicating the NMR spectra it was possible to characterise the product. With
comparison to the quinoline reagent (Figure 83A), the 1H NMR spectrum of the product had
substantially similar signals consistent with a 3-substituted quinoline compound, specifically
the four coupled signals for the second quinoline ring and the H4 singlet signal. Of those
signals, the H4 signal had the largest shift difference compared to the reagent, and the upfield
shift of this signal demonstrated that the electron-withdrawing aldehyde substituent was no
longer present in the product. In addition, the product had a large 2H signal appearing
much further upfield at 4.93 ppm, which would be consistent with reduction of the aldehyde
to an alcohol. The NMR data was entirely consistent with previous literature reports for
(2-chloroquinolin-3-yl)methanol 152,56 and HRMS analysis of the quinolinol demonstrated
that the mass was consistent with the structure of 152, including the expected 3:1 isotopic
mass peaks for the chloro-substituted compound.
Once the identity of the side-product had been confirmed, it was possible to determine the
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Figure 83: Comparison of 1H NMR spectra for A: quinoline reagent 144, and B: the reaction mixture after
treating 144 with LiHMDS in THF, giving the product 152.
product mixture for each attempted Horner-Emmons reaction by integration of the signals for
the two products (Table 30). The mechanism for formation of the quinolinol side product was
not evident from these results, however the synthesis of an alcohol from an aldehyde under
basic conditions could be achieved by a Cannizzaro-type disproportionation reaction. While
LiHMDS is not used as a base in Cannizzaro reactions, one Cannizzaro-type disproportionation
reaction in the presence of LiHMDS has been previously reported, although low yields were
obtained unless a lanthanide chloride was also added.93 A Cannizzaro reaction would be
expected to give an additional carboxylate-substituted product 153 (or the analogous amide,
as previously reported for the Cannizzaro reaction using LiHMDS under different reaction
conditions).93 Due to the aqueous work-up, however, another quinoline product was never
observed and therefore could not be used to confirm the hypothesis (Scheme 96).
















Scheme 96: Proposed Cannizzaro-type disproportionation reaction of aldehyde-substituted
2-chloroquinoline 144 under Horner-Emmons reaction conditions to give isolated quinolinol product 152,
and un-isolated proposed product 153.
occur, and so a comparison of reaction conditions with a different solvent, DMF, were obtained
(Table 30). The direct comparison between solvents gave the unexpected result that using
DMF gives significantly more conversion to the desired product. With sodium tert-butoxide
or sodium hydride as the base, the reactions in DMF only gave the desired alkene products
with good yield and none of the quinolinol product 152 was obtained. The quinolinol product
was still observed when LiHMDS was used as the base, however as the LiHMDS was added as
a commercially available solution in THF it is possible that the presence of THF is promoting
the formation of quinolinol. A clear improvement using primarily DMF instead of THF as the
reaction solvent even in this case demonstrates the large contribution of the solvent to the
distribution of reaction products.
From the successful synthesis of 145c via Horner-Emmons reaction, the Suzuki coupling of
145c and 4-pyridinylboronic acid to make the biaryl compound was attempted to synthesise
147c (Scheme 97). Initially, the reaction conditions used previously to synthesise biaryl-
extended piperidine compounds via a Suzuki reaction were attempted (see Figure 85, page
137), however this gave a complex mixture of products. From the mixture, there was only one
product (154c) produced in a sufficient quantity to be isolated by column chromatography
and characterised.
The major product was confirmed to be an alkene due to the presence of the distinctive
doublet signals with large coupling constants in the 1H NMR spectrum, and both isomers
of this major product were observed to be present in the mixture. Only the major isomer
could be isolated by column chromatography and this was confirmed to be the E -isomer
of the product, distinguished by the larger alkene coupling constant compared to the minor
isomer (3JH,H = 16.1 Hz, compared to 3JH,H = 12.2 Hz for the Z -isomer). The alkene signals
and the distinctive coupling pattern corresponding to the 2-,3-substituted quinoline ring clearly
demonstrated that the isolated compound was a product of a reaction of the quinoline reagent
145c. Additional 2H signals with chemical shifts consistent with a 4-substituted pyridine ring
were also present which strongly indicated a coupling reaction with the 4-pyridine boronic acid
reagent had occurred, however the other expected 2H signals consistent with the p-substituted
benzene ring of the expected product 147c were not present. Instead of the expected benzene




















Scheme 97: Attempted Suzuki reaction, with proposed structure of major product (154c) isolated from
the reaction mixture.
a mono-substituted benzene ring. HRMS analysis of the isolated product identified a mass
peak of 309.1390, without the 3:1 relative abundance peaks expected for the major isotopes
of a chloro-substituted product or 1:1 relative abundance peaks expected for a brominated
product despite both halogens being present in the reagent 145c.
2D NMR experiments were used to confirm the structure of the side-product 154c. HMBC
correlations showed that the coupling reaction of the 4-pyridine boronic acid had occurred at
the 2-position aryl chloride, instead of the desired coupling with the 3-position aryl bromide
substituent (Figure 84). HMBC and COSY correlations also demonstrated that the aryl
bromide bond had been lost, and therefore the product had an unsubstituted styryl substituent
at the 3-position of the quinoline ring. The synthesis of this product indicated that the Suzuki
coupling preferentially occurs at the 2-position of the chloroquinoline, and the aryl bromide
bond of the 3-position substituent was not retained under the reaction conditions.
The amount of major product recovered for this reaction was low, however no other products
could be isolated from the complex mixture. Identification of further products by 1H NMR
analysis of the crude mixture was not possible due to the large number of structurally similar
potential products, and it would be expected that both E - and Z -isomers of each quinoline
product would be present because a mixture of both isomers of the reagent 145c was used.
Instead, the presence of further products was investigated using HRMS analysis of the crude
reaction mixture, as the characteristic isotopic abundances of potential products were expected
to be evident and give an indication of the selectivity of the reaction (Table 31). Mass peaks
consistent with the isolated major product 154c were present, and the two isotopic mass




























Figure 84: Key HMBC correlations used to determine structure of 147c, the major product from
attempted quinoline Suzuki reaction. Key observed [1H,1H]-COSY correlations also indicated.
some of the desired Suzuki coupling reaction may have occurred. The masses consistent
with the 79Br and 81Br isotopes of the undesired 2-substituted side-product 155c were also
observed. The results demonstrate that the Suzuki reaction under these conditions favours
reaction with the 2-position aryl chloride of the quinoline ring rather than the aryl bromide as
desired, and also that the compounds are susceptible to loss of the aryl bromide bond using
this method.
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Table 31: Structures of potential products from Suzuki reaction and mass peaks identified by HRMS
analysis of crude reaction mixture.
[M+H]+ Corresponding [M+H]+
















Regioselective Suzuki reactions had been previously reported in the literature, including
selectivity for an aryl bromide over an activated aryl chloride.94,95,96 Several reaction conditions
were attempted for the synthesis of 147c using alternate catalysts, solvents, and procedures
that had been previously used in selective Suzuki reactions, however the crude reaction
mixtures in each case were still complex and contained many products which could not be
isolated. Due to the low amounts of the desired product produced in these reactions, and
the inability to properly separate the many similar components of the crude mixture, it was
determined that the alternate pathway (Pathway 1, Figure 80) was likely to be more successful.
Although the alternate pathway required more intermediate compounds to be synthesised, it
was anticipated this method would avoid yield loss due to competing side-reactions.
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Alternate reaction pathway for synthesis of 3-position extended 2-aminoquinoline
derivatives
The alternate pathway required synthesis of the biaryl-extended phosphonate derivatives
156-159 prior to the Horner-Emmons reaction with 144 to give the 2-chloroquinoline
derivatives 146-149. Of the target biaryl-phosphonate derivatives, only the biphenyl
derivatives 156(a-c) had been synthesised previously, and these were typically made from
the commercially available bromomethylbiphenyls (Scheme 98)97 or corresponding alcohols.98
The heterocyclic biarylphosphonate derivatives had no reported syntheses, and the range of
corresponding bromomethylbiaryls were not commerically available to use via the literature
method. It was expected that instead of the literature synthetic pathway, the bromo-
substituted benzylphosphonate derivatives 36(k-m) could be reacted with the aryl boronic
acids via a Suzuki reaction, and the products 156-159 would then be reacted with quinoline
reagent 144 using the Horner-Emmons reaction as the key bond-forming step of the synthesis.
As this synthetic procedure had not previously been attempted, initially the synthesis of only
two 2-aminoquinoline derivatives was investigated to determine whether the procedure would





















Figure 85: Initial target derivatives 138c and 139c used for investigation of alternate Horner-Emmons
synthesis pathway.
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Using the same Suzuki reaction conditions developed previously (see Scheme 85, page 137),
the syntheses of the two required phosphonate derivatives 156c and 157c from the
phosphonate 36m and the corresponding arylboronic acids were attempted (Scheme 99).
It was found that the reaction conditions were also highly effective in the synthesis of these
biaryl phosphonates and gave high yields of the desired products after purification by column
chromatography (157c: 97%, 156c: 90%), and therefore further optimisation of the reaction
conditions was not required. Success of the reaction was clearly shown in the NMR spectra of
the products, as in each case there was a slight downfield shift of the PCH2 doublet signal in
the 1H NMR spectrum compared to 36m, and the appearance and integration of the aromatic
peaks was consistent with the expected biaryl structures. Evidence of the successful coupling
of the second aromatic ring was best demonstrated by the splitting of the 13C NMR signal
corresponding to the quaternary carbon of the second ring. In both cases this signal appeared





















36m X = C: 156c, 90%
X = N: 157c, 97%
Scheme 99: Synthesis of biaryl-extended phosphonate derivatives 156c and 157c via Suzuki reaction.
From the phosphonates, the Horner-Emmons reaction with 144 could be attempted as the key
carbon-carbon bond forming reaction to make the target 3-position extended 2-aminoquinoline
derivatives. Similarly to the synthesis of 145, a brief test of reaction conditions for the
synthesis of 147c from 144 and 157c demonstrated that the reaction in THF gave more
quinolinol product (152) than the desired alkene products, with a large recovery of unreacted
phosphonate reagent (Scheme 100). In contrast, the preferred reaction conditions using
DMF as the solvent resulted in high isolated yields of 78% and 100% for 146c and 147c
respectively, with none of the quinolinol product observed in the reaction mixture for either
derivative (Scheme 101).
Two isomers of each alkene product were obtained from the Horner-Emmons reactions of
144 and each phosphonate derivative. In each case the reaction favoured formation of the
E -isomer as expected for the Horner-Emmons reaction, although some Z -isomer was also
produced, as evidenced by the distinctive doublet peaks in the 1H NMR spectra of the products
(3Jtrans = 16.3 Hz for 146c and 16.2 Hz for 147c, 3Jcis = 12.1 Hz for both products). For
the quinoline signals, conversion of the 3-position aldehyde group to the large vinyl-biaryl























Scheme 100: Attempted synthesis of a biaryl-extended quinoline derivative via Horner-Emmons reaction.















X = C: 156c
X = N: 157c
X = C: 146c, 78%
X = N: 147c, 100%
Scheme 101: Synthesis of biaryl-extended quinoline derivatives 146c and 147c via a Horner-Emmons
reaction.
signal was observed for the Z -isomer products due to the closer proximity of the large biaryl
group. HRMS data for the products was consistent with the target alkene products, with
distinctive isotopic masses showing the 2-position chloro substituent was retained, in contrast
to the products of the attempted reaction to make 147c from Suzuki coupling of 145c in the
pathway attempted previously. While 2D NMR experiments were more difficult to interpret for
the mixture of isomers in each case, small samples of pure E -isomer products were obtained
by column chromatography for both 146c and 147c, and 2D NMR experiments were used
to confirm connectivity of the aromatic rings in the desired structure after the sequence of
carbon-carbon bond forming reactions (Figure 86).
4.2.2 Synthesis of biaryl-extended 2-chloroquinoline derivatives
Using the same method, the remaining biaryl-extended 2-chloroquinoline derivative were also
prepared. The bromobenzylphosphonate derivatives 36(k,l,m) were reacted via a Suzuki
reaction with the arylboronic acids to give the range of biaryl phosphonates 156, 157, 158,

















Figure 86: Sample HMBC correlations observed for both Horner-Emmons reaction products 146c (X = C)
and 147c (X = N), demonstrating success of the sequence of carbon-carbon bond forming reactions to make
the target scaffold of the target molecules. Example HMBC spectrum is for E -isomer of 147c (X = N).
purified by column chromatography, with generally high yields (Table 32). In each case, there
was an increase in the integration and the number of 1H and 13C NMR signals compared to





































Scheme 102: Synthesis of biaryl-extended phosphonate derivatives via Suzuki reaction. Ar = 4-pyridinyl
(157), 3-pyridinyl (158), or 5-pyrimidinyl (159).
172
Table 32: Results of Suzuki reactions to yield biaryl-extended diethyl phosphonate derivatives, with key










156 X, Y, Z = C
157 Y = N ; X, Z = C
158 X = N ; Y, Z = C
159 X, Z = N ; Y = C
Yield (%) δH HA (ppm) 2JH,P (Hz) δC C1’ (ppm) JC,P (Hz)
156a: 89 3.18 22.2 141.2 4J = 0.9
156b: 87 3.22 21.6 141.0 -
156c: 90 3.19 21.7 140.8 6J = 1.5
157a: 90 3.13 22.3 149.1 4J = 1.6
157b: 91 3.23 21.7 148.12 -
157c: 97 3.21 21.8 147.9 6J = 1.5
158a: 96 3.12 22.3 136.9 4J = 1.0
158b: 68 3.23 21.7 136.4 -
158c: 59 3.21 21.7 136.3 6J = 1.4
159a: 89 3.10 22.3 134.8 4J = 1.6
159b: 71 3.24 21.7 134.1 -
159c: 94 3.22 21.9 134.0 6J = 1.5
For the 2- and 4-aryl substituted products, the corresponding 4J or 6J phosphorous-carbon
coupling to the C1’ carbon was evident as these 13C NMR signals appeared as doublets. For the
2-substituted products an upfield shift of the characteristic PCH2 doublet signal was observed
in the 1H NMR spectrum, and for the other derivatives a highly consistent downfield shift was
observed compared to the corresponding bromo-substituted reagents.
The previous experiments had effectively demonstrated that the success of the Horner-Emmons
reaction of biarylphosphonates with the quinoline 144 was dependant upon the base and
solvent, and some Horner-Emmons reaction conditions may instead promote formation of the
quinolinol side-product and give poor yields of the desired alkene product. Given these results,
the synthesis of the remaining 3-position extended quinoline derivatives via a Horner-Emmons
reaction utilised sodium tert-butoxide as the base and DMF as the solvent, and gave generally













Scheme 103: Synthesis of biaryl-extended 2-chloroquinoline derivatives via Horner-Emmons reaction. Ar =
Ph (146), 4-pyridinyl (147), 3-pyridinyl (148), or 5-pyrimidinyl (149).
Table 33: Results of Horner-Emmons reactions with biaryl-extended diethyl phosphonate derivatives to give
2-chloroquinoline products. Ratio of alkene products determined by 1H NMR integration, usually
comparison of H4 to *HA/*HB as these were typically isolated signals. All chemical shifts are reported in




















Ar Yield E :Z δH 3Jtrans δH δH 3Jcis δH
position (%) ratio HA,HB (Hz) H4 *HA,*HB (Hz) *H4
146a: 2’ 78 2:1 7.46,7.18 16.2 8.07 6.69,6.79 12.1 7.86
146b: 3’ 72 2:1 7.60,7.27 16.1 8.41 6.79,6.92 12.1 8.00
146c: 4’ 78 5:2 7.57,7.23 16.2 8.39 6.75,6.88 12.1 8.03
147a: 2’ 62 5:1 7.49,7.09 16.1 8.09 6.76,6.79 12.1 7.79
147b: 3’ 64 3:1 7.60,7.26 16.1 8.40 6.83,6.92 12.1 8.00
147c: 4’ 100 4:1 7.61,7.24 16.2 8.41 6.81,6.89 12.1 8.01
148a: 2’ 93 5:2 7.49,7.09 16.1 8.10 6.74,6.81 12.0 7.78
148b: 3’ 86 10:1 7.61,7.28 16.2 8.42 6.83,6.93 12.1 7.84
148c: 4’ 78 4:1 7.58,7.23 16.2 8.39 6.79,6.89 12.1 8.00
149a: 2’ 54 3:1 7.52,7.05 16.0 8.13 6.79,6.84 12.0 7.70
149b: 3’ 100 3:1 7.60,7.26 16.2 8.40 6.85,6.92 12.1 8.01
149c: 4’ 78 7:2 7.59,7.22 16.2 8.38 6.83,6.90 12.1 7.99
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In each reaction, none of the quinolinol product 152 was observed in either the crude reaction
mixture or in separated fractions after column chromatography, demonstrating that this
method with specific Horner-Emmons reaction conditions can be applied more generally while
avoiding the undesired side-reaction. The presence of both E - and Z -isomers of the desired
products could be observed in the 1H NMR spectra of the product mixture and therefore
the NMR signals corresponding to each isomer could be distinguished and assigned based
upon the relative magnitude of the 3Jcis and 3Jtrans coupling constants, which were typically
12 Hz and 16 Hz respectively. The E -isomer was the major product for each product of
146-149 and in most cases a pure sample could be obtained for characterisation of the
product. The Z -isomer was also obtained in significant enough quantities for observation of
the alkene hydrogen peaks in the 1H NMR spectrum as they always appeared isolated upfield
of other alkenyl hydrogen peaks, although in many cases this minor isomer product could
not be isolated and fully characterised. For each product the use of 2D NMR experiments
definitively showed that the vinyl substituent was attached at the 3-position of the quinoline
ring, and HRMS analysis of the products found signals corresponding to the desired products
with a 3:1 ratio of peaks consistent with the expected ratio of chlorine isotopic abundances
for the 2-chloroquinoline product.
4.2.3 Synthesis of 3-position extended 2-aminoquinoline derivatives via Buchwald-
Hartwig amination
As hydrogenation under standard conditions was previously reported to result in hydrogenolysis
of the aryl chloride bond for similar derivatives,56 the proposed method in this project instead
involved synthesis of the 2-aminoquinolines via a Buchwald-Hartwig amination prior to a
hydrogenation step to reduce the alkene bond. To achieve this, the same conditions utilised
for synthesis of the 6-position extended 2-aminoquinolines previously was also applied to the
attempted synthesis of these 3-position extended biaryl derivatives (Scheme 104, compared














Scheme 104: Attempted synthesis of 3-position extended 2-aminoquinoline derivatives via
Buchwald-Hartwig amination.
For the 3-position extended 2-chloroquinoline compounds, however, the attempted Buchwald-
Hartwig aminations with LiHMDS were not found to be effective (Table 34). In each case a
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complex mixture of products was produced under the sealed tube reaction conditions, and in
the majority of cases the presence of any 2-aminoquinoline product was not evident using 1H
NMR analysis of the crude mixture.




















Ar Yield δH 3Jtrans δH δH 3Jcis







161c: 4’ <5%b -c -c 8.06 6.63,6.87 12.6
N
162a: 2’ -a
162b: 3’ 11 7.20,7.22 16.5 8.05 6.63,6.89 12.2
162c: 4’ <5%b 7.18,7.20 16.5 8.06 6.81,6.86 12.2
N N
163a: 2’ -a
163b: 3’ <5%b -c -c 8.05 6.66,6.89 12.1
163c: 4’ -a
a Signals corresponding to the desired product were not evident in the 1H NMR spectra of crude reaction
mixtures. b Crude sample containing mostly the desired product was obtained by chromatographic
separation, but could not be purified. c Could not be determined due to overlap of signals in the 1H NMR
spectrum.
The presence of the desired 2-aminoquinoline product was only observed in the product mixture
for four of the attempted reactions, and in one case the product 2-aminoquinoline (162b)
could be isolated. A significant upfield shift was observed for the alkene doublet signals
and the H4 singlet signal in the 1H NMR spectrum, consistent with the introduction of an
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electron-donating amine substituent at the 2-position. A broad 2H signal further upfield for
the amino group was also present, and HRMS analysis was consistent with replacement of
the chloro-subsituent with an amine. Despite the low yield of 11%, the spectroscopic data
demonstrates that the conversion of a 2-chloroquinoline to a 2-aminoquinoline can still be
achieved under the established Buchwald-Hartwig amination conditions. When compared to
the results of the amination of 6-position extended 2-chloroquinolines (for example, Scheme
62), it is apparent the reaction conditions are not readily generalisable to the synthesis of all
extended 2-aminoquinolines.
The characteristic chemical shifts of signals corresponding to the products in the 1H NMR
spectra were used to identify the presence of any product in the instances the reaction mixture
could not be purified. Specifically, the H4 singlet signal was typically distinctive and shifted
upfield compared to the H4 signal for the reagent, as expected due to the electron-donating
amino group at the 2-position instead of the electron donating chloro-substituent. Similarly,
the HB alkene signals were generally observable as they appeared further upfield of other
aromatic 1H NMR signals, and for the 2-aminoquinoline product the HB signals were shifted
upfield compared to the corresponding signals in the 2-chloroquinoline reagent. The presence
of a broad signal further upfield was also evident for the introduced 2-position amino group
when the reaction was successful.
The excessively complex mixture of products obtained from these amination reactions was
unexpected, and it was therefore suspected that the conditions used for the Buchwald-
Hartwig amination resulted in degradation of the product. Alternate reaction conditions
were attempted, including shorter reaction times or conducting reactions at reflux instead of
in sealed pressure tubes. Similar poor and complex results were observed in each case and
therefore the Buchwald-Hartwig method was not deemed a useful pathway for the 3-position
extended compounds.
4.2.4 Alternate synthesis of 3-position extended 2-aminoquinoline
derivatives
For a subset of derivatives, the alternate amination strategy involving substitution of the
2-position amino group first as a para-methoxybenyl protected amine was instead attempted
(Scheme 105). The amination was achieved using the previously reported conditions, with a
large excess of 4-methoxybenzylamine and high temperatures.56
Distillation of the excess reagent and attempted purification of the products via column
chromatography gave an impure mixture of the desired product and the excess reagent
4-methoxybenzylamine, however complete separation of the amines was not possible. The























Scheme 105: Alternate synthesis of biaryl-extended 2-aminoquinoline derivatives from the corresponding
2-chloroquinolines in a three-step amination procedure. Ar = Ph (138), 4-pyridinyl (139), 3-pyridinyl
(140), or 5-pyrimidinyl (141).
used without further purification. In one instance, the E -isomer of an amination product
(165c) was exclusively obtained by recrystallisation from dichloromethane to enable better
characterisation of the product.
Similarly to the Buchwald-Hartwig amination products above (see Table 34), the products of
the nucleophilic aromatic substitution reaction showed significantly upfield chemical shifts for
the H4 and alkene HB signals in the 1H NMR spectrum compared to the 2-chloroquinoline
reagents due to the electron-donating amine at the 2-position instead of the chloro-substituent
of the reagent (Figure 87A and 87B, Table 35). The key signals corresponding to the para-
methoxybenzyl protected amine were also evident in the 1H NMR spectra of the products.
The 3H singlet peak at 3.80 ppm for the methoxy group as well as the triplet and doublet
peaks corresponding to the coupled NH and benzylic CH2 groups were particularly distinctive
as these signals appeared upfield of the more complicated and overlapping signals for the
aromatic and alkene hydrogen atoms. HRMS analysis also showed peaks consistent with the
target structure, and the absence of the distinctive chlorine isotopic peaks for the reagents

















































Figure 87: Comparison of 1H NMR spectra for products obtained from 3-step amination procedure, to yield
3-position extended 2-aminoquinoline products. Example shown is for synthesis of biphenyl-extended
compound 138a. A: 2-Chloroquinoline reagent 146a, B: amination product mixture containing 164a,
C: hydrogenation product mixture containing 168a, and D: target 2-aminoquinoline compound 138a. Only
key signals are annotated, and * denotes signal corresponding to Z -isomer of an alkene product.
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Table 35: Results of amination and hydrogenation procedure and characteristic NMR signals demonstrating
successful reaction at each step. Only E -isomer signals with the vicinal coupling constant (in Hz) are
reported for alkene products. Signals for HA and HB were not assigned individually due to the impure



























Ar group/ δH HA,HB 3Jcis δH H4 δH HA,HB δH H4
position (ppm) (Hz) (ppm) (ppm) (ppm)
2’ 164a: 6.90,7.09 15.8 7.72 168a: 2.63,2.98 7.38
N
2’ 165a: 6.98,7.02 15.9 7.72 170a: 2.67,2.98 7.40
4’ 165c: 7.10,7.14 16.0 7.95 170c: 2.84,3.08 7.62
N
3’ 166b: 7.11,7.16 15.9 7.94 171b: 2.87,3.09 7.63
4’ 166c: 7.09,7.14 15.9 7.95 171c: 2.82,3.05 7.61
N N
3’ 167b: 7.12,7.16 15.9 7.95 169b: 2.86,3.11 7.72
4’ 167c: 7.11,7.15 16.2 7.95 169c: 2.95,3.08 7.61
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Hydrogenation was used to reduce the alkenes 164-167 to give the phenethyl-substituted
products 168-169 under standard hydrogenation conditions (Scheme 105). In some cases
the reagents had low solubility in methanol, which resulted in low conversion to the desired
product, and therefore in some cases a 1:1 methanol/ethanol mixture was used as the solvent
and the reaction mixture was heated to 40°C to give a better conversion. The products of this
step were again used without complete purification due to the difficulties in purifying amines
by column chromatography.
The success of the hydrogenation reactions was clearly demonstrated using spectroscopic
methods. The 1H NMR spectra of the products showed that the distinctive alkene doublet
signals with large coupling constants were no longer present, and instead upfield 2H triplet-
like signals corresponding to the CH2 groups in the ethylene chain were evident (Figure 87C,
Table 35). The signals corresponding to the para-methoxybenzyl-protected amino substituent
were also still present, showing that the protecting group had not been removed under the
hydrogenation conditions.
Treatment of the amine-protected compounds 168-169 with trifluoroacetic acid removed
the para-methoxybenzyl protecting group to achieve the target 2-aminoquinoline products
138-141. The excess trifluoroacetic acid was removed by evaporation under reduced pressure,
and the salt residue was treated with saturated aqueous sodium bicarbonate solution and
extracted into dichloromethane, then purified by column chromatography to yield the pure
free amine products, with 19F NMR spectra collected to confirm that there was no residual
trifluoroacetic acid present. Aside from the loss of signals corresponding to the protecting
group there were only small differences in the 1H and 13C NMR spectra compared to the
reagents. HRMS analysis showed a loss in the mass of the product consistent with the
absence of the protecting group, and the integration of the broad amine signal in the 1H
NMR spectrum was consistent with an NH2 group for the 2-aminoquinoline instead of the
NH of the N-protected reagents (Figure 87D).
A moderate yield of the 2-aminoquinolines from 2-chloroquinolines was generally achieved
over the three steps using this method (Scheme 106, Table 36). The loss of yield over
during the process was likely due to the attempted purification of the amine products using
column chromatography after the introduction of the para-methoxybenzyl protected amine
at the 2-position of the quinoline ring, and some product may have also been lost in the
aqueous work-up to remove the residual trifluoroacetic acid and salts in the final step of
the procedure. Despite this, the procedure yielded each of the derivatives targeted in the












Scheme 106: Synthesis of biaryl-extended 2-aminoquinoline derivatives from the corresponding
2-chloroquinolines in a three-step amination procedure. Ar = Ph (138), 4-pyridinyl (139), 3-pyridinyl
(140), or 5-pyrimidinyl (141).
Table 36: Results of three-step amination procedure, and characteristic NMR signals demonstrating
successful removal of the para-methoxybenzyl group.
Ar group/ Deprotection
position δH HA,HB (ppm) δH H4 (ppm) Overall Yield (%)
2 138a: 2.59,2.96 7.50 36
N
2 139a: 2.67,3.01 7.41 31
4 139c: 2.98,3.13 7.78 33
N
3 140b: 2.95,3.13 7.69 31
4 140c: 2.95,3.12 7.70 18
N N
3 141b: 2.96,3.16 7.66 31
4 141c: 2.95,3.14 7.69 32
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4.3 Binding studies of 3-position extended 2-aminoquinoline
derivatives
Each of the 3-position 2-aminoquinoline ligands with a biaryl substituent was tested for binding
with the murine Tec SH3 domain using the SPR assay method (Table 37, see Section 2.4.2,
page 114 for method). The previous 3-substituted quinoline lead compound 137 was also
tested, but was found to be completely insoluble under the assay conditions and therefore
the Kd value determined from the SPR method could not be directly compared to the value
determined by the NMR chemical shift perturbation assay method.
The novel biphenyl-extended 2-aminoquinoline compound 138a was also insoluble under the
assay conditions, but the other biaryl compounds with pyridine or pyrimidine rings did appear
to remain soluble. These observations demonstrate that the incorporation of heteroaromatic
rings instead of benzene rings is an effective strategy for incorporation larger aromatic scaffolds
while maintaining water solubility, and therefore a highly useful strategy addressing the aim of
designing more drug-like small-molecule compounds compared to the previous lead compound.
While promising differences in solubility of the ligands were observed with this range of
biaryl extended ligands compared to the previous 3-position extended 2-aminoquinoline lead
compound 137, unfortunately there were not any measurable differences in binding using the
SPR assay method. This assay technique was not able to effectively measure the binding
affinity for compound if the Kd value was higher than approximately 20 µM. The Kd reported
for the lead compound 137 was Kd = 40 ± 8 µM,56 and therefore a 3- or 4-fold improvement in
the binding affinity would be required for a determination of the Kd value using the SPR assay
method. The results from the attempted assays showed that none of the ligands appeared
to reach saturation binding with the SH3 domain for any concentration range tested, and
therefore substantial improvement in the strength of the binding affinity with the Tec SH3
domain was not achieved. Due to the lack of improvement in the strength of the binding
activity observed with this range of compounds, the synthesis of other 3-position biaryl-
extended 2-aminoquinoline ligands was not pursued further.
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N 140a > 50a
N 140b > 50a
N




a Response-concentration curve not at plateau, saturation binding not achieved.
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4.4 Synthesis of pyridinylethyl-extended quinoline derivatives
A similar Horner-Emmons reaction pathway as not anticipated to be an effective method for
the synthesis of 142 derivatives, as the synthesis of similar pyridinylmethylidene compounds
had been unsuccessfully pursued previously (e.g. compound 34c, Scheme 40). In the previous
attempted synthesis, the required pyridinylmethyl-extended phosphonate reagents could not
be synthesised or isolated in sufficient quantities to make the reaction pathway feasible. As
the same reagent would be required for the Horner-Emmons synthesis of 142 derivatives,
this pathway was likewise not deemed feasible in the synthesis of these target compounds.
The most effective method which was utilised in the previous project was the similar Wittig
reaction, which is more feasible due to the achievable synthesis of the required Wittig reagents.
From the results of the previous work, it was therefore expected that a synthesis from previously
synthesised quinoline reagent 144 and Wittig reagents 52(a-c) via a Wittig reaction would
effectively yield the 2-chloroquinolines (172). Subsequently, the required 2-aminoquinolines
(142) could be obtained via either amination to give a N-protected intermediate (Pathway




























Figure 88: Proposed synthetic pathways to yield pyridinylethyl extended 2-aminoquinoline derivatives
(142) via a Wittig reaction.
Using the same Wittig reaction conditions used for the synthesis of the substituted piperidines
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50 previously, the quinoline reagent 144 was reacted with the Wittig reagents 52 using
LiHMDS and THF (Scheme 107). In each case low to moderate yields of the desired products
were obtained (32-52%), and signals corresponding to the quinolinol side-product 152 were
observed in the 1H NMR spectra of the crude reaction mixtures. Similar results had been
observed in attempted Horner-Emmons reactions of 144 previously when LiHMDS and THF
were used as the base and solvent, and it had been determined in that case that using
sodium tert-butoxide and DMF had resulted in substantially improved results. The same
conditions were then attempted in the Wittig reaction, and again this resulted in improved

























Scheme 107: Attempted synthesis of pyridinylvinyl extended 2-chloroquinoline derivatives 172(a-c) via
















Scheme 108: Synthesis of pyridinylvinyl extended 2-chloroquinoline derivatives 172(a-c) using modified
Wittig reaction conditions.
The 1H NMR spectra of the isolated products showed substantial differences in the isomer
selectivity of the reaction (Table 38). The signals corresponding to each alkene isomer of
the products 172b and 172c could be assigned as both isomers of the product were present.
The alkene signals for the Z -isomer appeared further upfield of the other signals, and had
a smaller coupling constant of approximately 12 Hz, whereas the larger coupling constant
of the E -alkene signals was typically 16 Hz. 2D NMR experiments were used in each case
to demonstrate that the desired carbon-carbon bond-forming reaction had occurred to give
the 3-position pyridinylvinyl quinoline product. For the 3-pyridine and 4-pyridine derivatives
(172b and 172c respectively) the product was almost exclusively produced as the Z -isomer.
In contrast, for the 2-pyridine product 172a only one isomer was obtained, and the large alkene
coupling constant of 16.1 Hz indicated that the product was only present as the E -isomer.
None of the Z -isomer was observed in the NMR spectra of the crude mixture or the column
fractions after purification. Syntheses of these compounds had not been published previously,
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and data used to determine the distribution of product isomers for similar reported Wittig
reactions was not available. Further investigation into reactions of pyridinylmethyl-extended
Wittig reagents with aldehydes would be necessary to explain the differences in alkene isomer
selectivity observed in these Wittig reactions.
Table 38: Results of Wittig reactions to give pyridinylvinyl-extended 2-chloroquinoline products 172. Ratio
of alkene products determined by 1H NMR integration, usually comparison of H4 to *HA/*HB as these were

















Pyridinyl Yield E :Z δH 3Jtrans δH δH 3Jcis δH
position (%) ratio HA,HB (Hz) H4 *HA,*HB (Hz) *H4
172a: 2’ 81 1:0 8.03,7.28 16.1 8.42 - - -
172b: 3’ 69 1:99 7.59,7.17 16.3 8.48 6.89,6.83 12.1 7.89
172c: 4’ 45 1:20 7.73,7.12 16.2 8.41 6.96,6.80 12.2 7.87
The Buchwald-Hartwig amination to give the 2-aminoquinoline product was attempted, and
in two cases the desired products 173a and 173b were successfully synthesised and isolated,
although with low yields (Scheme 109). Spectroscopic methods were used to determine that
the isolated products were the desired 2-aminoquinoline products. In the 1H NMR spectra
of the products a broad signal with integration corresponding to two hydrogen atoms was
present, consistent with the introduced 2-position amino group (Figure 89B). Upfield shifts
of the H4 signal and HB alkene signal compared to the reagent were also consistent with
the introduction of the electron-donating amino substituent at the 2-position instead of the
chloro substituent of the reagent (Figure 89A). HRMS analysis of the products also showed
a reduction in the mass found which was consistent with the product, and the 3:1 peaks













































Figure 89: Comparison of 1H NMR spectra for synthesis of 2-aminoquinolines 142 via Buchwald-Hartwig
reaction pathway. Spectra shown are for synthesis of compound 142a. A: 2-Chloroquinoline reagent 172a,
B: product of Buchwald-Hartwig amination 173a, and C: target 2-aminoquinoline compound 142a.
From the available pyridinyl-extended 2-aminoquinoline compounds 173a and 173b, a
hydrogenation reaction under standard conditions reduced the alkene bond formed in the
Wittig reaction to give the target compounds 142a and 142b in quantitative yield (Scheme
110). HRMS analysis of the isolated products showed a mass increase consistent with two
hydrogen atoms, and the alkene doublet signals with large coupling constants in the 1H NMR
spectra were no longer present (Figure 89C). A pair of strongly coupled 2H signals was present
upfield in the 1H NMR spectra of the products instead, and 2D NMR experiments were used
to demonstrate that these signals correspond to an ethylene bridge attaching the pyridine ring
to the 3-position of the aminoquinoline.
One of the desired 2-aminoquinoline compounds (173c) could not be synthesised using the
Buchwald-Hartwig procedure, which was low yielding for all derivatives, and instead the three-












Scheme 110: Synthesis of pyridinylethyl extended 2-aminoquinoline derivatives via hydrogenation reaction.
first step of the procedure, the 2-chloroquinolines 172b and 172c synthesised via the Wittig
reaction were treated with para-methoxybenzylamine at high temperatures. The desired
2-position substituted products 174b and 174c were not completely purified but the 1H
NMR data was used to demonstrate that the desired products were obtained in each case, with
distinctive upfield signals observed for the para-methoxybenzyl group and, compared to the
2-chloroquinoline reagent, upfield shifts of quinoline ring signals consistent with replacement


























33% over three steps
Scheme 111: Attempted synthesis of pyridinylethyl extended 2-aminoquinoline derivatives 142b and 142c
via three-step amination procedure.
The recovery of 174c from the amination reaction and partial purification by column
chromatography was very low (<15%) and insufficient for the remaining steps of the synthetic
procedure. For the 3-pyridine derivative (174b) the nucleophilic aromatic substitution reaction
was followed by hydrogenation of the alkene bond formed in the Wittig reaction under
standard conditions. Again, loss of the distinctive alkene doublet signals in the 1H NMR
spectra confirmed that the reduction had proceeded successfully. The appearance of two
upfield signals corresponding to the ethylene bridge also confirmed the desired products 175b
and 175c had been formed, and the signals corresponding to the para-methoxybenzyl group
showed the N-protecting group was still present.
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The final step was removal of the para-methoxybenzyl group by treatment with trifluoroacetic
acid. The 3-pyridine product 142b had previously been made via the Buchwald-Hartwig
amination pathway, and the spectroscopic data collected for the product via the N-protected
pathway was found to be directly comparable to the previously obtained data. For the products
obtained by trifluoroacetic acid removal of the para-methoxybenzyl group, the HRMS data
was consistent with loss of the amine-protecting group, and the signals corresponding to the
para-methoxybenzyl group were not observed in the NMR spectra of the products, confirming
the desired reaction had occurred.
The yield of the 2-aminoquinolines obtained from the 2-chloroquinolines via this three step
method was higher than via the Buchwald-Hartwig pathway (33% c.f. 7% for synthesis of
142b respectively). It was suspected that the Buchwald-Hartwig amination conditions resulted
in significant degradation of the quinoline compounds present, resulting in the low yield of the
desired product by the first method. In contrast, the low yield via the para-methoxybenzyl
protected pathway was due to the substantial solubility of the product in the aqueous layer
during liquid-liquid extraction in the work-up procedure, and therefore a significant amount
of the product was not recovered. Ideally, a synthetic pathway using Buchwald-Hartwig
amination conditions which do not cause degradation of the 3-position extended quinoline
compounds would likely result in the highest yield, but effective conditions were not identified
during this project.
4.5 Synthesis of simple 3-phenethyl-extended quinoline derivatives
The synthetic methods developed for the 3-position biaryl-extended quinoline ligands were
readily adapted to make the simpler target ligands 143a and 143b. The same Horner-
Emmons synthetic pathway was used due to the similar but simpler structure of these target
ligands compared to the biaryl compounds, requiring a shorter four step synthetic pathway.
The required phosphonate derivatives 36p and 36s had already been synthesised for a previous
section of this project (see Chapter 2). These were reacted in a Horner-Emmons reaction with
the quinoline reagent 144, using sodium tert-butoxide as the base in DMF, which were the
conditions found to be most effective in the synthesis of the similar compound 145c (Scheme
112). The reaction gave good yields of the desired products 176a and 176b, which were
obtained predominantly as the E -isomer (Table 39). Spectroscopic results were consistent
with the 2-chloroquinoline products isolated previously, in particular the characteristic alkene














144 36 R = CF3: 176a, 72%
R = CN: 176b, 69%
Scheme 112: Horner-Emmons synthesis of simple phenethyl extended 2-chloroquinoline derivatives 176a
and 176b.
Table 39: Results of Horner-Emmons reactions with diethyl benzylphosphonate derivatives, to give
3-position extended 2-chloroquinoline products. Ratio of alkene products determined by 1H NMR
integration, usually comparison of H4 to *HA/*HB as these were typically isolated signals. * denotes
Z -isomer.
E-isomer Z-isomer
Yield E :Z δH 3Jtrans δH δH 3Jcis δH
R (%) ratio HA,HB (Hz) H4 *HA,*HB (Hz) *H4
176a: CF3 72 3:1 7.61,7.21 16.2 8.39 6.88,6.86 12.9 7.87
176b: CN 69 2:1 7.64,7.19 16.2 8.40 6.91,6.85 12.2 7.70
The three step amination procedure via a para-methoxybenzyl protected intermediate was
then used to give the products 177a and 177b (Scheme 113). Characteristic changes in the
spectroscopic data was used at each step to demonstrate successful reaction (Tables 40, 41),



















178a/178bR = CF3: 143a
R = CN: 143b
Scheme 113: Procedure for conversion of 2-chloroquinolines 176a and 176b to 2-aminoquinolines 143a
and 143b via three step amination method.
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Table 40: Results of amination and hydrogenation procedure for simple 3-position phenethyl-extended
2-aminoquinolines, and characteristic NMR signals demonstrating successful reaction at each step. Only
E -isomer signals with the vicinal coupling constant are reported for alkene products. Signals for HA and HB
were not assigned individually due to the impure mixtures and the overlap of signals.
Amination Hydrogenation
δH HA,HB (3Jcis) δH H4 δH HA,HB δH H4
R = (ppm) (Hz) (ppm) (ppm) (ppm)
CF3 177a: 7.10,7.13 16.3 7.94 178a 2.81,3.08 7.58
CN 177b: 7.08,7.11 16.0 7.94 178b 2.80,3.06 7.52
Table 41: Results of 3-step amination procedure, and characteristic NMR signals demonstrating successful
removal of the para-methoxybenzyl group.
Deprotection
R = δH HA,HB (ppm) δH H4 (ppm) Overall Yield (%)
CF3 143a: 2.90,3.11 7.63 53
CN 143b: 2.90,3.12 7.59 49
Spectroscopic methods were used to demonstrate that the desired products 143a and 143b
had been synthesised and isolated in each case. The HRMS peaks for each product were
consistent with the expected structures, and the 1H NMR spectra did not show alkene doublet
signals with large coupling constants or signals corresponding to the para-methoxybenzyl
group. Two upfield signals for the ethylene linker chain were observed, and 2D NMR
experiments were used to demonstrate that these signals had correlations to the substituted
benzyl group and to the quinoline ring consistent with a 3-position phenethyl-substituted
quinoline structure.
4.6 Binding studies of simple 3-position extended 2-aminoquinoline
derivatives
The simple 3-position extended 2-aminoquinoline ligands were also assayed with the Tec SH3
Domain using the SPR assay method, to investigate whether substantial improvements in the
strength of the binding interaction had been achieved (Table 42).
One of the ligands, 143a, was insoluble under the assay conditions. The other compounds
contained an additional pyridine ring or the more hydrophilic amide substituent, and therefore
had sufficient aqueous solubility for the SPR assay method and could be tested for binding
affinity with the Tec SH3 domain. Even though they appeared to remain soluble under the
assay conditions, however, none of the 3-position extended 2-aminoquinolines appeared to
reach saturation binding of the Tec SH3 domain target under the concentrations tested. From
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a Response-concentration curve not at plateau, saturation binding not achieved.
the collected data it was therefore apparent that the tested ligands did not have a sufficiently
strong binding interaction with the protein target to enable determination of the Kd value
using the SPR assay method. Based upon these results, any difference or improvement in the
strength of the binding interaction of these ligands could not be ascertained.
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5 Conclusions and Future Directions
5.1 6-Position extended 2-aminoquinoline ligands
A large range of 6-position extended 2-aminoquinoline derivatives were synthesised and the
binding affinity with the murine Tec SH3 domain was investigated using the SPR method.
The assayed compounds were based upon the 4-benzylpiperidine extended compound which
was previously the strongest binding small-molecule ligand for the Tec SH3 domain. The
range of compounds prepared varied in size, scaffold, functional groups, and hydrophilicity,
and were all prepared according to a similar general procedure. The synthesis methodology
developed was widely generalisable to yield the majority of the target compounds, showing
the versatility of the process.
Several of the compounds bound with stronger binding affinity than the previous lead
compound. The strongest binding ligands varied in scaffold, size, and functional groups
(Figure 90), which indicated that a range of different factors were tolerated upon binding to
the Tec SH3 domain. These compounds are the strongest binding small-molecule ligands for


















Kd = 2.0 ± 0.1 µM Kd = 1.9 ± 0.1 µM
Figure 90: 6-Position extended 2-aminoquinoline derivatives with strongest binding affinity for the Tec SH3
domain, as determined by the SPR assay method.
In addition to the improved binding affinity, these compounds all included additional hydrophilic
functional groups (101 and 19s) or contained pyridine rings replacing benzene rings in the
previously reported compounds (23b and 116c). The previous studies had identified that a
benzyl group in the 6-position quinoline substituent improved the binding affinity, but in this
work it was found that electron poor benzene rings resulted in a further improvement in the
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strength of the binding interaction, whether it was due to the comparatively electron poor
pyridine ring, or by addition of an electron-withdrawing substituent. Addition of even the
largest 6-position substituents with biaryl groups was found to be tolerated, and a range of
substituent shapes were also tolerated, which potentially indicates that there is substantial
space to accommodate further extensions without causing steric clashes with the protein
structure.
Most importantly, it was found that significant improvements in binding affinity could be
achieved while still reducing the overall hydrophobicity of the ligand. One of the most
significant challenges of designing inhibitors for protein-protein interaction surfaces are the
largely flat and hydrophobic binding surfaces which are typical of these targets, for which
structure-based design typically leads to large and lipophilic ligand compounds with poor water
solubility. From the success of the design strategies employed in this work, the incorporation
of pyridine rings and hydrophilic functional groups may be a useful and broadly applicable to
improve the drug-like characteristics of some inhibitors without compromising the strength of
the binding interaction.
5.2 3-Position extended 2-aminoquinoline ligands
A range of 3-position extended 2-aminoquinoline derivatives were prepared to further explore
promising results in previous studies, which identified a potential favourable binding interaction.
While a range of the target compounds were successfully prepared via a series of general
synthetic procedures, no substantial improvement in binding affinity could be measured using
the SPR assay method, as the range of concentrations which could be tested did not indicate
a substantial interaction of the ligands with the Tec SH3 domain target.
The previously reported compound which identified the additional binding interaction was
insoluble under the SPR assay conditions, so no comparison or indication of the binding
affinity could be made. In contrast to this compound, however, the majority of the 3-position
extended 2-aminoquinoline derivatives prepared in this work did appear to be soluble under
the assay conditions, which would indicate that aqueous solubility of the compounds was
somewhat improved. While this does address the aim of reducing the overall hydrophobic
character of the ligand and improving the drug-like characteristics of the tested compounds,
a very significant improvement in the strength of the binding interactions with the Tec SH3
domain would be required before the 3-position extended compounds might be considered
as ’effective’ ligands for the Tec SH3 domain. From the results of this work, however, no
progress was made into designing ligands which could better access the additional favourable
binding interaction.
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5.3 Development of extended 2-aminoquinoline ligands for the Tec
SH3 Domain
A lack of substantial improvement in binding affinity was observed for the range of novel
3-position extended 2-aminoquinolines assayed. In contrast, a large variation in the measured
binding affinity was observed for the 6-position extended 2-aminoquinoline compounds tested
even with small structural differences between compounds, and several compounds were
obtained which bound to the Tec SH3 domain with stronger binding affinity than any other
small-molecule ligand tested to date.
These results indicate that further studies of novel 6-position extended 2-aminoquinoline SH3
domain ligands is the most promising area for further investigation and optimisation of binding
affinity. Addition of the phenethyl-type substituents at the 3-position of the 2-aminoquinoline
results in a large reduction in the drug-like characteristics due to the increased lipophilicity and
size of substituent required to access the favourable binding interaction identified in previous
work. The results of this project demonstrate that so far this has not resulted in a substantial
improvement in binding affinity.
While combined 3-,6-position extended 2-aminoquinoline ligands might be expected to access
both favourable binding interactions, the large size of these compounds and the lipophilic
substituent that appears to be required at the 3-position means that this type of compound
is unlikely to have suitable water solubility for assays with the Tec SH3 domain. It also seems
unlikely that the 3-position substituent would significantly contribute to improving the binding
affinity when weighed against the undesirable costs of increased size and hydrophobicity of
the substituent, and a significantly longer and more complicated synthesis would be required
to make these larger quinoline compounds.
The 6-position extended 2-aminoquinoline ligands made in this work were determined to have
a substantial improvement in binding affinity, with results indicating that further improvements
are likely, and this was achieved even while improving the water solubility of the ligands. From
this, it is apparent that further exploration in that area is more likely to yield the strongest
binding ligands with improved drug-like characteristics.
5.4 Proposed future work
5.4.1 Investigation of tetrahydropyridine formation and stability
The production of a tetrahydropyridine side-product under Horner-Emmons conditions was
among the more unexpected synthetic results of the project. Tetrahydropyridines are notoriously
difficult to selectively synthesise, and no previous synthesis of these types of compounds using
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similar conditions has been reported previously. The mechanism for this was not explored as
part of this project, although it was experimentally verified that the tetrahydropyridine and





Figure 91: Isomerisation of benzylidenepiperidine and tetrahydropyridine compounds.
In some cases, depending upon the benzyl substituent, the tetrahydropyridine product was
the major product. As these unsaturated heterocyclic structures are of interest in organic
synthesis and drug design, it would be desirable to investigate the mechanism of formation of
this product under the basic reaction conditions, and investigate the factors determining which
of the isomers is the major product. If reaction or isolation conditions could be determined
which exclusively produce the tetrahydropyridine product, this would be a convenient and
much milder synthesis of these types of compounds than methods reported in the literature.
Extended 2-aminoquinoline compounds with a 6-position tetrahydropyridine substituent
(Figure 92) are desirable future targets as they are structurally similar to the piperidine-
extended compounds which have proven to be the most effective ligands for the Tec SH3
domain to date. It was found that while 2-chloroquinolines with a 6-position tetrahydropyridine
substituent could be readily synthesised using the non-selective methods, the corresponding
2-aminoquinolines could not be successfully isolated. If an alternate and reliable synthesis
were developed it is possible the tetrahydropyridine-extended 2-aminoquinoline ligands would
be more viable targets, and the effect of this structural change upon the strength of the




Figure 92: Target tetrahydropyridine-extended 2-aminoquinoline compounds.
5.4.2 Binding assays of most effective ligands
The SPR assay method was effectively utilised as a high-throughput screening method to
identify the most promising Tec SH3 domain ligands, but further information is required
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to investigate the binding interaction. The NMR chemical shift perturbation experiments
could be used to investigate which SH3 domain residues are affected upon binding of the
2-aminoquinoline ligands. In particular, the shift of surface residue signals including the
tryptophan W215 would indicate whether these higher affinity ligands have a similar binding
model and binding site to the lead compounds.
For any ligands which bind in fast exchange with the protein-ligand complex, the Kd can also
be determined via this method and used as a comparison to the SPR method. As none of the
previously studied compounds were sufficiently stable or had strong enough affinity for the
protein target to be assayed using the SPR method, there are currently no 2-aminoquinoline
derivatives which have been assayed using both SPR and NMR assay methods. A direct
comparison between the two methods would be useful, and could confirm whether the SPR
method is in fact an effective high-throughput method for these screening studies, and whether
the affinity results are consistent across the two methods.
It is plausible, however, that for some of the 2-aminoquinoline ligands the protein and protein-
ligand complex are in intermediate exchange on the NMR timescale, in which case an affinity
analysis and determination of the Kd value is not possible. If this is the case, the affected
residues will still give some highly valuable indication of the binding site and possibly some
insight into the binding model.
The piperidine-extended 2-aminoquinoline derivatives with a biaryl group are perhaps the
most interesting compounds which should be assayed using the NMR method. Biphenyl
compounds reported previously exhibited atypical binding behaviour when assayed with the
Tec SH3 domain, and it was postulated that this was due to alternating binding to two
favourable interactions which could not be accessed simultaneously by those ligands. With
the different structures of the biaryl-extended piperidine compounds investigated for binding
using the SPR method, it is possible that the issues with the multiple binding sites may
have been resolved and the NMR chemical shift perturbation assays may indicate that both
interactions are accessed simultaneously. If this is not the case, then design of alternate
biaryl-type structures which optimally bind to the SH3 domain needs further investigation.
5.4.3 Further development of strong binding Tec SH3 domain ligands
While significantly improvements in binding affinity were obtained with these extended
2-aminoquinoline compounds, a stronger binding ligand would enable determination of the
3D structure of the protein-ligand complex by NMR spectroscopy or X-ray crystallography.
With the accurate information on the ligand binding site and orientation, the 3D structure
would enable any additional binding opportunities to be optimally accessed, and potentially
enable more efficient and informed design if SH3 domain ligands for other potential targets.
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The SPR assay results gave promising indications that stronger binding ligands could be
achieved. The 6-position extended 2-aminoquinolines are the strongest binding ligands for
the Tec SH3 domain found to date, and many large and structurally diverse substituents
were tolerated, and therefore further structural changes can reasonably be expected to bind
favourably with the Tec SH3 domain. A 4-piperidine extension at the 6-position of the
quinoline ring with an electron deficient benzyl-type substituent was the most favoured scaffold
in the strongest binding ligands, particularly
In cases where an aromatic ring accessed an additional favourable binding interaction, it was
always found that replacing a benzene ring with a heteroaromatic ring could improve the
strength of the binding interaction. This replacement is also favourable from a drug design
perspective as heteroaromatic rings, especially pyrimidines, reduce the largely hydrophobic
character of the ligands. From this, it is proposed that the strongly binding ligands which
contained a benzene ring (101 and 116c) would be even more effective ligands if a pyridine










Figure 93: Proposed pyridine analogues of strongest binding ligands to date (101 and 116c), predicted to
have improved binding affinity and improved aqueous solubility.
A broad range of substituted benzylpiperidines were investigated as 6-position 2-aminoquinoline
extensions, and the most favourable substituents were all groups which were comparatively
hydrophilic and electron withdrawing by resonance. These substituents were prepared as
para-substituted derivatives due to the complications in the synthetic pathway, but alternate
structures should also be investigated given the observed favourable impact upon binding.
A wider array of functionalisations could be considered using simple substituents such as
amidines, ketones, or charged groups (Figure 94). Alternatively, larger heteroaromatic systems
such as quinoline or quinazoline rings could be investigated as alternate electron-poor structures.
A wide variety of substituent shapes and sizes were tolerated upon binding to the Tec SH3
domain, and larger substituents may also be tolerated. Addition of a biaryl group improved
the strength of the binding interaction, but when compared to previous studies of biphenyl
extended ligands it appears plausible that the optimal position has not been achieved. The
binding affinity of ortho-biaryls (such as 114a, 116a) was not as strong, and therefore further
spacing between the 2-aminoquinoline ring and the biaryl group may be more likely to reach
the optimal binding position. As mentioned above, NMR chemical shift perturbation assays















Figure 94: 6-Position extended 2-aminoquinoline derivatives with alternate electron-withdrawing
functional groups.
behaviour with the results for previously reported biphenyl ligands would indicate whether the
binding issues have been resolved.
One possibility is that the biaryl group is too rigid or planar to bind optimally to the SH3
domain surface, or that the biaryl group has a separate binding site on the Tec SH3 domain
binding surface. In this case, alternate structures which have the second of the aromatic
rings further away from the 2-aminoquinoline core structure could be favoured instead. As
electron-withdrawing by resonance substituents on the 6-position benzylpiperidine extended
ligands were found to be favourable for binding affinity, the use of groups such as ketones or














X = C or N
Figure 95: Alternate structures of 6-position extended 2-aminoquinoline derivatives with bridging of
heteroaromatic rings.
Interestingly, none of the small structural changes which led to the strongest binding ligands in
this work are mutually incompatible. More complex exotic structures can be envisaged which
combine biaryl groups, electron-withdrawing functional groups, and heteroaromatic rings into
a compound which has even more favourable drug-like characteristics (for example, Figure
96).
Due to the low millimolar-range Kd values obtained in this work, it is expected that such








Figure 96: Structure of complex potential ligand, combining favourable structures identified from SPR
assays of 2-aminoquinoline derivatives with the Tec SH3 domain.
Even if not required for affinity, the results of this work indicate that there is substantial scope
to modify the 6-position 2-aminoquinoline structure while still being readily accommodated
by the Tec SH3 domain, which may be useful to further improve the drug-like characteristics
of the ligands or better achieve more targeted selectivity for one SH3 domain once proximate




Commercially available reagents and reagent grade solvents were used without further
purification unless otherwise indicated. Anhydrous THF was collected from a PureSolv
Micro Solvent Purification System and stored over 4Å molecular sieves under nitrogen gas.
Anhydrous DMF was stored on 4Å molecular sieves. Other required reagents and solvents
were purified according to accepted methods.99
Reactions were monitored where possible by TLC on MERCK aluminium-backed silica gel
60 F254 plates and visualized under UV light at 254 nm before staining with permanganate
stain and heating. Flash column chromatography was performed using Davisil (40-63 micron)
grade silica gel. All 1H NMR (499.818 MHz), 13C NMR (125.692 MHz) and 19F NMR
(470.256 MHz) spectra were obtained using an Agilent DD2 NMR spectrometer at 26°C
unless otherwise indicated. NMR spectra of samples were collected as solutions in CDCl3,
D2O, d6-DMSO or d6-acetone. Chemical shifts for samples in D2O, d6-DMSO or d6-acetone
were calibrated against the residual solvent signal,100 and chemical shifts of samples dissolved
in CDCl3 were reported relative to tetramethylsilane (0.03% v/v) as an internal reference.
The following abbreviations for hydrogen multiplicities were used: s, singlet; d, doublet; t,
triplet; q, quartet; p, pentet; br, broad; m, multiplet. ‡ Indicates an unresolved J coupling
constant. Chemical shifts were measured directly from the collected spectra except where
non-first order analysis was used, in which case the multiplicity of the strongly-coupled spin
system is denoted using Pople notation as ’AB’ or ’ABX ’ and the reported chemical shifts and
J values were determined using established analytical methods.101 For 6-membered saturated
heterocycles which adopt a chair-like conformation, inequivalent axial and equatorial hydrogen
atoms are distinguished with subscripts ’ax’ and ’eq’ respectively (e.g. Hax and Heq).
The 1H and 13C NMR signals of previously unreported compounds were assigned with the
assistance of COSY, ROESY, HSQC and HMBC 2D NMR experiments where required. HRMS
(ESI, positive ion mode) experiments of samples dissolved in acetonitrile were run using an
Agilent Series 6230 TOF LC/MS spectrometer. Indicative melting points for solids were
obtained using a DigiMelt MPA161 apparatus.
Aside from novel compounds, all spectroscopic data obtained in this project was compared to
literature and a notation indicates that the results are consistent with that reported previously.
In some instances only 1H NMR data had been reported in the literature and this data was
inconsistent with that obtained in this project, and these are also noted.
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6.2 2-Aminoquinolines with a 6-position benzylpiperidine substituent
6.2.1 Synthesis of 4-benzylpiperidine derivatives








A mixture of the benzyl halide derivative (1 eq) and triethylphosphite (3 eq) was heated at
reflux for 18 hr. The excess triethylphosphite was removed by short-path distillation under
reduced pressure to give the phosphonate which was used without further purification.



























A solution of benzylphosphonate 36 (2 eq) in dry THF was added to a suspension of sodium
hydride (60% in mineral oil, 4 eq) in THF under an atmosphere of nitrogen. The mixture
was stirred for 30 min and a solution of N-protected piperidone (1 eq) in THF was added
dropwise. The mixture was stirred at 50°C for the specified time then quenched with brine
solution and extracted with ethyl acetate (3 x 40 mL). The organic extracts were dried over
MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was
chromatographed on silica gel with the specified eluant.















The benzylidenepiperidine derivative was dissolved in methanol and stirred for the specified
time under an atmosphere of hydrogen with a catalytic amount of 5% palladium on carbon
(Pd-C) catalyst. The mixture was filtered through Celite® washing with methanol, and solvent
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was removed under reduced pressure. The residue was purified by column chromatography
on silica gel using the specified eluant where necessary, or used without further purification.














The Boc-protected piperidine derivative (1 eq) was dissolved in dichloromethane (4.0 mL/100
mg reagent). Trifluoroacetic acid (1.0 mL/100 mg reagent) was added dropwise and the
mixture was stirred at room temperature for 1 hr. The mixture was quenched with saturated
aqueous sodium bicarbonate solution (30 mL) and extracted with dichloromethane (3 x 40
mL). The organic extracts were dried over MgSO4, filtered, and the solvent was removed under
reduced pressure. The residue was resuspended in dichloromethane (10 mL) and concentrated
to dryness by evaporation under reduced pressure, and this was repeated until there was no
trace of residual trifluoroacetic acid by 19F NMR spectroscopy. The product was used without
further purification.
















A solution of benzylphosphonate 36 (2 eq) in dry THF was added to a suspension of sodium
hydride (60% in mineral oil, 4 eq) in THF under an atmosphere of nitrogen. The mixture
was stirred for 30 min and a solution of Boc-protected piperidone (1 eq) in THF was added
dropwise. The mixture was stirred at 50°C until complete then quenched with brine solution
and extracted with ethyl acetate. The solvent was removed under reduced pressure then the
residue was dissolved in methanol and stirred for 2 hr under an atmosphere of hydrogen with
a catalytic amount of 5% palladium on carbon (Pd-C). The mixture was filtered through
Celite®, washed with methanol, then the solvent was removed under reduced pressure. The
crude residue was resuspended in ether and filtered to remove insoluble impurities. Hydrogen
chloride solution (1M in diethyl ether or 4M in 1,4-dioxane) was added then the mixture was
stirred at room temperature overnight. The precipitate was collected by vacuum filtration
and washed with diethyl ether.
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General Method 6: Conversion of benzylpiperidine hydrochloride derivatives to free
amines
The benzylpiperidine hydrochloride derivative was suspended in dichloromethane and stirred
at room temperature. Saturated aqueous sodium bicarbonate solution (20 mL) was added
dropwise and the mixture was stirred for 10 minutes. The solvent was removed by evaporation
under reduced pressure to give a dry residue which was extracted with dichloromethane (3
x 30 mL). The organic extracts were dried over MgSO4, filtered, and solvent was removed
under reduced pressure. The residue was used without further purification.






The chloromethylpyridine hydrochloride or bromomethylpyridine hydrobromide derivative (1.0
eq) was suspended in toluene (10 mL/1 g reagent). Saturated aqueous sodium bicarbonate
solution (10 mL/1 g reagent) was slowly added and the mixture was left until visible signs
of reaction ceased. The layers were separated and the aqueous layer was further extracted
with toluene (2 x 30 mL). The combined organic extracts were dried over MgSO4 and filtered.
Triphenylphosphine (1.5 eq) was added to the filtrate and the mixture was heated at reflux for
the specified time. The reaction mixture was cooled to 0°C and the precipitate was collected







Using General Method 1, 3-methylbenzyl chloride (3.06 g, 22 mmol) and triethylphosphite
(11.2 mL, 65 mmol) was were reacted for 18 hr. Removal of the excess reagent via distillation
gave 36c as a clear oil (5.61 g, >100%*). 1H NMR (500 MHz, CDCl3): δ 1.24 [6H, t, 3J
= 7.1 Hz, 2 x CH3], 2.33 [3H, s, CH3], 3.11 [2H, d, 2JH,P = 21.5 Hz, PCH2], 3.96-4.06 [4H,
m, 2 x OCH2], 7.02-7.14 [3H, m, H(2) + H(4) + H(6)], 7.19 [1H, t, 3J4,5 = 3J5,6 = 7.6 Hz,
H(5)].
This data is consistent with that reported in literature.66





Synthesis method a. Using General Method 2, 36c (0.50 g, 2.1 mmol), N-Boc-4-piperidone
(250 mg, 1.3 mmol), and sodium hydride (60% dispersion in paraffin oil, 300 mg, 7.5
mmol) were reacted in THF (5 mL) for 18 hr. The crude product was purified by column
chromatography on silica gel eluting with 1:9 ethyl acetate/hexane to give 45c as a colourless
oil (312 mg, 87%). Rf = 0.27 (1:19 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for
C18H25NO2 − C(CH3)3: 232.1338; found 232.1332. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H,
s, tBu], 2.27-2.37 [5H, m, H(5) + CH3], 2.43-2.51 [2H, m, H(3)], 3.33-3.44 [2H, m, H(2)],
3.45-3.55 [2H, m, H(6)], 6.33 [1H, s, H(A)], 6.97-7.05 [3H, m, H(2’) + H(4’) + H(6’)], 7.20
[1H, t, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, H(5’)]. 13C NMR (126 MHz, CDCl3): δ 21.57 [CH3], 28.60
[tBu], 29.37 [C(3)], 36.35 [C(5)], 45.24 [br, C(2) + C(6)], 79.65 [tBu], 124.71 [C(A)], 126.06
[C(6’)], 127.19 [C(4’)], 128.18 [C(5’)], 129.72 [C(2’)], 137.50 [C(4)], 137.84 [C(1’)], 138.33
[C(3’)], 154.90 [C=O].
Synthesis method b. N-Boc-4-piperidone (100 mg, 0.05 mmol) and 36c (146 mg, 0.60 mmol)
were combined in ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.14 g,
2.5 mmol) were added over 10 minutes. The mixture was stirred at room temperature for 30
min then 70°C for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture
was extracted with ethyl acetate (3 x 30 mL) to give recovered starting materials.
1-Benzyl-4-(3-methylbenzylidene)piperidine (47c)
N
Using General Method 2, 36c (0.38 g, 1.6 mmol), N-Bn-4-piperidone 46 (0.20 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.13 g, 3.2 mmol) were reacted in THF
(5 mL) for 4 hr. The crude product was purified by column chromatography on silica gel
eluting with 3:7 ethyl acetate/hexane to give 47c as a colourless oil (176 mg, 60%). Rf
= 0.24 (1:4 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C20H23N: 278.1909;
found 278.1904. 1H NMR (500 MHz, CDCl3): δ 2.35 [2H, s, CH3], 2.37-2.47 [4H, m, H(3) +
H(5)], 2.51-2.58 [4H, m, H(2) + H(6)], 3.55 [2H, s, CH2], 6.26 [1H, s, H(A)], 6.99-7.05 [3H,
m, H(2’) + H(4’) + H(6’)], 7.17-7.24 [1H, m, H(5’)], 7.30-7.38 [5H, m, Ph]. 13C NMR (126
MHz, CDCl3): δ 21.59 [CH3], 29.34 [C(3)], 36.65 [C(5)], 54.59 [*C(2) or C(6)], 55.24 [*C(2)
or C(6)], 63.16 [CH2], 123.31 [C(A)], 126.13 [C(6’)], 126.92 [C(4’)], 127.10 [C(4”)], 128.10
206
[C(5’)], 128.31 [C(3”) + C(5”)], 129.29 [C(2”) + C(6”)], 129.78 [C(2’)], 137.73 [C(1’)],
137.95[C(1”)], 138.63 [C(4)], 139.70 [C(3’)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment




Using General Method 3, 45c (138 mg, 0.48 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up and column chromatography
on silica gel eluting with 1:9 ethyl acetate/hexane gave 48c as a colourless oil (137 mg,
99%). Rf = 0.44 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C18H27NO2:
290.2120; found 290.2121*. 1H NMR (500 MHz, CDCl3): δ 1.13 [2H, qd, 2J(3/5)ax,(3/5)eq
= 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.0 Hz, 3J(2/6)eq,(3/5)ax = 3.3 Hz, H(3ax) + H(5ax)], 1.45
[9H, s, tBu], 1.56-1.70 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.33 [3H, s, CH3], 2.49 [2H, d,
3J4ax,A = 6.9 Hz, H(A)], 2.63 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.0 Hz, H(2ax)
+ H(6ax)], 3.82-4.29 [2H, m, H(2eq) + H(6eq)], 6.90-6.97 [2H, m, H(2’) + H(6’)], 7.00 [1H,
br d‡, 3J4’,5’ = 7.5 Hz, H(4’)], 7.16 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, H(5’)]. 13C NMR
(126 MHz, CDCl3): δ 21.53 [CH3], 28.61 [tBu], 32.17 [br, C(3) + C(5)], 38.30 [C(4)], 43.22
[C(A)], 44.05 [br, C(2) + C(6)], 79.31 [tBu], 126.26 [C(6’)], 126.78 [C(4’)], 128.22 [C(5’)],
130.04 [C(2’)], 137.88 [C(3’)], 140.31 [C(1’)], 155.00 [C=O].
*Only trace of parent ion mass peak observed. Predominant mass peak corresponds to




Synthesis method a. Using General Method 4, 48c (89 mg, 0.31 mmol) and trifluoroacetic
acid (1 mL) were reacted in dichloromethane (4 mL) to give 31c as a yellow oil (51 mg,
88%). HRMS (ESI+) [M+H]+ calcd. for C13H19N: 190.1596; found 190.1587. 1H NMR
(500 MHz, CDCl3): δ 1.43 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.7
Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.65-1.81 [3H, m, H(3eq) + H(4ax) + H(5eq)],
2.33 [3H, s, CH3], 2.53 [2H, d, 3JA,4ax = 7.0 Hz, H(A)], 2.71 [2H, td, 2J(2/6)ax,(2/6)eq =
207
3J(2/6)ax,(3/5)ax = 12.7 Hz, 3J(2/6)ax,(3/5)eq = 2.7 Hz, H(2ax) + H(6ax)], 3.00 [1H, br s, NH],
3.26 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.7 Hz, H(2eq) + H(6eq)], 6.90-6.97 [2H, m, H(2’) +
H(6’)], 7.02 [1H, br d‡, 3J4’,5’ = 7.6 Hz, H(4’)], 7.17 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)].
13C NMR (126 MHz, CDCl3): δ 21.50 [CH3], 31.02 [C(3) + C(5)], 37.34 [C(4)], 43.11 [C(A)],
45.33 [C(2) + C(6)], 126.21 [C(6’)], 126.94 [C(4’)], 128.30 [C(5’)], 129.98 [C(2’)], 138.00
[C(3’)], 139.76 [C(1’)].
This data is consistent with that reported in literature.58
Synthesis method b. Using General Method 6, 49c (87 mg, 0.39 mmol) was treated with
saturated aqueous sodium bicarbonate solution (10 mL) in dichloromethane (10 mL) to give
31c as a yellow oil (50 mg, 69%). Data as above.
4-(3-Methylbenzyl)piperidine hydrochloride (49c)
NH2Cl
Synthesis method a. Using General Method 5, 36c (0.50 g, 2.1 mmol), N-Boc-4-piperidone
(0.21 g, 1.1 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.34 g, 8.5 mmol) were
reacted for 18 hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by
hydrogen chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49c
as a brown solid (0.14 g, 60%). 1H NMR (500 MHz, D2O): δ 1.32 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.8 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.70-1.85
[3H, m, H(3eq) + H(4ax) + H(5eq)], 2.21 [3H, s, CH3], 2.49 [2H, d, 3J4ax,A = 6.9 Hz, H(A)],
2.82 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.8 Hz, H(2ax) + H(6ax)], 3.29 [2H, br d‡,
2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq) + H(6eq)], 6.97 [1H, d, 3J4’,5’ = 7.7 Hz, H(4’)], 6.99-7.06
[2H, m, H(2’) + H(6’)], 7.17 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.7 Hz, H(5’)]. 13C NMR (126 MHz,
D2O): δ 22.94 [CH3], 30.74 [C(3) + C(5)], 37.64 [C(4)], 43.90 [C(A)], 46.66 [C(2) + C(6)],
128.86 [C(6’)], 129.46 [C(4’)], 131.13 [C(5’)], 132.50 [C(2’)], 141.25 [C(3’)], 142.68 [C(1’)].
Synthesis method b. Using General Method 5, 36c (0.50 g, 2.1 mmol), N-Boc-4-piperidone
(0.21 g, 1.1 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.34 g, 8.5 mmol)
were reacted for 18 hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed
by hydrogen chloride solution (4M in 1,4-dioxane, 2 mL), to give 49c as a brown solid (89







Using General Method 1, 4-(tert-butyl)benzyl bromide (2.50 g, 11 mmol) was reacted with
triethylphosphite (5.6 mL, 33 mmol) to give 36a as a clear oil (3.25 g, >100%*). 1H NMR
(500 MHz, CDCl3): δ 1.24 [6H, t, 3J = 7.1 Hz, 2 x CH3], 1.30 [9H, s, tBu], 3.12 [2H, d,
2JH,P = 21.4 Hz, PCH2], 3.96-4.07 [4H, m, 2 x OCH2], 7.20-7.26 [2H, m, H(2) + H(6)],
7.30-7.35 [2H, m, H(3) + H(5)].
This data is consistent with that reported in literature.102






Using General Method 1, 2-methylbenzyl bromide (3.0 g, 16 mmol) was reacted with
triethylphosphite (8.3 mL, 49 mmol) to give 36b as a clear oil (3.92 g, 100%). 1H NMR (500
MHz, CDCl3): δ 1.23 [6H, t, 3J = 7.1 Hz, 2 x CH3], 2.39 [3H, s, CH3], 3.17 [2H, d, 2JH,P
= 22.0 Hz, PCH2], 3.91-4.09 [4H, m, 2 x OCH2], 7.11-7.20 [3H, m, H(4) + H(5) + H(6)],
7.23-7.31 [1H, m, H(3)].







Using General Method 1, 2-methoxybenzyl chloride (0.36 g, 2.3 mmol) was reacted with
triethylphosphite (1.2 mL, 7.0 mmol) to give 36e as a pale yellow oil (0.52 g, 88%). 1H NMR
(500 MHz, CDCl3): δ 1.24 [6H, t, 3J = 7.2 Hz, 2 x CH3], 3.25 [2H, d, 2JH,P = 21.7 Hz,
PCH2], 3.84 [3H, s, OCH3], 4.02 [4H, p, 3J = 3JH,P = 7.2 Hz, 2 x OCH2], 6.86 [1H, d, 3J3,4
= 7.8 Hz, H(3)], 6.91 [1H, t, 3J4,5 = 3J5,6 = 7.8 Hz, H(5)], 7.22 [1H, br t‡, 3J3,4 = 3J4,5 =
7.8 Hz, H(4)], 7.32 [1H, br d‡, 3J5,6 = 7.8 Hz, H(6)].
209







Using General Method 1, 3-methoxybenzyl chloride (2.50 g, 16 mmol) was reacted with
triethylphosphite (8.21 mL, 48 mmol) to give 36f as a pale yellow oil (3.82 g, 93%). 1H
NMR (500 MHz, CDCl3): δ 1.25 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.13 [2H, d, 2JH,P = 21.6
Hz, PCH2], 3.80 [3H, s, OCH3], 3.96-4.08 [4H, m, 2 x OCH2], 6.79 [1H, ddt, 3J5,6 = 8.1 Hz,
4JH,P = 2.4 Hz, 4J2,6 = 4J4,6 = 1.0 Hz, H(6)], 6.84-6.91 [2H, m, H(2) + H(4)], 7.22 [1H, t,
3J4,5 = 3J5,6 = 8.1 Hz, H(5)].







Using General Method 1, 4-methoxybenzyl chloride (2.50 g, 16 mmol) was reacted with
triethylphosphite (8.21 mL, 48 mmol) to give 36g as a pale yellow oil (3.91 g, 95%). 1H
NMR (500 MHz, CDCl3): δ 1.24 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.09 [2H, d, 2JH,P = 21.2
Hz, PCH2], 3.79 [3H, s, OCH3], 3.95-4.06 [4H, m, 2 x OCH2], 6.82-6.88 [2H, m, H(3) +
H(5)], 7.18-7.25 [2H, m, H(2) + H(6)].







Using General Method 1, 2-fluorobenzyl chloride (3.15 g, 21.8 mmol) was reacted with
triethylphosphite (11.2 mL, 65.3 mmol) to give 36h as a yellow oil (5.21 g, 97%). 1H
NMR (500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.20 [2H, d, 2JH,P = 21.6
Hz, PCH2], 3.99-4.10 [4H, m, 2 x OCH2], 7.05 [1H, dd, 3JH,F = 9.5 Hz, 3J3,4 = 8.7 Hz,
H(3)], 7.10 [1H, t, 3J4,5 = 3J5,6 = 7.6 Hz, H(5)], 7.23 [1H, ddddd, 3J3,4 = 8.7 Hz, 3J4,5 =
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7.6 Hz, 4JH,F = 5.3 Hz, 6JH,P = 2.1 Hz, 4J4,6 = 2.0 Hz, H(4)], 7.38 [1H, tt, 3J5,6 = 4JH,F =
7.6 Hz, 4J4,6 = 4JH,P = 2.0 Hz, H(6)].







Using General Method 1, 3-fluorobenzyl bromide (2.84 g, 15.0 mmol) was reacted with
triethylphosphite (7.7 mL, 45.1 mmol) to give 36i as a yellow oil (3.31 g, 89%). 1H NMR
(500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.14 [2H, d, 2JH,P = 21.8 Hz,
PCH2], 3.98-4.10 [4H, m, 2 x OCH2], 6.95 [1H, tt, 3J4,5 = 3JH,F = 8.4 Hz, 4J2,4 = 4J4,6 =
2.5 Hz, H(4)], 7.03 [1H, dq, 3JH,F = 9.6 Hz, 4J2,4 = 4J4,6 = 4JH,P = 2.5 Hz, H(2)], 7.06-7.10
[1H, m, H(6)], 7.27 [1H, q, 3J4,5 = 3J5,6 = 4JH,F = 8.4 Hz, H(5)].







Using General Method 1, 4-fluorobenzyl chloride (3.15 g, 21.1 mmol) was reacted with
triethylphosphite (11.2 mL, 65.3 mmol) to give 36j as a colourless oil (5.20 g, 96%). 1H
NMR (500 MHz, CDCl3): δ 1.25 [6H, t, 3J = 7.0 Hz, 2 x CH3], 3.11 [2H, d, 2JH,P = 21.4
Hz, PCH2], 3.97-4.06 [4H, m, 2 x OCH2], 6.96-7.05 [2H, m, H(3) + H(5)], 7.22-7.31 [2H,
m, H(2) + H(6)].







Using General Method 1, 2-bromobenzyl bromide (5.00 g, 20.0 mmol) was reacted with
triethylphosphite (10.3 mL, 60.0 mmol) to give 36k as a colourless oil (6.52 g, >100%*). 1H
NMR (500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.41 [2H, d, 2JH,P = 22.0
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Hz, PCH2], 4.01-4.09 [4H, m, 2 x OCH2], 7.10 [1H, tt, 3J3,4 = 3J4,5 = 7.8 Hz, 4J4,6 = 6JH,P
= 2.0 Hz, H(4)], 7.27 [1H, t, 3J4,5 = 3J5,6 = 7.8 Hz, H(5)], 7.47 [1H, ddd, 3J5,6 = 7.8 Hz,
4JH,P = 2.4 Hz, 4J4,6 = 2.0 Hz, H(6)], 7.58 [1H, d, 3J3,4 = 7.8 Hz, H(3)].
This data is consistent with that reported in literature.66







Using General Method 1, 3-bromobenzyl bromide (7.27 g, 23.3 mmol) was reacted with
triethylphosphite (12.0 mL, 70.0 mmol) to give 36l as a colourless oil (7.21 g, >100%*). 1H
NMR (500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.11 [2H, d, 2JH,P = 21.7
Hz, PCH2], 3.98-4.08 [4H, m, 2 x OCH2], 7.18 [1H, t, 3J4,5 = 3J5,6 = 7.8 Hz, H(5)], 7.25
[1H, br d‡, 3J5,6 = 7.8 Hz, H(6)], 7.38 [1H, br d‡, 3J4,5 = 7.8 Hz, H(4)], 7.45 [1H, br s‡,
H(2)].
This data is consistent with that reported in literature.105







Using General Method 1, 4-bromobenzyl bromide (5.83 g, 23.3 mmol) was reacted with
triethylphosphite (12.0 mL, 70.0 mmol) to give 36m as a colourless oil (7.27 g, 100%*). 1H
NMR (500 MHz, CDCl3): δ 1.25 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.09 [2H, d, 2JH,P = 21.7
Hz, PCH2], 3.96-4.09 [4H, m, 2 x OCH2], 7.14-7.20 [2H, m, H(2) + H(6)], 7.41-7.46 [2H,
m, H(3) + H(5)].
This data is consistent with that reported in literature.66








Using General Method 1, 2-trifluoromethylbenzyl chloride (2.00 g, 10 mmol) was reacted with
triethylphosphite (5.18 mL, 30 mmol) to give 36n as a pale yellow oil (2.71 g, 89%). 1H
NMR (500 MHz, CDCl3): δ 1.23 [6H, t, 3J = 7.0 Hz, 2 x CH3], 3.37 [2H, d, 2JH,P = 22.7
Hz, PCH2], 3.96-4.09 [4H, m, 2 x OCH2], 7.35 [1H, br t‡, 3J4,5 = 3J5,6 = 7.6 Hz, H(5)], 7.51
[1H, t, 3J3,4 = 3J4,5 = 7.6 Hz, H(4)], 7.65 [1H, d, 3J3,4 = 7.6 Hz, H(3)], 7.69 [1H, br d‡,
3J4,5 = 7.6 Hz, H(6)]. 13C NMR (126 MHz, CDCl3): δ 16.27 [d, 3JC,P = 6.2 Hz, CH3], 30.19
[dq, 1JC,P = 139.7 Hz, 4JC,F = 1.9 Hz, PCH2], 62.32 [d, 2JC,P = 7.2 Hz, OCH2], 124.26 [qd,
1JC,F = 273.8 Hz, 4JC,P = 1.6 Hz, CF3], 126.24 [qd, 3JC,F = 5.3 Hz, 4JC,P = 2.4 Hz, C(3)],
127.02 [br d‡, 3JC,P = 3.3 Hz, C(6)], 129.08 [qd, 2JC,F = 29.6 Hz, 3JC,P = 8.1 Hz, C(2)],
130.52 [dq, 2JC,P = 8.3 Hz, 3JC,F = 1.6 Hz, C(1)], 131.75 [br d‡, 4JC,P = 2.8 Hz, C(5)],
132.32 [br d‡, 5JC,P = 4.8 Hz, C(4)].







Using General Method 1, 3-trifluoromethylbenzyl chloride (2.00 g, 10 mmol) was reacted with
triethylphosphite (5.18 mL, 30 mmol) to give 36o as a pale yellow oil (2.85 g, 94%). 1H
NMR (500 MHz, CDCl3): δ 1.25 [6H, t, 3J = 7.2 Hz, 2 x CH3], 3.20 [2H, d, 2JH,P = 21.8
Hz, PCH2], 4.04 [4H, p, 3JH,P = 3J = 7.2 Hz, 2 x OCH2], 7.41-7.56 [4H, m, H(2) + H(4)
+ H(5) + H(6)]. 13C NMR (126 MHz, CDCl3): δ 16.32 [d, 3JC,P = 6.2 Hz, CH3], 33.68 [d,
1JC,P = 138.8 Hz, PCH2], 62.29 [d, 2JC,P = 6.7 Hz, OCH2], 123.75 [p, 4JC,F = 5JC,P = 3.8
Hz, C(4)], 124.01 [q, 1JC,F = 272.1 Hz, CF3], 126.52 [dq, 3JC,P = 7.6 Hz, 4JC,F = 3.8 Hz,
C(2)], 129.00 [d, 4JC,P = 2.9 Hz, C(5)], 130.84 [qd, 2JC,F = 32.4 Hz, 4JC,P = 3.2 Hz, C(3)],
132.88 [d, 2JC,P = 9.5 Hz, C(1)], 133.18 [dq, 3JC,P = 6.2 Hz, 5JC,F = 1.0 Hz, C(6)].








Using General Method 1, 4-trifluoromethylbenzyl chloride (2.0 g, 10.3 mmol) was reacted
with triethylphosphite (5.18 mL, 30.2 mmol) to give 36p as a pale yellow oil (3.00 g, 99%).
1H NMR (500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.20 [2H, d, 2JH,P = 22.0
Hz, PCH2], 4.00-4.08 [4H, m, 2 x OCH2], 7.39-7.46 [2H, m, H(2) + H(6)], 7.54-7.60 [2H,
m, H(3) + H(5)]. 13C NMR (126 MHz, CDCl3): δ 16.46 [d, 3JC,P = 5.7 Hz, CH3], 33.86 [d,
1JC,P = 137.8 Hz, PCH2], 62.40 [d, 2JC,P = 6.7 Hz, OCH2], 124.25 [qd, 1JC,F = 272.0 Hz,
6JC,P = 1.7 Hz, CF3], 125.52 [p, 3JC,F = 4JC,P = 5.6 Hz, C(3) + C(5)], 129.31 [dq, 2JC,P =
32.3 Hz, 5JC,F = 4.0 Hz, C(4)], 130.18 [d, 3JC,P = 6.7 Hz, C(2) + C(6)], 136.12 [dq, 2JC,P
= 9.0 Hz, 5JC,F = 1.1 Hz, C(1)].







Using General Method 1, 3-(bromomethyl)benzonitrile (3.0 g, 15.3 mmol) was reacted with
triethylphosphite (7.9 mL, 46.1 mmol) to give 36r as a pale yellow oil (4.11 g, 100%*). 1H
NMR (500 MHz, CDCl3): δ 1.27 [6H, t, 3J = 7.0 Hz, 2 x CH3], 3.17 [2H, d, 2JH,P = 21.9 Hz,
PCH2], 4.01-4.09 [4H, m, 2 x OCH2], 7.43 [1H, t, 3J4,5 = 3J5,6 = 7.8 Hz, H(5)], 7.53-7.61
[3H, m, H(2) + H(4) + H(6)].
*contains residual triethylphosphite, <7% by 1H NMR analysis.







Using General Method 1, 4-(chloromethyl)benzonitrile (3.0 g, 19.8 mmol) was reacted with
triethylphosphite (10.2 mL, 59.5 mmol) to give 36s as a yellow oil (4.55 g, 91%). 1H NMR
(500 MHz, CDCl3): δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.20 [2H, d, 2JH,P = 22.3 Hz,
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PCH2], 4.00-4.09 [4H, m, 2 x OCH2], 7.38-7.46 [2H, m, H(2) + H(6)], 7.57-7.65 [2H, m,
H(3) + H(5)].






Using General Method 1, benzyl bromide (4.60 mL, 38.9 mmol) was reacted with triethyl-
phosphite (20.0 mL, 117 mmol) to give 36x as a yellow oil (8.87 g, 100%). 1H NMR (500
MHz, CDCl3): δ 1.24 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.15 [2H, d, 2JH,P = 21.6 Hz, PCH2],
3.94-4.07 [4H, m, 2 x OCH2], 7.19-7.35 [5H, m, H(2) + H(3) + H(4) + H(5) + H(6)].







Synthesis method a. 4-(Bromomethyl)pyridine hydrobromide (0.20 g, 1.98 mmol) was
suspended in toluene (15 mL). Saturated aqueous sodium bicarbonate solution (20 mL) was
added, and after visible signs of reaction ceased the mixture was extracted with toluene (3
x 20 mL). The organic extracts were dried over MgSO4 and filtered, then heated at reflux
with triethylphosphite (1.02 mL, 5.94 mmol) for 4 hr. The resultant mixture contained a
black solid which was collected by vacuum filtration. 1H NMR analysis indicated there was
no product 50c or pyridine reagent present in solid or filtrate.
Synthesis method b. 4-(Bromomethyl)pyridine hydrobromide (0.20 g, 1.98 mmol) was
suspended in dichloromethane (5 mL). Saturated aqueous sodium bicarbonate solution (20
mL) was added, and after visible signs of reaction ceased the mixture was extracted with
dichloromethane (3 x 20 mL). The organic extracts were dried over MgSO4 and filtered,
then heated at reflux with triethylphosphite (1.02 mL, 5.94 mmol) for 4 hr. The remaining
dichloromethane was removed by evaporation under reduced pressure. Partial removal of
the triethylphosphite by short-path distillation gave a pink precipitate which was removed by
gravity filtration and found by crude 1H NMR analysis to contain no product. The remaining
triethylphosphite was removed from the filtrate by short-path distillation to give a crude brown
oil, found by 1H NMR analysis to contain 50c, which was used without further purification
(86 mg, <20% yield). HRMS (ESI+) [M+H]+ calcd. for C10H16NO3P: 230.0946; found
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230.0939. 1H NMR (500 MHz, CDCl3): δ 1.27 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.13 [2H,
d, 2JH,P = 22.3 Hz, PCH2], 4.01-4.10 [4H, m, 2 x OCH2], 7.22-7.27 [2H, m, H(2) + H(6)],
8.52-8.57 [2H, m, H(3) + H(5)].




Using General Method 7, 4-(bromomethyl)pyridine hydrobromide (2.0 g, 7.9 mmol) in toluene
was treated with saturated aqueous sodium bicarbonate solution then heated at reflux with
triphenylphosphine (3.11 g, 11.9 mmol) for 3 hr to give 52c as a pink solid (2.49 g, 75%).
MP: 247-249°C. 1H NMR (500 MHz, d6-DMSO): δ 5.34 [2H, d, 2JH,P = 16.6 Hz, PCH2],
7.00-7.07 [2H, m, H(3) + H(5)], 7.64-7.98 [15H, m, 3 x Ph], 8.42-8.49 [2H, m, H(2) +
H(6)]. 13C NMR (126 MHz, d6-DMSO): δ 27.41 [d, 1JC,P = 47.2 Hz, PCH2], 117.34 [d,
1JC,P = 86.3 Hz, C(1’)], 125.99 [d, 3JC,P = 5.7 Hz, C(3) + C(5)], 130.25 [d, 3JC,P = 12.4
Hz, C(3’) + C(5’)], 134.00 [d, 2JC,P = 10.0 Hz, C(2’) + C(6’)], 135.34 [d, 4JC,P = 2.9 Hz,
C(4’)], 138.50 [d, 2JC,P = 8.0 Hz, C(4)], 149.42 [d, 4JC,P = 2.4 Hz, C(2) + C(6)].




Using General Method 7, 2-(bromomethyl)pyridine hydrobromide (2.50 g, 9.9 mmol) in toluene
was reacted with saturated aqueous sodium bicarbonate solution then heated at reflux with
triphenylphosphine (4.03 g, 15.4 mmol) for 3 hr to give 52a as a pale yellow solid (3.67 g,
85%). MP: 261-262°C. 1H NMR (500 MHz, CDCl3): δ 5.63 [2H, d, 2JH,P = 14.4 Hz, PCH2],
7.09-7.19 [1H, m, H(4)], 7.56 [1H, t, 3J4,5 = 3J5,6 = 7.7 Hz, H(5)], 7.58-7.69 [6H, m, H(3’)
+ H(5’)], 7.75 [3H, t, 3J3’,4’ = 3J4’,5’ = 7.8 Hz, H(4’)], 7.78-7.86 [6H, m, H(2’) + H(6’)],
7.88 [1H, d, 3J5,6 = 7.7 Hz, H(6)], 8.25 [1H, d, 3J4,5 = 4.7 Hz, H(3)]. 13C NMR (126 MHz,
CDCl3): δ 32.95 [d, 1JC,P = 52.0 Hz, PCH2], 118.76 [d, 1JC,P = 87.3 Hz, C(1’)], 123.01 [d,
5JC,P = 1.9 Hz, C(5)], 126.98 [d, 3JC,P = 7.6 Hz, C(3)], 129.98 [d, 3JC,P = 12.9 Hz, C(3’) +
C(5’)], 134.21 [d, 2JC,P = 10.0 Hz, C(2’) + C(6’)], 134.72 [d, 4JC,P = 2.9 Hz, C(4’)], 137.42
[br‡, C(4)], 148.62 [br‡, C(6)], 149.61 [d, 2JC,P = 8.6 Hz, C(2)].




Using General Method 7, 3-(chloromethyl)pyridine hydrochloride (1.96 g, 11.9 mmol) in
toluene (20 mL) was treated with saturated aqueous sodium bicarbonate solution then heated
at reflux with triphenylphosphine (4.71 g, 18.0 mmol) for 3 hr to give 52b as a pink solid (1.37
g, 34%). MP: >260°C. 1H NMR (500 MHz, CDCl3): δ 5.83 [2H, d, 2JH,P = 14.9 Hz, PCH2],
7.09 [1H, dd, 3J4,5 = 7.9 Hz, 3J5,6 = 4.8 Hz, H(5)], 7.58-7.67 [6H, m, Ph], 7.72-7.79 [3H, m,
Ph], 7.79-7.88 [6H, m, Ph], 7.91-7.96 [1H, m, H(4)], 8.08-8.12 [1H, m, H(2)], 8.40-8.44 [1H,
m, H(6)]. 13C NMR (126 MHz, d6-DMSO): δ 25.47 [d, 1JC,P = 47.7 Hz, PCH2], 117.44 [d,
1JC,P = 85.8 Hz, C(1’)], 123.73 [d, 4JC,P = 2.9 Hz, C(5)], 124.59 [d, 2JC,P = 8.6 Hz,C(3)],
130.25 [d, 3JC,P = 12.4 Hz, C(3’) + C(5’)], 134.04 [d, 2JC,P = 10.0 Hz, C(2’) + C(6’)],
135.27 [d, 4JC,P = 3.3 Hz,C(4’)], 138.23 [d, 3JC,P = 5.3 Hz, C(4)], 149.36 [d, 5JC,P = 3.8
Hz, C(6)], 151.20 [d, 3JC,P = 6.2 Hz, C(2)].




Synthesis method a. Using General Method 2, 36a (0.71 g, 2.5 mmol), N-Boc-4-piperidone
(0.25 g, 1.3 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.40 g, 10.0 mmol)
were reacted in THF (5 mL) for 18 hr. The crude product was purified by column
chromatography on silica gel eluting with 1:9 ethyl acetate/hexane to give 45a as a colourless
oil (162 mg, 39%). Rf = 0.39 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for
C21H31NO2 − C(CH3)3: 274.1807; found 274.1795. 1H NMR (500 MHz, CDCl3): δ 1.32 [9H,
s, tBu], 1.48 [9H, s, tBu], 2.27-2.38 [2H, m, H(5)], 2.43-2.54 [2H, m, H(3)], 3.33-3.44 [2H,
m, H(2)], 3.46-3.55 [2H, m, H(6)], 6.32 [1H, s, H(A)], 7.11-7.16 [2H, m, H(3’) + H(5’)],
7.31-7.38 [2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 28.63 [tBu], 29.22 [tBu],
29.38 [C(3)], 31.49 [tBu], 34.64 [C(5)], 36.35 [br, C(2)], 44.59 [br, C(6)], 79.66 [tBu], 124.45
[C(A)], 125.23 [C(3’) + C(5’)], 128.73 [C(2’) + C(6’)], 134.70 [C(1’)], 138.00 [C(4)], 149.38
[C(4’)], 154.94 [C=O].
Synthesis method b. N-Boc-4-piperidone (200 mg, 1.0 mmol) and 36a (0.36 g, 1.24 mmol)
were combined in ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.28 g,
5.0 mmol) were added over 10 minutes. The mixture was stirred at room temperature for 30
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min then 70°C for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture




Using General Method 2, 36d (0.50 g, 2.1 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.30 g, 7.5 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45d as a white solid (163 mg, 51%). Rf =
0.31 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C18H25NO2 − C(CH3)3:
232.1338; found 232.1329. 1H NMR (500 MHz, CDCl3): δ 1.47 [9H, s, tBu], 2.27-2.37 [5H,
m, H(5) + CH3], 2.41-2.50 [2H, m, H(3)], 3.34-3.43 [2H, m, H(2)], 3.45-3.54 [2H, m, H(6)],
6.32 [1H, s, H(A)], 7.05-7.17 [4H, m, H(2’) + H(3’) + H(5’) + H(6’)]. 13C NMR (126 MHz,
CDCl3): δ 21.27 [CH3], 28.61 [tBu], 29.33 [C(3)], 36.35 [C(5)], 45.28 [br, C(2) + C(6)],
79.65 [tBu], 124.51 [C(A)], 128.91 [C(2’) + C(6’)], 129.00 [C(3’) + C(5’)], 134.65 [C(1’)],





Using General Method 2, 36e (0.57 g, 2.2 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.35 g, 8.8 mmol) were reacted in THF (5
mL) for 18 hr. The crude product was purified by column chromatography on silica gel eluting
with 1:9 ethyl acetate/hexane to give 45e as a colourless oil (190 mg, 56%). 1H NMR (500
MHz, CDCl3): δ 1.47 [9H, s, tBu], 2.30-2.42 [4H, m, H(3) + H(5)], 3.36-3.45 [2H, m, H(2)],
3.48-3.56 [2H, m, H(6)], 3.82 [3H, s, OCH3], 6.35 [1H, s, H(A)], 6.87 [1H, d, 3J3’,4’ = 7.8
Hz, H(3’)], 6.91 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.8 Hz, H(5’)], 7.11 [1H, dd, 3J5’,6’ = 7.8 Hz, 4J4’,6’
= 1.7 Hz, H(6’)], 7.21 [1H, td, 3J3’,4’ = 3J4’,5’ = 7.8 Hz, 4J4’,6’ = 1.7 Hz, H(4’)]. 13C NMR
(126 MHz, CDCl3): δ 28.58 [tBu], 29.66 [C(3)], 36.34 [C(5)], 45.28 [br, C(2) + C(6)], 55.48
[OCH3], 79.55 [tBu], 110.57 [C(3’)], 120.09 [C(5’)], 120.17 [C(1’)], 126.32 [C(4’)], 128.02






Using General Method 2, 36g (0.57 g, 2.2 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.18 g, 4.4 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45g as a colourless oil (90 mg, 27%). Rf =
0.24 (1:9 ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.24-2.36
[2H, m, H(5)], 2.39-2.50 [2H, m, H(3)], 3.33-3.44 [2H, m, H(2)], 3.45-3.55 [2H, m, H(6)],
3.80 [3H, s, OCH3], 6.30 [1H, s, H(A)], 6.80-6.91 [2H, m, H(3’) + H(5’)], 7.07-7.17 [2H,
m, H(2’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 28.60 [tBu], 29.26 [C(3)], 36.30 [C(5)],
45.14 [br, C(2) + C(6)], 55.38 [OCH3], 79.63 [tBu], 113.74 [C(3’) + C(5’)], 124.10 [C(A)],
130.12 [C(2’) + C(6’)], 137.21 [C(1’)], 154.91 [C=O], 158.19 [C(4’)].






Using General Method 2, 36i (0.54 g, 2.2 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.7 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45i as a colourless oil (270 mg, 84%). Rf =
0.41 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C17H22FNO2 − C(CH3)3:
236.1087; found 236.1080. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.25-2.39 [2H,
m, H(5)], 2.39-2.54 [2H, m, H(3)], 3.32-3.46 [2H, m, H(2)], 3.46-3.58 [2H, m, H(6)], 6.32
[1H, s, H(A)], 6.86-6.93 [2H, m, H(2’) + H(4’)], 6.95 [1H, d, 3J5’,6’ = 7.8 Hz, H(6’)], 7.27
[1H, td, 3J4’,5’ = 3J5’,6’ = 7.8 Hz, 4JH,F = 6.4 Hz, H(5’)]. 13C NMR (126 MHz, CDCl3): δ
28.46 [tBu], 29.22 [C(3)], 36.16 [C(5)], 44.94 [br, C(2) + C(6)], 79.62 [tBu], 113.18 [d, 2JC,F
= 21.5 Hz, C(4’)], 115.60 [d, 2JC,F = 21.0 Hz, C(2’)], 123.49 [d, 4JC,F = 1.9 Hz, C(A)],
124.61 [d, 4JC,F = 2.9 Hz, C(6’)], 129.59 [d, 3JC,F = 8.6 Hz, C(5’)], 139.66 [d, 3JC,F = 7.8






Using General Method 2, 36j (0.50 g, 2.0 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.30 g, 7.5 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45j as a colourless oil (223 mg, 69%). Rf =
0.25 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C17H22FNO2 − C(CH3)3:
236.1087; found 236.1083. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.25-2.36 [2H,
m, H(5)], 2.37-2.47 [2H, m, H(3)], 3.34-3.44 [2H, m, H(2)], 3.45-3.56 [2H, m, H(6)], 6.31
[1H, s, H(A)], 7.96-7.04 [2H, m, H(3’) + H(5’)], 7.11-7.18 [2H, m, H(2’) + H(6’)]. 13C NMR
(126 MHz, CDCl3): δ 28.46 [tBu], 29.10 [C(3)], 36.13 [C(5)], 44.98 [br, C(2) + C(6)], 79.59
[tBu], 115.03 [d, 2JC,F = 21.5 Hz, C(3’) + C(5’)], 123.44 [C(A)], 130.38 [d, 3JC,F = 7.6 Hz,
C(2’) + C(6’)], 133.38 [d, 4JC,F = 3.3 Hz, C(1’)], 138.48 [br, C(4)], 154.75 [C=O], 161.35
[d, 1JC,F = 245.6 Hz, C(4’)].






Using General Method 2, 36k (1.02 g, 3.3 mmol), N-Boc-4-piperidone (0.35 g, 1.8 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.26 g, 6.5 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica
gel eluting with 1:9 ethyl acetate/hexane to give 45k as a white solid (617 mg, 100%).
Rf = 0.34 (1:9 ethyl acetate/hexane). MP: 89-90°C. HRMS (ESI+) [M+H]+ calcd. for
C17H2279BrNO2/C17H2281BrNO2 − C(CH3)3: 296.0286/298.0266; found 296.0294/298.0276.
1H NMR (500 MHz, CDCl3): δ 1.47 [9H, s, tBu], 2.22-2.33 [2H, m, H(5)], 2.32-2.42 [2H, m,
H(3)], 3.34-3.45 [2H, m, H(2)], 3.48-3.58 [2H, m, H(6)], 6.31 [1H, s, H(A)], 7.09 [1H, td,
3J3’,4’ = 3J4’,5’ = 7.7 Hz, 4J4’,6’ = 1.5 Hz, H(4’)], 7.17 [1H, dd, 3J5’,6’ = 7.7 Hz, 4J4’,6’ = 1.5
Hz, H(6’)], 7.25 [1H, br t‡, 3J4’,5’ = 3J5’,6’ = 7.7 Hz, H(5’)], 7.57 [1H, dd, 3J3’,4’ = 7.7 Hz,
4J3’,5’ = 0.9 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 28.61 [tBu], 29.54 [C(3)], 36.02
[C(5)], 45.24 [br, C(2) + C(6)], 79.73 [tBu], 124.17 [C(A)], 124.43 [C(2’)], 127.04 [C(4’)],






Synthesis method a. Using General Method 2, 36l (0.75 g, 2.4 mmol), N-Boc-4-piperidone
(243 mg, 1.22 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.20 g, 5.0
mmol) were reacted in THF (5 mL) for 18 hr. The crude product was purified by column
chromatography on silica gel eluting with 1:9 ethyl acetate/hexane to give 45l as a white
solid (289 mg, 67%). Rf = 0.27 (1:9 ethyl acetate/hexane). MP: 83-84°C. HRMS (ESI+)
[M+H]+ calcd. for C17H2279BrNO2/C17H2281BrNO2 − C(CH3)3: 296.0286/298.0266; found
296.0278/298.0258. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.27-2.37 [2H, m,
H(5)], 2.38-2.48 [2H, m, H(3)], 3.36-3.44 [2H, m, H(2)], 3.47-3.56 [2H, m, H(6)], 6.29 [1H,
s, H(A)], 7.11 [1H, br d‡, 3J5’,6’ = 7.7 Hz, H(6’)], 7.18 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.7 Hz,
H(5’)], 7.29-7.38 [2H, m, H(2’) + H(4’)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.33
[C(3)], 36.27 [C(5)], 45.12 [br, C(2) + C(6)], 79.78 [tBu], 122.40 [C(3’)], 123.31 [C(A)],
127.63 [C(6’)], 129.44 [C(5’)], 129.82 [C(2’)], 131.88 [C(4’)], 139.68 [C(1’)], 140.11 [C(4)],
154.84 [C=O].
Synthesis method b. N-Boc-4-piperidone (100 mg, 0.50 mmol) and 36l (190 mg, 0.62 mmol)
were combined in ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.14 g,
2.50 mmol) were added over 10 minutes. The mixture was stirred at room temperature for
30 min then 70°C for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture
was extracted with ethyl acetate (3 x 30 mL) and chromatographed on silica gel eluting
with 1:9 ethyl acetate/hexane to give an inseparable mixture of products containing mostly
recovered reagents. 1H NMR analysis of the crude material indicated the mixture contained
45l and tert-butyl 4-(3-bromobenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55l), with an
approximate ratio of 5:1 45l and 55l. 1H NMR (500 MHz, CDCl3): δ 1.46 [1.35H, s, *tBu],
1.48 [7.65H, s, tBu], 1.97 [0.3H, br s, *H(5)], 2.26-2.38 [1.7H, m, H(5)], 2.38-2.48 [1.7H,
m, H(3)], 3.27 [0.3H, br s, *H(A)], 3.35-3.57 [3.7H, m, H(2) + H(6) + *H(6)], 3.89 [0.3H,
br s‡, *H(2)], 5.40 [0.15H, br s‡, *H(3)], 6.29 [0.85H, s, H(A)], 7.03-7.23 [2H, m, H(5’) +
H(6’) + *H(5’) + *H(6’)], 7.28-7.40 [2H, m, H(2’) + H(4’) + *H(2’) + *H(4’)].










Using General Method 2, 36m (0.75 g, 2.4 mmol), N-Boc-4-piperidone (243 mg, 1.22 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.20 g, 5.0 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica
gel eluting with 1:9 ethyl acetate/hexane to give 45m as a white solid (301 mg, 70%).
Rf = 0.40 (1:9 ethyl acetate/hexane). MP: 66-67°C. HRMS (ESI+) [M+H]+ calcd. for
C17H2279BrNO2/C17H2281BrNO2 − C(CH3)3: 296.0286/298.0266; found 296.0278/298.0258.
1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.24-2.37 [2H, m, H(5)], 2.36-2.48 [2H,
m, H(3)], 3.33-3.44 [2H, m, H(2)], 3.45-3.56 [2H, m, H(6)], 6.28 [1H, s, H(A)], 7.00-7.09
[2H, m, H(3’) + H(5’)], 7.38-7.47 [2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ
28.37 [tBu], 29.62 [C(3)], 36.12 [C(5)], 44.98 [br, C(2) + C(6)], 79.54 [tBu], 120.06 [C(4’)],
123.33 [C(A)], 130.43 [C(2’) + C(6’)], 131.19 [C(3’) + C(5’)], 136.20 [C(1’)], 139.27 [C(4)],
154.63 [C=O].





Using General Method 2, 36n (0.33 g, 2.2 mmol), N-Boc-4-piperidone (0.22 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.35 g, 8.8 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45n as a white solid (310 mg, 82%). Rf = 0.21
(1:9 ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.47 [9H, s, tBu], 2.13-2.25 [2H,
m, H(5)], 2.29-2.41 [2H, m, H(3)], 3.30-3.42 [2H, m, H(2)], 3.46-3.57 [2H, m, H(6)], 6.50
[1H, s, H(A)], 7.20 [1H, d, 3J5’,6’ = 7.6 Hz, H(6’)], 7.33 [1H, t, 3J3’,4’ = 3J4’,5’ = 7.6 Hz,
H(4’)], 7.47 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)], 7.65 [1H, d, 3J3’,4’ = 7.6 Hz, H(3’)].
13C NMR (126 MHz, CDCl3): δ 28.45 [tBu], 29.52 [C(3)], 36.00 [C(5)], 45.14 [br, C(2) +
C(6)], 79.59 [tBu], 121.17 [C(A)], 124.24 [q, 1JC,F = 273.8 Hz, CF3], 125.76 [q, 3JC,F = 5.4
Hz, C(3’)], 126.66 [C(4’)], 128.80 [q, 2JC,F = 29.3 Hz, C(2’)], 131.33 [C(5’)], 131.42 [C(6’)],
136.38 [C(1’)], 140.45 [C(4)], 154.74 [C=O].
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Synthesis method b. N-Boc-4-piperidone (100 mg, 0.50 mmol) and 36n (180 mg, 0.62 mmol)
were combined in ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.14 g,
2.50 mmol) were added over 10 minutes. The mixture was stirred at room temperature for
30 min then 70°C for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture
was extracted with ethyl acetate (3 x 30 mL) and chromatographed on silica gel eluting with
1:9 ethyl acetate/hexane to give an inseparable mixture containing mostly recovered reagents.
1H NMR analysis of the material indicated the mixture contained 45n and tert-butyl 4-(2-
(trifluoromethyl)benzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55n), with an approximate









Using General Method 2, 36o (0.65 g, 2.2 mmol), N-Boc-4-piperidone (220 mg, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.35 g, 8.8 mmol) were reacted in THF
(5 mL) for 18 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 45o as a colourless oil (223 mg, 59%). Rf =
0.32 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C18H22F3NO2 −C(CH3)3:
286.1055; found 286.1051. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.30-2.39 [2H,
m, H(5)], 2.40-2.48 [2H, m, H(3)], 3.37-3.46 [2H, m, H(2)], 3.48-3.57 [2H, m, H(6)], 6.37
[1H, s, H(A)], 7.36 [1H, d, 3J5’,6’ = 7.6 Hz, H(6’)], 7.40-7.50 [3H, m, H(2’) + H(4’) + H(5’)].
13C NMR (126 MHz, CDCl3): δ 28.56 [tBu], 29.29 [br, C(3)], 36.27 [br, C(5)], 45.03 [br,
C(2) + C(6)], 79.80 [tBu], 123.14 [q, 3JC,F = 3.8 Hz, C(2’)], 123.38 [C(A)], 124.27 [q, 1JC,F
= 272.3 Hz, CF3], 125.68 [q, 3JC,F = 3.8 Hz, C(4’)], 128.73 [C(5’)], 130.73 [q, 2JC,F = 32.0






Synthesis method a. Using General Method 2, 36p (0.75 g, 2.5 mmol), N-Boc-4-piperidone
(0.25 g, 1.3 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.40 g, 10.0 mmol)
were reacted in THF (5 mL) for 18 hr. The crude product was purified by column
chromatography on silica gel eluting with 1:19 ethyl acetate/hexane to give 45p as a colourless
oil (242 mg, 57%). Rf = 0.31 (1:9 ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ
1.48 [9H, s, tBu], 2.29-2.39 [2H, m, H(5)], 2.40-2.50 [2H, m, H(3)], 3.35-3.45 [2H, m, H(2)],
3.48-3.58 [2H, m, H(6)], 6.37 [1H, s, H(A)], 7.26-7.32 [2H, m, H(2’) + H(6’)], 7.53-7.61
[2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.39 [br, C(3)], 36.39
[br, C(5)], 45.18 [br, C(2) + C(6)], 79.84 [tBu], 123.53 [C(A)], 124.38 [q, 1JC,F = 272.3 Hz,
CF3], 125.26 [q, 3JC,F = 3.8 Hz, C(3’) + C(5’)], 128.51 [q, 2JC,F = 32.5 Hz, C(4’)], 129.24
[C(2’) + C(6’)], 140.86 [C(1’)], 141.22 [br, C(4)], 154.85 [C=O].
1H NMR data for this compound has been reported previously,115 but was inconsistent with
data obtained in this work.
Synthesis method b. N-Boc-4-piperidone (200 mg, 0.10 mmol) and 36p (0.37 g, 1.24 mmol)
were combined in ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.28
g, 5.0 mmol) were added over 10 minutes. The mixture was stirred at room temperature
for 30 min then 70°C for 2 hr, before cooling to 60°C and adding ice water (10 mL). The
mixture was extracted with ethyl acetate (3 x 30 mL) to give an inseparable mixture of 45p
and tert-butyl 4-(4-(trifluoromethyl)benzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55p) as
a white solid (134 mg, 39%). 1H NMR analysis indicated the mixture contained approximately









tert-butyl 4-(4-(trifluoromethyl)benzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55p) and tert-
Butyl 4-(4-trifluoromethylbenzylidene)piperidine-1-carboxylate (45p): Rf = 0.30 (1:9 ethyl
acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.46 [6.75H, s, *tBu], 1.48 [2.25H, s, tBu],
1.98 [1.5H, br s‡, *H(5)], 2.29-2.39 [0.5H, m, H(5)], 2.40-2.50 [0.5H, m, H(3)], 3.33-3.48
[3.5H, m, H(2) + *H(A) + *H(6)], 3.48-3.58 [0.5H, m, H(6)], 3.89 [1.5H, br s‡, *H(2)], 5.40
224
[0.75H, br s‡, *H(3)], 6.37 [0.25H, s, H(A)], 7.24-7.32 [2H, m, H(2’) + H(6’) + *H(2’) +
*H(6’)], 7.51-7.61 [2H, m, H(3’) + H(5’) + *H(3’) + *H(5’)].




Using General Method 3, 45a (152 mg, 0.46 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 48a as a
colourless oil, which was used without further purification (151 mg, 99%). 1H NMR (500
MHz, CDCl3): δ 1.08-1.19 [2H, m, H(3ax) + H(5ax)], 1.31 [9H, s, tBu], 1.45 [9H, s, tBu],
1.47-1.70 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.49 [2H, d, 3J4ax,A = 6.9 Hz, H(A)], 2.64 [2H,
br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.9 Hz, H(2ax) + H(6ax)], 3.02-3.10 [2H, m, H(2eq)
+ H(6eq)], 7.04-7.09 [2H, m, H(2”) + H(6”)], 7.27-7.32 [2H, m, H(3”) + H(5”)].




Using General Method 3, 45d (163 mg, 0.57 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 48d as a
colourless oil which was used without further purification (164 mg, 100%). HRMS (ESI+)
[M+H]+ calcd. for C18H27NO2 − C(CH3)3: 234.1494; found 234.1490. 1H NMR (500
MHz, CDCl3): δ 1.13 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz,
3J(2/6)eq,(3/5)ax = 3.3 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.56-1.69 [3H, m, H(3eq) +
H(4ax) + H(5eq)], 2.32 [3H, s, CH3], 2.49 [2H, d, 3J4ax,A = 6.8 Hz, H(A)], 2.63 [2H, br t‡,
2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.2 Hz, H(2ax) + H(6ax)], 3.95-4.17 [2H, m, H(2eq) +
H(6eq)], 7.00-7.05 [2H, m, H(2’) + H(6’)], 7.06-7.12 [2H, m, H(3’) + H(5’)].






Using General Method 3, 45e (190 mg, 0.63 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48e as a colourless
oil which was used without further purification (192 mg, 100%). HRMS (ESI+) [M+H]+
calcd. for C18H27NO3 −C(CH3)3: 250.1443; found 250.1443. 1H NMR (500 MHz, CDCl3): δ
1.15 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.7
Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.60 [2H, br d‡, 2J(3/5)ax,(3/5)eq = 12.1 Hz, H(3eq) +
H(5eq)], 1.70 [1H, ttt, 3J(3/5)ax,4ax = 12.1 Hz, 3J4ax,A = 7.1 Hz, 3J(3/5)eq,4ax = 3.7 Hz, H(4ax)],
2.54 [2H, d, 3J4ax,A = 7.1 Hz, H(A)], 2.64 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.2
Hz, H(2ax) + H(6ax)], 3.81 [3H, s, OCH3], 3.96-4.12 [2H, m, H(2eq) + H(6eq)], 6.82-6.90 [2H,
m, H(3’) + H(5’)], 7.06 [1H, br dd‡, 3J5’,6’ = 7.8 Hz, 4J4’,6’ = 1.6 Hz, H(6’)], 7.18 [1H, td,





Using General Method 3, 45g (105 mg, 0.35 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48g as a colourless
oil (106 mg, 100%). 1H NMR (500 MHz, CDCl3): δ 1.12 [2H, br q‡, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.55-1.67
[3H, m, H(3eq) + H(4ax) + H(5eq)], 2.47 [2H, d, 3J4ax,A = 6.7 Hz, H(A)], 2.63 [2H, br t‡,
2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 11.0 Hz, H(2ax) + H(6ax)], 3.79 [3H, s, OCH3], 3.94-4.23
[2H, m, H(2eq) + H(6eq)], 6.79-6.86 [2H, m, H(3’) + H(5’)], 7.01-7.08 [2H, m, H(2’) +
H(6’)]. 13C NMR (126 MHz, CDCl3): δ 28.62 [tBu], 32.09 [br, C(3) + C(5)], 38.48 [C(4)],
42.36 [C(A)], 44.14 [br, C(2) + C(6)], 55.38 [OCH3], 79.33 [tBu], 113.77 [C(3’) + C(5’)],
130.11 [C(2’) + C(6’)], 132.43 [C(1’)], 155.01 [C=O], 158.01 [C(4’)].






Using General Method 3, 45i (260 mg, 0.89 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48i as a colourless oil (261
mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C17H24FNO2 − C(CH3)3: 238.1243; found
238.1234. 1H NMR (500 MHz, CDCl3): δ 1.14 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax =
3J(3/5)ax,4ax = 12.5 Hz, 3J(3/5)ax,(2/6)eq = 4.4 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.54-
1.72 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.53 [2H, d, 3J4ax,A = 7.1 Hz, H(A)], 2.64 [2H, br
t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.5 Hz, H(2ax) + H(6ax)], 4.08 [2H, br s‡, H(2eq) +
H(6eq)], 6.81-6.93 [3H, m, H(2’) + H(4’) + H(6’)], 7.23 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.8 Hz,
4JH,F = 6.1 Hz, H(5’)]. 13C NMR (126 MHz, CDCl3): δ 31.12 [tBu], 34.57 [br, C(3) + C(5)],
40.66 [C(4)], 45.50 [d, 4JC,F = 1.4 Hz, C(A)], 46.46 [br, C(2) + C(6)], 81.93 [tBu], 115.48
[d, 2JC,F = 21.0 Hz, C(4)], 118.48 [d, 2JC,F = 20.5 Hz, C(2’)], 127.40 [d, 4JC,F = 2.9 Hz,
C(6’)], 132.26 [d, 3JC,F = 8.6 Hz, C(5’)], 145.45 [d, 3JC,F = 6.7 Hz, C(1’)], 157.48 [C=O],





Using General Method 3, 45j (223 mg, 0.76 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48j as a colourless oil which
was used without further purification (224 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for
C17H24FNO2 − C(CH3)3: 238.1243; found 238.1239. 1H NMR (500 MHz, CDCl3): δ 1.13
[2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.0 Hz, 3J(3/5)ax,(2/6)eq = 3.0 Hz,
H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.52-1.72 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.50 [2H,
d, 3J4ax,A = 7.1 Hz, H(A)], 2.63 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.0 Hz, H(2ax)
+ H(6ax)], 4.07 [2H, br s‡, H(2eq) + H(6eq)], 6.93-6.99 [2H, m, H(3’) + H(5’)], 7.05-7.11
[2H, m, H(2’) + H(6’)].






Using General Method 3, 45n (310 mg, 0.91 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48n as a colourless
oil which was used without further purification (312 mg, 100%). HRMS (ESI+) [M+H]+
calcd. for C18H24F3NO2 −C(CH3)3: 288.1211; found 288.1206. 1H NMR (500 MHz, CDCl3):
δ 1.20 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.3 Hz, 3J(3/5)ax,(2/6)eq =
4.0 Hz, H(3ax) + H(5ax)], 1.46 [9H, s, tBu], 1.61 [2H, br d‡, 2J(3/5)ax,(3/5)eq = 12.3 Hz, H(3eq)
+ H(5eq)], 1.74 [1H, ttt, 3J(3/5)ax,4ax = 12.3 Hz, 3J4ax,A = 7.1 Hz, 3J(3/5)eq,4ax = 3.7 Hz,
H(4ax)], 2.62 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.3 Hz, H(2ax) + H(6ax)], 2.72
[2H, d, 3J4ax,A = 7.1 Hz, H(A)], 4.09 [2H, br s‡, H(2eq) + H(6eq)], 7.25-7.33 [2H, m, H(4’)
+ H(6’)], 7.46 [1H, br t‡, 3J4’,5’ = 3J5’,6’ = 7.4 Hz, H(5’)], 7.63 [1H, br d‡, 3J3’,4’ = 7.8 Hz,
H(3’)].





Using General Method 3, 45o (223 mg, 0.65 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up and column
chromatography on silica gel eluting with 9:1 hexane/ethyl acetate gave 48o as a colourless
oil (224 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C14H16F3NO2 − C(CH3)3: 288.1211;
found 288.1206. 1H NMR (500 MHz, CDCl3): δ 1.16 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.0 Hz, 3J(3/5)ax,(2/6)eq = 3.4 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.55-
1.74 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.50-2.77 [4H, m, H(A) + H(2ax) + H(6ax)], 4.09
[2H, br s‡, H(2eq) + H(6eq)], 7.31 [1H, br d‡, 3J5’,6’ = 8.0 Hz, H(6’)], 7.42-7.49 [2H, m, H(2’)
+ H(5’)], 7.46 [1H, br d‡, 3J4’,5’ = 8.0 Hz, H(4’)]. 13C NMR (126 MHz, CDCl3): δ 28.60
[tBu], 32.03 [br, C(3) + C(5)], 38.19 [C(4)], 43.07 [C(A)], 43.97 [br, C(2) + C(6)], 79.46
[tBu], 123.04 [q, 3JC,F = 3.8 Hz, C(4’)], 124.36 [q, 1JC,F = 272.3 Hz, CF3], 125.81 [q, 3JC,F
= 3.8 Hz, C(2’)], 128.80 [C(6’)], 130.77 [q, 2JC,F = 32.0 Hz, C(3’)], 132.62 [q, 4JC,F = 1.0






Using General Method 3, 45p (232 mg, 0.68 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 48p as a colourless
oil (215 mg, 92%). HRMS (ESI+) [M+H]+ calcd. for C18H24F3NO2 − C(CH3)3: 288.1211;
found 288.1205. 1H NMR (500 MHz, CDCl3): δ 1.16 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.1 Hz, 3J(3/5)ax,(2/6)eq = 3.7 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.54-
1.75 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.54-2.73 [4H, m, H(A) + H(2ax) + H(6ax)], 4.08
[2H, br s‡, H(2eq) + H(6eq)], 7.21-7.27 [2H, m, H(2’) + H(6’)], 7.51-5.57 [2H, m, H(3’) +
H(5’)]. 13C NMR (126 MHz, CDCl3): δ 28.60 [tBu], 32.04 [br, C(3) + C(5)], 38.16 [C(4)],
43.07 [C(A)], 44.16 [br, C(2) + C(6)], 79.47 [tBu], 124.46 [q, 1JC,F = 271.73 Hz, CF3],
125.32 [q, 3JC,F = 3.8 Hz, C(3’) + C(5’)], 128.52 [q, 2JC,F = 32.4 Hz, C(4’)], 129.51 [C(2’)
+ C(6’)], 144.48 [br‡, C(1’)], 154.96 [C=O].






Using General Method 3, 45k (20 mg, 0.06 mmol) was reacted with Pd-C catalyst in methanol





tert-Butyl 4-benzylpiperidine-1-carboxylate (48x): Rf = 0.39 (1:9 ethyl acetate/hexane).
HRMS (ESI+) [M+H]+ calcd. for C17H25NO2 − C(CH3)3: 220.1338; found 220.1337. 1H
NMR (500 MHz, CDCl3): δ 1.14 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax
229
= 12.0 Hz, 3J(3/5)ax,(2/6)eq = 3.6 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.55-1.72 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.53 [2H, d, 3J4ax,A = 7.0 Hz, H(A)], 2.63 [2H, br t‡, 2J(2/6)ax,(2/6)eq
= 3J(2/6)ax,(3/5)ax = 12.0 Hz, H(2ax) + H(6ax)], 4.07 [2H, br s‡, H(2eq) + H(6eq)], 7.10-7.15
[2H, m, H(2’) + H(6’)], 7.19 [1H, t, 3J3’,4’ = 3J4’/5’ = 7.4 Hz, H(4’)], 7.24-7.30 [2H, m,
H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 28.62 [tBu], 32.13 [br, C(3) + C(5)], 38.32
[C(4)], 43.29 [C(A)], 43.95 [br, C(2) + C(6)], 79.34 [tBu], 126.07 [C(4’)], 128.37 [C(3’) +
C(5’)], 129.25 [C(2’) + C(6’)], 140.37 [C(1’)], 155.01 [C=O].





Using General Method 3, 45l (20 mg, 0.06 mmol) in methanol (30 mL) was treated with
Pd-C catalyst under a hydrogen atmosphere for 2 hr. Work-up gave 48x as an orange oil (20





Using General Method 3, 45m (310 mg, 0.91 mmol) in methanol (30 mL) was treated with
Pd-C catalyst under a hydrogen atmosphere for 2 hr. Work-up gave 48x as an orange oil
(311 mg, 100%). Data as above.
4-(4-tert-Butylbenzyl)piperidine (31a)
NH
Synthesis method a. Using General Method 4, 48a (148 mg, 0.45 mmol) in dichloromethane
(8 mL) was treated with trifluoroacetic acid (2 mL) to give 31a as a yellow oil (103 mg,
100%). 1H NMR (500 MHz, CDCl3): δ 1.22 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax =
3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 2.3 Hz, H(3ax) + H(5ax)], 1.32 [9H, s, tBu], 1.60-
1.71 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.51 [2H, d, 3J4ax,A = 6.7 Hz, H(A)], 2.57 [2H, td,
230
2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.2 Hz, 3J(2/6)ax,(3/5)eq = 2.0 Hz, H(2ax) + H(6ax)], 3.04
[2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.2 Hz, H(2eq) + H(6eq)], 7.02-7.09 [2H, m, H(2’) + H(6’)],
7.26-7.31 [2H, m, H(3’) + H(5’)]. 13C NMR (500 MHz, CDCl3): δ 31.58 [tBu], 32.15 [C(3) +
C(5)], 38.25 [C(4)], 42.81 [C(A)], 45.93 [C(2) + C(6)], 85.14 [tBu], 125.15 [C(3’) + C(5’)],
125.28 [C(1’)], 128.90 [C(2’) + C(6’)], 148.65 [C(4’)].
Synthesis method b. Using General Method 6, 49a (98 mg, 0.37 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL) to
give 31a as a yellow oil (67 mg, 79%). Data as above.
4-(2-Methylbenzyl)piperidine (31b)
NH
Using General Method 6, 49b (118 mg, 0.52 mmol) and saturated aqueous sodium bicarbonate
solution (10 mL) were reacted in dichloromethane (10 mL) to give 31b as a yellow oil (69
mg, 70%). 1H NMR (500 MHz, CDCl3): δ 1.20 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax =
3J(3/5)ax,4ax = 11.8 Hz, 3J(2/6)eq,(3/5)ax = 3.1 Hz, H(3ax) + H(5ax)], 1.55-1.70 [3H, m, H(3eq)
+ H(4ax) + H(5eq)], 1.94 [1H, br s, NH], 2.30 [3H, s, CH3], 2.47-2.62 [4H, m, H(A) + H(2ax)
+ H(6ax)], 3.05 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 11.8 Hz, H(2eq) + H(6eq)], 7.04-7.17 [4H, m,
H(3’) + H(4’) + H(5’) + H(6’)].
4-(4-Methylbenzyl)piperidine (31d)
NH
Synthesis method a. Using General Method 6, 49d (137 mg, 0.61 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL) to
give 31d as a yellow oil (47 mg, 41%). 1H NMR (500 MHz, CDCl3): δ 1.30 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.5 Hz, 3J(2/6)eq,(3/5)ax = 3.2 Hz, H(3ax) +
H(5ax)], 1.60-1.77 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.32 [3H, s, CH3], 2.51 [2H, d, 3J4ax,A
= 7.0 Hz, H(A)], 2.63 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.5 Hz, 3J(2/6)ax,(3/5)eq =
3.2 Hz, H(2ax) + H(6ax)], 3.16 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.5 Hz, H(2eq) + H(6eq)], 4.57
[1H, br s, NH], 7.00-7.04 [2H, m, H(2’) + H(6’)], 7.06-7.11 [2H, m, H(3’) + H(5’)].
Synthesis method b. Using General Method 4, 48d (164 mg, 0.57 mmol) and trifluoroacetic
acid (2 mL) were reacted in dichloromethane (8 mL) to give 31d as a yellow oil (107 mg,





Synthesis method a. Using General Method 6, 49e (110 mg, 0.45 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL) to
give 31e as a yellow oil (79 mg, 85%). 1H NMR (500 MHz, CDCl3): δ 1.17 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.8 Hz, H(3ax) +
H(5ax)], 1.54-1.74 [3H, m, H(3eq) + H(4ax) + H(5eq)], 1.89 [1H, br s, NH], 2.46-2.61 [4H,
m, H(A) + H(2ax) + H(6ax)], 3.04 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.2 Hz, H(2eq) + H(6eq)],
3.81 [3H, s, OCH3], 6.81-6.90 [2H, m, H(3’) + H(5’)], 7.07 [1H, d, 3J5’,6’ = 7.5 Hz, H(6’)],
7.18 [1H, t, 3J3’,4’ = 3J4’,5’ = 7.5 Hz, H(4’)]. 13C NMR (126 MHz, CDCl3): δ 33.55 [C(3) +
C(5)], 36.73 [C(4)], 37.78 [C(A)], 46.73 [C(2) + C(6)], 55.25 [OCH3], 110.28 [C(3’)], 120.06
[C(5’)], 127.01 [C(4’)], 129.00 [C(1’)], 130.93 [C(6’)], 157.65 [C(2’)].
Synthesis method b. Using General Method 4, 48e (192 mg, 0.63 mmol) and trifluoroacetic
acid (2 mL) were reacted in dichloromethane (8 mL) to give 31e as a pale orange oil (129




Using General Method 6, 49f (123 mg, 0.51 mmol) in dichloromethane (10 mL) was treated
with saturated aqueous sodium bicarbonate solution (10 mL) to give 31f as a yellow oil (96
mg, 92%). 1H NMR (500 MHz, CDCl3): δ 1.15 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax =
3J(3/5)ax,4ax = 12.3 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.56-1.69 [3H, m, H(3eq)
+ H(4ax) + H(5eq)], 2.04 [1H, br s, NH], 2.41-2.62 [4H, m, H(A) + H(2ax) + H(6ax)], 3.04
[2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.3 Hz, H(2eq) + H(6eq)], 3.79 [3H, s, OCH3], 6.66-6.77 [3H,




Synthesis method a. Using General Method 6, 49g (140 mg, 0.58 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL) to
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give 31g as a yellow oil (91 mg, 77%). HRMS (ESI+) [M+H]+ calcd. for C13H19NO:
206.1545; found 206.1536. 1H NMR (500 MHz, CDCl3): δ 1.52 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.0 Hz, 3J(2/6)eq,(3/5)ax = 3.7 Hz, H(3ax) + H(5ax)], 1.71 [1H,
ttt, 3J3ax,4ax = 3J4ax,5ax = 12.0 Hz, 3J4ax,A = 7.3 Hz, 3J3eq,4ax = 3J4ax,5eq = 3.6 Hz, H(4ax)],
1.80 [2H, br d‡, 2J(3/5)ax,(3/5)eq = 12.0 Hz, H(3eq) + H(5eq)], 2.53 [2H, d, 3J4ax,A = 7.3 Hz,
H(A)], 2.78 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.0 Hz, 3J(2/6)ax,(3/5)eq = 1.9 Hz,
H(2ax) + H(6ax)], 3.34 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.0 Hz, H(2eq) + H(6eq)], 3.79 [3H, s,
OCH3], 6.78-6.90 [2H, m, H(3’) + H(5’)], 7.00-7.11 [2H, m, H(2’) + H(6’)]. 13C NMR (126
MHz, CDCl3): δ 28.99 [C(3) + C(5)], 36.67 [C(4)], 41.69 [C(A)], 44.32 [C(2) + C(6)], 55.40
[OCH3], 114.02 [C(3’) + C(5’)], 130.05 [C(2’) + C(6’)], 131.19 [C(1’)], 158.30 [C(4’)].
1H NMR data for this compound has been reported previously,120,121 but was not consistent
with data reported here.
Synthesis method b. Using General Method 4, 48g (106 mg, 0.35 mmol) and trifluoroacetic
acid (1 mL) were reacted in dichloromethane (4 mL) to give 31g as a yellow oil (71 mg,




Using General Method 6, 49h (120 mg, 0.52 mmol) and saturated aqueous sodium bicarbonate
solution (10 mL) were reacted in dichloromethane (10 mL) to give 31i as a yellow oil (66 mg,
66%). HRMS (ESI+) [M+H]+ calcd. for C12H16FN: 194.1345; found 194.1341. 1H NMR
(500 MHz, CDCl3): δ 1.32-1.45 [2H, m, H(3ax) + H(5ax)], 1.67-1.82 [3H, m, H(3eq) + H(4ax)
+ H(5eq)], 2.54-2.71 [4H, m, H(A) + H(2ax) + H(6ax)], 3.20 [2H, br d‡, 2J(2/6)ax,(2/6)eq =





Synthesis method a. Using General Method 6, 49i (107 mg, 0.47 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL)
to give 31i as a yellow oil (61 mg, 68%). HRMS (ESI+) [M+H]+ calcd. for C12H16FN:
194.1345; found 194.1341. 1H NMR (500 MHz, CDCl3): δ 1.15 [2H, qd, 2J(3/5)ax,(3/5)eq =
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3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.0 Hz, H(3ax) + H(5ax)], 1.46-1.75
[4H, m, NH + H(3eq) + H(4ax) + H(5eq)], 2.42-2.61 [4H, m, H(A) + H(2ax) + H(6ax)], 3.04
[2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.2 Hz, H(2eq) + H(6eq)], 6.80-6.95 [3H, m, H(2’) + H(4’) +
H(6’)], 7.22 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, 4J5’,F = 6.7 Hz, H(5’)].
This data is consistent with that reported previously.122
Synthesis method b. Using General Method 4, 48i (261 mg, 0.89 mmol) and trifluoroacetic
acid (3 mL) were reacted in dichloromethane (12 mL) to give 31i as a clear oil (162 mg,




Synthesis method a. Using General Method 6, 49j (150 mg, 0.65 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL)
to give 31j as a yellow oil (94 mg, 74%). HRMS (ESI+) [M+H]+ calcd. for C12H16FN:
194.1345; found 194.1355. 1H NMR (500 MHz, CDCl3): δ 1.15 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 2.8 Hz, H(3ax) + H(5ax)], 1.51-1.68
[3H, m, H(3eq) + H(4ax) + H(5eq)], 2.21 [1H, br s, NH], 2.45-2.61 [4H, m, H(A) + H(2ax)
+ H(6ax)], 3.06 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.2 Hz, H(2eq) + H(6eq)], 6.91-6.99 [2H, m,
H(3’) + H(5’)], 7.05-7.12 [2H, m, H(2’) + H(6’)].
Synthesis method b. Using General Method 4, 48j (224 mg, 0.76 mmol) and trifluoroacetic





Using General Method 4, 48n (311 mg, 0.91 mmol) and trifluoroacetic acid (3 mL) were
reacted in dichloromethane (12 mL) to give 31n as an orange oil (220 mg, 100%). HRMS
(ESI+) [M+H]+ calcd. for C13H16F3N: 244.1313; found 244.1317. 1H NMR (500 MHz,
CDCl3): δ 1.59 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.9 Hz,
3J(2/6)eq,(3/5)ax = 3.1 Hz, H(3ax) + H(5ax)], 1.75-1.89 [3H, m, H(4ax) + H(3eq) + H(5eq)],
2.73-2.83 [4H, m, H(A) + H(2ax) + H(6ax)], 3.35 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.9 Hz, H(2eq)
+ H(6eq)], 7.26 [1H, d, 3J5’,6’ = 7.6 Hz, H(6’)], 7.33 [1H, t, 3J3’,4’ = 3J4’,5’ = 7.6 Hz, H(4’)],
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7.47 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)], 7.65 [1H, d, 3J3’,4’ = 7.6 Hz, H(3’)], 7.78 [1H,
br s, NH]. 13C NMR (126 MHz, CDCl3): δ 29.12 [C(3) + C(5)], 35.97 [C(4)], 39.03 [C(A)],
44.26 [C(2) + C(6)], 124.54 [q, 1JC,F = 271.9 Hz, CF3], 126.43 [q, 3JC,F = 5.7 Hz, C(3’)],
126.63 [C(5’)], 128.89 [q, 2JC,F = 29.6 Hz, C(2’)], 131.84 [C(6’)], 137.66 [q, 4JC,F = 1.4 Hz,




Using General Method 4, 48o (224 mg, 0.65 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (8 mL) to give 31o as a yellow oil (159 mg, 100%). HRMS (ESI+)
[M+H]+ calcd. for C13H16F3N: 244.1313; found 244.1308. 1H NMR (500 MHz, CDCl3): δ
1.50 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.6 Hz, 3J(2/6)eq,(3/5)ax = 3.6
Hz, H(3ax) + H(5ax)], 1.69-1.85 [3H, m, H(4ax) + H(3eq) + H(5eq)], 2.64 [2H, d, 3J4ax,A =
6.8 Hz, H(A)], 2.75 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.6 Hz, 3J(2/6)ax,(3/5)eq = 1.9
Hz, H(2ax) + H(6ax)], 3.30 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.6 Hz, H(2eq) + H(6eq)], 7.17-7.36
[2H, m, NH + H(6’)], 7.36-7.45 [2H, m, H(2’) + H(5’)], 7.48 [1H, br d‡, 3J4’,5’ = 7.8 Hz,
H(4’)]. 13C NMR (126 MHz, CDCl3): δ 33.18 [C(3) + C(5)], 38.12 [C(4)], 43.64 [C(A)],
46.59 [C(2) + C(6)], 122.85 [q, 3JC,F = 3.8 Hz, C(4’)], 124.38 [q, 1JC,F = 272.2 Hz, CF3],
125.81 [q, 3JC,F = 3.8 Hz, C(2’)], 128.66 [C(5’)], 130.61 [q, 2JC,F = 31.8 Hz, C(3’)], 132.66




Synthesis method a. Using General Method 4, 48p (210 mg, 0.61 mmol) and trifluoroacetic
acid (2 mL) were reacted in dichloromethane (8 mL) to give 31p as a yellow oil (143 mg,
96%). HRMS (ESI+) [M+H]+ calcd. for C13H16F3N: 244.1313; found 244.1326. 1H NMR
(500 MHz, CDCl3): δ 1.58 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0
Hz, 3J(2/6)eq,(3/5)ax = 3.4 Hz, H(3ax) + H(5ax)], 1.74-1.85 [3H, m, H(4ax) + H(3eq) + H(5eq)],
2.66 [2H, d, 3J4ax,A = 6.7 Hz, H(A)], 2.80 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 13.0
Hz, 3J(2/6)ax,(3/5)eq = 2.9 Hz, H(2ax) + H(6ax)], 3.36 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 13.0 Hz,
H(2eq) + H(6eq)], 7.21-7.28 [2H, m, H(2’) + H(6’)], 7.52-7.59 [2H, m, H(3’) + H(5’)]. 13C
NMR (126 MHz, CDCl3): δ 28.73 [C(3) + C(5)], 36.13 [C(4)], 42.21 [C(A)], 44.05 [C(2) +
C(6)], 124.18 [q, 1JC,F = 271.9 Hz, CF3], 125.47 [q, 3JC,F = 3.8 Hz, C(3’) + C(5’)], 128.89
[q, 2JC,F = 32.5 Hz, C(4’)], 129.31 [C(2’) + C(6’)], 143.06 [C(1’)].
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Synthesis method b. Using General Method 6, 49p (200 mg, 0.71 mmol) and saturated
aqueous sodium bicarbonate solution (10 mL) were reacted in dichloromethane (10 mL) to
give 31p as a yellow oil (150 mg, 86%). Data as above.
4-(4-tert-Butylbenzyl)piperidine hydrochloride (49a)
NH2Cl
Using General Method 5, 36a (0.50 g, 1.8 mmol), N-Boc-4-piperidone (0.18 g, 0.90 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.28 g, 7.0 mmol) were reacted for 18
hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49a as a pale
brown solid (0.11 g, 45%). 1H NMR (500 MHz, D2O): δ 1.19 [9H, s, tBu], 1.32 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) +
H(5ax)], 1.73-1.84 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.50 [2H, d, 3J4ax,A = 6.9 Hz, H(A)],
2.83 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/5)ax,(3/6)ax = 13.0 Hz, 3J(2/6)ax,(3/5)eq = 2.8 Hz, H(2ax)
+ H(6ax)], 3.29 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 13.0 Hz, H(2eq) + H(6eq)], 7.10-7.16 [2H, m,
H(3’) + H(5’)], 7.32-7.39 [2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, D2O): δ 30.70 [C(3)
+ C(5)], 33.15 [tBu], 36.36 [tBu], 37.61 [C(4)], 43.42 [C(A)], 46.60 [C(2) + C(6)], 127.99
[C(3’) + C(5’)], 131.75 [C(2’) + C(6’)], 139.65 [C(1’)], 152.28 [C(4’)].
4-(2-Methylbenzyl)piperidine hydrochloride (49b)
NH2Cl
Using General Method 5, 36b (0.50 g, 2.1 mmol), N-Boc-4-piperidone (0.21 g, 1.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.34 g, 8.5 mmol) were reacted for 18
hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49b as a pale
brown solid (0.12 g, 52%). 1H NMR (500 MHz, D2O): δ 1.38 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.71-1.85
[3H, m, H(3eq) + H(4ax) + H(5eq)], 2.21 [3H, s, CH3], 2.55 [2H, d, 3J4ax,A = 6.9 Hz, H(A)],
2.82 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 13.0 Hz, 3J(2/6)ax,(3/5)eq = 2.8 Hz, H(2ax)
+ H(6ax)], 3.30 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 13.0 Hz, H(2eq) + H(6eq)], 7.06-7.21 [4H, m,
H(3) + H(4) + H(5) + H(6)]. 13C NMR (126 MHz, D2O): δ 21.06 [CH3], 30.90 [C(3) +
C(5)], 36.57 [C(4)], 41.27 [C(A)], 46.67 [C(2) + C(6)], 128.42 [C(5’)], 129.13 [C(4’)], 132.82
[C(6’)], 132.91 [C(3’)], 139.51 [C(2’)], 140.78 [C(1’)].
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Using General Method 5, 36e (0.50 g, 1.9 mmol), N-Boc-4-piperidone (0.19 g, 0.95 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.8 mmol) were reacted for 18
hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49e as a pale
brown solid (0.12 g, 53%). 1H NMR (500 MHz, D2O): δ 1.34 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.8 Hz, 3J(2/6)eq,(3/5)ax = 4.1 Hz, H(3ax) + H(5ax)], 1.69-
1.87 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.52 [2H, d, 3J4ax,A = 7.2 Hz, H(A)], 2.81 [2H, td,
2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.8 Hz, 3J(2/6)ax,(3/5)eq = 2.4 Hz, H(2ax) + H(6ax)], 3.28
[2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq) + H(6eq)], 3.74 [3H, s, OCH3], 6.89 [1H, td,
3J4’,5’ = 3J5’,6’ = 7.5 Hz, 4J3’,5’ = 1.0 Hz, H(5’)], 6.97 [1H, dd, 3J3’,4’ = 7.5 Hz, 4J3’,5’ =
1.0 Hz, H(3’)], 7.12 [1H, dd, 3J5’,6’ = 7.5 Hz, 4J4’,6’ = 1.7 Hz, H(6’)], 7.20 [1H, td, 3J3’,4’
= 3J4’,5’ = 7.5 Hz, 4J4’,6’ = 1.7 Hz, H(4’)]. 13C NMR (126 MHz, D2O): δ 30.83 [C(3) +
C(5)], 36.31 [C(4)], 38.26 [C(A)], 46.66 [C(2) + C(6)], 58.20 [OCH3], 114.25 [C(3’)], 123.47
[C(5’)], 130.54 [C(4’)], 130.68 [C(1’)], 133.79 [C(6’)], 159.94 [C(2’)].




Using General Method 5, 36f (0.50 g, 1.9 mmol), N-Boc-4-piperidone (0.19 g, 0.95 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.8 mmol) were reacted for 18 hr
in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen chloride
solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49f as a pale brown solid
(0.14 g, 59%). 1H NMR (500 MHz, D2O): δ 1.32 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.9 Hz, 3J(2/6)eq,(3/5)ax = 4.0 Hz, H(3ax) + H(5ax)], 1.71-1.86 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.51 [2H, d, 3J4ax,A = 7.1 Hz, H(A)], 2.82 [2H, td, 2J(2/6)ax,(2/6)eq
= 3J(2/6)ax,(3/5)ax = 12.9 Hz, 3J(2/6)ax,(3/5)eq = 2.6 Hz, H(2ax) + H(6ax)], 3.29 [2H, br d‡,
2J(2/6)ax,(2/6)eq = 12.9 Hz, H(2eq) + H(6eq)], 3.72 [3H, s, OCH3], 6.75-6.84 [3H, m, H(2’) +
H(4’) + H(6’)], 7.21 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.8 Hz, H(5’)]. 13C NMR (126 MHz, D2O): δ
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30.72 [C(3) + C(5)], 37.57 [C(4)], 43.99 [C(A)], 46.65 [C(2) + C(6)], 57.90 [OCH3], 114.33
[C(4’)], 117.46 [C(2’)], 124.77 [C(6’)], 132.31 [C(5’)], 144.49 [C(1’)], 161.50 [C(3’)].




Using General Method 5, 36g (0.50 g, 1.9 mmol), N-Boc-4-piperidone (0.19 g, 0.95 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.8 mmol) were reacted for 18 hr
in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen chloride
solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49g as a yellow solid
(0.15 g, 65%). 1H NMR (500 MHz, D2O): δ 1.30 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax = 4.3 Hz, H(3ax) + H(5ax)], 1.67-1.82 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.47 [2H, d, 3J4ax,A = 6.9 Hz, H(A)], 2.81 [2H, td, 2J(2/6)ax,(2/6)eq
= 3J(2/6)ax,(3/5)ax = 13.0 Hz, 3J(2/6)ax,(3/5)eq = 1.9 Hz, H(2ax) + H(6ax)], 3.28 [2H, br d‡,
2J(2/6)ax,(2/6)eq = 13.0 Hz, H(2eq) + H(6eq)], 3.71 [3H, s, OCH3], 6.83-6.89 [2H, m, H(3’)
+ H(5’)], 7.07-7.14 [2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, D2O): δ 30.65 [C(3)
+ C(5)], 37.73 [C(4)], 43.04 [C(A)], 46.64 [C(2) + C(6)], 57.98 [OCH3], 116.50 [C(3’) +
C(5’)], 132.96 [C(2’) + C(6’)], 135.15 [C(1’)], 159.75 [C(4’)].




Using General Method 5, 36i (0.50 g, 2.0 mmol), N-Boc-4-piperidone (0.20 g, 1.0 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.32 g, 8.0 mmol) were reacted for 18 hr
in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen chloride
solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49i as a yellow solid
(0.12 g, 52%). 1H NMR (500 MHz, D2O): δ 1.32 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.8 Hz, 3J(2/6)eq,(3/5)ax = 4.0 Hz, H(3ax) + H(5ax)], 1.70-1.89 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.54 [2H, d, 3J4ax,A = 7.1 Hz, H(A)], 2.83 [2H, td, 2J(2/6)ax,(2/6)eq
= 3J(2/6)ax,(3/5)ax = 12.8 Hz, 3J(2/6)ax,(3/5)eq = 2.8 Hz, H(2ax) + H(6ax)], 3.29 [2H, br d‡,
2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq) + H(6eq)], 6.87-6.95 [2H, m, H(2’) + H(4’)], 6.97 [1H,
d, 3J5’,6’ = 7.5 Hz, H(6’)], 7.25 [1H, dt, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, 3JH,F = 5.7 Hz, H(5’)].
13C NMR (126 MHz, D2O): δ 30.62 [C(3) + C(5)], 37.46 [C(4)], 43.67 [C(A)], 46.60 [C(2)
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+ C(6)], 115.47 [d, 2JC,F = 21.0 Hz, C(4’)], 118.33 [d, 2JC,F = 21.0 Hz, C(2’)], 127.62 [d,
4JC,F = 2.9 Hz, C(6’)], 132.57 [d, 3JC,F = 8.6 Hz, C(5’)], 145.08 [d, 3JC,F = 7.6 Hz, C(1’)],
165.21 [d, 1JC,F = 242.7 Hz, C(3’)].




Using General Method 5, 36j (0.50 g, 2.0 mmol), N-Boc-4-piperidone (0.20 g, 1.0 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.32 g, 8.0 mmol) were reacted for 18 hr
in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen chloride
solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49j as a brown solid
(0.17 g, 74%). 1H NMR (500 MHz, D2O): δ 1.30 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.9 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.69-1.84 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.50 [2H, d, 3J4ax,A = 6.9 Hz, H(A)], 2.82 [2H, td, 2J(2/6)ax,(2/6)eq
= 3J(2/6)ax,(3/5)ax = 12.9 Hz, 3J(2/6)ax,(3/5)eq = 2.2 Hz, H(2ax) + H(6ax)], 3.28 [2H, br d‡,
2J(2/6)ax,(2/6)eq = 12.9 Hz, H(2eq) + H(6eq)], 6.94-7.01 [2H, m, H(3’) + H(5’)], 7.10-7.17
[2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, D2O): δ 30.60 [C(3) + C(5)], 37.68 [C(4)],
43.12 [C(A)], 46.62 [C(2) + C(6)], 117.52 [d, 2JC,F = 21.5 Hz, C(3’) + C(5’)], 133.26 [d,
3JC,F = 8.1 Hz, C(2’) + C(6’)], 138.16 [d, 4JC,F = 2.9 Hz, C(1’)], 163.80 [d, 1JC,F = 241.3
Hz, C(4’)].




Using General Method 5, 36n (0.50 g, 1.7 mmol), N-Boc-4-piperidone (0.19 g, 0.95 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.32 g, 8.0 mmol) were reacted for 18 hr
in THF (5 mL), then with Pd-C catalyst in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49n as a
brown solid (72 mg, 27%). 1H NMR (500 MHz, D2O): δ 1.52 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax = 4.0 Hz, H(3ax) + H(5ax)], 1.85-1.95
[2H, m, H(3eq) + H(5eq)], 1.95-2.08 [1H, m, H(4ax)], 2.84 [2H, d, 3J4ax,A = 7.2 Hz, H(A)],
2.95 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 13.0 Hz, 3J(2/6)ax,(3/5)eq = 2.8 Hz, H(2ax) +
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H(6ax)], 3.43 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 13.0 Hz, H(2eq) + H(6eq)], 7.45 [1H, t, 3J3’,4’ =
3J4’,5’ = 7.7 Hz, H(4’)], 7.48 [1H, d, 3J5’,6’ = 7.7 Hz, H(6’)], 7.61 [1H, t, 3J4’,5’ = 3J5’,6’ =
7.7 Hz, H(5’)], 7.77 [1H, d, 3J3’,4’ = 7.7 Hz, H(3’)]. 13C NMR (126 MHz, D2O): δ 30.83
[C(3) + C(5)], 37.48 [C(4)], 40.51 [C(A)], 46.69 [C(2) + C(6)], 127.25 [q, 1JC,F = 273.0 Hz,
CF3], 128.77 [q, 3JC,F = 5.7 Hz, C(3’)], 129.21 [C(5’)], 130.78 [q, 2JC,F = 29.3 Hz, C(2’)],




Using General Method 5, 36o (0.50 g, 1.7 mmol), N-Boc-4-piperidone (0.19 g, 0.95 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.8 mmol) were reacted for 18
hr in THF (5 mL), then with Pd-C in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL), to give 49o as a pale
yellow solid (158 mg, 59%). 1H NMR (500 MHz, D2O): δ 1.30 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax = 4.2 Hz, H(3ax) + H(5ax)], 1.65-
1.85 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.56 [2H, d, 3J4ax,A = 7.2 Hz, H(A)], 2.78 [2H, td,
2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 13.0 Hz, 3J(2/6)ax,(3/5)eq = 2.8 Hz, H(2ax) + H(6ax)], 3.25
[2H, br d‡, 2J(2/6)ax,(2/6)eq = 13.0 Hz, H(2eq) + H(6eq)], 7.32-7.40 [2H, m, H(5’) + H(6’)],
7.40-7.48 [2H, m, H(2’) + H(4’)]. 13C NMR (126 MHz, D2O): δ 30.61 [C(3) + C(5)], 37.53
[C(4)], 43.70 [C(A)], 46.61 [C(2) + C(6)], 125.62 [q, 3JC,F = 3.9 Hz, C(4’)], 128.27 [q, 3JC,F
= 3.8 Hz, C(2’)], 131.60 [C(5’)], 132.52 [q, 2JC,F = 31.6 Hz, C(3’)], 135.53 [C(6’)], 143.35
[C(1’)].
This data is consistent with that reported previously.58





Synthesis method a. Using General Method 2, 36r (0.50 g, 2.0 mmol), N-Boc-4-piperidone
(0.22 g, 1.1 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.30 g,7.5 mmol) were
reacted in THF (5 mL) for 18 hr. The crude product was purified by column chromatography
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on silica gel eluting with 1:9 ethyl acetate/hexane to give a mixture of 45r and tert-butyl 4-
(3-cyanobenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55r) as a colourless oil which could
not be purified (122 mg, 37%). 1H NMR analysis indicated the mixture after column









tert-butyl 4-(3-cyanobenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55r) and tert-Butyl 4-
(3-cyanobenzylidene)piperidine-1-carboxylate (45r): Rf = 0.13 (1:9 ethyl acetate/hexane).
HRMS (ESI+) [M+H]+ calcd. for C17H23NO2 − C(CH3)3: 243.1134; found 243.1140. 1H
NMR (500 MHz, CDCl3): δ 1.42-1.51 [9H, s, tBu + *tBu], 1.97 [1.2H, br s‡, *H(5)], 2.31-
2.38 [1.6H, H(3) + H(5)], 3.34 [1.2H, br s, *H(A)], 3.37-3.57 [2.8H, m, H(2) + H(6) +
*H(6)], 3.90 [1.2H, br s‡, *H(2)], 5.40 [0.6H, br s‡, *H(3)], 6.32 [0.4H, s, H(A)], 7.32-7.60
[4H, m, Ar H + *Ar H].
Synthesis method b. A solution of LiHMDS (1M in THF, 3.0 mL, 3.0 mmol) was added to a
stirring solution of 36r (750 mg, 3.0 mmol) in anhydrous THF (5 mL) under an atmosphere
of nitrogen. The reaction mixture was stirred for 15 minutes and a solution of N-Boc-4-
piperidone (320 mg, 1.60 mmol) in THF (2 mL) was added dropwise. The mixture was stirred
for 16 hr then the reaction was quenched with water and extracted with ethyl acetate (3 x 40
mL), with the organic extracts dried over MgSO4 and filtered. Volatile solvent was removed
by evaporation under reduced pressure and the residue purified by column chromatography on
silica gel eluting with 1:9 ethyl acetate/hexane to give 45r as a white solid (258 mg, 54%). Rf
= 0.13 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C17H23NO2 −C(CH3)3:
243.1134; found 243.1140. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.29-2.46 [4H,
m, H(3) + H(5)], 3.36-3.46 [2H, m, H(2)], 3.48-3.58 [2H, m, H(6)], 6.32 [1H, s, H(A)],
7.37-7.53 [4H, m, H(2’) + H(4’) + H(5’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 28.58
[tBu], 29.32 [br, C(3)], 36.29 [br, C(5)], 45.29 [br, C(2) + C(6)], 79.90 [tBu], 112.57 [C(3’)],
118.98 [CN], 122.61 [C(A)], 129.17 [C(5’)], 130.00 [C(2’)], 132.46 [C(4’)], 133.40 [C(6’)],
138.75 [C(1’)], 141.35 [C(4)], 154.81 [C=O].







Synthesis method a. Using General Method 2, 36s (0.56 g, 2.2 mmol), N-Boc-4-piperidone
(0.22 g, 1.1 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.18 g, 4.4 mmol)
were reacted in THF (5 mL) for 18 hr. Separation of the crude mixture* was attempted using
repeated flash column chromatography on silica gel eluting with 6% ethyl acetate in hexane,
which yielded a sample of pure 45s as a white solid (22 mg, 7%), and a sample of tert-butyl
4-(4-cyanobenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55s) as a clear oil (44 mg, 13%).
The remaining mixture of co-eluted products was also collected but could not be purified.
*Note: 1H NMR analysis of the crude mixture before column chromatography indicated a
product ratio of 1:3.7 45s/55s.
tert-Butyl 4-(4-cyanobenzylidene)piperidine-1-carboxylate (45s): Rf = 0.33 (1:4 ethyl
acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C18H22N2O2 − C(CH3)3: 243.1134;
found 243.1128. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.30-2.40 [2H, m, H(5)],
2.40-2.51 [2H, m, H(3)], 3.36-3.46 [2H, m, H(2)], 3.48-3.59 [2H, m, H(6)], 6.36 [1H, s,
H(A)], 7.25-7.32 [2H, m, H(2’) + H(6’)], 7.57-7.63 [2H, m, H(3’) + H(5’)]. 13C NMR (126
MHz, CDCl3): δ 28.44 [tBu], 29.32 [br, C(3)], 36.30 [br, C(5)], 44.71 [br, C(2) + C(6)], 79.77
[tBu], 109.83 [C(4’)], 118.99 [CN], 123.23 [C(A)], 129.49 [C(2’) + C(6’)], 132.01 [C(3’) +









tert-Butyl 4-(4-cyanobenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (55s): Rf = 0.26 (1:4
ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.46 [9H, s, tBu], 1.96 [2H, br s‡,
H(5)], 3.37 [2H, br s, H(A)], 3.42-3.51 [2H, m, H(6)], 3.89 [2H, br s‡, H(2)], 5.41 [1H, br
s‡, H(3)], 7.25-7.31 [2H, m, H(2’) + H(6’)], 7.56-7.63 [2H, m, H(3’) + H(5’)]. 13C NMR
(126 MHz, CDCl3): δ 28.22 [br, C(5)], 28.56 [tBu], 39.75 [br, C(6)], 43.51 [br, C(2)], 43.85
[C(A)], 79.74 [tBu], 110.35 [C(4’)], 119.05 [CN], 121.03 [br, C(3)], 129.85 [C(2’) + C(6’)],
132.31 [C(3’) + C(5’)], 134.84 [br, C(4)], 144.95 [C(1’)], 154.97 [C=O].
This data is consistent with that reported previously.70
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Synthesis method b. A solution of LiHMDS (1M in THF, 4.0 mL, 4.0 mmol) was added to a
stirring solution of 36s (1.00 g, 4.0 mmol) in anhydrous THF (6 mL) under an atmosphere
of nitrogen. The reaction mixture was stirred for 15 minutes and a solution of N-Boc-4-
piperidone (400 mg, 2.0 mmol) in THF (2 mL) was added dropwise. The mixture was stirred
for 16 hr then quenched with water and extracted with ethyl acetate (3 x 40 mL), and
the organic extracts were dried over MgSO4 and filtered. Volatile solvent was removed by
evaporation under reduced pressure and the residue purified by column chromatography on
silica gel eluting with 1:9 ethyl acetate/hexane to give 45s as a white solid (593 mg, 99%).
Rf = 0.40 (1:4 ethyl acetate/hexane). Data as above.
Synthesis method c. A sample of pure 45s (25 mg, 0.08 mmol) was stirred in THF (3 mL)
with sodium hydride (60% in mineral oil, 50 mg, 1.25 mmol) at 30°C for 16 hr. The mixture
was quenched with water, and extracted with ethyl acetate (3 x 25 mL). Volatile solvent was
removed by evaporation under reduced pressure, and the residue was chromatographed over
silica gel with 5% ethyl acetate/hexane as eluant to give a mixture of 45s and 55s as a
colourless oil (15 mg, 60%). 1H NMR analysis of the mixture determined a product ratio of
1:3.8 45s/55s. 1H NMR (500 MHz, CDCl3): δ 1.39-1.51 [9H, m, tBu + *tBu], 1.96 [1.6H,
br s‡, *H(5)], 2.32-2.41 [0.4H, m, H(5)], 2.40-2.48 [0.4H, m, H(3)], 3.36 [1.6H, br s, *H(A)],
3.38-3.50 [2H, m, H(2) + *H(6)], 3.50-3.56 [0.4H, m, H(6)], 3.89 [1.6H, br s‡, *H(2)], 5.41
[0.8H, br s‡, *H(3)], 6.36 [0.2H, s, H(A)], 7.22-7.33 [2H, m, H(2’) + H(6’) + *H(2’) +
*H(6’)], 7.54-7.63 [2H, m, H(3’) + H(5’) + *H(3’) + *H(5’)].
* denotes signals corresponding to side-product 55s.
Synthesis method d. A sample of pure 55s (25 mg, 0.08 mmol) was stirred in THF (3 mL)
with sodium hydride (60% in mineral oil, 50 mg, 1.25 mmol) at 30°C overnight. The mixture
was quenched with water, and extracted with ethyl acetate (3 x 25 mL). Volatile solvent was
removed by evaporation under reduced pressure, and the residue was chromatographed over
silica gel with 1:19 ethyl acetate/hexane as eluant to give a mixture of 45s and 45s as a
colourless oil (17 mg, 68%). 1H NMR analysis of the mixture determined a product ratio of




Using General Method 2, 36s (0.67 g, 2.6 mmol), N-Bn-4-piperidone 46 (0.25 g, 1.3 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.21 g, 5.3 mmol) were reacted in THF
(5 mL) for 4 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:1 ethyl acetate/hexane to give 47s as a white powder (301 mg, 81%) and
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4-((1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile (56s) as a clear oil (38 mg,
10%).
4-((1-Benzylpiperidin-4-ylidene)methyl)benzonitrile (47s): Rf = 0.50 (1:1 ethyl acetate/
hexane). HRMS (ESI+) [M+H]+ calcd. for C20H20N2: 289.1705; found 289.1701. 1H NMR
(500 MHz, CDCl3): δ 2.37-2.46 [4H, m, H(3) + H(5)], 2.46-2.58 [4H, m, H(2) + H(6)], 3.52
[2H, s, CH2], 6.25 [1H, s, H(A)], 7.21-7.36 [7H, m, H(2’) + H(6’) + Ph], 7.53-7.60 [2H, m,
H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 29.41 [C(3)], 36.73 [C(5)], 54.25 [*C(2)
or C(6)], 54.91 [*C(2) or C(6)], 62.94 [CH2], 109.57 [C(4’)], 119.21 [CN], 121.97 [C(A)],
127.15 [C(4”)], 128.31 [C(3”) + C(5”)], 129.18 [C(2”) + C(6”)], 129.60 [C(2’) + C(6’)],
132.00 [C(3’) + C(5’)], 138.36 [C(1”)], 142.76 [C(1’)], 143.44 [C(4)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment








4-((1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzonitrile (56s): Rf = 0.23 (1:1 ethyl
acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C20H20N2: 289.1705; found 289.1712.
1H NMR (500 MHz, CDCl3): δ 1.98-2.04 [2H, m, H(5)], 2.54 [2H, t, 3J5,6 = 5.8 Hz, H(6)],
2.99 [2H, br s‡, H(2)], 3.33 [2H, br s, H(A)], 3.57 [2H, s, CH2], 5.38 [1H, br s‡, H(3)],
7.22-7.35 [7H, m, H(2’) + H(6’) + Ph], 7.55-7.60 [2H, m, H(3’) + H(5’)]. 13C NMR (126
MHz, CDCl3): δ 29.10 [C(5)], 43.65 [C(A)], 49.80 [C(6)], 52.87 [C(2)], 62.77 [CH2], 110.18
[C(4’)], 119.20 [CN], 122.25 [C(3)], 127.25 [C(4”)], 128.37 [C(3”) + C(5”)], 129.35 [C(2”)





Synthesis method a. Using General Method 3, 47s (288 mg, 1.00 mmol) was reacted with
Pd-C catalyst in methanol (30 mL) under a hydrogen atmosphere for 2 hr to give 57s as a
clear oil, which was used without further purification (187 mg, 64%). HRMS (ESI+) [M+H]+
calcd. for C20H22N2: 291.1861; found 291.1864. 1H NMR (500 MHz, CDCl3): δ 1.31 [2H,
qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 11.7 Hz, 3J(2/6)eq,(3/5)ax = 3.5 Hz, H(3ax)
+ H(5ax)], 1.47-1.60 [3H, m, H(3eq) + H(4ax) + H(5eq)], 1.90 [2H, br t‡, 2J(2/6)ax,(2/6)eq =
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3J(2/6)ax,(3/5)ax = 11.7 Hz, H(2ax) + H(6ax)], 2.58 [2H, d, 3J4ax,A = 6.7 Hz, H(A)], 2.86 [2H,
br d‡, 2J(2/6)ax,(2/6)eq = 11.7 Hz, H(2eq) + H(6eq)], 3.47 [2H, s, CH2], 7.18-7.40 [7H, m, H(2’)
+ H(6’) + Ph], 7.51-7.59 [2H, m, H(3’) + H(5’)].
Synthesis method b. Using General Method 3, 56s (20 mg, 0.07 mmol) was reacted with
Pd-C catalyst in methanol (20 mL) under a hydrogen atmosphere for 2 hr to give an impure
mixture containing 57s and 56s (3:2 ratio, determined by 1H NMR analysis).
Synthesis method c. Using General Method 3, 56s (20 mg, 0.07 mmol) was reacted with
Pd-C catalyst in methanol (20 mL) under a hydrogen atmosphere for 16 hr to give 57s as a






N-Boc-4-piperidone (250 mg, 1.25 mmol) and 36s (400 mg, 1.58 mmol) were combined in
ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.35 g, 6.24 mmol) were
added over 10 minutes. The mixture was stirred at room temperature for 30 min then 70°C
for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture was stirred at 0°C
for 30 min and no precipitate was formed. The ethanol was removed by evaporation under
reduced pressure and mixture extracted with ethyl acetate. The volatile solvent was removed
by evaporation under reduced pressure and the residue was purified by column chromatography
on silica gel eluting with 1:4 ethyl acetate/hexane to give an inseparable mixture of 59 and
tert-butyl 4-(4-carbamoylbenzyl)-5,6-dihydropyridine-1(2H)-carboxylate (60) as a white solid
(264 mg, combined yield 67%). Rf = 0.21 (1:1 ethyl acetate/hexane). 1H NMR (500 MHz,
CDCl3): δ 1.45 [5.4H, s, *tBu], 1.48 [3.6H, s, tBu], 1.98 [1.2H, br s‡, *H(5)], 2.32-2.38
[0.8H, m, H(5)], 2.43-2.49 [0.8H, m, H(3)], 3.36 [1.2H, br s, *H(A)], 3.38-3.48 [2H, m, H(2)
+ *H(6)], 3.49-3.56 [0.8H, m, H(6)], 3.89 [1.2H, br s‡, *H(2)], 5.40 [0.6H, br s‡, *H(3)],
5.49-6.20 [2H, m, CONH2 + *CONH2], 6.38 [0.4H, s, H(A)], 7.21-7.30 [2H, m, H(2’) +
H(6’) + *H(2’) + *H(6’)], 7.71-7.80 [2H, m, H(3’) + H(5’) + *H(3’) + *H(5’)].







A sample of pure 59 was obtained by repeated recrystallisation from hexane for the purposes
of characterisation. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.29-2.40 [2H, m,
H(5)], 2.41-2.51 [2H, m, H(3)], 3.36-3.46 [2H, m, H(2)], 3.48-3.57 [2H, m, H(6)], 5.76-6.25
[2H, m, CONH2], 6.38 [1H, s, H(A)], 7.22-7.30 [2H, m, H(2’) + H(6’)], 7.73-7.82 [2H, m,
H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.44 [C(3)], 36.42 [C(5)],
45.07 [br, C(2) + C(6)], 79.84 [tBu], 123.84 [C(A)], 127.47 [C(3’) + C(5’)], 129.18 [C(2’)





N-Bn-4-piperidone (240 mg, 1.3 mmol) and 36s (400 mg, 1.58 mmol) were combined in
ethanol (4 mL) with water (1 drop). Potassium hydroxide pellets (0.35 g, 6.2 mmol) were
added over 10 minutes. The mixture was stirred at room temperature for 30 min then 70°C
for 2 hr, before cooling to 60°C and adding ice water (10 mL). The mixture was stirred at
0°C for 30 min and the resulting precipitate collected by vacuum filtration, washing with ice
cold water to give an inseparable mixture of 58 and 4-((1-benzyl-1,2,3,6-tetrahydropyridin-
4-yl)methyl)benzamide (61) as a white solid (264 mg, combined yield 68%). HRMS (ESI+)
[M+H]+ calcd. for C20H22N2O: 307.1810; found 307.1807. 1H NMR (500 MHz, CDCl3): δ
1.92-2.13 [0.2H, m, *H(5)], 2.37-2.58 [3.4H, m, H(2) + H(3) + H(5) + H(6) + *H(6)], 2.98
[0.2H, br s‡, *H(2)], 3.33 [0.2H, br s, *H(A)], 3.53 [1.8H, s, CH2], 3.56 [0.2H, s, *CH2], 5.38
[0.1H, br s‡, *H(3)], 5.69-6.23 [2H, m, CONH2 + *CONH2], 6.28 [0.9H, s, H(A)], 7.20-7.36
[7H, m, H(2’) + H(6’) + Ph + *H(2’) + *H(6’) + *Ph], 7.70-7.78 [2H, m, H(3’) + H(5’)
+ *H(3’) + *H(5’)].
















Using General Method 3, a mixture of 59 and 60 (254 mg, 0.80 mmol) was reacted with Pd-C
catalyst in methanol (30 mL) under an atmosphere of hydrogen for 18 hr to give crude 64 as
a clear oil which was used without further purification (241 mg, 94%). Rf = 0.30 (1:4 ethyl
acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C18H26N2O3: 263.1396; found 263.1390.
1H NMR (500 MHz, CDCl3): δ 1.15 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax
= 12.2 Hz, 3J(3/5)ax,(2/6)eq = 3.7 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.54-1.75 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.53-2.73 [4H, m, H(A) + H(2ax) + H(6ax)], 4.07 [2H, br s‡,
H(2eq) + H(6eq)], 5.78-6.32 [2H, m, CONH2], 7.17-7.26 [2H, m, H(2’) + H(6’)], 7.70-7.79
[2H, m, H(3’) + H(5’)].





Using General Method 4, 64 (230 mg, 0.72 mmol) was reacted with trifluoroacetic acid (2
mL) to give 65 as a clear oil (72 mg, 46%). HRMS (ESI+) [M+H]+ calcd. for C13H18N2O:
219.1497; found 219.1494. 1H NMR (500 MHz, CDCl3): δ 1.18 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.1 Hz, 3J(2/6)eq,(3/5)ax = 3.5 Hz, H(3ax) + H(5ax)], 1.57-1.71
[3H, m, H(3eq) + H(4ax) + H(5eq)], 2.10 [1H, br s, NH], 2.51-2.61 [4H, m, H(A) + H(2ax)
+ H(6ax)], 3.06 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.1 Hz, H(2eq) + H(6eq)], 5.67-6.29 [2H, m,
CONH2], 7.17-7.25 [2H, m, H(2’) + H(6’)], 7.69-7.76 [2H, m, H(3’) + H(5’)].





Synthesis method a. Anhydrous THF (4 mL) was added to methyltriphenylphosphonium
bromide (0.54 g, 1.5 mmol) under an N2 atmosphere. The mixture was cooled to -78°C
and n-BuLi (2M in hexanes, 753 µL, 1.51 mmol) was added dropwise. The mixture was
stirred for 30 min then a solution of N-Boc-4-piperidone (0.20 g, 1.00 mmol) in THF was
added over 5 min. The mixture was warmed to room temperature and stirred for 48 hr then
quenched with brine and extracted with ethyl acetate (3 x 30 mL). The organic extracts
were dried over MgSO4, filtered, and solvent removed by evaporation under reduced pressure.
The residue was re-suspended in 1:1 ethyl acetate/hexane (10 mL) and filtered to remove
insoluble by-products, then purified by column chromatography on silica gel eluting with 3:7
ethyl acetate/hexane to give 66 as a pale yellow oil (76 mg, 40%). Rf = 0.72 (1:1 ethyl
acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.47 [9H, s, tBu], 2.13-2.22 [2H, m, H(3)
+ H(5)], 3.37-3.46 [2H, m, H(2) + H(6)], 4.74 [2H, s, =CH2].
This data is consistent with that reported in literature previously.125
Synthesis method b. Anhydrous THF (6 mL) was added to a mixture of methyltriphenyl-
phosphonium bromide (0.54 g, 1.5 mmol) and sodium hydride (60% in mineral oil, 0.18 g,
4.5 mmol) under an N2 atmosphere and the mixture was stirred for 30 min. A solution of
N-Boc-4-piperidone (0.20 g, 1.00 mmol) in THF was added and the mixture stirred for 48
hr then quenched with brine solution (25 mL) and extracted with ethyl acetate (3 x 30 mL).
The organic extracts were dried over MgSO4, filtered, and solvent removed by evaporation
under reduced pressure. The residue was purified by column chromatography on silica gel





Synthesis method a. Bromobenzene (100 mg, 0.64 mmol) and 5 (25 mg, 0.13 mmol)
were combined with potassium carbonate (53 mg, 0.38 mmol), tri-o-tolylphosphine (2.7
mg, 8.9 µmmol) and Pd(OAc)2 (1.4 mg, 6.3 µmmol) in DMF (2 mL) and the mixture
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was stirred at 80°C for 48 hours. The mixture was cooled and filtered through Celite®
washing with methanol, and the solvent was removed by evaporation under reduced pressure
to give an orange residue. 1H NMR analysis of crude mixture indicated the presence of 45x,
but attempted purification by column chromatography on silica gel eluting with 1:9 ethyl
acetate/hexane did not yield any pure product.
Synthesis method b. Using General Procedure 2, 36x (0.50 g, 2.2 mmol), N-Boc-4-piperidone
(0.20 g, 1.0 mmol) and sodium hydride (60% dispersion in paraffin oil, 0.30 g, 7.5 mmol) were
reacted in THF (5 mL) for 18 hr. The crude product was purified by column chromatography
on silica gel eluting with 1:9 ethyl acetate/hexane to give 45x as a white solid (135 mg, 49%).
Rf = 0.36 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C17H23NO2 −
C(CH3)3: 218.1181; found 218.1171. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu],
2.26-2.38 [2H, m, H(5)], 2.41-2.51 [2H, m, H(3)], 3.33-3.44 [2H, m, H(2)], 3.46-3.57 [2H,
m, H(6)], 6.36 [1H, s, H(A)], 7.15-7.23 [3H, m, H(2’) + H(4’) + H(6’)], 7.27-7.35 [2H, m,
H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.31 [br, C(3)], 36.34 [br,
C(5)], 45.31 [br, C(2) + C(6)], 79.65 [tBu], 124.64 [C(A)], 126.42 [C(4’)], 128.28 [C(2’) +
C(6’)], 128.99 [C(3’) + C(5’)], 137.56 [C(1’)], 138.53 [C(4)], 154.88 [C=O].
This data is consistent with that reported previously.126




Using General Method 2, 36c (0.75 g, 3.1 mmol), N-Boc-3-piperidone (0.31 g, 1.6 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.40 g, 10.0 mmol) were reacted in THF
(5 mL) for 48 hrs. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 67c as a colourless oil (176 mg, 39%). Rf =
0.30 (1:9 ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.29 [1.8H, br s, *tBu],
1.48 [7.2H, s, tBu], 1.56-1.65 [1.6H, m, H(5)], 1.67-1.74 [0.4H, m, *H(5)], 2.34 [3H, s,
CH3 + *CH3], 2.36-2.41 [0.4H, m, *H(4)], 2.48-2.55 [1.6H, m, H(4)], 3.45-3.53 [2H, m,
H(6) + *H(6)], 4.00 [1.6H, br s, H(2)], 4.18 [0.4H, br s, *H(2)], 6.30 [0.2H, br s, *H(A)],
6.38 [0.8H, br s, H(A)], 6.97-7.08 [3H, m, H(2’) + H(4’) + H(6’) + *H(2’) + *H(4’) +
*H(6’)], 7.17-7.24 [1H, m, H(5’) + *H(5’)]. 13C NMR (126 MHz, CDCl3): δ 21.56 [CH3 +
*CH3], 26.13 [br, C(5)], 26.99 [*C(5)], 27.53 [C(4)], 28.35 [br, *tBu], 28.63 [br, tBu], 34.84
[br, *C(4)], 44.51 [br, C(6) + *C(6)], 51.22-53.35 [C(2) + *C(2)], 79.44 [br, *tBu], 79.60
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[br, tBu], 125.10 [C(A) + *C(A’)], 125.91-126.17 [C(4’) + *C(4’)], 127.21-127.58 [C(6’)
+ *C(6’)], 128.01-128.30 [C(5’) + *C(5’)], 129.48-129.86 [C(2’) + *C(2’)], 135.75-136.44
[C(3) +*C(3)], 137.19 [C(3’) + *C(3’)], 137.70-137.89 [C(1’) + *C(1’)], 154.81 [*C=O],
154.92 [C=O].





Using General Method 2, 36f (0.78 g, 3.0 mmol), N-Boc-3-piperidone (0.30 g, 1.5 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.48 g, 12.0 mmol) were reacted in THF
(5 mL) for 48 hrs. The crude product was purified by column chromatography on silica gel
eluting with 1:19 ethyl acetate/hexane to give 67f as a colourless oil (96 mg, 21%). Rf =
0.25 (1:9 ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.30 [2.7H, br s, *tBu],
1.48 [6.3H, s, tBu], 1.57-1.65 [1.4H, m, H(5)], 1.68-1.75 [0.6H, m, *H(5)], 2.36-2.41 [0.6H,
m, *H(4)], 2.49-2.55 [1.4H, m, H(4)], 3.46-3.53 [2H, m, H(6) + *H(6)], 3.78-3.83 [3H, m,
OCH3 + *OCH3], 4.01 [1.4H, br s, H(2)], 4.19 [0.6H, br s, *H(2)], 6.30 [0.3H, br s, *H(A)],
6.39 [0.7H, br s, H(A)], 6.73-6.86 [3H, m, H(2’) + H(4’) + H(6’) + *H(2’) + *H(4’) +
*H(6’)], 7.20-7.26 [1H, m, H(5’) + *H(5’)]. 13C NMR (126 MHz, CDCl3): δ 26.10 [br, C(5)],
26.91 [*C(5)], 27.58 [C(4)], 28.36 [br, *tBu], 28.62 [br, tBu], 34.82 [br, *C(4)], 44.59 [br,
C(6)], 46.12 [br, *C(6)], 51.62 [br, *C(2)], 52.77 [br, C(2)], 55.30 [OCH3], 55.32 [*OCH3],
79.52 [br, *tBu], 79.64 [br, tBu], 112.11 [C(4’) + *C(4’)], 114.66 [C(2’) + *C(2’)], 121.41
[*C(6’)], 121.52 [C(6’)], 124.90 [br, C(A) + *C(A)], 129.24 [br, C(5’) + *C(5’)], 136.58 [br,
C(3) + *C(3)], 138.65 [br, C(1’) + *C(1’)], 154.76 [*C=O], 154.92 [C=O], 159.52 [C(3’)],
159.62 [*C(3’)].





Using General Method 2, 36h (0.50 g, 2.0 mmol), N-Boc-3-piperidone (0.20 g, 1.0 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.31 g, 7.8 mmol) were reacted in THF
(5 mL) for 48 hrs. The crude product was purified by column chromatography on silica gel
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eluting with 1:9 ethyl acetate/hexane to give 67h as a colourless oil (80 mg, 27%). Rf =
0.20 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C17H22FNO2 − C(CH3)3:
236.1087; found 236.1080. 1H NMR (500 MHz, CDCl3): δ 1.23-1.53 [9H, m, *tBu + tBu],
1.57-1.77 [2H, m, H(5) + *H(5)], 2.35-2.46 [2H, m, H(4) + *H(4)], 3.46-3.56 [2H, m, H(6)
+ *H(6)], 3.97-4.12 [2H, m, H(2) + *H(2)], 6.27 [0.2H, br s, *H(A)], 6.34 [0.8H, br s,
H(A)], 6.98-7.25 [4H, m, H(3’) + *H(3’) + H(4) + *H(4’) + H(5’) + *H(5’) + H(6) +
*H(6’)]. 13C NMR (126 MHz, CDCl3): δ 26.13 [br, C(5)], 26.98 [*C(5)], 27.98 [C(4)], 28.35
[br, *tBu], 28.62 [br, tBu], 34.74 [br, *C(4)], 44.51 [br, C(6) + *C(6)], 50.58-53.47 [C(2)
+ *C(2)], 79.53 [*tBu], 79.72 [tBu], 115.14-115.68 [C(3’) + *C(3’)], 117.28-118.35 [C(A)
+ *C(A)], 123.08-124.11 [C(5’) + *C(5’)], 124.51-125.01 [C(1’) + *C(1’)], 128.20-128.79
[C(4’) + *C(4’)], 130.58-131.22 [C(6) + *C(6)], 138.58 [br, C(3) + *C(3)], 154.71 [*C=O],
154.96 [C=O], 159.08-161.47 [C(2’) + *C(2’)].





Using General Method 2, 36j (0.74 g, 3.0 mmol), N-Boc-3-piperidone (0.30 g, 1.5 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.48 g, 12.0 mmol) were reacted in THF (5
mL) for 48 hr. The crude product was purified by column chromatography on silica gel eluting
with 1:9 ethyl acetate/hexane to give 67j as a colourless oil (101 mg, 23%). HRMS (ESI+)
[M+H]+ calcd. for C17H22FNO2 − C(CH3)3: 236.1087; found 236.1084. 1H NMR (500 MHz,
CDCl3): δ 1.32 [2.7H, br s, *tBu], 1.48 [6.3H, s, tBu], 1.57-1.65 [1.4H, m, H(5)], 1.68-1.75
[0.6H, m, *H(5)], 2.36-2.41 [0.6H, m, *H(4)], 2.45-2.50 [1.4H, m, H(4)], 3.47-3.53 [2H, m,
H(6) + *H(6)], 4.00 [1.4H, br s, H(2)], 4.14 [0.6H, br s, *H(2)], 6.27 [0.3H, br s, *H(A)],
6.36 [0.7H, br s, H(A)], 6.97-7.05 [2H, m, H(3’) + H(5’) + *H(3’) + *H(5’)], 7.14-7.24 [2H,
m, H(2’) + H(6’) + *H(2) + *H(6’)]. 13C NMR (126 MHz, CDCl3): δ 26.06 [C(5)], 26.93
[br, *C(5)], 27.39 [C(4)], 28.43 [br s, *tBu], 28.62 [tBu], 34.78 [br, *C(4)], 44.47 [br, C(6) +
*C(6)], 45.89 [br, *C(2)], 51.57 [br, C(2)], 79.59 [*tBu], 79.68 [tBu], 115.16 [d, 2JC,F = 21.3
Hz, C(3’) + C(5’) + *C(3’) + *C(5’)], 123.54-124.36 [m, C(A) + *C(A)], 130.35-130.68
[m, C(2’) + C(6’) + *C(2’) + *C(6’)], 133.19 [d, 4JC,F = 3.3 Hz, C(1’) + *C(1’)], 136.23
[br, C(3) + *C(3)], 154.90 [C=O + *C=O], 160.58-162.73 [m, C(4’) + *C(4’)].





Synthesis method a. Using General Method 2, 36x (0.75 g, 3.3 mmol), N-Boc-3-piperidone
(0.33 g, 1.7 mmol), and sodium hydride (60% dispersion in paraffin oil, 0.50 g, 12.5 mmol)
were reacted in THF (5 mL) for 48 hr. The crude product was purified by column
chromatography on silica gel eluting with 3:7 ethyl acetate/hexane to give 67x as a colourless
oil (214 mg, 47%). Rf = 0.29 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd.
for C17H23NO2 − C(CH3)3: 218.1181; found 218.1174. 1H NMR (500 MHz, CDCl3): δ 1.30
[2.7H, br s, *tBu], 1.48 [6.3H, s, tBu], 1.61 [1.4H, br p, 3J4,5 = 3J5,6 = 6.0 Hz, H(5)],
1.72 [0.6H, br p, 3J4,5 = 3J5,6 = 6.0 Hz, *H(5)], 2.40 [0.6H, td, 3J4,5 = 6.0 Hz, 4J4,6 =
1.0 Hz, *H(4)], 2.52 [1.4H, td, 3J4,5 = 6.0 Hz, 4J4,6 = 1.0 Hz, H(4)], 3.46-3.54 [2H, m,
H(6) + *H(6)], 4.01 [1.4H, br s, H(2)], 4.18 [0.6H, br s, *H(2)], 6.33 [0.3H, br s, *H(A)],
6.41 [0.7H, br s, H(A)], 7.17-7.26 [3H, m, H(2’) + *H(2’) + H(4’) + *H(4’) + H(6’) +
*H(6’)], 7.29-7.35 [2H, m, H(3’) + *H(3’) + H(5’) + *H(5’)]. 13C NMR (126 MHz, CDCl3):
δ 26.13 [C(5)], 27.02 [br, *C(5)], 27.49 [C(4)], 28.42 [br s, *tBu], 28.64 [tBu], 34.90 [br,
*C(4)], 44.54 [br, C(6) + *C(6)], 46.00 [br, *C(2)], 52.28 [br, C(2)], 79.53 [*tBu], 79.65
[tBu], 125.04 [br, C(A) + *C(A)], 126.64 [br, *C(4’)], 126.66 [C(4’)], 128.28 [C(3’) + *C(3’)
+ C(5’) + *C(5’)], 128.93 [*C(2’) + *C(6’)], 129.03 [C(2’) + C(6’)], 136.29 [br, C(3) +
*C(3)], 137.27 [br, C(1’) + *C(1’)], 154.94 [C=O], 155.05 [br, *C=O].
*denotes Z -isomer
Synthesis method b. Bromobenzene (100 mg, 0.64 mmol) and 14 (25 mg, 0.13 mmol) were
combined with potassium carbonate (53 mg, 0.38 mmol), tri-o-tolylphosphine (2.7 mg, 8.9
µmmol) and Pd(OAc)2 (1.4 mg, 6.3 µmmol) in DMF (2 mL) and the mixture was stirred
at 80°C for 48 hours. The mixture was cooled and filtered through Celite® washing with
methanol, and the solvent was removed by evaporation under reduced pressure to give an





Using General Method 5, 36j (0.50 g, 2.0 mmol), N-Boc-3-piperidone (0.20 g, 1.0 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.32 g, 8.0 mmol) were reacted for 48 hr
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in THF (5 mL), then with Pd-C catalyst in methanol (20 mL) for 2 hr followed by hydrogen
chloride solution (1M in diethyl ether, 1.5 mL) in diethyl ether (3 mL). A brown gum formed
which was isolated by filtration. HRMS and 1H NMR analysis indicated product was present










Synthesis method a. Anhydrous THF (4 mL) was added to methyltriphenylphosphonium
bromide (0.54 g, 1.5 mmol) under an N2 atmosphere. The mixture was cooled to -78°C and
n-BuLi (2M in hexanes, 1.5 mL, 3.0 mmol) was added dropwise. The mixture was stirred for
30 min then solution of N-Boc-3-piperidone (0.20 g, 1.00 mmol) in THF was added over 5 min
before the mixture was warmed to room temperature and stirred for 48 hr. The mixture was
quenched with brine and extracted with ethyl acetate. The organic extracts were dried over
MgSO4, filtered, and solvent removed by evaporation under reduced pressure. Only starting
materials were recovered.
Synthesis method b. Anhydrous THF (6 mL) was added to a mixture of methyltriphenyl-
phosphonium bromide (0.32 g, 0.90 mmol) and sodium hydride (60% in mineral oil, 0.16 g,
4.0 mmol) under an N2 atmosphere and the mixture was stirred for 30 min. A solution of
N-Boc-3-piperidone (0.10 g, 0.50 mmol) in THF was added and the mixture stirred for 48 hr
then quenched with brine solution (25 mL) and extracted with ethyl acetate (3 x 30 mL). The
organic extracts were dried over MgSO4, filtered, and solvent removed by evaporation under
reduced pressure. The residue was purified by column chromatography on silica gel eluting
with ethyl acetate/hexane (1:1) to give a crude mixture containing 70 as an orange oil (12
mg, <12%). 1H NMR (500 MHz, CDCl3): δ 1.46 [9H, s, tBu], 1.58-1.66 [2H, m, H(5)],
2.23-2.29 [2H, m, H(4)], 3.39-3.48 [2H, m, H(6)], 3.87 [2H, br s, H(2)], 4.75 [1H, s, H(A)],
4.82 [1H, br s, H(B)].






Using General Method 2, 36h (0.80 g, 3.2 mmol), N-Boc-3-pyrrolidinone (0.31 g, 1.7 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.26 g, 6.5 mmol) were reacted in THF
(5 mL) for 48 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 68h as a colourless oil (38 mg, 8%). Rf = 0.24
(9:1 hexane/ethyl acetate). 1H NMR (500 MHz, CDCl3): δ 1.42-1.50 [9H, m, tBu + *tBu],
2.45-2.59 [2H, m, H(4a) + H(4b) + *H(4a) + *H(4b)], 3.33-3.45 [2H, m, H(2a) + H(2b)
+ *H(2a) + *H(2b)], 3.62-3.78 [2H, m, H(5a) + H(5b) + *H(5a) + *H(5b)], 6.19-6.33
[1H, m, H(A) + *H(A)], 6.95-7.12 [2H, m, H(3’) + H(5’) + *H(3’) + *H(5’)], 7.13-7.24
[2H, m, H(2’) + H(6’) + *H(2’) + *H(6’)]. 13C NMR (126 MHz, CDCl3): 27.80-28.07
[m, C(2) + *C(2)], 28.44-28.73 [m, tBu + *tBu], 31.09 [C(4)], 32.33 [*C(4)], 45.42 [C(5)],
45.92 [*C(5)], 79.88 [*tBu], 80.09 [tBu], 115.30-115.58 [m, C(3’) + *C(3’)], 124.09-124.25
[m, C(5’) + *C(5’)], 125.37-125.60 [m, C(A) + *C(A)], 126.12-126.35 [m, C(1’) + *C(1’)],
128.05-128.26 [m, C(4’) + *C(4’)], 130.85 [br‡, C(6’)], 130.99 [br‡, *C(6’)], 141.21-141.35
[m, C(3) + *C(3)], 151.49-151.77 [m, C=O + *C=O], 159.96-162.36 [m, C(2’) + *C(2’)].





Using General Method 2, 36i (0.66 g, 2.7 mmol), N-Boc-3-pyrrolidinone (0.25 g, 1.3 mmol),
and sodium hydride (60% dispersion in paraffin oil, 0.43 g, 10.8 mmol) were reacted in THF
(5 mL) for 48 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 68i as a colourless oil (7 mg, 4%). 1H NMR
(500 MHz, CDCl3): δ 1.41-1.55 [9H, m, tBu + *tBu], 2.38-2.55 [2H, m, H(4a) + H(4b) +
*H(4a) + *H(4b)], 3.21-3.50 [2H, m, H(2a) + H(2b) + *H(2a) + *H(2b)], 3.63-3.79 [2H, m,
H(5a) + H(5b) + *H(5a) + *H(5b)], 6.22-6.39 [1H, m, H(A) + *H(A)], 6.84-7.01 [3H, m,
H(2’) + H(4’) + H(6’) + *H(2’) + *H(4’) + *H(6’)], 7.19-7.29 [1H, m, H(5’) + *H(5’)]. 13C
NMR (126 MHz, CDCl3): δ 28.44-28.73 [m, tBu + *tBu], 30.92 [C(4)], 32.09 [*C(4)], 34.91
254
[C(2)], 34.98 [*C(2)], 45.42 [C(5)], 45.90 [*C(5)], 79.95 [*tBu], 80.16 [tBu], 113.04-113.50
[m, C(4’) + *C(4’)], 115.33-115.83 [m, C(3) + C(2’) + *C(3) + *C(2’)], 124.17-124.62
[m, C(A) + *C(A)], 125.51-125.82 [m, C(6’) + *C(6’)], 129.79-130.11 [m, C(5’) + *C(5’)],





Using General Method 2, 36x (1.85 g, 8.1 mmol), N-Boc-3-pyrrolidinone (0.75 g, 4.1 mmol),
and sodium hydride (60% dispersion in paraffin oil, 1.29 g, 32.4 mmol) were reacted in THF
(5 mL) for 48 hr. The crude product was purified by column chromatography on silica gel
eluting with 1:9 ethyl acetate/hexane to give 68x as a colourless oil (94 mg, 9%). Rf = 0.22
(1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C16H21NO2: 260.1651; found
260.1644. 1H NMR (500 MHz, CDCl3): δ 1.39-1.53 [9H, m, tBu + *tBu], 2.40-2.54 [2H,
m, H(4a) + H(4b) + *H(4a) + *H(4b)], 3.22-3.50 [2H, m, H(2a) + H(2b) + *H(2a) +
*H(2b)], 3.62-3.78 [2H, m, H(5a) + H(5b) + *H(5a) + *H(5b)], 6.21-6.37 [1H, m, H(A) +




Using General Method 3, 67c (156 mg, 0.54 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 69c as a
colourless oil which was used without further purification (157 mg, 100%). HRMS (ESI+)
[M+H]+ calcd. for C18H27NO2 − C(CH3)3: 234.1494; found 234.1487. 1H NMR (500 MHz,
CDCl3): δ 0.94-1.25 [1H, m, H(4ax)], 1.27-1.55 [10H, m, tBu + H(5ax)], 1.54-1.84 [3H, m,
H(3ax) + H(4eq) + H(5eq)], 2.18-2.92 [7H, m, CH3 + H(A) + H(A’) + H(2ax) + H(6ax)],
3.68-4.18 [2H, m, H(2eq) + H(6eq)], 6.91-7.03 [3H, m, H(2’) + H(4’) + H(6’)], 7.16 [1H, t,






Using General Method 3, 67f (85 mg, 0.28 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 69f as a colourless oil
which was used without further purification (86 mg, 100%). 1H NMR (500 MHz, CDCl3):
δ 1.04-1.19 [1H, m, H(4ax)], 1.32-1.53 [10H, m, tBu + H(5ax)], 1.58-1.66 [1H, m, H(4eq)],
1.68-1.80 [2H, m, H(3ax) + H(5eq)], 2.32-2.68 [3H, m, H(A) + H(A’) + H(2ax)], 2.69-2.88
[1H, m, H(6ax)], 3.74-4.12 [5H, m, H(2eq) + H(6eq) + OCH3], 6.67-6.78 [3H, m, H(2’) +




Using General Method 3, 67h (64 mg, 0.22 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up and column chromatography on
silica gel eluting with 9:1 hexane/ethyl acetate gave 69h as a colourless oil (45 mg, 70%). Rf
= 0.35 (9:1 hexane/ethyl acetate). 1H NMR (500 MHz, CDCl3): δ 1.07-1.22 [1H, m, H(4ax)],
1.30-1.53 [10H, m, tBu + H(5ax)], 1.57-1.68 [1H, m, H(4eq)], 1.70-1.82 [2H, m, H(3ax) +
H(5eq)], 2.40-2.67 [3H, m, H(A) + H(A’) + H(2ax)], 2.69-2.86 [1H, m, H(6ax)], 3.68-4.15
[2H, m, H(2eq) + H(6eq)], 7.00 [1H, br dd‡, 3J3’,F = 9.4 Hz, 3J3’,4’ = 8.5 Hz, H(3’)], 7.05
[1H, br t, 3J4’,5’ = 3J5’,6’ = 7.7 Hz, H(5’)], 7.12-7.21 [2H, m, H(4’) + H(6’)]. 13C NMR
(126 MHz, CDCl3): δ 24.96 [br, C(5)], 28.54 [tBu], 30.75 [C(4)], 33.13 [br, C(3)], 36.89 [br‡,
C(A)], 44.58 [br, C(6)], 49.53 [br, C(2)], 79.34 [tBu], 115.34 [d, 2JC,F = 22.3 Hz, C(3’)],
123.96 [d, 4JC,F = 3.5 Hz, C(5’)], 126.91 [d, 2JC,F = 15.8 Hz, C(1’)], 127.88 [d, 3JC,F = 8.2







Using General Method 3, 67j (101 mg, 0.35 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up and column chromatography on
silica gel eluting with 9:1 hexane/ethyl acetate gave 69j as a colourless oil (99 mg, 97%). 1H
NMR (500 MHz, CDCl3): δ 1.02-1.20 [1H, m, H(4ax)], 1.31-1.52 [10H, m, tBu + H(5ax)],
1.58-1.79 [3H, m, H(3ax) + H(4eq) + H(5eq)], 2.32-2.90 [4H, m, H(A) + H(A’) + H(2ax) +
H(6ax)], 3.69-4.13 [2H, m, H(2eq) + H(6eq)], 6.93-6.99 [2H, m, H(3’) + H(5’)], 7.07-7.13
[2H, m, 2JC,F = 21.2 Hz, H(2’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 25.00 [br, C(5)],
28.55 [tBu], 30.72 [br, C(4)], 37.91 [br‡, C(A)], 39.38 [br, C(3)], 44.54 [br, C(6)], 49.55 [br,
C(2)], 79.42 [tBu], 115.13 [d, 3JC,F = 21.2 Hz, C(3’) + C(5’)], 130.44 [d, 3JC,F = 7.8 Hz,




Using General Method 3, 67x (197 mg, 0.72 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 69x as a
colourless oil which was used without further purification (198 mg, 100%). 1H NMR (500
MHz, CDCl3): δ 1.02-1.21 [1H, m, H(4ax)], 1.31-1.53 [10H, m, tBu + H(5ax)], 1.58-1.82
[3H, m, H(3ax) + H(4eq) + H(5eq)], 2.33-2.89 [4H, m, H(A) + H(A’) + H(2ax) + H(6ax)],
3.70-4.14 [2H, m, H(2eq) + H(6eq)], 7.11-7.23 [3H, m, H(2’) + H(4’) + H(6’)], 7.23-7.34





Using General Method 3, 68h (25 mg, 0.09 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave 71h as a colourless oil (25
mg, 99%). Rf = 0.22 (9:1 hexane/ethyl acetate). 1H NMR (500 MHz, CDCl3): δ 1.34-1.69
[10H, m, tBu] + H(4a)], 1.83-1.99 [1H, m, H(4b)], 2.37-2.52 [1H, m, H(3)], 2.61-2.80 [2H,
m, H(A) + H(A’)], 2.92-3.07 [1H, m, H(2a)], 3.18-3.34 [1H, m, H(5a)], 3.34-3.57 [2H, m,
H(2b) + H(5b)], 6.95-7.12 [2H, m, H(3’) + H(5’)], 7.11-7.25 [2H, m, H(4’) + H(6’)]. 13C
NMR (126 MHz, CDCl3): δ 28.42-28.79 [m, tBu], 30.59-31.66 [m, C(4)], 32.25-32.44 [m,
C(A)], 38.57-40.07 [m, C(3)], 44.94-45.95 [m, C(5)], 50.69-51.59 [m, C(2)], 79.05-79.24 [m,
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tBu], 115.26-115.60 [m, C(3’)], 124.08-124.17 [m, C(5’)], 127.16-127.45 [m, C(1’)], 127.93-





Using General Method 3, 68x (94 mg, 0.36 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr. Work-up gave crude 71x as a colourless oil
which was used without further purification (95 mg, 100%). HRMS (ESI+) [M+H]+ calcd.
for C16H23NO2 − C(CH3)3: 206.1181; found 206.1175. 1H NMR (500 MHz, CDCl3): δ 1.40-
1.50 [9H, m, tBu], 1.53-1.63 [1H, m, H(4a)], 1.86-1.98 [1H, m, H(4b)], 2.32-2.49 [1H, m,
H(3)], 2.59-2.75 [2H, m, H(A) + H(A’)], 2.92-3.06 [1H, m, H(2a)], 3.16-3.33 [1H, m, H(5a)],




Using General Method 4, 69c (157 mg, 0.54 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (8 mL) to give 32c as a yellow oil (101 mg, 98%). 1H NMR (500
MHz, CDCl3): δ 1.11 [1H, qd, 2J4ax,4eq = 3J3ax,4ax = 3J4ax,5ax = 12.7 Hz, 3J4ax,5eq = 3.6 Hz,
H(4ax)], 1.58 [1H, qt, 2J5ax,5eq = 3J4ax,5ax = 3J5ax,6ax = 12.7 Hz, 3J4eq,5ax = 3J5ax,6eq = 3.6
Hz, H(5ax)], 1.73 [1H, br d‡, 2J5ax,5eq = 12.7 Hz, H(5eq)], 1.82 [1H, br d‡, 2J4ax,4eq = 12.7 Hz,
H(4eq)], 1.91 [1H, ttt, 3J2ax,3ax = 3J3ax,4ax = 12.7 Hz, 3J3ax,A = 3J3ax,A’ = 7.4 Hz, 3J2eq,3ax
= 3J3ax,4eq = 3.6 Hz, H(3ax)], 2.32 [3H, s, CH3], 2.38 [1H, dd, 3J2ax,3ax = 12.7 Hz, 2J2ax,2eq
= 11.4 Hz, H(2ax)], 2.42-2.53 [2H, m, H(A) + H(A’)], 2.62 [1H, td, 2J6ax,6eq = 3J5ax,6ax =
12.7 Hz, 3J5eq,6ax = 3.6 Hz, H(6ax)], 3.05-3.15 [2H, m, H(2eq) + H(6eq)], 4.90 [1H, br s, NH],
6.89-6.97 [2H, m, H(2’) + H(4’)], 7.01 [1H, br d‡, 3J5’,6’ = 7.5 Hz, H(6’)], 7.16 [1H, t, 3J4’,5’





Using General Method 4, 69f (96 mg, 0.31 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give crude 32f as a yellow oil which was used without
further purification (61 mg, 95%). 1H NMR (500 MHz, CDCl3): δ 1.09 [1H, qd, 2J4ax,4eq =
3J3ax,4ax = 3J4ax,5ax = 12.7 Hz, 3J4ax,5eq = 3.5 Hz, H(4ax)], 1.59 [1H, qt, 2J5ax,5eq = 3J4ax,5ax
= 3J5ax,6ax = 12.7 Hz, 3J4eq,5ax = 3J5ax,6eq = 3.5 Hz, H(5ax)], 1.67 [1H, br d‡, 2J5ax,5eq = 12.7
Hz, H(5eq)], 1.72-1.86 [2H, m, H(3ax) + H(4eq)], 2.32 [1H, dd, 3J2ax,3ax = 12.7 Hz, 2J2ax,2eq =
11.0 Hz, H(2ax)], 2.44 and 2.48 [2H, ABX, A:dd, B:dd, 2JA,A’(JAB) = 13.6 Hz, 3JA,3’ax(JAX )
= 7.1 Hz, 3JA’,3’ax(JBX ) = 7.2 Hz, H(A) + H(A’)], 2.56 [1H, td, 2J6ax,6eq = 3J5ax,6ax = 12.7
Hz, 3J5eq,6ax = 2.7 Hz, H(6ax)], 2.99-3.08 [2H, m, H(2eq) + H(6eq)], 3.48 [1H, br s, NH], 3.79
[3H, s, OCH3], 6.69 [1H, br s‡, H(2’)], 6.70-6.77 [2H, m, H(4’) + H(6’)], 7.18 [1H, t, 3J4’,5’




Using General Method 4, 69h (33 mg, 0.11 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give crude 32h as a yellow oil which was used without
further purification (20 mg, 92%). HRMS (ESI+) [M+H]+ calcd. for C12H16FN: 194.1345;
found 194.1341. 1H NMR (500 MHz, CDCl3): δ 1.15 [1H, qd, 2J4ax,4eq = 3J3ax,4ax = 3J4ax,5ax
= 12.5 Hz, 3J4ax,5eq = 3.5 Hz, H(4ax)], 1.59 [1H, qt, 2J5ax,5eq = 3J4ax,5ax = 3J5ax,6ax = 12.5
Hz, 3J4eq,5ax = 3J5ax,6eq = 3.5 Hz, H(5ax)], 1.73 [1H, br d‡, 2J5ax,5eq = 12.5 Hz, H(5eq)], 1.81
[1H, br d‡, 2J4ax,4eq = 12.5 Hz, H(4eq)], 1.94 [1H, ttt, 3J2ax,3ax = 3J3ax,4ax = 12.5 Hz, 3J3ax,A
= 3J3ax,A’ = 7.3 Hz, 3J2eq,3ax = 3J3ax,4eq = 3.5 Hz, H(3ax)], 2.42 [1H, t, 2J2ax,2eq = 3J2ax,3ax
= 12.5 Hz, H(2ax)], 2.48-2.66 [3H, m, H(A) + H(A’) + H(6ax)], 3.06-3.18 [2H, m, H(2eq) +





Using General Method 4, 69j (99 mg, 0.34 mmol) and trifluoroacetic acid (1 mL) were reacted
in dichloromethane (4 mL) to give 32j as a yellow oil (60 mg, 92%). 1H NMR (500 MHz,
CDCl3): δ 1.12 [1H, qd, 2J4ax,4eq = 3J3ax,4ax = 3J4ax,5ax = 12.4 Hz, 3J4ax,5eq = 3.5 Hz, H(4ax)],
1.64 [1H, qt, 2J5ax,5eq = 3J4ax,5ax = 3J5ax,6ax = 12.4 Hz, 3J4eq,5ax = 3J5ax,6eq = 3.5 Hz, H(5ax)],
1.73-1.85 [2H, m, H(4eq) + H(5eq)], 1.96 [1H, ttt, 3J2ax,3ax = 3J3ax,4ax = 12.4 Hz, 3J3ax,A =
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3J3ax,A’ = 7.5 Hz, 3J2eq,3ax = 3J3ax,4eq = 3.5 Hz, H(3ax)], 2.41 [1H, t, 2J2ax,2eq = 3J2ax,3ax =
12.4 Hz, H(2ax)], 2.47-2.53 [2H, m, H(A) + H(A’)], 2.65 [1H, td, 2J6ax,6eq = 3J5ax,6ax = 12.5
Hz, 3J5eq,6ax = 3.5 Hz, H(6ax)], 3.10 [1H, br d‡, 2J2ax,2eq = 12.4 Hz, H(2eq)], 3.16 [1H, br d‡,
2J6ax,6eq = 12.4 Hz, H(6eq)], 6.75 [1H, br s, NH], 6.93-7.00 [2H, m, H(3’) + H(5’)], 7.04-7.11
[2H, m, H(2’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 23.69 [C(5)], 29.78 [C(4)], 36.60
[C(3)], 39.73 [C(A)], 45.18 [C(6)], 50.09 [C(2)], 115.40 [d, 2JC,F = 21.1 Hz, C(3) + C(5)],
130.44 [d, 3JC,F = 7.8 Hz, C(2) + C(6)], 134.44 [d, 4JC,F = 3.4 Hz, C(1)], 161.68 [d, 1JC,F
= 244.3 Hz, C(4)].
This data is consistent with that reported in literature.129
3-Benzylpiperidine (32x)
NH
Using General Method 4, 69x (229 mg, 0.83 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (8 mL) to give 32x as a yellow oil (141 mg, 96%). 1H NMR (500
MHz, CDCl3): δ 1.11 [1H, qd, 2J4ax,4eq = 3J3ax,4ax = 3J4ax,5ax = 12.5 Hz, 3J4ax,5eq = 3.7 Hz,
H(4ax)], 1.57 [1H, qt, 2J5ax,5eq = 3J4ax,5ax = 3J5ax,6ax = 12.5 Hz, 3J4eq,5ax = 3J5ax,6eq = 3.7
Hz, H(5ax)], 1.72 [1H, br d‡, 2J5ax,5eq = 12.5 Hz, H(5eq)], 1.81 [1H, br d‡, 3J4eq,5ax = 12.5 Hz,
H(4eq)], 1.90 [1H, ttt, 3J2ax,3ax = 3J3ax,4ax = 12.5 Hz, 3J3ax,A = 3J3ax,A’ = 7.4 Hz, 3J2eq,3ax
= 3J3ax,4eq = 3.7 Hz, H(3ax)], 2.38 [1H, t, 2J2ax,2eq = 3J2ax,3ax = 12.5 Hz, H(2ax)], 2.46-2.55
[2H, m, H(A) + H(A’)], 2.61 [1H, br t‡, 2J6ax,6eq = 3J5ax,6ax = 12.5 Hz, H(6ax)], 3.03-3.15
[2H, m, H(2eq) + H(6eq)], 5.92 [1H, br s, NH], 7.09-7.15 [2H, m, H(2’) + H(6’)], 7.19 [1H,
br t‡, 3J3’,4’ = 3J4’,5’ = 7.3 Hz, H(4’)], 7.24-7.31 [2H, m, H(3’) + H(5’)].




Using General Method 4, 71h (19 mg, 0.07 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 33h as an orange oil (4 mg, 33%). 1H NMR (500
MHz, CDCl3): δ 1.67 [1H, dq, 2J4a,4b = 13.0 Hz, 3J3,4a = 3J4a,5a = 3J4a,5b = 8.0 Hz, H(4a)],
2.01 [1H, dtd, 2J4a,4b = 13.0 Hz, 3J4b,5a = 3J3,4b = 8.0 Hz, 3J4b,5b = 4.6 Hz, H(4b)], 2.54
[1H, septet, 3J3,A = 3J3,A’ = 3J2a,3 = 3J2b,3 = 3J3,4a = 3J3,4b = 8.0 Hz, H(3)], 2.67-2.83
[3H, m, H(A) + H(A’) + H(2a)], 3.10 [2H, dt, 2J5a,5b = 11.1 Hz, 3J4a,5a = 3J4b,5a = 8.0
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Hz, H(5a)], 3.16-3.29 [2H, m, H(2b) + H(5b)], 7.02 [1H, dd, 3J3’,F = 9.6 Hz, 3J3’,4’ = 8.7
Hz, H(3’)], 7.06 [1H, t, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, H(5’)], 7.11-7.24 [2H, m, H(4’) + H(6’)],
7.32 [1H, br s, NH]. 13C NMR (126 MHz, CDCl3): δ 31.07 [C(4)], 32.38 [d, 3JC,F = 1.7 Hz,
C(A)], 39.51 [C(3)], 45.27 [C(5)], 50.58 [C(2)], 115.55 [d, 2JC,F = 22.3 Hz, C(3’)], 124.30
[d, 4JC,F = 3.5 Hz, C(5’)], 126.79 [d, 2JC,F = 15.8 Hz, C(1’)], 128.38 [d, 3JC,F = 8.1 Hz,
C(4’)], 131.10 [d, 3JC,F = 4.8 Hz, C(6’)], 161.18 [d, 1JC,F = 224.7 Hz, C(2’)].
3-Benzylpyrrolidine (33x)
NH
Using General Method 4, 71x (95 mg, 0.36 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 33x as an orange oil (58 mg, 100%). HRMS
(ESI+) [M+H]+ calcd. for C11H15N: 162.1283; found 162.1279. 1H NMR (500 MHz,
CDCl3): δ 1.67 [1H, dq, 2J4a,4b = 13.1 Hz, 3J3,4a = 3J4a,5a = 3J4a,5b = 7.8 Hz, H(4a)],
2.02-2.10 [1H, m, H(4b)], 2.57 [1H, septet, 3J3,A = 3J3,A’ = 3J2a,3 = 3J2b,3 = 3J3,4a = 3J3,4b
= 7.8 Hz, H(3)], 2.69-2.74 [2H, m, H(A) + H(A’)], 2.83 [1H, dd, 2J2a,2b = 11.2 Hz, 3J2a,3 =
7.8 Hz, H(2a)], 3.15 [1H, dt, 2J5a,5b = 11.3 Hz, 3J4a,5a = 3J4b,5a = 7.8 Hz, H(5a)], 3.22-3.45
[3H, m, H(2b) + H(5b) + NH], 7.13-7.18 [2H, m, H(2’) + H(6’)], 7.22 [2H, t, 3J3’,4’ = 3J4’,5’
= 7.2 Hz, H(4’)], 7.27-7.33 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 31.98
[C(4)], 39.12 [C(A)], 40.46 [C(3)], 45.28 [C(5)], 50.54 [C(2)], 126.42 [C(4’)], 128.60 [C(2’)
+ C(3’) + C(5’) + C(6’)], 139.71 [C(1’)].
6.2.4 Synthesis of pyridinylmethylpiperidine derivatives






























LiHMDS (1.0 M in THF, 2 eq) was added to a stirring suspension of the triphenylphosphonium
halide Wittig reagent (1.4 eq) in THF under an atmosphere of nitrogen. The mixture was
stirred for 15 min and a solution of the Boc-protected piperidone reagent (1 eq) in THF
was then added dropwise. The reaction mixture was stirred for the specified time, then
quenched with methanol (30 mL) and concentrated to dryness by evaporation under reduced
pressure. The residue was suspended in ethyl acetate/hexane (2:3, 40 mL) then filtered to
remove insoluble solid. The filtrate was concentrated to dryness by evaporation under reduced
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Synthesis method a. Using General Method 2, a sample of crude 50c (74 mg, 0.32 mmol),
N-Boc-4-piperidone (32 mg, 0.16 mmol), and sodium hydride (60% dispersion in paraffin
oil, 38 mg, 0.96 mmol) were reacted in THF (5 mL) for 18 hr. Work-up and attempted
purification of the crude product by column chromatography on silica gel eluting with 1:1
ethyl acetate/hexane gave a crude brown oil containing 53c.
Synthesis method b. To a stirring mixture of 52c (0.94 g, 2.2 mmol) in dry THF at -78°C
under an atmosphere of nitrogen was added n-BuLi (2.0 M in hexanes, 3.3 mL, 6.6 mmol)
dropwise over 10 min. The mixture was stirred for 15 min before dropwise addition of N-Boc-
4-piperidone (0.33 g, 1.7 mmol) in THF. The reaction mixture was stirred a further 48 hr
then quenched with water. The mixture was concentrated to dryness under reduced pressure
and product purified by flash column chromatography on silica gel (1:1 ethyl acetate/hexane)
to give the desired product 53c as a pale yellow oil (240 mg, 53%*). Rf = 0.25 (1:1 ethyl
acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C16H22N2O2: 275.1760; found 275.1759.
1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.30-2.39 [2H, m, H(3)], 2.41-2.52 [2H,
m, H(5)], 3.36-3.47 [2H, m, H(2)], 3.47-3.58 [2H, m, H(6)], 6.28 [1H, s, H(A)], 7.05-7.12
[2H, m, H(2’) + H(6’)], 8.49-8.59 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3):
δ 28.58 [tBu], 29.49 [br, C(3)], 36.46 [br, C(5)], 43.52-46.51 [C(2) + C(6)], 79.91 [tBu],
122.46 [C(2’) + C(6’)], 123.82 [C(A)], 142.80 [C(4)], 145.20 [C(1’)], 149.87 [C(3’) + C(5’)],
154.80 [C=O].
*Sample obtained from column chromatography contains triphenylphosphine oxide impurity.
1H NMR (500 MHz, CDCl3): δ 7.41-7.48 [m], 7.52-7.58 [m], 7.58-7.67 [m].
Synthesis method c. To a stirring mixture of 52c (100 mg, 0.23 mmol) in dry THF under an
atmosphere of nitrogen was added LiHMDS (1.0 M in THF, 400 µL, 0.40 mmol) dropwise over
10 min. The mixture was stirred for 15 min before dropwise addition of N-Boc-4-piperidone
(35 mg, 0.18 mmol) in THF. The reaction mixture was stirred for 16 hr then quenched with
water. The mixture was concentrated to dryness under reduced pressure, then resuspended
in 1:1 ethyl acetate/hexane (50 mL) and filtered. The solvent was removed by evaporation
under reduced pressure and the product purified by flash column chromatography on silica
gel (1:1 ethyl acetate/hexane) to give the desired product 53c as a pale yellow oil (93 mg,





Using General Method 8, 52a (1.00 g, 2.3 mmol) was reacted with LiHMDS solution (1.0
M in THF, 3.0 mL, 3.0 mmol) and N-Boc-4-piperidone (0.33 g, 1.7 mmol) in THF (6 mL)
for 4 hr. The crude product was purified by column chromatography on silica gel eluting
with 1:1 ethyl acetate/hexane to give 53a as a white solid (0.37 g, 81%*). Rf = 0.59 (1:1
ethyl acetate/hexane). 1H NMR (500 MHz, CDCl3): δ 1.48 (9H, s, tBu), 2.30-2.41 [2H, m,
H(5)], 2.80-2.88 [2H, m, H(3)], 3.39-3.49 [2H, m, H(2)], 3.50-3.58 [2H, m, H(6)], 6.37 [1H,
s, H(A)], 7.08 [1H, br dd‡, 3J4’,5’ = 7.6 Hz, 3J3’,4’ = 4.8 Hz, H(4’)], 7.14 [1H, br d‡, 3J5’,6’ =
7.6 Hz, H(6’)], 7.61 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, 4J3’,5’ = 1.7 Hz, H(5’)], 8.57 [1H, br
d‡, 3J3’,4’ = 4.8 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.44 [br, C(3)],
36.77 [br, C(5)], 45.09 [br, C(2) + C(6)], 79.68 [tBu], 121.08 [C(4’)], 124.16 [br, C(A) +
C(6’)], 136.14 [C(5’)], 143.30 [br, C(4)], 149.31 [C(3’)], 154.90 [C=O], 156.72 [C(1’)].
*Sample obtained from column chromatography contains triphenylphosphine oxide impurity.





Synthesis method a. To a stirring mixture of 52b (0.29 g, 0.75 mmol) in dry THF at -78°C
under an atmosphere of nitrogen was added n-BuLi (2.0 M in hexanes, 1.0 mL, 2.0 mmol)
dropwise over 10 min. The mixture was stirred for 15 min before dropwise addition of N-Boc-
4-piperidone (0.10 g, 0.50 mmol) in THF. The reaction mixture was stirred at 0°C for 48 hr
then quenched with water. The mixture was concentrated to dryness under reduced pressure
and product purified by flash column chromatography on silica gel (20% - 100% ethyl acetate
in hexane) to give the desired product 53b as a pale yellow oil (50 mg, 36%*). Rf = 0.26
(1:1 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C16H22N2O2: 275.1760; found
275.1752. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.31-2.49 [4H, m, H(3) + H(5)],
3.35-3.46 [2H, m, H(2)], 3.48-3.57 [2H, m, H(6)], 6.30 [1H, s, H(A)], 7.25 [1H, dd, 3J4’,5’ =
4.9 Hz, 3J5’,6’ = 7.7 Hz, H(5’)], 7.50 [1H, d, 3J5’,6’ = 7.7 Hz, H(6’)], 8.45 [1H, d, 3J4’,5’ =
4.9 Hz, H(4’)], 8.46 [1H, s, H(2’)]. 13C NMR (126 MHz, CDCl3): δ 28.54 [tBu], 29.28 [br,
C(3)], 36.32 [br, C(5)], 45.05 [br, C(2) + C(6)], 79.81 [tBu], 120.96 [C(5’)], 123.17 [C(A)],
133.17 [C(1’)], 136.06 [C(6’)], 141.22 [C(4)], 147.50 [C(2’)], 150.08 [C(4’)], 154.78 [C=O].
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*Sample obtained from column chromatography contains triphenylphosphine oxide impurity.
1H NMR (500 MHz, CDCl3): δ 7.41-7.48 [m], 7.52-7.58 [m], 7.58-7.67 [m].
Synthesis method b. 3-Bromopyridine (72 mg, 0.15 mmol), and 5 (30 mg, 0.15 mmol) were
combined in DMF (2 mL) with potassium carbonate (63 mg, 0.46 mmol), tri-o-tolylphosphine
(2.3 mg, 7.6 µmol) and Pd(OAc)2 (1.4 mg, 6.2 µmol) and stirred at 80°C for 48 hr. Work up
as specified gave an oil residue. 1H NMR analysis of crude mixture indicated no 53b present
in mixture.
Synthesis method c. Using General Method 8, 52b (0.82 g, 2.1 mmol) was reacted with
LiHMDS (1.0 M in THF, 2.7 mL, 2.7 mmol) and N-Boc-4-piperidone (295 mg, 1.5 mmol) in
THF (6 mL) for 16 hr. The crude residue was purified by flash column chromatography on






Using General Method 8, 52a (0.98 g, 2.3 mmol) was reacted with N-Boc-3-piperidone
(0.30 g, 1.5 mmol) and LiHMDS solution (1M in THF, 3.0 mL, 3.0 mmol) in THF (8
mL) for 16 hr. Work-up and purification by column chromatography eluting with 2:3 ethyl
acetate/hexane gave a mixture of (E /Z )-75a as a yellow oil (250 mg, 61%). Rf = 0.36 (2:3
ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C16H22N2O2: 275.1760; found
275.1755. 1H NMR (500 MHz, CDCl3): δ 1.29 [4H, br s, *tBu], 1.47 [5H, s, tBu], 1.67
[1.1H, p, 3J4,5 = 3J5,6 = 5.5 Hz, H(5)], 1.74 [0.9H, p, 3J4,5 = 3J5,6 = 5.5 Hz, *H(5)], 2.44
[0.9H, t, 3J4,5 = 5.5 Hz, *H(4)], 2.88 [1.1H, br s, H(4)], 3.51 [2H, br t, 3J5,6 = 5.5 Hz, H(6)
+ *H(6)], 4.05 [1.1H, s, H(2)], 4.57 [0.9H, br s, *H(2)], 6.34 [0.45H, s, *H(A)], 6.42 [0.55H,
br s, H(A)], 7.06-7.13 [1H, m, H(4’) + *H(4’)], 7.18 [0.55H, d, 3J5’,6’ = 7.8 Hz, H(6’)], 7.21
[0.45H, br s, *H(6’)], 7.59-7.67 [1H, m, H(5’) + *H(5’)], 8.58 [1H, d, 3J3’,4’ = 4.7 Hz, H(3’) +
*H(3’)]. 13C NMR (126 MHz, CDCl3): δ 25.85 [*C(3)], 26.76 [C(3)], 28.38 [br, *tBu], 28.57
[tBu], 35.03 [br, C(4) + *C(4)], 44.10 [C(6)], 45.90 [*C(6)], 51.57 [*C(2)], 52.88 [C(2)],
79.35 [*tBu], 79.62 [tBu], 121.19 [C(A)], 121.25 [*C(A)], 123.98 [C(4’)], 124.38 [*C(4’)],
136.10 [C(6’)], 136.16 [*C(6’)], 140.75 [C(5’) + *C(5’)], 149.25 [br, C(3’) + *C(3’)], 154.77
[C(3)], 154.88 [*C(3)], 156.13 [br, *C(1’)], 156.45 [C(1’)].





To a stirring mixture of 52b (0.90 g, 2.3 mmol) in dry THF at -78°C under an atmosphere of
nitrogen was added n-BuLi (2.0 M in hexanes, 3.0 mL, 3.0 mmol) dropwise over 10 min. The
mixture was stirred for 15 min before dropwise addition of N-Boc-3-piperidone (0.30 g, 1.5
mmol) in THF. The reaction mixture was stirred at 0°C for 48 hr then quenched with water.
The mixture was concentrated to dryness under reduced pressure to give a crude mixture. 1H





Using General Method 8, 52c (0.98 g, 2.3 mmol) was reacted with N-Boc-3-piperidone (0.30
g, 1.5 mmol) and LiHMDS (1M in THF, 3.0 mL, 3.0 mmol) in THF (8 mL) for 16 hr. Work-





Using General Method 3, 53a (0.35 g, 1.3 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr to give 76a as an orange oil (0.34 g, 96%*).
1H NMR (500 MHz, CDCl3): δ 1.20 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax
= 12.0 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.61 [2H, br d‡,
2J(3/5)ax,(3/5)eq = 12.0 Hz, H(3eq) + H(5eq)], 1.96 [1H, ttt, 3J3ax,4ax = 3J4ax,5ax = 12.0 Hz,
3J4ax,A = 7.5 Hz, 3J3eq,4ax = 3J4ax,5eq = 3.9 Hz, H(4ax)], 2.55-2.81 [4H, m, H(2ax) + H(6ax)
+ H(A)], 4.07 [2H, br s‡, H(2eq) + H(6eq)], 7.06-7.17 [2H, m, H(4’) + H(6’)], 7.59 [1H, t,
3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)], 8.55 [1H, d, 3J3’,4’ = 4.9 Hz, H(3’)].






Using General Method 3, 53b (40 mg, 0.15 mmol) was reacted with Pd-C catalyst in methanol
(30 mL) under a hydrogen atmosphere for 2 hr to give 76b as an orange oil which was used
without further purification (39 mg, 97%*). 1H NMR (500 MHz, CDCl3): δ 1.16 [2H, br
q‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.0 Hz, H(3ax) + H(5ax)], 1.45 [9H, s,
tBu], 1.56-1.73 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.55 [2H, d, 3J4ax,A = 6.9 Hz, H(A)],
2.64 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.0 Hz, H(2ax) + H(6ax)], 4.08 [2H, br
s‡, H(2eq) + H(6eq)], 7.24 [1H, br dd‡, 3J5’,6’ = 7.7 Hz, 3J4’,5’ = 4.4 Hz, H(5’)], 7.49 [1H, br
d‡, 3J5’,6’ = 7.7 Hz, H(6’)], 8.38 [1H, br s‡, H(2’)], 8.42 [1H, br d‡, 3J4’,5’ = 4.4 Hz, H(4’)].




Using General Method 3, 53c (240 mg, 0.87 mmol) in methanol (30 mL) was reacted with Pd-
C catalyst under a hydrogen atmosphere for 2 hr. Work up afforded crude 76c as an orange
oil which was used without further purification (250 mg, 97%*). HRMS (ESI+) [M+H]+
calcd. for C16H24N2O2: 277.1916; found 277.1910. 1H NMR (500 MHz, CDCl3): δ 1.16 [2H,
br q‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, H(3ax) + H(5ax)], 1.45 [9H,
s, tBu], 1.53-1.76 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.53 [2H, d, 3J4ax,A = 7.1 Hz, H(A)],
2.64 [2H, br t‡, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.2 Hz, H(2ax) + H(6ax)], 4.08 [2H, br
s‡, H(2eq) + H(6eq)], 6.98-7.12 [2H, m, H(2’) + H(6’)], 8.42-8.59 [2H, m, H(3’) + H(5’)].
*Sample contained impurities including triphenylphosphine oxide from previous reaction.
2-(Piperidin-4-ylmethyl)pyridine (34a)
N NH
Using General Method 4, 76a (330 mg, 1.19 mmol) in dichloromethane (12 mL) was reacted
with trifluoroacetic acid (3.0 mL) for 1 hr. Work up afforded crude 34a as an orange oil
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which was used without further purification (90 mg, 43%*). HRMS (ESI+) [M+H]+ calcd.
for C11H16N2: 177.1392; found 177.1386. 1H NMR (500 MHz, CDCl3): δ 1.47 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.8 Hz, 3J(2/6)eq,(3/5)ax = 3.6 Hz, H(3ax)
+ H(5ax)], 1.75 [2H, br d‡, 2J(3/5)ax,(3/5)eq = 12.8 Hz, H(3eq) + H(5eq)], 2.05 [1H, ttt,
3J(3’/5’)ax,4’ax = 12.8 Hz, 3J4’ax,A = 7.4 Hz, 3J(3’/5’)eq,4’ax = 3.5 Hz, H(4’ax)], 2.65-2.84 [4H,
m, H(A) + H(2ax) + H(6ax)], 3.26 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq) + H(6eq)],
4.83 [1H, br s, NH], 7.07-7.18 [2H, m, H(4’) + H(6’)], 7.60 [1H, br t‡, 3J4’,5’ = 3J5’,6’ = 7.6
Hz, H(5’)], 8.54 [1H, br d‡, 3J3’,4’ = 4.7 Hz, H(3’)].




Using General Method 4, 76b (32 mg, 0.12 mmol) in dichloromethane (5 mL) was reacted
with trifluoroacetic acid (0.5 mL) for 1 hr. Work up did not yield any product.
4-(Piperidin-4-ylmethyl)pyridine (34c)
N NH
Using General Method 4, 76c (261 mg, 0.94 mmol) in dichloromethane (5 mL) was reacted
with trifluoroacetic acid (2.0 mL) for 1 hr. Work up afforded crude 34c as an orange oil
which was used without further purification (101 mg, 61%*). HRMS (ESI+) [M+H]+ calcd.
for C11H16N2: 177.1392; found 177.1390. 1H NMR (500 MHz, CDCl3): δ 1.17 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.1 Hz, 3J(2/6)eq,(3/5)ax = 3.5 Hz, H(3ax) +
H(5ax)], 1.57-1.74 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.49-2.60 [4H, m, H(A) + H(2ax) +
H(6ax)], 3.05 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.3 Hz, H(2eq) + H(6eq)], 4.74 [1H, br s, NH],
7.03-7.13 [2H, m, H(2’) + H(6’)], 8.43-8.54 [2H, m, H(3’) + H(5’)].





Using General Method 3, 75a (250 mg, 0.91 mmol) was reacted in methanol (30 mL) with
Pd-C catalyst under a hydrogen atmosphere for 2 hr. Work-up and column chromatography
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on silica gel eluting with 3:7 ethyl acetate/hexane gave 77a as a yellow oil (251 mg, 100%).
Rf = 0.19 (3:7 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C16H24N2O2:
277.1916; found 277.1915. 1H NMR (500 MHz, CDCl3): δ 1.19 [2H, qd, 2J4ax,4eq = 3J3,4ax =
3J4ax,5ax = 12.0 Hz, 3J4ax,5eq = 3.8 Hz, H(4ax)], 1.30-1.51 [11H, m, H(5ax) + tBu], 1.59-1.70
[1H, m, H(5eq)], 1.72-1.81 [1H, m, H(4eq)], 1.98 [1H, ttt, 3J2ax,3 = 3J3,4ax = 12.0 Hz, 3J3,A
= 3J3,A’ = 7.4 Hz, H(3’)], 2.49-2.69 [2H, m, H(2ax) + H(A)], 2.72 [1H, dd, 2JA,A’ = 13.5
Hz, 3J3,A’ = 7.4 Hz, H(A’)], 2.81 [1H, ddd, 2J6ax,6eq = 13.5 Hz, 3J5ax,6ax = 10.7 Hz, 3J5eq,6ax
= 3.0 Hz, H(6ax)], 3.68-4.07 [2H, m, H(2eq) + H(6eq)], 7.08-7.16 [2H, m, H(4’) + H(6’)],
7.59 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.7 Hz, 4J3’,5’ = 1.7 Hz, H(5’)], 8.54 [1H, br d‡, 3J3’,4’ =
4.0 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 24.93 [br, C(5)], 28.54 [tBu], 30.91 [C(4)],
36.71 [C(3)], 42.49 [br, C(A)], 44.48 [br, C(6)], 49.89 [br, C(2)], 79.30 [tBu], 121.28 [C(4’)],




Using General Method 4, 77a (241 mg, 0.87 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (8 mL) to give 35a as a yellow oil (129 mg, 84%). HRMS (ESI+)
[M+H]+ calcd. for C11H16N2: 177.1392; found 177.1391. 1H NMR (500 MHz, CDCl3):
δ 1.18-1.31 [1H, m, H(4ax)], 1.67-1.90 [3H, m, H(4eq) + H(5ax) + H(5eq)], 2.32 [1H, ttt,
3J2ax,3ax = 3J3ax,4ax = 11.4 Hz, 3J3ax,A = 7.4 Hz, 3J2eq,3ax = 3J3ax,4eq = 3.8 Hz, H(3ax)], 2.60
[1H, dd, 2J2ax,2eq = 12.0 Hz, 3J2ax,3ax = 11.4 Hz, H(2ax)], 2.70-2.80 [3H, m, H(A) + H(6ax)],
3.20-3.28 [2H, m, H(2eq) + H(6eq)], 4.74 [1H, br s, NH], 7.07-7.17 [2H, m, H(4’) + H(6’)],
7.61 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, 4J3’,5’ = 1.8 Hz, H(6’)], 8.51 [1H, br d‡, 3J3’,4’ =
4.7 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 22.83 [C(5)], 29.35 [C(4)], 34.71 [C(3)],
42.34 [C(A)], 44.65 [C(6)], 49.30 [C(2)], 121.74 [C(6)], 123.59 [C(4’)], 136.70 [C(5’)], 149.54
[C(3’)], 158.68 [C(1’)].
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6.2.5 Synthesis of 2-chloroquinoline derivatives



















The benzylpiperidine derivative (1.0 eq) and 6-bromo-2-chloroquinoline (1.2 eq) were combined
in a thick-walled glass pressure vessel with anhydrous (trifluoromethyl)benzene. To the flask
was added Pd(OAc)2 (0.5 mol %), CataCXium® A ligand (1 mol %) and sodium tert-butoxide
(1.3 eq) and the vessel was purged with N2 gas and sealed. The reaction mixture was heated
at 150°C in a 300W Discover® Microwave System for the time specified, then cooled and
filtered through Celite®, washing with methanol. The solvent was removed under reduced
pressure and the mixture chromatographed on silica gel with the specified eluant.
General Method 10: Synthesis of 6-substituted 2-chloroquinolines via sealed-tube
Buchwald-Hartwig amination52
The benzylpiperidine derivative (1.0 eq) and 6-bromo-2-chloroquinoline (1.2 eq) were combined
in a glass pressure vessel with Pd(OAc)2 (0.5 mol %), CataCXium® A ligand (1 mol %) and
sodium tert-butoxide (1.3 eq). Anhydrous (trifluoromethyl)benzene (2 mL) was added and
the vessel was purged with N2 gas and sealed. The reaction mixture was heated at 110°C
for 16 hr, then cooled and filtered through Celite® washing with methanol. The solvent was








A solution of cinnamoyl chloride (10.0 g, 60.0 mmol) in dichloromethane (20 mL) was added
dropwise to a stirring solution of 4-(dimethylamino)pyridine (0.74 g, 6.0 mmol) and pyridine
(4.8 mL, 60.0 mmol) in dichloromethane at 0°C under a nitrogen atmosphere. The mixture
was stirred for 15 min. A solution of 4-bromoaniline (10.33 g, 60.0mmol) in dichloromethane
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(20 mL) was added dropwise over 15 min and the mixture was stirred for 15 min at 0°C then
30 min at room temperature. The resultant precipitate was collected by vacuum filtration,
washed with dichloromethane, and dried to give 78 as a pale purple solid (9.18 g, 51%). MP:
194-197°C (lit.52 193-195°) HRMS (ESI+) [M+H]+ calcd. for C15H1279BrNO/C15H1281BrNO:
312.0181/304.0160; found 302.0169/304.0151.1H NMR (500 MHz, CDCl3): δ 6.53 [1H, d,






Aluminium trichloride (11.9 g, 89.2 mmol) and 78 (9.0 g, 29.8 mmol) were ground together
with a mortar and pestle until combined. The mixture was transferred to a round-bottom
flask and heated to melting with a heat gun then at 110°C for 1.5 hr. The mixture was
cooled to 0°C and quenched with ice-cold water. The precipitate was collected by vacuum
filtration and washed with water to give a mixture of the desired product 79 and side-product
quinolin-2(1H)-one (179) as a brown-pink solid which was used without further purification
(6.04 g, <91%). Small samples of each product were isolated for characterisation.
6-Bromoquinolin-2(1H)-one (79): HRMS (ESI+) [M+H]+ calcd. for
C9H679BrNO/C9H681BrNO: 223.9711/225.9691; found 223.9706/225.9686. 1H NMR (500
MHz, CDCl3): δ 6.75 [1H, d, 3J3,4 = 9.5 Hz, H(3)], 7.31 [1H, d, 3J7,8 = 8.8 Hz, H(8)], 7.61





Quinolin-2(1H)-one (179): HRMS (ESI+) [M+H]+ calcd. for C9H7NO: 146.0606; found
146.0600. 1H NMR (500 MHz, CDCl3): δ 6.73 [1H, d, 3J3,4 = 9.5 Hz, H(3)], 7.23 [1H, t,
3J5,6 = 3J6,7 = 7.8 Hz, H(6)], 7.45 [1H, d, 3J7,8 = 7.8 Hz, H(8)], 7.52 [1H, t, 3J6,7 = 3J7,8 =
7.8 Hz, H(7)], 7.57 [1H, d, 3J5,6 = 7.8 Hz, H(5)], 7.83 [1H, d, 3J3,4 = 9.5 Hz, H(4)], 12.36





A mixture of 79 and 179 (7.60 g, <33.9 mmol of reagent 79*) was treated with phosphoryl
chloride (32 mL, 0.34 mmol) and heated at reflux for 1 hr. The mixture was cooled to 0°C
and slowly quenched with water. The precipitate was collected by vacuum filtration** and
washed with ice water, then purified by flash column chromatography on silica gel eluting with
4:1 dichloromethane/hexane to give pure 24 as an off-white solid (2.63 g, >32%*). MP: 158-
160°C (lit.131 157-158°C) HRMS (ESI+) [M+H]+ calcd. for C9H579Br35ClN/C9H581Br35ClN:
241.9372/243.9352; found 241.9366/243.9345. 1H NMR (500 MHz, CDCl3): δ 7.42 [1H, d,
3J3,4 = 8.6 Hz, H(3)], 7.81 [1H, dd, 3J7,8 = 9.0 Hz, 4J5,7 = 2.2 Hz, H(7)], 7.90 [1H, d, 3J7,8
= 9.0 Hz, H(8)], 7.99 [1H, d, 4J5,7 = 2.2 Hz, H(5)], 8.03 [1H, d, 3J3,4 = 8.6 Hz, H(4)].
*Reagent 79 was not be purified and mixture contained a large amount of 179. Minimum
yield calculated assuming pure 79 used as reagent.
**Slow crystallisation of the aqueous filtrate over 5 days yielded a crude sample of 24 and
2-chloroquinoline (180) as an off-white solid. HRMS (ESI+) [M+H]+ calcd. for
C9H635ClN/C9H637ClN: 164.0267/166.0238; found 164.0260/166.0232. 1H NMR (500 MHz,
CDCl3): δ 7.37-7.44 [1H, m, H(3) + *H(3)], 7.57 [0.3H, ddd, 3J*5,*6 = 8.1 Hz, 3J*6,*7 = 7.0
Hz, 4J*6,*8 = 1.1 Hz, *H(6)], 7.75 [0.3H, ddd, 3J*7,*8 = 8.5 Hz, 3J*6,*7 = 7.0 Hz, 4J*5,*7 =
1.4 Hz, *H(7)], 7.78-7.85 [1H, m, H(7) + *H(5)], 7.90 [0.7H, d, 3J7,8 = 9.0 Hz, H(8)], 7.99
[0.7H, d, 4J5,7 = 2.2 Hz, H(5)], 8.00-8.05 [1H, m, H(4) + *H(8)], 8.11 [0.3H, d, 3J*3,*4 =
8.6 Hz, *H(4)].






Synthesis method a. Using General Method 9, 31c (43 mg, 0.22 mmol) and 24 (46 mg, 0.19
mmol) were combined in a thick-walled glass pressure vessel with (trifluoromethyl)benzene
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(2 mL) and Pd(OAc)2 (0.2 mg, 0.8 µmol), CataCXium® A ligand (0.8 mg, 2.2 µmol) and
sodium tert-butoxide (22 mg, 0.22 mmol). The vessel was purged with N2 gas and sealed.
The reaction mixture was heated at 150°C in a 300W Discover® Microwave System for 20
min with 5 min ramp time. Work-up followed by column chromatography on silica gel eluting
with 4:1 dichloromethane/hexane gave 82c as a yellow oil (31 mg, 46%). Rf = 0.29 (4:1
dichloromethane/hexane). 1H NMR (500 MHz, CDCl3): δ 1.43 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq =
3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.4 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)],
1.66-1.92 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.35 [3H, s, CH3], 2.56 [2H, d, 3J4’ax,A = 7.1
Hz, H(A)], 2.76 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.4 Hz, 3J(2’/6’)ax,(3’/5’)eq =
2.1 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.4 Hz, H(2’eq) + H(6’eq)],
6.94-7.06 [4H, m, H(5) + H(2”) + H(4”) + H(6”)], 7.19 [1H, t, 3J4”,5” = 3J5”,6” = 7.6 Hz,
H(5”)], 7.25 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.48 [1H, dd, 3J7,8 = 9.4 Hz, 4J5,7 = 2.6 Hz,
H(7)], 7.85 [1H, d, 3J7,8 = 9.4 Hz, H(8)], 7.89 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126
MHz, CDCl3): δ 21.44 [CH3], 31.86 [C(3’) + C(5’)], 37.84 [C(4’)], 43.03 [C(A)], 49.65 [C(2’)
+ C(6’)], 108.74 [C(5)], 122.25 [C(3)], 123.60 [C(7)], 126.15 [*C(4”) or C(5”) or C(6”)],
126.70 [*C(4”) or C(5”) or C(6”)], 128.13 [*C(4”) or C(5”) or C(6”)], 128.15 [C(4a)], 128.99
[C(8)], 129.92 [C(2”)], 137.35 [C(4)], 137.82 [*C(1”) or C(3”)], 140.19 [*C(1”) or C(3”)],
142.87 [C(8a)], 147.15 [C(2)], 150.01 [C(6)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment
of all NMR signals due to overlapped signals in the 1H NMR spectrum.
Synthesis method b. Using General Method 10, 31c (50 mg, 0.26 mmol) and 24 (58 mg,
0.24 mmol) were reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (0.9 mg,
2.5 µmol) and sodium tert-butoxide (28 mg, 0.3 mmol) in (trifluoromethyl)benzene (2 mL).
Work-up as specified and column chromatography on silica gel eluting with dichloromethane




Using General Method 10, 31a (50 mg, 0.22 mmol) and 24 (43 mg, 0.18 mmol) were
reacted with Pd(OAc)2 (0.2 mg, 0.9 µmol), CataCXium® A ligand (0.8 mg, 2.2 µmol) and
sodium tert-butoxide (24 mg, 0.25 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with 1:9 hexane/dichloromethane
gave 82a as a yellow oil (48 mg, 69%). Rf = 0.12 (dichloromethane). HRMS (ESI+) [M+H]+
calcd. for C25H2935ClN2: 393.2098; found 393.2110. 1H NMR (500 MHz, CDCl3): δ 1.32
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[9H, s, tBu], 1.43 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz,
3J(2’/6’)eq,(3’/5’)ax = 3.1 Hz, H(3’ax) + H(5’ax)], 1.68-1.86 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)],
2.57 [2H, d, 3J4’ax,A = 7.0 Hz, H(A)], 2.76 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax =
12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.8 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.2 Hz, H(2’eq) + H(6’eq)], 6.97 [1H, d, 4J5,7 = 2.5 Hz, H(5)], 7.07-7.14 [2H, m, H(2”) +
H(6”)], 7.25 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.29-7.35 [2H, m, H(3”) + H(5”)], 7.48 [1H,
dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.5 Hz, H(7)], 7.84 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.88 [1H, d,
3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.56 [tBu], 31.99 [C(3’) + C(5’)],
34.52 [tBu], 37.89 [C(4’)], 42.67 [C(A)], 49.80 [C(2’) + C(6’)], 108.89 [C(5)], 122.39 [C(3)],
123.74 [C(7)], 125.27 [C(3”) + C(5”)], 128.29 [C(4a)], 128.92 [C(2”) + C(6”)], 129.13





Using General Method 10, 31b (69 mg, 0.36 mmol) and 24 (105 mg, 0.43 mmol) were
reacted with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.3 mg, 3.6 µmol) and
sodium tert-butoxide (46 mg, 0.48 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82a as
a yellow oil (30 mg, 23%). HRMS (ESI+) [M+H]+ calcd. for C22H2335ClN2/C22H2337ClN2:
351.1628/353.1599; found 351.1622/353.1599. 1H NMR (500 MHz, CDCl3): δ 1.49 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4
Hz, H(3’ax) + H(5’ax)], 1.67-1.88 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.33 [3H, s, CH3],
2.61 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 2.76 [2H, t, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax =
12.2 Hz, H(2’ax) + H(6’ax)], 3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)],
6.98 [1H, br s‡, H(5)], 7.07-7.21 [4H, m, H(3”) + H(4”) + H(5”) + H(6”)], 7.23-7.28 [1H,
m, H(3)], 7.49 [1H, br d‡, 3J7,8 = 9.3 Hz, H(7)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90
[1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 19.71 [CH3], 32.15 [C(3’)
+ C(5’)], 36.87 [C(4’)], 40.31 [C(A)], 49.80 [C(2’) + C(6’)], 108.87 [C(5)], 122.36 [C(3)],
123.70 [C(7)], 125.78 [C(5”)], 126.22 [C(4”)], 128.26 [C(4a)], 129.10 [C(8)], 130.12 [C(6”)],






Using General Method 10, 31d (100 mg, 0.53 mmol) and 24 (153 mg, 0.63 mmol) were
reacted with Pd(OAc)2 (0.6 mg, 2.6 µmol), CataCXium® A ligand (1.9 mg, 6.8 µmol) and
sodium tert-butoxide (66 mg, 0.69 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82d as
a yellow oil (132 mg, 71%). Rf = 0.15 (dichloromethane). HRMS (ESI+) [M+H]+ calcd.
for C22H2335ClN2: 351.1628; found 351.1627. 1H NMR (500 MHz, CDCl3): δ 1.43 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.3 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.9 Hz,
H(3’ax) + H(5’ax)], 1.71 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.3 Hz, 3J4’ax,A = 7.4 Hz, 3J(3’/5’)eq,4’ax =
3.9 Hz, H(4’ax)], 1.80 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.3 Hz, H(3’eq) + H(5’eq)], 2.33 [3H, s,
CH3], 2.56 [2H, d, 3J4’ax,A = 7.4 Hz, H(A)], 2.76 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 12.3 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.9 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.3 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.03-7.09 [2H, m, H(2”) +
H(6”)], 7.09-7.15 [2H, m, H(3”) + H(5”)], 7.26 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.48 [1H, dd,
3J7,8 = 9.3 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4
= 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 21.17 [CH3], 31.99 [C(3’) + C(5’)], 38.07
[C(4’)], 42.79 [C(A)], 49.82 [C(2’) + C(6’)], 108.91 [C(5)], 122.41 [C(3)], 123.77 [C(7)],
128.30 [C(4a)], 129.11 [C(3”) + C(5”)], 129.15 [C(8)], 129.16 [C(2”) + C(6”)], 135.59





Using General Method 10, 31e (70 mg, 0.34 mmol) and 24 (99 mg, 0.41 mmol) were
reacted with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.2 mg, 3.3 µmol) and
sodium tert-butoxide (43 mg, 0.45 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82e as
a yellow oil (66 mg, 53%). Rf = 0.12 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C22H2335ClN2O/C22H2337ClN2O: 367.1577/369.1548; found 367.1571/369.1551. 1H NMR
(500 MHz, CDCl3): δ 1.45 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
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= 12.6 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.3 Hz, H(3’ax) + H(5’ax)], 1.73-1.85 [3H, m, H(3’eq) +
H(4’ax) + H(5’eq)], 2.61 [2H, d, 3J4’ax,A = 6.6 Hz, H(A)], 2.77 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.6 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.1 Hz, H(2’ax) + H(6’ax)], 3.79 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.6 Hz, H(2’eq) + H(6’eq)], 3.83 [3H, s, OCH3], 6.85-6.92 [2H, m, H(3”)
+ H(5”)], 6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.11 [1H, dd, 3J5”,6” = 7.3 Hz, 4J4”,6” = 1.7
Hz, H(6”)], 7.21 [1H, td, 3J3”,4” = 3J4”,5” = 7.9 Hz, 4J4”,6” = 1.7 Hz, H(4”)], 7.25 [1H, d,
3J3,4 = 8.6 Hz, H(3)], 7.49 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.84 [1H, d, 3J7,8
= 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.94
[C(3’) + C(5’)], 36.21 [C(A)], 37.13 [C(4’)], 49.66 [C(2’) + C(6’)], 55.27 [OCH3], 108.66
[C(5)], 110.36 [C(3”)], 120.17 [C(5”)], 122.23 [C(3)], 123.60 [C(7)], 127.24 [C(4”)], 128.19
[C(4a)], 128.72 [C(1”)], 128.96 [C(8)], 130.92 [C(6”)], 137.35 [C(4)], 142.83 [C(8a)], 147.08





Using General Method 10, 31f (96 mg, 0.47 mmol) and 24 (102 mg, 0.42 mmol) were
reacted with Pd(OAc)2 (0.5 mg, 2.2 µmol), CataCXium® A ligand (1.5 mg, 4.2 µmol) and
sodium tert-butoxide (49 mg, 0.51 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82f as
a yellow oil (107 mg, 68%). Rf = 0.08 (dichloromethane). HRMS (ESI+) [M+H]+ calcd.
for C22H2335ClN2O: 367.1577; found 367.1578. 1H NMR (500 MHz, CDCl3): δ 1.43 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.4 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.9
Hz, H(3’ax) + H(5’ax)], 1.66-1.90 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.57 [2H, d, 3J4’ax,A =
7.0 Hz, H(A)], 2.76 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.4 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 1.4 Hz, H(2’ax) + H(6’ax)], 3.74-3.87 [5H, m, H(2’eq) + H(6’eq) + OCH3], 6.68-6.83 [3H,
m, H(2”) + H(4”) + H(6”)], 6.97 [1H, d, 4J5,7 = 2.3 Hz, H(5)], 7.17-7.28 [2H, m, H(3) +
H(5”)], 7.47 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.3 Hz, H(7)], 7.84 [1H, d, 3J7,8 = 9.3 Hz, H(8)],
7.89 [1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.84 [C(3’) + C(5’)],
37.75 [C(4’)], 43.11 [C(A)], 49.63 [C(2’) + C(6’)], 55.15 [OCH3], 108.78 [C(5)], 111.01
[*C(4”)], 115.06 [*C(2”)], 121.58 [*C(6”)], 122.25 [C(3)], 123.60 [C(7)], 128.14 [C(4a)],
128.99 [C(8)], 129.21 [C(5”)], 137.35 [C(4)], 141.89 [C(1”)], 142.87 [C(8a)], 147.16 [C(2)],
149.98 [C(6)], 159.58 [C(3”)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment






Using General Method 10, 31g (50 mg, 0.24 mmol) and 24 (70 mg, 0.29 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (0.9 mg, 2.5 µmol) and
sodium tert-butoxide (30 mg, 0.31 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82g as
a yellow oil (50 mg, 56%). Rf = 0.20 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C22H2335ClN2O/C22H2337ClN2O: 367.1577/369.1548; found 367.1571/369.1552. 1H NMR
(500 MHz, CDCl3): δ 1.42 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax =
12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.9 Hz, H(3’ax) + H(5’ax)], 1.63-1.75 [1H, m, H(4’)], 1.79 [2H, br
d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.5 Hz, H(3’eq) + H(5’eq)], 2.54 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 2.76
[2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.5 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.9 Hz, H(2’ax) +
H(6’ax)], 3.77-3.83 [5H, m, H(2’eq) + H(6’eq) + OCH3], 6.82-6.88 [2H, m, H(3”) + H(5”)],
6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.06-7.12 [2H, m, H(2”) + H(6”)], 7.26 [1H, d, 3J3,4 =
8.6 Hz, H(3)], 7.48 [1H, dd, 3J7,8 = 9.4 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.85 [1H, d, 3J7,8 = 9.4
Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.79 [C(3’)
+ C(5’)], 38.02 [C(4’)], 42.16 [C(A)], 49.67 [C(2’) + C(6’)], 55.26 [OCH3], 108.77 [C(5)],
113.68 [C(3”) + C(5”)], 122.27 [C(3)], 123.63 [C(7)], 128.16 [C(4a)], 129.00 [C(8)], 130.00






Using General Method 10, 31h (56 mg, 0.29 mmol) and 24 (69 mg, 0.28 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (1.0 mg, 2.8 µmol) and
sodium tert-butoxide (33 mg, 0.34 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave crude
82h as a yellow oil which was used without further purification (67 mg, *70%). Rf =
0.17 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for C21H2035ClFN2/C21H2037ClFN2:
355.1377/357.1348; found 355.1375/357.1352. 1H NMR (500 MHz, CDCl3): δ 1.47 [2H, qd,
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2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 2.9 Hz,
H(3’ax) + H(5’ax)], 1.73-1.84 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.65 [2H, d, 3J4’ax,A = 6.5
Hz, H(A)], 2.77 [2H, br t‡, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.5 Hz, H(2’ax) + H(6’ax)],
3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.5 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.5 Hz,
H(5)], 7.00-7.11 [2H, m, H(3”) + H(5”)], 7.14-7.23 [2H, m, H(4”) + H(6”)], 7.26 [1H, d,
3J3,4 = 8.6 Hz, H(3)], 7.48 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.5 Hz, H(7)], 7.85 [1H, d, 3J7,8
= 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.6 Hz, H(4)].






Using General Method 10, 31i (162 mg, 0.84 mmol) and 24 (222 mg, 0.92 mmol) were reacted
with Pd(OAc)2 (0.9 mg, 4.0 µmol), CataCXium® A ligand (3.0 mg, 8.4 µmol) and sodium
tert-butoxide (105 mg, 1.09 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 82i as a yellow
oil (168 mg, 56%). Rf = 0.15 (dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.44 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 4.0
Hz, H(3’ax) + H(5’ax)], 1.69-1.83 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.60 [2H, d, 3J4’ax,A =
7.0 Hz, H(A)], 2.77 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.5 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 2.4 Hz, H(2’ax) + H(6’ax)], 3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.5 Hz, H(2’eq) + H(6’eq)],
6.86-6.97 [3H, m, H(2”) + H(4”) + H(6”)], 6.99 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.23-7.29
[2H, m, H(3) + H(5”)], 7.48 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.85 [1H, d, 3J7,8
= 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.90
[C(3’) + C(5’)], 37.84 [C(4’)], 42.94 [d, 4JC,F = 1.9 Hz, C(A)], 49.77 [C(2’) + C(6’)], 109.00
[C(5)], 113.04 [d, 2JC,F = 21.0 Hz, C(4”)], 116.00 [d, 2JC,F = 20.5 Hz, C(2”)], 122.45 [C(3)],
123.77 [C(7)], 124.92 [d, 4JC,F = 2.9 Hz, C(6”)], 128.29 [C(4a)], 129.18 [C(8)], 129.81 [d,
3JC,F = 8.6 Hz, C(5”)], 137.52 [C(4)], 142.96 [d, 3JC,F = 7.2 Hz, C(1”)], 143.07 [C(8a)],






Using General Method 10, 31j (120 mg, 0.62 mmol) and 24 (180 mg, 0.74 mmol) were reacted
with Pd(OAc)2 (0.7 mg, 3.1 µmol), CataCXium® A ligand (2.2 mg, 6.1 µmol) and sodium
tert-butoxide (78 mg, 0.81 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with 1:4 hexane/dichloromethane gave 82j as
a yellow oil (99 mg, 45%). Rf = 0.58 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C21H2035ClFN2/C21H2037ClFN2: 355.1377/357.1348; found 355.1372/357.1350. 1H NMR
(500 MHz, CDCl3): δ 1.41 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz, H(3’ax) + H(5’ax)], 1.63-1.84 [3H, m, H(3’eq) +
H(4’ax) + H(5’eq)], 2.56 [2H, d, 3J4’ax,A = 7.1 Hz, C(A)], 2.75 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.1 Hz, H(2’ax) + H(6’ax)], 3.79 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)], 6.95-7.02 [3H, m, H(5) + H(2”) + H(6”)],
7.08-7.15 [2H, m, H(3”) + H(5”)], 7.24 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.47 [1H, dd, 3J7,8 =
9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.84 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.88 [1H, d, 3J3,4 = 8.6
Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.83 [C(3’) + C(5’)], 38.02 [C(4’)], 42.33 [br‡,
C(A)], 49.72 [C(2’) + C(6’)], 108.93 [C(5)], 115.14 [d, 2JC,F = 21.0 Hz, C(3”) + C(5”)],
122.39 [C(3)], 123.72 [C(7)], 128.26 [C(4a)], 129.11 [C(8)], 130.51 [d, 3JC,F = 7.6 Hz, C(2”)
+ C(6”)], 135.93 [d, 4JC,F = 3.3 Hz, C(1”)], 137.48 [C(4)], 143.01 [C(8a)], 147.31 [C(2)],





Using General Method 10, 31n (178 mg, 0.73 mmol) and 24 (194 mg, 0.80 mmol) were
reacted with Pd(OAc)2 (0.8 mg, 3.6 µmol), CataCXium® A ligand (2.6 mg, 7.3 µmol) and
sodium tert-butoxide (91 mg, 0.95 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82n as
a yellow oil (96 mg, 32%). Rf = 0.33 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C22H2035ClF3N2/C22H2037ClF3N2: 405.1345/407.1316; found 405.1340/407.1319. 1H NMR
(500 MHz, CDCl3): δ 1.50 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax =
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12.6 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz, H(3’ax) + H(5’ax)], 1.75-1.88 [3H, m, H(4’) + H(3’eq)
+ H(5’eq)], 2.71-2.82 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.82 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq
= 12.6 Hz, H(2’eq) + H(6’eq)], 6.99 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.26 [1H, d, 3J3,4 = 8.6
Hz, H(3)], 7.29-7.36 [2H, m, H(4’) + H(6’)], 7.45-7.52 [2H, m, H(7) + H(5’)], 7.66 [1H,
d, 3J3’,4’ = 7.6 Hz, H(3’)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.6 Hz,
H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.93 [C(3’) + C(5’)], 37.49 [q, 4JC,F = 0.8 Hz,
C(4’)], 39.37 [q, 4JC,F = 1.4 Hz, C(A)], 49.70 [C(2’) + C(6’)], 108.86 [C(5)], 122.29 [C(3)],
123.64 [C(7)], 124.63 [q, 1JC,F = 273.8 Hz, CF3], 126.19 [C(6”)], 126.23 [q, 3JC,F = 5.7 Hz,
C(3”)], 128.14 [C(4a)], 128.89 [q, 2JC,F = 29.3 Hz, C(2”)], 129.03 [C(8)], 131.41 [q, 4JC,F
= 0.8 Hz, C(4”)], 131.74 [C(5”)],137.39 [C(4)], 138.90 [q, 3JC,F = 1.8 Hz, C(1”)], 142.93





Using General Method 10, 31o (58 mg, 0.24 mmol) and 24 (69 mg, 0.29 mmol) were reacted
with Pd(OAc)2 (0.3 mg, 1.2 µmol), CataCXium® A ligand (0.9 mg, 2.4 µmol) and sodium
tert-butoxide (30 mg, 0.31 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 82o as a yellow
oil (49 mg, 51%). HRMS (ESI+) [M+H]+ calcd. for C22H2035ClF3N2/C22H2037ClF3N2:
405.1345/407.1316; found 405.1341/407.1321. 1H NMR (500 MHz, CDCl3): δ 1.46 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.1
Hz, H(3’ax) + H(5’ax)], 1.70-1.84 [3H, m, H(4’) + H(3’eq) + H(5’eq)], 2.67 [2H, d, 3J4’ax,A =
6.7 Hz, H(A)], 2.78 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.0 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 1.8 Hz, H(2’ax) + H(6’ax)], 3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)],
6.99 [1H, d, 4J5,7 = 2.5 Hz, H(5)], 7.26 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.36 [1H, br d‡, 3J5”,6”
= 7.6 Hz, H(6”)], 7.38-7.45 [2H, m, H(2”) + H(5”)], 7.45-7.52 [2H, m, H(7) + H(4”)],
7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz,
CDCl3): δ 31.85 [C(3’) + C(5’)], 37.89 [C(4’)], 43.00 [C(A)], 49.73 [C(2’) + C(6’)], 109.03
[C(5)], 122.45 [C(3)], 123.10 [q, 3JC,F = 3.9 Hz, C(4”)], 123.76 [C(7)], 124.38 [q, 1JC,F =
272.3 Hz, CF3], 125.83 [q, 3JC,F = 3.8 Hz, C(2”)], 128.28 [C(4a)], 128.85 [C(5”)], 129.20
[C(8)], 130.81 [q, 2JC,F = 32.0 Hz, C(3”)], 132.66 [br‡, C(6”)], 137.52 [C(4)], 141.25 [C(1”)],






Using General Method 10, 31p (131 mg, 0.54 mmol) and 24 (157 mg, 0.65 mmol) were
reacted with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A ligand (1.9 mg, 5.3 µmol) and
sodium tert-butoxide (67 mg, 0.70 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 82p as a
yellow oil (136 mg, 62%). Rf = 0.22 (dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.45
[2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.3 Hz, 3J(2’/6’)eq,(3’/5’)ax =
2.7 Hz, H(3’ax) + H(5’ax)], 1.70-1.83 [3H, m, H(4’) + H(3’eq) + H(5’eq)], 2.66 [2H, d, 3J4’ax,A =
6.7 Hz, H(A)], 2.76 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.3 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 1.8 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.3 Hz, H(2’eq) + H(6’eq)],
6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.25 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.26-7.31 [2H, m,
H(2”) + H(6”)], 7.47 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.53-7.58 [2H, m,
H(3”) + H(5”)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 31.87 [C(3’) + C(5’)], 37.82 [C(4’)], 42.99 [C(A)], 49.71 [C(2’)
+ C(6’)], 109.01 [C(5)], 122.43 [C(3)], 123.74 [C(7)], 124.47 [q, 1JC,F = 271.9 Hz, CF3],
125.35 [q, 3JC,F = 3.8 Hz, C(3’) + C(5’)], 128.26 [C(4a)], 128.55 [q, 2JC,F = 32.3 Hz, C(4’)],
129.17 [C(8)], 129.52 [C(2’) + C(6’)], 137.51 [C(4)], 143.07 [C(8a)], 144.49 [q, 5JC,F = 1.4




Synthesis method a. Using General Method 10, 4-benzylpiperidine (100 mg, 0.57 mmol) and
24 (137 mg, 0.56 mmol) were reacted with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A
ligand (2.0 mg, 5.6 µmol) and sodium tert-butoxide (66 mg, 0.69 mmol) in (trifluoromethyl)-
benzene (2 mL). Work-up as specified and column chromatography on silica gel eluting with
dichloromethane gave 82x as a yellow solid (143 mg, 75%). Rf = 0.17 (dichloromethane). 1H
NMR (500 MHz, CDCl3): δ 1.45 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.4 Hz, 3J(2’/6’)eq,(3’/5’)ax = 4.0 Hz, H(3’ax) + H(5’ax)], 1.68-1.85 [3H, m, H(3’ eq) +
H(4’ ax) + H(5’eq)], 2.60 [2H, d, 3J4’ax,A = 7.0 Hz, H(A)], 2.77 [2H, td, 2J(2’/6’)ax,(2’/6’)eq =
3J(2’/6’)ax,(3’/5’)ax = 12.4 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.1 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡,
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2J(2’/6’)ax,(2’/6’)eq = 12.4 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.13-7.19
[2H, m, H(2”) + H(6”)], 7.22 [1H, br t‡, 3J3”,4” = 3J4”,5” = 7.3 Hz, H(4”)], 7.26 [1H, d,
3J3,4 = 8.6 Hz, H(3)], 7.27-7.34 [2H, m, H(3”) + H(5”)], 7.48 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7
= 2.6 Hz, H(7)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4 = 8.6 Hz, H(4)].
This data is consistent with that reported in literature.52
Synthesis method b. 4-Benzylpiperidine (9.0 mg, 0.05 mmol) and 24 (15 mg, 0.06 mmol)
were combined in a glass pressure tube with CataCXium® A ligand (0.2 mg, 0.5 µmol) and
sodium tert-butoxide (6.4 mg, 0.07 mmol). (Trifluoromethyl)benzene (1.5 mL) was added
and the vessel was purged with N2 gas and sealed. The reaction mixture was heated at 110°C
for 16 hr, then cooled and filtered through Celite® washing with methanol. The solvent was
removed under reduced pressure and the mixture chromatographed on silica gel eluting with




2-(4-Benzylpiperidin-1-yl)-6-bromoquinoline (89x): Rf = 0.44 (dichloromethane). HRMS
(ESI+) [M+H]+ calcd. for C21H2179BrN2/C21H2181BrN2: 381.0966/383.0946; found
381.0964/383.0946. 1H NMR (500 MHz, CDCl3): δ 1.31 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq =
3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.7 Hz, H(3’ax) + H(5’ax)],
1.73-1.89 [3H, m, H(3’ eq) + H(4’ ax) + H(5’eq)], 2.57 [2H, d, 3J4’ax,A = 7.4 Hz, H(A)], 2.89
[2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.9 Hz, H(2’ax)
+ H(6’ax)], 4.52 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)], 6.97 [1H, d, 3J3,4
= 9.2 Hz, H(3)], 7.14-7.18 [2H, m, H(2”) + H(6”)], 7.21 [1H, t, 3J3”,4” = 3J4”,5” = 7.5 Hz,
H(4”)], 7.26-7.32 [2H, m, H(3”) + H(5”)], 7.52 [1H, d, 3J7,8 = 8.9 Hz, H(8)], 7.55 [1H, dd,
3J7,8 = 8.9 Hz, 4J5,7 = 1.9 Hz, H(7)], 7.69 [1H, d, 4J5,7 = 1.9 Hz, H(5)], 7.74 [1H, d, 3J3,4
= 9.2 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 32.14 [C(3’) + C(5’)], 38.63 [C(4’)], 43.36
[C(A)], 45.63 [C(2’) + C(6’)], 110.70 [C(3)], 114.82 [C(6)], 124.10 [C(4a)], 126.12 [C(4”)],
128.39 [C(8)], 128.42 [C(3”) + C(5”)], 129.25 [C(5)], 129.30 [C(2”) + C(6”)], 132.64 [C(7)],
136.39 [C(4)], 140.45 [C(1”)], 147.00 [C(8a)], 157.56 [C(2)].
Synthesis method c. 4-Benzylpiperidine (50 mg, 0.29 mmol) and 24 (83 mg, 0.34 mmol)
were combined in a glass pressure tube with Pd(OAc)2 (0.3 mg, 1.4 µmol), CataCXium® A
ligand (1.0 mg, 2.9 µmol) and sodium tert-butoxide (36 mg, 0.37 mmol). 1,4-Dioxane (2
mL) was added and the vessel was purged with N2 gas and sealed. The reaction mixture was
heated at 100°C for 16 hr, then cooled and filtered through Celite® washing with methanol.
The solvent was removed under reduced pressure to give a crude residue which could not be
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purified. 1H NMR analysis indicated that the mixture contained a 5:1 ratio of 82x and 27x,
when compared to data above.
Synthesis method d. 4-Benzylpiperidine (50 mg, 0.29 mmol) and 24 (83 mg, 0.34 mmol)
were combined in a glass pressure tube with Pd(OAc)2 (0.3 mg, 1.4 µmol), JohnPhos ligand
(0.9 mg, 2.9 µmol) and sodium tert-butoxide (36 mg, 0.37 mmol). 1,4-Dioxane (2 mL) was
added and the vessel was purged with N2 gas and sealed. The reaction mixture was heated at
100°C for 16 hr, then cooled and filtered through Celite® washing with methanol. The solvent
was removed under reduced pressure to give a crude residue which was not purified. 1H NMR
analysis determined that the mixture contained a 2:3 ratio of 82x and 27x, compared to data
above.
Synthesis method e. 4-Benzylpiperidine (50 mg, 0.29 mmol) and 24 (83 mg, 0.34 mmol) were
combined in a glass pressure tube with Pd(OAc)2 (0.3 mg, 1.4 µmol), CyJohnPhos ligand
(1.0 mg, 2.9 µmol) and sodium tert-butoxide (36 mg, 0.37 mmol). 1,4-Dioxane (2 mL) was
added and the vessel was purged with N2 gas and sealed. The reaction mixture was heated at
100°C for 16 hr, then cooled and filtered through Celite® washing with methanol. The solvent
was removed under reduced pressure to give a crude residue which was not purified. 1H NMR





Using General Method 10, 32c (100 mg, 0.53 mmol) and 24 (153 mg, 0.63 mmol) were
reacted with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A ligand (1.9 mg, 5.3 µmol) and
sodium tert-butoxide (66 mg, 0.69 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with 4:1 dichloromethane/hexane
gave 83c as a yellow oil (78 mg, 42%). Rf = 0.60 (dichloromethane). 1H NMR (500 MHz,
CDCl3): δ 1.22 [1H, qd, 3J3’ax,4’ax = 2J4’ax,4’eq = 3J4’ax,5’ax = 13.8 Hz, 3J4’ax,5’eq = 5.9 Hz,
H(4’ax)], 1.63-1.75 [1H, m, H(5’ax)], 1.80-1.91 [2H, m, H(4’eq) + H(5’eq)], 1.97-2.08 [1H, m,
H(3’ax)], 2.36 [3H, s, CH3], 2.55-2.67 [3H, m, H(2’ax) + H(A)], 2.87 [1H, td, 3J5’ax,6’ax =
2J6’ax,6’eq = 11.9 Hz, 3J5’eq,6’ax = 2.6 Hz, H(6’ax)], 3.67 [1H, br d‡, 2J2’ax,2’eq = 12.2 Hz,
H(2’eq)], 3.72 [1H, br d‡, 2J6’ax,6’eq = 12.4 Hz, H(6’eq)], 6.92 [1H, d, 4J5,7 = 2.6 Hz, H(5)],
7.01 [1H, d, 3J4”,5” = 7.6 Hz, H(4”)], 7.03 [1H, s, H(2”)], 7.06 [1H, d, 3J5”,6” = 7.6 Hz,
H(6”)], 7.22 [1H, t, 3J4”,5” = 3J5”,6” = 7.5 Hz, H(5”)], 7.26 [1H, d, 3J3,4 = 8.6 Hz, H(3)],
7.42 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.83 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.87
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[1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 21.44 [CH3], 24.82 [C(5’)],
36.73 [C(4’)], 37.44 [C(3’)], 40.52 [C(A)], 50.03 [C(6’)], 55.37 [C(2’)], 108.65 [C(5)], 122.23
[C(3)], 123.53 [C(7)], 126.04 [C(4”)], 126.84 [C(6”)], 128.16 [C(4a)], 128.25 [C(5”)], 128.96






Using General Method 10, 32f (60 mg, 0.29 mmol) and 24 (85 mg, 0.35 mmol) were reacted
with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (1.0 mg, 2.8 µmol) and sodium
tert-butoxide (37 mg, 0.39 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with 4:1 dichloromethane/hexane yielded





6-Bromo-2-(3-(3-methoxybenzyl)piperidin-1-yl)quinoline (87f): Rf = 0.43 (dichloromethane).
HRMS (ESI+) [M+H]+ calcd. for C22H2379BrN2O/C22H2381BrN2O: 411.1072/413.1052;
found 411.1066/413.1048. 1H NMR (500 MHz, CDCl3): δ 1.28 [1H, br qd‡, 2J4’ax,4’eq =
3J3’ax,4’ax = 3J4’ax,5’ax = 12.0 Hz, 3J4’ax,5’eq = 3.9 Hz, H(4’ax)], 1.55 [1H, qt, 2J5’ax,5’eq =
3J4’ax,5’ax = 3J5’ax,6’ax = 12.0 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 3.9 Hz, H(5’ax)], 1.74-1.97 [3H, m,
H(3’ax) + H(4’eq) + H(5’eq)], 2.54 and 2.66 [2H, ABX, A:dd, B:dd, 2JA,A’(JAB) = 13.6 Hz,
3JA,3’ax(JAX ) = 7.5 Hz, 3JA’,3’ax(JBX ) = 7.1 Hz, H(A) + H(A’)], 2.77 [1H, dd, 2J2’ax,2’eq =
13.0 Hz, 3J2’ax,3’ax = 10.2 Hz, H(2’ax)], 3.05 [1H, ddd, 2J6’ax,6’eq = 13.1 Hz, 3J5’ax,6’ax = 12.0
Hz, 3J5’eq,6’ax = 3.0 Hz, H(6’ax)], 3.80 [3H, s, OCH3], 4.29-4.42 [2H m, H(2’eq) + H(6’eq)],
6.73-6.82 [3H, m, H(2”) + H(4”) + H(6”)], 6.87 [1H, d, 3J3,4 = 9.2 Hz, H(3)], 7.23 [1H, t,
3J4’,5’ = 3J5’,6’ = 7.8 Hz, H(5”)], 7.51 and 7.55 [2H, ABX, A:d, B:dd, 3J7,8(JAB) = 8.9 Hz,
4J5,7(JBX ) = 2.1 Hz, H(8) + H(7)], 7.68 [1H, d, 4J5,7 = 2.1 Hz, H(5)], 7.71 [1H, d, 3J3,4 = 9.2
Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 25.07 [C(5’)], 31.25 [C(4’)], 37.67 [C(3’)], 40.60
[C(A)], 46.05 [C(6’)], 51.29 [C(2’)], 55.31 [OCH3], 110.65 [C(3)], 111.45 [C(4”)], 114.77
[C(6)], 114.96 [C(2”)], 121.64 [C(6”)], 124.06 [C(4a)], 128.37 [C(8)], 129.22 [C(5)], 129.41
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Using General Method 10, 32h (20 mg, 0.10 mmol) and 24 (30 mg, 0.13 mmol) were reacted
with Pd(OAc)2 (0.1 mg, 0.5 µmol), CataCXium® A ligand (0.4 mg, 1.0 µmol) and sodium
tert-butoxide (13 mg, 0.14 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 83h as a yellow
oil (16 mg, 54%). Rf = 0.29 (dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.23 [1H,
qd, 3J3’ax,4’ax = 2J4’ax,4’eq = 3J4’ax,5’ax = 12.0 Hz, 3J4’ax,5’eq = 4.0 Hz, H(4’ax)], 1.68 [1H,
qt, 3J4’ax,5’ax = 2J5’ax,5’eq = 3J5’ax,6’ax = 12.0 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 4.0 Hz, H(5’ax)],
1.79-1.91 [2H, m, H(4’eq) + H(5’eq)], 2.05 [1H, ttt, 3J2’ax,3’ax = 3J3’ax,4’ax = 12.0 Hz, 3JA,3’ax
= 3JA’,3’ax = 7.8 Hz, 3J2’eq,3’ax = 3J3’ax,4’eq = 4.0 Hz, H(3’ax)], 2.58-2.74 [3H, m, H(2’ax) +
H(A) + H(A’)], 2.84 [1H, td, 3J5’ax,6’ax = 2J6’ax,6’eq = 12.0 Hz, 3J5’eq,6’ax = 2.9 Hz, H(6’ax)],
3.63-3.75 [2H, m, H(2’eq) + H(6’eq)], 6.93 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.02-7.13 [2H, m,
H(3”) + H(5”)], 7.16-7.28 [3H, m, H(3) + H(4”) + H(6”)], 7.42 [1H, dd, 3J7,8 = 9.3 Hz,
4J5,7 = 2.7 Hz, H(7)], 7.83 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.87 [1H, d, 3J3,4 = 8.6 Hz, H(4)].
13C NMR (126 MHz, CDCl3): δ 24.99 [C(5’)], 30.68 [C(4’)], 33.68 [d, 3JC,F = 1.9 Hz, C(A)],
36.78 [C(3’)], 50.24 [C(6’)], 55.49 [C(2’)], 108.94 [C(5)], 115.50 [d, 2JC,F = 22.9 Hz, C(3”)],
122.40 [C(3)], 123.78 [C(7)], 124.09 [d, 4JC,F = 3.3 Hz, C(5”)], 127.01 [d, 2JC,F = 16.2 Hz,
C(1”)], 128.07 [d, 3JC,F = 8.1 Hz, C(4”)], 128.28 [C(4a)], 129.15 [C(8)], 131.48 [d, 3JC,F =
5.2 Hz, C(6”)], 137.51 [C(4)], 143.01 [C(8a)], 147.31 [C(2)], 150.19 [C(6)], 161.42 [d, 1JC,F





Using General Method 10, 32j (181 mg, 0.94 mmol) and 24 (274 mg, 1.13 mmol) were
reacted with Pd(OAc)2 (1.1 mg, 4.7 µmol), CataCXium® A ligand (3.4 mg, 9.4 µmol) and
sodium tert-butoxide (117 mg, 1.22 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 83j
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as a yellow oil (120 mg, 36%). 1H NMR (500 MHz, CDCl3): δ 1.13-1.27 [1H, m, H(4’ax)],
1.63-1.74 [1H, m, H(5’ax)], 1.79-1.90 [2H, m, H(4’eq) + H(5’eq)], 1.98 [1H, ttt, 3J2’ax,3’ax =
3J3’ax,4’ax = 12.0 Hz, 3JA,3’ax = 3JA’,3’ax = 7.8 Hz, 3J2’eq,3’ax = 3J3’ax,4’eq = 3.8 Hz, H(3’ax)],
2.53-2.66 [3H, m, H(2’ax) + H(A) + H(A’)], 2.85 [1H, td, 3J5’ax,6’ax = 2J6’ax,6’eq = 12.0 Hz,
3J5’eq,6’ax = 2.5 Hz, H(6’ax)], 3.64 [1H, dd, 2J6’ax,6’eq = 12.0 Hz, 3J5’ax,6’eq = 2.1 Hz, H(6’eq)],
3.70 [1H, br d‡, 2J2’ax,2’eq = 12.0 Hz, H(2’eq)], 6.91 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 6.97-7.04
[2H, m, H(3”) + H(5”)], 7.11-7.17 [2H, m, H(2”) + H(6”)], 7.25 [1H, d, 3J3,4 = 8.6 Hz,
H(3)], 7.40 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.83 [1H, d, 3J7,8 = 9.3 Hz,
H(8)], 7.87 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 24.95 [C(5’)],
30.70 [C(4’)], 37.79 [C(A)], 39.91 [C(3’)], 50.21 [C(6’)], 55.47 [C(2’)], 108.90 [C(5)], 115.31
[d, 2JC,F = 21.0 Hz, C(3”) + C(5”)], 122.43 [C(3)], 123.71 [C(7)], 128.28 [C(4a)], 129.17
[C(8)], 130.44 [d, 3JC,F = 7.6 Hz, C(2”) + C(6”)], 135.70 [d, 4JC,F = 3.3 Hz, C(1”)], 137.48




Using General Method 10, 32x (171 mg, 0.98 mmol) and 24 (284 mg, 1.17 mmol) were
reacted with Pd(OAc)2 (1.1 mg, 4.9 µmol), CataCXium® A ligand (3.5 mg, 9.8 µmol) and
sodium tert-butoxide (122 mg, 1.27 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with 1:9 hexane/dichloromethane
gave 83x as a yellow oil (104 mg, 32%). Rf = 0.20 (dichloromethane). HRMS (ESI+)
[M+H]+ calcd. for C21H2135ClN2/C21H2137ClN2: 337.1472/339.1442; found
337.1465/339.1445. 1H NMR (500 MHz, CDCl3): δ 1.21 [1H, qd, 3J3’ax,4’ax = 2J4’ax,4’eq
= 3J4’ax,5’ax = 12.2 Hz, 3J4’ax,5’eq = 4.9 Hz, H(4’ax)], 1.68 [1H, qt, 3J4’ax,5’ax = 2J5’ax,5’eq =
3J5’ax,6’ax = 12.2 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 3.8 Hz, H(5’ax)], 1.78-1.90 [2H, m, H(4’eq) +
H(5’eq)], 1.96-2.08 [1H, m, H(3’ax)], 2.56-2.68 [3H, m, H(2’ax) + H(A) + H(A’)], 2.85 [1H, td,
3J5’ax,6’ax = 2J6’ax,6’eq = 12.2 Hz, 3J5’eq,6’ax = 2.3 Hz, H(6’ax)], 3.66 [1H, dd, 2J2’ax,2’eq = 12.1
Hz, 3J2’eq,3’ax = 1.5 Hz, H(2’eq)], 3.71 [1H, dt, 2J6’ax,6’eq = 12.2 Hz, 4J4’eq,6’eq = 3J5’ax,6’eq
= 3.8 Hz, H(6’eq)], 6.90 [1H, d, 4J5,7 = 2.3 Hz, H(5)], 7.16-7.28 [4H, m, H(2”) + H(3) +
H(4”) + H(6”)], 7.28-7.36 [2H, m, H(3”) + H(5”)], 7.41 [1H, dd, 3J7,8 = 9.4 Hz, 4J5,7 =
2.3 Hz, H(7)], 7.82 [1H, d, 3J7,8 = 9.4 Hz, H(8)], 7.86 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 25.00 [C(5’)], 30.85 [C(4’)], 37.67 [C(3’)], 40.79 [C(A)], 39.91
[C(3’)], 50.21 [C(6’)], 55.53 [C(2’)], 108.84 [C(5)], 122.39 [C(3)], 123.70 [C(7)], 126.27
[C(4”)], 128.30 [C(4a)], 128.54 [C(3”) + C(5”)], 129.14 [C(8)], 129.17 [C(2”) + C(6”)],





Using General Method 10, 33h (12 mg, 70.0 µmol) and 24 (19 mg, 78.4 µmol) were reacted
with Pd(OAc)2 (0.1 mg, 0.4 µmol), CataCXium® A ligand (0.3 mg, 0.8 µmol) and sodium
tert-butoxide (8.0 mg, 0.083 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 84h as a yellow
oil (10 mg, 44%). Rf = 0.30 (dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.84 [1H,
dq, 2J4’a,4’b = 12.2 Hz, 3J3’,4’a = 3J4’a,5’a = 8.0 Hz, H(4’a)], 2.17 [1H, dtd, 2J4’a,4’b = 12.2
Hz, 3J3’,4’b = 3J4’b,5’a = 8.0 Hz, 3J4’b,5’b = 4.1 Hz, H(4’b)], 2.70 [1H, septet, 3J2’a,3’ = 3J2’b,3’
= 3J3’,A = 3J3’,A’ = 3J3’,4’a = 3J3’,4’b = 8.0 Hz, H(3’)], 2.83 and 2.85 [2H, ABX, A:dd, B:dd,
2JA,A’(JAB) = 13.9 Hz, 3JA,3’ax(JAX ) = 8.0 Hz, 3JA’,3’ax(JBX ) = 8.0 Hz, H(A) + H(A’)], 3.14
[1H, dd, 2J2’a,2’b = 8.8 Hz, 3J2’a,3’ = 8.0 Hz, H(2’a)], 3.40 [1H, q, 2J5’a,5’b = 3J4’a,5’a = 3J4’b,5’a
= 8.0 Hz, H(5’a)], 3.46-3.56 [2H, m, H(2’b) + H(5’b)], 6.58 [1H, d, 4J5,7 = 2.5 Hz, H(5)],
7.06 [1H, dd, 3J3”,F = 9.6 Hz, 3J3”,4” = 8.8 Hz, H(3”)], 7.10 [1H, t, 3J4”,5” = 3J5”,6” = 7.5
Hz, H(5”)], 7.15 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.5 Hz, H(7)], 7.18-7.28 [3H, m, H(3) +
H(4”) + H(6”)], 7.83 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.83 [1H, d, 3J3,4 = 8.5 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 31.47 [C(4’)], 32.89 [C(A)], 39.63 [C(3’)], 47.61 [C(5’)], 53.26
[C(2’)], 103.43 [C(5)], 115.59 [d, 2JC,F = 22.3 Hz, C(3”)], 119.46 [C(7)], 122.41 [C(3)],
124.24 [d, 4JC,F = 3.5 Hz, C(5”)], 126.11 [d, 2JC,F = 14.6 Hz, C(1”)], 128.24 [d, 3JC,F = 8.2
Hz, C(4”)], 128.82 [C(4a)], 129.35 [C(8)], 131.17 [d, 3JC,F = 4.8 Hz, C(6”)], 136.73 [C(4)],




Using General Method 10, 33x (42 mg, 0.26 mmol) and 24 (76 mg, 0.32 mmol) were reacted
with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (0.9 mg, 2.5 µmol) and sodium
tert-butoxide (33 mg, 0.34 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 84x as a yellow
oil (45 mg, 54%). Rf = 0.34 (dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.81 [1H,
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dq, 2J4’a,4’b = 12.3 Hz, 3J3’,4’a = 3J4’a,5’a = 3J4’a,5’b = 8.4 Hz, H(4’a)], 2.13-2.21 [1H, m,
H(4’b)], 2.66 [1H, pdd, 3J3’,4’a = 3J3’,4’b = 3J3’,4’a = 3J3’,4’b = 8.4 Hz, 3JA,3’ = 7.7 Hz, 3JA’,3’
= 7.3 Hz, H(3’)], 2.78 and 2.80 [2H, ABX, A:dd, B:dd, 2JA,A’(JAB) = 13.5 Hz, 3JA,3’(JAX )
= 7.7 Hz, 3JA’,3’(JBX ) = 7.3 Hz, H(A) + H(A’)], 3.11 [1H, t, 2J2’a,2’b = 3J2’a,3’ = 8.4 Hz,
H(2’a)], 3.38 [1H, q, 2J5’a,5’b = 3J4’a,5’b = 3J4’b,5’b = 8.4 Hz, H(5’a)], 3.44-3.54 [2H, m,
H(2’b) + H(5’b)], 6.56 [1H, d, 4J5,7 = 2.4 Hz, H(5)], 7.13 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7
= 2.4 Hz, H(7)], 7.18-7.25 [4H, m, H(3) + H(2”) + H(4”) + H(6”)], 7.29-7.35 [2H, m,
H(3”) + H(5”)], 7.82 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.83 [1H, d, 3J3,4 = 8.5 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 31.59 [C(4’)], 39.88 [C(A)], 40.73 [C(3’)], 47.64 [C(5’)], 53.30
[C(2’)], 103.39 [C(5)], 119.44 [C(7)], 122.38 [C(3)], 126.40 [C(4”)], 128.67 [C(3”) + C(5”)],
128.81 [C(4a)], 128.84 [C(2”) + C(6”)], 129.31 [C(8)], 136.71 [C(4)], 140.54 [C(1”)], 141.33




Using General Method 10, 34a (80 mg, 0.45 mmol) and 24 (131 mg, 0.54 mmol) were reacted
with Pd(OAc)2 (0.5 mg, 2.2 µmol), CataCXium® A ligand (1.6 mg, 4.5 µmol) and sodium
tert-butoxide (57 mg, 0.59 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with 5% methanol in dichloromethane gave
85a as a yellow oil (74 mg, 48%). Rf = 0.57 (1:9 methanol/dichloromethane). 1H NMR (500
MHz, CDCl3): δ 1.50 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.6
Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)], 1.80 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.6
Hz, H(3’eq) + H(5’eq)], 1.97-2.10 [1H, m, H(4’)], 2.74-2.84 [4H, m, H(2’ax) + H(6’ax) + H(A)],
3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.4 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.2 Hz,
H(5)], 7.10-7.17 [2H, m, H(4”) + H(6”)], 7.25 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 7.48 [1H, dd,
3J7,8 = 9.3 Hz, 4J5,7 = 2.2 Hz, H(7)], 7.61 [1H, t, 3J4”,5” = 3J5”,6” = 7.6 Hz, H(5”)], 7.85
[1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.7 Hz, H(4)], 8.57 [1H, br d‡, 3J3”,4” =
5.4 Hz, H(3”)]. 13C NMR (126 MHz, CDCl3): δ 31.92 [C(3’) + C(5’)], 36.64 [C(4’)], 45.31
[C(A)], 49.70 [C(2’) + C(6’)], 108.92 [C(5)], 121.28 [C(4”)], 122.35 [C(3)], 123.74 [C(7)],
123.79 [C(6”)], 128.24 [C(4a)], 129.08 [C(8)], 136.31 [C(5”)], 137.47 [C(4)], 142.99 [C(8a)],





Using General Method 10, 34c (97 mg, 0.55 mmol) and 24 (158 mg, 0.65 mmol) were reacted
with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A ligand (2.0 mg, 5.6 µmol) and sodium
tert-butoxide (68 mg, 0.71 mmol) in (trifluoromethyl)benzene (2 mL). Reaction work-up gave






Synthesis method a. Using General Method 10, 65 (50 mg, 0.23 mmol) and 24 (67 mg,
0.28 mmol) were reacted with Pd(OAc)2 (0.3 mg, 1.1 µmol), CataCXium® A ligand (0.8 mg,
2.3 µmol) and sodium tert-butoxide (29 mg, 0.30 mmol) in (trifluoromethyl)benzene (2 mL).
Work-up as specified and column chromatography on silica gel eluting with dichloromethane
gave an inseparable mixture which did not contain 88. Signals indicating the presence of 4-






Synthesis method b. A mixture of 65 (125 mg, 0.57 mmol) and 24 (167 mg, 0.69 mmol)
were combined with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A ligand (2.1 mg, 5.9 µmol)
and sodium tert-butoxide (72 mg, 0.75 mmol) in a glass pressure tube with 1,4-dioxane (2
mL). The flask was sealed and heated to 90°C for 16 hr, then cooled, diluted with methanol
(5 mL), and filtered through Celite®, washing with methanol. The solvent was removed
by evaporation under reduced pressure, and purification of the residue was attempted using
column chromatography on silica gel eluting with dichloromethane to give a crude yellow oil
(5 mg, 2%*). Characteristic signals corresponding to 181 were observed in 1H NMR data.
Rf = 0.34 (1% methanol in dichloromethane)
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Using General Method 4, a mixture of 59 and 60 (302 mg, 0.99 mmol) was reacted with
trifluoroacetic acid (3 mL) in dichloromethane (12 mL) for 1 hr, to give a mixture of 90 and
182 as a clear oil (30 mg, 14%). 1H NMR (500 MHz, CDCl3): δ 1.92 [0.6H, br s‡, *H(5)],
2.31-2.39 [1.4H, m, H(5)], 2.41-2.50 [1.4H, m, H(3)], 2.82-2.91 [1.4H, m, H(2)], 2.93 [0.6H,
t, 3J*5,*6 = 5.7 Hz, *H(6)], 2.95-3.03 [1.4H, m, H(6)], 3.30-3.39 [1.2H, m, *H(A) + *H(2)],
5.48 [0.3H, br s‡, *H(5)], 5.76-6.27 [3H, m, NH + CONH2 + *NH + *CONH2], 6.30 [0.7H,
s, H(A)], 7.22-7.31 [2H, m, H(2’) + H(6’) + *H(2’) + *H(6’)], 7.70-7.80 [2H, m, H(3) +
H(5) + *H(3) + *H(5)].
* denotes signals corresponding to the minor product 182.
A small sample of almost pure 90 was isolated for the purposes of characterisation. 1H NMR
(500 MHz, CDCl3): δ 2.31-2.39 [2H, m, H(5)], 2.41-2.50 [2H, m, H(3)], 2.82-2.91 [2H, m,
H(2)], 2.95-3.03 [2H, m, H(6)], 5.66 [1H, br s, CONH2], 6.05 [1H, br s, CONH2], 6.31 [1H, s,
H(A)], 7.21-7.31 [3H, m, NH + H(2’) + H(6’)], 7.73-7.79 [2H, m, H(3’) + H(5’)]. 13C NMR
(126 MHz, CDCl3): δ 31.08 [C(3)], 38.21 [C(5)], 47.76 [C(2)], 48.53 [C(6)], 122.62 [C(A)],













Using General Method 10, a mixture of 90 and 182 (20 mg, 0.09 mmol) and 24 (27 mg, 0.11
mmol) were reacted with Pd(OAc)2 (1.0 mg, 0.5 µmol), CataCXium® A ligand (0.3 mg, 0.9
µmol) and sodium tert-butoxide (12 mg, 0.12 mmol) in (trifluoromethyl)benzene (2 mL). The
volatile solvent was removed by evaporation under reduced pressure to give a crude residue.
The mixture could not be separated using chromatographic methods, however 1H NMR
analysis of the crude mixture showed signals which may be consistent with the desired product
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92, as well as 4-((1-(2-chloroquinolin-6-yl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzamide
(93), 4-((1-(6-bromoquinolin-2-yl)piperidin-4-ylidene)methyl)benzamide (91),













Using General Method 10, 95f (42 mg, 0.21 mmol) and 24 (60 mg, 0.25 mmol) were reacted
with Pd(OAc)2 (0.2 mg, 1.0 µmol), CataCXium® A ligand (0.7 mg, 2.1 µmol) and sodium tert-
butoxide (26 mg, 0.27 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified and
column chromatography on silica gel eluting with dichloromethane gave crude mixture which
could not be purified. 1H NMR analysis of the crude material indicated the mixture contained









Synthesis method a. Using General Method 10, 35a (30 mg, 0.17 mmol) and 24 (49 mg,
0.20 mmol) were reacted with Pd(OAc)2 (0.2 mg, 0.9 µmol), CataCXium® A ligand (0.6
mg, 1.7 µmol) and sodium tert-butoxide (22 mg, 0.23 mmol) in (trifluoromethyl)benzene
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(2 mL). Work-up as specified and column chromatography on silica gel eluting with 19:1






2-( tert-Butoxy)-6-(3-(2-pyridinylmethyl)piperidin-1-yl)quinoline (99a): Rf = 0.60 (9:1
dichloromethane/methanol). HRMS (ESI+) [M+H]+ calcd. for C24H29N3O − OC(CH3)3:
304.1814; found 304.1807. 1H NMR (500 MHz, CDCl3): δ 1.17-1.28 [1H, m, H(4’ax)], 1.66
[9H, s, OtBu], 1.69-1.86 [3H, m, H(4’eq) + H(5’ax) + H(5’eq)], 2.22-2.33 [1H, m, H(3’ax)],
2.57 [1H, dd, 2J2’ax,2’eq = 11.9 Hz, 3J2’ax,3’ax = 10.2 Hz, H(2’ax)], 2.72-2.87 [3H, m, H(6’ax)
+ H(A)], 3.52-3.63 [2H, m, H(2’eq) + H(6’eq)], 6.72 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96 [1H,
d, 4J5,7 = 2.7 Hz, H(5)], 7.11-7.18 [2H, m, H(4”) + H(6”)], 7.30 [1H, dd, 3J7,8 = 9.2 Hz,
4J5,7 = 2.7 Hz, H(7)], 7.61 [1H, td, 3J4”,5” = 3J5”,6” = 7.7 Hz, 4J3”,5” = 1.7 Hz, H(5”)], 7.65
[1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.57 [1H, ddd, 3J3”,4” =
4.9 Hz, 4J3”,5” = 1.7 Hz, 5J3”,6” = 0.8 Hz, H(3”)]. 13C NMR (126 MHz, CDCl3): δ 25.18
[C(5’)], 28.83 [OtBu], 30.87 [C(4’)], 36.83 [C(3’)], 43.08 [C(A)], 51.42 [C(6’)], 56.76 [C(2’)],
79.70[OtBu], 111.08 [C(5)], 115.12 [C(3)], 121.33 [C(6”)], 122.99 [C(7)], 123.60 [C(4”)],
125.30 [C(4a)], 128.16 [C(8)], 136.41 [C(5”)], 137.22 [C(4)], 141.52 [C(8a)], 148.49 [C(6)],
149.46 [C(3”)], 160.49 [C(1”)], 160.57 [C(2)].
Synthesis method b. Using General Method 10, 35a (92 mg, 0.52 mmol) and 24 (183 mg,
0.75 mmol) were reacted with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.4
mg, 3.9 µmol) and sodium tert-butoxide (37 mg, 0.39 mmol) in (trifluoromethyl)benzene
(2 mL). Work-up as specified and column chromatography on silica gel eluting with 19:1
dichloromethane/methanol yielded a crude mixture containing recovered reagents.
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6.2.6 Synthesis of 2-aminoquinoline derivatives by Buchwald-Hartwig amination



















The 2-chloroquinoline derivative (1.0 eq) was added to a glass pressure tube with Pd(dba)2
(1.0 mol %) and DavePhos (1.2 mol %). 1,4-Dioxane was added followed by LiHMDS
solution (1.0 M in THF, 2.2 eq) and the tube was purged with N2 gas and sealed. The
reaction mixture was heated at 100°C for 16 hr, then cooled and filtered through Celite®,
washing with methanol. The solvent was removed under reduced pressure and the mixture




Using General Method 11, 82a (50 mg, 0.13 mmol) was reacted with LiHMDS solution (1.0 M
in THF, 280 µL, 0.28 mmol), Pd(dba)2 (0.7 mg, 1.2 µmol) and DavePhos (0.6 mg, 1.5 µmol)
in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel eluting
with 19:1 dichloromethane/methanol gave 19a as a tan solid (42 mg, 88%). Rf = 0.26 (1:9
methanol/dichloromethane). MP: 184-187°C. HRMS (ESI+) [M+H]+ calcd. for C25H31N3:
374.2596; found 374.2590. 1H NMR (500 MHz, CDCl3): δ 1.32 [9H, s, tBu], 1.46 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.7 Hz,
H(3’ax) + H(5’ax)], 1.68 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J4’ax,A = 7.2 Hz, 3J(3’/5’)eq,4’ax =
3.7 Hz, H(4’ax)], 1.80 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.1 Hz, H(3’eq) + H(5’eq)], 2.57 [2H,
d, 3J4’ax,A = 7.2 Hz, H(A)], 2.67 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.1 Hz,
3J(2’/6’)ax,(3’/5’)eq = 1.5 Hz, H(2’ax) + H(6’ax)], 3.67 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz,
H(2’eq) + H(6’eq)], 4.67 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.95 [1H, d,
4J5,7 = 2.3 Hz, H(5)], 7.07-7.15 [2H, m, H(2”) + H(6”)], 7.28-7.39 [3H, m, H(7) + H(3”)
+ H(5”)], 7.56 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.75 [1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR
(126 MHz, CDCl3): δ 31.57 [tBu], 32.30 [C(3’) + C(5’)], 34.51 [tBu], 37.86 [C(4’)], 42.73
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[C(A)], 50.96 [C(2’) + C(6’)], 111.31 [C(5)], 111.86 [C(3)], 123.72 [C(7)], 124.32 [C(4a)],
125.22 [C(3”) + C(5”)], 126.46 [C(8)], 128.94 [C(2”) + C(6”)], 137.47 [C(1”)], 137.50




Using General Method 11, 82b (50 mg, 0.14 mmol) was reacted with LiHMDS solution (1.0
M in THF, 313 µL, 0.31 mmol), Pd(dba)2 (0.8 mg, 1.4 µmol) and DavePhos (0.7 mg, 1.7
µmmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 3% methanol in dichloromethane gave 19b as a yellow solid (29 mg, 61%).
Rf = 0.23 (1:9 methanol/dichloromethane). MP: 191-193°C. HRMS (ESI+) [M+H]+ calcd.
for C22H25N3: 332.2127; found 332.2122. 1H NMR (500 MHz, CDCl3): δ 1.51 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz,
H(3’ax) + H(5’ax)], 1.68 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J4’ax,A = 7.7 Hz, 3J(3’/5’)eq,4’ax =
3.8 Hz, H(4’ax)], 1.80 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.2 Hz, H(3’eq) + H(5’eq)], 2.33 [3H, s,
CH3], 2.61 [2H, d, 3J4’ax,A = 7.7 Hz, H(A)], 2.66 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.2 Hz, H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq
= 12.2 Hz, H(2’eq) + H(6’eq)], 4.66 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.96
[1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.09-7.19 [4H, m, H(3”) + H(4”) + H(5”) + H(6”)], 7.36
[1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76
[1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 19.74 [CH3], 32.51 [C(3’)
+ C(5’)], 36.89 [C(4’)], 40.41 [C(A)], 51.04 [C(2’) + C(6’)], 111.36 [C(5)], 111.85 [C(3)],
123.73 [C(7)], 124.37 [C(4a)], 125.78 [C(5”)], 126.17 [C(4”)], 126.60 [C(8)], 130.17 [C(6”)],





Using General Method 11, 82c (72 mg, 0.21 mmol) was reacted with LiHMDS solution (1.0
M in THF, 450 µL, 0.45 mmol), Pd(dba)2 (1.2 mg, 2.1 µmol) and DavePhos (1.0 mg, 2.5
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
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eluting with 19:1 dichloromethane/methanol gave 19c as a yellow solid (31 mg, 46%). MP:
155-157°C. HRMS (ESI+) [M+H]+ calcd. for C22H25N3: 332.2127; found 332.2122. 1H
NMR (500 MHz, CDCl3): δ 1.46 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.5 Hz, H(3’ax) + H(5’ax)], 1.68 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.2
Hz, 3J4’ax,A = 7.1 Hz, 3J(3’/5’)eq,4’ax = 3.5 Hz, H(4’ax)], 1.79 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq =
12.2 Hz, H(3’eq) + H(5’eq)], 2.35 [3H, s, CH3], 2.56 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 2.67
[2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.7 Hz, H(2’ax) +
H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)], 4.72 [2H, br s, NH2],
6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.91-7.08 [4H, m, H(5) + H(2”) + H(4”) + H(6”)], 7.19
[1H, t, 3J4”,5” = 3J5”,6” = 7.5 Hz, H(5”)], 7.36 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.5 Hz, H(7)],
7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz,
CDCl3): δ 21.59 [CH3], 32.33 [C(3’) + C(5’)], 37.97 [C(4’)], 43.26 [C(A)], 50.94 [C(2’) +
C(6’)], 111.31 [C(5)], 111.85 [C(3)], 123.76 [C(7)], 124.34 [C(4a)], 126.33 [C(6”)], 126.39
[C(8)], 126.78 [C(4”)], 128.25 [C(5”)], 130.10 [C(2”)], 137.62 [C(4)], 137.93 [C(3”)], 140.57
[C(1”)], *142.17 [C(8a)], 147.90 [C(6)], 155.33 [C(2)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was





Using General Method 11, 82d (122 mg, 0.35 mmol) was reacted with LiHMDS solution (1.0
M in THF, 765 µL, 0.77 mmol), Pd(dba)2 (2.0 mg, 3.5 µmol) and DavePhos (1.6 mg, 4.1
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 19d as a yellow solid (43 mg, 41%). Rf =
0.36 (1:9 methanol/dichloromethane). MP: degraded 190°C. HRMS (ESI+) [M+H]+ calcd.
for C22H25N3: 332.2127; found 332.2121. 1H NMR (500 MHz, CDCl3): δ 1.45 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz,
H(3’ax) + H(5’ax)], 1.61 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J4’ax,A = 7.3 Hz, 3J(3’/5’)eq,4’ax =
3.8 Hz, H(4’ax)], 1.79 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.1 Hz, H(3’eq) + H(5’eq)], 2.33 [3H, s,
CH3], 2.56 [2H, d, 3J4’ax,AH = 7.3 Hz, H(A)], 2.66 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 12.1 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.1 Hz, H(2’ax) + H(6’ax)], 3.67 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq
= 12.1 Hz, H(2’eq) + H(6’eq)], 4.64 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.95
[1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.05-7.09 [2H, m, H(3”) + H(5”)], 7.09-7.13 [2H, m, H(2”)
+ H(6”)], 7.35 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.56 [1H, d, 3J7,8 = 9.2 Hz,
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H(8)], 7.75 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 21.16 [CH3], 32.30
[C(3’) + C(5’)], 38.04 [C(4’)], 42.86 [C(A)], 50.98 [C(2’) + C(6’)], 111.32 [C(5)], 111.83
[C(3)], 123.71 [C(7)], 124.37 [C(4a)], 126.61 [C(8)], 129.06 [C(2”) + C(6”)], 129.17 [C(3”) +






Using General Method 11, 82e (53 mg, 0.14 mmol) was reacted with LiHMDS solution (1.0
M in THF, 318 µL, 0.32 mmol), Pd(dba)2 (0.8 mg, 1.4 µmol) and DavePhos (0.7 mg, 1.8
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 19e as a yellow solid (31 mg, 62%).
Rf = 0.22 (1:9 methanol/dichloromethane). MP: 169-171°C. HRMS (ESI+) [M+H]+ calcd.
for C22H25N3O: 348.2076; found 348.2085. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.2 Hz,
H(3’ax) + H(5’ax)], 1.68-1.81 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.62 [2H, d, 3J4’ax,A = 6.7
Hz, H(A)], 2.67 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.0 Hz, 3J(2’/6’)ax,(3’/5’)eq =
2.1 Hz, H(2’ax) + H(6’ax)], 3.67 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)],
3.83 [3H, s, OCH3], 4.67 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.84-6.92 [2H,
m, H(3”) + H(4”)], 6.96 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.11 [1H, dd, 3J5”,6” = 7.6 Hz, 4J4”,6”
= 1.4 Hz, H(6”)], 7.20 [1H, td, 3J4”,5” = 3J5”,6” = 7.6 Hz, 4J3”,5” = 1.4 Hz, H(5”)], 7.36 [1H,
dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.56 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76 [1H, d,
3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 32.41 [C(3’) + C(5’)], 36.32 [C(4’)],
37.32 [C(A)], 50.98 [C(2’) + C(6’)], 55.41 [OCH3], 110.48 [C(3”)], 111.26 [C(5)], 111.82
[C(3)], 120.29 [C(5”)], 123.73 [C(7)], 124.38 [C(4a)], 126.51 [C(8)], 127.29 [C(1”)], 129.08







Using General Method 11, 82f (82 mg, 0.22 mmol) was treated with LiHMDS solution (1.0
M in THF, 490 µL, 0.49 mmol), Pd(dba)2 (1.3 mg, 2.3 µmol) and DavePhos (1.1 mg, 2.8
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 19f as a yellow solid (72 mg, 93%). Rf =
0.10 (1:9 methanol/dichloromethane). MP: degraded 160°C. HRMS (ESI+) [M+H]+ calcd.
for C22H25N3O: 348.2078; found 348.2069. 1H NMR (500 MHz, CDCl3): δ 1.46 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.9 Hz,
H(3’ax) + H(5’ax)], 1.70 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J4’ax,A = 7.6 Hz, 3J(3’/5’)eq,4’ax =
3.9 Hz, H(4’ax)], 1.80 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.2 Hz, H(3’eq) + H(5’eq)], 2.58 [2H,
d, 3J4’ax,A = 7.6 Hz, H(A)], 2.68 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz,
3J(2’/6’)ax,(3’/5’)eq = 1.8 Hz, H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz,
H(2’eq) + H(6’eq)], 3.81 [3H, s, OCH3], 4.78 [2H, br s, NH2], 6.68 [1H, d, 3J3,4 = 8.8 Hz,
H(3)], 6.71-6.81 [3H, m, H(2”) + H(4”) + H(6”)], 6.96 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.22
[1H, t, 3J4”,5” = 3J5”,6” = 7.8 Hz, H(5”)], 7.36 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.6 Hz, H(7)],
7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.77 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz,
CDCl3): δ 32.28 [C(3’) + C(5’)], 37.87 [C(4’)], 43.33 [C(A)], 50.89 [C(2’) + C(6’)], 55.30
[OCH3], 111.13 [C(4”)], 111.34 [C(5)], 111.96 [C(3)], 115.18 [C(2”)], 121.76 [C(6”)], 123.80
[C(7)], 124.21 [C(4a)], 126.02 [C(8)], 129.31 [C(5”)], 137.83 [C(4)], 141.56 [C(1”)], 142.25





Using General Method 11, 82g (30 mg, 0.08 mmol) was reacted with LiHMDS solution (1.0
M in THF, 180 µL, 0.18 mmol), Pd(dba)2 (0.5 mg, 0.8 µmol) and DavePhos (0.4 mg, 1.0
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 19g as a tan solid (16 mg, 56%). MP:
172-174°C. HRMS (ESI+) [M+H]+ calcd. for C22H25N3O: 348.2076; found 348.2069. 1H
NMR (500 MHz, CDCl3): δ 1.44 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
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= 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz, H(3’ax) + H(5’ax)], 1.70 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.2
Hz, 3J4’ax,A = 7.1 Hz, 3J(3’/5’)eq,4’ax = 3.6 Hz, H(4’ax)], 1.78 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.2
Hz, H(3’eq) + H(5’eq)], 2.54 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 2.67 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.1 Hz, H(2’ax) + H(6’ax)], 3.67 [2H, br
d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)], 3.80 [3H, s, OCH3], 4.81 [2H, br s, NH2],
6.66 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.81-6.88 [2H, m, H(3”) + H(5”)], 6.95 [1H, d, 4J5,7 =
2.7 Hz, H(5)], 7.05-7.12 [2H, m, H(2”) + H(6”)], 7.35 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7
Hz, H(7)], 7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76 [1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR
(126 MHz, CDCl3): δ 32.25 [C(3’) + C(5’)], 38.13 [C(4’)], 42.38 [C(A)], 50.95 [C(2’) +
C(6’)], 55.42 [OCH3], 111.33 [C(5)], 111.91 [C(3)], 113.81 [C(3”) + C(5”)], 123.75 [C(7)],
124.29 [C(4a)], 126.32 [C(8)], 130.15 [C(2”) + C(6”)], 132.68 [C(1”)], 137.60 [C(4)], 142.12





Using General Method 11, 82h (17 mg, 0.05 mmol) was reacted with LiHMDS solution (1.0
M in THF, 105 µL, 0.10 mmol), Pd(dba)2 (0.3 mg, 0.5 µmol) and DavePhos (0.2 mg, 0.5
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 19h as a yellow solid (14 mg, 87%).
HRMS (ESI+) [M+H]+ calcd. for C21H22FN3: 336.1876; found 336.1871. 1H NMR (500
MHz, CDCl3): δ 1.49 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz,
3J(2’/6’)eq,(3’/5’)ax = 3.7 Hz, H(3’ax) + H(5’ax)], 1.68-1.84 [3H, m, H(4’ax) + H(3’eq) + H(5’eq)],
2.61-2.73 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz,
H(2’eq) + H(6’eq)], 4.96 [2H, br s, NH2], 6.69 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96 [1H, d, 4J5,7
= 2.7 Hz, H(5)], 7.00-7.10 [2H, m, H(3”) + H(5”)], 7.14-7.23 [2H, m, H(4”) + H(6”)], 7.36
[1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.58 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.77 [1H, d,
3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 32.18 [C(3’) + C(5’)], 36.17 [C(A)],
36.90 [C(4’)], 50.81 [C(2’) + C(6’)], 111.35 [C(5)], 111.97 [C(3)], 115.39 [d, 2JC,F = 22.5
Hz, C(3”)], 123.83 [br, C(7)], 123.92 [d, 4JC,F = 3.6 Hz, C(5”)], 124.20 [br, C(4a)], 125.90
[br, C(8)], 127.42 [d, 2JC,F = 16.1 Hz, C(1”)], 127.86 [d, 3JC,F = 8.0 Hz, C(4”)], 131.71 [d,
3JC,F = 5.1 Hz, C(6”)], 137.95 [C(4)], *141.34 [C(8a)], 147.95 [C(6)], 155.22 [C(2)], 161.45
[d, 1JC,F = 244.5 Hz, C(2”)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was







Using General Method 11, 82i (159 mg, 0.45 mmol) was reacted with LiHMDS solution (1.0
M in THF, 980 µL, 0.98 mmol), Pd(dba)2 (2.6 mg, 4.5 µmol) and DavePhos (2.1 mg, 5.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 19i as a yellow solid (67 mg, 45%).
Rf = 0.18 (1:9 methanol/dichloromethane). MP: 158-161°C. HRMS (ESI+) [M+H]+ calcd.
for C21H22FN3: 336.1876; found 336.1869. 1H NMR (500 MHz, CDCl3): δ 1.46 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5)ax = 3.7 Hz,
H(3’ax) + H(5’ax)], 1.64-1.84 [3H, m, H(4’ax) + H(3’eq) + H(5’eq)], 2.60 [2H, d, 3J4’ax,A = 7.1
Hz, H(A)], 2.68 [2H, br t‡, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.1 Hz, H(2’ax) + H(6’ax)],
3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz, H(2’eq) + H(6’eq)], 5.00 [2H, br s, NH2], 6.70
[1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.85-7.00 [4H, m, H(5) + H(2”) + H(4”) + H(6”)], 7.25 [1H,
q, 3J4”,5” = 3J5”,6” = 4JH,F = 7.6 Hz, H(5”)], 7.36 [1H, dd, 3J7,8 = 9.1 Hz, 4J5,7 = 2.0 Hz,
H(7)], 7.58 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.78 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126
MHz, CDCl3): δ 32.20 [C(3’) + C(5’)], 37.81 [C(4’)], 43.01 [C(A)], 50.89 [C(2’) + C(6’)],
111.39 [C(5)], 111.90 [C(3)], 112.95 [d, 2JC,F = 21.0 Hz, C(4”)], 116.02 [d, 2JC,F = 20.5
Hz, C(2”)], 123.78 [C(7)], 124.29 [C(4a)], 124.95 [d, 4JC,F = 2.9 Hz, C(6”)], 126.36 [C(8)],
129.76 [d, 3JC,F = 8.6 Hz, C(5”)], 137.66 [C(4)], 143.17 [d, 3JC,F = 6.9 Hz, C(1”)], 147.80





Using General Method 11, 82j (89 mg, 0.25 mmol) was reacted with LiHMDS solution (1.0 M
in THF, 554 µL, 0.55 mmol), Pd(dba)2 (1.4 mg, 2.4 µmol) and DavePhos (1.2 mg, 3.0 µmol)
in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel eluting
with 19:1 dichloromethane/methanol gave 19j as a yellow solid (24 mg, 29%). Rf = 0.26 (9:1
dichloromethane/methanol). MP: 224-227°C. HRMS (ESI+) [M+H]+ calcd. for C21H22FN3:
336.1876; found 336.1868. 1H NMR (500 MHz, CDCl3): δ 1.45 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 11.9 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)],
298
1.65 [1H, ttt, 3J(3’/5’)ax,4’ax = 11.9 Hz, 3J4’ax,A = 7.7 Hz, 3J(3’/5’)eq,4’ax = 3.8 Hz, H(4’ax)],
1.77 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 11.9 Hz, H(3’eq) + H(5’eq)], 2.57 [2H, d, 3J4’ax,A = 7.7
Hz, H(A)], 2.67 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 11.9 Hz, 3J(2’/6’)ax,(3’/5’)eq =
2.2 Hz, H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 11.9 Hz, H(2’eq) + H(6’eq)],
4.65 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.94-7.01 [3H, m, H(5) + H(3”)
+ H(5”)], 7.09-7.15 [2H, m, H(2”) + H(6”)], 7.35 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz,
H(7)], 7.56 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.75 [1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126
MHz, CDCl3): δ 32.18 [C(3’) + C(5’)], 38.04 [C(4’)], 42.43 [C(A)], 50.94 [C(2’) + C(6’)],
111.37 [C(5)], 111.86 [C(3)], 115.12 [d, 2JC,F = 21.0 Hz, C(3”) + C(5”)], 123.71 [C(7)],
124.35 [C(4a)], 126.62 [C(8)], 130.55 [d, 3JC,F = 7.6 Hz, C(2”) + C(6”)], 136.16 [d, 4JC,F =
3.3 Hz, C(1”)], 137.44 [C(4)], 142.54 [C(8a)], 147.74 [C(6)], 155.46 [C(2)], 161.49 [d, 1JC,F





Using General Method 11, 82n (77 mg, 0.19 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 440 µL, 0.44 mmol), Pd(dba)2 (1.1 mg, 1.9 µmol) and DavePhos (0.9
mg, 2.3 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on
silica gel eluting with 19:1 dichloromethane/methanol gave 19n as a yellow solid (47 mg,
63%). Rf = 0.20 (1:9 methanol/dichloromethane). MP: 160-163°C. HRMS (ESI+) [M+H]+
calcd. for C22H22F3N3: 386.1844; found 386.1848. 1H NMR (500 MHz, CDCl3): δ 1.53
[2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax =
2.9 Hz, H(3’ax) + H(5’ax)], 1.71-1.84 [3H, m, H(4’ax) + H(3’eq) + H(5’eq)], 2.67 [2H, br t‡,
2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.1 Hz, H(2’ax) + H(6’ax)], 2.79 [2H, d, 3J4’ax,A = 6.4
Hz, H(A)], 3.69 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz, H(2’eq) + H(6’eq)], 4.66 [2H, br s,
NH2], 6.66 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.98 [1H, d, 4J5,7 = 2.5 Hz, H(5)], 7.28-7.39 [3H,
m, H(7) + H(4”) + H(6”)], 7.48 [1H, t, 3J4”,5” = 3J5”,6” = 7.7 Hz, H(5”)], 7.57 [1H, d, 3J7,8
= 9.2 Hz, H(8)], 7.65 [1H, d, 3J3”,4” = 7.7 Hz, H(3”)], 7.75 [1H, d, 3J3,4 = 8.7 Hz, H(4)].
13C NMR (126 MHz, CDCl3): δ 32.38 [C(3’) + C(5’)], 37.58 [C(4’)], 39.56 [C(A)], 51.00
[C(2’) + C(6’)], 111.41 [C(5)], 111.86 [C(3)], 123.69 [C(7)], 124.35 [C(4a)], 124.78 [q, 1JC,F
= 273.9 Hz, CF3], 126.23 [C(8)], 126.31 [q, 3JC,F = 5.7 Hz, C(3”)], 126.63 [C(5”)], 129.02
[q, 2JC,F = 29.6 Hz, C(2”)], 131.50 [br‡, C(6”)], 131.90 [C(4”)], 137.42 [C(4)], 139.26 [q,






Using General Method 11, 82o (38 mg, 0.09 mmol) was reacted with LiHMDS solution (1.0
M in THF, 206 µL, 0.21 mmol), Pd(dba)2 (0.5 mg, 1.4 µmol) and DavePhos (0.4 mg, 0.7
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 19n as a yellow solid (23 mg, 64%). MP:
116-119°C. HRMS (ESI+) [M+H]+ calcd. for C22H22F3N3: 386.1844; found 386.1836. 1H
NMR (500 MHz, CDCl3): δ 1.48 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)], 1.64-1.84 [3H, m, H(4’ax) + H(3’eq)
+ H(5’eq)], 2.61-2.73 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.0 Hz, H(2’eq) + H(6’eq)], 4.71 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96
[1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.32-7.38 [2H, m, H(7) + H(6”)], 7.38-7.45 [2H, m, H(2”) +
H(5”)], 7.47 [1H, br d‡, 3J4”,5” = 7.7 Hz, H(4”)], 7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.76
[1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 32.15 [C(3’) + C(5’)], 37.85
[C(4’)], 43.06 [C(A)], 50.87 [C(2’) + C(6’)], 111.42 [C(5)], 111.90 [C(3)], 123.01 [q, 3JC,F =
3.8 Hz, C(4”)], 123.70 [C(7)], 124.32 [C(4a)], 124.40 [q, 1JC,F = 272.3 Hz, CF3], 125.84 [q,
3JC,F = 3.8 Hz, C(2”)], 126.56 [C(8)], 128.79 [C(5”)], 130.75 [q, 2JC,F = 31.9 Hz, C(3”)],






Using General Method 11, 82p (125 mg, 0.31 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 680 µL, 0.68 mmol), Pd(dba)2 (1.8 mg, 3.1 µmol) and DavePhos (1.5 mg,
3.8 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 4% methanol in dichloromethane gave 19p as a tan solid (39 mg, 33%).
Rf = 0.38 (1:9 methanol/dichloromethane). MP: 140-142°C. HRMS (ESI+) [M+H]+ calcd.
for C22H22F3N3: 386.1844; found 386.1838. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.2 Hz,
H(3’ax) + H(5’ax)], 1.65-1.82 [3H, m, H(4’ax) + H(3’eq) + H(5’eq)], 2.61-2.72 [4H, m, H(A) +
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H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 4.84 [2H,
br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.95 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.26-7.32
[2H, m, H(2”) + H(6”)], 7.35 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.52-7.61 [3H,
m, H(8) + H(3”) + H(5”)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3):
δ 32.20 [C(3’) + C(5’)], 37.82 [C(4’)], 43.08 [C(A)], 50.87 [C(2’) + C(6’)], 111.43 [C(5)],
111.96 [C(3)], 123.74 [C(7)], 124.26 [C(4a)], 124.50 [q, 1JC,F = 271.8 Hz, CF3], 125.33 [q,
3JC,F = 3.8 Hz, C(3”) + C(5”)], 126.33 [C(8)], 128.49 [q, 2JC,F = 31.9 Hz, C(4”)], 129.55





Using General Method 11, 83c (70 mg, 0.20 mmol) was reacted with LiHMDS solution (1.0
M in THF, 439 µL, 0.44 mmol), Pd(dba)2 (1.1 mg, 1.9 µmol) and DavePhos (0.9 mg, 2.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 9:1 dichloromethane/methanol with 0.001% triethylamine gave 20c as a yellow oil
(52 mg, 79%). Rf = 0.37 (9:1 dichloromethane/methanol). MP: 102-105°C. HRMS (ESI+)
[M+H]+ calcd. for C22H25N3: 332.2127; found 332.2124. 1H NMR (500 MHz, CDCl3): δ
1.13 [1H, qd, 2J4’ax,4’eq = 3J3’ax,4’ax = 3J4’ax,5’ax = 11.5 Hz, 3J4’ax,5’eq = 4.3 Hz, H(4’ax)], 1.69
[1H, qt, 2J5’ax,5’eq = 3J4’ax,5’ax = 3J5’ax,6’ax = 11.5 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 4.3 Hz, H(5’ax)],
1.76-1.87 [2H, m, H(4’eq) + H(5’eq)], 2.03 [1H, ttt, 3J2’ax,3’ax = 3J3’ax,4’ax = 11.5 Hz, 3J3’ax,A
= 3J3’ax,A’ = 7.6 Hz, 3J2’eq,3’ax = 3J3’ax,4’eq = 3.8 Hz, H(3’ax)], 2.34 [1H, s, CH3], 2.49 [1H,
t, 2J2’ax,2’eq = 3J2’ax,3’ax = 11.5 Hz, H(2’ax)], 2.55 [1H, dd, 2JA,A’ = 13.5 Hz, 3J3’ax,A = 7.6
Hz, H(A)], 2.61 [1H, dd, 2JA,A’ = 13.5 Hz, 3J3’ax,A’ = 7.6 Hz, H(A’)], 2.74 [1H, td, 2J6’ax,6’eq
= 3J5’ax,6’ax = 11.5 Hz, 3J5’eq,6’ax = 2.4 Hz, H(6’ax)], 3.51-3.61 [2H, m, H(2’eq) + H(6’eq)],
4.65 [2H, br s, NH2], 6.65 [1H, d, 3J3,4 = 8.7 Hz, H(3)], 6.91 [1H, d, 4J5,7 = 2.3 Hz, H(5)],
6.97-7.06 [3H, m, H(2”) + H(4”) + H(6”)], 7.19 [1H, t, 3J4”,5” = 3J5”,6” = 7.5 Hz, H(5”)],
7.30 [1H, dd, 3J7,8 = 9.1 Hz, 4J5,7 = 2.3 Hz, H(7)], 7.54 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.73
[1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 21.43 [CH3], 25.15 [C(5’)],
30.69 [C(4’)], 37.76 [C(3’)], 40.68 [C(A)], 51.23 [C(6’)], 56.75 [C(2’)], 111.18 [C(5)], 111.68
[C(3)], 123.57 [C(7)], 124.23 [C(4a)], 126.07 [C(6”)], 126.44 [C(8)], 126.71 [C(4”)], 128.18







Using General Method 11, 83h (14 mg, 0.04 mmol) was reacted with LiHMDS solution (1.0
M in THF, 87 µL, 0.09 mmol), Pd(dba)2 (0.2 mg, 0.4 µmol) and DavePhos (0.2 mg, 0.5
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 3% methanol in dichloromethane with 0.001% triethylamine gave 20h as a
yellow solid (10 mg, 78%). Rf = 0.40 (9:1 dichloromethane/methanol). MP: 166-168°C.
HRMS (ESI+) [M+H]+ calcd. for C21H22FN3: 336.1876; found 336.1874. 1H NMR (500
MHz, CDCl3): δ 1.12-1.23 [1H, m, H(4’ax)], 1.63-1.76 [1H, m, H(5’ax)], 1.77-1.90 [2H, m,
H(4’eq) + H(5’eq)], 2.06 [1H, ttt, 3J2’ax,3’ax = 3J3’ax,4’ax = 10.6 Hz, 3J3’ax,A = 3J3’ax,A’ = 7.0
Hz, 3J2’eq,3’ax = 3J3’ax,4’eq = 3.7 Hz, H(3’ax)], 2.53 [1H, dd, 2J2’ax,2’eq = 11.4 Hz, 3J2’ax,3’ax =
10.6 Hz, H(2’ax)], 2.59-2.80 [3H, m, H(6’ax) + H(A) + H(A’)], 3.50-3.63 [2H, m, H(2’eq) +
H(6’eq)], 4.87 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.92 [1H, d, 4J5,7 = 2.6
Hz, H(5)], 6.99-7.11 [2H, m, H(3”) + H(5”)], 7.16-7.24 [2H, m, H(4”) + H(6”)], 7.30 [1H,
dd, 3J7,8 = 9.1 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.55 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.75 [1H, d,
3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 25.29 [C(5’)], 30.66 [C(4’)], 33.76 [d,
3JC,F = 1.4 Hz, C(A)], 37.08 [d, 4JC,F = 1.3 Hz, C(3’)], 51.41 [C(6’)], 56.75 [C(2’)], 111.42
[C(5)], 111.87 [C(3)], 115.43 [d, 2JC,F = 22.4 Hz, C(3”)], 123.83 [C(7)], 124.01 [d, 4JC,F =
3.8 Hz, C(5”)], 124.30 [C(4a)], 126.36 [br, C(8)], 127.24 [d, 2JC,F = 15.7 Hz, C(1”)], 127.92
[d, 3JC,F = 8.1 Hz, C(4”)], 131.51 [d, 3JC,F = 5.3 Hz, C(6”)], 137.60 [C(4)], 142.15 [C(8a)],





Using General Method 11, 83j (98 mg, 0.28 mmol) was reacted with LiHMDS solution (1.0 M
in THF, 610 µL, 0.61 mmol), Pd(dba)2 (1.6 mg, 2.8 µmol) and DavePhos (1.3 mg, 3.3 µmol)
in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel eluting
with 19:1 dichloromethane/methanol with 0.001% triethylamine gave 20j as a yellow oil (48
mg, 52%). MP: 146-148°C. HRMS (ESI+) [M+H]+ calcd. for C21H22FN3: 336.1876; found
336.1872. 1H NMR (500 MHz, CDCl3): δ 1.06-1.20 [1H, m, H(4’ax)], 1.69 [1H, qt, 2J5’ax,5’eq
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= 3J4’ax,5’ax = 3J5’ax,6’ax = 12.0 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 4.2 Hz, H(5’ax)], 1.77-1.86 [2H,
m, H(4’eq) + H(5’eq)], 1.99 [1H, ttt, 3J2’ax,3’ax = 3J3’ax,4’ax = 10.6 Hz, 3J3’ax,A = 3J3’ax,A’ = 7.3
Hz, 3J2’eq,3’ax = 3J3’ax,4’eq = 3.4 Hz, H(3’ax)], 2.48 [1H, dd, 2J2’ax,2’eq = 11.3 Hz, 3J2’ax,3’ax =
10.6 Hz, H(2’ax)], 2.56 and 2.66 [2H, ABX, A:dd, B:dd, 2JA,A’(JAB) = 13.7 Hz, 3JA,3’ax(JAX )
= 7.3 Hz, 3JA’,3’ax(JBX ) = 7.3 Hz, H(A) + H(A’)], 2.74 [1H, td, 2J6’ax,6’eq = 3J5’ax,6’ax =
12.0 Hz, 3J5’eq,6’ax = 2.5 Hz, H(6’ax)], 3.48-3.62 [2H, m, H(2’eq) + H(6’eq)], 4.78 [2H, br s,
NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.91 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 6.95-7.03 [2H,
m, H(3”) + H(5”)], 7.10-7.18 [2H, m, H(2”) + H(6”)], 7.29 [1H, dd, 3J7,8 = 9.1 Hz, 4J5,7
= 2.6 Hz, H(7)], 7.55 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.75 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 25.25 [C(5’)], 30.68 [C(4’)], 38.07 [C(3’)], 40.05 [C(A)], 51.33
[C(6’)], 56.70 [C(2’)], 111.39 [C(5)], 111.94 [C(3)], 115.24 [d, 2JC,F = 21.0 Hz, C(3”) +
C(5”)], 123.83 [C(7)], 124.22 [C(4a)], 126.04 [br, C(8)], 130.47 [d, 3JC,F = 8.1 Hz, C(2”)
+ C(6”)], 135.92 [d, 4JC,F = 3.2 Hz, C(1”)], 137.86 [C(4)], *142.17 [C(8a)], 148.00 [C(6)],
155.25 [C(2)], 161.54 [d, 1JC,F = 243.6 Hz, C(4”)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was





Using General Method 11, 83x (94 mg, 0.28 mmol) was reacted with LiHMDS solution (1.0
M in THF, 614 µL, 0.61 mmol), Pd(dba)2 (1.6 mg, 2.8 µmol) and DavePhos (1.3 mg, 3.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol with 0.001% triethylamine gave 20x as a
yellow oil (35 mg, 40%). Rf = 0.07 (19:1 dichloromethane/methanol). MP: degraded 145°C.
HRMS (ESI+) [M+H]+ calcd. for C21H23N3: 318.1970; found 318.1979. 1H NMR (500
MHz, CDCl3): δ 1.08-1.19 [1H, m, H(4’ax)], 1.69 [1H, qt, 2J5’ax,5’eq = 3J4’ax,5’ax = 3J5’ax,6’ax
= 12.0 Hz, 3J4’eq,5’ax = 3J5’ax,6’eq = 4.3 Hz, H(5’ax)], 1.76-1.87 [2H, m, H(4’eq) + H(5’eq)],
2.04 [1H, ttt, 3J2’ax,3’ax = 3J3’ax,4’ax = 10.4 Hz, 3J3’ax,A = 3J3’ax,A’ = 7.2 Hz, 3J2’eq,3’ax =
3J3’ax,4’eq = 3.3 Hz, H(3’ax)], 2.48 [1H, dd, 2J2’ax,2’eq = 11.5 Hz, 3J2’ax,3’ax = 10.4 Hz, H(2’ax)],
2.58 [1H, dd, 2JA,A’ = 13.5 Hz, 3J3’ax,A = 7.2 Hz, H(A)], 2.61 [1H, dd, 2JA,A’ = 13.5 Hz,
3J3’ax,A’ = 7.2 Hz, H(A’)], 2.73 [1H, td, 2J6’ax,6’eq = 3J5’ax,6’ax = 12.0 Hz, 3J5’eq,6’ax = 2.3
Hz, H(6’ax)], 3.51-3.62 [2H, m, H(2’eq) + H(6’eq)], 4.66 [2H, br s, NH2], 6.65 [1H, d, 3J3,4
= 8.7 Hz, H(3)], 6.90 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.16-7.24 [3H, m, H(2”) + H(4”) +
H(6”)], 7.27-7.34 [3H, m, H(7) + H(3”) + H(5”)], 7.54 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.72
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[1H, d, 3J3,4 = 8.7 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 25.30 [C(5’)], 30.76 [C(4’)],
37.94 [C(3’)], 40.91 [C(A)], 51.38 [C(6’)], 56.86 [C(2’)], 111.33 [C(5)], 111.81 [C(3)], 123.69
[C(7)], 124.34 [C(4a)], 126.10 [C(8)], 126.62 [C(4”)], 128.43 [C(3”) + C(5”)], 129.17 [C(2”)




Using General Method 11, 84x (41 mg, 0.13 mmol) was reacted with LiHMDS solution (1.0 M
in THF, 280 µL, 0.28 mmol), Pd(dba)2 (0.7 mg, 1.3 µmol) and DavePhos (0.6 mg, 1.5 µmol)
in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel eluting
with 4% methanol in dichloromethane with 0.001% triethylamine gave 21x as a yellow oil
(27 mg, 70%). Rf = 0.19 (1:9 methanol/dichloromethane). MP: 145-148°C. HRMS (ESI+)
[M+H]+ calcd. for C20H21N3: 304.1814; found 304.1809. 1H NMR (500 MHz, CDCl3): δ
1.79 [1H, qd, 2J4’a,4’b = 12.3 Hz, 3J3’,4’a = 3J4’a,5’a = 3J4’a,5’b = 8.0 Hz, H(4’a)], 2.10-2.19
[1H, m, H(4’b)], 2.64 [1H, septet, 3J2’a,3’ = 3J2’b,3’ = 3J3’,4’a = 3J3’,4’b = 3J3’,A = 3J3’,A’
= 8.0 Hz, H(3’)], 2.74-2.84 [2H, m, H(A) + H(A’)], 3.08 [1H, t, 2J2’a,2’b = 3J2’a,3’ = 8.0
Hz, H(2’a)], 3.36 [1H, q, 2J5’a,5’b = 3J4’a,5’a = 3J4’b,5’a = 8.0 Hz, H(5’a)], 3.41-3.51 [2H, m,
H(2’b) + H(5’b)], 4.78 [2H, br s, NH2], 6.55 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 6.67 [1H, d, 3J3,4
= 8.8 Hz, H(3)], 7.02 [1H, dd, 3J7,8 = 9.1 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.18-7.28 [3H, m,
H(2”) + H(4”) + H(6”)], 7.28-7.36 [2H, m, H(3”) + H(5”)], 7.56 [1H, d, 3J7,8 = 9.1 Hz,
H(8)], 7.74 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.63 [C(4’)],
40.10 [C(A)], 40.69 [C(3’)], 47.81 [C(5’)], 53.56 [C(2’)], 105.17 [C(5)], 112.20 [C(3)], 118.52
[C(7)], 124.95 [C(4a)], 126.16 [C(8)], 126.29 [C(4”)], 128.61 [C(3”) + C(5”)], 128.87 [C(2”)




Using General Method 11, 85a (64 mg, 0.19 mmol) was reacted with LiHMDS solution (1.0
M in THF, 419 µL, 0.42 mmol), Pd(dba)2 (1.1 mg, 1.9 µmol) and DavePhos (0.9 mg, 2.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
304
gel eluting with 7% methanol in dichloromethane gave 22a as a yellow solid (32 mg, 53%).
Rf = 0.36 (1:9 methanol/dichloromethane). MP: 182-184°C. HRMS (ESI+) [M+H]+ calcd.
for C20H22N4: 319.1923; found 319.1916. 1H NMR (500 MHz, CDCl3): δ 1.53 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.4 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz,
H(3’ax) + H(5’ax)], 1.79 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.4 Hz, H(3’eq) + H(5’eq)], 1.98 [1H,
ttt, 3J(3’/5’)ax,4’ax = 12.4 Hz, 3J4’ax,A = 7.1 Hz, 3J(3’/5’)eq,4’ax = 3.6 Hz, H(4’ax)], 2.71 [2H, td,
2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.4 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.3 Hz, H(2’ax) + H(6’ax)],
2.78 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.4 Hz, H(2’eq)
+ H(6’eq)], 4.77 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.98 [1H, d, 4J5,7 =
2.7 Hz, H(5)], 7.10-7.18 [2H, m, H(4”) + H(6”)], 7.36 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 =
2.7 Hz, H(7)], 7.57 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.61 [1H, td, 3J4”,5” = 3J5”,6” = 7.7
Hz, 4J3”,5” = 1.8 Hz, H(5”)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.57 [1H, br d‡, 3J3”,4”
= 4.9 Hz, H(3”)]. 13C NMR (126 MHz, CDCl3): δ 32.28 [C(3’) + C(5’)], 36.69 [C(4’)],
45.44 [C(A)], 50.89 [C(2’) + C(6’)], 111.37 [C(5)], 111.88 [C(3)], 121.26 [C(4”)], 123.78
[C(6”)], 123.84 [C(7)], 124.30 [C(4a)], 126.35 [C(8)], 136.30 [C(5”)], 137.63 [C(4)], 142.13
[br, C(8a)], 147.85 [C(6)], 149.56 [C(3”)], 155.38 [C(2)], 160.62 [C(1”)].
6.2.7 Synthesis of 2-aminoquinolines via benzylidenepiperidines
4-Benzylidenepiperidine (103x)
NH
Hydrogen chloride solution (1M in diethyl ether, 3 mL) was added dropwise to a stirring
suspension of 45x (134 mg, 0.49 mmol) in diethyl ether (1 mL) and the mixture was stirred
for 1 hr. The precipitate was collected by vacuum filtration, washed with ice-cold diethyl
ether, then added to saturated aqueous sodium bicarbonate solution (30 mL) and stirred for
30 min. The mixture was extracted with dichloromethane (3 x 30 mL), dried over MgSO4,
filtered, and concentrated to dryness under reduced pressure to give 103x as a colourless oil
(68 mg, 80%) which was used without further purification. HRMS (ESI+) [M+H]+ calcd.
for C12H15N: 174.1283; found 174.1278. 1H NMR (500 MHz, CDCl3): δ 1.97 [1H, br s, NH],
2.26-2.37 [2H, m, H(5’)], 2.42-2.49 [2H, m, H(3’)], 2.78-2.90 [2H, m, H(2’)], 2.91-3.04 [2H,
m, H(6’)], 6.29 [1H, s, H(A)], 7.15-7.23 [3H, m, H(2’) + H(4’) + H(6’)], 7.27-7.34 [2H, m,
H(3’) + H(5’)].





Using General Method 10, 103x (68 mg, 0.39 mmol) and 24 (113 mg, 0.47 mmol) were
reacted with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.4 mg, 3.9 µmol) and
sodium tert-butoxide (49 mg, 0.51 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 106x
as a yellow oil (84 mg, 64%). Rf = 0.63 (dichloromethane). HRMS (ESI+) [M+H]+ calcd.
for C21H1935ClN2/C21H1937ClN2: 335.1315/337.1286; found 335.1308/337.1286. 1H NMR
(500 MHz, CDCl3): δ 2.53-2.60 [2H, m, H(5’)], 2.66-2.73 [2H, m, H(3’)], 3.33-3.41 [2H,
m, H(2’)], 3.45-3.52 [2H, m, H(6’)], 6.42 [1H, s, H(A)], 7.01 [1H, d, 4J5,7 = 2.7 Hz, H(5)],
7.19-7.30 [4H, m, H(3) + H(2”) + H(4”) + H(6”)], 7.31-7.38 [2H, m, H(3”) + H(5”)], 7.51
[1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.88 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.91 [1H,
d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 28.98 [C(3’)], 35.91 [C(5’)], 50.25
[C(2’)], 51.12 [C(6’)], 108.97 [C(5)], 122.52 [C(3)], 123.52 [C(7)], 124.45 [C(A)], 126.50
[C(4”)], 128.33 [C(4a)], 128.36 [C(3”) + C(5”)], 129.05 [C(2”) + C(6”)], 129.33 [C(8)],




Using General Method 11, 106x (74 mg, 0.22 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 488 µL, 0.49 mmol), Pd(dba)2 (1.3 mg, 2.3 µmol) and DavePhos (1.0 mg,
2.5 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 2% methanol in dichloromethane with 0.001% triethylamine gave 102x as
a yellow oil (28 mg, 40%). HRMS (ESI+) [M+H]+ calcd. for C21H21N3: 316.1814; found
316.1810. 1H NMR (500 MHz, CDCl3): δ 2.51-2.61 [2H, m, H(5’)], 2.64-2.76 [2H, m, H(3’)],
3.20-3.30 [2H, m, H(2’)], 3.31-3.41 [2H, m, H(6’)], 4.71 [2H, br s, NH2], 6.39 [1H, s, H(A)],
6.68 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.19-7.29 [3H, m, H(2”)
+ H(4”) + H(6”)], 7.28-7.37 [2H, m, H(3”) + H(5”)], 7.39 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 =
2.6 Hz, H(7)], 7.59 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.77 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 29.25 [C(3’)], 36.35 [C(5’)], 51.58 [C(2’)], 52.41 [C(6’)], 111.53
[C(5)], 111.94 [C(3)], 123.66 [C(7)], 124.02 [C(A)], 124.37 [C(4a)], 126.39 [C(4”)], 126.61
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[C(8)], 128.32 [C(3”) + C(5”)], 129.10 [C(2”) + C(6”)], 137.57 [C(4)], 137.81 [C(1”)],
138.95 [C(4’)], *142.29 [C(8a)], 147.24 [C(6)], 155.44 [C(2)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was





Using General Method 3, 102x (20 mg, 0.06 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 2 hr. Work-up and column chromatography
on silica gel eluting with 10% methanol in dichloromethane gave 15 as a tan solid (18
mg, 91%). Rf = 0.21 (1:9 methanol/dichloromethane). HRMS (ESI+) [M+H]+ calcd.
for C21H23N3: 318.1970; found 318.1966. 1H NMR (500 MHz, CDCl3): δ 1.47 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz,
H(3’ax) + H(5’ax)], 1.70 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J4’ax,A = 7.3 Hz, 3J(3’/5’)eq,4’ax =
3.8 Hz, H(4’ax)], 1.79 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.2 Hz, H(3’eq) + H(5’eq)], 2.61 [2H,
d, 3J4’ax,A = 7.3 Hz, H(A)], 2.67 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz,
3J(2’/6’)ax,(3’/5’)eq = 2.2 Hz, H(2’ax) + H(6’ax)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz,
H(2’eq) + H(6’eq)], 4.73 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96 [1H, d, 4J5,7
= 2.6 Hz, H(5)], 7.14-7.24 [3H, m, H(2”) + H(4”) + H(6”)], 7.27-7.33 [2H, m, H(3”) +
H(5”)], 7.36 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.57 [1H, d, 3J7,8 = 9.2 Hz,
H(8)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)].




Using General Method 4, 45s (394 mg, 1.32 mmol) was reacted with trifluoroacetic acid (1.5
mL) in dichloromethane (5 mL) for 1 hr, to give 103s as a pale yellow oil (264 mg, 100%).
HRMS (ESI+) [M+H]+ calcd. for C13H14N2: 199.1235; found 199.1236. 1H NMR (500
MHz, CDCl3): δ 2.34-2.45 [2H, m, H(5)], 2.45-2.55 [2H, m, H(3)], 2.85-2.97 [2H, m, H(2)],
2.98-3.09 [2H, m, H(6)], 3.26 [1H, br s, NH], 6.31 [1H, s, H(A)], 7.24-7.33 [2H, m, H(2’)
+ H(6’)], 7.55-7.64 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 30.22 [C(3)],
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37.32 [C(5)], 47.13 [C(2)], 47.88 [C(6)], 109.84 [C(4’)], 119.15 [CN], 122.71 [C(A)], 129.61





Synthesis method a. Using General Method 10, 103s (110 mg, 0.55 mmol) and 24 (161 mg,
0.66 mmol) were reacted with Pd(OAc)2 (0.6 mg, 2.4 µmol), CataCXium® A ligand (2.0 mg,
5.6 µmol) and sodium tert-butoxide (69 mg, 0.72 mmol) in (trifluoromethyl)benzene (2 mL).
Work-up as specified and column chromatography on silica gel eluting with 1% methanol in
dichloromethane gave 106s as a yellow oil (70 mg, 35%). Rf = 0.22 (dichloromethane).
HRMS (ESI+) [M+H]+ calcd. for C22H1835ClN3/C22H1837ClN3: 360.1268/362.1238; found
360.1260/362.1239. 1H NMR (500 MHz, CDCl3): δ 2.55-2.63 [2H, m, H(5’)], 2.63-2.71 [2H,
m, H(3’)], 3.34-3.43 [2H, m, H(2’)], 3.46-3.54 [2H, m, H(6’)], 6.41 [1H, s, H(A)], 7.02 [1H, d,
4J5,7 = 2.7 Hz, H(5)], 7.28 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.30-7.36 [2H, m, H(2”) + H(6”)],
7.51 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.59-7.66 [2H, m, H(3”) + H(5”)], 7.89
[1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.91 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz,
CDCl3): δ 29.12 [C(3’)], 36.01 [C(5’)], 50.06 [C(2’)], 50.97 [C(6’)], 109.12 [C(5)], 110.03
[C(4”)], 119.14 [CN], 122.61 [C(3)], 123.14 [C(A)], 123.45 [C(7)], 128.27 [C(4a)], 129.45
[C(8)], 129.65 [C(2”) + C(6”)], 132.19 [C(3”) + C(5”)], 137.50 [C(4)], 141.86 [C(4’)], 142.36
[C(1”)], 143.13 [C(8a)], 147.61 [C(6)], 149.18 [C(2)].
Synthesis method b. A mixture of 103s (150 mg, 0.76 mmol) and 24 (220 mg, 0.91 mmol)
were combined in a glass pressure tube with Pd(OAc)2 (0.8 mg, 3.6 µmol), CataCXium® A
ligand (2.7 mg, 7.5 µmol) and sodium tert-butoxide (95 mg, 0.98 mmol). 1,4-dioxane (2
mL) was added and the tube was sealed and heated to 90°C for 16 hr. The mixture was
cooled, diluted with methanol (5 mL) and filtered through Celite®, washing with methanol.
The solvent was removed by evaporation under reduced pressure and the residue was purified
by column chromatography on silica gel eluting with 1% methanol in dichloromethane to give






Using General Method 11, 106s (32 mg, 0.09 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 195 µL, 0.20 mmol), Pd(dba)2 (0.5 mg, 0.9 µmol) and DavePhos (0.4 mg,
1.1 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 5% methanol in dichloromethane with 0.001% triethylamine gave 102s as
a yellow oil (23 mg, 77%). Rf = 0.10 (1:19 methanol/dichloromethane). HRMS (ESI+)
[M+H]+ calcd. for C22H20N4: 341.1766; found 341.1764. 1H NMR (500 MHz, CDCl3): δ
2.55-2.62 [2H, m, H(5’)], 2.63-2.72 [2H, m, H(3’)], 3.22-3.30 [2H, m, H(2’)], 3.33-3.43 [2H,
m, H(6’)], 4.70 [2H, br s, NH2], 6.38 [1H, s, H(A)], 6.69 [1H, d, 3J3,4 = 8.8 Hz, H(3)],
6.98 [1H, d, 4J5,7 = 2.3 Hz, H(5)], 7.29-7.35 [2H, m, H(2”) + H(6”)], 7.38 [1H, dd, 3J7,8
= 9.1 Hz, 4J5,7 = 2.3 Hz, H(7)], 7.56-7.66 [3H, m, H(8) + H(3”) + H(5”)], 7.77 [1H, d,
3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 29.37 [C(3’)], 36.45 [C(5’)], 51.40
[C(2’)], 52.26 [C(6’)], 109.88 [C(4”)], 111.66 [C(5)], 112.04 [C(3)], 119.21 [CN], 122.71
[C(A)], 123.54 [C(7)], 124.32 [C(4a)], 126.77 [C(8)], 129.68 [C(2”) + C(6”)], 132.16 [C(3”)
+ C(5”)], 137.46 [C(4)], 142.51 [*C(4’)], 142.57 [*C(1”)], 142.59 [*C(8a)], 146.83 [C(6)],
155.60 [C(2)].







A sample of 102s (32 mg, 0.09 mmol) was dissolved in ethanol (4 mL) with water (1 drop).
Potassium hydroxide pellets (28 mg, 0.47 mmol) were added over 10 minutes. The mixture
was stirred at room temperature for 30 min then 70°C for 2 hr, before cooling to 60°C and
adding ice water (10 mL). The mixture was stirred at 0°C for 30 min and no precipitate
was formed. The ethanol was removed by evaporation under reduced pressure and mixture
extracted with ethyl acetate. The volatile solvent was removed by evaporation under reduced
pressure and the residue was purified by column chromatography on silica gel eluting with
10% methanol in dichloromethane. A small amount (7 mg) of a mixture of products was
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obtained, with 1H NMR analysis indicating that the mixture contained predominantly 104 and
4-((1-(2-aminoquinolin-6-yl)-1,2,3,6-tetrahydropyridin-4-yl)methyl)benzamide (105). HRMS
(ESI+) [M+H]+ calcd. for C22H22N4O: 359.1872; found 359.1865. 1H NMR (500 MHz,
CDCl3): δ 2.20 [0.4H, br s‡, *H(5’)], 2.54-2.62 [1.6H, m, H(5’)], 2.65-2.72 [1.6H, m, H(3’)],
3.21-3.30 [1.6H, m, H(2’)], 3.33-3.40 [2H, m, H(6’) + *H(6’)], 3.43 [0.4H, br s, *H(A)],
3.75 [0.4H, br s‡, *H(2’)], 4.96-5.18 [2H, br s, NH2 + *NH2], 5.47-6.16 [2.4H, m, CONH2
+ *CONH2 + *H(3’)], 6.41 [0.8H, s, H(A)], 6.67-6.72 [1H, m, H(3) + *H(3)], 6.95 [0.2H,
d, 4J5,7 = 2.6 Hz, *H(5)], 6.99 [0.8H, d, 4J5,7 = 2.6 Hz, H(5)], 7.27-7.34 [2H, m, H(2”) +
H(6”) + *H(2”) + *H(6”)], 7.35-7.42 [1H, m, H(7) + *H(7)], 7.58-7.63 [1H, m, H(8) +
*H(8)], 7.73-7.82 [3H, m, H(4) + H(3”) + H(5”) + *H(4) + *H(3”) + *H(5”)].











Using General Method 3, a mixture of 104 and 105 (7 mg, 20 µmol) was reacted with Pd-C
catalyst under a hydrogen atmosphere for 2 hr. Work-up and column chromatography on
silica gel eluting with 1:9 methanol/dichloromethane gave 101 as a white solid (6 mg, 85%).
Rf = 0.15 (1:9 methanol/dichloromethane). MP: degraded 190°C. HRMS (ESI+) [M+H]+
calcd. for C22H24N4O: 361.2028; found 361.2024. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.3 Hz,
H(3’ax) + H(5’ax)], 1.63-1.83 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.62-2.73 [4H, m, H(2’ax) +
H(6’ax) + H(A)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 5.13 [2H, br
s, NH2], 5.54 [1H, br s, CONH2], 6.01 [1H, br s, CONH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)],
6.98 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.22-7.31 [2H, m, H(2”) + H(6”)], 7.36 [1H, dd, 3J7,8 =
9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.59 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.72-7.81 [2H, m, H(3”)
+ H(5”)]. 13C NMR (126 MHz, (CD3)2CO): δ 32.85 [C(3’) + C(5’)], 38.59 [C(4’)], 43.44
[C(A)], 51.07 [C(2’) + C(6’)], 112.18 [C(5)], 113.28 [C(3)], 124.27 [C(7)], 124.27 [C(8)],
124.57 [C(4a)], 128.39 [C(3”) + C(5”)], 129.89 [C(2”) + C(6”)], 133.16 [C(4”)], 138.96






Using General Method 3, 102s (25 mg, 0.07 mmol) was reacted with Pd-C catalyst in
methanol (20 mL) under a hydrogen atmosphere for 2 hr. Work-up and column chromatography
on silica gel eluting with 1:9 methanol/dichloromethane gave 19s as a yellow solid (18
mg, 72%). Rf = 0.31 (1:9 methanol/dichloromethane). HRMS (ESI+) [M+H]+ calcd.
for C22H22N4: 343.1923; found 343.1919. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.0 Hz,
H(3’ax) + H(5’ax)], 1.59-1.87 [3H, m, H(4’ax) + H(3’eq) + H(5’eq)], 2.59-2.75 [4H, m, H(2’ax)
+ H(6’ax) + H(A)], 3.68 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz, H(2’eq) + H(6’eq)], 4.67 [2H,
br s, NH2], 6.68 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96 [1H, d, 4J5,7 = 2.0 Hz, H(5)], 7.26-7.32
[2H, m, H(2”) + H(6”)], 7.35 [1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.0 Hz, H(7)], 7.53-7.64
[3H, m, H(8) + H(3”) + H(5”)], 7.76 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz,
CDCl3): δ 32.18 [C(3’) + C(5’)], 37.76 [C(4’)], 43.40 [C(A)], 50.84 [C(2’) + C(6’)], 110.09
[C(4”)], 111.47 [C(5)], 111.94 [C(3)], 119.19 [CN], 123.76 [C(7)], 124.26 [C(4a)], 126.38
[C(8)], 130.04 [C(2”) + C(6”)], 132.28 [C(3”) + C(5”)], 137.68 [C(4)], 142.57 [C(8a)],




Using General Method 4, 45r (44 mg, 0.15 mmol) and trifluoroacetic acid (0.5 mL) were
reacted in dichloromethane (4 mL) to give 103r as an orange oil (29 mg, 100%). 1H NMR
(500 MHz, CDCl3): δ 2.36-2.43 [2H, m, H(5)], 2.43.2.49 [2H, m, H(3)], 2.77-2.99 [3H, m,
H(2) + NH], 2.99-3.06 [2H, m, H(6)], 6.28 [1H, s, H(A)], 7.39-7.51 [4H, m, H(2’) + H(3’)
+ H(5’) + H(6’)]. 13C NMR (126 MHz, CDCl3): δ 30.14 [C(3)], 37.23 [C(5)], 47.20 [C(2)],
47.94 [C(6)], 112.47 [C(3’)], 119.02 [CN], 121.91 [C(A)], 129.13 [C(5’)], 129.91 [C(2’)],






Using General Method 10, 103r (90 mg, 0.45 mmol) and 24 (130 mg, 0.54 mmol) were
reacted with Pd(OAc)2 (0.5 mg, 2.2 µmol), CataCXium® A ligand (1.6 mg, 4.5 µmol) and
sodium tert-butoxide (56 mg, 0.58 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with 1% methanol in dichloromethane
gave 106r as a yellow oil (103 mg, 63%). 1H NMR (500 MHz, CDCl3): δ 2.54-2.60 [2H, m,
H(5’)], 2.61-2.67 [2H, m, H(3’)], 3.34-3.40 [2H, m, H(2’)], 3.46-3.52 [2H, m, H(6’)], 6.37
[1H, s, H(A)], 7.02 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.28 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.39-7.47
[2H, m, H(7) + H(4”)], 7.48-7.54 [3H, m, H(2”) + H(5”) + H(6”)], 7.88 [1H, d, 3J7,8 = 9.3
Hz, H(8)], 7.91 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 28.93 [C(3)],
35.82 [C(5)], 50.06 [C(2)], 50.97 [C(6)], 109.12 [C(5)], 112.54 [C(3”)], 118.99 [CN], 122.34
[C(A)], 122.56 [C(3)], 123.47 [C(7)], 128.25 [C(4a)], 129.20 [C(5”)], 129.38 [C(8)], 130.00
[C(2”)], 132.43 [C(4”)], 133.41 [C(6”)], 137.51 [C(4)], 138.74 [C(1”)], 141.12 [C(4’)], 143.09





Using General Method 11, 106r (93 mg, 0.26 mmol) was reacted with LiHMDS solution (1.0
M in THF, 570 µL, 0.57 mmol), Pd(dba)2 (1.5 mg, 2.6 µmol) and DavePhos (1.2 mg, 3.0
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with dichloromethane/methanol with 0.001% triethylamine gave 102r as a yellow oil
(39 mg, 42%). HRMS (ESI+) [M+H]+ calcd. for C22H20N4: 341.1766; found 341.1758. 1H
NMR (500 MHz, CDCl3): δ 2.54-2.60 [2H, m, H(5’)], 2.60-2.67 [2H, m, H(3’)], 3.21-3.29
[2H, m, H(2’)], 3.32-3.41 [2H, m, H(6’)], 4.91 [2H, br s, NH2], 6.35 [1H, s, H(A)], 6.70 [1H,
d, 3J3,4 = 8.8 Hz, H(3)], 6.99 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.39 [1H, dd, 3J7,8 = 9.1 Hz,
4J5,7 = 2.7 Hz, H(7)], 7.41-7.47 [2H, m, H(4”) + H(5”)], 7.48-7.54 [2H, m, H(2”) + H(6”)],





Using General Method 4, 53b (200 mg, 0.73 mmol) was reacted with trifluoroacetic acid (2
mL) to give 110b, which was used without further purification (25 mg, 20%). HRMS (ESI+)
[M+H]+ calcd. for C11H14N2: 175.1235; found 175.1232. 1H NMR (500 MHz, CDCl3): δ
2.29-2.35 [2H, m, H(5)], 2.36-2.42 [2H, m, H(3)], 2.74-2.89 [3H, m, H(2) + NH], 2.90-2.98
[2H, m, H(6)], 6.17 [1H, s, H(A)], 7.17 [1H, dd, 3J5’,6’ = 7.8 Hz, 3J4’,5’ = 4.8 Hz, H(5’)],
7.42 [1H, dt, 3J5’,6’ = 7.8 Hz, 4J2’,6’ = 4J4’,6’ = 1.6 Hz, H(6’)], 8.31-8.42 [2H, m, H(2’)
+ H(4’)]. 13C NMR (126 MHz, CDCl3): δ 32.93 [C(3)], 40.08 [C(5)], 49.93 [C(2)], 50.66







Using General Method 10, 110b (25 mg, 0.14 mmol) and 24 (42 mg, 0.17 mmol) were reacted
with Pd(OAc)2 (0.2 mg, 0.9 µmol), CataCXium® A ligand (0.5 mg, 1.4 µmol) and sodium
tert-butoxide (18 mg, 0.19 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with 1% methanol in dichloromethane gave
111b as an orange oil (22 mg, 46%). HRMS (ESI+) [M+H]+ calcd. for C20H1835ClN3/
C20H1837ClN3: 336.1268/338.1238; found 336.1260/338.1240. 1H NMR (500 MHz, CDCl3):
δ 2.57-2.62 [2H, m, H(5’)], 2.63-2.69 [2H, m, H(3’)], 3.35-3.42 [2H, m, H(2’)], 3.47-3.53
[2H, m, H(6’)], 6.36 [1H, s, H(A)], 7.02 [1H, d, 4J5,7 = 2.2 Hz, H(5)], 7.24-7.31 [2H, m, H(3)
+ H(5”)], 7.48-7.57 [2H, m, H(7) + H(6”)], 7.89 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.92 [1H, d,
3J3,4 = 8.6 Hz, H(4)], 8.47 [1H, br d‡, 3J4”,5” = 4.7 Hz, H(4”)], 8.51 [1H, br s‡, H(2”)]. 13C
NMR (126 MHz, CDCl3): δ 28.98 [C(3’)], 35.93 [C(5’)], 50.19 [C(2’)], 51.05 [C(6’)], 109.12
[C(5)], 120.78 [C(A)], 122.58 [C(3)], 123.26 [C(5”)], 123.51 [C(7)], 128.29 [C(4a)], 129.41
[C(8)], 133.25 [C(1”)], 136.13 [C(6”)], 137.51 [C(4)], 141.06 [C(4’)], 143.12 [C(8a)], 147.56






Using General Method 11, 111b (22 mg, 0.07 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 144 µL, 0.14 mmol), Pd(dba)2 (0.4 mg, 0.7 µmol) and DavePhos (0.3 mg,
0.8 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 3% methanol in dichloromethane with 0.001% triethylamine gave 108b as
a yellow oil (11 mg, 53%). HRMS (ESI+) [M+H]+ calcd. for C20H20N4: 317.1766; found
317.1760. 1H NMR (500 MHz, CDCl3): δ 2.53-2.61 [2H, m, H(5’)], 2.62-2.70 [2H, m, H(3’)],
3.20-3.30 [2H, m, H(2’)], 3.34-3.42 [2H, m, H(6’)], 5.19 [2H, br s, NH2], 6.33 [1H, s, H(A)],
6.70 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.98 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.24-7.29 [1H, m,
H(5”)], 7.39 [1H, dd, 3J7,8 = 9.1 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.54 [1H, br d, 3J5”,6” = 7.9
Hz, H(6”)], 7.61 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.79 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.46 [1H,
br d‡, 3J4”,5” = 4.0 Hz, H(4”)], 8.51 [1H, br s‡, H(2”)]. 13C NMR (126 MHz, CDCl3): δ
29.20 [C(3’)], 36.31 [C(5’)], 51.40 [C(2’)], 52.22 [C(6’)], 111.65 [C(5)], 112.22 [C(3)], 120.39
[C(A)], 123.23 [C(5”)], 123.70 [C(7)], 124.07 [C(4a)], 125.84 [C(8)], 133.39 [C(1”)], 136.16
[C(6”)], 138.02 [C(4)], 141.22 [br, C(8a)], 141.59 [C(4’)], 147.13 [C(6)], 147.50 [C(4”)],




Using General Method 4, 55s (219 mg, 0.73 mmol) was reacted with trifluoroacetic acid (2
mL) for 1 hr. Work-up followed by purification by column chromatography on silica gel eluting
with dichloromethane gave 112s as a red oil (59 mg, 41%). HRMS (ESI+) [M+H]+ calcd.
for C13H14N2: 199.1235; found 199.1229. 1H NMR (500 MHz, CDCl3): δ 2.25 [2H, br s‡,
H(5)], 3.21 [2H, t, 3J5,6 = 6.0 Hz, H(6)], 3.42 [2H, s, H(A)], 3.62 [2H, br s‡, H(2)], 5.44 [1H,
br s‡, H(3)], 6.44 [1H, br s, NH], 7.26-7.32 [2H, m, H(2’) + H(6’)], 7.55-7.63 [2H, m, H(3’)
+ H(5’)]. 13C NMR (126 MHz, CDCl3): δ 25.17 [C(5)], 40.92 [C(6)], 41.96 [C(2)], 43.47
[C(A)], 110.90 [C(4’)], 117.28 [C(3)], 118.87 [CN], 129.91 [C(2’) + C(6’)], 132.56 [C(3’) +







Using General Method 10, 112s (45 mg, 0.23 mmol) and 24 (66 mg, 0.27 mmol) were reacted
with Pd(OAc)2 (0.3 mg, 1.1 µmol), CataCXium® A ligand (0.8 mg, 2.3 µmol) and sodium
tert-butoxide (28 mg, 0.30 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave a crude mixture
containing largely 184s as a red oil (38 mg, 47%). 1H NMR (500 MHz, CDCl3): δ 2.19 [2H,
br s‡, H(5’)], 3.44 [2H, br s, H(A)], 3.48 [2H, t, 3J5’,6’ = 5.7 Hz, H(6’)], 3.83 [2H, br s‡,
H(2’)], 5.59 [1H, br s‡, H(3’)], 6.95 [1H, d, 4J5,7 = 2.5 Hz, H(5)], 7.27 [1H, d, 3J3,4 = 8.6
Hz, H(3)], 7.29-7.35 [2H, m, H(2”) + H(6”)], 7.47 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.5 Hz,
H(7)], 7.57-7.63 [2H, m, H(3”) + H(5”)], 7.87 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90 [1H, d,
3J3,4 = 8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 28.84 [C(5’)], 43.69 [C(A)], 45.59
[C(6’)], 48.04 [C(2’)], 107.81 [C(5)], 110.46 [C(4”)], 119.07 [CN], 121.33 [C(3’)], 122.26
[C(7)], 122.55 [C(3)], 128.31 [C(4a)], 129.30 [C(8)], 129.90 [C(2”) + C(6”)], 132.40 [C(3”)







Using General Method 11, 184s (28 mg, 0.08 mmol) was reacted with LiHMDS solution
(1.0 M in THF, 170 µL, 0.17 mmol), Pd(dba)2 (0.5 mg, 0.8 µmol) and DavePhos (0.3 mg,
0.9 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 1% methanol in dichloromethane gave an inseparable mixture of 109s and
19s as a red oil (11 mg). HRMS (ESI+) [M+H]+ calcd. for C22H20N4: 341.1766; found
341.1758. HRMS (ESI+) [M+H]+ calcd. for C22H22N4: 343.1923; found 343.1913. 1H
NMR (500 MHz, CDCl3): δ 1.48 [0.8H, qd, 2J(*3’/*5’)ax,(*3’/*5’)eq = 3J(*2’/*6’)ax,(*3’/*5’)ax =
3J(*3’/*5’)ax,*4’ax = 12.1 Hz, 3J(*2’/*6’)eq,(*3’/*5’)ax = 3.0 Hz, *H(3’ax) + *H(5’ax)], 1.59-1.87
[1.2H, m, *H(4’ax) + *H(3’eq) + *H(5’eq)], 2.18 [1.2H, br s‡, H(5’)], 2.61-2.74 [1.6H, m,
*H(2’ax) + *H(6’ax) + *H(A)], 3.37 [1.2H, t, 3J5’,6’ = 5.7 Hz, H(6’)], 3.43 [1.2H, s, H(A)],
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3.68 [0.8H, br d‡, 2J(*2’/*6’)ax,(*2’/*6’)eq = 12.1 Hz, *H(2’eq) + *H(6’eq)], 3.75 [1.2H, br s‡,
H(2’)], 4.72 [2H, br s, NH2 + *NH2], 5.58 [0.6H, br s‡, H(3’)], 6.64-6.72 [1H, m, H(3)
+ *H(3)], 6.90-6.98 [1H, m, H(5) + *H(5)], 7.27-7.39 [3H, m, H(7) + H(2”) + H(6”) +
*H(7) + *H(2”) + *H(6”)], 7.53-7.65 [3H, m, H(8) + H(3”) + H(5”) + *H(8) + *H(3”)
+ *H(5”)], 7.73-7.81 [1H, m, H(4) + *H(4)].
*Denotes signals corresponding to minor product 19s.
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6.3 2-Aminoquinolines with 6-position biaryl substituents
6.3.1 Synthesis of biaryl-extended 4-piperidine derivatives















A mixture of the aryl bromide (1.0 eq) and phenylboronic acid (1.2 eq) was combined with
Pd(OAc)2 (3 mol %), PPh3 (5 mol %) and potassium carbonate (1.5 eq) in toluene in a glass
pressure tube. The tube was sealed and heated at 100°C for the given time, then cooled and
filtered through Celite® washing with methanol. The solvent was removed by evaporation
under reduced pressure and purified by column chromatography with the specified eluant.

















A mixture of the aryl bromide (1.0 eq) and arylboronic acid derivative (1.2 eq) was combined
with Pd(OAc)2 (3 mol %), PPh3 (5 mol %) and potassium carbonate (1.5 eq) in toluene/
ethanol (1:1) in a glass pressure tube. The tube was sealed and heated at 100°C for the
given time, then cooled and filtered through Celite® washing with methanol. The solvent was





Synthesis method a.133 A mixture of 45m (100 mg, 0.28 mmol), phenylboronic acid (52 mg,
0.43 mmol), Pd(PPh3)4 (9.8 mg, 8.5 µmol), and potassium carbonate (59 mg, 0.43 mmol)
in toluene (2.5 mL) were combined in a glass pressure tube in toluene (2 mL). The tube
was sealed and heated to 80°C for 2 hr, then cooled, quenched with water, and extracted
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with dichloromethane (3 x 30 mL). Removal of volatile solvent under reduced pressure gave a
crude residue. 1H NMR analysis demonstrated the mixture contained a 3:1 mixture of starting
material 45m and target product 121b.
Synthesis method b.92 A mixture of 45m (100 mg, 0.28 mmol), phenylboronic acid (52 mg,
0.43 mmol), Pd(OAc)2 (0.6 mg, 2.7 µmol), and sodium carbonate (60 mg, 0.57 mmol) in
toluene (2.5 mL) were combined in H2O/DMF (3.5:3, 3 mL) and heated to 35°C for 2 hr,
then cooled, quenched with water, and extracted with dichloromethane (3 x 30 mL). Removal
of volatile solvent under reduced pressure gave a crude residue containing only unreacted
starting material.
Synthesis method c. Using General Method 12, 45m (400 mg, 1.14 mmol) and phenylboronic
acid (208 mg, 1.71 mmol) were reacted in a glass pressure tube with Pd(OAc)2 (7.6 mg, 32
µmol), PPh3 (15 mg, 57 µmol) and potassium carbonate (235 mg, 1.70 mmol) in toluene
(2.5 mL) for 4 hr. The residue was purified by column chromatography on silica gel eluting
with 1:19 ethyl acetate/hexane to give 121b as a white solid (288 mg, 73%). Rf = 0.24 (1:9
ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C23H27NO2 − C(CH3)3: 294.1494;
found 294.1488. 1H NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.30-2.40 [2H, m, H(5)],
2.47-2.57 [2H, m, H(3)], 3.37-3.47 [2H, m, H(2)], 3.49-3.57 [2H, m, H(6)], 6.39 [1H, s,
H(A)], 7.24-7.30 [2H, m, H(2’) + H(6’)], 7.33 [1H, br t‡, 3J3”,4” = 3J4”,5” = 7.4 Hz, H(4”)],
7.40-7.47 [2H, m, H(3”) + H(5”)], 7.53-7.57 [2H, m, H(3’) + H(5’)], 7.57-7.62 [2H, m,
H(2”) + H(6”)]. 13C NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.43 [br, C(3)], 36.41 [br,
C(5)], 45.17 [br, C(2) + C(6)], 79.67 [tBu], 124.27 [C(A)], 126.98 [C(3’) + C(5’)], 127.06
[C(2”) + C(6”)], 127.32 [C(4”)], 128.88 [C(3”) + C(5”)], 129.43 [C(2’) + C(6’)], 136.58




Using General Method 12, 45l (278 mg, 0.79 mmol), phenylboronic acid (149 mg, 1.22
mmol), Pd(OAc)2 (5.3 mg, 24 µmol), PPh3 (10 mg, 38 µmol) and potassium carbonate
(164 mg, 1.19 mmol) in toluene (2.5 mL) were reacted for 4 hr. Work-up as specified and
column chromatography on silica gel eluting with 1:19 ethyl acetate/hexane gave 121a as a
pale yellow oil (223 mg, 81%). Rf = 0.20 (1:9 ethyl acetate/hexane). 1H NMR (500 MHz,
CDCl3): δ 1.48 [9H, s, tBu], 2.30-2.42 [2H, m, H(5)], 2.46-2.58 [2H, m, H(3)], 3.36-3.47
[2H, m, H(2)], 3.48-3.58 [2H, m, H(6)], 6.42 [1H, s, H(A)], 7.18 [1H, br d‡, 3J5’,6’ = 7.5 Hz,
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H(6’)], 7.32-7.48 [6H, m, H(2’) + H(4’) + H(5’) + H(3”) + H(4”) + H(5”)], 7.55-7.62 [2H,





Synthesis method a. Using General Method 12, 45l (104 mg, 0.30 mmol), 4-pyridinyl-
boronic acid (73 mg, 0.59 mmol), Pd(OAc)2 (2.0 mg, 8.9 µmol), PPh3 (3.9 mg, 14.9 µmol)
and potassium carbonate (82 mg, 0.59 mmol) in toluene (2.5 mL) were reacted for 16 hr.
Work-up as specified gave a mixture of recovered reagents and none of the desired product.
Synthesis method b. Using General Method 13, 45l (167 mg, 0.47 mmol) and 4-pyridinyl-
boronic acid (117 mg, 0.95 mmol) were reacted with Pd(OAc)2 (3.2 mg, 14 µmol), PPh3 (6.3
mg, 24 µmol) and potassium carbonate (132 mg, 0.96 mmol) in toluene/ethanol (1:1, 2.5
mL) for 16 hr. The crude mixture was purified by column chromatography on silica gel eluting
with 1:1 ethyl acetate/hexane to give 122b as a pale yellow solid (166 mg, 100%). Rf = 0.33
(1:1 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd. for C22H26N2O2: 351.2073; found
351.2068. 1H NMR (500 MHz, CDCl3): δ 1.49 [9H, s, tBu], 2.33-2.42 [2H, m, H(5)], 2.46-
2.54 [2H, m, H(3)], 3.39-3.47 [2H, m, H(2)], 3.50-3.58 [2H, m, H(6)], 6.43 [1H, s, H(A)],
7.26-7.29 [1H, m, H(6’)], 7.42-7.53 [5H, m, H(2’) + H(4’) + H(5’) + H(2”) + H(6”)],
8.64-8.69 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 28.60 [tBu], 29.45 [br,
C(3)], 36.35 [br, C(5)], 45.01 [br, C(2) + C(6)], 79.78 [tBu], 121.77 [C(2”) + C(6”)], 124.13
[C(A)], 125.11 [C(5’)], 127.69 [C(2’)], 129.12 [C(4’)], 129.65 [C(6’)], 138.30 [C(3’)], 138.48





Using General Method 13, 45k (164 mg, 0.47 mmol), 4-pyridinylboronic acid (80 mg, 0.65
mmol), Pd(OAc)2 (3.1 mg, 14 µmol), PPh3 (6.1 mg, 23 µmol) and potassium carbonate (129
mg, 0.93 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
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and column chromatography on silica gel eluting with 2:3 ethyl acetate/hexane gave 122a
as a pale yellow oil (101 mg, 62%). Rf = 0.21 (2:3 ethyl acetate/hexane). HRMS (ESI+)
[M+H]+ calcd. for C22H26N2O2: 351.2073; found 351.2069. 1H NMR (500 MHz, CDCl3):
δ 1.46 [9H, s, tBu], 2.16-2.26 [4H, m, H(3) + H(5)], 3.19-3.29 [2H, m, H(2)], 3.39-3.46
[2H, m, H(6)], 6.16 [1H, s, H(A)], 7.23-7.41 [6H, m, H(3’) + H(4’) + H(5’) + H(6’) +
H(2”) + H(6”)], 8.59-8.65 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 28.55
[tBu], 29.43 [br, C(3)], 36.00 [br, C(5)], 44.94 [br, C(2) + C(6)], 79.72 [tBu], 123.53 [C(A)],
124.61 [C(2”) + C(6”)], 127.37 [*C(3’)], 128.35 [*C(6’)], 129.51 [*C(4’)], 130.58 [*C(5’)],
135.56 [C(2’)], 138.56 [C(1’)], 139.12 [C(4)], 149.35 [C(1”)], 149.58 [C(3”) + C(5”)], 154.77
[C=O].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment




Using General Method 13, 45m (160 mg, 0.45 mmol), 4-pyridinylboronic acid (98 mg, 0.80
mmol), Pd(OAc)2 (3.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate
(157 mg, 1.14 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up
as specified and column chromatography on silica gel eluting with 2:3 ethyl acetate/hexane
gave 122c as a pale colourless oil (159 mg, 100%). Rf = 0.18 (3:7 ethyl acetate/hexane).
HRMS (ESI+) [M+H]+ calcd. for C22H26N2O2 − C(CH3)3: 295.1447; found 295.1446. 1H
NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.32-2.40 [2H, m, H(5)], 2.46-2.55 [2H, m,
H(3)], 3.39-3.47 [2H, m, H(2)], 3.50-3.57 [2H, m, H(6)], 6.40 [1H, s, H(A)], 7.29-7.34 [2H,
m, H(2’) + H(6’)], 7.48-7.53 [2H, m, H(2”) + H(6”)], 7.58-7.63 [2H, m, H(3’) + H(5’)],
8.63-8.67 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 28.61 [tBu], 29.49 [br,
C(5)], 36.45 [br, C(3)], 45.54 [br, C(2) + C(6)], 79.79 [tBu], 121.50 [C(2”) + C(6”)], 123.97
[C(A)], 126.90 [C(3’) + C(5’)], 129.77 [C(2’) + C(6’)], 136.06 [C(4’)], 138.56 [C(1’)], 139.84






Using General Method 13, 36k (200 mg, 0.57 mmol), 3-pyridinylboronic acid (140 mg, 1.1
mmol), Pd(OAc)2 (2.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate (157
mg, 1.1 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 1:1 ethyl acetate/hexane gave 123a
as a colourless oil (113 mg, 57%). Rf = 0.47 (1:1 ethyl acetate/hexane). HRMS (ESI+)
[M+H]+ calcd. for C22H26N2O2: 351.2073; found 351.2066. 1H NMR (500 MHz, CDCl3):
δ 1.46 [9H, s, tBu], 2.12-2.31 [4H, m, H(3) + H(5)], 3.15-3.32 [2H, m, H(2)], 3.36-3.46
[2H, m, H(6)], 6.16 [1H, s, H(A)], 7.23-7.39 [5H, m, H(3’) + H(4’) + H(5’) + H(6’) +
H(5”)], 7.65-7.70 [1H, m, H(6”)], 8.56 [1H, d, 3J4”,5” = 4.5 Hz, H(4”)], 8.62 [1H, s, H(2”)].
13C NMR (126 MHz, CDCl3): δ 28.55 [tBu], 29.46 [br, C(3)], 35.98 [br, C(5)], 44.83 [br,
C(2) + C(6)], 79.59 [tBu], 122.97 [C(5”)], 123.66 [C(A)], 127.37 [C(4’)], 127.92 [*C(3’)
or C(5’)], 129.93 [*C(3’) or C(5’)], 130.52 [C(6’)], 135.91 [C(1’)], 136.85 [C(6”)], 137.11
[C(2’)], 137.60 [C(1”)], 139.04 [C(4)], 148.19 [C(4”)], 150.45 [C(2”)], 154.80 [C=O].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment





Using General Method 13, 36l (200 mg, 0.57 mmol), 3-pyridinylboronic acid (98 mg, 0.80
mmol), Pd(OAc)2 (3.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate (157
mg, 1.14 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 1:3 ethyl acetate/hexane gave 123b
as a colourless oil (182 mg, 91%). Rf = 0.14 (1:3 ethyl acetate/hexane). HRMS (ESI+)
[M+H]+ calcd. for C22H26N2O2: 351.2073; found 351.2068. 1H NMR (500 MHz, CDCl3): δ
1.48 [9H, s, tBu], 2.33-2.40 [2H, m, H(5)], 2.47-2.53 [2H, m, H(3)], 3.39-3.46 [2H, m, H(2)],
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3.50-3.56 [2H, m, H(6)], 6.43 [1H, s, H(A)], 7.21-7.26 [1H, m, H(5’)], 7.36 [1H, dd, 3J5”,6”
= 7.9 Hz, 3J4”,5” = 4.8 Hz, H(5”)], 7.39 [1H, s, H(2’)], 7.41-7.47 [2H, m, H(4’) + H(6’)],
7.84-7.89 [1H, m, H(6”)], 8.60 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.2 Hz, H(4”)], 8.84 [1H,
d, 4J2”,6” = 2.0 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 28.60 [tBu], 29.47 [br, C(3)],
36.36 [br, C(5)], 45.24 [br, C(2) + C(6)], 79.76 [tBu], 123.67 [C(5”)], 124.25 [C(A)], 125.27
[C(4’)], 127.85 [C(2’)], 128.73 [C(5’)], 129.08 [C(6’)], 134.47 [C(6’)], 136.70 [C(3”)], 137.97





Using General Method 13, 36m (300 mg, 0.98 mmol), 3-pyridinylboronic acid (180 mg, 1.46
mmol), Pd(OAc)2 (6.6 mg, 29 µmol), PPh3 (13 mg, 49 µmol) and potassium carbonate (270
mg, 2.0 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 2:3 ethyl acetate/hexane gave 123c as
a colourless oil (151 mg, 51%). HRMS (ESI+) [M+H]+ calcd. for C22H26N2O2: 351.2073;
found 351.2072. 1H NMR (500 MHz, CDCl3): δ 1.49 [9H, s, tBu], 2.33-2.41 [2H, m, H(5)],
2.47-2.55 [2H, m, H(3)], 3.38-3.48 [2H, m, H(2)], 3.49-3.58 [2H, m, H(6)], 6.40 [1H, s,
H(A)], 7.28-7.33 [2H, m, H(2’) + H(6’)], 7.35 [1H, dd, 3J5”,6” = 7.9 Hz, 3J4”,5” = 4.8 Hz,
H(5”)], 7.52-7.58 [2H, m, H(3’) + H(5’)], 7.87 [1H, ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.2 Hz,
4J4”,6” = 1.6 Hz, H(6”)], 8.58 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.6 Hz, H(4”)], 8.86 [1H, d,
4J2”,6” = 2.2 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 28.57 [tBu], 29.43 [br, C(3)], 36.39
[br, C(5)], 45.22 [br, C(2) + C(6)], 79.71 [tBu], 123.64 [C(5”)], 124.01 [C(A)], 126.98 [C(3’)
+ C(5’)], 129.72 [C(2’) + C(6’)], 134.19 [C(6”)], 135.80 [C(4’)], 136.35 [C(1”)], 137.49





Using General Method 13, 45k (200 mg, 0.57 mmol), 5-pyrimidinylboronic acid (85 mg, 0.69
mmol), Pd(OAc)2 (3.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate (157
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mg, 1.14 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 2:3 ethyl acetate/hexane gave 124a
as a colourless oil (172 mg, 86%). Rf = 0.26 (2:3 ethyl acetate/hexane). HRMS (ESI+)
[M+H]+ calcd. for C21H25N3O2: 352.2025; found 352.2028. 1H NMR (500 MHz, CDCl3): δ
1.46 [9H, s, tBu], 2.13-2.31 [4H, m, H(3) + H(5)], 3.22-3.36 [2H, m, H(2)], 3.40-3.48 [2H,
m, H(6)], 6.17 [1H, s, H(A)], 7.29 [1H, d, 3J5’,6’ = 7.3 Hz, H(6’)], 7.34 [1H, d, 3J3’,4’ =
7.3 Hz, H(3’)], 7.36-7.45 [2H, m, H(4’) + H(5’)], 8.76 [2H, s, H(2”) + H(6”)], 9.17 [1H, s,
H(4”)]. 13C NMR (126 MHz, CDCl3): δ 28.53 [tBu], 29.49 [br, C(3)], 35.95 [br, C(5)], 44.98
[br, C(2) + C(6)], 79.78 [tBu], 122.92 [C(A)], 127.72 [C(4’)], 128.84 [C(5’)], 129.74 [C(3’)],
130.83 [C(6’)], 133.81 [C(2’)], 134.98 [C(1”)], 136.06 [C(1’)], 140.31 [C(4)], 154.73 [C=O],






Using General Method 13, 36l (200 mg, 0.57 mmol), 5-pyrimidinylboronic acid (99 mg, 0.80
mmol), Pd(OAc)2 (3.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate (157
mg, 1.14 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 1:1 ethyl acetate/hexane gave 124b
as a yellow solid (173 mg, 87%). Rf = 0.41 (1:1 ethyl acetate/hexane). MP: 120-121°C.
HRMS (ESI+) [M+H]+ calcd. for C21H25N3O2 − C(CH3)3: 296.1399; found 296.1394. 1H
NMR (500 MHz, CDCl3): δ 1.48 [9H, s, tBu], 2.34-2.41 [2H, m, H(5)], 2.46-2.53 [2H, m,
H(3)], 3.39-3.46 [2H, m, H(2)], 3.51-3.57 [2H, m, H(6)], 6.43 [1H, s, H(A)], 7.30 [1H, d,
3J5’,6’ = 7.6 Hz, H(6’)], 7.39 [1H, s, H(2’)], 7.43 [1H, d, 3J4’,5’ = 7.6 Hz, H(4’)], 7.48 [1H,
t, 3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)], 8.95 [2H, s, H(2”) + H(6”)], 9.21 [1H, s, H(4”)]. 13C
NMR (126 MHz, CDCl3): δ 28.59 [tBu], 29.47 [br, C(3)], 36.34 [br, C(5)], 45.15 [br, C(2)
+ C(6)], 79.81 [tBu], 123.90 [C(A)], 125.06 [C(4’)], 127.64 [C(2’)], 129.44 [C(5’)], 129.61
[C(6’)], 134.42 [C(3’) + C(1”)], 138.85 [C(1’)], 139.99 [C(4)], 154.85 [C=O], 155.04 [C(2”)







Using General Method 13, 36m (200 mg, 0.57 mmol), 5-pyrimidinylboronic acid (85 mg, 0.69
mmol), Pd(OAc)2 (3.8 mg, 17 µmol), PPh3 (7.4 mg, 28 µmol) and potassium carbonate (157
mg, 1.14 mmol) in toluene/ethanol (1:1, 2.5 mL) were reacted for 16 hr. Work-up as specified
and column chromatography on silica gel eluting with 1:4 ethyl acetate/hexane gave 124c as
a colourless oil (184 mg, 92%). HRMS (ESI+) [M+H]+ calcd. for C21H25N3O2 − C(CH3)3:
296.1399; found 296.1389. 1H NMR (500 MHz, CDCl3): δ 1.49 [9H, s, tBu], 2.31-2.43 [2H,
m, H(5)], 2.46-2.56 [2H, m, H(3)], 3.37-3.49 [2H, m, H(2)], 3.50-3.60 [2H, m, H(6)], 6.41
[1H, s, H(A)], 7.32-7.38 [2H, m, H(2’) + H(6’)], 7.52-7.58 [2H, m, H(3’) + H(5’)], 8.96 [2H,
s, H(2”) + H(6”)], 9.19 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 28.55 [tBu], 29.42
[br, C(3)], 36.38 [br, C(5)], 44.42 [br, C(2)], 45.47 [br, C(6)], 79.72 [tBu], 123.73 [C(A)],
126.81 [C(3’) + C(5’)], 130.02 [C(2’) + C(6’)], 132.16 [C(4’)], 134.06 [C(1”)], 138.43 [C(1’)],




Using General Method 3, 121a (223 mg, 0.64 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 125a as a colourless
oil (224 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C18H21N: 252.1752; found 252.1749.
1H NMR (500 MHz, CDCl3): δ 1.05-1.26 [2H, m, H(3ax) + H(5ax)], 1.45 [9H, s, tBu],
1.55-1.85 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.49-2.79 [4H, m, H(2ax) + H(6ax) + H(A)],
3.88-4.28 [2H, m, H(2eq) + H(6eq)], 7.12 [1H, br d‡, 3J5’,6’ = 7.5 Hz, H(6’)], 7.30-7.50 [6H,





Using General Method 3, 121b (278 mg, 0.80 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 125b as a white
solid (280 mg, 100%). Rf = 0.32 (1:9 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd.
for C23H29NO2 − C(CH3)3: 296.1651; found 296.1643. 1H NMR (500 MHz, CDCl3): δ
1.10-1.25 [2H, m, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.61-1.76 [3H, m, H(3eq) + H(4ax)
+ H(5eq)], 2.51-2.74 [4H, m, H(2ax) + H(6ax) + H(A)], 3.96-4.23 [2H, m, H(2eq) + H(6eq)],
7.17-7.24 [2H, m, H(2’) + H(6’)], 7.32 [1H, t, 3J3”,4” = 3J4”,5” = 7.5 Hz, H(4”)], 7.39-7.46
[2H, m, H(3”) + H(5”)], 7.48-7.54 [2H, m, H(3’) + H(5’)], 7.55-7.61 [2H, m, H(2”) +
H(6”)]. 13C NMR (126 MHz, CDCl3): δ 28.62 [tBu], 32.17 [br, C(3) + C(5)], 38.33 [C(4)],
42.92 [C(A)], 44.33 [br, C(2) + C(6)], 79.38 [tBu], 127.11 [C(3’) + C(5’)], 127.11 [C(2”)
+ C(6”)], 127.19 [C(4”)], 128.86 [C(3”) + C(5”)], 129.67 [C(2’) + C(6’)], 139.04 [C(4’)],





Using General Method 3, 122a (111 mg, 0.32 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 126a as a colourless
oil (112 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C22H28N2O2 − C(CH3)3: 297.1603;
found 297.1593. 1H NMR (500 MHz, CDCl3): δ 0.94 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.1 Hz, 3J(2/6)eq,(3/5)ax = 3.6 Hz, H(3ax) + H(5ax)], 1.36-1.52 [12H, m, tBu
+ H(3eq) + H(4ax) + H(5eq)], 2.39-2.63 [4H, m, H(2ax) + H(6ax) + H(A)], 3.97 [2H, br
s‡, H(2eq) + H(6eq)], 7.16 [1H, br d‡, 3J3’,4’ = 7.7 Hz, H(3’)], 7.20-7.25 [2H, m, H(2”) +
H(6”)], 7.25-7.31 [2H, m, H(4’) + H(6’)], 7.34 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.7 Hz, 4J3’,5’ =
1.2 Hz, H(5’)], 8.62-8.69 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 28.56
[tBu], 32.98 [br, C(3) + C(5)], 37.92 [C(4)], 39.65 [C(A)], 43.67 [br, C(2) + C(6)], 79.38
[tBu], 124.57 [C(2”) + C(6”)], 126.35 [C(4’)], 128.38 [C(5’)], 129.68 [C(3’)], 130.36 [C(6’)],






Using General Method 3, 122b (137 mg, 0.39 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 126b as a yellow
oil (138 mg, 100%). Rf = 0.29 (1:1 ethyl acetate/hexane). HRMS (ESI+) [M+H]+ calcd.
for C22H28N2O2: 353.2229; found 353.2222. 1H NMR (500 MHz, CDCl3): δ 1.18 [2H, qd,
2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 11.8 Hz, 3J(2/6)eq,(3/5)ax = 2.9 Hz, H(3ax) +
H(5ax)], 1.45 [9H, s, tBu], 1.59-1.78 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.57-2.71 [4H, m,
H(2ax) + H(6ax) + H(A)], 3.95-4.26 [2H, m, H(2eq) + H(6eq)], 7.22 [1H, d, 3J5’,6’ = 7.5 Hz,
H(6’)], 7.38-7.43 [2H, m, H(2’) + H(5’)], 7.46-7.53 [3H, m, H(4’) + H(2”) + H(6”)], 8.63-
8.68 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 28.61 [tBu], 32.13 [br, C(3)
+ C(5)], 38.36 [C(4)], 43.32 [C(A)], 44.09 [br, C(2) + C(6)], 79.44 [tBu], 121.82 [C(2”) +
C(6”)], 124.86 [C(4’)], 127.88 [C(2’)], 129.18 [C(5’)], 130.00 [C(6’)], 138.34 [C(3’)], 141.37




Using General Method 3, 122c (167 mg, 0.48 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 126c as a yellow oil
(130 mg, 77%). HRMS (ESI+) [M+H]+ calcd. for C22H28N2O2: 353.2229; found 353.2224.
1H NMR (500 MHz, CDCl3): δ 0.94 [2H, br qd‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax
= 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.7 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.59-1.77 [3H, m,
H(3eq) + H(4ax) + H(5eq)], 2.55-2.73 [4H, m, H(2ax) + H(6ax) + H(A)], 3.94-4.27 [2H, m,
H(2eq) + H(6eq)], 7.22-7.30 [2H, m, H(2’) + H(6’)], 7.45-7.52 [2H, m, H(2”) + H(6”)],
7.53-7.60 [2H, m, H(3’) + H(5’)], 8.62-8.66 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz,
CDCl3): δ 28.61 [tBu], 32.11 [br, C(3) + C(5)], 38.26 [C(4)], 42.95 [C(A)], 44.04 [br, C(2) +
C(6)], 79.42 [tBu], 121.54 [C(2”) + C(6”)], 126.98 [C(3’) + C(5’)], 130.02 [C(2’) + C(6’)],






Using General Method 3, 123a (110 mg, 0.31 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 127a as a pale
yellow oil (103 mg, 93%). HRMS (ESI+) [M+H]+ calcd. for C22H28N2O2: 353.2229; found
353.2218. 1H NMR (500 MHz, CDCl3): δ 0.94 [2H, br qd‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.1 Hz, 3J(2/6)eq,(3/5)ax = 3.3 Hz, H(3ax) + H(5ax)], 1.35-1.51 [12H, m, tBu
+ H(3eq) + H(4ax) + H(5eq)], 2.43-2.58 [4H, m, H(2ax) + H(6ax) + H(A)], 3.96 [2H, br s‡,
H(2eq) + H(6eq)], 7.19 [1H, br d‡, 3J3’,4’ = 7.6 Hz, H(3’)], 7.32-7.38 [2H, m, H(5’) + H(5”)],
7.32-7.38 [2H, m, H(4’) + H(6’)], 7.61 [1H, dt, 3J5”,6” = 7.8 Hz, 4J2”,6” = 4J4”,6” = 1.5 Hz,
H(6”)], 8.56 [1H, d, 4J2”,6” = 1.5 Hz, H(2”)], 8.61 [1H, dd, 3J4”,5” = 4.6 Hz, 4J4”,6” = 1.5
Hz, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 28.58 [tBu], 32.01 [br, C(3) + C(5)], 37.93
[C(4)], 39.78 [C(A)], 44.13 [br, C(2) + C(6)], 79.39 [tBu], 123.15 [C(6’)], 126.34 [C(5”)],
128.20 [C(4’)], 130.34 [C(5’)], 130.45 [C(3’)], 136.74 [C(6”)], 137.64 [C(1”)], 138.11 [C(1’)],





Using General Method 3, 123b (182 mg, 0.52 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 127b as a colourless
oil (183 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C22H28N2O2: 353.2229; found
353.2226. 1H NMR (500 MHz, CDCl3): δ 1.18 [2H, br qd‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.6 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.58-
1.78 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.55-2.74 [4H, m, H(2ax) + H(6ax) + H(A)], 4.09
[2H, br s‡, H(2eq) + H(6eq)], 7.18 [1H, br d‡, 3J3’,4’ = 7.1 Hz, H(6’)], 7.32-7.45 [4H, m, H(2’)
+ H(4’) + H(5’) + H(5”)], 7.87 [1H, ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.0 Hz, 4J4”,6” = 1.6
Hz, H(6”)], 8.59 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.6 Hz, H(4”)], 8.84 [1H, d, 4J2”,6” =
2.0 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 28.60 [tBu], 32.13 [br, C(3) + C(5)], 38.32
327
[C(4)], 43.31 [C(A)], 44.07 [br, C(2) + C(6)], 79.39 [tBu], 123.62 [C(5”)], 124.98 [C(4’)],
128.04 [C(2’)], 129.02 [C(6’)], 129.12 [C(5’)], 134.47 [C(6”)], 136.79 [C(1”)], 138.00 [C(3’)],





Using General Method 3, 123c (135 mg, 0.39 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 127c as a colourless
oil (135 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C22H28N2O2: 353.2229; found
353.2225. 1H NMR (500 MHz, CDCl3): δ 1.18 [2H, br qd‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax
= 3J(3/5)ax,4ax = 12.4 Hz, 3J(2/6)eq,(3/5)ax = 4.1 Hz, H(3ax) + H(5ax)], 1.45 [9H, s, tBu], 1.58-
1.77 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.56-2.73 [4H, m, H(2ax) + H(6ax) + H(A)], 4.09
[2H, br s‡, H(2eq) + H(6eq)], 7.22-7.28 [2H, m, H(2’) + H(6’)], 7.35 [1H, ddd, 3J5”,6” = 7.9
Hz, 3J4”,5” = 4.8 Hz, 5J2”,5” = 0.6 Hz, H(5”)], 7.47-7.54 [2H, m, H(3’) + H(5’)], 7.86 [1H,
ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.0 Hz, 4J4”,6” = 1.6 Hz, H(6”)], 8.57 [1H, dd, 3J4”,5” = 4.8
Hz, 4J4”,6” = 1.6 Hz, H(4”)], 8.84 [1H, br d‡, 4J2”,6” = 2.0 Hz, H(2”)]. 13C NMR (126 MHz,
CDCl3): δ 28.59 [tBu], 32.11 [br, C(3) + C(5)], 38.27 [C(4)], 42.89 [C(A)], 44.10 [br, C(2)
+ C(6)], 79.38 [tBu], 123.63 [C(5”)], 127.09 [C(3’) + C(5’)], 129.97 [C(2’) + C(6’)], 134.25
[C(6”)], 135.63 [C(4’)], 136.55 [C(1”)], 140.47 [C(1’)], 148.31 [*C(2”)], 148.38 [*C(4”)],
154.97 [C=O].






Using General Method 3, 124a (162 mg, 0.46 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 128a as a
colourless oil (156 mg, 96%). HRMS (ESI+) [M+H]+ calcd. for C21H27N3O2 − C(CH3)3:
298.1556; found 298.1557. 1H NMR (500 MHz, CDCl3): δ 0.96 [2H, br qd‡, 2J(3/5)ax,(3/5)eq =
328
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 2.9 Hz, H(3ax) + H(5ax)], 1.36-1.51
[12H, m, tBu + H(3eq) + H(4ax) + H(5eq)], 2.46-2.59 [4H, m, H(A) + H(2ax) + H(6ax)], 3.99
[2H, br s‡, H(2eq) + H(6eq)], 7.19 [1H, d, 3J3’,4’ = 7.4 Hz, H(3’)], 7.29-7.36 [2H, m, H(4’)
+ H(6’)], 7.40 [1H, br t‡, 3J4’,5’ = 3J5’,6’ = 7.4 Hz, H(5’)], 8.71 [2H, s, H(2”) + H(6”)],
9.23 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 28.54 [tBu], 31.96 [C(3) + C(5)], 38.02
[C(4)], 39.75 [C(A)], 43.90 [br, C(2) + C(6)], 79.44 [tBu], 126.70 [C(4’)], 129.05 [C(5’)],
130.43 [C(3’)], 130.61 [C(6’)], 134.67 [C(2’)], 135.54 [C(1”)], 138.21 [C(1’)], 154.80 [C=O],






Using General Method 3, 124b (173 mg, 0.49 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 128b as a
colourless oil (174 mg, 100%). 1H NMR (500 MHz, CDCl3): δ 1.19 [2H, qd, 2J(3/5)ax,(3/5)eq =
3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 3.9 Hz, H(3ax) + H(5ax)], 1.45 [9H,
s, tBu], 1.59-1.79 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.55-2.75 [4H, m, H(A) + H(2ax) +
H(6ax)], 3.97-4.23 [2H, m, H(2eq) + H(6eq)], 7.25 [1H, dt, 3J5’,6’ = 6.9 Hz, 4J2’,6’ = 4J4’,6’ =
1.7 Hz, H(6’)], 7.35 [1H, br s‡, H(2’)], 7.39-7.47 [2H, m, H(4’) + H(5’)], 8.95 [2H, s, H(2”)
+ H(6”)], 9.20 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 28.56 [tBu], 32.07 [br, C(3)
+ C(5)], 38.26 [C(4)], 43.21 [C(A)], 43.99 [br, C(2) + C(6)], 79.39 [tBu], 124.79 [C(4’)],
127.78 [C(2’)], 129.45 [C(5’)], 129.89 [C(6’)], 134.42 [*C(3’) or C(1”)], 134.45 [*C(3’) or
C(1”)], 141.72 [C(1’)], 154.90 [C=O], 155.00 [C(2”) + C(6”)], 157.56 [C(4”)].







Using General Method 3, 124c (160 mg, 0.46 mmol) was reacted with Pd-C catalyst in
methanol (30 mL) under a hydrogen atmosphere for 16 hr. Work-up gave 128c as a colourless
oil (161 mg, 100%). HRMS (ESI+) [M+H]+ calcd. for C21H27N3O2 − C(CH3)3: 298.1556;
329
found 298.1559. 1H NMR (500 MHz, CDCl3): δ 1.11-1.25 [2H, m, H(3ax) + H(5ax)], 1.46
[9H, s, tBu], 1.59-1.79 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.58-2.74 [4H, m, H(A) + H(2ax)
+ H(6ax)], 3.91-4.23 [2H, m, H(2eq) + H(6eq)], 7.27-7.33 [2H, m, H(2’) + H(6’)], 7.48-7.54
[2H, m, H(3’) + H(5’)], 8.94 [2H, s, H(2”) + H(6”)], 9.19 [1H, s, H(4”)]. 13C NMR (126
MHz, CDCl3): δ 28.56 [tBu], 32.06 [br, C(3) + C(5)], 38.21 [C(4)], 42.87 [C(A)], 44.12 [br,
C(2) + C(6)], 79.37 [tBu], 126.92 [C(3’) + C(5’)], 130.29 [C(2’) + C(6’)], 132.04 [C(4’)],
134.22 [C(1”)], 141.51 [C(1’)], 154.81 [C(2”) + C(6”)], 154.91 [C=O], 157.40 [C(4”)].
4-((1,1’-Biphenyl)-3-ylmethyl)piperidine (117a)
NH
Using General Method 4, 125a (211 mg, 0.60 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (10 mL) to give 117a as a yellow oil (151 mg, 100%). 1H NMR
(500 MHz, CDCl3): δ 1.27-1.40 [2H, m, H(3ax) + H(5ax)], 1.65-1.83 [3H, m, H(3eq) + H(4ax)
+ H(5eq)], 2.54-2.72 [4H, m, H(A) + H(2ax) + H(6ax)], 3.17 [2H, br d‡, 2J(2/6)ax,(2/6)eq =
12.2 Hz, H(2eq) + H(6eq)], 4.89 [1H, br s, NH], 7.12 [1H, br d‡, 3J5’,6’ = 7.6 Hz, H(6’)],




Using General Method 4, 125b (134 mg, 0.38 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 117b as a white solid (95 mg, 99%). HRMS (ESI+)
[M+H]+ calcd. for C18H21N: 252.1752; found 252.1751. 1H NMR (500 MHz, CDCl3): δ
1.34 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.2 Hz, 3J(2/6)eq,(3/5)ax = 2.6
Hz, H(3ax) + H(5ax)], 1.65-1.80 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.52-2.70 [4H, m, H(A)
+ H(2ax) + H(6ax)], 3.18 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.1 Hz, H(2eq) + H(6eq)], 5.12 [1H,
br s, NH], 7.17-7.24 [2H, m, H(2’) + H(6’)], 7.32 [1H, tt, 3J3”,4” = 3J4”,5” = 7.4 Hz, 4J2”,4”
= 4J4”,6” = 1.1 Hz, H(4”)], 7.39-7.45 [2H, m, H(3”) + H(5”)], 7.48-7.54 [2H, m, H(3’) +
H(5’)], 7.55-7.60 [2H, m, H(2”) + H(6”)]. 13C NMR (126 MHz, CDCl3): δ 31.82 [C(3)
+ C(5)], 37.74 [C(4)], 43.06 [C(A)], 45.86 [C(2) + C(6)], 127.11 [C(2”) + C(6”)], 127.15
[C(3’) + C(5’)], 127.21 [C(4”)], 128.87 [C(3”) + C(5”)], 129.66 [C(2’) + C(6’)], 139.14





Using General Method 4, 126a (112 mg, 0.32 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 118a as a yellow oil (80 mg, 100%). HRMS (ESI+)
[M+H]+ calcd. for C17H20N2: 253.1705; found 253.1700. 1H NMR (500 MHz, CDCl3): δ
1.14-1.30 [2H, m, H(3ax) + H(5ax)], 1.37-1.62 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.48-2.65
[4H, m, H(A) + H(2ax) + H(6ax)], 3.13 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.4 Hz, H(2eq) +
H(6eq)], 4.68 [1H, br s, NH], 7.17 [1H, br d‡, 3J3’,4’ = 7.5 Hz, H(3’)], 7.20-7.38 [5H, m,
H(4’) + H(5’) + H(6’) + H(2”) + H(6”)], 8.59-8.70 [2H, m, H(3”) + H(5”)]. 13C NMR
(126 MHz, CDCl3): δ 30.46 [C(3) + C(5)], 36.53 [C(4)], 39.62 [C(A)], 44.99 [C(2) + C(6)],
124.44 [C(2”) + C(6”)], 126.63 [C(4’)], 128.48 [C(5’)], 129.83 [C(3’)], 130.46 [C(6’)], 136.66




Using General Method 4, 126b (127 mg, 0.36 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 118b as a yellow oil (57 mg, 63%). HRMS (ESI+)
[M+H]+ calcd. for C17H20N2: 253.1705; found 253.1701. 1H NMR (500 MHz, CDCl3): δ
1.51-1.64 [2H, m, H(3ax) + H(5ax)], 1.75-1.88 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.67
[2H, d, 3J4’ax,A = 6.7 Hz, H(A)], 2.79 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.8 Hz,
3J(2/6)ax,(3/5)eq = 1.9 Hz, H(2ax) + H(6ax)], 3.35 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq)
+ H(6eq)], 7.21 [1H, br d‡, 3J5’,6’ = 7.5 Hz, H(6’)], 7.37-7.45 [2H, m, H(2’) + H(5’)], 7.46-
7.77 [4H, m, NH + H(4’) + H(2”) + H(6”)], 8.62-8.69 [2H, m, H(3”) + H(5”)]. 13C NMR
(126 MHz, CDCl3): δ 31.69 [C(3) + C(5)], 39.07 [C(4)], 45.17 [C(A)], 46.87 [C(2) + C(6)],
124.30 [C(2”) + C(6”)], 127.78 [C(4’)], 130.27 [C(2’)], 131.95 [C(5’)], 132.37 [C(6’)], 141.12





Using General Method 4, 126c (124 mg, 0.35 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 118c as a pale yellow solid (85 mg, 96%).
HRMS (ESI+) [M+H]+ calcd. for C17H20N2: 253.1705; found 253.1704. 1H NMR (500
MHz, CDCl3): δ 1.48 [2H, br qd‡, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.8 Hz,
3J(2/6)eq,(3/5)ax = 3.3 Hz, H(3ax) + H(5ax)], 1.71-1.83 [3H, m, H(3eq) + H(4ax) + H(5eq)],
2.64 [2H, d, 3J4ax,A = 6.7 Hz, H(A)], 2.74 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.8
Hz, 3J(2/6)ax,(3/5)eq = 2.7 Hz, H(2ax) + H(6ax)], 3.29 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.8 Hz,
H(2eq) + H(6eq)], 5.58 [1H, br s, NH], 7.22-7.29 [2H, m, H(2’) + H(6’)], 7.46-7.51 [2H, m,
H(2”) + H(6”)], 7.53-7.61 [2H, m, H(3’) + H(5’)], 8.60-8.67 [2H, m, H(3”) + H(5”)]. 13C
NMR (126 MHz, CDCl3): δ 30.31 [C(3) + C(5)], 37.00 [C(4)], 42.64 [C(A)], 44.99 [C(2)
+ C(6)], 121.55 [C(2”) + C(6”)], 127.11 [C(3’) + C(5’)], 129.97 [C(2’) + C(6’)], 136.20




Using General Method 4, 127a (103 mg, 0.29 mmol) and trifluoroacetic acid (1 mL) were
reacted in dichloromethane (4 mL) to give 119a as a yellow oil (73 mg, 99%). HRMS (ESI+)
[M+H]+ calcd. for C17H20N2: 253.1705; found 253.1702. 1H NMR (500 MHz, CDCl3): δ
1.25 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.4 Hz, 3J(2/6)eq,(3/5)ax = 3.7
Hz, H(3ax) + H(5ax)], 1.47 [1H, ttt, 3J(3/5)ax,4ax = 12.4 Hz, 3J4ax,A = 7.5 Hz, 3J(3/5)eq,4ax =
3.7 Hz, H(4ax)], 1.56 [1H, br d‡, 2J(3/5)ax,(3/5)eq = 12.4 Hz, H(3eq) + H(5eq)], 2.55-2.64 [4H,
m, H(A) + H(2ax) + H(6ax)], 3.16 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.4 Hz, H(2eq) + H(6eq)],
4.20 [1H, br s, NH], 7.20 [1H, dd, 3J3’,4’ = 7.5 Hz, 4J3’,5’ = 1.4 Hz, H(3’)], 7.25 [1H, dd,
3J5’,6’ = 7.5 Hz, 4J4’,6’ = 1.4 Hz, H(6’)], 7.30 [1H, td, 3J3’,4’ = 3J4’,5’ = 7.5 Hz, 4J4’,6’ =
1.4 Hz, H(4’)], 7.32-7.39 [2H, m, H(5’) + H(5”)], 7.61 [1H, dt, 3J5”,6” = 7.7 Hz, 4J2”,6” =
4J4”,6” = 1.8 Hz, H(6”)], 8.54 [1H, d, 4J2”,6” = 1.8 Hz, H(2”)], 8.60 [1H, dd, 3J4”,5” = 4.8
Hz, 4J4”,6” = 1.8 Hz, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 29.83 [C(3) + C(5)], 36.27
[C(4)], 39.51 [C(A)], 44.65 [C(2) + C(6)], 123.26 [C(5”)], 126.69 [C(4’)], 128.34 [C(5’)],
332
130.39 [C(6’)], 130.58 [C(3’)], 136.66 [C(6”)], 137.18 [C(1’)], 137.39 [C(1”)], 138.53 [C(2’)],




Using General Method 4, 127b (159 mg, 0.45 mmol) and trifluoroacetic acid (2 mL) were
reacted in dichloromethane (8 mL) to give 119b as a yellow oil (114 mg, 100%). HRMS
(ESI+) [M+H]+ calcd. for C17H20N2: 253.1705; found 253.1700. 1H NMR (500 MHz,
CDCl3): δ 1.50-1.63 [2H, m, H(3ax) + H(5ax)], 1.76-1.89 [3H, m, H(3eq) + H(4ax) + H(5eq)],
2.67 [2H, d, 3J4ax,A = 6.8 Hz, H(A)], 2.79 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.6
Hz, 3J(2/6)ax,(3/5)eq = 2.4 Hz, H(2ax) + H(6ax)], 3.34 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.6 Hz,
H(2eq) + H(6eq)], 7.07 [1H, br s, NH], 7.18 [1H, br d‡, 3J5’,6’ = 7.3 Hz, H(6’)], 7.32-7.47
[4H, m, H(2’) + H(4’) + H(5’) + H(5”)], 7.86 [1H, ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.0 Hz,
4J4”,6” = 1.6 Hz, H(6”)], 8.59 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.6 Hz, H(4”)], 8.83 [1H,
d, 4J2”,6” = 2.0 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 29.37 [C(3) + C(5)], 36.63
[C(4)], 42.72 [C(A)], 44.46 [C(2) + C(6)], 123.68 [C(5”)], 125.36 [C(4’)], 127.93 [C(2’)],
128.93 [C(6’)], 129.36 [C(5’)], 134.50 [C(6”)], 136.61 [C(1”)], 138.25 [C(3’)], 140.21 [C(1’)],




Using General Method 4, 127c (127 mg, 0.36 mmol) and trifluoroacetic acid (1.5 mL) were
reacted in dichloromethane (6 mL) to give 119c as a yellow oil (89 mg, 98%). 1H NMR
(500 MHz, CDCl3): δ 1.34-1.46 [2H, m, H(3ax) + H(5ax)], 1.68-1.80 [3H, m, H(3eq) + H(4ax)
+ H(5eq)], 2.56-2.74 [4H, m, H(A) + H(2ax) + H(6ax)], 3.22 [2H, br d‡, 2J(2/6)ax,(2/6)eq =
12.3 Hz, H(2eq) + H(6eq)], 4.03 [1H, br s, NH], 7.21-7.28 [2H, m, H(2’) + H(6’)], 7.35 [1H,
ddd, 3J5”,6” = 7.9 Hz, 3J4”,5” = 4.8 Hz, 5J2”,5” = 0.6 Hz, H(5”)], 7.47-7.54 [2H, m, H(3’) +
H(5’)], 7.86 [1H, ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.1 Hz, 4J4”,6” = 1.7 Hz, H(6”)], 8.57 [1H,
dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.7 Hz, H(4”)], 8.84 [1H, dd, 4J2”,6” = 2.1 Hz, 5J2”,5” = 0.6
Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 31.09 [C(3) + C(5)], 37.42 [C(4)], 42.85 [C(A)],
45.46 [C(2) + C(6)], 123.67 [C(5”)], 127.23 [C(3’) + C(5’)], 129.97 [C(6”)], 134.29 [C(2’)





Using General Method 4, 128a (156 mg, 0.44 mmol) and trifluoroacetic acid (1.5 mL) were
reacted in dichloromethane (6 mL) to give 120a as a yellow oil (85 mg, 76%). HRMS (ESI+)
[M+H]+ calcd. for C16H19N3: 254.1657; found 254.1653. 1H NMR (500 MHz, CDCl3): δ
1.16 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 13.0 Hz, 3J(2/6)eq,(3/5)ax =
4.0 Hz, H(3ax) + H(5ax)], 1.39-1.58 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.47-2.61 [4H, m,
H(A) + H(2ax) + H(6ax)], 3.09 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.6 Hz, H(2eq) + H(6eq)], 5.20
[1H, br s, NH], 7.19 [1H, dd, 3J3’,4’ = 7.5 Hz, 4J3’,5’ = 1.4 Hz, H(3’)], 7.28-7.36 [2H, m,
H(4’) + H(6’)], 7.40 [1H, td, 3J4’,5’ = 3J5’,6’ = 7.5 Hz, 4J3’,5’ = 1.4 Hz, H(5’)], 8.70 [2H, s,
H(2”) + H(6”)], 9.22 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 31.25 [C(3) + C(5)],
37.17 [C(4)], 39.88 [C(A)], 45.43 [C(2) + C(6)], 126.84 [C(4)], 129.08 [C(5)], 130.50 [C(3)],






Using General Method 4, 128b (146 mg, 0.41 mmol) and trifluoroacetic acid (1.5 mL) were
reacted in dichloromethane (6 mL) to give 120b as a yellow oil (68 mg, 65%). HRMS (ESI+)
[M+H]+ calcd. for C16H19N3: 254.1657; found 254.1654. 1H NMR (500 MHz, CDCl3): δ
1.39 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.7 Hz, 3J(2/6)eq,(3/5)ax = 3.2
Hz, H(3ax) + H(5ax)], 1.68-1.85 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.59-2.75 [4H, m, H(A) +
H(2ax) + H(6ax)], 3.21 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.7 Hz, H(2eq) + H(6eq)], 4.35 [1H, br s,
NH], 7.25 [1H, br d‡, 3J5’,6’ = 6.8 Hz, H(6’)], 7.34 [1H, br s‡, H(2’)], 7.39-7.47 [2H, m, H(4’)
+ H(5’)], 8.94 [2H, s, H(2”) + H(6”)], 9.20 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ
31.43 [C(3) + C(5)], 37.57 [C(4)], 43.29 [C(A)], 45.61 [C(2) + C(6)], 124.96 [C(4’)], 127.80
[C(2’)], 129.56 [C(5’)], 129.93 [C(6’)], 134.46 [*C(3’) or C(1”)], 134.54 [*C(3’) or C(1”)],
141.38 [C(1’)], 155.05 [C(2”) + C(6”)], 157.62 [C(4”)].







Using General Method 4, 128c (135 mg, 0.38 mmol) and trifluoroacetic acid (1.5 mL) were
reacted in dichloromethane (6 mL) to give 120c as a yellow oil (79 mg, 82%). HRMS (ESI+)
[M+H]+ calcd. for C16H19N3: 254.1657; found 254.1658. 1H NMR (500 MHz, CDCl3): δ
1.47 [2H, qd, 2J(3/5)ax,(3/5)eq = 3J(2/6)ax,(3/5)ax = 3J(3/5)ax,4ax = 12.8 Hz, 3J(2/6)eq,(3/5)ax = 2.8
Hz, H(3ax) + H(5ax)], 1.72-1.84 [3H, m, H(3eq) + H(4ax) + H(5eq)], 2.65 [2H, d, 3J4ax,A = 6.7
Hz, H(A)], 2.73 [2H, td, 2J(2/6)ax,(2/6)eq = 3J(2/6)ax,(3/5)ax = 12.8 Hz, 3J(2/6)ax,(3/5)eq = 2.0 Hz,
H(2ax) + H(6ax)], 3.28 [2H, br d‡, 2J(2/6)ax,(2/6)eq = 12.8 Hz, H(2eq) + H(6eq)], 6.32 [1H, br s,
NH], 7.27-7.33 [2H, m, H(2’) + H(6’)], 7.47-7.58 [2H, m, H(3’) + H(5’)], 8.94 [2H, s, H(2”)
+ H(6”)], 9.19 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 30.49 [C(3) + C(5)], 37.10
[C(4)], 42.68 [C(A)], 45.10 [C(2) + C(6)], 127.11 [C(3’) + C(5’)], 130.29 [C(2’) + C(6’)],
132.37 [C(4’)], 134.19 [C(1”)], 140.81 [C(1’)], 154.88 [C(2”) + C(6”)], 157.51 [C(4”)].





Using General Method 10, 117a (176 mg, 0.70 mmol) and 24 (202 mg, 0.83 mmol) were
reacted with Pd(OAc)2 (0.8 mg, 3.6 µmol), CataCXium® A ligand (2.5 mg, 7.0 µmol) and
sodium tert-butoxide (87 mg, 0.91 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 129a as
a yellow oil (121 mg, 42%). Rf = 0.26 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C27H2535ClN2/C27H2537ClN2: 413.1785/415.1755; found 413.1778/415.1761. 1H NMR (500
MHz, CDCl3): δ 1.47 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz,
3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz, H(3’ax) + H(5’ax)], 1.73-1.91 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)],
2.67 [2H, d, 3J4’ax,A = 7.0 Hz, H(A)], 2.77 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.0
Hz, H(2’ax) + H(6’ax)], 3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 6.98
335
[1H, d, 4J5,7 = 1.8 Hz, H(5)], 7.16 [1H, d, 3J5”,6” = 7.2 Hz, H(6”)], 7.25 [1H, d, 3J3,4 = 8.6
Hz, H(3)], 7.32-7.51 [7H, m, H(7) + H(2”) + H(4”) + H(5”) + H(3”’) + H(4”’) + H(5”’)],
7.57-7.64 [2H, m, H(2”’) + H(6”’)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4 =
8.6 Hz, H(4)]. 13C NMR (126 MHz, CDCl3): δ 31.99 [C(3’) + C(5’)], 38.05 [C(4’)], 43.33
[C(A)], 49.80 [C(2’) + C(6’)], 108.93 [C(5)], 122.41 [C(3)], 123.76 [C(7)], 125.03 [*C(4”)],
127.31 [C(2”’) + C(6”’)], 127.41 [C(4”’)], 128.14 [*C(6”)], 128.22 [*C(5”)], 128.29 [C(4a)],
128.84 [*C(2”)], 128.89 [C(3”’) + C(5”’)], 129.15 [C(8)], 137.51 [C(4)], 140.87 [*C(1”)],
141.38 [*C(1”’)], 141.39 [*C(3”)], 143.03 [C(8a)], 147.32 [C(2)], 150.12 [C(6)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment




Using General Method 10, 117b (130 mg, 0.52 mmol) and 24 (150 mg, 0.62 mmol) were
reacted with Pd(OAc)2 (0.6 mg, 2.7 µmol), CataCXium® A ligand (1.9 mg, 5.3 µmol) and
sodium tert-butoxide (95 mg, 0.68 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 129b as
a yellow oil (118 mg, 55%). Rf = 0.22 (dichloromethane). HRMS (ESI+) [M+H]+ calcd. for
C27H2535ClN2/C27H2537ClN2: 413.1785/415.1755; found 413.1776/415.1757. 1H NMR (500
MHz, CDCl3): δ 1.46 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 11.8 Hz,
3J(2’/6’)eq,(3’/5’)ax = 2.8 Hz, H(3’ax) + H(5’ax)], 1.72-1.89 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)],
2.63 [2H, d, 3J4’ax,A = 6.9 Hz, H(A)], 2.77 [2H, br t‡, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax =
11.8 Hz, H(2’ax) + H(6’ax)], 3.80 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 11.8 Hz, H(2’eq) + H(6’eq)],
6.97 [1H, d, 4J5,7 = 1.8 Hz, H(5)], 7.21-7.27 [3H, m, H(3) + H(2”) + H(6”)], 7.33 [1H, t,
3J3”’,4”’ = 3J4”’,5”’ = 7.2 Hz, H(4”’)], 7.39-7.45 [2H, m, H(3”’) + H(5”’)], 7.48 [1H, dd, 3J7,8
= 9.3 Hz, 4J5,7 = 1.8 Hz, H(7)], 7.51-7.56 [2H, m, H(3”) + H(5”)], 7.56-7.62 [2H, m, H(2”’)
+ H(6”’)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.88 [1H, d, 3J3,4 = 8.6 Hz, H(4)]. 13C NMR
(126 MHz, CDCl3): δ 31.97 [C(3’) + C(5’)], 37.96 [C(4’)], 42.83 [C(A)], 49.77 [C(2’) +
C(6’)], 108.91 [C(5)], 122.38 [C(3)], 123.74 [C(7)], 127.08 [C(2”’) + C(6”’)], 127.11 [C(3”)
+ C(5”)], 127.21 [C(4”’)], 128.27 [C(4a)], 128.87 [C(3”’) + C(5”’)], 129.11 [C(8)], 129.67
[C(2”) + C(6”)], 137.49 [C(4)], 139.06 [C(4”)], 139.48 [C(1”)], 141.08 [C(1”’)], 143.01






Using General Method 10, 118a (84 mg, 0.33 mmol) and 24 (97 mg, 0.40 mmol) were
reacted with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.2 mg, 3.3 µmol) and
sodium tert-butoxide (42 mg, 0.44 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 130a as
a yellow oil (92 mg, 67%). HRMS (ESI+) [M+H]+ calcd. for C26H2435ClN3/C26H2437ClN3:
414.1737/416.1708; found 414.1727/416.1711. 1H NMR (500 MHz, CDCl3): δ 1.25 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.3 Hz,
H(3’ax) + H(5’ax)], 1.45-1.64 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.55-2.71 [4H, m, H(A) +
H(2’ax) + H(6’ax)], 3.69 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 6.92 [1H,
d, 4J5,7 = 2.5 Hz, H(5)], 7.19 [1H, br d‡, 3J3”,4” = 7.1 Hz, H(3”)], 7.22-7.40 [6H, m, H(3) +
H(4”) + H(5”) + H(6”) + H(2”’) + H(6”’)], 7.42 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.5 Hz,
H(7)], 7.82 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.87 [1H, d, 3J3,4 = 8.6 Hz, H(4)], 8.62-8.70 [2H, m,
H(3”’) + H(5”’)]. 13C NMR (126 MHz, CDCl3): δ 31.91 [C(3’) + C(5’)], 37.55 [C(4’)], 39.69
[C(A)], 49.76 [C(2’) + C(6’)], 109.03 [C(5)], 122.43 [C(3)], 123.78 [C(7)], 124.60 [C(2”’)
+ C(6”’)], 126.45 [C(4”)], 128.24 [C(4a)], 128.44 [C(5”)], 129.15 [C(8)], 129.77 [C(3”)],
130.46 [C(6”)], 137.44 [C(1”)], 137.50 [C(4)], 139.71 [C(2”)], 143.09 [C(8a)], 147.41 [C(2)],





Using General Method 10, 118b (75 mg, 0.30 mmol) and 24 (86 mg, 0.35 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (1.1 mg, 3.1 µmol) and
sodium tert-butoxide (37 mg, 0.39 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 130b as
a yellow oil (74 mg, 60%). HRMS (ESI+) [M+H]+ calcd. for C26H2435ClN3/C26H2437ClN3:
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414.1737/416.1708; found 414.1730/416.1714. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.2
Hz, H(3’ax) + H(5’ax)], 1.74-1.89 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.69 [2H, d, 3J4’ax,A =
6.7 Hz, H(A)], 2.78 [2H, t, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.0 Hz, H(2’ax) + H(6’ax)],
3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.0 Hz,
H(5)], 7.22-7.29 [2H, m, H(3) + H(6”)], 7.39-7.54 [6H, m, H(7) + H(2”) + H(4”) + H(5”)
+ H(2”’) + H(6”’)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.88 [1H, d, 3J3,4 = 8.6 Hz, H(4)],
8.64-8.69 [2H, m, H(3”’) + H(5”’)]. 13C NMR (126 MHz, CDCl3): δ 31.94 [C(3’) + C(5’)],
38.01 [C(4’)], 43.22 [C(A)], 49.75 [C(2’) + C(6’)], 108.96 [C(5)], 121.79 [C(2”’) + C(6”’)],
122.41 [C(3)], 123.70 [C(7)], 124.89 [C(4”)], 127.86 [C(2”)], 128.26 [C(4a)], 129.16 [C(8)],
129.21 [C(5”)], 130.00 [C(6”)], 137.47 [C(4)], 138.36 [C(3”)], 141.36 [C(1”)], 143.04 [C(8)],





Using General Method 10, 118c (75 mg, 0.30 mmol) and 24 (87 mg, 0.36 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (1.1 mg, 3.1 µmol)
and sodium tert-butoxide (37 mg, 0.39 mmol) in (trifluoromethyl)benzene (2 mL). Work-
up as specified and column chromatography on silica gel eluting with 2.5% methanol in
dichloromethane gave 130c as a yellow oil (69 mg, 56%). HRMS (ESI+) [M+H]+ calcd. for
C26H2435ClN3/C26H2437ClN3: 414.1737/416.1708; found 414.1732/416.1716. 1H NMR (500
MHz, CDCl3): δ 1.48 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz,
3J(2’/6’)eq,(3’/5’)ax = 2.9 Hz, H(3’ax) + H(5’ax)], 1.73-1.90 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)],
2.67 [2H, d, 3J4’ax,A = 6.8 Hz, H(A)], 2.79 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax =
12.1 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.0 Hz, H(2’ax) + H(6’ax)], 3.82 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.1 Hz, H(2’eq) + H(6’eq)], 6.99 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.26 [1H, d, 3J3,4 = 8.6
Hz, H(3)], 7.27-7.33 [2H, m, H(2”) + H(6”)], 7.45-7.55 [3H, m, H(7) + H(2”’) + H(6”’)],
7.56-7.64 [2H, m, H(3”) + H(5”)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d, 3J3,4 =
8.6 Hz, H(4)], 8.61-8.71 [2H, m, H(3”’) + H(5”’)]. 13C NMR (126 MHz, CDCl3): δ 31.98
[C(3’) + C(5’)], 37.96 [C(4’)], 42.91 [C(A)], 49.80 [C(2’) + C(6’)], 109.00 [C(5)], 121.55
[C(2”’) + C(6”’)], 122.45 [C(3)], 123.75 [C(7)], 127.03 [C(3”) + C(5”)], 128.29 [C(4a)],
129.20 [C(8)], 130.06 [C(2”) + C(6”)], 136.00 [C(4”)], 137.50 [C(4)], 141.65 [C(1”)], 143.08






Using General Method 10, 119a (79 mg, 0.31 mmol) and 24 (91 mg, 0.38 mmol) were reacted
with Pd(OAc)2 (0.4 mg, 1.8 µmol), CataCXium® A ligand (1.1 mg, 3.1 µmol) and sodium
tert-butoxide (39 mg, 0.41 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as specified
and column chromatography on silica gel eluting with dichloromethane gave 131a as a yellow
oil (43 mg, 33%). Rf = 0.27 (5% methanol in dichloromethane). HRMS (ESI+) [M+H]+
calcd. for C26H2435ClN3/C26H2437ClN3: 414.1737/416.1708; found 414.1729/416.1710. 1H
NMR (500 MHz, CDCl3): δ 1.24 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)], 1.53 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.0
Hz, 3J4’ax,A = 7.3 Hz, 3J(3’/5’)eq,4’ax = 3.7 Hz, H(4’ax)], 1.61 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq =
12.0 Hz, H(3’eq) + H(5’eq)], 2.59-2.68 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.68 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 6.92 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.22
[1H, d, 3J3”,4” = 7.6 Hz, H(3”)], 7.25 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.28-7.40 [4H, m,
H(4”) + H(5”) + H(6”) + H(5”’)], 7.42 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.7 Hz, H(7)],
7.64 [1H, dt, 3J5”’,6”’ = 7.7 Hz, 4J2”’,6”’ = 4J4”’,6”’ = 1.4 Hz, H(6”’)], 7.82 [1H, d, 3J7,8 =
9.3 Hz, H(8)], 7.87 [1H, d, 3J3,4 = 8.6 Hz, H(4)], 8.59 [1H, d, 4J2”’,6”’ = 1.4 Hz, H(2”’)],
8.61 [1H, dd, 3J4”’,5”’ = 4.8 Hz, 4J4”’,6”’ = 1.4 Hz, H(4”’)]. 13C NMR (126 MHz, CDCl3):
δ 31.88 [C(3’) + C(5’)], 37.59 [C(4’)], 39.76 [C(A)], 49.73 [C(2’) + C(6’)], 108.99 [C(5)],
122.41 [C(3)], 123.14 [C(5”’)], 123.75 [C(7)], 126.41 [C(4”)], 128.24 [C(4a) + C(5”)], 129.14
[C(8)], 130.40 [C(6”)], 130.49 [C(3”)], 136.74 [C(6”’)], 137.50 [C(4)], 137.65 [C(1”’)], 138.14






Using General Method 10, 119b (113 mg, 0.45 mmol) and 24 (130 mg, 0.54 mmol) were
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reacted with Pd(OAc)2 (0.5 mg, 2.2 µmol), CataCXium® A ligand (1.6 mg, 4.5 µmol) and
sodium tert-butoxide (56 mg, 0.58 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 131b as
a yellow oil (103 mg, 56%). HRMS (ESI+) [M+H]+ calcd. for C26H2435ClN3/C26H2437ClN3:
414.1737/416.1708; found 414.1728/416.1710. 1H NMR (500 MHz, CDCl3): δ 1.48 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.3 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.1
Hz, H(3’ax) + H(5’ax)], 1.74-1.88 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.68 [2H, d, 3J4’ax,A =
6.8 Hz, H(A)], 2.78 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.3 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 2.2 Hz, H(2’ax) + H(6’ax)], 3.81 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.3 Hz, H(2’eq) + H(6’eq)],
6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.20-7.28 [2H, m, H(3) + H(6”)], 7.34-7.50 [5H, m, H(7)
+H(2”) + H(4”) + H(5”) + H(5”’)], 7.82-7.91 [3H, m, H(4) + H(8) + H(6”’)], 8.59 [1H,
dd, 3J4”’,5”’ = 4.8 Hz, 4J4”’,6”’ = 1.6 Hz, H(4”’)], 8.86 [1H, br d‡, 4J2”’,6”’ = 1.8 Hz, H(2”’)].
13C NMR (126 MHz, CDCl3): δ 31.94 [C(3’) + C(5’)], 37.99 [C(4’)], 43.23 [C(A)], 49.74
[C(2’) + C(6’)], 108.94 [C(5)], 122.39 [C(3)], 123.63 [C(5”’)], 123.70 [C(7)], 125.02 [C(4”)],
128.04 [C(2”)], 128.26 [C(4a)], 129.04 [C(6”)], 129.14 [C(8)], 129.16 [C(5”)], 134.46 [C(6”’)],
136.77 [C(1”’)], 137.47 [C(4)], 138.02 [C(3”)], 141.29 [C(1”)], 143.02 [C(8a)], 147.32 [C(2)],





Using General Method 10, 119c (75 mg, 0.30 mmol) and 24 (86 mg, 0.36 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.5 µmol), CataCXium® A ligand (1.1 mg, 3.0 µmol) and
sodium tert-butoxide (37 mg, 0.39 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 131c
as a yellow oil (32 mg, 26%), and impure 135c as a yellow oil (31 mg, 23%).
2-Chloro-6-(4-(4-(pyridin-3-yl)benzyl)piperidin-1-yl)quinoline (131c): Rf = 0.20 (2%
methanol in dichloromethane). HRMS (ESI+) [M+H]+ calcd. for C26H2435ClN3/
C26H2437ClN3: 414.1737/416.1708; found 414.1729/416.1712. 1H NMR (500 MHz, CDCl3):
δ 1.48 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax
= 3.3 Hz, H(3’ax) + H(5’ax)], 1.72-1.91 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.66 [2H, d, 3J4’ax,A
= 6.9 Hz, H(A)], 2.79 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 1.8 Hz, H(2’ax) + H(6’ax)], 3.82 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)],
6.99 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.26 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.27-7.32 [2H, m,
H(2”) + H(6”)], 7.36 [1H, dd, 3J5”’,6”’ = 7.8 Hz, 3J4”’,5”’ = 4.8 Hz, H(5”’)], 7.49 [1H, dd, 3J7,8
= 9.3 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.51-7.56 [2H, m, H(3”) + H(5”)], 7.82-7.92 [3H, m, H(4)
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+ H(8) + H(6”’)], 8.58 [1H, br d‡, 3J4”’,5”’ = 4.8 Hz, H(4”’)], 8.86 [1H, d, 4J2”’,6”’ = 1.3 Hz,
H(2”’)]. 13C NMR (126 MHz, CDCl3): δ 31.97 [C(3’) + C(5’)], 37.97 [C(4’)], 43.85 [C(A)],
49.79 [C(2’) + C(6’)], 108.97 [C(5)], 122.42 [C(3)], 123.66 [C(5”’)], 123.74 [C(7)], 127.15
[C(3”) + C(5”)], 128.28 [C(4a)], 129.17 [C(8)], 130.01 [C(2”) + C(6”)], 134.26 [C(6”’)],
135.71 [C(4”)], 136.55 [C(1”’)], 137.49 [C(4)], 140.49 [C(1”)], 143.06 [C(8a)], 147.36 [C(2)],






6-Bromo-2-(4-(4-(pyridin-3-yl)benzyl)piperidin-1-yl)quinoline (135c): HRMS (ESI+)
[M+H]+ calcd. for C26H2479BrN3/C26H2481BrN3: 458.1232/460.1211; found 458.1219/
460.1202. 1H NMR (500 MHz, CDCl3): δ 1.34 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 3J(3’/5’)ax,4’ax = 12.7 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)], 1.76-1.95 [3H, m,
H(3’eq) + H(4’ax) + H(5’eq)], 2.63 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 2.92 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.7 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.4 Hz, H(2’ax) + H(6’ax)], 4.54 [2H, br
d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.7 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 3J3,4 = 9.2 Hz, H(3)], 7.25-
7.30 [2H, m, H(2”) + H(6”)], 7.36 [1H, dd, 3J5”’,6”’ = 7.9 Hz, 3J4”’,5”’ = 4.8 Hz, H(5”’)],
7.49-7.58 [4H, m, H(7) + H(8) + H(3”) + H(5”)], 7.70 [1H, d, 4J5,7 = 1.9 Hz, H(5)],
7.74 [1H, d, 3J3,4 = 9.2 Hz, H(4)], 7.87 [1H, dt, 3J5”’,6”’ = 7.9 Hz, 4J2”’,6”’ = 4J4”’,6”’ =
1.7 Hz, H(6”’)], 8.58 [1H, br d‡, 3J4”’,5”’ = 4.8 Hz, H(4”’)], 8.85 [1H, br s‡, H(2”’)]. 13C
NMR (126 MHz, CDCl3): δ 32.11 [C(3’) + C(5’)], 38.59 [C(4’)], 42.96 [C(A)], 45.63 [C(2’)
+ C(6’)], 110.68 [C(3)], 114.88 [C(6)], 123.68 [C(5”’)], 124.10 [C(4a)], 127.15 [C(3”) +
C(5”)], 128.36 [C(8)], 129.25 [C(5)], 130.03 [C(2”) + C(6”)], 132.66 [C(7)], 134.30 [C(6”’)],
135.69 [C(4”)], 136.42 [C(4)], 136.60 [C(1”’)], 140.55 [C(1”)], 146.94 [C(1”)], 146.94 [C(8a)],





Using General Method 10, 120a (74 mg, 0.29 mmol) and 24 (85 mg, 0.35 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.5 µmol), CataCXium® A ligand (1.0 mg, 2.9 µmol) and
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sodium tert-butoxide (36 mg, 0.38 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 132a as
a yellow oil (56 mg, 46%). HRMS (ESI+) [M+H]+ calcd. for C25H2335ClN4/C25H2337ClN4:
415.1689/417.1660; found 415.1681/417.1663. 1H NMR (500 MHz, CDCl3): δ 1.26 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.6 Hz,
H(3’ax) + H(5’ax)], 1.47-1.68 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.57-2.70 [4H, m, H(A)
+ H(2’ax) + H(6’ax)], 3.70 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.5 Hz, H(2’eq) + H(6’eq)], 6.92
[1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.19-7.28 [2H, m, H(3) + H(3”)], 7.31-7.38 [2H, m, H(4”) +
H(6”)], 7.39-7.46 [2H, m, H(7) + H(5”)], 7.82 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.87 [1H, d,
3J3,4 = 8.6 Hz, H(4)], 8.73 [2H, s, H(2”’) + H(6”’)], 9.23 [1H, s, H(4”’)]. 13C NMR (126
MHz, CDCl3): δ 31.85 [C(3’) + C(5’)], 37.72 [C(4’)], 39.74 [C(A)], 49.68 [C(2’) + C(6’)],
109.04 [C(5)], 122.41 [C(3)], 123.71 [C(7)], 126.78 [C(4”)], 128.21 [C(4a)], 129.10 [C(5”)],
129.16 [C(8)], 130.48 [C(3”)], 130.67 [C(6”)], 134.72 [C(2”)], 135.57 [C(1”’)], 137.48 [C(4)],







Using General Method 10, 120b (58 mg, 0.23 mmol) and 24 (67 mg, 0.28 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.3 µmol), CataCXium® A ligand (0.8 mg, 2.2 µmol) and
sodium tert-butoxide (29 mg, 0.30 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 132b
as a yellow solid (57 mg, 60%), and a small amount of an impure mixture containing 136b
was also obtained.
2-Chloro-6-(4-(3-(pyrimidin-5-yl)benzyl)piperidin-1-yl)quinoline (132b): HRMS (ESI+)
[M+H]+ calcd. for C25H2335ClN4/C25H2337ClN4: 415.1689/417.1660; found 415.1684/
417.1666. 1H NMR (500 MHz, CDCl3): δ 1.49 [2H, br qd‡, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)], 1.73-1.90 [3H, m,
H(3’eq) + H(4’ax) + H(5’eq)], 2.70 [2H, d, 3J4’ax,A = 7.7 Hz, H(A)], 2.79 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.5 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.0 Hz, H(2’ax) + H(6’ax)], 3.82 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.5 Hz, H(2’eq) + H(6’eq)], 6.98 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.25 [1H,
d, 3J3,4 = 8.7 Hz, H(3)], 7.29 [1H, br d‡, 3J5”,6” = 7.1 Hz, H(6”)], 7.38 [1H, br s‡, H(2”)],
7.41-7.52 [3H, m, H(7) + H(4”) + H(5”)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.89 [1H, d,
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3J3,4 = 8.7 Hz, H(4)], 8.96 [2H, s, H(2”’) + H(6”’)], 9.21 [1H, s, H(4”’)]. 13C NMR (126
MHz, CDCl3): δ 31.94 [C(3’) + C(5’)], 37.99 [C(4’)], 43.18 [C(A)], 47.95 [C(2’) + C(6’)],
108.99 [C(5)], 122.43 [C(3)], 123.71 [C(7)], 124.88 [C(4”)], 127.83 [C(2”)], 128.26 [C(4a)],
129.19 [C(8)], 129.54 [C(5”)], 129.96 [C(6”)], 134.49 [*C(3”) or C(1”’)], 134.50 [*C(3”) or
C(1”’)], 137.48 [C(4)], 141.78 [C(1”)], 143.06 [C(8a)], 147.39 [C(2)], 150.03 [C(6)], 155.06
[C(2”’) + C(6”’)], 157.63 [C(4”’)].








6-Bromo-2-(4-(3-(pyrimidin-5-yl)benzyl)piperidin-1-yl)quinoline (136b): Obtained as an
impure sample of 136b and 132b (approximately 5:2 by 1H NMR analysis) by column
chromatography. HRMS (ESI+) [M+H]+ calcd. for C25H2379BrN4/C25H2381BrN4: 459.1184/
461.1164; found 459.1173/461.1157. 1H NMR (500 MHz, CDCl3): δ 1.35 [1.5H, br qd‡,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz,
H(3’ax) + H(5’ax)], 1.49 [0.5H, br qd‡, 2J(*3’/*5’)ax,(*3’/*5’)eq = 3J(*2’/*6’)ax,(*3’/*5’)ax =
3J(*3’/5’)ax,*4’ax = 12.5 Hz, 3J(*2’/*6’)eq,(*3’/*5’)ax = 3.4 Hz, *H(3’ax) + *H(5’ax)], 1.73-1.96
[3H, m, H(3’eq) + H(4’ax) + H(5’eq) + *H(3’eq) + *H(4’ax) + *H(5’eq)], 2.64-2.74 [2H,
m, H(A) + *H(A)], 2.79 [0.5H, td, 2J(*2’/*6’)ax,(*2’/*6’)eq = 3J(*2’/*6’)ax,(*3’/*5’)ax = 12.5 Hz,
3J(*2’/*6’)ax,(*3’/*5’)eq = 2.0 Hz, *H(2’ax) + *H(6’ax)], 2.91 [1.5H, td, 2J(2’/6’)ax,(2’/6’)eq =
3J(2’/6’)ax,(3’/5’)ax = 12.5 Hz, 3J(2’/6’)ax,(3’/5’)eq = 2.2 Hz, H(2’ax) + H(6’ax)], 3.82 [0.5H, br d‡,
2J(*2’/*6’)ax,(*2’/*6’)eq = 12.5 Hz, *H(2’eq) + *H(6’eq)], 4.55 [1.5H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.5 Hz, H(2’eq) + H(6’eq)], 6.95-7.01 [1H, m, H(3) + *H(5)], 7.24-7.32 [1.25H, m, H(6”) +
*H(5) + *H(6”)], 7.35-7.40 [1H, m, H(2”) + *H(2”)], 7.41-7.50 [2.25H, m, H(4”) + H(5”)
+ *H(7) + *H(4”) + *H(5”)], 7.52 and 7.55 [1.5H, ABX, A:d, B:dd, 3J7,8(JAB) = 8.9 Hz,
3J5,7(JBX ) = 2.1 Hz, H(8) + H(7)], 7.70 [0.75H, d, 3J5,7 = 2.1 Hz, H(5)], 7.75 [0.75H, d,
3J7,8 = 9.2 Hz, H(4)], 8.93-8.99 [2H, m, H(2”’) + H(6”’) + *H(2”’) + *H(6”’)], 9.18-9.24
[1H, s, H(4”’) + *H(4”’)].







Using General Method 10, 120c (63 mg, 0.25 mmol) and 24 (72 mg, 0.30 mmol) were
reacted with Pd(OAc)2 (0.3 mg, 1.2 µmol), CataCXium® A ligand (0.9 mg, 2.5 µmol) and
sodium tert-butoxide (31 mg, 0.32 mmol) in (trifluoromethyl)benzene (2 mL). Work-up as
specified and column chromatography on silica gel eluting with dichloromethane gave 132c as
a yellow oil (37 mg, 36%). HRMS (ESI+) [M+H]+ calcd. for C25H2335ClN4/C25H2337ClN4:
415.1689/417.1660; found 415.1681/417.1662. 1H NMR (500 MHz, CDCl3): δ 1.49 [2H,
qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 2.9
Hz, H(3’ax) + H(5’ax)], 1.74-1.90 [3H, m, H(3’eq) + H(4’ax) + H(5’eq)], 2.68 [2H, d, 3J4’ax,A =
6.8 Hz, H(A)], 2.79 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, 3J(2’/6’)ax,(3’/5’)eq
= 1.6 Hz, H(2’ax) + H(6’ax)], 3.83 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)],
6.99 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.26 [1H, d, 3J3,4 = 8.6 Hz, H(3)], 7.31-7.37 [2H, m,
H(2”) + H(6”)], 7.49 [1H, dd, 3J7,8 = 9.3 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.50-7.56 [2H, m,
H(3”) + H(5”)], 7.85 [1H, d, 3J7,8 = 9.3 Hz, H(8)], 7.90 [1H, d, 3J3,4 = 8.6 Hz, H(4)],
8.96 [2H, s, H(2”’) + H(6”’)], 9.20 [1H, s, H(4”’)]. 13C NMR (126 MHz, CDCl3): δ 31.96
[C(3’) + C(5’)], 37.96 [C(4’)], 42.88 [C(A)], 49.79 [C(2’) + C(6’)], 109.01 [C(5)], 122.45
[C(3)], 123.74 [C(7)], 127.02 [C(3”) + C(5”)], 128.27 [C(4a)], 129.20 [C(8)], 130.37 [C(2”)
+ C(6”)], 132.15 [C(4”)], 134.27 [C(1”’)], 137.49 [C(4)], 141.59 [C(1”)], 143.08 [C(8a)],




Using General Method 11, 129a (96 mg, 0.23 mmol) was treated with LiHMDS solution
(1.0 M in THF, 511 µL, 0.51 mmol), Pd(dba)2 (1.3 mg, 2.3 µmol) and DavePhos (1.1 mg,
2.8 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 9:1 dichloromethane/methanol gave 113a as a brown solid (40 mg, 44%).
Rf = 0.25 (1:9 methanol/dichloromethane). HRMS (ESI+) [M+H]+ calcd. for C27H27N3:
394.2283; found 394.2279. 1H NMR (500 MHz, CDCl3): δ 1.49 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq
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= 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)],
1.75 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.5 Hz, 3J4’ax,A = 7.4 Hz, 3J(3’/5’)eq,4’ax = 3.8 Hz, H(4’ax)],
1.83 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.5 Hz, H(3’eq) + H(5’eq)], 2.64-2.75 [2H, m, H(A)+
H(2’ax) + H(6’ax)], 3.69 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.5 Hz, H(2’eq) + H(6’eq)], 5.23 [2H,
br s, NH2], 6.70 [1H, d, 3J3,4 = 8.9 Hz, H(3)], 6.96 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.16 [1H,
br d‡, 3J5”,6” = 7.1 Hz, H(6”)], 7.32-7.49 [7H, m, H(7) + H(2”) + H(4”) + H(5”) + H(3”’)





Using General Method 11, 129b (78 mg, 0.19 mmol) was treated with LiHMDS solution
(1.0 M in THF, 418 µL, 0.42 mmol), Pd(dba)2 (1.1 mg, 1.9 µmol) and DavePhos (0.9 mg,
2.3 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 113b as a brown solid (40 mg, 54%).
Rf = 0.23 (1:9 methanol/dichloromethane). MP: 169-173°C. HRMS (ESI+) [M+H]+ calcd.
for C27H27N3: 394.2283; found 394.2274. 1H NMR (500 MHz, CDCl3): δ 1.50 [2H, qd,
2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 11.8 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.5 Hz,
H(3’ax) + H(5’ax)], 1.74 [1H, ttt, 3J(3’/5’)ax,4’ax = 11.8 Hz, 3J4’ax,A = 7.2 Hz, 3J(3’/5’)eq,4’ax =
3.5 Hz, H(4’ax)], 1.84 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 11.8 Hz, H(3’eq) + H(5’eq)], 2.65 [2H,
d, 3J4’ax,A = 7.2 Hz, H(A)], 2.70 [2H, td, 2J(2’/6’)ax,(2’/6’)eq = 3J(2’/6’)ax,(3’/5’)ax = 11.8 Hz,
3J(2’/6’)ax,(3’/5’)eq = 1.7 Hz, H(2’ax) + H(6’ax)], 3.69 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 11.8 Hz,
H(2’eq) + H(6’eq)], 4.84 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96 [1H, d,
4J5,7 = 2.6 Hz, H(5)], 7.21-7.29 [2H, m, H(2”) + H(6”)], 7.30-7.39 [2H, m, H(7) + H(4”’)],
7.39-7.47 [2H, m, H(3”’) + H(5”’)], 7.49-7.56 [2H, m, H(3”) + H(5”)], 7.55-7.62 [3H, m,
H(8) + H(2”’) + H(6”’)], 7.77 [1H, d, 3J3,4 = 8.8 Hz, H(4)]. 13C NMR (126 MHz, CDCl3):
δ 32.32 [C(3’) + C(5’)], 37.98 [C(4’)], 42.94 [C(A)], 50.95 [C(2’) + C(6’)], 111.36 [C(5)],
111.92 [C(3)], 123.78 [C(7)], 124.28 [C(4a)], 126.25 [br, C(8)], 127.12 [*C(2”’) + *C(6”’)],
127.13 [*C(3”) + *C(5”)], 127.20 [C(4”’)], 128.87 [C(3”’) + C(5”’)], 129.72 [C(2”) + C(6”)],
137.70 [br, C(4)], 139.04 [C(4”)], 139.73 [C(1”)], 141.19 [C(1”’)], **141.96 [C(8a)], 147.89
[C(6)], 155.37 [C(2)].
*Some 13C NMR signals could not be unambiguously assigned due to close proximity of
chemical shifts.
**The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was
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Using General Method 11, 130a (88 mg, 0.21 mmol) was treated with LiHMDS solution (1.0
M in THF, 470 µL, 0.47 mmol), Pd(dba)2 (1.2 mg, 2.1 µmol) and DavePhos (0.9 mg, 2.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 114a as a yellow solid (46 mg, 55%). MP:
degraded 180°C. HRMS (ESI+) [M+H]+ calcd. for C26H26N4: 395.2236; found 395.2241. 1H
NMR (500 MHz, CDCl3): δ 1.27 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.2 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.5 Hz, H(3’ax) + H(5’ax)], 1.41-1.54 [1H, m, H(4’ax)], 1.60
[2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.2 Hz, H(3’eq) + H(5’eq)], 2.55 [2H, br t‡, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.2 Hz, H(2’ax) + H(6’ax)], 2.63 [2H, d, 3J4’ax,A = 7.1 Hz, H(A)], 3.57
[2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.2 Hz, H(2’eq) + H(6’eq)], 5.03 [2H, br s, NH2], 6.69 [1H,
d, 3J3,4 = 8.8 Hz, H(3)], 6.90 [1H, d, 4J5,7 = 2.2 Hz, H(5)], 7.19 [1H, br d‡, 3J3”,4” = 7.5
Hz, H(3”)], 7.23-7.34 [5H, m, H(7) + H(4”) + H(5”) + H(6”) + H(2”’) + H(6”’)], 7.37
[1H, t, 3J4”,5” = 3J5”,6” = 7.40 Hz, H(5”)], 7.55 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.75 [1H, d,
3J3,4 = 8.8 Hz, H(4)], 8.63-8.69 [2H, m, H(3”’) + H(5”’)]. 13C NMR (126 MHz, CDCl3):
δ 32.16 [C(3’) + C(5’)], 37.53 [C(4’)], 39.70 [C(A)], 50.80 [C(2’) + C(6’)], 111.43 [C(5)],
112.00 [C(3)], 123.85 [C(7)], 124.09 [C(4a)], 124.62 [C(2”’) + C(6”’)], 125.66 [C(4”)], 126.35
[C(8)], 128.40 [C(5”)], 129.71 [C(3”)], 130.46 [C(6”)], 137.60 [C(4)], 138.04 [C(1”)], 139.71






Using General Method 11, 130b (72 mg, 0.17 mmol) was treated with LiHMDS solution (1.0
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M in THF, 385 µL, 0.38 mmol), Pd(dba)2 (1.0 mg, 1.7 µmol) and DavePhos (0.8 mg, 2.0
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 114b as a yellow powder (22 mg, 32%).
MP: 230-233°C. HRMS (ESI+) [M+H]+ calcd. for C26H26N4: 395.2236; found 395.2229. 1H
NMR (500 MHz, CDCl3): δ 1.51 [2H, dq, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.3 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.9 Hz, H(3’ax) + H(5’ax)], 1.69-1.88 [3H, m, H(3’eq) + H(4’ax)
+ H(5’eq)], 2.60-2.84 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.69 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq
= 12.3 Hz, H(2’eq) + H(6’eq)], 4.93 [2H, br s, NH2], 6.68 [1H, d, 3J3,4 = 8.8 Hz, H(3)],
6.98 [1H, d, 4J5,7 = 2.7 Hz, H(5)], 7.27 [1H, br d‡, 3J5”,6” = 7.4 Hz, H(6”)], 7.36 [1H,
dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.7 Hz, H(7)], 7.39-7.46 [2H, m, H(2”) + H(5”)], 7.47-7.55
[3H, m, H(4”) + H(2”’) + H(6”’)], 7.58 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.77 [1H, d, 3J3,4 =
8.8 Hz, H(4)], 8.63-8.70 [2H, m, H(3”’) + H(5”’)]. 13C NMR (126 MHz, CDCl3): δ 32.26
[C(3’) + C(5’)], 38.01 [C(4’)], 43.31 [C(A)], 50.88 [C(2’) + C(6’)], 111.39 [C(5)], 111.96
[C(3)], 121.84 [C(2”’) + C(6”’)], 123.78 [C(7)], 124.22 [C(4a)], 124.85 [C(4”)], 126.09 [C(8)],
127.91 [C(2”)], 129.19 [C(5”)], 130.06 [C(6”)], 137.82 [C(4)], 138.35 [C(3”)], 141.58 [C(8a)





Using General Method 11, 130c (57 mg, 0.14 mmol) was treated with LiHMDS solution (1.0
M in THF, 300 µL, 0.30 mmol), Pd(dba)2 (0.8 mg, 1.4 µmol) and DavePhos (0.7 mg, 1.8
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave 114c as a yellow solid (29 mg, 54%). MP:
degraded 255°C. HRMS (ESI+) [M+H]+ calcd. for C26H26N4: 395.2236; found 395.2234. 1H
NMR (500 MHz, CDCl3): δ 1.50 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax
= 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)], 1.69-1.88 [3H, m, H(3’eq) + H(4’ax)
+ H(5’eq)], 2.63-2.77 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.70 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.0 Hz, H(2’eq) + H(6’eq)], 4.92 [2H, br s, NH2], 6.69 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.97 [1H,
d, 4J5,7 = 2.5 Hz, H(5)], 7.28-7.33 [2H, m, H(2”) + H(6”)], 7.36 [1H, dd, 3J7,8 = 9.1 Hz,
4J5,7 = 2.5 Hz, H(7)], 7.48-7.54 [2H, m, H(2”’) + H(6”’)], 7.56-7.64 [3H, m, H(8) + H(3”)
+ H(5”)], 7.78 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.62-8.68 [2H, m, H(3”’) + H(5”’)]. 13C NMR
(126 MHz, CDCl3): δ 32.27 [C(3’) + C(5’)], 37.93 [C(4’)], 42.97 [C(A)], 50.87 [C(2’) +
C(6’)], 111.39 [C(5)], 111.97 [C(3)], 121.57 [C(2”’) + C(6”’)], 123.82 [C(7)], 124.21 [C(4a)],
125.99 [C(8)], 127.00 [C(3”) + C(5”)], 130.08 [C(2”) + C(6”)], 135.93 [C(4”)], 137.92
[C(4)], *141.42 [C(8a)], 141.86 [C(1”)], 147.91 [C(6)], 148.27 [C(1”’)], 150.40 [C(3”’) +
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C(5”’)], 155.24 [C(2)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was






Using General Method 11, 131a (33 mg, 0.08 mmol) was treated with LiHMDS solution
(1.0 M in THF, 175 µL, 0.18 mmol), Pd(dba)2 (0.5 mg, 0.9 µmol) and DavePhos (0.4 mg,
1.0 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 9:1 dichloromethane/methanol gave 115a as a yellow oil (21 mg, 67%). Rf
= 0.31 (10% methanol in dichloromethane). HRMS (ESI+) [M+H]+ calcd. for C26H26N4:
395.2236; found 395.2228. 1H NMR (500 MHz, CDCl3): δ 1.26 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.5 Hz, H(3’ax) + H(5’ax)],
1.48 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.0 Hz, 3J4’ax,A = 7.3 Hz, 3J(3’/5’)eq,4’ax = 3.8 Hz, H(4’ax)],
1.60 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq = 12.0 Hz, H(3’eq) + H(5’eq)], 2.55 [2H, td, 2J(2’/6’)ax,(2’/6’)eq
= 3J(2’/6’)ax,(3’/5’)ax = 12.0 Hz, 3J(2’/6’)ax,(3’/5’)eq = 1.7 Hz, H(2’ax) + H(6’ax)], 2.62 [2H, d,
3J4’ax,A = 7.3 Hz, H(A)], 3.56 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)],
5.06 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.89 [1H, d, 4J5,7 = 2.5 Hz, H(5)],
7.21 [1H, d, 3J3”,4” = 7.5 Hz, H(3”)], 7.27-7.39 [5H, m, H(7) + H(4”) + H(5”) + H(6”) +
H(5”’)], 7.55 [1H, d, 3J7,8 = 9.1 Hz, H(8)], 7.64 [1H, br d‡, 3J5”’,6”’ = 7.8 Hz, H(6”’)], 7.74
[1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.57-8.62 [2H, m, H(2”’) + H(4”’)]. 13C NMR (126 MHz,
CDCl3): δ 32.16 [C(3’) + C(5’)], 37.58 [C(4’)], 39.79 [C(A)], 50.83 [C(2’) + C(6’)], 111.44
[C(5)], 112.01 [C(3)], 123.12 [C(5”’)], 123.83 [C(7)], 124.09 [C(4a)], 125.76 [C(8)], 126.33
[C(4”)], 128.21 [C(5”)], 130.41 [C(6”)], 130.45 [C(3”)], 136.77 [C(6”’)], 137.70 [C(1”’)],
137.94 [C(4)], 138.33 [C(1”)], 138.64 [C(2”)], *141.17 [C(8a)], 147.86 [C(6)], 148.36 [C(4”’)],
150.23 [C(2”’)], 155.30 [C(2)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was







Using General Method 11, 131b (100 mg, 0.24 mmol) was treated with LiHMDS solution
(1.0 M in THF, 530 µL, 0.53 mmol), Pd(dba)2 (1.4 mg, 2.4 µmol) and DavePhos (1.1
mg, 2.8 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on
silica gel eluting with 19:1 dichloromethane/methanol gave 115b as a yellow oil (56 mg,
59%). MP: degraded 160°C. HRMS (ESI+) [M+H]+ calcd. for C26H26N4: 395.2236; found
395.2230. 1H NMR (500 MHz, CDCl3): δ 1.50 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax
= 3J(3’/5’)ax,4’ax = 12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)], 1.68-1.89 [3H, m,
H(3’eq) + H(4’ax) + H(5’eq)], 2.61-2.76 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.69 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz, H(2’eq) + H(6’eq)], 4.71 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 =
8.8 Hz, H(3)], 6.96 [1H, d, 4J5,7 = 2.5 Hz, H(5)], 7.23 [1H, br d‡, 3J5”,6” = 6.7 Hz, H(6”)],
7.31-7.41 [5H, m, H(7) + H(2”) + H(4”) + H(5”) + H(5”’)], 7.56 [1H, d, 3J7,8 = 9.2
Hz, H(8)], 7.75 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 7.88 [1H, br d‡, 3J5”’,6”’ = 7.9 Hz, H(6”’)],
8.59 [1H, d, 3J4”’,5”’ = 4.7 Hz, H(4”’)], 8.86 [1H, d, 4J2”’,6”’ = 2.0 Hz, H(2”’)]. 13C NMR
(126 MHz, CDCl3): δ 32.26 [C(3’) + C(5’)], 37.98 [C(4’)], 43.31 [C(A)], 50.91 [C(2’) +
C(6’)], 111.37 [C(5)], 111.88 [C(3)], 123.63 [C(5”’)], 123.67 [C(7)], 124.30 [C(4a)], 124.95
[C(4”)], 126.48 [C(8)], 128.08 [C(2”)], 129.08 [C(6”)], 129.12 [C(5”)], 134.49 [C(6”’)], 136.84
[C(1”’)], 137.47 [C(4)], 137.99 [C(3”)], 141.51 [C(1”)], 142.35 [C(8a)], 147.72 [C(6)], 148.52





Using General Method 11, 131c (20 mg, 0.05 mmol) was treated with LiHMDS solution
(1.0 M in THF, 106 µL, 0.11 mmol), Pd(dba)2 (0.3 mg, 0.5 µmol) and DavePhos (0.2
mg, 0.6 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on
silica gel eluting with 19:1 dichloromethane/methanol gave 115c as a yellow solid (12 mg,
63%). HRMS (ESI+) [M+H]+ calcd. for C26H26N4: 395.2236; found 395.2230. 1H NMR
(500 MHz, CDCl3): δ 1.50 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax =
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12.1 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.4 Hz, H(3’ax) + H(5’ax)], 1.74 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.1
Hz, 3J4’ax,A = 7.0 Hz, 3J(3’/5’)eq,(4’ax = 3.4 Hz, H(4’ax)], 1.83 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq =
12.1 Hz, H(3’eq) + H(5’eq)], 2.63-2.75 [4H, m, H(A) + H(2’ax) + H(6’ax)], 3.70 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.1 Hz, H(2’eq) + H(6’eq)], 4.80 [2H, br s, NH2], 6.67 [1H, d, 3J3,4 = 8.8
Hz, H(3)], 6.97 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.27-7.33 [2H, m, H(2”) + H(6”)], 7.33-7.39
[2H, m, H(7) + H(5”’)], 7.49-7.55 [2H, m, H(3”) + H(5”)], 7.58 [1H, d, 3J7,8 = 9.2 Hz,
H(8)], 7.77 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 7.87 [1H, ddd, 3J5”’,6”’ = 7.9 Hz, 4J2”’,6”’ = 2.0 Hz,
4J4”’,6”’ = 1.5 Hz, H(6”’)], 8.58 [1H, dd, 3J4”’,5”’ = 4.7 Hz, 4J4”’,6”’ = 1.5 Hz, H(4”’)], 8.86 [1H,
d, 4J2”’,6”’ = 2.0 Hz, H(2”’)]. 13C NMR (126 MHz, CDCl3): δ 32.29 [C(3’) + C(5’)], 37.96
[C(4’)], 42.94 [C(A)], 50.93 [C(2’) + C(6’)], 111.38 [C(5)], 111.92 [C(3)], 123.66 [C(5”’)],
123.76 [C(7)], 124.29 [C(4a)], 126.33 [br, C(8)], 127.14 [C(3”) + C(5”)], 130.05 [C(2”) +
C(6”)], 134.28 [br, C(6”’)], 135.65 [C(4”)], 136.61 [C(1”’)], 137.65 [br, C(4)], 140.73 [C(1”)],





Using General Method 11, 132a (46 mg, 0.11 mmol) was treated with LiHMDS solution
(1.0 M in THF, 244 µL, 0.22 mmol), Pd(dba)2 (0.6 mg, 1.0 µmol) and DavePhos (0.5
mg, 1.3 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on
silica gel eluting with 19:1 dichloromethane/methanol gave 116a as a yellow solid (23 mg,
52%). HRMS (ESI+) [M+H]+ calcd. for C25H25N5: 396.2188; found 396.2182. 1H NMR
(500 MHz, CDCl3): δ 1.28 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax =
12.0 Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.8 Hz, H(3’ax) + H(5’ax)], 1.49 [1H, ttt, 3J(3’/5’)ax,4’ax = 12.0
Hz, 3J4’ax,A = 7.6 Hz, 3J(3’/5’)eq,(4’ax = 3.8 Hz, H(4’ax)], 1.62 [2H, br d‡, 2J(3’/5’)ax,(3’/5’)eq =
12.0 Hz, H(3’eq) + H(5’eq)], 2.50-2.65 [4H, m, H(2’ax) + H(6’ax) + H(A)], 3.57 [2H, br d‡,
2J(2’/6’)ax,(2’/6’)eq = 12.0 Hz, H(2’eq) + H(6’eq)], 4.80 [2H, br s, NH2], 6.66 [1H, d, 3J3,4 = 8.8
Hz, H(3)], 6.90 [1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.21 [1H, br d‡, 3J3”,4” = 7.1 Hz, H(3”)], 7.29
[1H, dd, 3J7,8 = 9.2 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.32-7.39 [2H, m, H(4”) + H(6”)], 7.42 [1H, t,
3J4”,5” = 3J5”,6” = 7.5 Hz, H(5”)], 7.54 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.74 [1H, d, 3J3,4 = 8.8
Hz, H(4)], 8.75 [2H, s, H(2”’) + H(6”’)], 9.23 [1H, s, H(4”’)]. 13C NMR (126 MHz, CDCl3):
δ 32.16 [C(3’) + C(5’)], 37.73 [C(4’)], 39.80 [C(A)], 50.84 [C(2’) + C(6’)], 111.49 [C(5)],
111.90 [C(3)], 123.74 [C(7)], 124.21 [C(4a)], 126.30 [C(8)], 126.70 [C(4”)], 129.08 [C(5”)],
130.45 [C(3”)], 130.71 [C(6”)], 134.73 [C(2”)], 135.63 [C(1”’)], 137.63 [C(4)], 138.48 [C(1”)],
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Using General Method 11, 132b (37 mg, 0.09 mmol) was treated with LiHMDS solution
(1.0 M in THF, 200 µL, 0.20 mmol), Pd(dba)2 (0.5 mg, 0.9 µmol) and DavePhos (0.4 mg,
1.0 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 116b as a yellow oil (13 mg, 37%).
HRMS (ESI+) [M+H]+ calcd. for C25H25N5: 396.2188; found 396.2185. 1H NMR (500
MHz, CDCl3): δ 1.51 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.1
Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.3 Hz, H(3’ax) + H(5’ax)], 1.70-1.88 [3H, m, H(3’eq) + H(4’ax) +
H(5’eq)], 2.65-2.77 [4H, m, H(2’ax) + H(6’ax) + H(A)], 3.70 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.1 Hz, H(2’eq) + H(6’eq)], 5.07 [2H, br s, NH2], 6.70 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.96
[1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.29 [1H, br d‡, 3J5”,6” = 7.1 Hz, H(6”)], 7.36 [1H, dd, 3J7,8
= 9.2 Hz, 4J5,7 = 2.6 Hz, H(7)], 7.39 [1H, br s‡, H(2”)], 7.41-7.50 [2H, m, H(4”) + H(5”)],
7.58 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.78 [1H, d, 3J3,4 = 8.8 Hz, H(4)], 8.96 [2H, s, H(2”’) +
H(6”’)], 9.21 [1H, s, H(4”’)]. 13C NMR (126 MHz, CDCl3): δ 32.22 [C(3’) + C(5’)], 37.97
[C(4’)], 43.25 [C(A)], 50.81 [C(2’) + C(6’)], 111.42 [C(5)], 112.04 [C(3)], 123.85 [C(7)],
124.12 [C(4a)], 124.84 [C(4”)], 125.68 [br, C(8)], 127.88 [C(2”)], 129.52 [C(5”)], 130.02
[C(6”)], 134.48 [C(3”)], 134.57 [C(1”’)], 138.13 [br, C(4)], *140.96 [C(8a)], 141.98 [C(1”)],
147.93 [C(6)], 155.09 [C(2”’) + C(6”’)], 155.18 [C(2)], 157.62 [C(4”’)].
*The C(8a) signal was not observed in the 13C NMR spectrum, and the chemical shift was







Using General Method 11, 132c (27 mg, 0.07 mmol) was treated with LiHMDS solution
(1.0 M in THF, 143 µL, 0.14 mmol), Pd(dba)2 (0.4 mg, 0.7 µmol) and DavePhos (0.3 mg,
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0.8 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 116c as a brown oil (12 mg, 47%).
HRMS (ESI+) [M+H]+ calcd. for C25H25N5: 396.2188; found 396.2181. 1H NMR (500
MHz, CDCl3): δ 1.51 [2H, qd, 2J(3’/5’)ax,(3’/5’)eq = 3J(2’/6’)ax,(3’/5’)ax = 3J(3’/5’)ax,4’ax = 12.0
Hz, 3J(2’/6’)eq,(3’/5’)ax = 3.2 Hz, H(3’ax) + H(5’ax)], 1.69-1.89 [3H, m, H(3’eq) + H(4’ax) +
H(5’eq)], 2.64-2.76 [4H, m, H(2’ax) + H(6’ax) + H(A)], 3.70 [2H, br d‡, 2J(2’/6’)ax,(2’/6’)eq =
12.0 Hz, H(2’eq) + H(6’eq)], 5.08 [2H, br s, NH2], 6.70 [1H, d, 3J3,4 = 8.8 Hz, H(3)], 6.97
[1H, d, 4J5,7 = 2.6 Hz, H(5)], 7.31-7.40 [3H, m, H(7) + H(2”) + H(6”)], 7.50-7.55 [2H,
m, H(3”) + H(5”)], 7.59 [1H, d, 3J7,8 = 9.2 Hz, H(8)], 7.79 [1H, d, 3J3,4 = 8.8 Hz, H(4)],
8.96 [2H, s, H(2”’) + H(6”’)], 9.20 [1H, s, H(4”’)]. 13C NMR (126 MHz, CDCl3): δ 32.23
[C(3’) + C(5’)], 37.93 [C(4’)], 42.94 [C(A)], 50.83 [C(2’) + C(6’)], 111.41 [C(5)], 112.05
[C(3)], 123.87 [C(7)], 124.11 [C(4a)], 125.63 [C(8)], 127.00 [C(3”) + C(5”)], 130.40 [C(2”)
+ C(6”)], 132.08 [C(4”)], 134.33 [C(1”’)], 138.16 [C(4)], 140.85 [br, C(8a)], 141.78 [C(1”)],
147.96 [C(6)], 154.90 [C(2”’) + C(6”’)], 155.17 [C(2)], 157.46 [C(4”’)].
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6.4 2-Aminoquinolines with a 3-position phenethyl-type substituent
6.4.1 Investigation of synthetic pathway for 3-position extended quinolines
General Method 14: Horner-Emmons reaction for synthesis of 3-position extended















A solution of diethyl benzylphosphonate derivative (1.3 eq) in anhydrous THF was added to
a stirring suspension of sodium hydride (60% dispersion in mineral oil, 3 eq) in THF under an
atmosphere of nitrogen. The mixture was stirred for 30 min and a solution of quinoline 144
(1 eq) in THF was added dropwise. The mixture was stirred at room temperature for 4 hr or
until complete then quenched with water and extracted with ethyl acetate (3 x 30 mL). The
organic extracts were washed with water then dried over MgSO4, filtered, and concentrated by
evaporation under reduced pressure. The residue was chromatographed over silica gel using
the specified eluant.
General Method 15: Horner-Emmons reaction for synthesis of 3-position extended















A solution of diethyl benzylphosphonate derivative (1.4 eq) in anhydrous DMF was added
to a suspension of sodium tert-butoxide (1.6 eq) in DMF under an atmosphere of nitrogen.
The mixture was stirred for 30 min and a solution of quinoline 144 (1 eq) in DMF was
added dropwise. The mixture was stirred at room temperature for 4 hr or until complete
then quenched with water and extracted with ethyl acetate (x3). The organic extracts were
washed with water then dried over MgSO4, filtered, and concentrated by evaporation under









Phosphorous oxychloride (24.1 mL, 258 mmol) was added dropwise to DMF (7.2 mL, 93
mmol) stirred at 0°C. Acetanilide (5.00 g, 37 mmol) was added portionwise, and the mixture
was stirred at 0°C until homogeneous then at 80°C overnight. The solution was cooled to
0°C then added slowly to ice water (250 mL). The resultant precipitate was collected by
vacuum filtration and recrystallised from ethyl acetate to give 144 as a yellow needle-like
crystals (2.99 g, 42%). MP: 151-154°C (lit.134 148-149°C). HRMS (ESI+) [M+H]+ calcd.
for C10H635ClNO/C10H637ClNO: 192.0216/194.0187; found 192.0210/194.0183. 1H NMR
(500 MHz, CDCl3): δ 7.66 [1H, ddd, 3J5,6 = 8.1 Hz, 3J6,7 = 7.0 Hz, 4J6,8 = 1.1 Hz, H(6)],
7.89 [1H, ddd, 3J7,8 = 8.5 Hz, 3J6,7 = 7.0 Hz, 4J5,7 = 1.1 Hz, H(7)], 8.00 [1H, dd, 3J5,6 =
8.1 Hz, 4J5,7 = 1.1 Hz, H(5)], 8.09 [1H, br d‡, 3J7,8 = 8.5 Hz, H(8)], 8.77 [1H, s, H(4)],
10.57 [1H, s, CHO].




Synthesis method a. Using General Method 12, 36l (302 mg, 0.98 mmol) was reacted
with NaH (60% dispersion in mineral oil, 94 mg, 2.35 mmol) and 144 (150 mg, 0.78
mmol) in anhydrous THF (10 mL) for 16 hr. Work-up and purification by flash column
chromatography on silica gel eluting with 4:1 dichloromethane/hexane gave 151b as a white
solid (100 mg, 36%) and 145b as a white solid (86 mg, 25%).
A sample of (E )-3-(3-bromostyryl)-2-chloroquinoline (E -145b) was obtained by column
chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd. for
C17H1179BrClN/C17H1181BrClN: 343.9842/345.9821; found 343.9834/345.9815. 1H NMR
(500 MHz, CDCl3): δ 7.09 [1H, d, 3JA,B = 16.2 Hz, H(B)], 7.26 [1H, t, 3J4’,5’ = 3J5’,6’ = 8.0
Hz, H(5’)], 7.44 [1H, br d‡, 3J4’,5’ = 8.0 Hz, H(4’)], 7.49 [1H, br d‡, 3J5’,6’ = 8.0 Hz, H(6’)],
7.50 [1H, d, 3JA,B = 16.2 Hz, H(A)], 7.56 [1H, t, 3J5,6 = 3J6,7 = 7.8 Hz, H(6)], 7.67-7.73
[2H, m, H(7) + H(2’)], 7.83 [1H, d, 3J5,6 = 7.8 Hz, H(5)], 7.99 [1H, d, 3J7,8 = 8.5 Hz, H(8)],
8.34 [1H, s, H(4)]. 13C NMR (126 MHz, CDCl3): δ 123.15 [C(3’)], 125.09 [C(A)], 125.68
[C(6’)], 127.50 [C(6)], 127.54 [C(4a)], 127.72 [C(5)], 128.46 [C(8)], 129.90 [C(3)], 129.91
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[C(2’)], 130.46 [C(5’)], 130.58 [C(7)], 131.48 [C(4’)], 131.73 [C(B)], 134.12 [C(4)], 138.79




A sample of (E )-3-(3-bromostyryl)-2-ethoxyquinoline (E -151b) was isolated by column
chromatography for the purposes of characterisation. MP: 86-88°C. HRMS (ESI+) [M+H]+
calcd. for C19H1679BrNO/C19H1681BrNO: 354.0494/356.0473; found 354.0488/356.0471.
1H NMR (500 MHz, CDCl3): δ 1.52 [3H, t, 3J = 7.1 Hz, CH3], 4.63 [2H, q, 3J = 7.1 Hz,
OCH2], 7.21-7.28 [2H, m, H(B) + H(5’)], 7.33-7.42 [3H, m, H(6) + H(A) + H(4’)], 7.46
[1H, br d‡, 3J5’,6’ = 8.0 Hz, H(6’)], 7.58 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.0 Hz, 4J5,7 =
1.4 Hz, H(7)], 7.69-7.74 [2H, m, H(5) + H(2’)], 7.80 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 8.13
[1H, s, H(4)]. 13C NMR (126 MHz, CDCl3): δ 14.80 [CH3], 62.29 [OCH2], 122.22 [C(3)],
123.06 [C(3’)], 124.34 [C(6)], 124.58 [C(A)], 125.42 [C(4a)], 125.52 [C(6’)], 127.04 [C(8)],
127.58 [C(5)], 129.51 [C(7)], 129.64 [C(2’)], 130.06 [C(B)], 130.32 [C(5’)], 130.79 [C(4’)],
134.42 [C(4)], 139.84 [C(1’)], 146.12 [C(8a)], 159.72 [C(2)].
Synthesis method b. Using General Method 12, 36l (192 mg, 0.63 mmol) was reacted with
NaH (60% dispersion in mineral oil, 42 mg, 1.0 mmol) and 144 (100 mg, 0.52 mmol) in
anhydrous THF (10 mL) for 1 hr. Work-up and purification by flash column chromatography
on silica gel eluting with 4:1 dichloromethane/hexane gave 145b as a white solid (86 mg,




Synthesis method a. Using General Method 12, 36m (0.48 g, 1.5 mmol) was reacted with NaH
(60% dispersion in mineral oil, 0.12 g, 3.0 mmol) and 144 (250 mg, 1.3 mmol) in anhydrous
THF (10 mL) for 1 hr. Work-up and purification by flash column chromatography on silica gel
eluting with 4:1 dichloromethane/hexane gave 145c as a white solid (111 mg, 25%). HRMS
(ESI+) [M+H]+ calcd. for C17H1179BrClN/C17H1181BrClN: 343.9842/345.9821; found
343.9834/345.9814. 1H NMR (500 MHz, CDCl3): δ 6.77 and 6.77 [0.2H, AB, A:d, B:d,
3J*A,*B(JAB) = 12.6 Hz, *H(A) + *H(B)], 7.03-7.08 [0.2H, m, *H(2’) + *H(6’)], 7.10 [0.9H,
d, 3JA,B = 16.2 Hz, H(B)], 7.29-7.33 [0.2H, m, *H(3’) + *H(5’)], 7.40-7.46 [1.8H, m, H(2’)
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+ H(6’)], 7.46-7.60 [3.8H, m, H(A) + H(6) + H(3’) + H(5’) + *H(5) + *H(6)], 7.66-7.73
[1H, m, H(7) + *H(7)], 7.82 [0.9H, br d‡, 3J5,6 = 8.1 Hz, H(5)], 7.92 [0.1H, s, *H(4)],
7.96-8.02 [1H, m, H(8) + *H(8)], 8.34 [0.9H, s, H(4)].
*Denotes signals corresponding to Z -isomer.





Synthesis method b. LiHMDS solution (1M in THF, 2.6 mL, 2.6 mmol) was added dropwise
to a solution of 36m (750 mg, 2.4 mmol) in THF stirred under an atmosphere of nitrogen,
and mixture was stirred for 10 min. A solution of 144 (389 mg, 2.0 mmol) in THF (3 mL)
was added dropwise, and the mixture was stirred at room temperature for 1 hr then quenched
with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The organic extracts
were dried over MgSO4, filtered, and volatile solvent removed by evaporation under reduced
pressure to give a mixture containing recovered 36m and 152. The desired product 145c
was not observed.
Synthesis method c. Using General Method 12, 36m (0.48 g, 1.5 mmol) was reacted with
sodium tert-butoxide (176 mg, 1.8 mmol) and 144 (250 mg, 1.3 mmol) in anhydrous THF
(10 mL) for 1 hr. Work-up and purification by flash column chromatography on silica gel
eluting with 4:1 dichloromethane/hexane gave 145c as a white solid (160 mg, 36%). Data
as above.
A crude mixture of recovered 36m and (2-chloroquinolin-3-yl)methanol (152) was also
obtained.
Synthesis method d. Using General Method 12, 36m (0.48 g, 1.5 mmol) was reacted with
NaH (60% dispersion in mineral oil, 88 mg, 2.2 mmol) and 144 (250 mg, 1.3 mmol) in
anhydrous DMF (10 mL) for 1 hr. Work-up and purification by flash column chromatography
on silica gel eluting with 4:1 dichloromethane/hexane gave 145c as a white solid (347 mg,
77%). Data as above.
Synthesis method e. LiHMDS solution (1M in THF, 940 µL, 0.94 mmol) was added dropwise
to a solution of 36m (192 mg, 0.62 mmol) in DMF (6 mL) stirred under an atmosphere of
nitrogen, and mixture was stirred for 10 min. A solution of 144 (100 mg, 0.52 mmol) in
DMF (3 mL) was added dropwise, and the mixture was stirred at room temperature for 1
hr then quenched with water (30 mL) and extracted with ethyl acetate (3 x 40 mL). The
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organic extracts were washed with water (2 x 100 mL) dried over MgSO4, filtered, and volatile
solvent removed by evaporation under reduced pressure. 1H NMR analysis of the crude mixture
indicated low conversion to the desired product and a large amount of 152 was present, and
further purification was not attempted.
Synthesis method f. Using General Method 15, 36m (192 mg, 0.62 mmol), 144 (100 mg, 0.52
mmol), and sodium tert-butoxide (90 mg, 0.94 mmol) were reacted in DMF (6 mL) for 4 hr.
Work-up followed by column chromatography eluting with dichloromethane gave 145c as an
off-white solid (141 mg, 78%). Rf = 0.20 (1:1 ethyl acetate/hexane). HRMS (ESI+) [M+H]+
calcd. for C17H1179BrClN/C17H1181BrClN: 343.9842/345.9821; found 343.9834/345.9814.
Pure samples of each isomer were isolated by chromatography for the purposes of
characterisation.
(E)-3-(4-Bromostyryl)-2-chloroquinoline (E-145c): 1H NMR (500 MHz, CDCl3): δ 7.10 [1H,
d, 3JA,B = 16.2 Hz, H(B)], 7.40-7.46 [2H, m, H(2’) + H(6’)], 7.46-7.60 [4H, m, H(A) +
H(6) + H(3’) + H(5’)], 7.69 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.2 Hz, 4J5,7 = 1.2 Hz, H(7)],
7.82 [1H, br d‡, 3J5,6 = 8.1 Hz, H(5)], 7.99 [1H, d, 3J7,8 = 8.4 Hz, H(8)], 8.34 [1H, s, H(4)].
13C NMR (126 MHz, CDCl3): δ 122.61 [C(4’)], 124.34 [C(A)], 127.48 [C(6)], 127.59 [C(4a)],
127.68 [C(5)], 128.48 [C(8)], 128.54 [C(2’) + C(6’)], 130.08 [C(3)], 130.49 [C(7)], 132.05
[C(B)], 132.13 [C(3’) + C(5’)], 133.94 [C(4)], 135.62 [C(1’)], 147.05 [C(8a)], 150.21 [C(2)].
(Z)-3-(4-Bromostyryl)-2-chloroquinoline (Z-145c): 1H NMR (500 MHz, CDCl3): δ 6.77 and
6.77 [2H, AB, A:d, B:d, 3JA,B(JAB) = 12.6 Hz, H(A) + H(B)], 7.03-7.08 [2H, m, H(2’) +
H(6’)], 7.29-7.33 [2H, m, H(3’) + H(5’)], 7.49 [1H, ddd, 3J5,6 = 8.1 Hz, 3J6,7 = 6.9 Hz, 4J6,8
= 1.1 Hz, H(6)], 7.59 [1H, dd, 3J5,6 = 8.1 Hz, 4J5,7 = 1.4 Hz, H(5)], 7.70 [1H, ddd, 3J7,8 =
8.3 Hz, 3J6,7 = 6.9 Hz, 4J5,7 = 1.4 Hz, H(7)], 7.92 [1H, s, H(4)], 8.01 [1H, br d‡, 3J7,8 = 8.3
Hz, H(8)]. 13C NMR (126 MHz, CDCl3): δ 121.83 [C(4’)], 126.33 [C(A)], 127.06 [C(4a)],
127.30 [C(6)], 127.67 [C(5)], 128.42 [C(8)], 129.76 [C(3)], 130.59 [C(2’) + C(6’)], 130.66
[C(7)], 131.83 [C(3’) + C(5’)], 132.24 [C(B)], 134.83 [C(1’)], 138.45 [C(4)], 147.10 [C(8a)],
150.53 [C(2)].
Further investigation into reactivity of 2-chloroquinoline-3-carbaldehyde (144)
Synthesis method a. LiHMDS solution (1M in THF, 600 µL, 0.6 mmol) was added dropwise
to a solution of 36m (144 mg, 0.47 mmol) in THF stirred under an atmosphere of nitrogen,
and mixture was stirred for 10 min. The mixture was quenched with D2O (1 mL) and the
mixture was concentrated to dryness under reduced pressure. 1H NMR analysis of the crude
mixture identified signals corresponding to 36m and 185m. Integration of the HP doublet










Synthesis method b. A solution of 144 (10 mg, 0.05 mmol) in anhydrous THF was added to
anhydrous THF stirring under an atmosphere of nitrogen. The solution was stirred for 1 hr,
and then water (1 mL) was added. The mixture was concentrated to dryness by evaporation
under reduced pressure, to give recovered 144.
Synthesis method c. LiHMDS solution (1M in THF, 140 µL, 0.14 mmol) was added dropwise
to anhydrous THF (4 mL) stirring under an atmosphere of nitrogen, and then stirred for 10
min. A solution of 144 (15 mg, 0.08 mmol) in anhydrous THF was added dropwise, and the
mixture was stirred for 1 hr. The mixture was quenched with water (4 mL) and the mixture
was concentrated to dryness under reduced pressure. 1H NMR analysis identified the crude




(2-Chloroquinolin-3-yl)methanol (152): HRMS (ESI+) [M+H]+ calcd. for C10H835ClNO/
C10H837ClNO: 194.0373/196.0343; found 194.0369/196.0342. 1H NMR (500 MHz, CDCl3):
δ 4.93 [2H, s, OCH2], 7.57 [1H, ddd, 3J5,6 = 8.3 Hz, 3J6,7 = 7.0 Hz, 4J6,8 = 1.0 Hz, H(6)],
7.72 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.0 Hz, 4J5,7 = 1.3 Hz, H(7)], 7.84 [1H, br d‡, 3J5,6 =
8.3 Hz, H(5)], 8.02 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 8.30 [1H, s, H(4)].
This data is consistent with that reported previously.135
Synthesis method d. A solution of 144 (15 mg, 0.08 mmol) in anhydrous THF was added
dropwise to a stirring suspension of NaH (60% in mineral oil, 10 mg, 0.25 mmol) in THF
under an atmosphere of nitrogen. The mixture was stirred for 1 hr then quenched with water
(4 mL) and extracted with dichloromethane (3 x 20 mL). The organic extracts were dried
over MgSO4, filtered, and the volatile solvent removed by evaporation under reduced pressure.
1H NMR analysis identified the crude mixture contained mostly 152, and a small amount of





Synthesis method a. A mixture of 145c (110 mg, 0.32 mmol), 4-pyridinylboronic acid (39 mg,
0.32 mmol), Pd(OAc)2 (2.1 mg, 9 µmol), PPh3 (4.2 mg, 16 µmol), and K2CO3 (88 mg, 0.64
mmol) were combined in a glass pressure tube with toluene/ethanol (1:1, 3 mL). The tube was
sealed and heated to 100°C for 16 hr, then cooled to room temperature and filtered through
Celite®, washing with methanol. The solvent was removed by evaporation under reduced
pressure to give a complex crude mixture of products which could not be purified. Column
chromatography on silica gel eluting with methanol in dichloromethane (0-5%) yielded a small
















(E)-2-(Pyridin-4-yl)-3-styrylquinoline (E-154c): Rf = 0.01 (dichloromethane). HRMS (ESI+)
[M+H]+ calcd. for C13H19N: 309.1392; found 309.1386. 1H NMR (500 MHz, CDCl3):
δ 7.14 [1H, d, 3JA,B = 16.1 Hz, H(A)], 7.21 [1H, d, 3JA,B = 16.1 Hz, H(B)], 7.28-7.33 [1H,
m, H(4’)], 7.34-7.40 [H(3’) + H(5’)], 7.42-7.47 [2H, m, H(2’) + H(6’)], 7.60 [1H, ddd, 3J5,6
= 8.1 Hz, 3J6,7 = 6.9 Hz, 4J6,8 = 1.1 Hz, H(6)], 7.64-7.68 [2H, m, H(2”) + H(6”)], 7.74 [1H,
ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 6.9 Hz, 4J5,7 = 1.0 Hz, H(7)], 7.91 [1H, br dd‡, 3J5,6 = 8.1 Hz,
4J5,7 = 1.0 Hz, H(5)], 8.14 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 8.47 [1H, s, H(4)], 8.75-8.81
[2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 124.53 [C(2”) + C(6”)], 125.44
[C(A)], 126.90 [C(2’) + C(6’)], 127.60 [C(6)], 127.72 [C(5)], 127.99 [C(4a)], 128.51 [C(4’)],
129.02 [C(3’) + C(5’)], 129.67 [C(8)], 129.91 [C(3)], 130.05 [C(7)], 132.42 [C(B)], 133.50
[C(4)], 136.84 [C(1’)], 147.49 [C(8a)], 147.83 [C(1”)], 150.10 [C(3”) + C(5”)], 156.21 [C(2)].
HRMS analysis of the crude product mixture identified masses corresponding to other products
which could not be isolated; potential products reported below.
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2-Chloro-3-(4-(pyridin-4-yl)styryl)quinoline (147c): HRMS (ESI+) [M+H]+ calcd. for





3-(4-Bromostyryl)-2-(pyridin-4-yl)quinoline (155c): HRMS (ESI+) [M+H]+ calcd. for
C22H1579BrN2/C22H1581BrN2: 387.0497/389.0476; found 387.0517/389.0474.
Synthesis method b.95 A mixture of 145c (80 mg, 0.23 mmol), 4-pyridinylboronic acid (29
mg, 0.24 mmol), Pd(OAc)2 (1.6 mg, 7 µmol), PPh3 (3.0 mg, 11 µmol), and K2CO3 (64 mg,
0.46 mmol) were combined in a glass pressure tube with toluene (3 mL). The tube was sealed
and heated to 80°C for 16 hr, then cooled to room temperature and filtered through Celite®,
washing with methanol. The solvent was removed by evaporation under reduced pressure to
give a complex crude mixture of products which could not be purified.
Synthesis method c.96 A mixture of 145c (41 mg, 0.12 mmol), 4-pyridinylboronic acid (15
mg, 0.12 mmol), Pd(OAc)2 (0.8 mg, 3.6 µmol), P(o−tol)3 (1.8 mg, 5.9 µmol), and Na2CO3
(50 mg, 0.47 mmol) were combined in a glass pressure tube with 1,4-dioxane (3 mL). The
tube was sealed and heated to 55°C for 16 hr, then cooled to room temperature and filtered
through Celite®, washing with methanol. The solvent was removed by evaporation under
reduced pressure to give a complex crude mixture of products which could not be purified.
HRMS did not identify peaks consistent with the desired product.
Synthesis method d.96 A mixture of 145c (41 mg, 0.12 mmol), 4-pyridinylboronic acid (15
mg, 0.12 mmol), Pd(OAc)2 (0.8 mg, 3.6 µmol), P(o−tol)3 (1.8 mg, 5.9 µmol), and Na2CO3
(50 mg, 0.47 mmol) were combined in 1,4-dioxane (3 mL) and heated at reflux for 16 hr.
The mixture was cooled to room temperature and filtered through Celite®, washing with
methanol. The solvent was removed by evaporation under reduced pressure to give a complex
crude mixture of products which could not be purified. HRMS did not identify peaks consistent
with the desired product.
Synthesis method e. LiHMDS solution (1M in THF, 881 µL, 0.88 mmol) was added dropwise
to a solution of 157c (148 mg, 0.48 mmol) in THF stirred under an atmosphere of nitrogen,
and mixture was stirred for 10 min. A solution of 144 (84 mg, 0.44 mmol) in THF (3 mL) was
added dropwise, and the mixture was stirred at room temperature for 1 hr then quenched with
water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The organic extracts were dried
over MgSO4, filtered, and volatile solvent removed by evaporation under reduced pressure.
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The residue was chromatographed over silica gel eluting with dichloromethane, to give a crude
mixture containing predominantly 152 and a small amount of the desired product 147c.
Synthesis method f. Using General Method 15, 157c (263 mg, 0.86 mmol), 144 (118 mg, 0.62
mmol), and sodium tert-butoxide (142 mg, 1.48 mmol) were reacted in DMF (6 mL) for 4 hr.
Work-up followed by column chromatography eluting with dichloromethane gave 147c as a
yellow solid (211 mg, 100%). Rf = 0.12 (2.5% methanol in dichloromethane). MP: degraded
137°C. HRMS (ESI+) [M+H]+ calcd. for C22H1535ClN2/C22H1537ClN2: 343.1002/345.0973;
found 343.0999/345.0979. 1H NMR (500 MHz, CDCl3): δ 6.81 [0.15H, d, 3J*A,*B = 12.1
Hz, *H(A)], 6.89 [0.15H, d, 3J*A,*B = 12.1 Hz, *H(B)], 7.23 [0.85H, d, 3JA,B = 16.2 Hz,
H(B)], 7.28-7.32 [0.3H, m, *H(2’) + *H(6’)], 7.41-7.45 [0.3H, m, *H(2”) + *H(6”)], 7.45-
7.63 [3.85H, m, H(A) + H(6) + H(2”) + H(6”) + *H(6) + *H(3’) + *H(5’)], 7.65-7.74
[4.55H, m, H(7) + H(2’) + H(3’) + H(5’) + H(6’) + *H(5) + *H(7)], 7.85 [0.85H, d,
3J5,6 = 8.1 Hz, H(5)], 7.97-8.05 [1.15H, m, H(8) + *H(4) + *H(8)], 8.39 [0.85H, s, H(4)],
8.58-8.64 [0.3H, m, *H(3”) + *H(5”)], 8.65-8.71 [1.7H, m, H(3”) + H(5”)]. 13C NMR (126
MHz, CDCl3): δ 121.35 [*C(2”) + *C(6”)], 121.43 [C(2”) + C(6”)], 124.67 [C(A)], 126.51
[*C(A)], 127.07 [*C(5)], 127.11 [*C(3’) + *C(5’)], 127.24 [*C(6)], 127.49 [C(6)], 127.52
[C(3’) + C(5’)], 127.60 [*C(4a)], 127.61 [C(4a)], 127.69 [C(5)], 127.80 [C(2’) + C(6’)],
128.41 [*C(8)], 128.47 [C(8)], 129.76 [*C(2’) + *C(6’)], 129.98 [*C(3)], 130.12 [C(3)],
130.51 [C(7)], 130.60 [*C(7)], 132.34 [C(B)], 132.60 [*C(B)], 133.97 [C(4)], 136.83 [*C(1’)
+ *C(4’)], 137.28 [*C(1’) + *C(4’)], 137.52 [C(1’)], 138.10 [C(4’)], 138.49 [*C(4)], 147.06
[C(8a)], 147.09 [*C(8a)], 147.50 [*C(1”)], 147.59 [C(1”)], 150.26 [C(2)], 150.41 [*C(3”) +
*C(5”)], 150.48 [C(3”) + C(5”)], 150.57 [*C(2)].
* denotes signals corresponding to Z -isomer
A sample of pure (E )-2-chloro-3-(4-(pyridin-4-yl)styryl)quinoline (E -147c) was isolated by
column chromatography for the purposes of characterisation. 1H NMR (500 MHz, CDCl3):
δ 7.24 [1H, d, 3JA,B = 16.2 Hz, H(B)], 7.51-7.64 [4H, m, H(A) + H(6) + H(2”) + H(6”)],
7.67-7.74 [5H, m, H(7) + H(2’) + H(3’) + H(5’) + H(6’)], 7.86 [1H, br d‡, 3J5,6 = 8.1 Hz,
H(5)], 8.00 [1H, br d‡, 3J7,8 = 8.5 Hz, H(8)], 8.41 [1H, s, H(4)], 8.65-8.72 [2H, m, H(3”) +
H(5”)]. 13C NMR (126 MHz, CDCl3): δ 121.48 [br, C(2”) + C(6”)], 124.73 [C(A)], 127.52
[C(6)], 127.57 [C(3’) + C(5’)], 127.64 [C(4a)], 127.71 [C(5)], 127.83 [C(2’) + C(6’)], 128.52
[C(8)], 130.18 [C(3)], 130.54 [C(7)], 132.38 [C(B)], 134.01 [C(4)], 137.55 [C(1’)], 138.17







Using General Method 13, 36m (320 mg, 1.0 mmol), phenylboronic acid (152 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.1
mmol) in toluene/ethanol (1:1, 4 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 2% methanol in dichloromethane gave 156c as a pale yellow oil
(285 mg, 90%). Rf = 0.16 (2% methanol in dichloromethane). 1H NMR (500 MHz, CDCl3):
δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.19 [2H, d, 2JH,P = 21.7 Hz, PCH2], 3.97-4.11 [4H, m,
2 x OCH2], 7.33 [1H, tt, 3J3’,4’ = 3J4’,5’ = 7.4 Hz, 4J2’,4’ = 4J4,6’ = 1.1 Hz, H(4’)], 7.35-7.39
[2H, m, H(2) + H(6)], 7.40-7.46 [2H, m, H(3’) + H(5’)], 7.52-7.56 [2H, m, H(2’) + H(6’)],
7.56-7.60 [2H, m, H(3) + H(5)]. 13C NMR (126 MHz, CDCl3): δ 16.50 [d, 3JC,P = 6.0 Hz,
2 x CH3], 33.57 [d, 1JC,P = 138.2 Hz, PCH2], 62.27 [d, 2JC,P = 6.7 Hz, 2 x OCH2], 127.10
[d, 7JC,P = 0.8 Hz, C(2’) + C(6’)], 127.33 [br s, C(4’)], 127.36 [d, 4JC,P = 1.4 Hz, C(3) +
C(5)], 128.86 [C(3’) + C(5’)], 130.27 [d, 3JC,P = 6.6 Hz, C(2) + C(6)], 130.79 [d, 2JC,P =
9.1 Hz, C(1)], 139.87 [d, 5JC,P = 3.9 Hz, C(4)], 140.83 [d, 6JC,P = 1.5 Hz, C(1’)].







Using General Method 13, 36m (320 mg, 1.04 mmol), 4-pyridinylboronic acid (154 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.08
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in dichloromethane gave 157c as a clear oil (307
mg, 97%). Rf = 0.20 (1:19 methanol/dichloromethane). 1H NMR (500 MHz, CDCl3): δ
1.27 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.21 [2H, d, 2JH,P = 21.8 Hz, PCH2], 3.99-4.12 [4H, m,
2 x OCH2], 7.39-7.46 [2H, m, H(2) + H(6)], 7.47-7.53 [2H, m, H(2’) + H(6’)], 7.58-7.64
[2H, m, H(3) + H(5)], 8.60-8.70 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ
16.50 [d, 3JC,P = 6.0 Hz, 2 x CH3], 33.66 [d, 1JC,P = 138.1 Hz, PCH2], 62.33 [d, 2JC,P =
6.7 Hz, 2 x OCH2], 121.56 [br s, C(2’) + C(6’)], 127.21 [d, 4JC,P = 3.3 Hz, C(3) + C(5)],
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130.63 [d, 3JC,P = 6.5 Hz, C(3) + C(5)], 133.00 [d, 2JC,P = 9.4 Hz, C(1)], 136.76 [d, 5JC,P
= 3.8 Hz, C(4)], 147.94 [d, 6JC,P = 1.5 Hz, C(1’)], 150.35 [C(3’) + C(5’)].
3-(2-((1,1’-Biphenyl)-4-yl)vinyl)-2-chloroquinoline (146c)
N Cl
Using General Method 15, 156c (250 mg, 0.82 mmol), 144 (112 mg, 0.58 mmol), and
sodium tert-butoxide (135 mg, 1.4 mmol) were reacted in DMF (6 mL) for 4 hr. Work-
up followed by column chromatography eluting with dichloromethane gave 146c as an off-
white solid (156 mg, 78%). HRMS (ESI+) [M+H]+ calcd. for C23H1635ClN/C23H1637ClN:
342.1050/344.1020; found 342.1045/344.1021. 1H NMR (500 MHz, CDCl3): 6.75 [0.3H,
d, 3JA,B = 12.1 Hz, *H(A) or *H(B)], 6.88 [0.3H, d, 3JA,B = 12.1 Hz, *H(A) or *H(B)],
7.17-7.73 [12.7H, m, H(6) + H(7) + H(A) + H(B) + Ph + *H(5) + *H(6) + *H(7) + *Ph],
7.84 [0.7H, d, 3J5,6 = 8.0 Hz, H(5)], 7.97-8.05 [1.3H, m, H(8) + *H(4) + *H(8)], 8.39 [1H,
s, H(4)].
* denotes signals corresponding to Z -isomer
Due to overlap of signals in the product mixture the 13C NMR spectrum could not be
unambiguously assigned.
A sample of pure (E )-3-(2-((1,1’-biphenyl)-4-yl)vinyl)-2-chloroquinoline (E -146c )was isolated
by column chromatography for the purposes of characterisation. 1H NMR (500 MHz, CDCl3):
δ 7.23 [1H, d, 3JA,B = 16.3 Hz, H(B)], 7.37 [1H, tt, 3J3”,4” = 3J4”,5” = 7.4 Hz, 4J2”,4” =
4J4”,6” = 1.1 Hz, H(4”)], 7.43-7.49 [2H, m, H(3”) + H(5”)], 7.53-7.60 [2H, m, H(A) + H(6)],
7.61-7.72 [7H, m, H(7) + H(2’) + H(3’) + H(5’) + H(6’) + H(2”) + H(6”)], 7.85 [1H, br
d‡, 3J5,6 = 8.0 Hz, H(5)], 8.00 [1H, br d‡, 3J7,8 = 8.5 Hz, H(8)], 8.39 [1H, s, H(4)]. 13C NMR
(126 MHz, CDCl3): δ 123.64 [C(A)], 127.11 [C(2”) + C(6”)], 127.43 [C(6)], 127.59 [C(2’) +
C(6’)], 127.65 [C(3’) + C(5’)], 127.68 [*C(5)], 127.70 [*C(4”)],128.49 [C(8)], 129.01 [C(3”)
+ C(5”)], 130.35 [C(7)], 130.49 [C(3)], 132.91 [C(B)], 133.79 [C(4)], 135.75 [C(1’)], 140.59
[C(1”)], 141.47 C(4’)], 146.98 [C(8a)], 150.39 [C(2)].
*Some 13C NMR signals could not be unambiguously assigned due to close proximity of
chemical shifts. The C(4a) signal was not observed; 2D HMBC correlations indicated this
signal was overlapped with a signal at 127.7 ppm, but due to close proximity of several signals
in this range the C(4a) signal could not be unambiguously assigned.
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Using General Method 13, 36k (320 mg, 1.0 mmol), phenylboronic acid (152 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3(13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.1
mmol) in toluene/ethanol (1:1, 4 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 2% methanol in DCM gave 156a as a pale yellow oil (282 mg,
89%). Rf = 0.24 (2.5% methanol in dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.20
[6H, t, 3J = 7.1 Hz, 2 x CH3], 3.18 [2H, d, 2JH,P = 22.2 Hz, PCH2], 3.87-4.01 [4H, m, 2 x
OCH2], 7.22-7.45 [8H, m, H(3) + H(4) + H(5) + H(2’) + H(3’) + H(4’) + H(5’) + H(6’)],
7.54-7.60 [1H, m, H(6)]. 13C NMR (126 MHz, CDCl3): δ 16.41 [d, 3JC,P = 6.2 Hz, 2 x CH3],
30.36 [d, 1JC,P = 138.3 Hz, PCH2], 62.00 [d, 2JC,P = 6.7 Hz, 2 x OCH2], 126.88 [d, 4JC,P
= 3.5 Hz, *C(3) or C(5)], 127.17 [C(4’)], 127.46 [d, 4JC,P = 3.3 Hz, *C(3) or C(5)], 128.28
[C(3’) + C(5’)], 129.20 [d, 2JC,P = 8.5 Hz, C(1)], 129.62 [d, 5JC,P = 0.7 Hz, C(2’) + C(6’)],
130.52-130.57 [m, C(4) + C(6)], 141.24 [d, 4JC,P = 0.9 Hz, C(1’)], 142.70 [d, 3JC,P = 8.4
Hz, C(2)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment






Using General Method 12, 36l (500 mg, 1.6 mmol), phenylboronic acid (240 mg, 2.0 mmol),
Pd(OAc)2 (11 mg, 49 µmol), PPh3 (22 mg, 84 µmol) and K2CO3 (340 mg, 2.5 mmol) in
toluene (2.5 mL) were reacted for 16 hr. Work-up followed by column chromatography eluting
with 3% methanol in DCM gave 156b as a pale yellow oil (431 mg, 87%). Rf = 0.21 (2.5%
methanol in dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.25 [6H, t, 3J = 7.1 Hz, 2 x
CH3], 3.22 [2H, d, 2JH,P = 21.6 Hz, PCH2], 3.96-4.11 [4H, m, 2 x OCH2], 7.29 [1H, br d‡,
3J5,6 = 7.6 Hz, H(6)], 7.34 [1H, t, 3J3’,4’ = 3J4’,5’ = 7.7 Hz, H(4’)], 7.38 [1H, t, 3J4,5 = 3J5,6
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= 7.6 Hz, H(5)], 7.40-7.46 [2H, m, H(3’) + H(5’)], 7.48 [1H, br d‡, 3J4,5 = 7.6 Hz, H(4)],
7.53 [1H, br d‡, 4J2,P = 1.8 Hz, H(2)], 7.56-7.61 [2H, m, H(2’) + H(6’)]. 13C NMR (126
MHz, CDCl3): δ 16.53 [d, 3JC,P = 5.8 Hz, 2 x CH3], 34.01 [d, 1JC,P = 138.1 Hz, PCH2],
62.28 [d, 2JC,P = 6.7 Hz, 2 x OCH2], 125.83 [d, 5JC,P = 3.5 Hz, C(4)], 127.26 [C(2’) +
C(6’)], 127.49 [C(4’)], 128.75 [d, 3JC,P = 6.8 Hz, C(2)], 128.78 [d, 3JC,P = 6.4 Hz, C(6)],
128.87 [C(3’) + C(5’)], 129.06 [d, 4JC,P = 3.2 Hz, C(5)], 132.27 [d, 2JC,P = 9.2 Hz, C(1)],







Using General Method 13, 36k (320 mg, 1.04 mmol), 4-pyridinylboronic acid (154 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.08
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in dichloromethane gave 157a as a pale yellow oil
(285 mg, 90%). Rf = 0.20 (3% methanol in dichloromethane). 1H NMR (500 MHz, CDCl3):
δ 1.23 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.13 [2H, d, 2JH,P = 22.3 Hz, PCH2], 3.91-4.07 [4H,
m, 2 x OCH2], 7.23 [1H, br d‡, 3J3,4 = 7.6 Hz, H(3)], 7.33 [1H, tt, 3J4,5 = 3J5,6 = 7.5 Hz,
4J3,5 = 5J5,P = 1.5 Hz, H(5)], 7.36-7.42 [3H, m, H(4) + H(2’) + H(6’)], 7.58 [1H, br d‡,
3J5,6 = 7.5 Hz, H(6)], 8.65-8.70 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ
16.42 [d, 3JC,P = 5.9 Hz, 2 x CH3], 30.48 [d, 1JC,P = 138.9 Hz, PCH2], 62.15 [d, 2JC,P = 6.8
Hz, 2 x OCH2], 124.66 [C(2’) + C(6’)], 127.24 [d, 4JC,P = 3.4 Hz, C(5)], 128.51 [d, 5JC,P =
3.5 Hz, C(4)], 128.96 [d, 2JC,P = 8.5 Hz, C(1)], 129.97 [d, 4JC,P = 2.8 Hz, C(3)], 130.94 [d,
3JC,P = 4.8 Hz, C(6)], 139.94 [d, 3JC,P = 7.9 Hz, C(2)], 149.08 [d, 4JC,P = 1.6 Hz, C(1’)],







Using General Method 13, 36l (320 mg, 1.04 mmol), 4-pyridinylboronic acid (154 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.08
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
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chromatography eluting with 2% methanol in dichloromethane gave 157b as a pale yellow oil
(258 mg, 81%). Rf = 0.18 (1:19 methanol/dichloromethane). 1H NMR (500 MHz, CDCl3):
δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.23 [2H, d, 2JH,P = 21.7 Hz, PCH2], 3.97-4.13 [4H,
m, 2 x OCH2], 7.38 [1H, br d‡, 3J5,6 = 7.6 Hz, H(6)], 7.44 [1H, t, 3J4,5 = 3J5,6 = 7.6 Hz,
H(5)], 7.49-7.55 [3H, m, H(4) + H(2’) + H(6’)], 7.59 [2H, br q‡, 4JH,P = 4J2,4 = 4J2,6 =
1.9 Hz, H(2)], 8.63-8.68 [2H, m, H(3’) + H(5’)]. 13C NMR (126 MHz, CDCl3): δ 16.52 [d,
3JC,P = 6.1 Hz, 2 x CH3], 33.92 [d, 1JC,P = 138.5 Hz, PCH2], 62.34 [d, 2JC,P = 6.8 Hz, 2 x
OCH2], 121.75 [C(2’) + C(6’)], 125.68 [d, 5JC,P = 3.6 Hz, C(4)], 128.55 [d, 3JC,P = 6.6 Hz,
C(2)], 129.42 [d, 4JC,P = 3.1 Hz, C(5)], 130.57 [d, 3JC,P = 6.6 Hz, C(6)], 132.89 [d, 1JC,P







Using General Method 13, 36k (320 mg, 1.04 mmol), 3-pyridinylboronic acid (154 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.08
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in DCM gave 158a as a yellow oil (305 mg, 96%).
Rf = 0.12 (1:19 methanol/dichloromethane). 1H NMR (500 MHz, CDCl3): δ 1.22 [6H, t,
3J = 7.1 Hz, 2 x CH3], 3.12 [2H, d, 2JH,P = 22.3 Hz, PCH2], 3.88-4.06 [4H, m, 2 x OCH2],
7.24 [1H, br d‡, 3J3,4 = 7.6 Hz, H(3)], 7.30-7.41 [3H, m, H(4) + H(5) + H(5’)], 7.58 [1H, br
ddd‡, 3J5,6 = 7.6 Hz, 4JH,P = 2.4 Hz, 4J4,6 = 1.4 Hz, H(6)], 7.82 [1H, dt, 3J5’,6’ = 7.8 Hz,
4J2’,6’ = 4J4’,6’ = 2.0 Hz, H(6’)], 8.60-8.64 [2H, m, H(2’) + H(4’)]. 13C NMR (126 MHz,
CDCl3): δ 16.45 [d, 3JC,P = 6.0 Hz, 2 x CH3], 30.61 [d, 1JC,P = 138.8 Hz, PCH2], 62.17 [d,
2JC,P = 6.7 Hz, 2 x OCH2], 123.11 [C(5’)], 127.23 [d, 5JC,P = 3.6 Hz, C(4)], 128.34 [d, 4JC,P
= 3.4 Hz, C(5)], 129.68 [C(1)], 130.66 [d, 4JC,P = 2.9 Hz, C(3)], 130.93 [d, 3JC,P = 5.0 Hz,
C(6)], 136.89 [d, 4JC,P = 1.0 Hz, C(1’)], 137.09 [d, 5JC,P = 0.8 Hz, C(6’)], 138.95 [d, 2JC,P







Using General Method 13, 36l (300 mg, 0.98 mmol), 3-pyridinylboronic acid (180 mg, 1.5
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mmol), Pd(OAc)2 (6.6 mg, 29 µmol), PPh3 (13 mg, 50 µmol) and K2CO3 (270 mg, 2.0
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 2% methanol in dichloromethane gave 158b as a pale yellow oil
(204 mg, 68%). Rf = 0.28 (5% methanol in dichloromethane). 1H NMR (500 MHz, CDCl3):
δ 1.26 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.23 [2H, d, 2JH,P = 21.7 Hz, PCH2], 4.00-4.12 [4H,
m, 2 x OCH2], 7.33-7.38 [2H, m, H(6) + H(5’)], 7.43 [1H, t, 3J4,5 = 3J5,6 = 7.6 Hz, H(5)],
7.48 [1H, dq, 3J4,5 = 7.6 Hz, 4J2,4 = 4J4,6 = 6J4,P = 1.5 Hz, H(4)], 7.53 [1H, q, 4J2,4 = 4J2,6
= 4J2,P = 1.5 Hz, H(2)], 7.87 [1H, ddd, 3J5’,6’ = 7.9 Hz, 4J2’/6’ = 2.0 Hz, 4J4’/6’ = 1.6 Hz,
H(6’)], 8.59 [1H, dd, 3J4’,5’ = 4.8 Hz, 4J4’,6’ = 1.6 Hz, H(4’)], 8.84 [1H, d, 4J2’,6’ = 2.0 Hz,
H(2’)]. 13C NMR (126 MHz, CDCl3): δ 16.50 [d, 3JC,P = 5.8 Hz, 2 x CH3], 33.91 [d, 1JC,P
= 138.2 Hz, PCH2], 62.26 [d, 2JC,P = 6.8 Hz, 2 x OCH2], 123.61 [C(5’)], 125.79 [d, 5JC,P
= 3.5 Hz, C(4)], 128.65 [d, 3JC,P = 6.7 Hz, C(2)], 129.35 [d, 4JC,P = 2.9 Hz, C(5)], 129.59
[d, 3JC,P =6.5 Hz, C(6)], 132.77 [d, 2JC,P = 9.2 Hz, C(1)], 134.44 [C(6’)], 136.38 [C(1’)],







Using General Method 13, 36m (300 mg, 0.98 mmol), 3-pyridinylboronic acid (180 mg, 1.46
mmol), Pd(OAc)2 (6.6 mg, 29 µmol), PPh3 (13 mg, 49 µmol) and K2CO3 (270 mg, 1.95
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in dichloromethane gave 158c as a pale yellow oil
(176 mg, 59%). Rf = 0.20 (1:19 methanol/dichloromethane). 1H NMR (500 MHz, CDCl3):
δ 1.28 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.21 [2H, d, 2JH,P = 21.7 Hz, PCH2], 3.98-4.14 [4H, m,
2 x OCH2], 7.36 [1H, dd, 3J5’,6’ = 7.9 Hz, 3J4’,5’ = 4.8 Hz, H(5’)], 7.39-7.45 [2H, m, H(2) +
H(6)], 7.52-7.57 [2H, m, H(3) + H(5)], 7.86 [1H, br d‡, 3J5’,6’ = 7.9 Hz, H(6’)], 8.58 [1H, br
d‡, 3J4’,5’ = 4.8 Hz, 8.84 [1H, br d‡, 4J2’,6’ = 1.1 Hz, H(2’)]. 13C NMR (126 MHz, CDCl3):
δ 16.50 [d, 3JC,P = 6.1 Hz, 2 x CH3], 33.60 [d, 1JC,P = 138.2 Hz, PCH2], 62.28 [d, 2JC,P =
6.8 Hz, 2 x OCH2], 123.62 [C(5’)], 127.33 [d, 4JC,P = 3.1 Hz, C(3) + C(5)], 130.58 [d, 3JC,P
= 6.6 Hz, C(2) + C(6)], 131.89 [d, 2JC,P = 9.2 Hz, C(1)], 134.26 [C(6’)], 136.26 [d, 6JC,P









Using General Method 13, 36k (320 mg, 1.04 mmol), 5-pyrimidinylboronic acid (155 mg, 1.25
mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg, 2.08
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in dichloromethane gave 159a as a pale yellow oil
(284 mg, 89%). 1H NMR (500 MHz, CDCl3): δ 1.23 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.10
[2H, d, 2JH,P = 22.3 Hz, PCH2], 3.93-4.06 [4H, m, 2 x OCH2], 7.24 [1H, br d‡, 3J3,4 = 7.6
Hz, H(3)], 7.38 [1H, tt, 3J4,5 = 3J5,6 = 7.6 Hz, 4J3,5 = 5J5,P = 1.6 Hz, H(5)], 7.44 [1H, br
t‡, 3J3,4 = 3J4,5 = H(4)], 7.59 [1H, br d‡, 3J5,6 = 7.6 Hz, H(6)], 8.83 [2H, s, H(2’) + H(6’)],
9.24 [1H, s, H(4’)]. 13C NMR (126 MHz, CDCl3): δ 16.39 [d, 3JC,P = 5.8 Hz, 2 x CH3],
30.78 [d, 1JC,P = 139.1 Hz, PCH2], 62.23 [d, 2JC,P = 6.7 Hz, 2 x OCH2], 127.52 [d, 4JC,P =
3.5 Hz, C(5)], 129.12 [d, 5JC,P = 3.4 Hz, C(4)], 129.95 [d, 2JC,P = 8.7 Hz, C(1)], 130.62 [d,
4JC,P = 3.1 Hz, C(3)], 131.21 [d, 3JC,P = 4.9 Hz, C(6)], 134.81 [d, 4JC,P = 1.6 Hz, C(1’)],









Using General Method 13, 36l (250 mg, 0.81 mmol), 5-pyrimidinylboronic acid (150 mg, 1.21
mmol), Pd(OAc)2 (5.5 mg, 24 µmol), PPh3 (11 mg, 41 µmol) and K2CO3 (225 mg, 1.6
mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by column
chromatography eluting with 3% methanol in dichloromethane gave 159b as a pale yellow
oil (178 mg, 71%). Rf = 0.06 (2.5% methanol in dichloromethane). 1H NMR (500 MHz,
CDCl3): δ 1.27 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.24 [2H, d, 2JH,P = 21.7 Hz, PCH2], 4.07
[4H, p, 3J = 3JH,P = 7.1 Hz, 2 x OCH2], 7.38-7.51 [3H, m, H(4) + H(5) + H(6)], 7.54 [1H,
br s‡, H(2)], 8.95 [2H, s, H(2’) + H(6’)], 9.21 [1H, s, H(4’)]. 13C NMR (126 MHz, CDCl3):
δ 16.47 [d, 3JC,P = 5.9 Hz, 2 x CH3], 33.83 [d, 1JC,P = 138.4 Hz, PCH2], 62.26 [d, 2JC,P
= 6.7 Hz, 2 x OCH2], 125.59 [d, 5JC,P = 3.5 Hz, C(4)], 128.37 [d, 3JC,P = 6.6 Hz, C(2)],
129.67 [d, 4JC,P = 3.0 Hz, C(5)], 130.47 [d, 3JC,P = 6.5 Hz, C(6)], 133.31 [d, 2JC,P = 9.2
368









Using General Method 13, 36m (320 mg, 1.04 mmol), 5-pyrimidinylboronic acid (155 mg,
1.25 mmol), Pd(OAc)2 (7.0 mg, 31 µmol), PPh3 (13.7 mg, 52 µmol) and K2CO3 (288 mg,
2.08 mmol) in 1:1 toluene/ethanol (3 mL) were reacted for 16 hr. Work-up followed by
column chromatography eluting with 3% methanol in dichloromethane gave 159c as a pale
yellow oil (299 mg, 94%). Rf = 0.27 (1:19 methanol/dichloromethane). 1H NMR (500 MHz,
CDCl3): δ 1.28 [6H, t, 3J = 7.1 Hz, 2 x CH3], 3.22 [2H, d, 2JH,P = 21.9 Hz, PCH2], 4.00-4.13
[4H, m, 2 x OCH2], 7.45-7.49 [2H, m, H(2) + H(6)], 7.53-7.57 [2H, m, H(3) + H(5)], 8.95
[2H, s, H(2’) + H(6’)], 9.20 [1H, s, H(4’)]. 13C NMR (126 MHz, CDCl3): δ 16.51 [d, 3JC,P =
5.8 Hz, 2 x CH3], 33.67 [d, 1JC,P = 138.2 Hz, PCH2], 62.32 [d, 2JC,P = 6.7 Hz, 2 x OCH2],
127.17 [d, 4JC,P = 3.0 Hz, C(3)], 130.94 [d, 3JC,P = 6.6 Hz, C(2)], 132.93 [d, 5JC,P = 3.8
Hz, 133.09 [d, 2JC,P = 9.3 Hz, C(1)], 134.00 [d, 6JC,P = 1.5 Hz, C(1’)], 154.88 [d, 7JC,P =
0.7 Hz, C(2’) + C(6’)], 157.58 [C(4’)].




Using General Method 15, 156a (260 mg, 0.85 mmol), 144 (116 mg, 0.61 mmol), and sodium
tert-butoxide (140 mg, 1.46 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed
by column chromatography eluting with dichloromethane gave 146a as an off-white solid
(161 mg, 78%). Rf = 0.22 (1:1 dichloromethane/hexane). HRMS (ESI+) [M+H]+ calcd. for
C23H1635ClN/C23H1637ClN: 342.1050/344.1020; found 342.1044/344.1025. 1H NMR (500
MHz, CDCl3): δ 6.69 [0.3H, d, 3J*A,*B =12.1 Hz, *H(A)], 6.79 [0.3H, d, 3J*A,*B =12.1 Hz,
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*H(B)], 7.10 [0.3H, td, d, 3J*4’,*5’ = 3J*5’,*6’ =7.7 Hz, 4J*3’,*5’ = 1.4 Hz, *H(5’)], 7.15-7.21
[1H, m, H(B) + *H(6’)], 7.27 [0.3H, td, 3J*3’,*4’ = 3J*4’,*5’ = 7.7 Hz, 4J*4’,*6’ = 1.3 Hz,
*H(4’)], 7.29-7.52 [9.7H, m, H(A) + H(6) + H(3’) + H(4’) + H(5’) + Ph + *H(5) + *H(6)
+ *H(8) + *H(3’) + *Ph], 7.61-7.68 [1H, m, H(7) + *H(7)], 7.71 [0.7H, br d‡, 3J5,6 = 8.1
Hz, H(5)], 7.82 [0.7H, br d‡, 3J5’,6’ = 7.5 Hz, H(6’)], 7.86 [0.3H, s, *H(4)], 7.96 [0.7H, br d‡,
3J7,8 = 8.5 Hz, H(8)], 8.07 [0.7H, s, H(4)]. 13C NMR (126 MHz, CDCl3): δ 124.48 [C(A)],
125.47 [*C(A)], 126.60 [C(6’)], **127.03 [*C(6)], 127.06 [C(4a)], 127.12 [*C(4a)], **127.25
[C(6)], **127.41 [C(4”)], 127.45 [*C(5’)], 127.47 [C(5’)], **127.58 [*C(4”)], 127.61 [*C(5)],
127.67 [C(5)], **127.90 [*C(2”) + *C(6”)], 128.11 [*C(4’)], **128.28 [C(2”) + C(6”)],
128.38 [C(8) + *C(8)], 128.54 [C(4’)], **129.32 [*C(3”) + *C(5”)], 129.77 [*C(6’)], 129.85
[*C(3)], **130.05 [C(3”) + C(5”)], 130.24 [C(7)], 130.30 [*C(7)], 130.43 [*C(3’)], **130.54
[C(3’)], 130.65 [C(3)], 132.54 [C(B)], 133.63 [*C(B)], 133.94 [C(4)], 134.20 [*C(1’)], 134.87
[C(1’)], 138.09 [*C(4)], 140.78 [C(1”)], 140.83 [*C(1”)], 141.58 [*C(2’)], 141.67 [C(2’)],
146.76 [*C(8a)], 146.87 [C(8a)], 150.33 [C(2)], 150.79 [*C(2)].
* Denotes signals corresponding to Z -isomer.
** Interpretation of spectra and 2D NMR correlations could not achieve unambiguous
assignment of all NMR signals due to overlapped signals in the 1H NMR spectrum.
3-(2-((1,1’-Biphenyl)-3-yl)vinyl)-2-chloroquinoline (146b)
N Cl
Using General Method 15, 156b (225 mg, 0.74 mmol), 144 (101 mg, 0.53 mmol), and
sodium tert-butoxide (122 mg, 1.27 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up
followed by column chromatography eluting with dichloromethane gave 146b as an off-white
solid (130 mg, 72%). Rf = 0.24 (1:1 dichloromethane/hexane).
A sample of (E )-3-(2-((1,1’-biphenyl)-3-yl)vinyl)-2-chloroquinoline (E -146b) was obtained by
column chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd.
for C23H1637ClN: 344.1020; 344.1024. 1H NMR (500 MHz, CDCl3): δ 7.24-7.31 [1H, m,
H(B)], 7.36-7.44 [1H, m, H(4”)], 7.44-7.52 [3H, m, H(5’) + H(3”) + H(5”)], 7.53-7.67 [6H,
m, H(A) + H(6) + H(4’) + H(6’) + H(2”) + H(6”)], 7.68-7.74 [1H, m, H(7)], 7.79 [1H, br
s‡, H(2’)], 7.86 [1H, br d‡, 3J5,6 = 8.1 Hz, H(5)], 8.01 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 8.41
[1H, s, H(4)]. 13C NMR (126 MHz, CDCl3): δ 124.07 [C(A)], 125.94 [C(6’)], 126.09 [C(2’)],
127.37 [C(2”) + C(6”)], 127.46 [C(4’)], 127.63 [C(6)], 127.71 [*C(5)], 127.72 [*C(4”)],
128.51 [C(8)], 129.01 [C(3”) + C(5”)], 129.44 [C(5’)], 130.41 [C(7)], 133.37 [C(B)], 133.95
[C(4)], 137.21 [C(1’)], 141.00 [C(1”)], 142.11 [C(3’)], 147.04 [C(8a)], 150.40 [C(2)].
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*Some 13C NMR signals could not be unambiguously assigned due to close proximity of
chemical shifts. The C(4a) signal was not observed; 2D HMBC correlations indicated this
signal was overlapped with a signal at 127.7 ppm, but due to close proximity of several signals




Using General Method 15, 157a (285 mg, 0.93 mmol), 144 (128 mg, 0.67 mmol), and sodium
tert-butoxide (154 mg, 1.6 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed
by column chromatography eluting with 2% methanol in dichloromethane gave 147a as an
off-white solid (142 mg, 62%). Rf = 0.16 (2.5% methanol in dichloromethane). Samples of
each isomer were isolated by column chromatography for the purposes of characterisation.
(E)-2-Chloro-3-(2-(pyridin-4-yl)styryl)quinoline (E-147a): MP: 174-180°C. HRMS (ESI+)
[M+H]+ calcd. for C22H1535ClN2/C22H1537ClN2: 343.1002/345.0973; found 343.1000/
345.1983. 1H NMR (500 MHz, CDCl3): δ 7.09 [1H, d, 3JA,B = 16.1 Hz, H(B)], 7.32-7.39 [3H,
m, H(3’) + H(2”) + H(6”)], 7.41-7.56 [4H, m, H(A) + H(6) + H(4’) + H(5’)], 7.67 [1H, t,
3J7,8 = 8.3 Hz, H(7)], 7.75 [1H, d, 3J5,6 = 8.1 Hz, H(5)], 7.85 [1H, d, 3J5’,6’ = 7.8 Hz, H(6’)],
7.97 [1H, d, 3J7,8 = 8.3 Hz, H(8)], 8.09 [1H, s, H(4)], 8.66-8.74 [2H, m, H(3”) + H(5”)]. 13C
NMR (126 MHz, CDCl3): δ 124.86 [C(2”) + C(6”)], 125.70 [C(A)], 126.94 [C(6’)], 127.41
[C(6)], 127.47 [C(4a)], 127.73 [C(5)], 128.37 [C(8)], 128.78 [C(4’)], 129.12 [C(5’)], 130.01
[C(3’)], 130.13 [C(3)], 130.48 [C(7)], 131.24 [C(B)], 134.00 [C(4)], 134.79 [C(1’)], 138.69
[C(2’)], 146.99 [C(8a)], 148.64 [C(1”)], 149.93 [C(3”) + C(5”)], 150.15 [C(2)].
(Z)-2-Chloro-3-(2-(pyridin-4-yl)styryl)quinoline (Z-147a): HRMS (ESI+) [M+H]+ calcd. for
C22H1535ClN2/C22H1537ClN2: 343.1002/345.0973; found 343.1000/345.1983. 1H NMR (500
MHz, CDCl3): δ 6.76 and 6.79 [2H, AB, A:br d‡, B:d, 3JA,B(JAB) = 12.1 Hz, H(A) + H(B)],
7.17-7.26 [4H, m, H(5’) + H(6’) + H(2”) + H(6”)], 7.29-7.36 [2H, m, H(3’) + H(4’)],
7.44-7.53 [2H, m, H(5) + H(6)], 7.69 [1H, ddd, 3J7,8 = 8.5 Hz, 3J6,7 = 6.7 Hz, 4J5,7 = 1.6
Hz, H(7)], 7.79 [1H, s, H(4)], 7.98 [1H, d, 3J7,8 = 8.5 Hz, H(8)], 8.57-8.63 [2H, m, H(3”)
+ H(5”)]. 13C NMR (126 MHz, CDCl3): δ 124.12 [C(2”) + C(6”)], 126.80 [C(A)], 126.97
[C(4a)], 127.21 [C(6)], 127.58 [C(5)], 128.41 [C(8)], 128.45 [C(4’)], 128.76 [C(5’)], 129.51
[C(3)], 130.07 [C(3’)], 130.14 [C(6’)], 130.55 [C(7)], 132.59 [C(B)], 134.31 [C(1’)], 138.19





Using General Method 15, 157b (200 mg, 0.66 mmol), 144 (90 mg, 0.47 mmol), and
sodium tert-butoxide (108 mg, 1.12 mmol) were reacted in DMF (6 mL) for 4 hr. Work-
up followed by column chromatography eluting with dichloromethane gave 147b as an off-
white solid (103 mg, 64%). HRMS (ESI+) [M+H]+ calcd. for C22H1535ClN2/C22H1537ClN2:
343.1002/345.0973; found 343.0995/345.0975. 1H NMR (500 MHz, CDCl3): δ 6.81 [0.25H,
br d‡, 3J*A,*B = 12.1 Hz, *H(A)], 6.92 [0.25H, d, 3J*A,*B = 12.1 Hz, *H(B)], 7.19-7.31 [1.75H,
m, H(B) + *H(5’) + *H(6’) + *H(2”) + *H(6”)], 7.42-7.46 [0.5H, m, *H(2’) + *H(4’)],
7.47 [0.25H, ddd, 3J*5,*6 = 8.1 Hz, 3J*6,*7 = 6.9 Hz, 4J*6,*8 = 1.1 Hz, *H(6)], 7.53 [0.75H, t,
3J4’,5’ = 3J5’,6’ = 7.7 Hz, H(5’)], 7.53-7.63 [4H, m, H(A) + H(6) + H(4’) + H(2”) + H(6”)
+ *H(5)], 7.67 [0.75H, br d‡, 3J5’,6’ = 7.7 Hz, H(6’)], 7.69-7.73 [1H, m, H(7) + *H(7)], 7.80
[0.75H, br s‡, H(2’)], 7.85 [0.75H, br d‡, 3J5,6 = 8.0 Hz, H(5)], 7.98-8.04 [1.25H, H(8) + *H(4)
+ *H(8)], 8.40 [0.75H, s, H(4)], 8.51-8.54 [0.5H, m, *H(3”) + *H(5”)], 8.68-8.72 [1.5H,
m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3): δ 121.48 [*C(2”) + *C(6”)], 121.80
[C(2”) + C(6”)], 124.65 [C(A)], 125.82 [C(2’)], 126.41 [*C(4’)], 126.47 [*C(A)], 127.02
[*C(4a)], 127.24 [C(6)], 127.31 [*C(6)], 127.46 [C(6’)], 127.49 [C(4’)], 127.50 [C(4a)], 127.60
[*C(5)], 128.42 [*C(8)], 128.47 [C(8)], 129.41 [*C(5’)], 129.51 [*C(6’)], 129.78 [C(5’)],
129.91 [*C(3)], 130.13 [C(3)], 130.51 [C(7)], 130.66 [*C(7)], 132.70 [C(B)], 132.90 [*C(B)],
134.04 [C(4)], 136.80 [*C(1’)], 137.61 [C(1’)], 138.48 [*C(4)], 138.53 [*C(3’)], 139.03 [C(3’)],
147.07 [br, C(8a) + *C(8a)], 147.78 [*C(1”)]. 150.25 [C(2)], 150.33 [*C(3”) + *C(5”)],
150.49 [C(3”) + C(5”)], 150.59 [*C(2)].




Using General Method 15, 158a (267 mg, 0.87 mmol), 144 (120 mg, 0.63 mmol), and
sodium tert-butoxide (144 mg, 1.50 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up
followed by column chromatography eluting with dichloromethane gave 148a as a yellow
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solid (199 mg, 93%). HRMS (ESI+) [M+H]+ calcd. for C22H1535ClN2/C22H1537ClN2:
343.1002/345.0973; found 343.0996/345.0976. Pure samples of each isomer were separated
by column chromatography for characterisation.
(E)-2-Chloro-3-(2-(pyridin-3-yl)styryl)quinoline (E-148a): 1H NMR (500 MHz, CDCl3): δ
7.09 [1H, d, 3JA,B = 16.1 Hz, H(B)], 7.34-7.41 [2H, m, H(3’) + H(5”)], 7.42-7.55 [4H, m,
H(6) + H(A) + H(4’) + H(5’)], 7.67 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.0 Hz, 4J5,7 = 1.4
Hz, H(7)], 7.71-7.77 [2H, m, H(5) + H(6”)], 7.86 [1H, br d‡, 3J5’,6’ = H(6’)], 7.97 [1H, d,
3J7,8 = 8.4 Hz, H(8)], 8.10 [1H, s, H(4)], 8.65 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.6 Hz,
H(4”)], 8.71 [1H, br d‡, 4J2”,6” = 2.2 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 123.25
[C(5”)], 125.71 [C(A)], 126.91 [C(6’)], 127.36 [C(6)], 127.50 [C(4a)], 127.72 [C(5)], 128.38
[C(8)], 128.76 [**C(4’)], 128.78 [*C(5’)], 130.27 [C(3)], 130.42 [C(7)], 130.57 [C(3’)], 131.41
[C(B)], 134.07 [C(4)], 135.24 [C(1’)], 136.41 [C(1”)], 137.23 [C(6”)], 137.79 [C(2’)], 146.98
[C(8a)], 148.78 [C(4”)], 150.18 [C(2)], 150.49 [C(2”)].
*Some 13C NMR signals could not be unambiguously assigned due to close proximity of
chemical shifts.
(Z)-2-Chloro-3-(2-(pyridin-3-yl)styryl)quinoline (Z-148a): 1H NMR (500 MHz, CDCl3): δ
6.74 [1H, d, 3JA,B = 12.0 Hz, H(A)], 6.81 [1H, d, 3JA,B = 12.0 Hz, H(B)], 7.18-7.36 [5H, m,
H(3’) + H(4’) + H(5’) + H(6’) + H(5”)], 7.42-7.54 [3H, m, H(5) + H(6) + H(6”)], 7.68
[1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 6.7 Hz, 4J5,7 = 1.6 Hz, H(7)], 7.78 [1H, s, H(4)], 7.97 [1H,
d, 3J7,8 = 8.4 Hz, H(8)], 8.53-8.61 [2H, m, H(2”) + H(4”)]. 13C NMR (126 MHz, CDCl3): δ
123.12 [C(5”)], 126.65 [C(A)], 126.93 [C(4a)], 127.16 [C(6)], 127.55 [C(5)], 128.35 [*C(4’)
or C(5’)], 128.37 [C(8)], 128.41 [*C(4’) or C(5’)], 129.51 [C(3)], 130.06 [*C(3’) or C(6’)],
130.49 [*C(3’) or C(6’)], 130.50 [C(7)], 132.59 [C(B)], 134.57 [C(1’)], 136.26 [C(6”)], 136.45
[C(1”)], 137.72 [C(2’)], 138.09 [C(4)], 146.81 [C(8a)], 148.63 [C(4”)], 150.03 [C(2”)], 150.58
[C(2)].
*Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment
of all NMR signals due to overlapped signals in the 1H NMR spectrum.
2-Chloro-3-(3-(pyridin-3-yl)styryl)quinoline (148b)
N Cl N
Using General Method 15, 158b (164 mg, 0.54 mmol), 144 (94 mg, 0.49 mmol), and sodium
tert-butoxide (66 mg, 0.69 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed
by column chromatography eluting with dichloromethane gave (E/Z )-148b as an off-white
solid (145 mg, 86%).
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A sample of almost entirely (E )-2-chloro-3-(3-(pyridin-3-yl)styryl)quinoline (E -148b, 19:1
ratio of E/Z isomers) was separated by column chromatography for the purposes of
characterisation. Rf = 0.19 (2% methanol in dichloromethane). HRMS (ESI+) [M+H]+
calcd. for C22H1535ClN2/C22H1537ClN2: 343.1002/345.0973; found 343.0995/345.0974. 1H
NMR (500 MHz, CDCl3): δ 7.28 [1H, d, 3JA,B = 16.2 Hz, H(B)], 7.41 [1H, dd, 3J5”,6” =
7.8 Hz, 3J4”,5” = 4.8 Hz, H(5”)], 7.51-7.64 [4H, m, H(A) + H(6) + H(4’) + H(5’)]], 7.66
[1H, br d‡, 3J5’,6’ = H(6’)], 7.72 [1H, br dd‡, 3J7,8 = 8.3 Hz, 3J6,7 = 7.0 Hz, H(7)], 7.77 [1H,
br s‡, H(2’)], 7.86 [1H, d, 3J5,6 = 8.1 Hz, H(5)], 7.93 [1H, br d‡, 3J5”,6” = 7.9 Hz, H(6”)],
8.01 [1H, br d‡, 3J7,8 = 8.3 Hz, H(8)], 8.42 [1H, s, H(4)], 8.64 [1H, br d‡, 3J4”,5” = 4.8 Hz,
H(4”)], 8.91 [1H, br d‡, 4J2”,6” = 1.7 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 123.76
[C(5”)], 124.55 [C(A)], 126.05 [C(2’)], 126.62 [C(6’)], 127.48 [C(4’)], 127.50 [C(6)], 127.65
[C(4a)], 127.72 [C(5)], 128.50 [C(8)], 129.77 [C(5’)], 130.24 [C(3)], 130.51 [C(7)], 132.89
[C(B)], 134.05 [C(4)], 134.57 [C(6”)], 136.46 [C(1’)], 137.58 [C(1”)], 138.73 [C(3’)], 147.09




Using General Method 15, 158c (291 mg, 0.95 mmol), 144 (152 mg, 0.79 mmol), and sodium
tert-butoxide (138 mg, 1.44 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed by
column chromatography eluting with 1% methanol in dichloromethane gave 148c as a yellow
solid (212 mg, 78%). Rf = 0.08 (2% methanol in dichloromethane). HRMS (ESI+) [M+H]+
calcd. for C22H1535ClN2/C22H1537ClN2: 343.1002/345.0973; found 343.0999/345.0981. 1H
NMR (500 MHz, CDCl3): δ 1H NMR (500 MHz, CDCl3): δ 6.79 [0.2H, d, 3J*A,*B = 12.1 Hz,
*H(A)], 6.89 [0.2H, d, 3J*A,*B = 12.1 Hz, *H(B)], 7.23 [0.8H, d, 3JA,B = 16.2 Hz, H(B)],
7.28-7.34 [0.6H, m, *H(2’) + *H(6’) + *H(5”)], 7.38 [0.8H, dd, 3J5”,6” = 7.9 Hz, 3J4”,5” =
4.8 Hz, H(5”)], 7.40-7.44 [0.4H, m, *H(3’) + *H(5’)], 7.47 [0.2H, br t‡, 3J*5,*6 = 3J*6,*7 =
7.6 Hz, *H(6)], 7.53-7.73 [6.2H, m, H(A) + H(6) + H(7) + H(2’) + H(3’) + H(5’) + H(6’)
+ *H(5) + *H(7) + *H(8)], 7.81 [0.2H, dt, 3J*5”,*6” = 7.9 Hz, 4J*2”,*6” = 4J*4”,*6” = 2.1 Hz,
*H(6”)], 7.84 [0.8H, br d‡, 3J5,6 = 7.9 Hz, H(5)], 7.90 [0.8H, ddd, 3J5”,6” = 7.9 Hz, 4J2”,6”
= 2.0 Hz, 4J4”,6” = 1.7 Hz, H(6”)], 7.98-8.04 [1H, m, H(8) + *H(4)], 8.39 [0.8H, s, H(4)],
8.56 [0.2H, br d‡, 3J*4”,*5” = 4.8 Hz, *H(4”)], 8.61 [0.8H, br d‡, 3J4”,5” = 4.8 Hz, H(4”)],
8.80 [0.2H, br d‡, 4J*2”,*6” = 2.1 Hz, *H(2”)], 8.89 [0.8H, br d‡, 4J2”,6” = 2.1 Hz, H(2”)].
* Denotes signals corresponding to Z -isomer.
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Interpretation of spectra and 2D NMR correlations could not achieve unambiguous assignment
of all 13C NMR signals due to overlapped signals in the 1H and 13C NMR spectra.
A sample of pure (E )-2-chloro-3-(4-(pyridin-3-yl)styryl)quinoline (E -148c) was isolated by
column chromatography for the purposes of characterisation. 1H NMR (500 MHz, CDCl3):
δ 7.23 [1H, d, 3JA,B = 16.2 Hz, H(B)], 7.38 [1H, ddd, 3J5”,6” = 7.9 Hz, 3J4”,5” = 4.8 Hz,
4J2”,5” = 0.8 Hz, H(5”)], 7.53-7.59 [2H, m, H(A) + H(6)], 7.61-7.65 [2H, m, H(3’) + H(5’)],
7.67-7.73 [3H, m, H(7) + H(2’) + H(6’)], 7.84 [1H, br d‡, 3J5,6 = 7.9 Hz, H(5)], 7.90 [1H,
ddd, 3J5”,6” = 7.9 Hz, 4J2”,6” = 2.0 Hz, 4J4”,6” = 1.7 Hz, H(6”)], 8.00 [1H, br d‡, 3J7,8 =
8.2 Hz, H(8)], 8.39 [1H, s, H(4)], 8.61 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” = 1.7 Hz, H(4”)],
8.89 [1H, br d‡, 4J2”,6” = 2.0 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 123.72 [C(5”)],
124.25 [C(A)], 127.46 [C(6)], 127.62 [C(3’) + C(5’)], 127.62 [C(4a)], 127.68 [C(5)], 127.81
[C(2’) + C(6’)], 128.47 [C(8)], 130.24 [C(3)], 130.44 [C(7)], 132.51 [C(B)], 133.90 [C(4)],
134.21 [C(6”)], 136.03 [C(1”)], 136.57 [C(1’)], 137.95 [C(4’)], 147.02 [C(8a)], 148.30 [C(2”)],





Using General Method 15, 159a (264 mg, 0.86 mmol), 144 (118 mg, 0.62 mmol), and
sodium tert-butoxide (142 mg, 1.48 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up
followed by column chromatography eluting with dichloromethane gave 149a as an off-white
solid (114 mg, 54%).
A sample of (Z )-2-chloro-3-(2-(pyrimidin-5-yl)styryl)quinoline (Z -149a) was isolated by
chromatography for the purposes of characterisation. MP: degraded 90°C. HRMS (ESI+)
[M+H]+ calcd. for C21H1435ClN3/C21H1437ClN3: 344.0955/346.0925; found
344.0948/346.0938. 1H NMR (500 MHz, CDCl3): δ 6.79 and 6.83 [2H, AB, A:d, B:d,
3JA,B(JAB) = 12.0 Hz, H(A) + H(B)], 7.24-7.41 [4H, m, H(3’) + H(4’) + H(5’) + H(6’)],
7.43-7.51 [2H, m , H(5) + H(6)], 7.66-7.72 [2H, m, H(4) + H(7)], 7.98 [1H, br d‡, 3J7,8
= 8.5 Hz, H(8)], 8.58 [2H, s, H(2”) + H(6”)], 9.18 [1H, s, H(4”)]. 13C NMR (126 MHz,
CDCl3): δ 126.80 [C(4a)], 127.33 [C(6)], 127.49 [C(5)], 127.78 [C(A)], 128.53 [C(8)], 128.75
[C(4’)], 129.12 [C(3)], 129.31 [C(5’)], 130.35 [C(3’)], 130.38 [C(6’)], 130.73 [C(7)], 131.66
[C(B)], 133.89 [C(2’)], 134.44 [C(1”)], 134.81 [C(1’)], 138.12 [C(4)], 146.91 [C(8a)], 150.32





Using General Method 15, 159b (234 mg, 0.76 mmol), 144 (122 mg, 0.64 mmol), and
sodium tert-butoxide (147 mg, 1.6 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up
followed by column chromatography eluting with dichloromethane gave 149b as a yellow solid
(218 mg, 100%). Rf = 0.18 (2.5% methanol in dichloromethane). HRMS (ESI+) [M+H]+
calcd. for C21H1435ClN3/C21H1437ClN3: 344.0955/346.0925; found 344.0951/346.0939. 1H
NMR (500 MHz, CDCl3): δ 6.85 [0.2H, d, 3JA,B = 12.1 Hz, *H(A)], 6.92 [0.2H, d, 3JA,B =
12.1 Hz, *H(B)], 7.21-7.29 [1H, m, H(B) + *H(6’)], 7.32 [0.2H, t, 3J4’,5’ = 3J5’,6’ = 7.8 Hz,
*H(5’)], 7.36-7.43 [0.4H, m, *H(2’) + *H(4’)], 7.48 [0.2H, ddd, 3J5,6 = 8.1 Hz, 3J6,7 = 6.9
Hz, 4J6,8 = 1.0 Hz, *H(6)], 7.50-7.64 [3.4H, m, *H(5) + H(6) + H(A) + H(4’) + H(5’)],
7.66-7.76 [2.6H, m, H(7) + *H(7) + H(2’) + H(6’)], 7.85 [0.8H, d, 3J5,6 = 8.1 Hz, H(5)],
7.96-8.04 [1.2H, m, *H(4) + H(8) + *H(8)], 8.40 [0.8H, s, H(4)], 8.72 [0.4H, s, *H(2”)
+ *H(6”)], 9.00 [1.6H, s, H(2”) + H(6”)], 9.15 [0.2H, s, *H(4”)], 9.25 [0.8H, s, H(4”)].
13C NMR (126 MHz, CDCl3): δ 124.99 [C(A)], 125.79 [C(2’)], 126.38 [*C(4’)], 126.78
[*C(A)], 126.92 [*C(4a)], 127.12 [C(4’)], 127.32 [C(6’)], 127.36 [*C(6)], 127.41 [*C(2’)],
127.49 [C(6)], 127.55 [C(4a)], 127.61 [*C(5)], 127.68 [C(5)], 128.46 [C(8) + *C(8)], 129.35
[*C(6’)], 129.68 [*C(3)], 129.69 [*C(5’)], 129.96 [C(3)], 130.07 [C(5’)], 130.55 [C(7)], 130.72
[*H(7)], 132.35 [C(B)], 132.58 [*C(B)], 133.93 [C(1”)], 134.07 [C(4)], 134.14 [C(1”)], 134.77
[*C(3’)], 135.13 [C(3’)], 137.21 [*C(1’)], 137.93 [C(1’)], 138.40 [*C(4)], 147.06 [*C(8a)],
147.09 [C(8a)], 150.19 [C(2)], 150.48 [*C(2)], 154.82 [*C(2”) + *C(6”)], 155.05 [C(2”) +
C(6”)], 157.70 [*C(4”)], 157.86 [C(4”)].





Using General Method 15, 159c (299 mg, 0.98 mmol), 144 (134 mg, 0.70 mmol), and sodium
tert-butoxide (162 mg, 1.69 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed
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by column chromatography eluting with dichloromethane gave 149c as a yellow solid (188
mg, 78%).
A sample of (E )-2-chloro-3-(4-(pyrimidin-5-yl)styryl)quinoline (E -149c) was isolated by
chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd. for
C21H1435ClN3/C21H1437ClN3: 344.0955/346.0925; found 344.0950/346.0931. 1H NMR (500
MHz, CDCl3): δ 7.22 [1H, d, 3JA,B = 16.2 Hz, H(B)], 7.55-7.65 [4H, m, H(A) + H(6) +
H(3’) + H(5’)], 7.67-7.75 [3H, m, H(7) + H(2’) + H(6’)], 7.84 [1H, br d‡, 3J5,6 = 7.9 Hz,
H(5)], 7.99 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 8.38 [1H, s, H(4)], 8.98 [2H, s, H(2”) + H(6”)],
9.22 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 124.85 [C(A)], 127.41 [C(3’) + C(5’)],
127.48 [C(6)], 127.54 [C(4a)], 127.67 [C(5)], 128.04 [C(2’) + C(6’)], 128.44 [C(8)], 129.98
[C(3)], 130.52 [C(7)], 132.08 [C(B)], 133.73 [C(1”)], 133.98 [C(4)], 134.20 [C(4’)], 137.43
[C(1’)], 147.04 [C(8a)], 150.20 [C(2)], 154.78 [C(2”) + C(6”)], 157.70 [C(4”)].
6.4.4 Synthesis of 3-position biaryl-extended 2-aminoquinoline derivatives
Attempted synthesis of 3-(2-((1,1’-biphenyl)-2-yl)vinyl)quinolin-2-amine (160a)
N NH2
Using General Method 11, 146a (140 mg, 0.41 mmol) was treated with LiHMDS solution
(1.0 M in THF, 0.90 mL, 0.90 mmol), Pd(dba)2 (2.4 mg, 4.0 µmol) and DavePhos (1.9 mg,
4.9 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not
be purified. Analysis of the 1H NMR spectrum did not identify signals consistent with the
desired product.
Attempted synthesis of 3-(2-((1,1’-biphenyl)-3-yl)vinyl)quinolin-2-amine (160b)
N NH2
Using General Method 11, 146b (111 mg, 0.32 mmol) was treated with LiHMDS solution
(1.0 M in THF, 710 µL, 0.71 mmol), Pd(dba)2 (1.9 mg, 3.2 µmol) and DavePhos (1.5 mg,
3.9 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not
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be purified. Analysis of the 1H NMR spectrum did not identify signals consistent with the
desired product.
Attempted synthesis of 3-(2-((1,1’-biphenyl)-4-yl)vinyl)quinolin-2-amine (160c)
N NH2
Using General Method 11, 146c (156 mg, 0.46 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.0 mL, 1.0 mmol), Pd(dba)2 (2.6 mg, 4.5 µmol) and DavePhos (2.2 mg,
5.6 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not
be purified. Analysis of the 1H NMR spectrum did not identify signals consistent with the
desired product.
Attempted synthesis of 3-(2-(pyridin-4-yl)styryl)quinolin-2-amine (161a)
N NH2
N
Using General Method 11, 147a (132 mg, 0.39 mmol) was treated with LiHMDS solution
(1.0 M in THF, 850 µL, 0.85 mmol), Pd(dba)2 (2.2 mg, 3.9 µmol) and DavePhos (1.8 mg,
4.6 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not
be purified. Analysis of the 1H NMR spectrum did not identify signals consistent with the
desired product.
Attempted synthesis of 3-(3-(pyridin-4-yl)styryl)quinolin-2-amine (161b)
N NH2
N
Using General Method 11, 147b (65 mg, 0.19 mmol) was treated with LiHMDS solution (1.0
M in THF, 420 µL, 0.42 mmol), Pd(dba)2 (2.4 mg, 4.2 µmol) and DavePhos (0.9 mg, 2.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not be
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Using General Method 11, 147c (216 mg, 0.63 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.4 mL, 1.4 mmol), Pd(dba)2 (3.6mg, 6.3 µmol) and DavePhos (3.0 mg,
7.6 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 7.5% methanol in dichloromethane gave a crude mixture containing 161c as
a brown oil. Rf = 0.32 (7.5% methanol/dichloromethane). 1H NMR (500 MHz, CDCl3): δ
5.13-5.45 [2H, m, NH2 + *NH2], 6.61 [0.6H, d, 3J*A,*B = 12.1 Hz, *H(A)], 6.89 [0.6H, d,
3J*A,*B = 12.1 Hz, *H(B)], 7.16-7.77 [10.8H, m, H(A) + H(B) + Ar H + *Ar H], 7.81 [0.6H,
s, *H(4)], 8.07 [0.4H, s, H(4)], 8.55-8.72 [2H, m, H(3”) + H(5”) + *H(3”) + *H(5”)].
* Denotes signals corresponding to Z-isomer.
Attempted synthesis of 3-(2-(pyridin-3-yl)styryl)quinolin-2-amine (162a)
N NH2
N
Using General Method 11, 148a (162 mg, 0.47 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.0 mL, 1.0 mmol), Pd(dba)2 (2.7 mg, 4.7 µmol) and DavePhos (2.2 mg,
5.7 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not






Using General Method 11, 148b (171 mg, 0.50 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.1 mL, 1.1 mmol), Pd(dba)2 (2.9 mg, 5.0 µmol) and DavePhos (2.4 mg,
6.1 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave 162b as a yellow oil (18 mg, 11%).
A sample containing largely (E )-3-(3-(pyridin-3-yl)styryl)quinolin-2-amine (E -162b) was
isolated by column chromatography for the purposes of characterisation. HRMS (ESI+)
[M+H]+ calcd. for C22H17N3: 324.1501; found 324.1495. 1H NMR (500 MHz, CDCl3): δ
5.05 [2H, br s, NH2], 7.20 and 7.22 [2H, AB, A:d, B:d, 3JA,B(JAB) = 16.5 Hz, H(A) + H(B)],
7.29 [1H, t, 3J5,6 = 3J6,7 = 7.6 Hz, H(6)], 7.39 [1H, dd, 3J5”,6” = 7.8 Hz, 3J4”,5” = 4.8 Hz,
H(5”)], 7.49-7.62 [4H, m, H(7) + H(4’) + H(5’) + H(6’)], 7.65-7.71 [2H, m, H(5) + H(8)],
7.72 [1H, br s‡, H(2’)], 7.91 [1H, br d‡, 3J5”,6” = 7.8 Hz, H(6”)], 8.05 [1H, s, H(4)], 8.63 [1H,
br dd‡, 3J4”,5” = 4.8 Hz, 4J4”,6” = 0.9 Hz, H(4”)], 8.89 [1H, br d‡, 4J2”,6” = 1.6 Hz, H(2”)].
13C NMR (126 MHz, CDCl3): δ 121.42 [C(3)], 123.31 [C(6)], 123.68 [C(A)], 123.74 [C(5”)],
124.54 [C(4a)], 125.72 [C(2’)], 125.81 [C(8)], 126.42 [C(6’)], 127.24 [C(4’)], 127.70 [C(5)],
129.75 [C(5’)], 129.94 [C(7)], 133.05 [C(B)], 134.55 [C(6”)], 134.60 [C(4)], 136.47 [C(1”)],




Using General Method 11, 148c (180 mg, 0.53 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.2 mL, 1.2 mmol), Pd(dba)2 (3.0 mg, 5.3 µmol) and DavePhos (2.5 mg, 6.3
µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica gel
eluting with 19:1 dichloromethane/methanol gave a sample of crude 162c as a brown oil (18
mg, <5%). 1H NMR (500 MHz, CDCl3): δ 4.89-5.17 [2H, m, NH2 + *NH2], 6.60 [0.8H, d,
3J*A,*B = 12.1 Hz, *H(A)], 6.86 [0.8H, d, 3J*A,*B = 12.1 Hz, *H(B)], 7.14-7.82 [10.6H, m,
H(A) + H(B) + Ar H + *Ar H], 8.03 [0.2H, s, H(4)], 8.51-8.65 [1H, m, H(4”) + *H(4”)],
8.79 [0.8H, d, 4J*2”,*6” = 1.5 Hz, *H(2”)], 8.89 [0.8H, d, 4J2”,6” = 1.4 Hz, H(2”)].
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* Denotes signals corresponding to Z-isomer.




Using General Method 11, 149a (70 mg, 0.20 mmol) was treated with LiHMDS solution (1.0
M in THF, 450 µL, 0.45 mmol), Pd(dba)2 (1.2 mg, 2.0 µmol) and DavePhos (1.0 mg, 2.4
µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not be





Using General Method 11, 149b (249 mg, 0.72 mmol) was treated with LiHMDS solution
(1.0 M in THF, 1.6 mL, 1.6 mmol), Pd(dba)2 (4.2 mg, 7.2 µmol) and DavePhos (3.4 mg,
8.6 µmol) in 1,4-dioxane (2 mL). Work-up as specified and column chromatography on silica
gel eluting with 19:1 dichloromethane/methanol gave a crude mixture as a brown oil (19
mg, <5%), which could not be purified. 1H NMR analysis of the crude mixture was used
to identify signals consistent with the desired product 163b. Due to the large number of
impurities present, assignment of the spectrum was not possible.




Using General Method 11, 149c (100 mg, 0.29 mmol) was treated with LiHMDS solution
(1.0 M in THF, 640 µL, 0.64 mmol), Pd(dba)2 (1.7 mg, 2.9 µmol) and DavePhos (1.4 mg,
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3.5 µmol) in 1,4-dioxane (2 mL). Work-up as specified gave a crude mixture which could not
be purified. Analysis of the 1H NMR spectrum did not identify signals consistent with the
desired product.
6.4.5 Exploration of synthetic pathway for 3-position extended 2-aminoquinolines
General Method 16: Synthesis of extended 2-aminoquinolines via















A mixture of the 2-chloroquinoline derivative (1 eq) and 4-methoxybenzyl amine (10 eq)
was heated at 140°C for 16 hr, cooled, and the excess reagent was removed by short-path
distillation under reduced pressure or filtration through silica gel washing with dichloromethane.
The residue was added to methanol (30 mL) or 1:1 methanol/ethanol (30 mL) with a catalytic
amount of Pd-C catalyst (5%), and the mixture was stirred under a hydrogen atmosphere
for 16 hr. The reaction mixture was filtered through Celite®, washing with methanol, and
the solvent was removed by evaporation under reduced pressure. The residue was stirred in
trifluoroacetic acid at 60°C for 1 hr, then cooled, diluted with dichloromethane (20 mL), and
concentrated to dryness by evaporation under reduced pressure. The residue was again diluted
with dichloromethane and concentrated to dryness by evaporation under reduced pressure,
then diluted with saturated aqueous sodium bicarbonate solution (20 mL) and extracted with
dichloromethane (3 x 25 mL). The organic extracts were dried over anhydrous MgSO4, filtered,
and the solvent was removed by evaporation under reduced pressure. The crude residue was
purified by column chromatography on silica gel with the specified eluant.
3-(2-((1,1’-Biphenyl)-2-yl)ethyl)quinolin-2-amine (138a)
N NH2
Using General Method 16, 146a (157 mg, 0.46 mmol) was reacted with 4-methoxybenzyl
amine (1.2 mL, 9.2 mmol) for 16 hr. The excess reagent was removed by distillation
under reduced pressure, and the residue was dissolved in methanol (30 mL) and reacted
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under an atmosphere of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The
mixture was filtered through Celite® washing with methanol, and the volatile solvent was
removed by evaporation under reduced pressure. The crude residue was treated with TFA
(1.5 mL), and work-up followed by column chromatography on silica gel eluting with 1:19
methanol/dichloromethane yielded 138a as a white solid (53 mg, 36%). MP: 173-176°C.
HRMS (ESI+) [M+H]+ calcd. for C23H20N2: 325.1705; found 325.1699. 1H NMR (500
MHz, CDCl3): δ 2.55-2.64 [2H, m, H(A)], 2.91-3.00 [2H, m, H(B)], 4.30 [2H, br s, NH2],
7.21 [1H, td, 3J5,6 = 3J6,7 = 7.4 Hz, 4J6,8 = 1.0 Hz, H(6)], 7.24 [1H, br d‡, 3J3’,4’ = 7.1 Hz,
H(3’)], 7.27-7.36 [5H, m, H(4’) + H(5’) + H(6’) + H(2”) + H(6”)], 7.39 [1H, tt, 3J3”,4” =
3J4”,5” = 7.4 Hz, 4J2”,4” = 3J4”,6” = 2.4 Hz, H(4”)], 7.41-7.46 [2H, m, H(3”) + H(5”)], 7.46-
7.54 [3H, m, H(4) + H(5) + H(7)], 7.59 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)]. 13C NMR (126
MHz, CDCl3): δ 33.12 [C(B)], 33.80 [C(A)], 122.70 [C(6)], 123.00 [C(3)], 124.43 [C(4a)],
125.45 [br, C(8)], 126.61 [C(4’)], 127.01 [C(5)], 127.35 [C(4”)], 128.01 [C(5’)], 128.67 [C(3”)
+ C(5”)], 129.11 [C(7)], 129.44 [C(2”) + C(6”)], 129.63 [C(6’)], 130.41 [C(3’)], 136.30 [br,




Using General Method 16, 147a (110 mg, 0.32 mmol) was reacted with 4-methoxybenzylamine
(840 µL, 6.4 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1 mL), and work-up followed
by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane yielded
139a as a white solid (32 mg, 31%) and (E )-3-(2-(pyridin-2-yl)styryl)quinolin-2-amine (161a)
as a white powder (6 mg, 6%).
3-(2-(Pyridin-4-yl)phenethyl)quinolin-2-amine (139a): MP: 165-167°C. HRMS (ESI+)
[M+H]+ calcd. for C22H19N3: 326.1657; found 326.1653. 1H NMR (500 MHz, CDCl3): δ
2.63-2.72 [2H, m, H(A)], 2.96-3.05 [2H, m, H(B)], 4.45 [2H, br s, NH2], 7.14-7.21 [3H, m,
H(3’) + H(2”) + H(6”)], 7.23 [1H, br t‡, 3J5,6 = 3J6,7 = 7.4 Hz, H(6)], 7.33 [1H, br td‡,
3J3’,4’ = 3J4’,5’ = 7.1 Hz, 4J4’,6’ = 1.9 Hz, H(4’)], 7.35-7.44 [3H, m, H(4) + H(5’) + H(6’)],
7.47-7.54 [2H, m, H(5) + H(7)], 7.62 [1H, d, 3J7,8 = 8.3 Hz, H(8)], 8.57-8.63 [2H, m, H(3”)
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+ H(5”)]. 13C NMR (126 MHz, CDCl3): δ 32.16 [C(B)], 33.48 [C(A)], 122.39 [C(3)], 122.94
[C(6)], 124.37 [C(2”) + C(6”)], 124.47 [C(4a)], 125.63 [C(8)], 126.91 [C(4’)], 127.05 [C(5)],
129.00 [C(5’)], 129.28 [C(7)], 129.85 [C(3’) + C(6’)], 136.28 [br, C(4)], 138.12 [C(1’)],




(E)-3-(2-(Pyridin-2-yl)styryl)quinolin-2-amine (161a): HRMS (ESI+) [M+H]+ calcd. for
C22H17N3: 324.1501; found 324.1498. 1H NMR (500 MHz, CDCl3): δ 4.89 [2H, br s, NH2],
7.05-7.11 [2H, m, H(A) + H(B)], 7.25 [1H, t, 3J5,6 = 3J6,7 = 8.0 Hz, H(6)], 7.33-7.38 [3H,
m, H(3’) + H(2”) + H(6”)], 7.44 [1H, br t‡, 3J3’,4’ = 3J4’,5’ = 7.6 Hz, H(4’)], 7.49 [1H, br t‡,
3J4’,5’ = 3J5’,6’ = 7.6 Hz, H(5’)], 7.53 [1H, br t‡, 3J6,7 = 3J7,8 = 8.0 Hz, H(7)], 7.60 [1H, br d‡,
3J5,6 = 8.0 Hz, H(5)], 7.64 [1H, br d‡, 3J7,8 = 8.0 Hz, H(8)], 7.78 [1H, br d‡, 3J5’,6’ = 7.6 Hz,
H(6’)], 7.83 [1H, s, H(4)], 8.66-8.72 [2H, m, H(3”) + H(5”)]. 13C NMR (126 MHz, CDCl3):
δ 121.28 [C(3)], 123.31 [C(6)], 124.47 [C(4a)], 124.84 [br, C(2”) + C(6”)], 124.94 [C(A)],
125.89 [C(8)], 126.68 [C(6’)], 127.72 [br, C(5)], 128.63 [C(4’)], 129.09 [C(5’)], 129.95 [C(7)],
130.15 [C(3’)], 131.34 [C(B)], 134.42 [br, C(4)], 135.01 [C(1’)], 138.60 [C(2’)], 147.35 [br,






A mixture of 147c (161 mg, 0.47 mmol) and 4-methoxybenzyl amine (1.23 mL, 9.4 mmol) was
combined and stirred at 140°C for 16 hr. The mixture was purified by column chromatography
on silica gel eluting with 1% methanol in dichloromethane to give a crude mixture of (E /Z )-
165c as a yellow solid, which was used without further purification (152 mg, *73%). HRMS
(ESI+) [M+H]+ calcd. for C30H25N3O: 444.2076; found 444.2067.
* contains residual 4-methoxybenzyl amine.
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A sample of pure (E )-N-(4-methoxybenzyl)-3-(4-(pyridin-4-yl)styryl)quinolin-2-amine
(E -165c) was obtained by recrystallisation from dichloromethane for the purposes of
characterisation. HRMS (ESI+) [M+H]+ calcd. for C30H25N3O: 444.2076; found 444.2067.
1H NMR (500 MHz, CDCl3): δ 3.80 [3H, s, OCH3], 4.80 [2H, d, 3JH,H = 5.2 Hz, CH2], 4.96
[1H, br t, 3JH,H = 5.2 Hz, NH], 6.87-6.92 [2H, m, H(3”’) + H(5”’)], 7.11 and 7.13 [2H, AB,
A:d, B:d, 3JA,B(JAB) = 16.0 Hz, H(A) + H(B)], 7.24 [1H, ddd, 3J5,6 = 8.0 Hz, 3J6,7 = 7.0
Hz, 4J6,8 = 1.1 Hz, H(6)], 7.37-7.42 [2H, m, H(2”’) + H(6”’)], 7.49-7.57 [3H, m, H(7) +
H(2”) + H(6”)], 7.58-7.68 [5H, m, H(5) + H(2’) + H(3’) + H(5’) + H(6’)], 7.76 [1H, br
d, 3J7,8 = 8.4 Hz, H(8)], 7.95 [1H, s, H(4)], 8.64-8.69 [2H, m, H(3”) + H(5”)]. 13C NMR
(126 MHz, CDCl3): δ 45.52 [CH2], 55.44 [OCH3], 114.20 [C(3”’) + C(5”’)], 121.45 [C(2”)
+ C(6”)], 121.87 [C(3)], 122.66 [C(6)], 123.85 [C(A)], 123.92 [C(4a)], 126.49 [C(8)], 127.50
[C(3’) + C(5’)], 127.58 [C(2’) + C(6’)], 129.60 [C(7)], 129.72 [C(2”’) + C(6”’)], 131.90
[C(1”’)], 132.86 [C(B)], 133.94 [C(4)], 137.77 [C(1’)], 137.86 [C(4’)], 147.66 [C(1”)], 147.86






A solution of (E /Z )-165c (147 mg, 0.33 mmol) in methanol/ethanol (1:1, 40 mL) was heated
at 40°C with a catalytic amount of 5% Pd-C catalyst under an atmosphere of hydrogen for
16 hr. The mixture was filtered through Celite® washing with methanol, and the solvent was
removed by evaporation under reduced pressure to give 170c which was used without further
purification (102 mg, *69%). HRMS (ESI+) [M+H]+ calcd. for C30H27N3O: 446.2232;
found 446.2234. 1H NMR (500 MHz, CDCl3): δ 2.80-2.87 [2H, m, H(A)], 3.04-3.11 [2H, m,
H(B)], 3.78 [3H, s, OCH3], 4.69 [1H, br t, 3JH,H = 4.7 Hz, NH], 4.74 [2H, d, 3JH,H = 4.7 Hz,
NCH2], 6.84-6.89 [2H, m, H(3”’) + H(5”’)], 7.22 [1H, ddd, 3J5,6 = 8.0 Hz, 3J6,7 = 7.0 Hz,
4J6,8 = 1.1 Hz, H(6)], 7.24-7.28 [2H, m, H(2’) + H(6’)], 7.30-7.35 [2H, m, H(2”’) + H(6”’)],
7.45-7.48 [2H, m, H(2”) + H(6”)], 7.49-7.57 [4H, m, H(5) + H(7) + H(3’) + H(5’)], 7.62
[1H, br s‡, H(4)], 7.77 [1H, br d‡, 3J7,8 = 8.3 Hz, H(8)], 8.62-8.66 [2H, m, H(3”) + H(5”)].





A mixture of 170c (89 mg, 0.20 mmol) and trifluoroacetic acid (1 mL) was heated at 60°C
for 1 hr. The mixture was then cooled and diluted with dichloromethane (20 mL), and
concentrated to dryness by evaporation under reduced pressure. The residue was re-suspended
in dichloromethane and concentrated to dryness by evaporation under reduced pressure, then
diluted with saturated aqueous sodium bicarbonate solution (20 mL) and extracted with
dichloromethane (3 x 25 mL). The organic extracts were dried over anhydrous MgSO4, filtered,
and the solvent was removed by evaporation under reduced pressure. The residue was purified
by column chromatography on silica gel eluting with 5% methanol in dichloromethane, to give
139c as a white solid (42 mg, 65%). MP: 212-216°C. HRMS (ESI+) [M+H]+ calcd. for
C22H19N3: 326.1657; found 326.1651. 1H NMR (500 MHz, CDCl3): δ 2.91-2.98 [2H, m,
H(A)], 3.09-3.16 [2H, m, H(B)], 4.99 [2H, br s, NH2], 7.28 [1H, br t, 3J5,6 = 3J6,7 = 7.5 Hz,
H(6)], 7.32-7.35 [2H, m, H(2’) + H(6’)], 7.48-7.51 [2H, m, H(2”) + H(6”)], 7.54-7.62 [4H,





Using General Method 16, 148b (124 mg, 0.36 mmol) was reacted with 4-methoxybenzylamine
(945 µL, 7.2 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1.5 mL), and work-up
followed by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane
yielded 140b as a pale yellow solid (36 mg, 31%). MP: 172-176°C. HRMS (ESI+) [M+H]+
calcd. for C22H19N3: 326.1657; found 326.1653. 1H NMR (500 MHz, CDCl3): δ 2.91-3.00
[2H, m, H(A)], 3.09-3.19 [2H, m, H(B)], 5.43 [2H, br s, NH2], 7.22-7.29 [2H, m, H(6) +
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H(6’)], 7.32 [1H, dd, 3J5”,6” = 7.9 Hz, 3J4”,5” = 4.8 Hz, H(5”)], 7.37 [1H, br s, H(2’)],
7.39-7.47 [2H, m, H(4’) + H(5’)], 7.51-7.61 [2H, m, H(5) + H(7)], 7.66-7.73 [2H, m, H(4)
+ H(8)], 7.76 [1H, br d‡, 3J5”,6” = 7.9 Hz, H(6”)], 8.57 [1H, dd, 3J4”,5” = 4.8 Hz, 4J4”,6” =
1.0 Hz, 8.79 [1H, d, 4J2”,6” = 2.0 Hz, H(2”)]. 13C NMR (126 MHz, CDCl3): δ 33.06 [C(A)],
34.45 [C(B)], 122.81 [C(3)], 123.29 [C(6)], 123.65 [C(5”)], 124.05 [C(4a)], 124.66 [br, C(8)],
125.48 [C(4’)], 127.19 [C(5)], 127.49 [C(2’)], 128.28 [C(6’)], 129.54 [C(5’)], 129.67 [C(7)],
134.50 [C(6”)], 136.60 [C(1”)], 136.69 [C(4)], 138.41 [C(3’)], 141.71 [C(1’)], 145.12 [br,




Using General Method 16, 148c (129 mg, 0.38 mmol) was reacted with 4-methoxybenzylamine
(980 µL, 7.5 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1.5 mL), and work-up
followed by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane
yielded 140c as a pale yellow solid (22 mg, 18%). HRMS (ESI+) [M+H]+ calcd. for
C22H19N3: 326.1657; found 326.1658. 1H NMR (500 MHz, CDCl3): δ 2.89-3.02 [2H, m,
H(A)], 3.08-3.18 [2H, m, H(B)], 5.07 [2H, br s, NH2], 7.27 [1H, t, 3J5,6 = 3J6,7 = 7.7 Hz,
H(6)], 7.30-7.40 [3H, m, H(2’) + H(6’) + H(5”)], 7.49-7.57 [3H, m, H(7) + H(3’) + H(5’)],
7.59 [1H, d, 3J5,6 = 7.7 Hz, H(5)], 7.66-7.73 [2H, m, H(4) + H(8)], 7.86 [1H, br d‡, 3J5”,6”
= 7.9 Hz, H(6”)], 8.59 [1H, br d‡, 3J4”,5” = 4.6 Hz, H(4”)], 8.84 [1H, br s‡, H(2”)]. 13C
NMR (126 MHz, CDCl3): δ 33.09 [C(A)], 34.17 [C(B)], 122.77 [C(3)], 123.15 [C(6)], 123.69
[C(5”)], 124.32 [C(4a)], 125.19 [C(8)], 127.20 [C(5)], 127.52 [C(3’) + C(5’)], 129.34 [C(2’)
+ C(6’)], 129.48 [C(7)], 134.31 [C(6”)], 136.18 [C(4’)], 136.37 [br, C(4) + C(1”)], 140.98





Using General Method 16, 149b (116 mg, 0.34 mmol) was reacted with 4-methoxybenzylamine
(880 µL, 6.7 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1.5 mL), and work-up
followed by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane
yielded 141b as a pale yellow solid (34 mg, 31%). HRMS (ESI+) [M+H]+ calcd. for
C21H18N4: 327.1610; found 327.1590. 1H NMR (500 MHz, CDCl3): δ 2.92-2.99 [2H, m,
H(A)], 3.12-3.19 [2H, m, H(B)], 4.88 [2H, br s, NH2], 7.26 [1H, td, 3J5,6 = 3J6,7 = 7.4 Hz,
4J6,8 = 0.9 Hz, H(6)], 7.33 [1H, br d‡, 3J5’,6’ = 7.1 Hz, H(6’)], 7.37 [1H, br s, H(2’)], 7.41-7.50
[2H, m, H(4’) + H(5’)], 7.51-7.60 [2H, m, H(5) + H(7)], 7.64-7.70 [2H, m, H(4) + H(8)],
8.87 [2H, s, H(2”) + H(6”)], 9.20 [1H, s, H(4”)]. 13C NMR (126 MHz, CDCl3): δ 33.28
[C(A)], 34.49 [C(B)], 122.39 [C(3)], 123.05 [C(6)], 124.47 [C(4a)], 125.31 [C(4’)], 125.70
[C(8)], 127.10 [C(5)], 127.34 [C(2’)], 129.22 [C(6’)], 129.38 [C(7)], 129.90 [C(5’)], 134.39
[C(1”)], 134.84 [C(3’)], 136.17 [C(4)], 142.37 [C(1’)], 146.55 [br, C(8a)], 155.06 [C(2”) +





Using General Method 16, 149c (132 mg, 0.38 mmol) was reacted with 4-methoxybenzylamine
(1.0 mL, 7.7 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1.5 mL), and work-up
followed by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane
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yielded 141c as a pale yellow solid (40 mg, 32%). HRMS (ESI+) [M+H]+ calcd. for
C21H18N4: 327.1610; found 327.1591. 1H NMR (500 MHz, CDCl3): δ 2.91-2.99 [2H, m,
H(A)], 3.10-3.18 [2H, m, H(B)], 4.88 [2H, br s, NH2], 7.26 [1H, ddd, 3J5,6 = 8.0 Hz, 3J6,7 =
7.4 Hz, 4J6,8 = 0.9 Hz, H(6)], 7.35-7.39 [2H, m, H(2’) + H(6’)], 7.49-7.60 [4H, m, H(5) +
H(7) + H(3’) + H(5’)], 7.66-7.70 [2H, m, H(4) + H(8)], 8.94 [2H, s, H(2”) + H(6”)], 9.20
[1H, s, H(4”)].
6.4.6 Synthesis of 3-position pyridinylethyl-extended 2-aminoquinoline derivatives
General Method 17: Synthesis of 3-position pyridinylvinyl substituted










A suspension of triphenyl(pyridinylmethyl)phosphonium bromide derivative 52 (1.5 eq) in
anhydrous THF was stirred and cooled to 0°C under an atmosphere of nitrogen. LiHMDS
solution (1.0 M in THF, 2.0 eq) was added dropwise and the mixture was stirred for 10
minutes. A solution of 144 (1.0 eq) in anhydrous THF was added and the mixture was
stirred at 30 minutes for 0°C then at room temperature for 3 hr or until complete. The
reaction mixture was quenched with water (20 mL) then extracted with DCM (2 x 25 mL).
The organic extracts were dried over MgSO4, filtered, and solvent removed by evaporation
under reduced pressure. A solution of 2:3 ethyl acetate/hexane was added to the crude
residue and the mixture was filtered to remove insoluble solid impurities. The filtrate was
concentrated by evaporation under reduced pressure and the residue purified by flash column
chromatography on silica gel with the specified eluant.
General Method 18: Synthesis of 3-position pyridinylvinyl substituted










Sodium tert-butoxide (1.4 eq) was added to suspension of triphenylphosphonium halide Wittig
reagent (2.4 eq) stirred in anhydrous DMF (6 mL) under an atmosphere of nitrogen, and the
reaction mixture was stirred for 20 min. A solution of quinoline 144 (1 eq) in anhydrous
DMF was added and the mixture was stirred for 4 hr or until complete, and quenched with
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methanol. The mixture was concentrated to dryness by evaporation under reduced pressure,
then suspended in ethyl acetate/hexane (2:3, 40 mL) and filtered to remove insoluble solid
impurities. The filtrate was concentrated to dryness by evaporation under reduced pressure






Synthesis method a. Using General Method 17, 52a (0.68 g, 1.6 mmol), 144 (200 mg, 1.0
mmol), and LiHMDS solution (1.0M in THF, 2.09 mL, 2.1 mmol) were reacted in THF (10
mL). The crude residue was purified by column chromatography on silica gel eluting with 1%
methanol in dichloromethane to give 172a as a brown oil (144 mg, 52%). Rf = 0.25 (2%
methanol in dichloromethane).
A sample of (E )-2-chloro-3-(2-(pyridin-2-yl)vinyl)quinoline (E -172a) was isolated by column
chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd. for
C16H1135ClN2/C16H1137ClN2: 267.0689/269.0660; found 267.0684/269.0659. 1H NMR (500
MHz, CDCl3): δ 7.21 [1H, dd, 3J4’,5’ = 7.4 Hz, 3J3’,4’ = 4.8 Hz, H(4’)], 7.28 [1H, d, 3JA,B
= 16.1 Hz, H(B)], 7.49 [1H, d, 3J5’,6’ = 7.8 Hz, H(6’)], 7.56 [1H, t, 3J5,6 = 3J6,7 = 8.0 Hz,
H(6)], 7.68-7.73 [2H, m, H(7) + H(5’)], 7.84 [1H, d, 3J5,6 = 8.0 Hz, H(5)], 8.00 [1H, d, 3J7,8
= 9.0 Hz, H(8)], 8.03 [1H, d, 3JA,B = 16.1 Hz, H(A)], 8.42 [1H, s, H(4)], 8.66 [1H, d, 3J3’/4’
= 4.8 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 122.43 [C(6’)], 122.94 [C(4’)], 127.45
[C(6)], 127.52 [C(4a)], 127.65 [C(A)], 127.82 [C(5)], 128.44 [C(8)], 129.87 [C(3)], 130.65
[C(7)], 132.77 [C(B)], 134.58 [C(4)], 136.76 [C(5’)], 147.23 [C(8a)], 150.06 [C(3’)], 150.47
[C(2)], 154.93 [C(1’)].
Synthesis method b. Using General Method 17, 52a (254 mg, 0.58 mmol), 144 (80 mg, 0.42
mmol), and sodium tert-butoxide (96 mg, 1.0 mmol) in DMF (7 mL). The crude residue was
purified by column chromatography on silica gel eluting with 1% methanol in dichloromethane






Synthesis method a. Using General Method 17, 52b (0.85 g, 2.2 mmol), 144 (250 mg, 1.3
mmol), and LiHMDS solution (1.0M in THF, 3.1 mL, 3.1 mmol) were reacted in THF (10
mL). The crude residue was purified by column chromatography on silica gel eluting with 1%
methanol in dichloromethane to give 172b as a brown oil (115 mg, 33%). HRMS (ESI+)
[M+H]+ calcd. for C16H1135ClN2/C16H1137ClN2: 267.0689/269.0660; found
267.0686/269.0660.
A sample of (Z )-2-chloro-3-(2-(pyridin-3-yl)vinyl)quinoline (Z -172b) was isolated by column
chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd. for
C16H1135ClN2/C16H1137ClN2: 267.0689/269.0660; found 267.0684/269.0659. 1H NMR (500
MHz, CDCl3): δ 6.83 [1H, d, 3JA,B = 12.1 Hz, H(B)], 6.89 [1H, dd, 3JA,B = 12.1 Hz, 4J4,A
= 0.6 Hz, H(A)], 7.08 [1H, dd, 3J5’,6’ = 7.9 Hz, 3J4’,5’ = 4.8 Hz, H(5’)], 7.44 [1H, dt, 3J5’,6’
= 7.9 Hz, 4J2’,6’ = 4J4’,6’ = 1.8 Hz, H(6’)], 7.48 [1H, ddd, 3J5,6 = 8.1 Hz, 3J6,7 = 6.9 Hz,
4J6,8 = 1.0 Hz, H(6)], 7.56 [1H, dd, 3J5,6 = 8.1 Hz, 4J5,7 = 1.2 Hz, H(5)], 7.69 [1H, ddd,
3J7,8 = 8.5 Hz, 3J6,7 = 6.9 Hz, 4J5,7 = 1.2 Hz, H(7)], 7.89 [1H, br s‡, H(4)], 8.00 [1H, br
d‡, 3J7,8 = 8.5 Hz, H(8)], 8.41 [1H, dd, 3J4’,5’ = 4.8 Hz, 4J4’,6’ = 1.8 Hz, H(4’)], 8.47 [1H,
d, 4J2’,6’ = 1.8 Hz, H(2’)]. 13C NMR (126 MHz, CDCl3): δ 123.28 [C(5’)], 126.92 [C(4a)],
127.30 [C(6)], 127.55 [C(5)], 128.04 [C(A)], 128.33 [C(8)], 129.36 [C(3)], 129.70 [C(B)],
130.72 [C(7)], 131.76 [C(1’)], 135.79 [C(6’)], 138.30 [C(4)], 147.06 [C(8a)], 148.66 [C(4’)],
150.12 [C(2’)], 150.26 [C(2)].
Synthesis method b. Using General Method 18, 52b (228 mg, 0.58 mmol), 144 (80 mg, 0.42
mmol), and sodium tert-butoxide (96 mg, 1.0 mmol) were reacted in DMF (10 mL). The
crude residue was purified by column chromatography on silica gel eluting with 1% methanol
in dichloromethane to give 172b as a brown oil (77 mg, 69%). Rf = 0.20 (2% methanol in





Synthesis method a. Using General Method 17, 52c (0.47 g, 1.1 mmol), 144 (160 mg, 0.84
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mmol), and LiHMDS solution (1.0 M in THF, 1.7 mL, 1.7 mmol) were reacted in THF (10
mL). The crude residue was purified by column chromatography on silica gel eluting with
2.5% methanol in dichloromethane to give 172c as a brown oil (71 mg, 32%). Rf = 0.12 (2%
methanol in dichloromethane). HRMS (ESI+) [M+H]+ calcd. for C16H1135ClN2/C16H1137ClN2:
267.0689/269.0660; found 267.0685/269.0658. 1H NMR (500 MHz, CDCl3): δ 6.79 [0.8H,
d, 3JA,B = 12.2 Hz, H(B)], 6.95 [0.8H, d, 3JA,B = 12.2 Hz, H(A)], 7.03-7.08 [1.6H, m,
H(2’) + H(6’)], 7.12 [0.2H, d, 3J*A,*B = 16.2 Hz, *H(B)], 7.43-7.45 [0.4H, m, *H(2’) +
*H(6’)], 7.50 [0.8H, ddd, 3J5,6 = 8.1 Hz, 3J6,7 = 7.0 Hz, 4J6,8 = 1.0 Hz, H(6)], 7.54-7.61
[1H, m, H(5) + *H(6)], 7.68-7.76 [1.2H, m, H(7) + *H(7) + *H(A)], 7.84-7.89 [1H, m,
H(4) + *H(5)], 7.99-8.04 [1H, m, H(8) + *H(8)], 8.41 [0.2H, s, *H(4)], 8.42-8.47 [1.6H,
m, H(3’) + H(5’)], 8.63-8.67 [0.4H, m, *H(3’) + *H(5’)]. 13C NMR (126 MHz, CDCl3):
δ 121.23 [*C(2’) + *C(6’)], 123.40 [C(2’) + C(6’)], 126.87 [C(4a)], 127.42 [C(5)], 127.44
[C(6)], 127.64 [C(5)], 127.81 [*C(5)], 128.15 [*C(A)], 128.41 [C(8)], 128.51 [*C(8)], 128.54
[*C(4a)], 128.99 [C(3)], 129.28 [*C(3)], 129.46 [C(A)], 130.61 [*C(B)], 130.84 [C(B)], 130.92
[C(7)], 130.94 [*C(7)], 134.72 [*C(4)], 138.50 [C(4)], 143.61 [C(1’)], 143.78 [*C(1’)], 147.23
[C(8a)], 147.37 [*C(8a)], 150.08 [*C(2)], 150.11 [C(2)], 150.26 [C(3’) + C(5’)], 150.55
[*C(3’) + *C(5’)].
* denotes signals corresponding to the minor E -isomer.
Synthesis method b. Using General Method 18, 52c (254 mg, 0.58 mmol), 144 (80 mg, 0.42
mmol), and sodium tert-butoxide (96 mg, 1.0 mmol) were reacted in DMF (10 mL). The crude
residue was purified by column chromatography on silica gel eluting with dichloromethane/





Using General Method 11, 172a (134 mg, 0.50 mmol), Pd(dba)2 (2.9 mg, 5.0 µmol),
DavePhos (2.4 mg, 6.1 µmol), and LiHMDS solution (1.0M in THF, 1.10 mL, 1.1 mmol)
were reacted in 1,4-dioxane (2.5 mL) for 16 hr. Work-up as specified and flash column
chromatography on silica gel eluting with 1:19 methanol/dichloromethane gave 173a as a
pale yellow solid (15 mg, 12%).
A sample of (E )-3-(2-(pyridin-2-yl)vinyl)quinolin-2-amine (E -173a) was isolated by column
chromatography for the purposes of characterisation. 1H NMR (500 MHz, CDCl3): δ 5.15
[2H, br s, NH2], 7.16-7.23 [2H, m, H(B) + H(4’)], 7.27 [1H, td, 3J5,6 = 3J6,7 = 7.5 Hz, 4J6,8
= 0.8 Hz, H(6)], 7.36 [1H, br d‡, 3J5’,6’ = 7.8 Hz, H(6’)], 7.55 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7
392
= 7.5 Hz, 4J5,7 = 1.3 Hz, H(7)], 7.64-7.72 [3H, m, H(5) + H(8) + H(5’)], 7.76 [1H, d, 3JA,B
= 15.7 Hz, H(A)], 8.09 [1H, s, H(4)], 8.62 [1H, br d‡, 3J3’,4’ = 4.6 Hz, H(3’)]. 13C NMR
(126 MHz, CDCl3): δ 120.78 [C(3)], 122.80 [C(4’)], 122.91 [C(6’)], 123.13 [C(6)], 124.41
[C(4a)], 125.83 [C(8)], 126.98 [C(A)], 127.78 [C(5)], 130.02 [C(7)], 131.95 [C(B)], 134.77





Using General Method 11, 172b (110 mg, 0.41 mmol), Pd(dba)2 (2.4 mg, 4.1 µmol),
DavePhos (1.9 mg, 4.9 µmol), and LiHMDS solution (1.0M in THF, 0.91 mL, 0.91 mmol)
were reacted in 1,4-dioxane (2.5 mL) for 16 hr. Work-up as specified and flash column
chromatography on silica gel eluting with 1:19 methanol/dichloromethane gave 173b as a
pale yellow solid (14 mg, 14%). Rf = 0.38 (1:9 methanol/dichloromethane).
A sample of pure (Z )-3-(2-(pyridin-3-yl)vinyl)quinolin-2-amine (Z -173b) was isolated by
column chromatography for the purposes of characterisation. HRMS (ESI+) [M+H]+ calcd.
for C16H13N3: 248.1188; found 248.1184. 1H NMR (500 MHz, CDCl3): δ 5.02 [2H, br s,
NH2], 6.68 [1H, dd, 3JA,B = 12.1 Hz, 4JA,4 = 0.8 Hz, H(A)], 6.80 [1H, d, 3JA,B = 12.1 Hz,
H(B)], 7.06 [1H, dd, 3J5’,6’ = 8.0 Hz, 3J4’,5’ = 4.8 Hz, H(5’)], 7.23 [1H, ddd, 3J5,6 = 8.0 Hz,
3J6,7 = 7.0 Hz, 4J6,8 = 1.1 Hz, H(6)], 7.46 [1H, dt, 3J5’,6’ = 8.0 Hz, 4J2’,6’ = 4J4’,6’ = 1.8
Hz, H(6’)], 7.50 [1H, br d‡, 3J5,6 = 8.0 Hz, H(5)], 7.55 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 =
7.0 Hz, 4J5,7 = 1.4 Hz, H(7)], 7.67 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 7.71 [1H, br s‡, H(4)],
8.41 [1H, dd, 3J4’,5’ = 4.8 Hz, 4J4’,6’ = 1.8 Hz, H(4’)], 8.50 [1H, d, 4J4’,6’ = 1.8 Hz, H(2’)].
13C NMR (126 MHz, CDCl3): δ 119.91 [C(3)], 123.07 [C(6)], 123.37 [C(5’)], 123.79 [C(4a)],
125.74 [C(8)], 126.87 [C(A)], 127.63 [C(5)], 130.10 [C(7)], 130.85 [C(B)], 131.72 [C(1’)],





Using General Method 11, 172c (60 mg, 0.22 mmol), Pd(dba)2 (1.3 mg, 2.2 µmol), DavePhos
(1.1 mg, 2.7 µmol), and LiHMDS solution (1.0M in THF, 0.49 mL, 0.49 mmol) were reacted
in 1,4-dioxane (2.5 mL) for 16 hr. Work up as specified gave a crude mixture which could
393
not be purified. 1H NMR analysis of the crude mixture did not indicate signals corresponding





Using General Method 3, 173a (11 mg, 0.04 mmol) was combined in methanol (40 mL) with a
catalytic amount of 5% Pd-C catalyst and stirred for 16 hr under an atmosphere of hydrogen.
Work-up as specified and column chromatography on silica gel eluting with 2% methanol in
dichloromethane gave 142a as a yellow oil (11 mg, 97%). HRMS (ESI+) [M+H]+ calcd.
for C16H15N3: 250.1344; found 250.1341. 1H NMR (500 MHz, CDCl3): δ 3.05-3.12 [2H, m,
H(A)], 3.12-3.20 [2H, m, H(B)], 5.61 [2H, br s, NH2], 7.12 [1H, d, 3J5’,6’ = 7.8 Hz, H(6’)],
7.15 [1H, dd, 3J4’,5’ = 7.5 Hz, 3J3’,4’ = 4.9 Hz, H(4’)], 7.24 [1H, td, 3J5,6 = 3J6,7 = 7.2 Hz,
4J6,8 = 0.9 Hz, H(6)], 7.51 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.2 Hz, 3J5,7 = 1.3 Hz, H(7)],
7.55-7.61 [2H, m, H(5) + H(5’)], 7.66 [1H, br d‡, 3J7,8 = 8.4 Hz, H(8)], 7.71 [1H, s, H(4)],
8.59 [1H, br d‡, 3J3’,4’ = 4.9 Hz, H(3’)]. 13C NMR (126 MHz, CDCl3): δ 31.11 [C(A)], 37.00
[C(B)], 121.73 [C(4’)], 122.75 [C(6)], 123.25 [C(6’)], 123.59 [C(3)], 124.20 [C(4a)], 125.09
[br, C(8)], 127.09 [C(5)], 129.24 [C(7)], 136.33 [C(4)], 136.79 [C(5’)], 146.06 [br, C(8a)],





Synthesis method a. Using General Method 3, 173b (12 mg, 0.05 mmol) was combined in
methanol (40 mL) with a catalytic amount of 5% Pd-C catalyst and stirred for 16 hr under
an atmosphere of hydrogen. Work-up as specified and column chromatography on silica gel
eluting with 1% methanol in dichloromethane gave 142b as a yellow oil (6 mg, 50%). MP:
179-182°C. HRMS (ESI+) [M+H]+ calcd. for C16H15N3: 250.1344; found 250.1341. 1H
NMR (500 MHz, CDCl3): δ 2.84-2.96 [2H, m, H(A)], 3.01-3.13 [2H, m, H(B)], 4.85 [2H, br
s, NH2], 7.21 [1H, dd, 3J5’,6’ = 7.5 Hz, 3J4’,5’ = 4.9 Hz, H(5’)], 7.26 [1H, t, 3J5,6 = 3J6,7
= 7.4 Hz, H(6)], 7.47 [1H, br d, 3J5’,6’ = 7.5 Hz, H(6’)], 7.50-7.60 [2H, m, H(5) + H(7)],
7.63 [1H, s, H(4)], 7.67 [1H, d, 3J7,8 = 8.4 Hz, H(8)], 8.45-8.58 [2H, m, H(2’) + H(4’)]. 13C
NMR (126 MHz, CDCl3): δ 31.54 [C(B)], 32.98 [C(A)], 121.99 [C(3)], 123.01 [C(6)], 123.55
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[C(5’)], 124.45 [C(4a)], 125.77 [C(8)], 127.15 [C(5)], 129.34 [C(7)], 136.06 [C(6’)], 136.13
[C(4)], 136.22 [C(1’)], 146.70 [C(8a)], 148.10 [C(4’)], 150.02 [C(2’)], 155.94 [C(2)].
Synthesis method b. Using General Method 16, a mixture of (E /Z )-172b (55 mg, 0.21
mmol) was treated with 4-methoxybenzylamine (0.54 mL, 4.1 mmol) for 16 hr then cooled and
chromatographed through silica gel eluting with dichloromethane. The fractions containing
no excess reagent were reacted under an atmosphere of hydrogen with a catalytic amount
of 5% Pd-C catalyst in methanol (20 mL) and then treated with TFA (1 mL). Work-
up and purification by column chromatography on silica gel eluting with 1% methanol in





Using General Method 16, a mixture of (E /Z )-172c (62 mg, 0.23 mmol) was treated with
4-methoxybenzylamine (0.61 mL, 4.6 mmol) for 16 hr then cooled and chromatographed
through silica gel eluting with dichloromethane, to give a crude brown mixture which could
not be further purified (16 mg). 1H NMR analysis of the crude mixture was used to identify
signals corresponding to the desired product, however due to low recovery the subsequent
steps were not attempted.





Using General Method 15, 36p (161 mg, 0.54 mmol), 144 (80 mg, 0.42 mmol), and sodium
tert-butoxide (96 mg, 1.0 mmol) were reacted in DMF (6 mL) for 4 hr. Work-up followed
by column chromatography eluting with dichloromethane gave 176a as a white solid (139
mg, 100%). A sample of pure E -isomer was isolated by chromatography for the purposes of
characterisation. HRMS (ESI+) [M+H]+ calcd. for C18H1135ClF3N/C16H1137ClF3N:
334.0610/336.0581; found 334.0606/336.0581. 1H NMR (500 MHz, CDCl3): δ 7.21 [1H, d,
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3JA,B = 16.2 Hz, H(B)], 7.54-7.63 [2H, m, H(6) + H(A)], 7.63-7.70 [4H, m, H(2’) + H(3’)
+ H(5’) + H(6’)], 7.72 [1H, ddd, 3J7,8 = 8.4 Hz, 3J6,7 = 7.0 Hz, 4J5,7 = 1.3 Hz, H(7)], 7.85
[1H, br d‡, 3J5,6 = 8.1 Hz, H(5)], 8.01 [1H, d, 3J7,8 = 8.4 Hz, H(8)], 8.39 [1H, s, H(4)]. 13C
NMR (126 MHz, CDCl3): δ 124.22 [q, 1JC,F = 272.1 Hz, CF3], 125.96 [q, 3JC,F = 3.8 Hz,
C(3’) + C(5’)], 126.23 [C(A)], 127.23 [C(2’) + C(6’)], 127.55 [C(4a)], 127.59 [C(6)], 127.77
[C(5)], 128.53 [C(8)], 129.79 [C(3)], 130.34 [q, 2JC,F = 32.4 Hz, C(4’)], 130.74 [C(7)], 131.73
[C(B)], 134.32 [C(4)], 140.09 [q, 5JC,F = 1.4 Hz, C(1’)], 147.24 [C(8a)], 150.22 [C(2)].




Using General Method 15, 36s (370 mg, 1.46 mmol), 144 (200 mg, 1.04 mmol), and
sodium tert-butoxide (241 mg, 2.51 mmol) were reacted in DMF (6 mL) for 4 hr. Work-
up followed by column chromatography eluting with dichloromethane gave 176b as a white
solid (208 mg, 69%). HRMS (ESI+) [M+H]+ calcd. for C18H1135ClF3N/C16H1137ClF3N:
291.0689/293.0660; found 291.0685/293.0661. 1H NMR (500 MHz, CDCl3): δ 6.85 [0.1H,
d, 3J*A,*B = 12.2 Hz, *H(B)], 6.91 [0.1H, d, 3J*A,*B = 12.2 Hz, *H(A)], 7.19 [0.9H, d,
3JA,B = 16.2 Hz, H(B)], 7.25-7.29 [0.2H, m, *H(2’) + *H(6’)], 7.45-7.53 [0.3H, m, *H(6)
+ *H(3’) + *H(5’)], 7.55-7.61 [1H, m, H(6) + *H(5)], 7.61-7.77 [5.6H, m, H(A) + H(7)
+ H(2’) + H(3’) + H(5’) + H(6’) + *H(7) + *H(8)], 7.83-7.88 [1H, m, H(5) + *H(4)],
8.01 [0.9H, d, 3J7,8 = 8.5 Hz, H(8)], 8.40 [0.9H, s, H(4)]. 13C NMR (126 MHz, CDCl3): δ
111.33 [C(4’)], 111.78 [*C(4’)], 118.70 [*CN], 118.87 [CN], 126.91 [*C(4a)], 127.33 [C(A)],
127.44-127.56 [m, C(4a) + C(2’) + C(6’) + *C(6)], 127.61 [*C(5)], 127.67 [C(6)], 127.81
[C(5)], 128.46 [*C(8)], 128.54 [C(8)], 128.70 [*C(A)], 129.15 [C(3) + *C(3)], 129.43 [C(2’)
+ C(6’)], 129.61 [*C(2’) + *C(6’)], 130.93 [C(7)], 130.97 [*C(7)], 131.24 [C(B)], 131.64
[*C(B)], 132.41 [*C(3’) + *C(5’)], 132.77 [C(3’) + C(5’)], 134.50 [C(4)], 138.51 [*C(4)],
141.03 [C(1’) + *C(1’)], 147.24 [*C(8a)], 147.33 [C(8a)], 150.13 [C(2) + *C(2)].





Using General Method 16, 176a (197 mg, 0.59 mmol) was reacted with 4-methoxybenzylamine
(1.5 mL, 11.8 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1 mL), and work-up followed
by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane yielded
143a as a white solid (86 mg, 53%). HRMS (ESI+) [M+H]+ calcd. for C18H15F3N2:
317.1266; found 317.1263. 1H NMR (500 MHz, CDCl3): δ 2.84-2.94 [2H, m, H(A)], 3.06-
3.16 [2H, m, H(B)], 4.84 [2H, br s, NH2], 7.26 [1H, dd, 3J5,6 = 8.0 Hz, 3J6,7 = 7.2 Hz,
H(6)], 7.29-7.34 [2H, m, H(2’) + H(6’)], 7.50-7.60 [4H, m, H(5) + H(7) + H(3’) + H(5’)],




Using General Method 16, 176b (56 mg, 0.19 mmol) was reacted with 4-methoxybenzylamine
(503 µL, 3.9 mmol) for 16 hr. The excess reagent was removed by distillation under reduced
pressure, and the residue was dissolved in methanol (30 mL) and reacted under an atmosphere
of hydrogen with a catalytic amount of Pd-C catalyst for 16 hr. The mixture was filtered
through Celite® washing with methanol, and the volatile solvent was removed by evaporation
under reduced pressure. The crude residue was treated with TFA (1 mL), and work-up followed
by column chromatography on silica gel eluting with 1:19 methanol/dichloromethane yielded
143b as a white solid (26 mg, 49%). HRMS (ESI+) [M+H]+ calcd. for C18H15N3: 274.1344;
found 274.1338. 1H NMR (500 MHz, CDCl3): δ 2.87-2.94 [2H, m, H(A)], 3.08-3.16 [2H,
m, H(B)], 4.83 [2H, br s, NH2], 7.23-7.32 [3H, m, H(6) + H(2’) + H(6’)], 7.51-7.61 [5H,
m, H(4) + H(5) + H(7) + H(3’) + H(5’)], 7.67 [1H, d, 3J7,8 = 8.3 Hz, H(8)]. 13C NMR
(126 MHz, CDCl3): δ 32.74 [C(A)], 34.48 [C(B)], 110.55 [C(4’)], 118.97 [CN], 121.78 [C(3)],
123.10 [C(6)], 124.41 [C(4a)], 125.78 [C(8)], 127.14 [C(5)], 129.43 [C(7) + C(2’) + C(6’)],
132.56 [C(3’) + C(5’)], 136.15 [C(4)], 146.48 [C(1’)], 146.70 [C(8a)], 155.87 [C(2)].
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Appendix A: Assays of small-molecule ligands with Tec
SH3 domain via SPR method.
The Surface Plasmon Resonance (SPR) assays were conducted using a Biacore S200 system,
with Biacore S200 Evaluation Software used to display and analyse the assay results.
Protein and sample preparation
GST protein and the GST-SH3 fusion proteins were prepared by Mehrnaz Keyhanfar according
to methods previously developed and published.137 GST protein was used as the reference for
the assays to compensate the experimental results for shifts in the bulk refractive index of
solutions and for drift, and also to enable identification of non-specific binding events. GST-
SH3 fusion protein stocks were in 1 x PBS buffer at concentrations of approximately 1.6
mg/mL. GST protein stocks were in 1 x PBS buffer at concentrations of approximately 1
mg/mL.
The small-molecule ligand solutions were prepared from accurately weighed samples of pure
ligand (2-5 mg) dissolved in DMSO to a concentration of 100 mM. The samples were stored
in the dark until used to avoid photodegradation. The samples were diluted to 10 mM in
DMSO, then to 500 µM in running buffer (1 x PBS, 5% DMSO, 0.05% Tween20).
The sample solutions were diluted to the required assay sample concentrations into GE
Healthcare Life Sciences 96-well microplates using a Hamilton MicroLab Nimbus96 (enclosed)
pipetting robot.
Immobilisation onto sensor chip
The running buffer used during the immobilisation process was 1 x PBS with 0.05% Tween20.
The sensor chip surfaces were preconditioned with two successive injections of each of the
preconditioning solutions: 50 mM NaOH, 10 mM HCl, 0.1% SDS, 0.85% H3PO4, and 50 mM
glycine (pH = 9.5).
The sensor chip surfaces were activated by injection of a 1:1 mixture of NHS and EDC (100 µL
each) at a flow rate of 10 µL/min over 900 seconds. The protein was diluted to approximately
1 µM with 10 mM sodium acetate solution (pH 5.2) and injected across the surface at a flow
rate of 2 µL/min. Protein injections were repeated until response increases were not observed
upon injection of more protein, indicating saturation of surface. An typical increase in the
response of approximately 6000-8000 Response Units (RU) was observed at this step.
The remaining active NHS esters were blocked with two successive injections of 1.0 M
ethanolamine (pH 8.5) at a flow rate of 10 µL/min (2 x 210 seconds); a small decrease
in RU was observed as a result.
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The final amount of immobilised protein was determined as the difference in RU between
activation and blocking steps. Similar amounts of immobilised GST protein and GST-SH3
fusion protein were achieved.
Screening method
The running buffer used for the assay runs, including injection of small-molecule ligands, was
1 x PBS with 5% DMSO and 0.05% Tween20.
The addition of 5% DMSO in the running buffer and solutions assisted with solubility of the
small-molecule ligands. Solvent correction was required to compensate for the bulk refractive
index shift due to addition of DMSO. The solutions used for the solvent correction were
5.8-4.5% DMSO solutions in 1 x PBS with 0.05% Tween20.
Nine concentrations of each ligand (including a blank) were screened for binding with the
GST (reference) and GST-SH3 fusion protein. For screening, the concentrations tested are
shown in Table A-1.
Table A-1: Concentrations of small-molecule ligands used for screening assays.










A run of assays typically contained 10 small-molecule samples. For each run of assays, a
series of start-up cycles was followed by sample correction samples before assays of small-
molecule compounds. Solvent correction was repeated after 6 small-molecule compound runs
for consistency.
Data evaluation
The solvent correction samples were used to generate a calibration curve to correct for the
effect of the solvent upon the response measured (Figure A-1), and this correction was then
applied to all samples in the assay run to compensate for the DMSO bulk shift.
Reference subtraction and correction (using the GST reference samples) was applied to each
set of data.
The baselines before injection of small-molecule compound were overlaid (i.e. RU set to zero)
for each sensorgram to account for any loss of active protein on the sensor surface.
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Figure A-1: Example of solvent correction applied in assay runs to compensate for shift in bulk refractive
index due to addition of DMSO. For each solvent correction solution (5.8-4.5% DMSO), the relative
response difference upon sample injection was measured for the GST-SH3 fusion protein surface (Response
(Act-Ref)) and the reference GST protein surface (Response (Ref)), and these data points were plotted to
generate the solvent correction curve.
The resulting sensorgrams for each concentration were overlaid. Visual inspection determined
if the sensorgrams appeared stable over time. A report point was selected (6 seconds prior
to end of sample injection) in the region of equilibrium binding. The response around a five
second region of the report point was averaged, and this response was used as a measure of
the response at equilibrium binding (see Figure A-2).
Figure A-2: Example of assay sensorgrams and selected report point. Example shown is for 22a.
Affinity evaluation
For each concentration of small-molecule ligand, the response at the report point for equilibrium
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binding (Req, in RU) was plotted against the concentration (C, in µM). Using the software,






The curve fitting process used nonlinear regression analysis to fit the Kd value, Rmax, and RI
using the initial values shown in Table A-2, giving a binding isotherm which minimises the χ2
value (Figure A-3).
Table A-2: Fitted values determined by nonlinear regression analysis.
Fitted value Initial value
Kd Equilibrium dissociation 0.1 x maximum concentration
binding constant of ligand assayed
Rmax Maximum response, at saturation maximum response
of protein binding sites measured for assays
RI offset due to bulk 0.2 x maximum response
shift during injection measured for assays
Figure A-3: Example of steady-state affinity analysis used to determine the Kd value. Example is for 22a.
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Affinity evaluation Kd value for strongest binding ligands.
For small-molecule ligands where the screening Kd value was comparable or better than the
previous lead compound (i.e. Kd value < 10 µM) the assays were repeated in triplicate. The
range of concentrations tested was generally adjusted to appropriately cover the measured
Kd value, ideally using a maximum concentration approximately 10 x the Kd value. This
concentration typically ensured that sufficient data points were below and above the Kd value
to avoid extrapolation and minimise error, and that the higher concentrations were close to
saturation of the protein binding sites, to avoid extrapolation of the Rmax value.
The mean and standard deviation were reported for the Kd values determined by the SPR
assays if at least three assay measurements were collected.
Affinity evaluation for ligands with atypical assay results
In some cases, atypical or inconsistent response measurements meant that the sensorgrams for
each tested concentration of the screening assays could not be effectively used to determine
the Kd value. This was typically due to poor solubility, stability, or aggregation of the small-
molecule ligand at higher concentration, which resulted in a decrease in RU observed at higher
concentrations where saturation of protein binding had been achieved at lower concentrations.
In cases where the response values significantly decreased at higher concentrations (for
example, see Figure A-4), using these concentrations in the affinity evaluation results in a
significant underestimate and error in determination of the Kd value. In these cases, the
highest concentrations where reduced binding were removed from the affinity evaluation and
noted.
Affinity analysis for compound 108b
Affinity analysis Affinity analysis
with all assay results included with two highest concentrations removed
Kd = 0.97 µM Kd = 1.8 µM
Figure A-4: Example of anomalous behaviour affecting accuracy of results for some concentrations in the
SPR screening assays. Including all concentrations in the affinity analysis results in underestimate of Kd
value.
For the stronger binding ligands (such as 108b in Figure A-4), saturation binding was achieved
at significantly lower concentrations, so in the follow-up replicate assay lower concentrations
were used to obtain a better measurement of the Kd value. In cases where the response-
concentration curve did not appear to be reaching the saturation binding plateau, this was
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also indicated in the results as it may result in an increased error in the fit of the data.
In some cases low response values were observed. The compound 22a was used as a standard
in every assay run and gave consistent responses and calculated Kd values. Assays of some
small-molecule ligands had negligible response compared to the standard compound, which
could be due to weak interaction (or no interaction) with the protein surface or insolubility of
small-molecule ligand. In either case, the low response was noted. In some cases the affinity
analysis could still be used to calculate a ’Kd value’ despite the low response (for example,
see Figure A-5), however this calculated value does not accurately reflect the strength of
the protein-ligand binding interaction. The Kd value refers to the concentration of ligand
required to occupy half of the saturation binding sites of the protein target, and therefore
if the response is too low for saturation binding then the data cannot be used to determine
the Kd value. For this reason, assays results for ligands which gave low responses compared
to the standard 22a were not considered comparable, and therefore affinity analysis was not
pursued further.
Compound 22a Compound 19d
Rmax = 34 RU Rmax = 2.5 RU
Kd = 4.4 µM Kd = 9.4 µM
Figure A-5: Example of low response binding, giving results which are not representative of strength of
binding interaction. Response-concentration curves for the standard compound (22a) and weakly binding
sample 19d for the same assay run. Even though a curve can be fit to data for 19d, the low response
compared to 22a demonstrates saturation binding was not achieved and therefore the calculated Kd value is
not indicative of the binding affinity.
403
Appendix B: Summary of SPR assay results for extended
2-aminoquinoline derivatives with Tec SH3 domain.
6-Position extended 2-aminoquinoline ligands




R = Compound Kd (µM) Kd ± SD (µM)
N








































19s 1.7a 2.0 ± 0.5
NO
NH2












21x 9.6 9.7 ± 0.3a
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Screening Assay
R = Compound Kd (µM) Kd ± SD (µM)
NN






102s 2.9 2.2 ± 0.7
N
102x 9.0 20 ± 3
N
N


















115a 13.9 10 ± 4
N
N 115b > 20
N
N 115c 5.2 7 ± 4a
N
NN
116a 9.3 7 ± 1a
N
N




116c 3.2 2.4 ± 0.2
a Highest concentration data point removed due to precipitation or aggregation of compound under assay
conditions. b Response-concentration curve not at plateau, saturation binding not achieved. c Response too
low for saturation binding.
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3-Position extended 2-aminoquinoline ligands










N 140a > 50a
N 140b > 50a
N
N 141a > 50a
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Screening












a Response-concentration curve not at plateau, saturation binding not achieved.
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